



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 121415

TO: Minh-Tam Davis
Location: REM/3A24/3C18
Art Unit: 1642
Monday, May 17, 2004
Case Serial Number: 10/048046

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: (571)272-2527
paul.schulwitz@uspto.gov

Search Notes

Examiner Davis,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2527

07/99

STIC-Biotech/ChemLib

121415

From: Davis, Minh-Tam
Sent: Thursday, May 06, 2004 12:57 PM
To: STIC-Biotech/ChemLib
Subject: Search request for 10/048046

Please search in commercial database, PGPUB, issued patent files, and interference:

- 1) SEQ ID NO: 1, 2.
- 2) Oligomer search for SEQ ID NO: 1,
- 3) Amino acids 31-103, 303-346, 476-641 of SEQ ID NO: 2.

Thank you.

MINH TAM DAVIS
ART UNIT 1642
ROOM 3A24, MB 3C18
272-0830

RECEIVED
MAY - 6 2004
STIC/BIOTECH/ChemLib

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: 5/17
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____

Mon May 17 11:17:03 2004

```

; APPLICANT: OLEK, Alexander
; APPLICANT: PIEPENBROCK, Christian
; APPLICANT: BERLIN, Kurt
; TITLE OF INVENTION: Diagnosis of Diseases Associated with DNA Replication
; TITLE OF INVENTION: by Assessing DNA Methylation
; FILE REFERENCE: 5013.1012
; CURRENT APPLICATION NUMBER: US/10/204,708
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: PCT/EP01/03971
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: DE 10019055.8
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: DE 10032529.7
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: DE 10043826.1
; PRIOR FILING DATE: 2000-09-01
; NUMBER OF SEQ ID NOS: 98
; SEQ ID NO 62
; LENGTH: 6801
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
US-10-204-708-62

Query Match          1.6%; Score 42.4; DB 4; Length 6801;
Best Local Similarity 58.9%; Pred. No. 1.2; Indels 0; Gaps 0;
Matches 73; Conservative 0; Mismatches 51;

QY 2556 ATTTTATCTATTTTATTTTAAAGTTTGGTCTTCTCTTAATAGATTAAATCT 2615
DB 2997 ATAAATCCAACTTTTCTTTTCTTTTCTTATCTTATCTTATTAATTAATAA 2938

QY 2616 CACAACTGTAGCACAAATATATATTTTACAAATTCACAAATTCACAAAT 2675
DB 2937 ATTTCACCTAAACAAATTAATAATAAATAAATAAATAAATAAATAAATA 2878

QY 2676 AAAA 2679
DB 2877 AAAA 2874

RESULT 14
US-09-790-988-1
; Sequence 1, Application US/09790988
; Patent No. 6632935
; GENERAL INFORMATION:
; APPLICANT: SHIGENOBU, SHUJI
; APPLICANT: WATANABE, HIDEMI
; APPLICANT: HATTORI, MASAHISA
; APPLICANT: SAKAKI, YOSHIYUKI
; TITLE OF INVENTION: GENOME DNA OF BACTERIAL SYMBIONT OF APHIDS
; FILE REFERENCE: 081356/0159
; CURRENT APPLICATION NUMBER: US/09/790,988
; CURRENT FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: JF2000-107160
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 640681
; TYPE: DNA
; ORGANISM: Buchnera sp.
US-09-790-988-1

Query Match          1.6%; Score 42.4; DB 4; Length 640681;
Best Local Similarity 50.5%; Pred. No. 13; Indels 0; Gaps 0;
Matches 103; Conservative 0; Mismatches 101;

QY 2464 AAGTTTACAAACATTTGTTTCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2523
```

```

DB 625138 AAGCTATCTATTATATACAAATTTATATTTAAAAAGTAATAATTACAAATGGCTCTTCAT 625197
QY 2524 ACACATATCTCTGCTGCGGAAACACACAGCATTTTATCTATTTTATTTTAAATAGGT 2583
DB 625198 GCAAAATATATGCAATTTGGAAGAACACCTGCTCTTTTCTTTTATATATATAAAA 625257
QY 2584 TTGGTGTCTATCTTCTTAATAAGATTTAAATGTCCAAACTGTAGCACAATAATATAATT 2643
DB 625258 AAATTAATTTTCTTAAAGAAAGAAACAGTGAGATTTATTGAAATAATCAATAAAG 625317
QY 2644 TATTAATTACAAATTCACAAAAA 2667
DB 625318 ACAAATAAATAAATAATAGARTAA 625341

RESULT 15
US-09-293-322C-8
; Sequence 8, Application US/09293322C
; Patent No. 6232110
; GENERAL INFORMATION:
; APPLICANT: Pallas, David C
; APPLICANT: Du, Xianxing
; TITLE OF INVENTION: Coding Sequence for Protein Phosphatase Methyltransferase,
; Patent No. 6232110
; TITLE OF INVENTION: Recombinant DNA Molecules and Methods
; FILE REFERENCE: 105-97
; CURRENT APPLICATION NUMBER: US/09/293,322C
; CURRENT FILING DATE: 1999-04-16
; PRIOR APPLICATION NUMBER: US 60/082,202
; PRIOR FILING DATE: 1998-04-17
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 2409
; TYPE: DNA
; ORGANISM: Mus musculus
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(2409)
; OTHER INFORMATION: N is A, T, G or C.
US-09-293-322C-8
```

```

Query Match          1.6%; Score 42.2; DB 3; Length 2409;
Best Local Similarity 61.3%; Pred. No. 0.75; Indels 0; Gaps 0;
Matches 68; Conservative 0; Mismatches 43;

QY 2569 TTTATTTAATAGTTTGGTCTTATCTCTAATAGATTTTAAATGTCACAACTGTAGC 2628
DB 2294 TTTGTTCTTTGTTTATGATCTTTGTTTAAAGAAATAATATCTCCCACTTTAAA 2353
QY 2629 ACAAATAATAATAATTATAATTTTACAAATTCACAAATTCACAAATTCACAAAT 2679
DB 2354 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2404
```

Search completed: May 14, 2004, 20:10:15
Job time : 228 secs

262

STRADEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: FIBROT01
CLONE: 53219
US-08-910-925-2

Query Match 1.6%; Score 42.6; DB 3; Length 2369;
Best Local Similarity 58.1%; Pred. No. 0.58;
Matches 75; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

QY 1639 TTGCGCACCTGACTGGGCTGACCGGACCGGCTGCTACGGCTGCGCTGGCCCGGTTT 1698
Db 1873 TGCTGCCACCTGACTGGAGCTGCTACTGGAACCTACTGCGACTGCTACTTCCACTGC 1814
QY 1699 TGTGAGCTCAACCTGGGTGACAACTGCTGACGCGGCTGCTGACAAACACAGCTACGAG 1758
Db 1813 TGGNACTACTTCCACTGCTACTGTTGAACTGCTACTAGAACTGCTACTGCTACTGC 1754
QY 1759 TCAGACATC 1767
Db 1753 TTCGACTTC 1745

RESULT 10
US-09-252-991A-2236/c
Sequence 2236, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
CURRENT FILING DATE: 1999-02-18
PRIOR FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 2236
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-2236

Query Match 1.6%; Score 42.4; DB 4; Length 966;
Best Local Similarity 54.5%; Pred. No. 0.4;
Matches 85; Conservative 0; Mismatches 71; Indels 0; Gaps 0;

QY 74 CGGGGATGTGAATCCCGATGAGCGGCCGAGGAAGCAAGCAGTCCCGCGCGCAGC 133
Db 578 CGCTGCTGTTTCATGCCATCGATCGCTGACGACGACGAGCAGCGCTGCGGAGG 519
QY 134 CCTGGGACGCGCTCCTGCTGCTGGCGCGGAGGAGGAGCGCCACGCTCCTCTGAGGA 193
Db 518 CCGCTGGCGGGTCCGCGAGATGCGCGGCGAGGACCTGCCCGCGCGATCCTTGGAGCGG 459
QY 194 AGCGGAGTGGACCATCGCGGCGGAGACGAGGTTGCG 229
Db 458 AGCATCGGCTGCTGATCGTTCATGCGCGGTTGGCG 423

RESULT 11
US-09-252-991A-2607
Sequence 2607, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A

CURRENT FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 2607
LENGTH: 1734
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-2607

Query Match 1.6%; Score 42.4; DB 4; Length 1734;
Best Local Similarity 54.5%; Pred. No. 0.55;
Matches 85; Conservative 0; Mismatches 71; Indels 0; Gaps 0;

QY 74 CGGGGATGTGAATCCCGATGAGCGGCCGAGGAAGCAAGCAGTCCCGCGCGCAGC 133
Db 1212 CGCTGCTGTTTCATCGCATCGATCGCTGACGAAACGAGGAGCGCTTGGCGGAGG 1271
QY 134 CTTGGGACGCGCTCCTGCTGCTGGCGCGGAGGAGCGGACGCTCCTCTCTGAGGA 193
Db 1272 CCGCTGGCGGGTCCGCGAGATGCGCGCGCAGGACCTGCCCGCGCGATCCTTGGAGCGG 1331
QY 194 AGCGGAGTGGACCATCGCGCGGAGACGAGGTTGCG 229
Db 1332 AGCATCGGCTGCTGATCGTTCATGCGCGGTTGGCG 1367

RESULT 12
US-09-252-991A-2445
Sequence 2445, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
CURRENT FILING DATE: 1999-02-18
PRIOR FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 2445
LENGTH: 2016
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-2445

Query Match 1.6%; Score 42.4; DB 4; Length 2016;
Best Local Similarity 54.5%; Pred. No. 0.6;
Matches 85; Conservative 0; Mismatches 71; Indels 0; Gaps 0;

QY 74 CGGGGATGTGAATCCCGATGAGCGGCCGAGGAAGCAAGCAGTCCCGCGCGCAGC 133
Db 1454 CGCTGCTGTTTCATCGCATCGATCGCTGACGAAACGAGGAGCAGCGCTTGGCGGAGG 1513
QY 134 CTTGGGACGCGCTCCTGCTGCTGGCGCGGAGGAGCGGACGCTCCTCTCTGAGGA 193
Db 1514 CCGCTGGCGGGTCCGCGAGATGCGCGGCGCAGGACCTGCCCGCGCGATCCTTGGAGCGG 1573
QY 194 AGCGGAGTGGACCATCGCGGCGGAGACGAGGTTGCG 229
Db 1574 AGCATCGGCTGCTGATCGTTCATGCGCGGTTGGCG 1609

RESULT 13
US-10-204-708-62/c
Sequence 62, Application US/10204708
Patent No. 6677731
GENERAL INFORMATION:


```

Best Local Similarity 3.4%, Pred. No. 0.0055;
Matches 13; Conservative 219; Mismatches 155; Indels 0; Gaps 0;

QY 191 GGAAGCGGGAGTGGACCATCGGCGGAGACGAGGTTGCGACCTTCTTCCCGACAATA 250
    || : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1438 GTACRERERERERERERERERERERERERERERERERERERERERERERERER 1379

QY 251 AACTGGTCTCTGAGATCACTGTAGAATTGTAGTGGATGAAAAATCAGTTCAGTCAC 310
    : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1378 RRRERERERERERERERERERERERERERERERERERERERERERERERER 1319

QY 311 TGAAGATACCAAGCACGACGAGTGGACACAGTGTAAACAAGCTGAAGTGTGTTAAGAAGCAGA 370
    : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1318 RRRERERERERERERERERERERERERERERERERERERERERERERERER 1259

QY 371 CATGCCCTTTACAGACTGGGGATGTCATCTACTTGGTGTACAGAAAGATGAACCCGAAC 430
    : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1258 RRRERERERERERERERERERERERERERERERERERERERERERERERER 1199

QY 431 ACAAGCTGGCATACCTCATGAATCTTTAAAGTGAAGAAGCAAGCATGACACAAGAATCCT 490
    : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1198 RRRERERERERERERERERERERERERERERERERERERERERERERERER 1139

QY 491 TTGAAGCTACAGGAAATGTGTTCCATGGGACCAAGATACCTCAGGTGCAGGTGCAG 550
    : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1138 RRRERERERERERERERERERERERERERERERERERERERERERERERER 1079

QY 551 GGGCGAGGGCGGATCCCCGGGTCCCTC 577
    : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1078 RRRERERERERATCGCAAGTCCTC 1052

RESULT 2
US-09-621-976-16656
; Sequence 16656, Application US/09621976
; Patent No. 6639063
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Joubert, S. Y.
; APPLICANT: Giordano, J.Y.
; TITLE OF INVENTION: ESTs and Encoded Human Proteins.
; FILE REFERENCE: GENSET.054PR2
; CURRENT APPLICATION NUMBER: US/09/621.976
; CURRENT FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 19335
; SOFTWARE: Patent.pm
; SEQ ID NO 16656
; LENGTH: 430
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-621-976-16656

```

```

Db      296  ACTTACCAGCGCATGYKRAMCSCMMWMBKRAKKYMMMSRMSKYWARRRGSMMCYYY 355
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY      1828 GTGGCTCTCCAGCGGGGAGTGTTCGT 1854
      : : : : : : : : : : : : : : : : : : : : : : : :
Db      356  KGNMSXWYKSSGGRGAGGCTTCAATG 382
      : : : : : : : : : : : : : : : : : : : : : : : :
RESULT 3
US-09-807-258-13
; Sequence 13, Application US/09807258
; Patent No. 6670166
; GENERAL INFORMATION:
; APPLICANT: E. I. du Pont de Nemours and Company
; TITLE OF INVENTION: Arthropod Protein Disulfide Isomerases
; FILE REFERENCE: BB-1253 PCT
; CURRENT APPLICATION NUMBER: US/09/807,258
; CURRENT FILING DATE: 2001-06-11
; PRIOR APPLICATION NUMBER: 60/104,376
; PRIOR FILING DATE: 1998-10-15
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: Microsoft Office 97
; SEQ ID NO 13
; LENGTH: 1759
; TYPE: DNA
; ORGANISM: Scolopendra canidens DS
US-09-807-258-13

Query Match      1.7%; Score 45.8; DB 4; Length 1759;
Best Local Similarity 49.4%; Pred. No. 0.073;
Matches 119; Conservative 0; Mismatches 122; Indels 0; Gaps 0;

QY      2439 AGAAAAAGTTTCAAGGAGNAGGCGAAGTTTATCAAAAACATGTGTTTCAGGAGAGGGAG 2498
Db      1514 AGAAAAAGTTGAATTTGTTAAAGTAGCAATTTAGAAATTTTAAATATTGTTTCAGTAAAGC 1573
QY      2499 CATAAGTTTACAGCCTACAGGAGCTACAAATATCCTGCTGTGGGAAAACCCACAGCAT 2558
Db      1574 ACAATTTTATTATTTTAAAGGAATAAAATGTAATAATCAATTTATGATAATTTTAAATTT 1633
QY      2559 TTATCTATTTTTTATTTTAAATAGTTTGGTGCTTATCTTCTTAATAAGATTTAATGTCAC 2618
Db      1634 AGAGTGGCTTTATGTTGGTGCTAGCTATGTGCTTTATTCTTCTTGTAAAGATAAAATGTGAA 1693
QY      2619 AAAGCTGTAGCACAAATAATAATTTATATTTTACAAATTCACAAAAAAGAAAAA 2678
Db      1694 AATTAATCGAATAAATTTTTTTTAAATAGTTTITACAAAAGAAAAA 1753
QY      2679 A 2679
      |
Db      1754 A 1754

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 14, 2004, 12:14:23 ; Search time 215 Seconds
(without alignments)
6914.946 Million cell updates/sec

Title: US-10-048-046-1
Perfect score: 2679
Sequence: 1 aagaattcgagcgagcgccg.....acaaaaaaaaaaaaaaaaa 2679

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA:
1: /cgm2_6/ptodata/2/ina/5A COMB.seq:*
2: /cgm2_6/ptodata/2/ina/5B COMB.seq:*
3: /cgm2_6/ptodata/2/ina/6A COMB.seq:*
4: /cgm2_6/ptodata/2/ina/6B COMB.seq:*
5: /cgm2_6/ptodata/2/ina/PTUS COMB.seq:*
6: /cgm2_6/ptodata/2/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
C 1	51.4	1.9	7218	1	US-08-232-463-14		Sequence 14, Appl
2	46.2	1.7	430	4	US-09-621-976-16656		Sequence 16656, A
3	45.8	1.7	1759	4	US-09-807-258-13		Sequence 13, Appl
4	45.4	1.7	991	3	US-08-924-747-25		Sequence 25, Appl
5	45.4	1.7	991	3	US-09-247-373B-25		Sequence 25, Appl
6	45.4	1.7	991	3	US-09-296-715-25		Sequence 25, Appl
7	45.2	1.7	4403765	3	US-09-103-840A-2		Sequence 2, Appl
8	45.2	1.7	4411529	3	US-09-103-840A-1		Sequence 1, Appl
C 9	42.6	1.6	2369	3	US-08-910-925-2		Sequence 2, Appl
C 10	42.4	1.6	966	4	US-09-252-991A-2236		Sequence 2236, Ap
11	42.4	1.6	1734	4	US-09-252-991A-2607		Sequence 2607, Ap
12	42.4	1.6	2016	4	US-09-252-991A-2445		Sequence 2445, Ap
C 13	42.4	1.6	6801	4	US-10-204-708-62		Sequence 62, Appl
14	42.4	1.6	640681	4	US-09-790-988-1		Sequence 1, Appl
15	42.2	1.6	2409	3	US-09-293-322C-8		Sequence 8, Appl
16	42.2	1.6	2409	4	US-09-839-497A-8		Sequence 8, Appl
17	42.2	1.6	4255	5	PCT-US96-02331-14		Sequence 14, Appl
18	42.2	1.6	4835	5	PCT-US96-02331-9		Sequence 9, Appl
19	42.2	1.6	4835	5	PCT-US96-02331-9		Sequence 9, Appl
20	41.4	1.5	2271	4	US-09-205-258-243		Sequence 243, App
21	41.4	1.5	2276	4	US-09-205-258-193		Sequence 183, App
22	41.2	1.5	1037	4	US-09-489-847-112		Sequence 112, App
C 23	41.2	1.5	8093	4	US-10-204-708-31		Sequence 31, Appl
24	41	1.5	194	4	US-09-621-976-801		Sequence 801, App
25	41	1.5	1661	4	US-09-409-096-5		Sequence 5, Appl
26	40.8	1.5	1192	4	US-09-439-554-23		Sequence 23, Appl
C 27	40.8	1.5	26000	4	US-09-843-376-10		Sequence 10, Appl

28	40.6	1.5	1637	4	US-09-205-258-178		Sequence 178, App
29	40.4	1.5	370	4	US-09-376-113-1		Sequence 1, Appl
30	40.4	1.5	505	4	US-09-621-976-15639		Sequence 15639, A
31	40.4	1.5	611	4	US-09-376-113-4		Sequence 4, Appl
32	40.4	1.5	631	4	US-09-376-113-6		Sequence 6, Appl
33	40.4	1.5	1114	4	US-09-152-060-41		Sequence 41, Appl
34	40.4	1.5	1248	4	US-09-489-847-101		Sequence 101, App
35	40.4	1.5	3572	4	US-09-575-574-3		Sequence 3, Appl
36	40.4	1.5	1249	4	US-09-461-325-128		Sequence 128, App
37	40.2	1.5	1249	4	US-10-012-542-128		Sequence 128, App
C 38	40.2	1.5	1260	4	US-09-461-325-93		Sequence 93, Appl
C 39	40.2	1.5	1260	4	US-10-012-542-93		Sequence 93, Appl
40	40	1.5	450	4	US-09-252-991A-5753		Sequence 5753, Ap
C 41	40	1.5	837	4	US-09-252-991A-5702		Sequence 5702, Ap
C 42	40	1.5	1035	4	US-09-252-991A-5715		Sequence 5715, Ap
C 43	40	1.5	1245	4	US-09-252-991A-5725		Sequence 5725, Ap
44	40	1.5	1342	4	US-09-489-847-89		Sequence 89, Appl
45	39.8	1.5	593	4	US-09-904-615-59		Sequence 59, Appl

ALIGNMENTS

RESULT 1
US-08-232-463-14/c
; Sequence 14, Application US/08232463
; Patent No. 5670367
; GENERAL INFORMATION:
; APPLICANT: DORNER, F.
; APPLICANT: SCHEIFLINGER, F.
; APPLICANT: FALKNER, F. G.
; TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 1800 Diagonal Road, Suite 500
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22313-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,463
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/935,313
; FILING DATE:
; APPLICATION NUMBER: EP 91 114 300.6
; FILING DATE: 26-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: BENT, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 30472/114 IMMU
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)836-9300
; TELEFAX: (703)683-4109
; TELEX: 899149
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7218 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: pTZgpt-Fls
US-08-232-463-14

Query Match 1.9%; Score 51.4; DB 1; Length 7218;

expressed sequence tag; EST; probe; chemotactic; proliferative; immunomodulatory; haematopoietic; chemokine; analgesic; haemostatic; thrombolytic; anti-inflammatory; cytostatic; antibacterial; antifungal; antiviral; antidiabetic; antiasthmatic; vulnary; antiparkinsonian; antitumor; osteoprotective; neuroprotective; nootropic; antipsoriatic; cerebroprotective; anticonvulsant; antidepressant; gene therapy; vaccine; autoimmune disorder; multiple sclerosis; allergic condition; ulcer; insulin dependent diabetes; asthma; myeloid cell deficiency; stroke; lymphoid cell deficiency; burn; osteoporosis; osteoarthritis; central nervous system disorder; Alzheimer's disease; stroke; Parkinson's disease; Huntington's disease; coagulation disorder; haemophilia; thrombosis; inflammatory disorder; Crohn's disease; tumour; infection; depression; psoriasis; ss.

Homo sapiens.

WO20021991-A1.

20-APR-2000.

15-OCT-1999; 99WO-US024206.

15-OCT-1998; 98US-0104436P.

(GEM) GENETICS INST INC.

Jacobs K, McCoy JM, Lavallie ER, Collins-Racie LA, Evans C; Merberg D, Treacy M, Bowman MR;

WPI; 2000-317938/27.

Isolated polynucleotides, and encoded proteins, comprising secreted expressed sequence tags (sESTs), useful for treating various disorders such as autoimmune, infectious, and central nervous system disorders.

Claim 1; Page 437; 803pp; English.

AAA43426 to AAA45925 represent specifically claimed secreted expressed sequence tags (sESTs), isolated from human, mouse, chicken and rat tissue sources. The sESTs can have a range of activities depending on the tissues they were isolated from. The activities include: chemotactic; proliferative; immunomodulatory; haematopoietic; chemokine; analgesic; haemostatic; thrombolytic; anti-inflammatory; cytostatic; antibacterial; antifungal; antiviral; antidiabetic; antiasthmatic; vulnary; antitumor; osteopathic; neuroprotective; nootropic; antiparkinsonian; antipsoriatic; cerebroprotective; anticonvulsant; and antidepressant. The sESTs can be used for gene therapy and in vaccines. The sESTs are useful as probes for the identification and isolation of full-length cDNAs and genomic DNA molecules which correspond to the sESTs. Proteins encoded by the sESTs are useful in assays for determining biological activity and raising antibodies. They may be useful for treatment of autoimmune disorders (multiple sclerosis, insulin dependent diabetes), allergic conditions (asthma), myeloid or lymphoid cell deficiencies, wounds, burns, ulcers, osteoporosis, osteoarthritis, central nervous system disorders (Alzheimer's, Parkinson's, Huntington's disease, stroke), coagulation disorders (haemophilia, thrombosis), inflammatory disorders (Crohn's disease), tumours, bacterial, fungal or viral infections, depression and psoriasis. AAA45926 to AAA45931 represent linker variants which are given in the exemplification of the present invention

Sequence 575 BP; 124 A; 168 C; 165 G; 118 T; 0 U; 0 Other;

Query Match 18.5%; Score 495.8; DB 3; Length 575;
Best Local Similarity 94.8%; Pred No. 4e-109;
Matches 532; Conservative 0; Mismatches 7; Indels 22; Gaps 1;

623 CAACATGACGCTCAGACCTCTTCCACAGCCTCGGCTCTTCCACGAGCCTTCTCTG 682
10 CAAGAGCGCTACAGACCTCTTCCACAGCCTCGGCTCTTCCACGAGCCTTCTCTG 69

693 CAGGCGAGCGTCTCCAGTGTGGTCTGGGGTGGTGGCATCTCCCTAAAGGAA 742
70 CAGGCGAGCGTCTCCAGTGTGGTCTGGGGTGGTGGCATCTCCCTAAAGGAA 129

743 GTGCTCCCTCTGTGGCAAGTGATGAAGTCTCCAGCTTTCAGCTCTCCAGACAGAA 802
130 GTGCTCCCTCTGTGGCAAGTGATGAAGTCTCCAGCTTTCAGCTCTCCAGACAGAA 189
803 AGACTGCGTCTCTTTCGTTCGTTGGAACCCAGGATCAGGAGATTTCGAGCCCGTGAAGA 862
190 AGACTGCGTCTCTTTCGTTCGTTGGAACCCAGGATCAGGAGATTTCGAGCCCGTGAAGA 249
863 AGAAAATGAGAGG-----AGATGGGACCTTGACCTGAACGGG 900
250 AGAAAATGAGAGGAGAAACACATCCCTTTCCTGTAGATGGGACCTTGACCTGAACGGG 309
901 CAGTTGTTGGTTCGACCAACCCGCTAGAAATGCCAAACCCGCTCAGGAGCGTCAGAGCA 960
310 CAGTTGTTGGTTCGACCAACCCGCTAGAAATGCCAAACCCGCTCAGGAGCGTCAGAGCA 369
961 GCGGCTGGGAAAGCCAGACCAAGATGAGAGGAGCGCTGCATCATCATCTGCCAGGACCTG 1020
370 GCGGCTGGGAAAGCCAGACCAAGATGAGAGGAGCGCTGCATCATCATCTGCCAGGACCTG 429
1021 CTGCACGACTCGGTGAGTTTGCAGCCCTGCATGCACACGTTTCTCGCGGCTTGTACTCG 1080
430 CTGCACGACTCGGTGAGTTTGCAGCCCTGCATGCACACGTTTCTCGCGGCTTGTACTCG 489
1081 GCTGATGAGAGCGCTCGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1140
490 GCTGATGAGAGCGCTCGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 549
1141 AAAAACCACATCTCTCAACAAC 1161
550 AAAAACCACATCTCTCAACAAC 570

RESULT 15
AAH11859/c
ID AAH11859 standard; cDNA; 518 BP.
XX AC AAH11859;
XX DT 26-JUN-2001 (first entry)
XX DE Human cDNA clone (3'-primer) SEQ ID NO:8694.
XX KW Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX OS Homo sapiens.
XX PN BP1074617-A2.
XX PD 07-FEB-2001.
XX PF 28-JUL-2000; 2000EP-00116126.
XX PR 29-JUL-1999; 99JP-00248036.
XX PR 27-AUG-1999; 99JP-00300253.
XX PR 11-JAN-2000; 2000JP-00118776.
XX PR 02-MAY-2000; 2000JP-00183767.
XX PR 09-JUN-2000; 2000JP-00241899.
XX PA (HELI-) HELIX RES INST.
XX PI Ota T, Isogai T, Nishikawa T, Hayaashi K, Saito K, Yamamoto J;
XX PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX WPI; 2001-318749/34.
XX PT Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
XX PS Claim 3; SEQ ID NO 8694; 2537pp + Sequence Listing; English.

Best Local Similarity 92.5%; Pred. No. 6.5e-119;		Matches 608; Conservative 7; Mismatches 13; Indels 29; Gaps 4;	
QY	1044	GCCTGATGACACACGTTCTGCGGGCTTCTACTCGGGCTGGATGAGCGCTCGTCCCT	1103
DB	14	GCCTGATGACACACGTTCTGCGGGCTTCTACTCGGGCTGGATGAGCGCTCGTCCCT	73
QY	1104	GTGTCCTACCTGCGCGCTGTCCTGCGGAGCGGATCTGTAAGAACACATCTCTCAACACCT	1163
DB	74	GTGTCCTACCTGCGCGCTGTCCTGCGGAGCGGATCTGTAAGAACACATCTCTCAACACCT	133
QY	1164	CGTGAAGCATACCTCATTCAGCATCCAGACAGAGTCCGAGTGAAGAGATGTGCAAG	1223
DB	134	CGTGAAGCATACCTCATTCAGCATCCAGACAGAGTCCGAGTGAAGAGATGTGCAAG	193
QY	1224	TATGATGCCAGGAATAAATCACTCAAGACATCTCTGAGCCCAAGTTCAGGCGGTCTTT	1283
DB	194	TATGATGCCAGGAATAAATCACTCAAGACATCTCTGAGCCCAAGTTCAGGCGGTCTTT	253
QY	1284	TTCTGATGAAGAAGGAGTTTCAGAGGACCTGCTGGAGTGTTCAGAGTGTTCAGTGTGATC	1343
DB	254	TTCTGATGAAGAAGGAGTTTCAGAGGACCTGCTGGAGTGTTCAGAGTGTTCAGTGTGATC	313
QY	1344	CTCAGACATTAGCCAGCATACGTCGTCGCGGAGTGTCTCTGAGTACAGAGGCGGCGG	1403
DB	314	CTCAGACATTAGCCAGCATACGTCGTCGCGGAGTGTCTCTGAGTACAGAGGCGGCGG	373
QY	1404	GGCGCAGGCTCTCCCACTGCCCCAGCACCCGAGGCGGAGCCAGAGCCGCCACAGGCGCTGG	1463
DB	374	GGCGCAGGCTCTCCCACTGCCCCAGCACCCGAGGCGGAGCCAGAGCCGCCACAGGCGCTGG	433
QY	1464	GGATGACCTCTCCAGTCGCTGCGTCCGAGTACAGCAGGATCCAGGATACGTCGCTCT	1523
DB	434	GGATGACCTCTCCAGTCGCTGCGTCCGAGTACAGCAGGATCCAGGATACGTCGCTCT	489
QY	1524	GCAGGAAGCCACGCGCTGTGCACCTGCTGTTCAGCCCATGCCCGACCGAGAGCGGA	1583
DB	490	GCAGGAAGCCACGCGCTGTGCACCTGCTGTTCAGCCCATGCCCGACCGAGAGCGGA	548
QY	1584	GGCGAGAGGACCCCGCTGTGCGCCCTCAGAGTGTGCGGTCTGCTGAGCGCTTCTG	1643
DB	549	-CGCGAGCAGGACCCCGCTGTGCGCCCTCAGAGTGTGCGGTCTGCTGAGCGCTTCTG	584
QY	1644	CCACCTGTACTGGGCTGCACCCGAGCGGCTGTACGCTGCTGCGGCTGCTGCTGCTG	1700
DB	585	CCACCTGTACTGGGCTGCACCCGAGCGGCTGTACGCTGCTGCGGCTGCTGCTGCTG	641

RESULT 13
ABX73645
ID ABX73645 standard; DNA; 693 BP.
XX
AC ABX73645;
XX
DT 18-MAR-2003 (first entry)
XX
DE Human novel polynucleotide #473.
XX
KW Human; gene; ds; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.
XX
OS Homo sapiens.
XX
PN US2002132753-A1.
XX
PD 19-SEP-2002.
XX
PF 17-JAN-2001; 2001US-00764864.

08-NOV-2000; 2000US-0246513P.
17-NOV-2000; 2000US-0249207P.
17-NOV-2000; 2000US-0249208P.
17-NOV-2000; 2000US-0249209P.
17-NOV-2000; 2000US-0249210P.
17-NOV-2000; 2000US-0249211P.
17-NOV-2000; 2000US-0249212P.
17-NOV-2000; 2000US-0249213P.
17-NOV-2000; 2000US-0249214P.
17-NOV-2000; 2000US-0249215P.
17-NOV-2000; 2000US-0249216P.
17-NOV-2000; 2000US-0249217P.
17-NOV-2000; 2000US-0249218P.
17-NOV-2000; 2000US-0249244P.
17-NOV-2000; 2000US-0249245P.
17-NOV-2000; 2000US-0249264P.
17-NOV-2000; 2000US-0249265P.
17-NOV-2000; 2000US-0249297P.
17-NOV-2000; 2000US-0249299P.
17-NOV-2000; 2000US-0249300P.
01-DEC-2000; 2000US-0250160P.
01-DEC-2000; 2000US-0250391P.
05-DEC-2000; 2000US-0251030P.
05-DEC-2000; 2000US-0251988P.
05-DEC-2000; 2000US-0256719P.
06-DEC-2000; 2000US-0251479P.
08-DEC-2000; 2000US-0251856P.
08-DEC-2000; 2000US-0251868P.
08-DEC-2000; 2000US-0251869P.
08-DEC-2000; 2000US-0251989P.
08-DEC-2000; 2000US-0251990P.
11-DEC-2000; 2000US-0254097P.
05-JAN-2001; 2001US-0259678P.
(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-488783/53.
P-PSDB; AAU16317.
New nucleic acid molecules encoding 461 human secreted proteins for
diagnosing, preventing, treating or ameliorating medical conditions and
used as food additives or preservatives.
Claim 1; SEQ ID NO 483; 980pp; English.
The invention relates to isolated nucleic acid molecules and their
encoded secreted proteins. The nucleic acids and proteins are used to
prevent, treat or ameliorate a medical condition in e.g. humans, mice,
rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
in diagnosing a pathological condition or susceptibility to a
pathological condition. Antibodies to the proteins can also be used in
alleviating symptoms associated with the disorders and in diagnostic
immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
(ELISA). Disorders which are diagnosed or treated include autoimmune
diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiodenesis,
nervous system disorders e.g. Alzheimer's disease, infections caused by
bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
and many other disorders listed in the specification. The polypeptides
can also be used to aid wound healing and epithelial cell proliferation,
to prevent skin aging due to sunburn, to maintain organs before
transplantation, for supporting cell culture of primary tissues, to
regenerate tissues and in chemotaxis. The polypeptides can also be used
as a food additive or preservative to increase or decrease storage
capabilities, fat content, lipid, protein, carbohydrate, vitamins,
minerals, cofactors and other nutritional components. The present
sequence encodes a novel secreted protein of the invention. Note: The
sequence data for this patent did not form part of the printed
Query Match 20.0%; Score 536.6; DB 4; Length 693;

Db 598 TCCCTCTGTGCAAGTATGATGAGTCTCCAGCTTTTCCTCAGCTCTCCAGACAGAAAGAC 657
Qy 807 TGCCTCTCTTTTCGTCGTGGAACCCCGAGATCAGAGAGATTTGAGCCCGTGAAGAAGAA 866
Db 658 TGCCTCTCTTTTCGTCGTGGAACCCCGAGATCAGAGAGATTTGAGCCCGTGAAGAAGAA 717
Qy 867 AATCAGAGGAGATGGGACCTTGACCTGAACGGGCGAGTTGTTGTCGACACACCGCGTAG 926
Db 718 AATGAGAGAGATGGGACCTTGACCTGAACGGGCGAGTTGTTGTCGACACACCGCGTAG 777
Qy 927 AATGCCCCAAACCGTCCACGAGGAGCTCAGAGCAGCGCTGGGAAGC 973
Db 778 AATGCCCCAAACCGTCCACGAGGAGCTCAGAGCAGCGCTGGGAAGC 824

RESULT 12
AAS26304
ID AAS26304 standard; cDNA; 693 BP.
XX
AC AAS26304;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human cDNA encoding a novel secreted protein, Seq ID 483.
XX
KW Human; immunosuppressive; antiarthritic; ss; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX
OS Homo sapiens.
XX
PN WO200155322-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001341.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 14-AUG-2000; 2000US-0225759P.

PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 05-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239335P.
PR 13-OCT-2000; 2000US-0239337P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.

Db	481	-----GATACCTCAGGTGCAGGTGCAGGGCGAG
QY	557	GCGCCGATCCC GGTCCTCGTTCGCCCGCCACTCAGGTGTGCTTTGAGGAACCA
Dd	509	GCGCCGATCCC GGTCCTCGTTCGCCCGCCACTCAGGTGTGCTTTGAGGAACCA
QY	617	AGCCATCAACATCGACGTGACAAGCTCTTCCCAAGAGCTTGAGCTCTTCCACGGAGCTT
Dd	569	AGCCATCAACATCGACGTGACAAGCTCTTCCCAAGAGCTTGAGCTCTTCCACGGAGCTT
QY	677	CTTCCTCAGGCGGAGAGCGTTCCTCCAGTCTGGGTCTGGGGTGGTGGCATCTCCCTTA
Dd	629	CTTCCTCAGGCGGAGAGCGTTCCTCCAGTCTGGGTCTGGGGTGGTGGCATCTCCCTTA
QY	737	AAGGAAGTGGTCCCTCTGTGGCAAGTGATGAAGTCTCCAGCTTTGCTCAGCTCTCCGAG
Dd	689	AAGGAAGTGGTCCCTCTGTGGCAAGTGATGAAGTCTCCAGCTTTGCTCAGCTCTCCGAG
QY	797	ACAGAAGACTCGTCCCTTTGCTGGTGGAAAGCCAGGATCAGGAGGA-TTTGGAGGCC
Dd	749	ACAGAAGACTCGTCCCTTTGCTGGTGGAAAGCCAGGATCAGGAGGA-TTTGGAGGCC
QY	856	GTGAAGAA 863
Dd	809	GTGAAGAA 816
 RESULT 11 AAH06846		
ID	AAH06846	standard; cDNA; 824 BP.
XX	AAH06846;	
XX	AC	
XX	DT	
DE	26-JUN-2001	(first entry)
DE	Human cDNA clone (5'-primer)	SEQ ID NO:3681.
KW	Human; primer; detection; diagnosis;	antisense therapy; gene therapy; ss.
OS	Homo sapiens.	
XX	EPI074617-A2.	
XX	07-FEB-2001.	
XX	28-JUL-2000;	2000EP-00116126.
XX	29-JUL-1999;	99JP-00248036.
PR	27-AUG-1999;	99JP-00300253.
PR	11-JAN-2000;	2000JP-00118776.
PR	02-MAY-2000;	2000JP-00183767.
PR	09-JUN-2000;	2000JP-00241899.
XX	(HELI-) HELIX RES INST.	
XX	Ota T, Isogai T, Nishikawa T, Hayashi K,	Saito K, Yamamoto J;
PI	Ishii S, Sugiyama T, Wakamatsu A,	Nagai K, Otsuki T;
XX	WPI; 2001-318749/34.	
XX	Primer sets for synthesizing polynucleotides,	particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
XX	Claim 1; SEQ ID NO 3681; 2537pp + Sequence Listing;	English.
XX	The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises:	
CC	(a) an oligo-dT primer and an oligonucleotide complementary to the	
CC	complementary strand of a polynucleotide which comprises one of the 5602	
CC	nucleotide sequences defined in the specification, where the	
CC	polynucleotide comprises at least 15 nucleotides; or (b) a combination	

Db 911 GCCGCACTCAGGTGAAGCTCACACGCCATGAATTCATATCATATCTGTGACACACAA 970
Qy 2072 GGTTCAAAACTAAGCATCCAGAGGCCCTCAGCAGAGCTTTGAGAGAG 2131
Db 971 GGTTCAAAACTAAGCATCCAGAGGCCCTCAGCAGAGCTTTGAGAGAG 1030
Qy 2132 CGTGTCTTTTAAATACAGACAGCAAGCAGTCAGAGTGTCTTTCAGAGCCCTCAGGGAAG 2191
Db 1031 CGTGTCTTTTAAATACAGACAGCAAGCAGTCAGAGTGTCTTTCAGAGCCCTCAGGGAAG 1090
Qy 2192 GAGCGCAGGCTCCCGACAGGTCTCTGGGGTGAATCTTCTGTGGAGCTTTTACCTCT 2251
Db 1091 GAGCGCAGGCTCCCGACAGGTCTCTGGGGTGAATCTTCTGTGGAGCTTTTACCTCT 1148
Qy 2252 GAGTGACACCTCCCGACAGCCCGGGGGCGCAGCCGCCCTCTGTGAGCGCTGGGC 2311
Db 1149 GAGTGACACCTCCCGACAGCCCGGGGGCGCAGCCGCCCTCTGTGAGCGCTGGGC 1208
Qy 2312 AGGCTCGTGTGGCATCAGCAGCAGAGAGCAAGCCTTTCTGTAACATCGGCGCTCCCG 2371
Db 1209 AGGCTCGTGTGGCATCAGCAGCAGAGAGCAAGCCTTTCTGTAACATCGGCGCTCCCG 1268
Qy 2372 CCGAGAGGGCAGTTTGTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGTC 2431
Db 1269 CCGAGAGGGCAGTTTGTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGTC 1328
Qy 2432 TGTTTTCAGGAAAGTTTCAAGGAGAGGAGGCAAGTTTATCAAAAACATTTTTCAGGAG 2491
Db 1329 TGTTTTCAGGAAAGTTTCAAGGAGAGGAGGCAAGTTTATCAAAAACATTTTTCAGGAG 1388
Qy 2492 AAGGAGCATAAGTTTACAGCTACAGCAGTACACATATCTGCTGCTGGGAAACCA 2551
Db 1389 AAGGAGCATAAGTTTACAGCTACAGCAGTACACATATCTGCTGCTGGGAAACCA 1448
Qy 2552 CAGCATTTTATCTATTTTATTTTATAGTTTGTGCTTATCTTCTAATAAGATTAA 2611
Db 1449 CAGCATTTTATCTATTTTATTTTATAGTTTGTGCTTATCTTCTAATAAGATTAA 1508
Qy 2612 ATGTCAAACTGTAGCAGAAATTAATTAATTTATTAATTTACAAATTCAGAAAA 2666
Db 1509 ATGTCAAACTGTAGCAGAAATTAATTAATTTATTAATTTACAAATTTGACTAAA 1563

RESULT 10
AAH06828
ID AAH06828 standard; cDNA; 816 BP.
XX
AC AAH06828;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human cDNA clone (5'-primer) SEQ ID NO:3663.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN EPI074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-00116126.
XX
PR 29-JUL-1999; 99JP-00248036.
PR 27-AUG-1999; 99JP-00300253.
PR 11-JAN-2000; 2000JP-00118776.
PR 02-MAY-2000; 2000JP-00183767.
PR 09-JUN-2000; 2000JP-00241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Negai K, Otsuki T;

XX WPI; 2001-318749/34.
XX
PT Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
PT
XX
PS Claim 1; SEQ ID NO 3663; 2537pp + Sequence Listing; English.
XX
XX The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dT primer and an oligonucleotide complementary to the CC complementary strand of a polynucleotide which comprises one of the 5602 CC nucleotide sequences defined in the specification, where the CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination CC of an oligonucleotide comprising a sequence complementary to the CC complementary strand of a polynucleotide which comprises a 5'-end CC sequence and an oligonucleotide comprising a sequence complementary to a CC polynucleotide which comprises a 3'-end sequence, where the CC oligonucleotide comprises at least 15 nucleotides and the combination CC of the 5'-end sequence/3'-end sequence is selected from those defined in the CC specification. The primer sets can be used in antisense therapy and in CC gene therapy. The primers are useful for synthesizing polynucleotides, CC particularly full-length cDNAs. The primers are also useful for the CC detection and/or diagnosis of the abnormality of the proteins encoded by CC the full-length cDNAs. The primers allow obtaining of the full-length CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and CC AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to AAH95893 CC represent human amino acid sequences; and AAH13629 to AAH13632 represent CC oligonucleotides, all of which are used in the exemplification of the CC present invention
XX
SQ Sequence 816 BP; 182 A; 216 C; 253 G; 162 T; 0 U; 3 Other;
Query Match 27.1%; Score 727; DB 4; Length 816;
Best Local Similarity 93.5%; Pred. No. 9,4e-165;
Matches 793; Conservative 0; Mismatches 18; Indels 37; Gaps 2;
Qy 17 GCGCAATGTCTCTTGACAGCGCGCGCGCGCGCGTTCGGGTTTCGGCGCGGGGG 76
Db 5 GCGCAATGTCTCTTGACAGCGCGCGCGCGCGCGTTCGGGTTTCGGCGCGGGGG 64
Qy 77 GGATGTGAATCCCGATGGAGCGCGCGCGCGCGCGAGGCAAGCAGTCGCGCGCGCGAGCCCT 136
Db 65 GGATGTGAATCCCGATGGAGCGCGCGCGCGCGAGGCAAGCAGTCGCGCGCGCGAGCCCT 124
Qy 137 GGGGACGGCTCCTGCGTCTGGCGCGGAGGAGGCGGCGGCGGCGGCGGCGGCGGAGC 196
Db 125 GGGGACGGCTCCTGCGTCTGGCGCGGAGGAGGCGGCGGCGGCGGCGGCGGAGC 184
Qy 197 GGGAGTGACCATCGGCGGAGCAGAGTTCGACCTTTCTTCCCGAGCAATAAATCGG 256
Db 185 GGGAGTGACCATCGGCGGAGCAGAGTTCGACCTTTCTTCCCGAGCAATAAATCGG 244
Qy 257 TCTCTGGAGATCAGTGTAGATTTAGTGGATGAAATTCAGGTGAGTGACATGGAG 316
Db 245 TCTCTGGAGATCAGTGTAGATTTAGTGGATGAAATTCAGGTGAGTGACATGGAG 304
Qy 317 ATACGAGCAGCAGTGAACAGTGAATTAACAGCTGAAGTGTGTTAAGAGAGAGATGCC 376
Db 305 ATACGAGCAGCAGTGAACAGTGAATTAACAGCTGAAGTGTGTTAAGAGAGAGATGCC 364
Qy 377 CTTTACAGACTGGGATGTCATCTACTTGGTGTACAGGAAGTGAACCGGAAACACAG 436
Db 365 CTTTACAGACTGGGATGTCATCTACTTGGTGTACAGGAAGTGAACCGGAAACACAG 424
Qy 437 TGGCATACCTCTATGAATCTTTAAGTGAAGAGGAGGATGACACAGAAATCTTTTGAAG 496
Db 425 TGGCATACCTCTATGAATCTTTAAGTGAAGAGGAGGATGACACAGAAATCTTTT--- 480
Qy 497 CTAACAAAGAAAATGTGTTCATGGACCAAGATACCTCAGGTGAGTGCAGGCGGAG 556

Db 383 ----- 382
Qy 596 AGGTGTCTTTGAGGAACCAAGCCATCAACATCGAGCTTCTCCCAAGACCT 655
Db 383 ----- 382
Qy 656 CGGCTCTTCCACGGAGCCTTCTCTCTGAGGGGAGAGGCTTCTCCAGTTGAGGCTG 715
Db 383 ----- 382
Qy 716 GGGGTGTGTCATCTCCCTAAAGGAAGTGTCTCTGTGGCAAGTGAAGTCTCA 775
Db 389 GGGGTGTGTCATCTCCCTAAAGGAAGTGTCTCTGTGGCAAGTGAAGTCTCA 448
Qy 776 GCTTTGCTCAGCTCTCCCAAGCAAGAAAGTGTCTCTGTGGCAAGTGAAGTCTCA 835
Db 449 GCTTTGCTCAGCTCTCCCAAGCAAGAAAGTGTCTCTGTGGCAAGTGAAGTCTCA 508
Qy 836 ATCAGGAGGATTTGGAGCCCTGAAAGGAAGAAATGAGAGAGATGGGACCTTGA 895
Db 509 ATCAGGAGGATTTGGAGCCCTGAAAGGAAGAAATGAGAGAGATGGGACCTTGA 568
Qy 896 ACAGGAGGATTTGGAGCCCTGAAAGGAAGAAATGAGAGAGATGGGACCTTGA 955
Db 569 ACAGGAGGATTTGGAGCCCTGAAAGGAAGAAATGAGAGAGATGGGACCTTGA 628
Qy 956 GAGCAGCGGCTGGGAAGCCAGCAAGATGGAGGAGAGCTGACATGATCTGCGAGG 1015
Db 629 GAGCAGCGGCTGGGAAGCCAGCAAGATGGAGGAGAGCTGACATGATCTGCGAGG 688
Qy 1016 ACCTGTCTCAGCTGCTGAGTTTGAGCCCTGATGACATGATCTGCGAGGCTGCT 1075
Db 689 ACCTGTCTCAGCTGCTGAGTTTGAGCCCTGATGACATGATCTGCGAGGCTGCT 748
Qy 1076 ACTCGGCTGATGAGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1135
Db 749 ACTCGGCTGATGAGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 808
Qy 1136 TCTGTAAAGAACCATCTCTCAACAACTCTGGAAGCATACCTGACATGATCTGCGAGG 1195
Db 809 TCTGTAAAGAACCATCTCTCAACAACTCTGGAAGCATACCTGACATGATCTGCGAGG 868
Qy 1196 AGCTCCAGTGAAGAGATGTGCAAGATGATGATGATGATGATGATGATGATGATGATG 1255
Db 869 AGCTCCAGTGAAGAGATGTGCAAGATGATGATGATGATGATGATGATGATGATGATG 928
Qy 1256 TGCTGAGCCCAAGTCAAGGCTGCTTCTTCTGATGAGAGGAGTTCAGAGGACCTGC 1315
Db 929 TGCTGAGCCCAAGTCAAGGCTGCTTCTTCTGATGAGAGGAGTTCAGAGGACCTGC 988
Qy 1316 TGGAGCTGTGAGCTGTGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA 1375
Db 989 TGGAGCTGTGAGCTGTGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA 1048
Qy 1376 GGCAGTGTCTGATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1435
Db 1049 GGCAGTGTCTGATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1108
Qy 1436 GCGAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1495
Db 1109 GCGAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1168
Qy 1496 CAGCAGTCCAGATTTAGCTGTGCTCTCTGCAAGGAGGAGGAGGAGGAGGAGGAGGAGG 1555
Db 1169 CAGT-----CAGATTTAGCTGTGCTCTCTGCAAGGAGGAGGAGGAGGAGGAGGAGG 1224
Qy 1556 TCCAGCCCATGCCGAGCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1614
Db 1225 T-CAGCCCATGCCGAGCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1283
Qy 1615 CA 1616
Db 1284 CA 1285

RESULT 9

ADA52592
ID ADA52592 standard; cDNA; 2186 BP.

XX

AC ADA52592;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human coding sequence, SEQ ID 160.

XX

KW Cytostatic; Anti-inflammatory; Osteopathic; Neuroprotective; Nootropic;
Gene Therapy; human; secretory protein; membrane proteins; cancer;
inflammatory disease; osteoporosis; neurological disease; gene; ss.

XX

OS Homo sapiens.

XX

PN EP1293569-A2.

XX

PD 19-MAR-2003.

XX

PF 21-MAR-2002; 2002EP-00006586.

XX

PR 14-SEP-2001; 2001JP-00328381.

XX

PR 24-JAN-2002; 2002US-0350433P.

XX

PA (HELI-) HELIX RES INST.

XX

PA (REAS-) RES ASSOC BIOTECHNOLOGY.

XX

PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;

XX

PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;

XX

PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;

XX

DR WPI; 2003-395539/38.

XX

DR P-PSDB; ADA54231.

XX

PT New polynucleotides encoding full-length polypeptides, e.g. secretory

XX

PT and/or membrane proteins, useful for developing medicines for diseases in

XX

PT which the gene is involved, or as target molecules for gene therapy.

XX

PS Claim 1; SEQ ID NO 160; 205pp; English.

XX

CC The present invention relates to novel human secretory or membrane

XX

CC proteins (ADA54072-ADA55710) and their coding sequences (ADA52433-

XX

CC ADA54071). The coding sequences are useful in the gene therapy of

XX

CC diseases caused by abnormalities of the proteins, e.g. cancer,

XX

CC inflammatory diseases, osteoporosis or neurological disease.

XX

SQ Sequence 2186 BP; 493 A; 555 C; 539 G; 599 T; 0 U; 0 Other;

XX

Query Match 32.7%; Score 876.2; DB 7; Length 2186;

XX

Best Local Similarity 99.4%; Pred. No. 1.7e-200;

XX

Matches 890; Conservative 0; Mismatches 3; Indels 2; Gaps 1;

XX

Qy 1772 AGAATTACCTGGCAACCAAGAGGTTTGACATGGAATAAATGATGACGAGGCTCGTGG 1831

Db

671 AGAATTACCTGGCAACCAAGAGGTTTGACATGGAATAAATGATGACGAGGCTCGTGG 730

Qy

1832 CTCTCAGCGGGAGTGTTCCTGCTCTGATTACAGAGTCACGGGAGACACCGTCTGT 1891

Db

731 CTCTCAGCGGGAGTGTTCCTGCTCTGATTACAGAGTCACGGGAGACACCGTCTGT 790

Qy

1892 GTTACTGTCTGCTGCTGCGAGCTTCCGCTGAGCTCACCTATCAGTATCGGAGAACATTC 1951

Db

791 GTTACTGTCTGCTGCTGCGAGCTTCCGCTGAGCTCACCTATCAGTATCGGAGAACATTC 850

Qy

1952 CTGCTTCCAGTTGCCAGTGGCCGTAACATCCGCTCCTGACTGCTACTTGGGCGCTAACT 2011

Db

851 CTGCTTCCAGTTGCCAGTGGCCGTAACATCCGCTCCTGACTGCTACTTGGGCGCTAACT 910

Qy

2012 GCCGCACTCAGGTGAAGAGCTCACACGCGCATGAAATCAATCATATCTGTGAACAGACAA 2071

XX AC ABX73184;
XX DT 18-MAR-2003 (first entry)
XX DE Human novel polynucleotide #12.
XX KW Human; gene; ds; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.
XX OS Homo sapiens.
XX PN US2002132753-A1.
XX PD 19-SEP-2002.
XX PF 17-JAN-2001; 2001US-00764864.
XX PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225477P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 22-AUG-2000; 2000US-0226868P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 08-SEP-2000; 2000US-0229513P.
PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.

XX (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
XX Rosen CA, Ruben SM, Barash SC;
XX PI
XX WPI; 2003-147444/14.
XX P-PSDB; ABUS4924.
XX New polypeptides and nucleic acids, useful in gene therapy for treating,
PT inhibiting or preventing e.g. neural, immune system, muscular,
PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
PT renal disorders.
XX
PS Claim 1; SEQ ID NO 22; 402pp; English.
XX The invention relates to human novel polypeptides and their associated
CC polynucleotides. The polypeptides and polynucleotides are useful in gene
CC therapy for treating, inhibiting or preventing neural disorders, immune
CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
CC leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
CC infarction) and cancerous diseases. Sequences ABX73173-ABX74167 represent
CC human novel polynucleotides of the invention
XX
SQ Sequence 1311 BP; 306 A; 359 C; 399 G; 239 T; 0 U; 8 Other;
Query Match 35.3%; Score 945; DB 7; Length 1311;
Best Local Similarity 81.1%; Pred. No. 3.5e-217;
Matches 1267; Conservative 6; Mismatches 7; Indels 282; Gaps 4;
Qy 56 TCCGGGTTCCGCGCGGGGGGATGTGAATCCGATGAGCGGCCGAGGAAGCAAGC 115
Db 5 TCCGGGTTCCGCGCGGGGGGATGTGAATCCGATGAGCGGCCGAGGAAGCAAGC 64
Qy 116 AGTCGGCGCGCGCGAGCCCTGGGGACGGCTCTGGCTCTGGCGGGGAGGGGGGAGC 175
Db 65 AGTCGGCGCGCGCGAGCCCTGGGGACGGCTCTGGCTCTGGCGGGGAGGGGGGAGC 124
Qy 176 CGCACGTCTCTCTGAGGAAGCGGGAGTGGACCATCGGGCGGAGACGAGGTTCGACCTTT 235
Db 125 CGCACGTCTCTCTGAGGAAGCGGGAGTGGACCATCGGGCGGAGACGAGGTTCGACCTTT 184
Qy 236 CCTTCCCGAGCAATAACTGGTCTCTGGAGATCAGTGTAGAAATTTAGTGGATGAAAAT 295
Db 185 CCTTCCCGAGCAATAACTGGTCTCTGGAGATCAGTGTAGAAATTTAGTGGATGAAAAT 244
Qy 296 CAGGTGAGGTGACACTGGAAGATACCAGCACCACTGGAAACAGTGAATTAACAAGCTGAAG 355
Db 245 CAGGTGAGGTGACACTGGAAGATACCAGCACCACTGGAAACAGTGAATTAACAAGCTGAAG 304
Qy 356 TTGTTAAGAGAGAGACATGCCCTTTACAGACTGGGGATGTCTACTTCTGGTGACAGGA 415
Db 305 TTGTTAAGAGAGAGACATGCCCTTTACAGACTGGGGATGTCTACTTCTGGTGACAGGA 364
Qy 416 AGAATGAACCGGAACACAACTGGGCATACCTCTATGAATCTTTAAGTGAAGCAAGGCA 475
Db 365 AGAATGAACCGGAACACAACTGGGCATACCTCTATGAATCTTTAAGTGAAGCAAGGCA 382
Qy 476 TGACACAAGAAATCTTTTGAAGCTTAACAAGAAAATGTGTTCCATGGGACCAAGATACCT 535
Db 383 ----- 382
Qy 536 CAGGTGAGGTGAGGGCGAGGGGGCGGATCCCGGGTCCCTCCGTCGTCGCGGCACCTC 595

diagnosing, preventing, treating or ameliorating medical conditions and used as food additives or preservatives.

Claim 1: SEO ID NO 22; 980pp; English.

The invention relates to isolated nucleic acid molecules and their encoded secreted proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues and in chemoraxis. The polypeptides can also be used as a food additive or preservative to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors and other nutritional components. The present sequence encodes a novel secreted protein of the invention. Note: The sequence data for this patent did not form part of the printed

Query Match 35.3%; Score 945; DB 4; Length 1311;
Best Local Similarity 81.1%; Pred. No. 3.5e-217;
Matches 1267; Conservative 6; Mismatches 7; Indels 282; Gaps 4;

56	QC	TCGGGTTTCGGCGCGGGCGGGGATGTGAATCCGATGGAGCGCCCGCAGGAAGCGAAGC	115
5	DB	TCGGGTTTCGGCGCGGGCGGGGATGTGAATCCCGATGGAGCGCCCGCAGGAAGCAAGC	64
116	QC	AGTCGCCCGCGCCCGCAGCCCTTGGGAGCGGCTCCTCGGCTCTGGGCGCGGAGAGGCGGAGC	175
65	DB	AGTCGCCCGCGCCCGCAGCCCTTGGGAGCGGCTCCTCGGCTCTGGGCGCGGAGAGGCGGAGC	124
176	QC	CGCAGCTTCCTCTCAGGAGCGGGAGTGGACCATCGGCGCGAGACGAGGTTGCCACCTTT	235
125	DB	CGCAGCTTCCTCTCAGGAGCGGGAGTGGACCATCGGCGCGAGACGAGGTTGCCACCTTT	184
236	QC	CTTTCCCCAGCAATAAACTGGTCTCTGGAGATCACTGTAGAAATGTAGTGGATGAAAAT	295
185	DB	CTTTCCCCAGCAATAAACTGGTCTCTGGAGATCACTGTAGAAATGTAGTGGATGAAAAT	244
296	QC	CAGTCAAGGTGACACTCGGACATACCAAGCACCAGTGGAAACAGTGATTAACAAGCTGAAG	355
245	DB	CAGTCAAGGTGACACTCGGACATACCAAGCACCAGTGGAAACAGTGATTAACAAGCTGAAG	304
356	QC	TTGTTAAGAAGCAGACATGCCCTTTACAGACTGGGGATGTTCATCTACTTGGTGTACAGGA	415
305	DB	TTGTTAAGAARACAGACATGCCCTTTACAGACTGGGGATGTTCATCTACTTGGTGTACAGGA	364
416	QC	AGATGACCGGACACAACTGGCATACCTCTATGAATCTTTAAGTGAAGCAAGCA	475
365	DB	AGATGACCGGAAACACA-----	382
476	QC	TGACACAGAATCCTTTGAAGCTAACAGGAAAAATGTGTTCCATGGGACCAAGATACCT	535
383	DB	-----	382
536	QC	CAGTGCAGGTGCAGGGCGAGGGCGGATCCCGGGTCCCTCCGTCGTCGCCGCCACTC	595
383	DB	-----	382
596	QC	AGGTGTGCTTTGAGGAACCAAGGCATCAACATGACGTACAGCTCTTCCCAACAGCCT	655
383	DB	-----	382

RESULT 8
ABX73184
ID ABX

3184
ABX73184 standard; DNA; 1311 BP.

XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225288P.
PR 14-AUG-2000; 2000US-0225289P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 23-AUG-2000; 2000US-0227182P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234224P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.

PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 13-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239335P.
PR 13-OCT-2000; 2000US-0239337P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241828P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0244647P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0251989P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.

(HJMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI; 2001-488783/53.

F-PSDB; AAU15856.

PT New nucleic acid molecules encoding 461 human secreted proteins for

391 GATGTCATCTACTTGGTGTACAGGAAGTAAGTAAACCGGAACACACACGCTGGCATACCTCTAT 450
Db
301 GATGTCATCTACTTGGTGTACAGGAAGTAAGTAAACCGGAACACACACGCTGGCATACCTCTAT 360
Qy
451 GAATCTTTAAGTGAAGAACAGCAGGATGACACAGAAATCCTTTGAAGTAAACAGGAAAT 510
Db
361 GAATCTTTAAGTGAAGAACAGCAGGATGACACAGAAATCCTTTGAAGTAAACAGGAAAT 420
Qy
511 GTGTTCCATGGAGCAAGATACCTCAGGTGACGGTGCAGGGCGAGGGCGGATCCCGG 570
Db
421 GTGTTCCATGGAGCAAGATACCTCAGGTGACGGTGCAGGGCGAGGGCGGATCCCGG 480
Qy
571 GTCCCTCCGTGCGCCCGCCACTCAGGTGTCCTTTGAGGAACACACAGCCATCAACATCG 630
Db
481 GTCCCTCCGTGCGCCCGCCACTCAGGTGTCCTTTGAGGAACACACAGCCATCAACATCG 540
Qy
631 ACGTGAGACCTTTCGCCACAGCCCTCGGCTTTCACAGAGCCCTTCTCTGAGGGCGA 690
Db
541 ACGTGAGACCTTTCGCCACAGCCCTCGGCTTTCACAGAGCCCTTCTCTGAGGGCGA 600
Qy
691 GAGGTTCTCAGTTGCGGTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGGTCCC 750
Db
601 GAGGTTCTCAGTTGCGGTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGGTCCC 660
Qy
751 TCTGTGCAAGTGAAGTCTCAGCTTTCCAGCTTTCCTCAGCTTTCCTCAGACAGAAAGCTGCG 810
Db
661 TCTGTGCAAGTGAAGTCTCAGCTTTCCAGCTTTCCTCAGCTTTCCTCAGACAGAAAGCTGCG 720
Qy
811 TCCCTTTGCTGTTGGAAACCCAGATCAGAGGATTTGAGCCCTGGAAGAAAGTGA 870
Db
721 TCCCTTTGCTGTTGGAAACCCAGATCAGAGGATTTGAGCCCTGGAAGAAAGTGA 780
Qy
871 AGAGGAGATGGGACCTTGACCTGAAACCGGAGTGTGTCGACAAACCGCTGAGAAAT 930
Db
781 AGAGGAGATGGGACCTTGACCTGAAACCGGAGTGTGTCGACAAACCGCTGAGAAAT 840
Qy
931 GCCAAACCGTCCAGGAGAGTCCAGACAGCGCTGGAGCCGACAGACAGATGGAGGAG 990
Db
841 GCCAAACCGTCCAGGAGAGTCCAGACAGCGCTGGAGCCGACAGACAGATGGAGGAG 900
Qy
991 ACGTGACATGCATCATCTGCCAGGACCTGTGTGACGACACTGCGTGAGTTTGCAGCCCTGC 1050
Db
901 ACGTGACATGCATCATCTGCCAGGACCTGTGTGACGACACTGCGTGAGTTTGCAGCCCTGC 960
Qy
1051 ATGCACAGCTTCTGGCGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGTCT 1110
Db
961 ATGCACAGCTTCTGGCGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGTCT 1020
Qy
1111 ACCTGCCCTGTCCCGTGGAGCGATCTGTAAACACACATCCCTCAACACCTCGTGGAA 1170
Db
1021 ACCTGCCCTGTCCCGTGGAGCGATCTGTAAACACACATCCCTCAACACCTCGTGGAA 1080
Qy
1171 GCATACCTCATCCAGCATCCAGACAGAGTGCAGTGAAGATGTGCAAGATATGGAT 1230
Db
1081 GCATACCTCATCCAGCATCCAGACAGAGTGCAGTGAAGATGTGCAAGATATGGAT 1140
Qy
1231 GCCAGGAATAAATCACTCAAGACATCTGACGACCCCAAGTCAAGCGCTCTTTTCTGAT 1290
Db
1141 GCCAGGAATAAATCACTCAAGACATCTGACGACCCCAAGTCAAGCGCTCTTTTCTGAT 1200
Qy
1291 GAAGAAGGGAGTTTCAGAGGACCTGCTGAGCTGTGACGTTGACAGTGTCTCTAGAC 1350
Db
1201 GAAGAAGGGAGTTTCAGAGGACCTGCTGAGCTGTGACGTTGACAGTGTCTCTAGAC 1260
Qy
1351 ATTAGCCAGGATACGTCGTGCGGAGTCTCTGAGTACAGAGGAGCGGCGGCGAG 1410
Db
1261 ATTAGCCAGGATACGTCGTGCGGAGTCTCTGAGTACAGAGGAGCGGCGGCGAG 1320
Qy
1411 CCTCCCACTCTCCAGCACCCGAGGCGAGCCAGGAGCCCCACAGGCGCTGGGGGATGCA 1470
Db
1321 CCTCCCACTCTCCAGCACCCGAGGCGAGCCAGGAGCCCCACAGGCGCTGGGGGATGCA 1380

1471 CCTCCCACTCTCCAGCACCCGAGGCGAGCCAGGATTCAGTGTGCTTCAAGGA 1530
Db
1381 CCTCCCACTCTCCAGCACCCGAGGCGAGCCAGGATTCAGTGTGCTTCAAGGA 1440
Qy
1531 AGCCAGCCCTGTGACACCTGCTTCCAGCCATGCCGACCGGAGAGCGGCGAG 1590
Db
1441 AGCCAGCCCTGTGACACCTGCTTCCAGCCATGCCGACCGGAGAGCGGCGAG 1500
Qy
1591 CAGGACCCCGCTGTGCGCCCTCAGCAGTGTGCGGTCTGCTGACGCTTTTTCGCACCTG 1650
Db
1501 CAGGACCCCGCTGTGCGCCCTCAGCAGTGTGCGGTCTGCTGACGCTTTTTCGCACCTG 1560
Qy
1651 TACTGGGGTGTGACCCGAGCCGCTGTACGGCTGCTGCGCCCTTTTGTGAGTCAAC 1710
Db
1561 TACTGGGGTGTGACCCGAGCCGCTGTACGGCTGCTGCGCCCTTTTGTGAGTCAAC 1620
Qy
1711 CTGGGTGACAAAGTGTCTGACCGGCTGTGAAACAAACAGCTACGAGTCAGACATCCCTG 1770
Db
1621 CTGGGTGACAAAGTGTCTGACCGGCTGTGAAACAAACAGCTACGAGTCAGACATCCCTG 1680
Qy
1771 AAGAATTACTGGCAACAGAGGTTTGACATGGAATAAATGTTGACCGAGAGCCCTCGTG 1830
Db
1681 AAGAATTACTGGCAACAGAGGTTTGACATGGAATAAATGTTGACCGAGAGCCCTCGTG 1740
Qy
1831 GCTCTCAGCGGGAGTGTCTGCTGCTGATTAACAGAGTCACGGAGACACCGTTCG 1890
Db
1741 GCTCTCAGCGGGAGTGTCTGCTGCTGATTAACAGAGTCACGGAGACACCGTTCG 1800
Qy
1891 TGTACTGTGTGCGCTGCGCAGCTTCCGTGAGCTGACCTATCAGTATCGGAGAACATT 1950
Db
1801 TGTACTGTGTGCGCTGCGCAGCTTCCGTGAGCTGACCTATCAGTATCGGAGAACATT 1860
Qy
1951 CTGCTTCCGAGTTGCGCAGTGCCTGTAACATCCGCTCTGAGTCTACTTGGGGCGGTAAC 2010
Db
1861 CTGCTTCCGAGTTGCGCAGTGCCTGTAACATCCGCTCTGAGTCTACTTGGGGCGGTAAC 1920
Qy
2011 TGCCGCACTCAGGTGAAAGCTCACCACGCGCATCAATCAATCATATCTGTGAACAGACA 2070
Db
1921 TGCCGCACTCAGGTGAAAGCTCACCACGCGCATCAATCAATCATATCTGTGAACAGACA 1980
Qy
2071 AGGTTCAAAAATAA 2085
Db
1981 AGGTTCAAAAATAA 1995

RESULT 6
AA188903/c
ID AA188903 standard; cDNA; 2259 BP.
XX
AC AA188903;
XX
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 8963.
XX
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation; ss.
XX
OS Homo sapiens.
XX
FN WO200164835-A2.
PN
PD 07-SEP-2001.
XX
XX
PF 26-FEB-2001; 2001WO-US004927.
XX
PR 28-FEB-2000; 2000US-00515126.
PR 18-MAY-2000; 2000US-00577409.
XX
XX
PA (HYSE-) HYSEQ INC.

1636 CTTTCTGCCACCTGTACTGGGCTGACCCGACCGGCTGTACTGGCTGCTGGCCCG 1695
1518 CTTTCTGCCACCTGTACTGGGCTGACCCGACCGGCTGTACTGGCTGCTGGCCCG 1577
1696 TTTTGTGAGCTCAACCTGGGTGACAGTGTCTGGAGCGGCTGTGTAACCAACACAGCTAC 1755
1578 TTTTGTGAGCTCAACCTGGGTGACAGTGTCTGGAGCGGCTGTGTAACCAACACAGCTAC 1637
1756 GAGTCAGACATCTGGAAGATTAACCTGGGACACAGAGGTTTGACATGGAAGAAACATGTTG 1815
1638 GAGTCAGACATCTGGAAGATTAACCTGGGACACAGAGGTTTGACATGGAAGAAACATGTTG 1697
1816 ACCGAGAGCTCTGGGCTCTCCAGCGGGAGTGTCTGCTGTCTGATTACAGAGTCACG 1875
1698 ACCGAGAGCTCTGGGCTCTCCAGCGGGAGTGTCTGCTGTCTGATTACAGAGTCACG 1757
1876 GGAGACACCTCTCTGTACTGTCTGCTGGCTGCGGAGCTTCGCTGAGCTGACCTATCAG 1935
1758 GGAGACACCTCTCTGTACTGTCTGCTGGCTGCGGAGCTTCGCTGAGCTGACCTATCAG 1817
1936 TATCGGAGAACATCTCTGCTCTCCAGTTCGAGTGGCCGCTTAACATCCCGTCTGACTGC 1995
1818 TATCAGCAGAACATCTCTGCTCTCCAGTTCGAGTGGCCGCTTAACATCCCGTCTGACTGC 1877
1996 TACTGGGCGGTAACTCCGCACTCAGGTGAAGCTCACCAGCGCATGAATTCATCAT 2055
1878 TACTGGGCGGTAACTCCGCACTCAGGTGAAGCTCACCAGCGCATGAATTCATCAT 1937
2056 ATCTGTACAGACAGCAAGGTTCAAACTAAGCATCCAGAGCCCTGAGCAGCTTTCAGCA 2115
1938 ATCTGTACAGACAGCAAGGTTCAAACTAAGCATCCAGAGCCCTGAGCAGCTTTCAGCA 1997
2116 CTGAGGTGAAGAGAGCGGTGTTTTAAATATACAGACAAGCAGTCAAGGTGTTTTCAC 2175
1998 CTGAGGTGAAGAGAGCGGTGTTTTAAATATACAGACAAGCAGTCAAGGTGTTTTCAC 2057
2176 AGCCCTGTAGGAGGAGCGAGGTCCTCGACAGGTCTCTGGGTGACTCTCTGTG 2235
2058 AGCCCTGTAGGAGGAGCGAGGTCCTCGACAGGTCTCTGGGTGACTCTCTGTG 2117
2236 GAGCTTTTATCCCTCTGAGTGAGACCTCTCCAGAGCCCGGGCGCGCAGCCGCCCTC 2295
2118 GAGC--TTTACCCTCTGAGTGAGACCTCTCCAGAGCCCGGGCGCGCAGCCGCCCTC 2175
2296 CTGAGAGCGCTGGGAGGCTGTGTGGCATCAGCAGAGAGCGAAGCCTTCTGTA 2355
2176 CTGAGAGCGCTGGGAGGCTGTGTGGCATCAGCAGAGAGCGAAGCCTTCTGTA 2235
2356 ACATGCGGCGCTCCGCGGAGAGGCGAGTGTCTCTTTGTATCATTTTCCGAAACTAC 2415
2236 ACATGCGGCGCTCCGCGGAGAGGCGAGTGTGTCTTTGTATCATTTTCCGAAACTAC 2295
2416 AGTTAAAGCGAAGTCTGTTTTCAAGAAAGTTTCAAGGAGAGGCGCAAGTTTATCAAA 2475
2296 AGTTAAAGCGAAGTCTGTTTTCAAGAAAGTTTCAAGGAGAGGCGCAAGTTTATCAAA 2355
2476 AACATTTTTCAGGAGAGGAGCATTAAGTTTACAGCTTACAGAGCTACACATATCTCT 2535
2356 AACATTTTTCAGGAGAGGAGCATTAAGTTTACAGCTTACAGAGCTACACATATCTCT 2415
2536 GCTCTGGGAAACACACAGCATTTTATCTATTTTATTTAATAGTTTGGTGTATC 2595
2416 GCTCTGGGAAACACACAGCATTTTATCTATTTTATTTAATAGTTTGGTGTATC 2475
2596 TTCTAATAGATTTAATGTACAACTGTAGCAAAATATATATATTTATTTATCAAA 2655
2476 TTCTAATAGATTTAATGTACAACTGTAGCAAAATATATATATTTATTTATCAAA 2535
2656 ATTGACAAAAA 2666
2536 ATTGACTAAAA 2546

RESULT 5
AAF89709
ID AAF89709 standard; DNA; 1995 BP.
XX
AC AAF89709;
XX
DT 22-AUG-2001 (first entry)
XX
DE Nucleotide sequence of a human ring finger protein designated FHAR1.
XX
KW FHAR1; RING finger protein; cancer; vaccine; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..1995
FT /*tag= a
FT /product= "ring finger protein FHAR1"
XX
FN WO200142430-A1.
XX
PD 14-JUN-2001.
XX
PF 07-DEC-2000; 2000WO-US033094.
XX
PR 08-DEC-1999; 99US-00456876.
XX
PA (SMK) SMITHKLINE BEECHAM CORP.
XX
PI Zhou B, Zhu Y, Chaturvedi P, Hurler MR, Li X;
XX
DR WPI: 2001-381663/40.
DR P-PSDB; AAB83843.
XX
PT New FHAR1 polypeptide, a member of the RING finger protein family for
PT diagnosing and treating cancer, and for use in anti-cancer vaccines.
XX
PS Claim 2; Page 18-19; 28pp; English.
XX
CC The present sequence encodes a FHAR1 polypeptide, which is a member of
CC the RING finger protein family. FHAR1 is useful in the treatment of
CC cancer, and as a vaccine for inducing an immunological response in a
CC mammal. FHAR1 polynucleotides may also be used as a diagnostic reagent
CC through detection of mutations in the associated gene, and for chromosome
CC localization studies, and tissue expression studies. FHAR1 antibodies are
CC useful to isolate and to identify clones expressing the polypeptides, or
CC to purify the polypeptides by affinity chromatography and to treat cancer
XX
SQ Sequence 1995 BP; 465 A; 563 C; 580 G; 387 T; 0 U; 0 Other;
Query Match 74.5%; Score 1995; DB 5; Length 1995;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1995; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 91 ATGGAGCGCGCCGAGGAGGCAAGCAGTCGCGCGCGCGCGCGCGCGCGCGCTCTG 150
DB 1 ATGGAGCGCGCCGAGGAGGCAAGCAGTCGCGCGCGCGCGCGCGCGCGCGCTCTG 60
QY 151 CGTCTGGCGCGGAGGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 210
DB 61 CGTCTGGCGCGGAGGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 120
QY 211 GGCGCGGAGACGAGGTTCGCACTTTCTTCCCGCAAGATAAATCTGTCTCTGGAGATCAC 270
DB 121 GGCGCGGAGACGAGGTTCGCACTTTCTTCCCGCAAGATAAATCTGTCTCTGGAGATCAC 180
QY 271 TGTAGATTTGTAGTGAATGAATTCAGTTCAGGTGACATCGAGATACAGACACCACT 330
DB 181 TGTAGATTTGTAGTGAATGAATTCAGTTCAGGTGACATCGAGATACAGACACCACT 240
QY 331 GGAACAGTGAATTAACAAGCTGAAGTTTGTAAAGAGCAGACATGCCCTTTTACAGACTGG 390
DB 241 GGAACAGTGAATTAACAAGCTGAAGTTTGTAAAGAGCAGACATGCCCTTTTACAGACTGG 300

598 TCCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCTCAGCTCTCCAGAGCAGAAAGAC 657
807 TGGCTCTCTTTTCTGCTGTGGAACCCAGGATCAGGAGGATTTGGAGCCCGTGAAGAGAA 866
658 TGGCTCTCTTTTCTGCTGTGGAACCCAGGATCAGGAGGATTTGGAGCCCGTGAAGAGAA 717
867 AATGAGAGGAGTGGGACCTTGACCTGAACGGGCAAGTTGTTGGTGCACACCGGTAG 926
718 AATGAGAGGAGTGGGACCTTGACCTGAACGGGCAAGTTGTTGGTGCACACCGGTAG 777
927 AATGAGAGGAGTGGGACCTTGACCTGAACGGGCAAGTTGTTGGTGCACACCGGTAG 986
778 AATGAGAGGAGTGGGACCTTGACCTGAACGGGCAAGTTGTTGGTGCACACCGGTAG 837
987 GAGAGCGCTGACATGATCATCTGCGAGGACCTGCTGCAGCTGCGTGGTGGTGGTGG 1046
838 GAGAGCGCTGACATGATCATCTGCGAGGACCTGCTGCAGCTGCGTGGTGGTGGTGG 897
1047 CTGCATGCAACAGCTTTGCGCGGCTGCTGCTGCGGCTGATGAGGAGCTGCTGCTGCTG 1106
898 CTGCATGCAACAGCTTTGCGCGGCTGCTGCTGCGGCTGATGAGGAGCTGCTGCTGCTG 957
1107 TCCTACTGCGCTGCTGCGGCTGAGGAGCTGCTGTAACACCATCTCTCAACACCTGCT 1166
958 TCCTACTGCGCTGCTGCGGCTGAGGAGCTGCTGTAACACCATCTCTCAACACCTGCT 1017
1167 GGAAGCATACCTCATCAGCATCCAGACAGAGTCCGAGTGAAGAGATGTGCAAGATAT 1226
1018 GGAAGCATACCTCATCAGCATCCAGACAGAGTCCGAGTGAAGAGATGTGCAAGATAT 1077
1227 GGAAGCATACCTCATCAGCATCCAGACAGAGTCCGAGTGAAGAGATGTGCAAGATAT 1286
1078 GGAAGCATACCTCATCAGCATCCAGACAGAGTCCGAGTGAAGAGATGTGCAAGATAT 1137
1287 TGAATGAAGAGGAGTTCAGAGACCTGCTGAGGCTGTCAGAGTTCAGAGTTCAGAGTTC 1346
1138 TGAATGAAGAGGAGTTCAGAGACCTGCTGAGGCTGTCAGAGTTCAGAGTTCAGAGTTC 1197
1347 AGACATTAGCAGCCATACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1406
1198 AGACATTAGCAGCCATACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1257
1407 GAGCCTCCCATCTGCCAGCACCCAGGCGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAG 1466
1258 GAGCCTCCCATCTGCCAGCACCCAGGCGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAG 1317
1467 TGACACCTCCACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1526
1318 TGACACCTCCACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1377
1527 AGAAGCAGCCCTGTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1586
1378 AGAAGCAGCCCTGTGCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1437
1587 CGAGCAGGACCCGCTGCTGCCCTCAGCAGTGTGCGGCTGCTGCTGCTGCTGCTGCTG 1646
1438 CGAGCAGGACCCGCTGCTGCCCTCAGCAGTGTGCGGCTGCTGCTGCTGCTGCTGCTG 1497
1647 CTGTACTGCGGCTGCAACCGGACCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1706
1498 CTGTACTGCGGCTGCAACCGGACCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1557
1707 CAACCTGGGTGCAAGTGTCTGACCGGCTGCTGACCAACACAGCTCAGGTCAGACAT 1766
1558 CAACCTGGGTGCAAGTGTCTGACCGGCTGCTGACCAACACAGCTCAGGTCAGACAT 1617
1767 CTTGAAGAAATACCTGGCAACCGAGGTTGACATGGAAGAAACATGTTGACCGAGAGCT 1826
1618 CTTGAAGAAATACCTGGCAACCGAGGTTGACATGGAAGAAACATGTTGACCGAGAGCT 1677
1827 CTTGGCTCTCCAGCGGGAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1886

1678 CGTGGCTCTCCAGCGGGAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1737
1887 TCTGTGTTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1946
1738 TCTGTGTTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1797
1947 CATTCCTGCTTCCAGTGTCCAGTGGCCGTAAACATCCCGTCCCTGCTGCTGCTGCTG 2006
1798 CATTCCTGCTTCCAGTGTCCAGTGGCCGTAAACATCCCGTCCCTGCTGCTGCTGCTG 1857
2007 TAACTGCGCACTCAGGTGAAGCTCACCGCCATGAATTCATCATATCTGTTGAACA 2066
1858 TAACTGCGCACTCAGGTGAAGCTCACCGCCATGAATTCATCATATCTGTTGAACA 1917
2067 GACAAGGTTTCAAACTAAGCATCCAGAGCCCTGAGCAGCTTTCAGCAGCTGAGGAGTGA 2126
1918 GACAAGGTTTCAAACTAAGCATCCAGAGCCCTGAGCAGCTTTCAGCAGCTGAGGAGTGA 1977
2127 GAGAGCGTGTGTTTAAATACAGAGCAAGCAAGCTCAAGTGTGTTTTCAGAGCCCTGAG 2186
1978 GAGAGCGTGTGTTTAAATACAGAGCAAGCAAGCTCAAGTGTGTTTTCAGAGCCCTGAG 2037
2187 GGAAGGAGCGAGGCTCTCCGACAGGTGCTCTGGGGTGAATCTCTGCTGAGCTTTTAC 2246
2038 GGAAGGAGCGAGGCTCTCCGACAGGTGCTCTGGGGTGAATCTCTGCTGAGC--TTTAC 2095
2247 CCTCTGATGAGACCTTCCCGAGAGCCCGGGGCGCAGCCGCTCTCTGTTGAGCGC 2306
2096 CCTCTGATGAGACCTTCCCGAGAGCCCGGGGCGCAGCCGCTCTCTGTTGAGCGC 2155
2307 TGGCAGGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2366
2156 TGGCAGGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2215
2367 TCCGCGCGAGAGGGCGAGTGTGCTCTTTTGTACATTTCCGAACTACAGTTAAAGCAG 2426
2216 TCCTGCCGAGAGGGCGAGTGTGCTCTTTTGTACATTTCCGAACTACAGTTAAAGCAG 2275
2427 AAGTCTGTTTTCAGAAAAGTTTTCAGGAGAGGAGGAGGAGTTTTCAGAAAAGTTTTC 2486
2276 AAGTCTGTTTTCAGAAAAGTTTTCAGGAGAGGAGGAGGAGTTTTCAGAAAAGTTTTC 2335
2487 AGGAGAGGAGAGTAAAGTTTACAGCTTACAGGAGTACACAAATATCTGCTGCTGGAA 2546
2336 AGGAGAGGAGAGTAAAGTTTACAGCTTACAGGAGTACACAAATATCTGCTGCTGGAA 2395
2547 AACACAGCATTTTATCTATTTTATTTTAAATAGGTTTGGTGTATCTCTTAATAAGA 2606
2396 AACACAGCATTTTATCTATTTTATTTTAAATAGGTTTGGTGTATCTCTTAATAAGA 2455
2607 TTTAAATGTCAAACTGAGCAGAAATATATAATTTTAAATTTACAAATTTGACAAAA 2666
2456 TTTAAATGTCAAACTGAGCAGAAATATATAATTTTAAATTTTAAATTTGACTAAAA 2515

RESULT 4

ABN59646

ID ABN59646 standard; cDNA; 3181 BP.

XX ABN59646;

XX 28-JUN-2002 (first entry)

XX Novel human coding sequence SEQ ID NO: 57.

XX Human; antianaemic; vulnery; antiinflammatory; immunomodulator;
XX antineuritic; cerebroprotective; cytosolic; rheumatic; gene therapy;
XX neuroprotective; antiparkinsonian; protein therapy; ESR;
XX expressed sequence tag; gene; ss.

OS Homo sapiens.

FN W0200222660-R2.

1217	QY	TGCAAAAGTATGATGCGAGGAAATAAAATCACTCAAGACATGCTGAGCCCAAAAGTCAGCG	1276
1169	Db	TGCAAAAGTATGATGCGAGGAAATAAAATCACTCAAGACATGCTGAGCCCAAAAGTCAGCG	1228
1277	QY	GGTCTTTTTCTGATGAAGAAGGAGTTACAGAGCACTGCTGAGCTGTACAGCGTTTGACA	1336
1229	Db	GGTCTTTTTCTGATGAAGAAGGAGTTACAGAGCACTGCTGAGCTGTACAGCGTTTGACA	1288
1337	QY	GTGAGTCTCAGACATTAAGCCAGCCATAAGTCGTGTGCGGCGAGTGTCTCTGAGTACAGAA	1396
1289	Db	GTGAGTCTCAGACATTAAGCCAGCCATAAGTCGTGTGCGGCGAGTGTCTCTGAGTACAGAA	1348
1397	QY	GGCAGCGCGGAGCCTCCCACTGCCACAGACCCGAGGCGGAGCCAGAGCCCCACAGG	1456
1349	Db	GGCAGCGCGGAGCCTCCCACTGCCACAGACCCGAGGCGGAGCCAGAGCCCCACAGG	1408
1457	QY	CCCTGGGGGATGACCCCTCCACGTCCGCTGAGCCTTGACGACAGCAGTCCAGGATTACGTGT	1516
1409	Db	CCCTGGGGGATGACCCCTCCACGTCCGCTGAGCCTTGACGACAGCAGTCCAGGATTACGTGT	1468
1517	QY	GCCTCTCAAGGAAGCCAGCCCTGTGACACTGCTGCTTCAGAGCCCATGCCGACCGGA	1576
1469	Db	GCCTCTCAAGGAAGCCAGCCCTGTGACACTGCTGCTTCAGAGCCCATGCCGACCGGA	1528
1577	QY	GAGCGAGGCGGAGCAGGACCCGCGTGTGCGCCCTCAGCAGTGTGCGGTCTGCTCTCAGC	1636
1529	Db	GAGCGAGGCGGAGCAGGACCCGCGTGTGCGCCCTCAGCAGTGTGCGGTCTGCTCTCAGC	1588
1637	QY	CTTTCTGCCACCTGTACTGCGGCTGCACCGAGACCGCTGTCTACGCGTGCCTGGCCCGT	1696
1589	Db	CTTTCTGCCACCTGTACTGCGGCTGCACCGAGCCGCTGTCTACGCGTGCCTGGCCCGT	1648
1697	QY	TTTGTGAGTCAACCTGGGTGACAAGTGTCTGGACGGCGTCTGGAACAAACAGAGTACG	1756
1649	Db	TTTGTGAGTCAACCTGGGTGACAAGTGTCTGGACGGCGTCTGGAACAAACAGAGTACG	1708
1757	QY	AGTCAGACATCTCTGAAGAAATTACCTGGCAACACAGAGTTTGACATGGAAAAACATGTTGA	1816
1709	Db	AGTCAGACATCTCTGAAGAAATTACCTGGCAACACAGAGTTTGACATGGAAAAACATGTTGA	1768
1817	QY	CCGAGAGCTCGTGGCTCTCCAGCGGGAGTGTTCGTCTCTGATTACAGAGTACACGG	1876
1769	Db	CCGAGAGCTCGTGGCTCTCCAGCGGGAGTGTTCGTCTCTGATTACAGAGTACACGG	1828
1877	QY	GAGACACCGTTCGTGTTACTGTGTGGCTTGCGCAGCTTCGCTGAGCTGACCTATCAGT	1936
1829	Db	GAGACACCGTTCGTGTTACTGTGTGGCTTGCGCAGCTTCGCTGAGCTGACCTATCAGT	1888
1937	QY	ATCGGAGAAACATTCCTGCTTCGAGTTGCGAGTGGCGGTAAACATCCGTCCTGACTGCT	1996
1889	Db	ATCGGAGAAACATTCCTGCTTCGAGTTGCGAGTGGCGGTAAACATCCGTCCTGACTGCT	1948
1997	QY	ACTGGGCGGTAACTCCGCACTCAGGTGAAGCTCCACACGCCATGAATTCAAATCATA	2056
1949	Db	ACTGGGCGGTAACTCCGCACTCAGGTGAAGCTCCACACGCCATGAATTCAAATCATA	2008
2057	QY	TTGTGAACAGACAAAGTTCAAAAAATAAGATCCAGAGCCCTGAGAGCTTTTACGAC	2116
2009	Db	TTGTGAACAGACAAAGTTCAAAAAATAAGATCCAGAGCCCTGAGAGCTTTTACGAC	2068
2117	QY	TGGAGTGAAGAGAGCGTGTTTTTTAAATATACAGACAAGCAGTCAAGGTGTTTTCA	2176
2069	Db	TGGAGTGAAGAGAGCGTGTTTTTTAAATATACAGACAAGCAGTCAAGGTGTTTTCA	2128
2177	QY	GCCTCTGAGGGGAAGGACCGAGGTCTCCGACAGTGTCTTGGGTGACTCTTCTGTGG	2236
2129	Db	GCCTCTGAGGGGAAGGACCGAGGTCTCCGACAGTGTCTTGGGTGACTCTTCTGTGG	2188
2237	QY	AGCTTTTATCCCTCTCAGTGTAGACCTCCCGAGAGCCCGGGGGCGCAGCCCGCCCTCC	2296
2189	Db	AGCTTTTATCCCTCTCAGTGTAGACCTCCCGAGAGCCCGGGGGCGCAGCCCGCCCTCC	2248
2297	QY	TGCTGAGCGCTGGCGAGGGCTCGTGTGTGGCATCAGCAGCAGACGACGAAGCCTTCTGTAA	2356

QY	1681	GGCTGCTGGCCCGCTTTTGTGAGCTCAACCTGGGTGACAAAGTGTCTGGACGGCGTGTG	1740
Db	1681	GGCTGCTGGCCCGCTTTTGTGAGCTCAACCTGGGTGACAAAGTGTCTGGACGGCGTGTG	1740
QY	1741	AACAACAACAGCTACAGAGTACAGATCTCTGAAGATTTACCTGGCAACACAGAGTTTGACA	1800
Db	1741	AACAACAACAGCTACAGAGTACAGATCTCTGAAGATTTACCTGGCAACACAGAGTTTGACA	1800
QY	1801	TGGAATAAATGTTGACCGAGAGCTCTGGTCTCTCAGCGGGAGTGTTCGTCTGTCT	1860
Db	1801	TGGAATAAATGTTGACCGAGAGCTCTGGTCTCTCAGCGGGAGTGTTCGTCTGTCT	1860
QY	1861	GATTACAGAGTACAGGAGACACCGTCTGTGTACTGTCTGTCTGTCTGTCTGTCTGTCT	1920
Db	1861	GATTACAGAGTACAGGAGACACCGTCTGTGTACTGTCTGTCTGTCTGTCTGTCTGTCT	1920
QY	1921	GAGCTGACCTATCAGTATCGGAGAAATTCCTTCGAGTTGCGAGTTGCGCGGTAAACA	1980
Db	1921	GAGCTGACCTATCAGTATCGGAGAAATTCCTTCGAGTTGCGAGTTGCGCGGTAAACA	1980
QY	1981	TCCCGTCTGACTGCTACTGGGGCGGTAACTGCGGCACTCAGGTGAAGCTCACCAGCC	2040
Db	1981	TCCCGTCTGACTGCTACTGGGGCGGTAACTGCGGCACTCAGGTGAAGCTCACCAGCC	2040
QY	2041	ATGAATTTCAATCATATCTGTGAACAGACAAAGTTTCAAAATTAAGCATCCAGAGCCCT	2100
Db	2041	ATGAATTTCAATCATATCTGTGAACAGACAAAGTTTCAAAATTAAGCATCCAGAGCCCT	2100
QY	2101	GAGCAGTTTCACACTGAGAGTGAAGAGCGGTGTTTTAAATACAGAGCAACAGC	2160
Db	2101	GAGCAGTTTCACACTGAGAGTGAAGAGCGGTGTTTTAAATACAGAGCAACAGC	2160
QY	2161	TCAAGGTGTTTTACAGCCCTCTGAGGAAGGACGAGGCTCTCCAGAGGTGCTCTGG	2220
Db	2161	TCAAGGTGTTTTACAGCCCTCTGAGGAAGGACGAGGCTCTCCAGAGGTGCTCTGG	2220
QY	2221	GGTACTCTTCTGTGAGCTTTTACCTCTGAGTGAACCTCCCGAGAGCCCGGGG	2280
Db	2221	GGTACTCTTCTGTGAGCTTTTACCTCTGAGTGAACCTCCCGAGAGCCCGGGG	2280
QY	2281	CCGAGCCCGCTCTGTTGAGCGCTGGCGAGGCTCGTGGTGGCATCAGAGCAGAGA	2340
Db	2281	CCGAGCCCGCTCTGTTGAGCGCTGGCGAGGCTCGTGGTGGCATCAGAGCAGAGA	2340
QY	2341	CGAAGCTTTCTGTAAACATCGCCCGCTCCCGAGAGGGGCAAGTTTGTCTTTGTAC	2400
Db	2341	CGAAGCTTTCTGTAAACATCGCCCGCTCCCGAGAGGGGCAAGTTTGTCTTTGTAC	2400
QY	2401	ATTTTCGAACTACAGTTAAAGCAGAGTCTGTTTTCAGGAAAGTTTCAAGGGAGAG	2460
Db	2401	ATTTTCGAACTACAGTTAAAGCAGAGTCTGTTTTCAGGAAAGTTTCAAGGGAGAG	2460
QY	2461	GGCAAGTTTATCAAAACATTTGTTTCAGGAGAGGGAGCATAGTTTACAGCCTACAGGA	2520
Db	2461	GGCAAGTTTATCAAAACATTTGTTTCAGGAGAGGGAGCATAGTTTACAGCCTACAGGA	2520
QY	2521	CGTACACATATCTGCTGCTGGAAACACAGCAATTTATCTATTTTATTTAATA	2580
Db	2521	CGTACACATATCTGCTGCTGGAAACACAGCAATTTATCTATTTTATTTAATA	2580
QY	2581	GGTTTGTGCTTATCTTCTAATAAGATTTAAATGTCACAACTGTAGCAATAATATA	2640
Db	2581	GGTTTGTGCTTATCTTCTAATAAGATTTAAATGTCACAACTGTAGCAATAATATA	2640
QY	2641	ATTATAATTTACAAATTTGACAAAAAATAAAAAA	2679
Db	2641	ATTATAATTTACAAATTTGACAAAAAATAAAAAA	2679
RESULT 2			
AAHL4542			
ID			

AAHL4542 standard; cDNA; 2639 BP.

CC checkpoint protein Chfr (see AAB20219) having a forkhead associated
CC domain (FHA) and a ring finger domain. The protein is required for
CC regulation of the transition of cells from prophase to metaphase during
CC mitosis. It has ubiquitin-protein ligase activity. The Chfr checkpoint
CC was evident in primary human cells, but was inactivated in 4 of 8 human
CC cancer cell lines. In U2OS cells, a mutation was identified, which caused
CC a Val to Met amino acid substitution in the highly conserved C-terminal
CC Cys-rich region of the Chfr protein. In the absence of the Chfr
CC checkpoint cells subjected to mitotic stress condensed their chromosomes
CC despite failing to separate their chromosomes. Chfr may monitor
CC centrosome separation. Inactivation of the Chfr gene in human cancer is
CC theorized to underlie the increased sensitivity of cancer cells to
CC antimitotic drugs. Nucleic acids comprising the present sequence, or
CC sequences encoding at least amino acids 31-103, 303-346, 476-641 (or
CC their antisense sequences) are claimed. The Chfr cDNA was isolated from
CC an expressed sequence tag database sequence for cDNAs with FHA motifs.
CC Claimed methods of determining the tumorigenic potential of a cell
CC comprise examining the cell for the presence of Chfr nucleic acid
CC (absence or mutation indicating predisposition to tumorigenesis upon
CC exposure to mitotic stress). Also claimed is a diagnostic agent, e.g. an
CC antisense fragment of the present sequence, that binds to the Chfr
CC nucleic acid, and a diagnostic kit for detecting tumorigenic potential
CC of a cell. A composition which inhibits the biological activity of Chfr
CC may comprise a ligand selected from an antibody or its fragment. The Chfr
CC inhibitor is used in a claimed method of retarding the growth of a cancer
CC cells. Chfr polypeptides are useful in screening for drugs which can
CC inhibit the activity of Chfr in a cancer cell, rendering the cell more
CC sensitive to additional antitumour therapies

XX Sequence 2679 BP; 650 A; 715 C; 764 G; 550 T; 0 U; 0 Other;

Query Match 100.0%; Score 2679; DB 5; Length 2679;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AAGATTTCGGCAGAGCGCCCAATGCTCTTTGACAGCGCGCGGCGCAGCGGTTCCGG 60
DB 1 AAGATTTCGGCAGAGCGCCCAATGCTCTTTGACAGCGCGCGGCGCAGCGGTTCCGG 60
QY 61 GTTCGGCGCGGGCGGGGATGTGAATCCGATGAGCGCGCGCGGCGCAGAGCGCATGCG 120
DB 61 GTTCGGCGCGGGCGGGGATGTGAATCCGATGAGCGCGCGCGGCGCAGAGCGCATGCG 120
QY 121 CCGCGCGCGAGCCCTTGGGACAGCTCTCTGCTGCGGCGCGGAGGCGGCGCGCAC 180
DB 121 CCGCGCGCGAGCCCTTGGGACAGCTCTCTGCTGCGGCGCGGAGGCGGCGCGCAC 180
QY 181 GTCTCTCTGAGGAGCGGAGTGAGACCATCGGCGGAGAGCAGGTTGCGACCTTCTCTTC 240
DB 181 GTCTCTCTGAGGAGCGGAGTGAGACCATCGGCGGAGAGCAGGTTGCGACCTTCTCTTC 240
QY 241 CCAGCAATAACTGGTCTCTGGAGATCACTGTAGATTCTAGTGGATGAAATCAGGT 300
DB 241 CCAGCAATAACTGGTCTCTGGAGATCACTGTAGATTCTAGTGGATGAAATCAGGT 300
QY 301 CAGGTGACACTGGAAGATACAGCACAGTGGAAACAGTATTAAACAGCTGAAGGTTGTT 360
DB 301 CAGGTGACACTGGAAGATACAGCACAGTGGAAACAGTATTAAACAGCTGAAGGTTGTT 360
QY 361 AAGAGCAGACATGCCCTTTACAGACTGGGGATGTCATCTTCTGGTACAGAGAGAT 420
DB 361 AAGAGCAGACATGCCCTTTACAGACTGGGGATGTCATCTTCTGGTACAGAGAGAT 420
QY 421 GAACCGGAAACACACGTGGCATACCTCTATGAATCTTTTAAGTGAAGACGAGCATGACA 480
DB 421 GAACCGGAAACACACGTGGCATACCTCTATGAATCTTTTAAGTGAAGACGAGCATGACA 480
QY 481 CAAGAATCTTTGAAGCTAACAGAGAAATGTGTTCATGGGACCAAGATACCTCAGGT 540
DB 481 CAAGAATCTTTGAAGCTAACAGAGAAATGTGTTCATGGGACCAAGATACCTCAGGT 540
QY 541 GCAGGTGACGGCGAGGGCGGATCCCGGGTCCCTCCGTCGTCGCGCGGCACTCAGGTG 600
DB 541 GCAGGTGACGGCGAGGGCGGATCCCGGGTCCCTCCGTCGTCGCGCGGCACTCAGGTG 600

DB 541 GCAGGTGACGGCGAGGGCGGATCCCGGGTCCCTCCGTCGTCGCGCGGCACTCAGGTG 600
QY 601 TGCTTTTCAGGAACACACAGCCCATCAATCAAGCTCAGAGACCTCTTTCCCCACAGCCTCGGCC 660
DB 601 TGCTTTTCAGGAACACACAGCCCATCAATCAAGCTCAGAGACCTCTTTCCCCACAGCCTCGGCC 660
QY 661 TCTTCCACGAGACCTTCTCTGACGAGGCGAGAGGCTTCTCCAGTTGTGGGTTCTGGGGT 720
DB 661 TCTTCCACGAGACCTTCTCTGACGAGGCGAGAGGCTTCTCCAGTTGTGGGTTCTGGGGT 720
QY 721 GGTGGCATCTCCCTAAAGGAAGTGGTCCCTCTGTGGCAAGTGATGAAGTCTCCAGCTTT 780
DB 721 GGTGGCATCTCCCTAAAGGAAGTGGTCCCTCTGTGGCAAGTGATGAAGTCTCCAGCTTT 780
QY 781 GCCTCAGCTCTCCACAGAGAAAGTGCCTCTTTCTGCTGCTTGGTGGAAACCCAGGATCAG 840
DB 781 GCCTCAGCTCTCCACAGAGAAAGTGCCTCTTTCTGCTGCTTGGTGGAAACCCAGGATCAG 840
QY 841 GAGATTGGAGCCCGTGAGAGAAATGAGAGGATGGGACCTTGGACCTTGAACCGG 900
DB 841 GAGATTGGAGCCCGTGAGAGAAATGAGAGGATGGGACCTTGGACCTTGAACCGG 900
QY 901 CAGTTGTTGGTCGACAAACCGCGTAGAAATGCCAAACCGTCCACGAGGACGTGAGACGA 960
DB 901 CAGTTGTTGGTCGACAAACCGCGTAGAAATGCCAAACCGTCCACGAGGACGTGAGACGA 960
QY 961 CGGCTGGAGAGCCAGACAGATGGAGGAGCGCTGACATGCATCTGCGAGGACCTG 1020
DB 961 CGGCTGGAGAGCCAGACAGATGGAGGAGCGCTGACATGCATCTGCGAGGACCTG 1020
QY 1021 CTGCACGACTCGGTGAGTTTGCAGCCCTGCATGACACACGTTCTGCGGGGCTTGTACTCG 1080
DB 1021 CTGCACGACTCGGTGAGTTTGCAGCCCTGCATGACACACGTTCTGCGGGGCTTGTACTCG 1080
QY 1081 GGCTGGATGGAGCGCTCGTCCCTGTGCTTACCTGCGCGCTGTCCTGCGGAGCGGATCTGT 1140
DB 1081 GGCTGGATGGAGCGCTCGTCCCTGTGCTTACCTGCGCGCTGTCCTGCGGAGCGGATCTGT 1140
QY 1141 AAAAACACATCTCTCAACAACTCGTGAAGCATACCTCATCCAGCATCCAGACAGAGT 1200
DB 1141 AAAAACACATCTCTCAACAACTCGTGAAGCATACCTCATCCAGCATCCAGACAGAGT 1200
QY 1201 GCGAGTGAAGAGATGTGCAAGTATGGATGCCAGGAATAAAATCACTCAAGACATGCTG 1260
DB 1201 GCGAGTGAAGAGATGTGCAAGTATGGATGCCAGGAATAAAATCACTCAAGACATGCTG 1260
QY 1261 CAGCCCAAGTCAGCGGCTCTTTTCTGATGAAGAGGAGTTCAGAGGACCTGCTGGAG 1320
DB 1261 CAGCCCAAGTCAGCGGCTCTTTTCTGATGAAGAGGAGTTCAGAGGACCTGCTGGAG 1320
QY 1321 CTGTGACAGCTTGAAGTGTCTCAGACATTAAGCCAGCCATACGTGTGTCGGCGAG 1380
DB 1321 CTGTGACAGCTTGAAGTGTCTCAGACATTAAGCCAGCCATACGTGTGTCGGCGAG 1380
QY 1381 TGTCTGTAGTACAGAGGCGCGGCGAGCTCCCACTGCCAGACCCGAGGCGGAG 1440
DB 1381 TGTCTGTAGTACAGAGGCGCGGCGAGCTCCCACTGCCAGACCCGAGGCGGAG 1440
QY 1441 CCAGGAGCCCAAGGCGCTTGGGGATGACCCCTCCAGCTCCAGCTCCGTCAGCTCAGACGA 1500
DB 1441 CCAGGAGCCCAAGGCGCTTGGGGATGACCCCTCCAGCTCCAGCTCCGTCAGCTCAGACGA 1500
QY 1501 GTTCCAGGATTAAGTGTGCTTGTGCAAGAGCCAGCCCTGTGCACTGCTGCTTCCAG 1560
DB 1501 GTTCCAGGATTAAGTGTGCTTGTGCAAGAGCCAGCCCTGTGCACTGCTGCTTCCAG 1560
QY 1561 CCCATGCCGAGCCGAGAGCGGAGCGGAGCGGAGCCGAGCCGCTGCGCCCTCAGCAGTGT 1620
DB 1561 CCCATGCCGAGCCGAGAGCGGAGCGGAGCGGAGCCGAGCCGCTGCGCCCTCAGCAGTGT 1620
QY 1621 GCGGTTGCTGACGCTTTCTGCACTGTGATCTGAGGCGCTGCAACCGGAGCGGCTGTAC 1680
DB 1621 GCGGTTGCTGACGCTTTCTGCACTGTGATCTGAGGCGCTGCAACCGGAGCGGCTGTAC 1680

QY	2122	GTCAAGAGAGCGTGTGTTTTTAAATAACAGAGACAAGCAGCTCAAGGTGTTTTTACAGCCCC	2181
Db	1089	GTCAAGAGAGCGTGTGTTTTTAAATAACAGAGACAAGCAGCTCAAGGTGTTTTTACAGCCCC	1148
QY	2182	CTCAGGGAAGGACCGCAGGGTCTCCGACAGGTGCTCTGGGGTGACTCTCTCTGGAGCTT	2241
Db	1149	CTCAGGGAAGGACCGCAGGGTCTCCGACAGGTGCTCTGGGGTGACTCTCTCTGGAGCTT	1208
QY	2242	TTTACCCCTCTGAGTGAGACCCCTCCGAGAGCCCGGGGGCCGAGCCGCCCTCTGGTG	2301
Db	1209	TTTACCCCTCTGAGTGAGACCCCTCCGAGAGCCCGGGGGCCGAGCCGCCCTCTGGTG	1268
QY	2302	AGCGCTGGGACAGGGCTCGTGGTGCAATCAGCAGCAGAGAGCGAAGCCTTTCTGTAAATGC	2361
Db	1269	AGCGCTGGGACAGGGCTCATGGTGGCATCAGCAGCAGAGAGCGAAGCCTTTCTGTAAATGC	1328
QY	2362	GGCGCTCCCGCCGAGAGGGGCAAGTTTCTTTTGTACATTTCCGAAACTACAGTTAA	2421
Db	1329	GGCGCTCCCGCCGAGAGGGGCAAGTTTCTTTTGTACATTTCCGAAACTACAGTTAA	1388
QY	2422	AGCAGAAAGTCTGTTTTTCAAGAAAGTTTCAAGGAGAGAGGGCAAGTTTATCAAAAACATT	2481
Db	1389	AGCAGAAAGTCTGTTTTTCAAGAAAGTTTCAAGGAGAGAGGGCAAGTTTATCAAAAACATT	1448
QY	2482	GTTTCAGGAGAGGGAGCATAGTTTACAGCCTACAGGACGTACACAATATCTGCTGCT	2541
Db	1449	GTTTCAGGAGAGGGAGCATAGTTTACAGCCTACAGGACGTACACAATATCTGCTGCT	1508
QY	2542	GGGAAACACACAGCATTTTATCTATTTTATTTAATAGGTTGGTGCTTATCTTCTAA	2601
Db	1509	GGGAAACACACAGCATTTTATCTATTTTATTTAATAGGTTGGTGCTTATCTTCTAA	1568
QY	2602	TAAGATTTAAATGTCAAACTGTAGCACAATAATATTTATTAATTACAAATTGAC	2661
Db	1569	TAAGATTTAAATGTCAAACTGTAGCACAATAATATTTATTAATTACAAATTGAC	1628
QY	2662	AAAAA	2666
Db	1629	TAAAA	1633

Search completed: May 14, 2004, 17:19:06
Job time : 16450 secs

gene
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="MGC:59419 IMAGE:6510480"
/tissue_type="Limb, mouse, day 10.5 and 11.5, pool of
mesenchyme and early condensing mesenchyme."
/clone_lib="NIH_MGC_134"
/lab_host="DH10B"
/notes="Vector: pCMV-SPORT6.1"
1. 3194
/gene="5730484M20R1K"
/notes="synonym: C230082M18"
/db_xref="LocusID:231600"
/db_xref="MGI:2444898"
71. .2065
/codon_start=1
/product="RIKEN cDNA 5730484M20"
/protein_id="AAH49792.1"
/db_xref="LocusID:231600"
/translation="MELHGEQPPPPQEPWGRLLRLGAEDEPQILLKREWTIGRRR
GCDLSPFNKLVSQDCKLVDISGEVTLSTINGVINKLVQVKKQTYPLQSDI
IYLVRKNEPHEVAVYLSLQKSLTDSLEANKENPHVTKDCSGQGGDDPOV
LLSPMAQCLLEEQPSTSDLLPTASTSTELPSAGOKSHSSSGPNTSISPKGR
SSIVANGELSSLSPVQDKASFSILLESKDHLELPKAKKWKGDGRLDNLQLLVSGQ
RGAQTSSEVDKASVAPDKQKEETLICIQDLDLHDCVSLQPCNHHFCAKCYGWNHR
SSLCPTCRVERICKNHLNLLVEAYLIQHPDKRSSEEDVRMDARNKILQDMLQPK
VRRSFDEGSSDLELSVDSESDISQPIYVCRQPEYRQAVQSLFCFVPESEL
GATLALGGEAPSTASIPADPYMCPPLQSHAICTCCPQMPDRAREQDPVAPQ
QCAVLQPFCHLYGCTRCFCGLAPFCELNLDKDLGLVNNNYESDILKNYLAT
RGLTWKSLVLELALQGVFMFLSDVRICTNLVLCYCGGLSPRELTQYRQNPASE
LPVTIVSRPCYNGRCRTQVKAHAKFNHICEQTRPN"
182. .379
/notes="FHA; Region: FHA domain. The FHA
(Forkhead-associated) domain is a phosphopeptide binding
motif"
/db_xref="CDD:pfam00498"
974. 1105
/notes="HRD1; Region: COG5243, HRD1, HRD ubiquitin ligase
complex, ER membrane component [Posttranslational
modification, protein turnover, chaperones]"
/db_xref="CDD:COG5243"

misc_feature
Query Match 55.78; Score 1491; DB 10; Length 3194;
Best Local Similarity 75.28; Pred. No. 0;
Matches 2008; Conservative 0; Mismatches 615; Indels 48; Gaps 10;
36 GCGCGCGCGGCGAGCGGTTCCGGGTTCCGGGTCGGCGGGCGGGGATGTGAATCCCGATGGA 95
16 GCGGCGACTTAAGCGCGGTTCCGGGTCGGCGCGCGCGGCGGATGTGAGTCTCTATGGA 75
96 GCGGCGCGAGAGGCGAGCAGTCGCCCGCGCGCGCGCGGCGGCTCGTGGTCTCT 155
76 GCTACCGGGAAGAGCAGCGCGCGCGCGCGCGAGAACCTTCGGGAGGCTTCTTGCT 135
156 GGGCGCGGAGGCGGAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 215
136 AGCGCAGAGGAGGAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGAG 195
216 GAGACGAGGTTCGACGCTTCTTCCCGAGCAATTAACCTGCTCTGGAGATCACTGTAG 275
196 GAGAGAGGCTGTGACCTCTCTTCTTCCCGAGCAATTAACCTGCTCTGGAGATCACTGTAA 255
276 AATTGTAGTGGATGAATAAATCAGTCAAGTGTGACACTGGAGATACCGACACCACTGGAAC 335
256 ACTTACAGTGGATGAATAATCTGGTAGGTGACACTGGAGAGACACCGACCAATGGAAC 315
336 AGTGATTAAACAGCTGAAGTTGTTAAGACGACACATGCCCTTTACAGACTGGGATGT 395
316 AGTGATCAATAGCTGAAGTTGTTAAGACGACACTTACCTTTTACAGAGCGGGATAT 375

ORIGIN

QY 396 CATCTACTTGTGTACAGGAAGATGAAACCGGAACACAACTGGCATACCTCTATGAATC 455
Db 376 CATCTATTGTGTGTACAGGAAGATGAGCCAGAAACAAATGTGCATACCTCTATGAATC 435
QY 456 TTTAGTGAAGAGAGGATGACACAGAGATCTTTTGAAGCTTAACAGGAAATGTGTT 515
Db 436 TTTAGTGGGAAACAGAGCTTAACTCAAGACTCCCTTGAAGCCAAATAGGAAATATGTT 495
QY 516 CCATGGGACCAAGATACCTCAGGTGCGAGGGGCGAGGGGCGGATCCCGGGTCCC 575
Db 496 CCATGTGACCAAGATTGCT-----CAGGTCCAGGGCAGGGTGATGATCCCGAGTTCC 549
QY 576 TCGTCTGTGGCCGCCACTCAGGTGTGCTTTGAGGAACCAAGAGATCAACATCGACGTC 635
Db 550 ACTATTGTACCCCATGGCTCAGACATGCTTAGAGAACCAAGCATCAACATCGACATC 609
QY 636 AGACCTCTTCCCACAGGCTCGGCTCTTCCACGGAGCC-----TTCTCTCGCAGGGCG 689
Db 610 AGACCTCTCCCACAGGCTCTTACCTCTTACGGAGCCAGAGCTGACCTCTCGACGGCA 669
QY 690 AGAGGTTCTCTCAGTTTGGGTCTGGGGTGGTGGATCTCCCTAAAGAGAGTGGTCC 749
Db 670 AAAGCATTTCTTAGCTCTGGACCTGGGAAACAAAGCATCTCCCAAGAGCAGCGATT 729
QY 750 CTCTGTGGCAAGTGATGAAGTCTCCAGCTTTGCCCTCAGCTCTCCAGACACAAAGACTGC 809
Db 730 ACTTGTGCAATGGGAACCTCTTAGCTTTTCTCCAGTTTCCAGACAAGA---AGC 786
QY 810 GTCTTTTGTGTGGAAACCCAGGATCAGAGAGATTGGAGCCGTGGAAGAGAAAT 869
Db 787 ATCTCTTTCTTGTCTGGAAGATAAGACCATGAGGAATTGGAGCTGCCCAAAAAAGAT 846
QY 870 GAGAGAGATGGGACCTTGACCTGAAACGGCAGTTGTTGTCGCACAAACCGCTAGAAA 929
Db 847 GAAAGAGATGGGAACCTTGACCAAGACCTCCAGTTTATAGTTTTCAGGCCAGCGTGA 906
QY 930 TGCCCAAAACCTGTCACGAGGAGCTCAGAGCAGCGCTGGAGAGCAGACAAGATGAGGA 989
Db 907 TGCCCAAAACCTCAAGTGAAGATGTCAAAGATGCTCTGTGAAGCAGACAAGATGAGGA 966
QY 990 GAGCTGATGATCATCTGCGGAGGACCTGTCGACGACTGCGTGAAGTTTTCAGCCCTG 1049
Db 967 GACATAACCTGTATCATCTGCCAGGACCTTCTGCAAGATTGTGTGAGTTTGCAGCCCTG 1026
QY 1050 CATGCACACGTTCTCGCGGCTTGTCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGTCC 1109
Db 1027 TATGCACACATTTTGTGCGGCTTGCTACTCTGTTGGATGGAGCGTTTCTCTGTGCC 1086
QY 1110 TACTTGGCGCTGTCCCGTGGAGCGGATCTGTAAACACACATCTCAACAACCTCGTGA 1169
Db 1087 TACCTGGCGATGTCCAGTGGAGCGGATTGCAAAACACACATCTCTGAACAACTAGTGA 1146
QY 1170 AGCATACTCTATCCAGCATCCAGACAAGTCCGAGTGAAGAAGATGTGCAAAAGTATGA 1229
Db 1147 AGCATACTTATCCAGACACCCAGATAAAGTCCGAGTGAAGAAGATGTGAGAAGTATGA 1206
QY 1230 TGCCAGGAATAAATCACTCAAGACATGCTGAGCCCAAAGTCAAGCGGCTCTTTCTGA 1289
Db 1207 TGCAAGGAATAAATCACTCAAGATATGCTCAACCCAAAGTCAGGAGGCTCTTTCTCTGA 1266
QY 1290 TCAAGAAGGGAGTTTCAGAGGACCTCTGAGCTGTGACAGCTTGAAGTCAAGTCTCTCAGA 1349
Db 1267 TGAAAGGGAGTTTCAGAGGACCTGCTAGAGCTGTCTGATGTGACAGTGAATCTCTAGA 1326
QY 1350 CATTAGCAGGCATAGCTGTGTGCGGCGAGTCTCTGAGTACAGAGGCGAGGCGGCGCA 1409
Db 1327 TATCAGTCAGCCATACATTGTCTGAGACAGTGTCTGAAATACAGAGGCGAGCGGTGCA 1386
QY 1410 GCTCCCACTGCCCAGACACCGGGGCGAGCGAGGAGCCCAAGGCCCT---GGGGGA 1466
Db 1387 GTCTCTTCTTGGCCAGTCCAGAGAGTGAAGTGGAGCTACATGGGCCCTTGTGGGGGA 1446
QY 1467 TGCACCTCCACGCTCCGTGAGCTGACGACAGCAGTCCAGGATTACGTGTGCCCTCTGCA 1526

source

Db	1547	GGCTCTCCAGGGAGTGTTCGTGCTGCTGATTACAGAGTCCGGGACACCGTCTT	1606
Qy	1890	GTGTTACTGTGGCTCGCAGCTTCCGTGAGTGAACCTATCAGTATCGGAGAACAT	1949
Db	1607	GTGTTACTGTGGCTCGCAGCTTCCGTGAGTGAACCTATCAGTATCGGAGAACAT	1666
Qy	1950	TCTGCTTCGAGTTCGAGTGGCCGTAACATCCCGTCTGACTGCTACTTGGGGCGGTAA	2009
Db	1667	TCTGCTTCGAGTTCGAGTGGCCGTAACATCCCGTCTGACTGCTACTTGGGGCGGTAA	1726
Qy	2010	CTGCGCAGTCCAGTGAAGCTCACCGCCATGAATTCATATCATATCTGTGAACAGAC	2069
Db	1727	CTGCGCAGTCCAGTGAAGCTCACCGCCATGAATTCATATCATATCTGTGAACAGAC	1786
Qy	2070	AGGTTCAAAAATAAGCATCCAGAGCCCTGAGCAGCTTTCAGCAGTGGAGTGAAG	2129
Db	1787	AGGTTCAAAAATAAGCATCCAGAGCCCTGAGCAGCTTTCAGCAGTGGAGTGAAG	1846
Qy	2130	AGCGTGTGTTTAAATACAGAGCAAGCAGCTCAAGGTGTTTTACAGCCCCCTGAGGGA	2189
Db	1847	AGCGTGTGTTTAAATACAGAGCAAGCAGCTCAAGGTGTTTTACAGCCCCCTGAGGGA	1906
Qy	2190	AGGACCCAGGTTCTCGACAGGTGCTCTGGGTGACTCTCTGTGGAGCTTTTACCCT	2249
Db	1907	AGGACCCAGGTTCTCGACAGGTGCTCTGGGTGACTCTCTGTGGAGCTTTTACCCT	1966
Qy	2250	CTGAGTGAAGCTTCCCGAGAGCCCCGGGGCCGACCGCCCTCTCTGTGAGCGCTGG	2309
Db	1967	CTGAGTGAAGCTTCCCGAGAGCCCCGGGGCCGACCGCCCTCTCTGTGAGCGCTGG	2026
Qy	2310	GCAGGGCTGTGTGGCATCAGCAGCAGAGCAGAGCTTCTGTACATCGCGCGTCC	2369
Db	2027	GCAGGGCTGTGTGGCATCAGCAGCAGAGCAGAGCTTCTGTACATCGCGCGTCC	2086
Qy	2370	CGCGCAGAGGGGAGTTTGTCTCTTTTGTATATTTCCGAAACTACAGTTTAAAGCAGAAG	2429
Db	2087	CGCGCAGAGGGGAGTTTGTCTCTTTTGTATATTTCCGAAACTACAGTTTAAAGCAGAAG	2146
Qy	2430	TCTGTTTTCAGGAAAGTTTCAAGGAGAGAGGCAAGTTTATCAAAACATTTGTTTCAAG	2489
Db	2147	TCTGTTTTCAGGAAAGTTTCAAGGAGAGAGGCAAGTTTATCAAAACATTTGTTTCAAG	2206
Qy	2490	AGAGGGAGCATAGTTTACAGCTCAGCAGCTGACAGCAATATCTCTCTCTGGGAAAC	2549
Db	2207	AGAGGGAGCATAGTTTACAGCTCAGCAGCTGACAGCAATATCTCTCTCTGGGAAAC	2266
Qy	2550	CACAGCATTTTATCTATTTTATTTTATAGTTTGGTCTTATCTTCTTAATAAGATT	2609
Db	2267	CACAGCATTTTATCTATTTTATTTTATAGTTTGGTCTTATCTTCTTAATAAGATT	2326
Qy	2610	AAATGTCACAACTGTAGCACAATATATATTTAATTTACAAATTGACAAATA	2666
Db	2327	AAATGTCACAACTGTAGCACAATATATATTTAATTTACAAATTGACAAATA	2383
RESULT 12			
HSMB02304		2297 bp mRNA linear PRI 18-FEB-2000	
LOCUS			
DEFINITION		Homo sapiens mRNA; cDNA DKFZp434N2420 (from clone DKFZp434N2420); partial cds.	
ACCESSION		AL137561	
VERSION		AL137561.1 GI:6808265	
KEYWORDS			
SOURCE		Homo sapiens (human)	
ORGANISM		Homo sapiens	
REFERENCE		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
AUTHORS		Ostenwaelder, B., Obermaier, B., Mewes, H.W., Gassenhuber, J. and Wiemann, S.	
TITLE		Direct Submission	
JOURNAL		Submitted (15-JAN-2000) MIPS, Am Klopferspitze 18a, D-82152	

COMMENT	Martinsried, GERMANY Clone from S. Wiemann, Molecular Genome Analysis, German Cancer Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de; sequenced by MediGenomix (Martinsried/Germany) within the cDNA sequencing consortium of the German Genome Project. This clone (DKFZp434N2420) is available at the RZPD in Berlin. Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059 Berlin-Charlottenburg, GERMANY; Email: clone@rzd.de Further information about the clone and the sequencing project is available at http://www.mips.biochem.mpg.de/proj/cDNA/.			
FEATURES	Location/Qualifiers			
source	1..2297	/organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="DKFZp434N2420" /tissue_type="testis" /clone_lib="434 (synonym: htes3). Vector pSport1; host DH10B; sites NotI + SalI" /dev_stage="adult"		
gene	1..2297	/gene="DKFZp434N2420"		
CDS	1..921	/gene="DKFZp434N2420" /note="unknown" /codon_start=1 /product="hypothetical protein" /protein_id="CAB70812.1" /db_xref="GI:6808266" /db_xref="SPTREMBL:O9NT32" /translation="VEAYLIQHPDKSRSEEDVQSDANKKITQDWLQPKVRSFDEE GSSDLELSVDVDSSEDSISQYVVCQCPREVQAAOPHCPEAGPEGAPQALGDA PSTVSLTAVQDYVCPFLQSHALCTCFQPMRPREREDPBAVQCQACVCLQPCF HLYMCTTGTGCGCLAPFELNLDGKLDGVNNNSYEDSLKNYLATRLGTWKNLIT ESLVALQGVFLLSDYRTVGTVCYCGLRSRELTLYQYRQNI PASELPVAVTSRDP CYWGNCRTOVKAAHAKFNHICEQTRFKN"		
polyA_signal	2227..2232	/gene="DKFZp434N2420"		
polyA_site	2251	/gene="DKFZp434N2420"		
ORIGIN	Query Match 56.0%; Score 1500.4; DB 9; Length 2297; Best Local Similarity 99.9%; Pred. No. 0; Matches 1501; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			
QY	1165	GTGGAAGCATACTCTATCAGCATCCAGACAGAGTCCAGTGCAGTGAAGAGTGTGCAAGT	1224	
DB	1	GTGGAAGCATACTCTATCAGCATCCAGACAGAGTCCAGTGAAGAGTGTGCAAGT	60	
QY	1225	ATGGATGCCAGGAATAAATCACTCAAGACATGCTGCAGCCCAAGTCAAGCGTCTTTT	1284	
DB	61	ATGGATGCCAGGAATAAATCACTCAAGACATGCTGCAGCCCAAGTCAAGCGTCTTTT	120	
QY	1285	TCTGATGAAGAGGAGTTTCAGAGACCTGTGGAGCTGTGAGCTGTGACAGTGTGAGTCC	1344	
DB	121	TCTGATGAAGAGGAGTTTCAGAGACCTGTGGAGCTGTGACAGTGTGAGTCC	180	
QY	1345	TCAGACATTAGCAGCCATACGTCGTGCGGAGTGTCTGTAGTACAGAGGAGCGG	1404	
DB	181	TCAGACATTAGCAGCCATACGTCGTGCGGAGTGTCTGTAGTACAGAGGAGCGG	240	
QY	1405	GGCAGCCTTCCCACTGCCAGCACCAGGAGGCGAGGAGGAGGAGGAGGAGGAGGAG	1464	
DB	241	GGCAGCCTTCCCACTGCCAGCACCAGGAGGCGAGGAGGAGGAGGAGGAGGAGGAG	300	
QY	1465	GATGACCTTCCAGCTCGCTGTGAGTGTGAGCAGCAGTGTGAGTGTGAGTGTGAGTGTG	1524	
DB	301	GATGACCTTCCAGCTCGCTGTGAGTGTGAGCAGCAGTGTGAGTGTGAGTGTGAGTGTG	360	
QY	1525	CAAGGAGCAGCGCTGTGACCTGTCTTCCAGCCCATGCCCGAGGAGGAGGAGGAGGAG	1584	
DB	361	CAAGGAGCAGCGCTGTGACCTGTCTTCCAGCCCATGCCCGAGGAGGAGGAGGAGGAG	420	

Suzuki, Y., Sugano, S., Nagahara, K., Masuho, Y., Nagai, K. and
 Isogai, T.
 NEDO human cDNA sequencing project
 Unpublished
 2 (bases 1 to 2448)
 Isogai, T. and Yamamoto, J.
 Direct Submission
 Submitted (04-JUL-2002) Takao Isogai, FLJ Project (HRI Team); 2-6-7
 Kazusa-Kamatari, Kisarazu, Chiba 252-0812, Japan
 (E-mail: genomics@hri.co.jp, Tel: 81-438-52-3975, Fax: 81-438-52-3986)
 NEDO human cDNA sequencing project supported by Ministry of
 Economy, Trade and Industry of Japan; cDNA full insert sequencing:
 Research Association for Biotechnology (RAB); cDNA library
 construction: Helix Research Institute (HRI) (supported by Japan
 Key Technology Center etc.); 5'- & 3'-end one pass sequencing: RAB,
 HRI, and Biotechnology Center, National Institute of Technology and
 Evaluation; clone selection for full insert sequencing: HRI and
 RAB; annotation: HRI and RAB.

FEATURES
 source
 1..2448
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="TEST12033505"
 /tissue_type="testis"
 /clone_lib="TEST12"
 /note="cloning vector: pME18SFL3"

ORIGIN
 Query Match 71.6%; Score 1919.4; DB 9; Length 2448;
 Best Local Similarity 88.5%; Pred. No. 0;
 Matches 2227; Conservative 0; Mismatches 6; Indels 284; Gaps 2;

218 GACGAGGTGGACCTTCTCCAGCAATAACTGGTCTCTGGAGATCACTGTAGAA 277
 83 GACCTGTGGACCTTCTCCAGCAATAACTGGTCTCTGGAGATCACTGTAGAA 142
 278 TTGTAGTGGATGAATAATCAGGTGAGTGCATCTGGAAGATACAGACACAGTGGACAG 337
 143 TTGTAGTGGATGAATAATCAGGTGAGTGCATCTGGAAGATACAGACACAGTGGACAG 202
 338 TGATTAACAGCTCAAGAGTGTAAAGAGCAGATGCTTACAGACTGGGGATGTCA 397
 203 TGATTAACAGCTCAAGAGTGTAAAGAGCAGATGCTTACAGACTGGGGATGTCA 262
 398 TCTACTTGGTGTACAGGAAGATGAACCGGAACACAACTGGGATACCTCTATGAATCTT 457
 263 TCTACTTGGTGTACAGGAAGATGAACCGGAACACAACTGGGATACCTCTATGAATCTT 322
 458 TAAGTGAACAGCAGGATGACACAGAAATCCTTTTGAAGCTAACAGGAAATGTGTTC 517
 323 TAAGTGAACAGCAGGATGACACAGAAATCCTTTTGAAGCTAACAGGAAATGTGTTC 356
 518 ATGGGACCAAGATACCTCAGGTGAGTGCAGGGCGAGGGCGGATCCCGGGTCCCTC 577
 357 ----- 356
 578 CGTGTGCCCGCCACTCAGGTGTGCTTTGAGGAACACAGACCATCAACATCGACGTGAG 637
 357 ----- 356
 638 ACCTCTTCCCAACAGCTCGGCTCTTCCAGGAGCCTTTCTCTGCGGGCGAGAGCGTT 697
 357 ----- 356
 698 CCTCAGTTGGGTCTGGGGTGGTGCATCTCCCTTAAGGAAGTGGTCCCTCTGTGG 757
 357 -----TGGGTCTGGGGTGGTGGCATCTCCCTTAAAGGAAGTGGTCCCTCTGTGG 406
 758 CAAGTGAAGATCTCCAGCTTTGCTCAGCTCTCCAGACAGAAAGACTGCGTCTTTT 817
 407 CAAGTGAAGATCTCCAGCTTTGCTCAGCTCTCCAGACAGAAAGACTGCGTCTTTT 466

QY 818 CGTCTTGGAAACCCAGGATCAGGAGGATTTGAGCCCGTGAAGAAAGAAATGAGAGGAG 877
 DB 467 CGTCTTGGAAACCCAGGATCAGGAGGATTTGAGCCCGTGAAGAAAGAAATGAGAGGAG 526
 QY 878 ATGGGACCTTGTACCTGAACGGGAGTGTGCTCCGACAAACCGCTAGAAATGCCCAA 937
 DB 527 ATGGGACCTTGTACCTGAACGGGAGTGTGCTCCGACAAACCGCTAGAAATGCCCAA 586
 QY 938 CCGTCCACAGGAGCGTCCAGAGCAGCGCTGGGAAGCCAGACAAGATGGAGAGACGCTGA 997
 DB 587 CCGTCCACAGGAGCGTCCAGAGCAGCGCTGGGAAGCCAGACAAGATGGAGAGACGCTGA 646
 QY 998 CATGATCATCTGCAGGACCTGTGCAGACCTGCGTGCAGTGTTCGACCCCTGCATGCACA 1057
 DB 647 CATGATCATCTGCAGGACCTGTGCAGACCTGCGTGCAGTGTTCGACCCCTGCATGCACA 706
 QY 1058 CGTCTGCGCGCTGTCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGCTTCTACCTGCC 1117
 DB 707 CGTCTGCGCGCTGTCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGCTTCTACCTGCC 766
 QY 1118 GCTGTCCCGTGGAGCGGATCTGTAAAAACCAATCTCAACAGCTCGTGGAGACATACC 1177
 DB 767 GCTGTCCCGTGGAGCGGATCTGTAAAAACCAATCTCAACAGCTCGTGGAGACATACC 826
 QY 1178 TCATCCAGCATCCAGCAAGAGTGCAGTGAAGAGATGTCAAGATATGATGCCAGGA 1237
 DB 827 TCATCCAGCATCCAGCAAGAGTGCAGTGAAGAGATGTCAAGATATGATGCCAGGA 886
 QY 1238 ATAAATCACTCAAGACATCTGCAGCGCCAAAGTCAGCGCTCTTTTCTGATGAAGAAG 1297
 DB 887 ATAAATCACTCAAGACATCTGCAGCGCCAAAGTCAGCGCTCTTTTCTGATGAAGAAG 946
 QY 1298 GGAGTTCAGAGACCTGCTGGAGTGTTCAGAGTGTGACAGTGAAGTCTTCAGACATATGCC 1357
 DB 947 GGAGTTCAGAGACCTGCTGGAGTGTTCAGAGTGTGACAGTGAAGTCTTCAGACATATGCC 1006
 QY 1358 AGCCATAGCTGTGTGCGCGCAGTGTCTCTGAGTACAGAAAGCAGCGCGCGAGCTCCCC 1417
 DB 1007 AGCCATAGCTGTGTGCGCGCAGTGTCTCTGAGTACAGAAAGCAGCGCGCGAGCTCCCC 1066
 QY 1418 ATGCCAGCACCCAGCGCGAGCCAGAGCCGACAGCGCCCTGGGGATGCACCTCCA 1477
 DB 1067 ACTGCCAGCACCCAGCGCGAGCCAGAGCCGACAGCGCCCTGGGGATGCACCTCCA 1126
 QY 1478 CGTCCGTGAGCTGACGACAGCAGTCCAGGATTAAGTGTGCTGCTTGCAGGAAGCCACG 1537
 DB 1127 CGTCCGTGAGCTGACGACAGCAGTCCAGGATTAAGTGTGCTGCTTGCAGGAAGCCACG 1186
 QY 1538 CCCTGTGACACCTGCTGCTTCCAGCCCATCCCGACCGGAGCGGAGCGGAGCGAGACC 1597
 DB 1187 CCCTGTGACACCTGCTGCTTCCAGCCCATCCCGACCGGAGCGGAGCGGAGCGAGACC 1246
 QY 1598 CGCGTGTGCCCTCCAGCAGTGTGCGGTCTGCTGACGCTTCTGCGCACCTGTACTGGG 1657
 DB 1247 CGCGTGTGCCCTCCAGCAGTGTGCGGTCTGCTGACGCTTCTGCGCACCTGTACTGGG 1306
 QY 1658 GCTGCACCCGGACCGGCTGCTACGGCTGCTGCGGCCCTGTTTGT----- 1701
 DB 1307 GCTGCACCCGGACCGGCTGCTACGGCTGCTGCGGCCCTGTTTGTGTCGCGGACAGACT 1366
 QY 1702 -----GAGCTCAA 1709
 DB 1367 GCTTCTCCGACATCATATATAAAGGTAAACATTTGCCCTTCATCTCGGAGAGACTCAA 1426
 QY 1710 CTTGGGTGACAGTGTCTGGAACGGGCTGTGTAACAAACACAGCTACAGTACAGATCCT 1769
 DB 1427 CTTGGGTGACAGTGTCTGGAACGGGCTGTGTAACAAACACAGCTACAGTACAGATCCT 1486
 QY 1770 GAAGAATTAACCTGGGACCAACAGAGGTTTGCATGGAAGAACATGTTGACCGGAGGCTCGT 1829
 DB 1487 GAAGAATTAACCTGGGACCAACAGAGGTTTGCATGGAAGAACATGTTGACCGGAGGCTCGT 1546
 QY 1830 GGCTCTCCAGCGGGAGTGTCTTCTGCTGCTCATTAACAGAGTCAAGGGAGACACCGTCTCT 1889

467	Db	CGTCTGTTGGAAACCCCAAGATCAGGAGGATTTGGAGCCCGTGAAGAGAAATAATCAGAGGAG	526
878	Qy	ATGGGGACCTTGACCTGAAACGGGACAGTTGTTGTCGCAACACGCGTAGAAATGCCCAA	937
527	Db	ATGGGACCTTGACCTGAAACGGGACAGTTGTTGTCGCAACACGCGTAGAAATGCCCAA	586
938	Qy	CCGTCCACAGGAGAGTCAGAGACAGCGCTCGGAAGCCAGACAAGATGGAGGAGACGCTGA	997
587	Db	CCGTCCACAGGAGAGTCAGAGACAGCGCTGGGAAGCCAGACNAGATGGAGGAGACGCTGA	646
998	Qy	CATGCATCATCTGCCAGGACCTGTCGACACACTGCGTGAATTTGACGCCCTGCATGCACA	1057
647	Db	CATGCATCATCTGCCAGGACCTGTCGACACACTGCGTGAATTTGACGCCCTGCATGCACA	706
1058	Qy	CGTTCTCGCGGCTTGCTACTCGGGCTGGAATGGAGCGCTGCTCCCTGTCCTACCTGCC	1117
707	Db	CGTTCTCGCGGCTTGCTACTCGGGCTGGAATGGAGCGCTGCTCCCTGTCCTACCTGCC	766
1118	Qy	GCTGTCCCTGGAGCGGATCTGTAAAAACCACTCCCTCAACAACCTCGTGGAAAGCATACC	1177
767	Db	GCTGTCCCTGGAGCGGATCTGTAAAAACCACTCCCTCAACAACCTCGTGGAAAGCATACC	826
1178	Qy	TCATCCAGCATCCAGACAAGAGTCCGAGTGAAGAAGATGTGCAAAAGTATGATGCCAGGA	1237
827	Db	TCATCCAGCATCCAGACAAGAGTCCGAGTGAAGAAGATGTGCAAAAGTATGATGCCAGGA	886
1238	Qy	ATAAAACTACTCAAGACATGCTGCAGAGCCCAAGTCAGCGCTCTTTTCTGATGAAGAAG	1297
887	Db	ATAAAACTACTCAAGACATGCTGCAGAGCCCAAGTCAGCGGCTCTTTTCTGATGAAGAAG	946
1298	Qy	GGAGTTCAGAGGACCTGCTGGAGCTGTCCAGAGTTGACAGTGAAGTCTCCAGACAAATTAGCC	1357
947	Db	GGAGTTCAGAGGACCTGCTGGAGCTGTCCAGAGTTGACAGTGAAGTCTCCAGACAAATTAGCC	1006
1358	Qy	AGCATACGTGCTGTGCGGCAGTGTCTTGAGTACAGAGCAGCGCGCGCAGCCTCCCC	1417
1007	Db	AGCATACGTGCTGTGCGGCAGTGTCTTGAGTACAGAGCAGCGCGCGCAGCCTCCCC	1066
1418	Qy	ACTGCCACGACCCGAGCGGAGCCAGAGGCCCAACAGAGCCCTCGGGGATGACACCTCCA	1477
1067	Db	ACTGCCACGACCCGAGCGGAGCCAGAGGCCCAACAGAGCCCTCGGGGATGACACCTCCA	1126
1478	Qy	CGTCCGTGACGCTGACACAGCAGCTCAGAGNTTACGTGTCCTCTCCAGGAGCCACG	1537
1127	Db	CGTCCGTGACGCTGACACAGCAGCTCAGAGNTTACGTGTCCTCTCCAGGAGCCACG	1186
1538	Qy	CCCTGTGCACCTGCTTCCAGGCCCATGCCGACCGGAGCGAGCGGAGCAGGACG	1597
1187	Db	CCCTGTGCACCTGCTTCCAGGCCCATGCCGACCGGAGCGGAGCGGAGCAGGACG	1246
1598	Qy	CGCGTGTGCCCTTCAGACAGTGTGCGTGTGCTGCGACGCTTTCTGCCACCTGTACTGGG	1657
1247	Db	CGCGTGTGCCCTTCAGACAGTGTGCGTGTGCTGCGACGCTTTCTGCCACCTGTACTGGG	1306
1658	Qy	GCTGCACCGGACCGGCTGCTACGGCTGCGCTGGCCCGCCGTTTGTG	1701
1307	Db	GCTGCACCGGACCGGCTGCTACGGCTGCGCTGGCCCGCCGTTTGTG	1366
1702	Qy	-----GAGCTCAA	1709
1367	Db	GCITTTCTCGACATCATTAATAACAGGTAACATTGCCCTTCATCTCGGCAGAGCTCAA	1426
1710	Qy	CCTGGGTGACAGTGTCTGACGCGGCTGCTGAACAAACAAGCTACGAGTCAGACATCCT	1769
1427	Db	CCTGGGTGACAGTGTCTGACGCGGCTGCTGAACAAACAAGCTACGAGTCAGACATCCT	1486
1770	Qy	GAAGAAATTACTCGGCAACAGAGGTTTGACATGGAATAACATGTTGACCGGAGCCCTCGT	1829
1487	Db	GAAGAAATTACTCGGCAACAGAGGTTTGACATGGAATAACATGTTGACCGGAGCCCTCGT	1546
1830	Qy	GGCTCTCCAGCGGGAGTGTCTGCTGCTGATTAACAGTCAAGGAGACACGCTTCT	1889
1547	Db	GGCTCTCCAGCGGGAGTGTCTGCTGCTGATTAACAGTCAAGGAGACACGCTTCT	1606

RESULT 11	
AKO97671	2448 bp mRNA linear PRI 15-JUL-2002
LOCUS	Homo sapiens cDNA FLJ40352 fis, clone TESTI2033505, highly similar to Homo sapiens cell cycle checkpoint protein CHFR mRNA.
DEFINITION	
AKO97671	
ACCESSION	
VERSION	AKO97671.1 GI:21757518
KEYWORDS	oligo capping; fis (full insert sequence).
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
Eukaryota;	Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia;	Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE	1
AUTHORS	Oshima,A., Takahashi-Fujii,A., Tanase,T., Imose,N., Takeuchi,K., Arita,M., Musashino,K., Yuuki,H., Hara,H., Sugiyama,T., Irie,R., Kusuki,T., Sato,H., Wakamatsu,A., Ishii,S., Yamamoto,J., Isono,Y., Kawai-Hio,Y., Saito,K., Nishikawa,T., Kimura,K., Yanasaita,H., Matsuo,K., Nakamura,Y., Sekine,M., Kikuchi,H., Kanda,K., Wacatusuma,M., Murakawa,K., Kanehori,K., Sugiyama,A., Kawakami,B.,

QY	1636	CCTTTCTGCCACCTGTACTGGGCTGCACCCGGACCGGCTGCTACGGCTGCTCTGGGCCCG	1699
DB	1518	CCTTTCTGCCACCTGTACTGGGCTGCACCCGGACCGGCTGCTACGGCTGCTCTGGGCCCG	1577
QY	1696	TTTTGTGAGCTCAACCTGGGTGACAACTGCTCGACGGCGGTGCTGAACAAACAACAGCTAC	1755
DB	1578	TTTTGTGAGCTCAACCTGGGTGACAACTGCTCGACGGCGGTGCTGAACAAACAACAGCTAC	1637
QY	1756	GAGTCAGACATCCTGTGAAGAAATTACTCTGGCAACCGAGGTTTGACATGGAAAAACATGTTG	1815
DB	1638	GAGTCAGACATCCTGTGAAGAAATTACTCTGGCAACCGAGGTTTGACATGGAAAAACATGTTG	1697
QY	1816	ACCGAGAGCCTCGTGGCTCTCCACGGGGGAGTGTTCCTGCTGCTGCTGATTACAGAGTCACG	1875
DB	1698	ACCGAGAGCCTCGTGGCTCTCCACGGGGGAGTGTTCCTGCTGCTGCTGATTACAGAGTCACG	1757
QY	1876	GGAGACACCGTTCGTGTGTTACTGCTGTGGCTTCGGCAGCTTCGTGAGCTGACCTATCAG	1935
DB	1758	GGAGACACCGTTCGTGTGTTACTGCTGTGGCTTCGGCAGCTTCGTGAGCTGACCTATCAG	1817
QY	1936	TATCGGCAGAACATTCCTGCTTCCGAGTGTCCAGTGGCCGTAAACATCCCGTCTCTGACTGC	1995
DB	1818	TATCAGCAGAACATTCCTGCTTCCGAGTGTCCAGTGGCCGTAAACATCCCGTCTCTGACTGC	1877
QY	1996	TACTGGGGCCGTAACTCCCGGACCTCAGGTGAAGCTCACACGCCATGAATAATCAATCAT	2055
DB	1878	TACTGGGGCCGTAACTCCCGGACCTCAGGTGAAGCTCACACGCCATGAATAATCAATCAT	1937
QY	2056	ATCTGTCAACAGACAAAGTTCAAAAAATAAGCATCCAGAGGCCCTGAGCAGCTTTTCAGCA	2115
DB	1938	ATCTGTCAACAGACAAAGTTCAAAAAATAAGCATCCAGAGGCCCTGAGCAGCTTTTCAGCA	1997
QY	2116	CTGAGGTGAAGAGAGCGTGTTTTTAAATAACAGACACAGCAGCTCAAGGTGTTTTTCAC	2175
DB	1998	CTGAGGTGAAGAGAGCGTGTTTTTAAATAACAGACACAGCAGCTCAAGGTGTTTTTCAC	2057
QY	2176	AGCCCCCTGAGGGAAGGACCGCAGGCTCTCCGACAGGTGCTCTGGGGTGACTCTTTCTGTG	2235
DB	2058	AGCCCCCTGAGGGAAGGACCGCAGGCTCTCCGACAGGTGCTCTGGGGTGACTCTTTCTGTG	2117
QY	2236	GAGCTTTTACCTCTGAGTGAGACCTTCCCAGAGCCCCGGGGCCGCGACGCCGCCCTC	2295
DB	2118	GAGC- -TTTACCTCTCTGAGTGAGACCTTCCCAGAGCCCCGGGGCCGCGACGCCGCCCTC	2175
QY	2296	CTGCTGAGCGCTGGCGCAGGCTCGTGTGGCATCAGCAGCAGAGACGAAGCCCTTTCTGTA	2355
DB	2176	CTGCTGAGCGCTGGCGCAGGCTCGTGTGGCATCAGCAGCAGAGACGAAGCCCTTTCTGTA	2235
QY	2356	ACATGGCGCGTCCCGCGAGAGGGCAGTTTGCTCTTTTGTACATTTCCGGAACATC	2415
DB	2236	ACATGGCGCGTCCCGCGAGAGGGCAGTTTGCTCTTTTGTACATTTCCGGAACATC	2295
QY	2416	AGTTAAAGCGAAGTCTGTGTTTTTCAGGAAAAAGTTTCAAGGGAGAGGCAAGTTTATCAAA	2475
DB	2296	AGTTAAAGCGAAGTCTGTGTTTTTCAGGAAAAAGTTTCAAGGGAGAGGCAAGTTTATCAAA	2355
QY	2476	AACATTGTTTCAGAGAGAGGAGCATAGTTTACAGCTACAGGACGTACACATATCCT	2535
DB	2356	AACATTGTTTCAGAGAGAGGAGCATAGTTTACAGCTACAGGACGTACACATATCCT	2415
QY	2536	GCTGCTGGGAAAAACACAGCATTTTATCTATTTTTTTTAAATAGTTTGGTGCTTATC	2595
DB	2416	GCTGCTGGGAAAAACACAGCATTTTATCTATTTTTTTTAAATAGTTTGGTGCTTATC	2475
QY	2596	TTCTAAATAAGATTTTAAATGTCAAACTGTAGCAAAATAATAATTTTATAATTTTACAA	2655
DB	2476	TTCTAAATAAGATTTTAAATGTCAAACTGTAGCAAAATAATAATTTTATAATTTTACAA	2535
QY	2656	ATTGACAAAAA	2666
DB	2536	ATTGACTAAAA	2546

RESULT 10	AX834949	2448 bp	DNA	linear	PAT 15-DEC-2003
LOCUS	AX834949	2448 bp	DNA	linear	PAT 15-DEC-2003
DEFINITION	Sequence 2073 from Patent EP1347046.				
ACCESSION	AX834949				
VERSION	AX834949.1	GI:39921084			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	Mammalia; Euthera; Primates; Catarrhini; Hominoidea; Homo.				
	1				
	Isogai, T., Sugiyama, T., Otsuki, T., Wakamatsu, A., Sato, H., Ishii, S.,				
	Yanamoto, J. I., Isono, Y., Hio, Y., Otsuka, K., Nagai, K., Irie, R.,				
	Tanechika, I., Seki, N., Yoshikawa, T., Otsuka, M., Nagahari, K. and				
	Masuh, Y.				
TITLE	Full-length cDNA sequences				
JOURNAL	Patent: EP 1347046-A 2073 24-SEP-2003;				
FEATURES	Research Association for Biotechnology (JP)				
source	Location/Qualifiers				
	1..2448				
	/organism="Homo sapiens"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:9606"				
ORIGIN					
	Query Match 71.6%; Score 1919.4; DB 6; Length 2448;				
	Best Local Similarity 88.5%; Pred. No. 0;				
	Matches 2227; Conservative 0; Mismatches 6; Indels 284; Gaps 2;				
QY	218	GACGAGGTTCGACCTTCTCTCCCGACCAATAACCTGGTCTCTGGAGATCACCTGTGAA	277		
DB	83	GACCTGTTCGACCTTCTCTCCCGACCAATAACCTGGTCTCTGGAGATCACCTGTGAA	142		
QY	278	TTGTAGTGGATGAAATACAGTTCAGGTGACACCTGGAAGATACACGACCCAGTGGAAACAG	337		
DB	143	TTGTAGTGGATGAAATACAGTTCAGGTGACACCTGGAAGATACACGACCCAGTGGAAACAG	202		
QY	338	TGATTACACCTGAAGTGTGTTAAGAGCGACATGCCCTTTACAGACTGGGGATGCA	397		
DB	203	TGATTACACCTGAAGTGTGTTAAGAGCGACATGCCCTTTACAGACTGGGGATGCA	262		
QY	398	TCTACTTGGTCTACAGGAAGATGAACCGGAACACACCTGGGCATCCTCTATGAATCTT	457		
DB	263	TCTACTTGGTCTACAGGAAGATGAACCGGAACACACCTGGGCATCCTCTATGAATCTT	322		
QY	458	TAAGTGAAGCAAGGCGATGACCAAGATCCTTTGAAGCTAAACAGGAAAATGTGTTC	517		
DB	323	TAAGTGAAGCAAGGCGATGACCAAGATCCTTTGAAGCTAAACAGGAAAATGTGTTC	356		
QY	518	ATGGGACCAAGATACCTCAGTTCAGGTGACGGCGAGGGCCGATCCCGGGTCCCTC	577		
DB	357	ATGGGACCAAGATACCTCAGTTCAGGTGACGGCGAGGGCCGATCCCGGGTCCCTC	356		
QY	578	CGTCGTCCCGCCACTCAGGTGTGTTTGAAGAACCAACGCCATCAACATCGAGCTCAG	637		
DB	357	CGTCGTCCCGCCACTCAGGTGTGTTTGAAGAACCAACGCCATCAACATCGAGCTCAG	356		
QY	638	ACCTCTTCCACACGCTTCGGCTTCCACGAGCTTCTCTCCTCGAGGGGAGAGCGTT	697		
DB	357	ACCTCTTCCACACGCTTCGGCTTCCACGAGCTTCTCTCCTCGAGGGGAGAGCGTT	356		
QY	698	CCTCAGTGTGGTCTGGGGTGGTGGCATCTCCCTTAAAGGAAGTGGTCCCTCTGTGG	757		
DB	357	-----TGGGTCTGGGGTGGTGGCATCTCCCTTAAAGGAAGTGGTCCCTCTGTGG	406		
QY	758	CAAGTGATGAAGTCTCCAGCTTTTGCTCAGCTCTCCACAGACAGAAAGACTGGCTCTTT	817		
DB	407	CAAGTGATGAAGTCTCCAGCTTTTGCTCAGCTCTCCACAGACAGAAAGACTGGCTCTTT	466		
QY	818	CGTCGTGGAAACCCAGGATCAGGAGGATTTGGAGCCCGTGAAGAAAGAAATGAGAGAG	877		

KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Tang Y.T., Liu C., Zhou P., Asundi V., Zhang J., Zhao Q.A., Ren F., Xue A.J., Yang Y., Wehrman T. and Drmanac R.T.
TITLE Novel nucleic acids and polypeptides
JOURNAL Patent: WO 0222660-A 57 21-MAR-2002;
HYSEQ, INC. (US)
FEATURES
source Location/Qualifiers
1..3181
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
96..1967
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAD34749.1"
/db_xref="GI:21438724"
/db_xref="REVIEW:CAD34749"
/translations="MERPEGGKPPPPWGRLLRLGABEGPHVLLRKREWTIGRR
GCDLSPNKLVSQDRIIVDKSQVLTEDTSTGINKLVKKQTCPLQTDV
IYLVKRNPEHNVAYLYSLSKQMTQESFEMVPCVQAQKLLGSSDPTLASQ
SIVITSGGGGIPKSGSPVADSVSSPASALPDRKTASFSLEPDQEDLEPVKKK
MRGDLGLDQGLLVQPRNAOTVHEDVRAAKPKDMEETLTCICODLLHDCVSL
QPCWHTFCACYSQWMSRLCTCRPVERICKNHLNLYEAYLIHQDPKRSRSD
VQSMARKKITQMLQPKVRRSDESGESDLELSDVDSSESDISQPVVCRQCP
YRQAAQPHCPPEPQALGADPPTVSLITAVQDQYVCPLOGSHALCTCCFPQ
MPDRAREQDPVPAQCAVCIQPFCHLYGCTRTGCGCAAPFCELMKCLDGV
LNNYSYSDILKNYLATRGITWMLTESLVALQGVLLSYRVGTDLVLCYCGGLR
SPRELTVYQONIPASELPVAVTSRDPYVGRNCRTPQVKAHAKFNHICEQTRFN"

Query Match 83.8%; Score 2244.6; DB 6; Length 3181;
Best Local Similarity 52.3%; Pred. No. 0;
Matches 2447; Conservative 0; Mismatches 79; Indels 125; Gaps 3;
ORIGIN
501 ATGTGCTTGTGTGTTGCCAGGCTGGTCTAATACTCTCTGGGATCAAGT----- 551
556 GGGGCCGATCCCGGGTCCCTCGTCTGCCGCCGCCACTCAGGTGTCTTGGAGACCA 615
552 -----GATCTCCCACTTGGCTCCCAAGTATTGTGATTACA----- 590
616 CAGCCATCAACATCGACGTGAGACCTCTTCTCCACAGCCTCGGCTCTTCCACGAGCCT 675
591 ----- 590
676 TCTCTGAGGGCGAGAGCGTCTCTCAGTTGTGGGTCTGGGGTGTGGGATCTCCCT 735
591 -----GGGTCTGGGGTGTGGGATCTCCCT 617
736 AAAGAACTGTCTCTGTGCGCAAGTATGAAGTCTCCAGCTTTGCTCAGCTCTCCCA 795
618 AAAGAACTGTCTCTGTGCGCAAGTATGAAGTCTCCAGCTTTGCTCAGCTCTCCCA 677
796 GACAAAGACTGCGTCTCTTCTGCGTTGGAACCCAGAGATCAGAGGATTTGGAGCC 855
678 GACAAAGACTGCGTCTCTTCTGCGTTGGAACCCAGAGATCAGAGGATTTGGAGCC 737
856 GTGAAAGAAATGAGAGGATGGGACCTTGACCTGAACGGGCACTTGTGTGTGCA 915
738 GTGAAAGAAATGAGAGGATGGGACCTTGACCTGAACGGGCACTTGTGTGTGCA 797
916 CAACCGCTAGAAATGCCAAACCGTCCACGAGGACGTGACAGCAGCGCTGGGAAGCA 975
798 CAACCGCTAGAAATGCCAAACCGTCCACGAGGACGTGACAGCAGCGCTGGGAAGCA 857
976 GACAAAGTGGAGAGCGCTGACATGATCTGACAGGACCTGCTCCAGCAGCTCGCTG 1035
858 GACAAAGTGGAGAGCGCTGACATGATCTGACAGGACCTGCTCCAGCAGCTCGCTG 917
1036 AGTTTGCAGCGCTGATGACACACGCTTCTGCGCGCTTGTCTACTCGGGTGGATGGAGCG 1095
918 AGTTTGCAGCGCTGATGACACACGCTTCTGCGCGCTTGTCTACTCGGGTGGATGGAGCG 977
1096 TCGTCCCTGTGTCTTACTGCGCTGCTCCGTTGGAGCGGATCTGTAAACACCATCTC 1155
978 TCGTCCCTGTGTCTTACTGCGCTGCTCCGTTGGAGCGGATCTGTAAACACCATCTC 1037
1156 AACAACTCTGTGGAAGCATACCTCATCAGCATCCAGACAGAGTCGAGTGAAGAAGAT 1215
1038 AACAACTCTGTGGAAGCATACCTCATCAGCATCCAGACAGAGTCGAGTGAAGAAGAT 1097
1216 GTGAAAGTATGATGCGCAGGAATAAATCACTCAAGACATGCTGACGCCCAAGTACAG 1275
1098 GTGAAAGTATGATGCGCAGGAATAAATCACTCAAGACATGCTGACGCCCAAGTACAG 1157
1276 CGGTCTTTTCTGATGAAGAGGAGTTCAGAGGACCTGCTGGAGCTGTCAAGCTTAC 1335
1158 CGGTCTTTTCTGATGAAGAGGAGTTCAGAGGACCTGCTGGAGCTGTCAAGCTTAC 1217
1336 AGTGAATCTCAGACATTAAGCAGCATACCTGCTGTCGCGGACAGTGTCTTGAATACAG 1395
1218 AGTGAATCTCAGACATTAAGCAGCATACCTGCTGTCGCGGACAGTGTCTTGAATACAG 1277
1396 AGGAGGCGGCGCAGCTCCCACTGCGCAGCACCCGAGGCGGAGGAGGAGGAGGAGGAG 1455
1278 AGGAGGCGGCGCAGCTCCCACTGCGCAGCACCCGAGGCGGAGGAGGAGGAGGAGGAG 1337
1456 GCGCTGGGGGATGACCTTCCAGCTGCGTCCGTCAGCTGACGACAGCAGTCCAGGATTA 1515
1338 GCGCTGGGGGATGACCTTCCAGCTGCGTCCGTCAGCTGACGACAGCAGTCCAGGATTA 1397
1516 TCGCTCTGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1575
1398 TCGCTCTGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1457
1576 AGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1635
1458 AGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1517

etc.) and Department of Virology, Institute of Medical Science, University of Tokyo.

FEATURES
source

1. .3138
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="NT2RP4000648"
/cell_line="NT2"
/cell_type="teratocarcinoma"
/clone_lib="NT2RP4"
/notes="cloning vector: pME18SFL3-mRNA from NT2 neuronal precursor cells after 2-weeks retinoic acid (RA) induction."
65. .1936
/notes="unnamed protein product"
/codon_start=1
/protein_id="BAA91817.1"
/db_xref="GI:7023051"
/translation="MERPEEGKQSPPOPWGRLRLRGABEGPHVLLRKREWTIGRRR
GDGLSPSNKLVDGHCRIYVDEKSGQVLEDTSTGTVINKLVKKVKOTCPLOTGDV
IYLVYKNEPHENVAYLVESLAEKQOMTOSFEMVPCVAAQGLKLGGSDPPTLASQ
SIVITGSGGGGIPKSGSGPSVASDEVSSPASPALPDRKTAFSLELPQDDQDLEPEKK
MRGDDGLDGLQLLVAPARNACTVHEDVRAAGRPDKMEETLTCICQDLHDCVSL
QSCMTFTCAACYSMMWRSLSCTRCPCVERICNNILNNLVEAYLIQHPDKRSRSED
VQMDARNKITQDMLQKPYRSGSESDILLESVDSSSDISQPYVVCRCQPE
YRROAARPHCPAPEGAPALGDAPPTVSLTTAVQDYVCPLOGSHALCTCCFQP
MDPRAERSDPRVAPQOCACVCLQPFCHLYWGCRTGCGCLAPFCELNLDGKCLQGV
LNNYSIEDILKNYLATRGLTWKNMLTESLVALQRGVFLISDYRVYTGDTVLCXCCGLR
SPRELYTYQQNIPASELPVAVTSRDPDYGWGRNCRITQVRAHHAHKNHICEQTRFN"

ORIGIN

Query Match 84.4%; Score 2262.4; DB 9; Length 3138;
Best Local Similarity 93.0%; Pred. No. 0;
Matches 2454; Conservative 0; Mismatches 61; Indels 125; Gaps 3;

Qy 27 CTCTTGACACGCGCGCGCGACCGCGTTCCGGGTTCCGGCGCGGGCGGGGATGTGAAT 86
Db 1 CTCTTGACACGCGCGCGCGACCGCGTTCCGGGTTCCGGCGCGGGCGGGGATGTGAAT 60

Qy 87 CCGCATGGACGCGCCCGAGGAAGGCAAGCAGTCGCGCGCGCGCGCGCTTGGGACGCGCT 146
Db 61 CCGCATGGACGCGCCCGAGGAAGGCAAGCAGTCGCGCGCGCGCGCGCTTGGGACGCGCT 120

Qy 147 CCTGCGCTCTGGGCGCGGAGGAGGCGGACGCGACGTCCTCTGAGGAAGCGGAGTGGAC 206
Db 121 CCTGCGCTCTGGGCGCGGAGGAGGCGGACGCGACGTCCTCTGAGGAAGCGGAGTGGAC 180

Qy 207 CATCGGGCGGACGAGGTTGCACTTTCTTCCCGACGCAATAAATGGTCTCTGGAGA 266
Db 181 CATCGGGCGGACGAGGTTGCACTTTCTTCCCGACGCAATAAATGGTCTCTGGAGA 240

Qy 267 TCACTGTAGAAATTGATGGATGAAAAATCAGGTCAAGTGCAGTGCACCTGGAAGATACCAAGCAC 326
Db 241 TCACTGTAGAAATTGATGGATGAAAAATCAGGTCAAGTGCAGTGCACCTGGAAGATACCAAGCAC 300

Qy 327 CAGTGGAAACAGTGATTAACAAAGTGAAGGTTGTTAAGAGCAGACATGCCCTTTACAGAC 386
Db 301 CAGTGGAAACAGTGATTAACAAAGTGAAGGTTGTTAAGAGCAGACATGCCCTTTACAGAC 360

Qy 387 TGGGGATGTCATCTACTTGGTGTACAGGAAGATGAACCGGAACACAAAGTGGCATACCT 446
Db 361 TGGGGATGTCATCTACTTGGTGTACAGGAAGATGAACCGGAACACAAAGTGGCATACCT 420

Qy 447 CTATGAATCTTTAAGTGAAGCAAGGCATGACACAAAGAAATCCTTTGAAGCTAACAAAGGA 506
Db 421 CTATGAATCTTTAAGTGAAGCAAGGCATGACACAAAGAAATCCTTTGAAGCTAACAAAGGA 480

Qy 507 AAATGTGTTCCATGGGACCAAGATACCTCAGGTGCAGGTGCGAGGCGGAGCCCGATCC 566
Db 481 CTGTGTTGCCCGCTGGTCTAAATCTCTGGGATCAAGT----- 520

Qy 567 CCGGGTCCCTCGTCGTCGCCGCCACTCAGGTGTGCTTTTGAGGAACCAAGCCATCAAC 626

QY	2067	GACAAAGTTTCAAAAACCTAAGCATCCAGAGGCCCTCAGCAGCTTTTCAGCACTCGAGGTGAA	2126
Db	1918	GACAAAGTTTCAAAAACCTAAGCATCCAGAGGCCCTCAGCAGCTTTTCAGCACTCGAGGTGAA	1977
QY	2127	GAGAGCGTGTTTTTAAAAATACAGAGACAAGCAAGTCAGAGTGTTTTCACAGCCCCCTGAG	2186
Db	1978	GAGAGCGTGTTTTTAAAAATACAGAGACAAGTCAGAGTGTTTTCACAGCCCCCTGAG	2037
QY	2187	GGAAGGGACGACGGGTCTCCGACAGGTGCTCTTGGGTGACTCTTCTGTGGAGCTTTTTTAC	2246
Db	2038	GGAAGGGACGACGGGTCTCCGACAGGTGCTCTTGGGTGACTCTTCTGTGGAGCTTTTTTAC	2095
QY	2247	CCCTCTGAGTGAGACCTCCCTCCAGAGCCCCGGGGCCGACGCCGCCCTCTCTGTGTAGCGC	2306
Db	2096	CCCTCTGAGTGAGACCTCCCTCCAGAGCCCCGGGGCCGACGCCGCCCTCTCTGTGTAGCGC	2155
QY	2307	TGGGCAAGGGCTCGTGTGGCATCAGCAGCAGACACAAGGCCCTTCTGTAACTATCGCGCGG	2366
Db	2156	TGGGCAAGGGCTCGTGTGGCATCAGCAGCAGACACAAGGCCCTTCTGTAACTATCGCGCGG	2215
QY	2367	TCCGCCGAGAGGGGCAGTTTTCCTCTTTTGTACATTTTCCGAAATCTACAGTTTAAAGCAG	2426
Db	2216	TCTTCCGAGAGGGGCAGTTTTCCTCTTTTGTACATTTTCCGAAATCTACAGTTTAAAGCGG	2275
QY	2427	AAGTCTGTTTTTCAGGAAAAGTTTTCAGGGAGAGGCGAAGTTTATCAAAAACATTTGTTTC	2486
Db	2276	AAGTCTGTTTTTCAGGAAAAGTTTTCAGGGAGAGGCGAAGTTTATCAAAAACATTTGTTTC	2335
QY	2487	AGGAAAGGGAGCATTAAGTTTACAGCTACAGACGCTACACAATATCTCTGCTCTGGAA	2546
Db	2336	AGGAGAGGGAGCATTAAGTTTACAGCTACAGACGCTACACAATATCTCTGCTCTGGAA	2395
QY	2547	AACCACAGCATTTTATCTATTTTTTTTAAATAGTTTGGTCTTATCTTCTTAATAAGA	2606
Db	2396	AACCACAGCATTTTATCTATTTTTTTTAAATAGTTTGGTCTTATCTTCTTAATAAGA	2455
QY	2607	TTTTAAATGTCAAAACTGTAGCAAAATATAATAATTTATAATTTACAAATTGACAAAAA	2666
Db	2456	TTTTAAATGTCAAAACTGTAGCAAAATATAATAATTTATAATTTACAAATTGACAAAAA	2515

RESULT 7	BD156548	3138 bp	DNA	linear	PAT 17-JAN-2003
LOCUS	BD156548				
DEFINITION	Primer for synthesizing full-length cDNA and use thereof.				
ACCESSION	BD156548				
VERSION	BD156548.1	GI:27862306			
KEYWORDS	JP 2002191363-A/11391.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
AUTHORS	1. (bases 1 to 3138)				
	Ota, T., Isogai, T., Nishikawa, T., Hayaishi, K., Saito, K., Yamamoto, J., Ishii, S., Sugiyama, T., Wakamatsu, A., Nagai, K. and Otsuki, T.				
TITLE	Primer for synthesizing full-length cDNA and use thereof				
JOURNAL	Patent: JP 2002191363-A/11391 09-JUL-2002;				
	HELIX RESEARCH INSTITUTE				
COMMENT	OS Homo sapiens (human)				
	PN JP 2002191363-A/11391				
	PD 09-JUL-2002				
	PF 28-JUL-2000 JP 2000280990				
	PI TOSHIO OTA, TAKAO ISOGAI, TETSUO NISHIKAWA, KOJI HAYASHI, KAORU SAITO,				
	PI JUN-ICHI YAMAMOTO, SHIZUKO ISHII, TOMOYASU SUGIYAMA, AI WAKAMATSU, PI KEIICHI NAGAI, TETSUJI OTSUKI				
	PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12P1/02, C12Q1/68/ C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC				
	Primer for synthesizing full-length cDNA and use thereof				PH Key
	Location/Qualifiers				

complex, ER membrane component [Posttranslational
modification, protein turnover, chaperones]"
/db_xref="CDD:COG5243"

ORIGIN

Query Match 93.2%; Score 2497.2; DB 9; Length 3189;
Best Local Similarity 98.5%; Pred. No. 0; Mismatches 3; Indels 36; Gaps 1;
Matches 2545; Conservative 0;

83 GAATCCCGATGAGCGGCCGAGGAGGCAAGCAAGTCCGCGCCGCGAGCCCTGGGAC 142
1 GAATCCCGATGAGCGGCCGAGGAGGCAAGCAAGTCCGCGCCGCGAGCCCTGGGAC 60

143 GCCTCTGCTGCTGGCGCGGAGGAGGCGAGCCCAAGTCTCTGAGGAGCGGAGT 202
61 GCCTCTGCTGCTGGCGCGGAGGAGGCGAGCCCAAGTCTCTGAGGAGCGGAGT 120

203 GGACCATCGGCGGAGAGCAGGCTTGCACCTTTCCTTCCCAAGCAATAAATCGTCTCTG 262
121 GGACCATCGGCGGAGAGCAGGCTTGCACCTTTCCTTCCCAAGCAATAAATCGTCTCTG 180

263 GAGATCACTGTAGATTTGATGTGATGAAATATCAAGTCAAGTGAACATGGAAGATACA 322
181 GAGATCACTGTAGATTTGATGTGATGAAATATCAAGTCAAGTGAACATGGAAGATACA 240

323 GCACCAAGTGGACAGTATTAAAGTGAAGTGTAAAGAGCAGACATGCCCTTTAC 382
241 GCACCAAGTGGACAGTATTAAAGTGAAGTGTAAAGAGCAGACATGCCCTTTAC 300

383 AGACTGGGATGTCATCTATTGTTGTACAGAAAGATGAACCGGAAACAAACGTTGGCAT 442
301 AGACTGGGATGTCATCTATTGTTGTACAGAAAGATGAACCGGAAACAAACGTTGGCAT 360

443 ACCTCTATGAAATCTTTAAGTGAAGAGCAGGATGACACAGAAATCTCTTT 502
361 ACCTCTATGAAATCTTTAAGTGAAGAGCAGGATGACACAGAAATCTCTTT 410

503 AGGAAATGTTTCCATGGGACAAAGATACCTCAGGTGCGAGGTGCGAGGCGGCGG 562
411 -----GATACTCAGGTGCGAGGTGCGAGGCGGCGGCGG 444

563 ATCCCGGGTCCCTCGTGGTCCGCGGCACTCAGGTGCTTTGAGGAAACACAGCCAT 622
445 ATCCCGGGTCCCTCGTGGTCCGCGGCACTCAGGTGCTTTGAGGAAACACAGCCAT 504

623 CAACATCGACGTCAGACCTCTTCCCAACAGCCTCGGCTCTTCCACGAGCCTTCTCCTG 682
505 CAACATCGACGTCAGACCTCTTCCCAACAGCCTCGGCTCTTCCACGAGCCTTCTCCTG 564

683 CAGGCGGAGAGCGTTCCTCAGTTGTGGTCTGGGGTGGTGGATCTCCCTTAAGAA 742
565 CAGGCGGAGAGCGTTCCTCAGTTGTGGTCTGGGGTGGTGGATCTCCCTTAAGAA 624

743 GTGGTCCCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCCCTCAGCTCTCCACAGACAA 802
625 GTGGTCCCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCCCTCAGCTCTCCACAGACAA 684

803 AGACTGCGTCTTTTGTGGTGAACCCAGGATCAGAGGATTTGAGCCCGTGAAGA 862
685 AGACTGCGTCTTTTGTGGTGAACCCAGGATCAGAGGATTTGAGCCCGTGAAGA 744

863 AGAATGAGAGAGATGGGACCTTACCTGAAACCGGAGTGTGTGTCGACACACCGC 922
745 AGAATGAGAGAGATGGGACCTTACCTGAAACCGGAGTGTGTGTCGACACACCGC 804

923 GTAGAAATGCCCAACCGTCCACGAGGACGTCCAGAGCAGCGCTGGGAGCCAGACAGA 982
805 GTAGAAATGCCCAACCGTCCACGAGGACGTCCAGAGCAGCGCTGGGAGCCAGACAGA 864

983 TGGAGAGACGCTGATGATCATCTGCCAGGACCTCTGCACGACTGCGTGAATTGC 1042
865 TGGAGAGACGCTGATGATCATCTGCCAGGACCTCTGCACGACTGCGTGAATTGC 924

1043 AGCCTGCATGACACGTTCTGCGCGCTTGTACTCGGGCTGGATGGAGCGCTCGTCCC 1102
925 AGCCTGCATGACACGTTCTGCGCGCTTGTACTCGGGCTGGATGGAGCGCTCGTCCC 984

1103 TGTGTCTTACTGCTGCTGCGGAGCGGATCTGTAAACACACATCTCTCAACAAC 1162
985 TGTGTCTTACTGCTGCTGCGGAGCGGATCTGTAAACACACATCTCTCAACAAC 1044

1163 TGTGTGAAGCATCTCTCATCCAGCATCCAGCAAGAGTGCAGTGAAGAAGATGTGAAA 1222
1045 TGTGTGAAGCATCTCTCATCCAGCATCCAGCAAGAGTGCAGTGAAGAAGATGTGAAA 1104

1223 GTATGGATGCCAGGAAATAAATCACTCAAGACATGTCTGAGCCCAAGTTCAGGCGGTCT 1282
1105 GTATGGATGCCAGGAAATAAATCACTCAAGACATGTCTGAGCCCAAGTTCAGGCGGTCT 1164

1283 TTTCTGATGAAGAGGAGTTTCAAGAGACCTGCTGAGAGTGTCTGAGCTTTGACAGTGA 1342
1165 TTTCTGATGAAGAGGAGTTTCAAGAGACCTGCTGAGAGTGTCTGAGCTTTGACAGTGA 1224

1343 CCTCAGACATTTGCCAGCCATACGTCTGTCGCGGAGTGTCTCTGAGTACAGAAAGCAGG 1402
1225 CCTCAGACATTTGCCAGCCATACGTCTGTCGCGGAGTGTCTCTGAGTACAGAAAGCAGG 1284

1403 CGGCGCAGCCTCTCCCACTGCTCCAGCAGCCGAGGCGGAGCCAGGAGCCCAACAGGCGCTTG 1462
1285 CGGCGCAGCCTCTCCCACTGCTCCAGCAGCCGAGGCGGAGCCAGGAGCCCAACAGGCGCTTG 1344

1463 GGGATGACACCTCTCAGCTCCGTCAGCTGACAGCAGCAGTCCAGGATTAAGTGTGCGCTC 1522
1345 GGGATGACACCTCTCAGCTCCGTCAGCTGACAGCAGCAGTCCAGGATTAAGTGTGCGCTC 1404

1523 TGCAAGAAAGCCACGCGCTGTGCACTGTCTGCTTCCAGCCCAATGCCCGAGCAGAGCGG 1582
1405 TGCAAGAAAGCCACGCGCTGTGCACTGTCTGCTTCCAGCCCAATGCCCGAGCAGAGTGG 1464

1583 AGCGCAGCAGGACCCGCGTGTGCGCTCTCAGCAGTGTGCGGTCTGCTGACGCTTTCT 1642
1465 AGCGCAGCAGGACCCGCGTGTGCGCTCTCAGCAGTGTGCGGTCTGCTGACGCTTTCT 1524

1643 GCCACCTGTACTGCGGCTGCAACCGGAGCAGGCTGTCTACGCTGCTGCGCCGCTTTGTG 1702
1525 GCCACCTGTACTGCGGCTGCAACCGGAGCAGGCTGTCTACGCTGCTGCGCCGCTTTGTG 1584

1703 AGCTCAACCTGGGTGACAGTGTCTGAGCGGCTGTCTGAACAAACAGCTACGAGTCA 1762
1585 AGCTCAACCTGGGTGACAGTGTCTGAGCGGCTGTCTGAACAAACAGCTACGAGTCA 1644

1763 ACATCTGAGATTTACCTGGCAACAGAGGTTTGACATGGAAACATGTTGACCGAGA 1822
1645 ACATCTGAGATTTACCTGGCAACAGAGGTTTGACATGGAAACATGTTGACCGAGA 1704

1823 GCCTCGTGGCTCTCCAGCGGAGTGTCTGCTGTCTGATTTACAGAGTCAAGGAGACA 1882
1705 GCCTCGTGGCTCTCCAGCGGAGTGTCTGCTGTCTGATTTACAGAGTCAAGGAGACA 1764

1883 CGCTTCTGTGTTACTGCTGCGCTGCGAGCTTCCGTCAGTGAATATCATGATTCGCG 1942
1765 CGCTTCTGTGTTACTGCTGCGCTGCGAGCTTCCGTCAGTGAATATCATGATTCGCG 1824

1943 AGAACATTCCTGCTTCCGAGTTCCAGTGCCTGAATATCCCGTCTGCTACTGCG 2002
1825 AGAACATTCCTGCTTCCGAGTTCCAGTGCCTGAATATCCCGTCTGCTACTGCG 1884

2003 GCGTAACTGCCGCACTCAGGTGAAAGTCAACAACCGCATGAAATTCATATCATCTGTG 2062
1885 GCGTAACTGCCGCACTCAGGTGAAAGTCAACAACCGCATGAAATTCATATCATCTGTG 1944

2063 AACAGCAAGGTTCAAAACTAAGCATCCAGAGGCTTCCAGGAGCTTTCAGGAGTGGAGG 2122
1945 AACAGCAAGGTTCAAAACTAAGCATCCAGAGGCTTCCAGGAGCTTTCAGGAGTGGAGG 2004

2123 TGAAGAGAGCGTGTGTTTTTAAATAACAGACAAAGCAGCTCAAGGTTGTTTTTCAAGCCCC 2182

Query Match	95.8%;	Score 2566.4;	DB 9;	Length 2639;
Best Local Similarity	98.6%;	Pred. No. 0;		
Matches 2613;	Conservative	0;	Mismatches	1;
			Indels	Gaps
			36;	1;
QY	17	GCCGCAATGCTCTTGACAGCGGGCGGCGCAGCCGGTTCGGGGTTCGGCGCGGGCGG	76	
DB	5	GCCGCAATGCTCTTGACAGCGGGCGGCGCAGCCGGTTCGGGGTTCGGCGCGGGCGG	64	
QY	77	GGATGTGAATCCCGATGGAGCGGCCCGAGGAAGCAAGCATGTCGCCCGCCGCGAGCCCT	136	
DB	65	GGATGTGAATCCCGATGGAGCGGCCCGAGGAAGCAAGCATGTCGCCCGCGAGCCCT	124	
QY	137	GGGACCGCTCCTCGCTCTGGCGCGGAGGAGGCGCGCCAGTGCCTCTCTGTAGGAAGC	196	
DB	125	GGGACCGCTCCTCGCTCTGGCGCGGAGGAGGCGCGCCAGTGCCTCTCTGTAGGAAGC	184	
QY	197	GGGAGTGGACCATCGGCGGAGACGAGGTTGCGACCTTTCCTTCCCGACAAATAAATCGG	256	
DB	185	GGGAGTGGACCATCGGCGGAGACGAGGTTGCGACCTTTCCTTCCCGACAAATAAATCGG	244	
QY	257	TCTCTGGAGATCACTGTAGATTTCTAGTGGATGAATAATCAGTGCAGTGCACCTGGAG	316	
DB	245	TCTCTGGAGATCACTGTAGATTTCTAGTGGATGAATAATCAGTGCAGTGCACCTGGAG	304	
QY	317	ATACCAGCACCGAGTGGAAACAGTGAATTAACAGCTGAAGTTGTTTAAGAAGCAGACATGCC	376	
DB	305	ATACCAGCACCGAGTGGAAACAGTGAATTAACAGCTGAAGTTGTTTAAGAAGCAGACATGCC	364	
QY	377	CTTTACAGACTGGGATGTCACTCTACTTGGTATCAGGAGAAATGAACCGGAAACACAACG	436	
DB	365	CTTTACAGACTGGGATGTCACTCTACTTGGTATCAGGAGAAATGAACCGGAAACACAACG	424	
QY	437	TGGCATACCTCTATGAATCTTTAAGTGAAGAAGCAAGGCATGACACAAGAATCTCTTGAAG	496	
DB	425	TGGCATACCTCTATGAATCTTTAAGTGAAGAAGCAAGGCATGACACAAGAATCTCTT---	480	
QY	497	CTAAACAGGAAAATGTGTTCCATGGGACCAAGATACCTCAGGTGCAGGTGCAGGCGAG	556	
DB	481	-----GATACCTCAGGTGCAGGTGCAGGCGAG	508	
QY	557	GGGCGGATCCCGGGTCCCTCCGTGTCGCCCGCCACTCAGGTGTGCTTTGAGGAAACAC	616	
DB	509	GGGCGGATCCCGGGTCCCTCCGTGTCGCCCGCCACTCAGGTGTGCTTTGAGGAAACAC	568	
QY	617	AGGCATCAACATCGAAGTCAGACTCTTTCGCCACAGCCTGGCCCTTTCACGAGAGCTT	676	
DB	569	AGGCATCAACATCGAAGTCAGACTCTTTCGCCACAGCCTGGCCCTTTCACGAGAGCTT	628	
QY	677	CTCTCGAGGCGGAGAGCGTTCTCTCCAGTTGTGGGTCTGGGGTGGTGGCATCTCCCTTA	736	
DB	629	CTCTCGAGGCGGAGAGCGTTCTCTCCAGTTGTGGGTCTGGGGTGGTGGCATCTCCCTTA	688	
QY	737	AAGGAAGTGTCCCTCTGTGGCAAGTGAATGAAGTCTCCAGCTTTCAGCTCTCCAG	796	
DB	689	AAGGAAGTGTCCCTCTGTGGCAAGTGAATGAAGTCTCCAGCTTTCAGCTCTCCAG	748	
QY	797	ACAGAAAGCTGGTCTCTTTCTGTCGTTGGAAACCCAGGATCAGAGAGATTTGGAGCCG	856	
DB	749	ACAGAAAGCTGGTCTCTTTCTGTCGTTGGAAACCCAGGATCAGAGAGATTTGGAGCCG	808	
QY	857	TGAAGAAAGAAATGAGAGGAGATGGGACCTTGAACCTTGAACCGGCGAGTTGTGTGCGAC	916	
DB	809	TGAAGAAAGAAATGAGAGGAGATGGGACCTTGAACCTTGAACCGGCGAGTTGTGTGCGAC	868	
QY	917	AACCGCGTGAAGATGCCCAACCGTCCACGAGGACGTCAGAGCAGCGCTGGGAAGCCAG	976	
DB	869	AACCGCGTGAAGATGCCCAACCGTCCACGAGGACGTCAGAGCAGCGCTGGGAAGCCAG	928	
QY	977	ACAAGATGGAGGAGACGCTGATGATCATCTGCCAGGACCTGCTGACAGACTGCGTGA	1036	
DB	929	ACAAGATGGAGGAGACGCTGATGATCATCTGCCAGGACCTGCTGACAGACTGCGTGA	988	

Db 1409 CCTGGGGGATGACCTCTCACTGCTGCTGAGCTGAGCAGCAGCTCCAGGATTACGTGT 1468
QY 1517 GCCTCTGCAAGGAGCCAGCCCTGTGACCTGTGCTGCTTCCAGCCATGCCCCGACCGGA 1576
Db 1469 GCCTCTGCAAGGAGCCAGCCCTGTGACCTGTGCTTCCAGCCATGCCCCGACCGGA 1528
QY 1577 GAGCGAGCGCAGCAGGAGCCCGCTGTGCGCCCTCAGCAGTGTGCGGTCTGCTGCGAGC 1636
Db 1529 GAGCGAGCGCAGCAGGAGCCCGCTGTGCGCCCTCAGCAGTGTGCGGTCTGCTGCGAGC 1588
QY 1637 CTTTCTGCCACCTGTACTCTGGGGGTGACCCCGGACCGGCTGCTACGCTGCTGCGCCCTGT 1696
Db 1589 CTTTCTGCCACCTGTACTCTGGGGGTGACCCCGGACCGGCTGCTACGCTGCTGCGCCCTGT 1648
QY 1697 TTTGTGAGCTCAACCTGGGTGACAGTGTCTGACGCGGTCTGACCAACAGCAGTACG 1756
Db 1649 TTTGTGAGCTCAACCTGGGTGACAGTGTCTGACGCGGTCTGACCAACAGCAGTACG 1708
QY 1757 AGTCAGACATCCTGGAAGATTACTGCGCAACAGAGGTTTGACATGGAAAAACATGTGA 1816
Db 1709 AGTCAGACATCCTGGAAGATTACTGCGCAACAGAGGTTTGACATGGAAAAACATGTGA 1768
QY 1817 CCAGAGCCTGCTGCTCTCAGCGGGAGTGTTCGTGCTGTCTGATTACAGAGTCACCG 1876
Db 1769 CCAGAGCCTGCTGCTCTCAGCGGGAGTGTTCGTGCTGTCTGATTACAGAGTCACCG 1828
QY 1877 GAGACACGTTCTGTGTTACTGCTGCTGCGCCTGCGCAGCTTCCGTGAGCTACACCTACGT 1936
Db 1829 GAGACACGTTCTGTGTTACTGCTGCTGCGCCTGCGCAGCTTCCGTGAGCTACACCTACGT 1888
QY 1937 ATCGGCAGAACATTCCTGCTTCGAGTTGCGCAGTGGCGGTAAACATCCGTCCTGACTGCT 1996
Db 1889 ATCGGCAGAACATTCCTGCTTCGAGTTGCGCAGTGGCGGTAAACATCCGTCCTGACTGCT 1948
QY 1997 ACTGGGCGCTAACTGCGCACTCAGTGTGAAGCTCACCAGCGCATGAATTCACATCA 2056
Db 1949 ACTGGGCGCTAACTGCGCACTCAGTGTGAAGCTCACCAGCGCATGAATTCACATCA 2008
QY 2057 TCTGTGAACAGACAAAGTTCAAAAACCTAAGCATCCAGAGCGCTGAGCAGCTTTAGACAC 2116
Db 2009 TCTGTGAACAGACAAAGTTCAAAAACCTAAGCATCCAGAGCGCTGAGCAGCTTTAGACAC 2068
QY 2117 TGGAGGTGAAGAGAGCTGTTTTTAAATAACAGAGCAACAGCTCAAGTGTTTTTCA 2176
Db 2069 TGGAGGTGAAGAGAGCTGTTTTTAAATAACAGAGCAACAGCTCAAGTGTTTTTCA 2128
QY 2177 GCCCCTGAGGGAAGGACGAGGCTCTCCGACAGGTGCTCTGCGGTGACTCTTCTGTGG 2236
Db 2129 GCCCCTGAGGGAAGGACGAGGCTCTCCGACAGGTGCTCTGCGGTGACTCTTCTGTGG 2188
QY 2237 AGCTTTTACCTCTGAGTGAGACCTTCCGAGAGCCCGGGGCGCGCAGCCCGCTCC 2296
Db 2189 AGCTTTTACCTCTGAGTGAGACCTTCCGAGAGCCCGGGGCGCGCAGCCCGCTCC 2248
QY 2297 TGGTGAAGCTGGGCGAGGCTCTGCTGGGTGATCAGCAGCAGAGCAAGCTTTCTGTAA 2356
Db 2249 TGGTGAAGCTGGGCGAGGCTCTGCTGGGTGATCAGCAGCAGAGCAAGCTTTCTGTAA 2308
QY 2357 CATCGGCGCTGCCGCGAGAGGGGCGAGTTTGTCTCTTTTGTATATTTCCGAAACATCA 2416
Db 2309 CATCGGCGCTGCCGCGAGAGGGGCGAGTTTGTCTCTTTTGTATATTTCCGAAACATCA 2368
QY 2417 GTTAAAGCAGAAAGTCTGTTTTTCAAGAAAGTTTCAAGGAGAGGGGCAAGTTTATCAAAA 2476
Db 2369 GTTAAAGCAGAAAGTCTGTTTTTCAAGAAAGTTTCAAGGAGAGGGGCAAGTTTATCAAAA 2428
QY 2477 ACATTGTTTACAGGAGAGGGAGCAATAGTTTACAGCCTACAGGACGTACACATATCTGT 2536
Db 2429 ACATTGTTTACAGGAGAGGGAGCAATAGTTTACAGCCTACAGGACGTACACATATCTGT 2488
QY 2537 CTGCTGGGAAACACACAGCATTTTATCTATTTTATTTTAAATAGGTTTCTGCTTATCT 2596

Db 2489 CTGCTGGGAAACACACAGCATTTTATCTATTTTATTTTAAATAGGTTTCTGCTTACT 2548
QY 2597 TCTAATAGATTAAATGTCACAACTGTAGCACAATAATAATAATTTATAATTTACAAA 2656
Db 2549 TCTAATAGATTAAATGTCACAACTGTAGCACAATAATAATAATTTATAATTTACAAA 2608
QY 2657 TTGACAAAA 2666
Db 2609 TTGACTAAA 2618

RESULT 4
AK027687
LOCUS
DEFINITION
Homo sapiens CDNA FLJ14781 fis, clone NT2RP4000455, weakly similar to TRANS-ACTING TRANSCRIPTIONAL PROTEIN ICP0.
ACCESSION
AK027687
VERSION
AK027687.1 GI:14042552
KEYWORDS
cligo capping; fis (full insert sequence).
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1
Ishigai, T., Ota, T., Hayashi, K., Sugiyama, T., Otsuki, T., Suzuki, Y., Nishikawa, T., Negai, K., Sugano, S., Aotsuka, S., Yoshikawa, Y., Matsumura, H., Ishii, S., Kawai, Y., Saito, K., Yamamoto, J., Wakamatsu, A., Nakamura, Y., Nagahara, K., Masuho, Y. and Sasaki, N. NEDO human cDNA sequencing project
Unpublished
2 (bases 1 to 2639)
Ishigai, T. and Otsuki, T.
Direct Submission
Submitted (10-MAY-2001) Takao Ishigai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail: genomics@helix.co.jp, Tel: 81-438-52-3975, Fax: 81-438-52-3986) NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing; Research Association for Biotechnology; cDNA library construction; 5'- & 3'- end one pass sequencing and clone selection; Helix Research Institute (supported by Japan Key Technology Center etc.) and Department of Virology, Institute of Medical Science, University of Tokyo.

FEATURES
Location/Qualifiers
1..2639
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="NT2RP4000455"
/cell_line="NT2"
/cell_type="teratocarcinoma"
/clone_lib="NT2RP4"
/note="cloning vector: pME18SFL3-mRNA from NT2 neuronal precursor cells after 2-weeks retinoic acid (RA) induction."
79..2037
/note="unnamed protein product"
/codon_start=1
/protein_id="BAB5297.1"
/db_xref="GI:14042553"
/translation="MEEPGEKQSPFPQPGWGLLRLGAEGEHPHLLRKREWTIGRR GCDLSPFNKLVGSDHCRIVVDKSGQVTLTDETSSTGTVINKLVKVKQCTPLQGDV IYLVYKNEPHNVAYLYESLSEKQGTQESFDTSGAGAGGADPVPFSPATQVCF EEPQSTSLDFTASASTEPSPAGRSSSCGSGGGISPKSGSPSVASDEVSF ASALPDRKTASFSLEPQDQEDLPVKKRGGDGLDLNGQLLVAPRRNAQTVHEDY RAACPKDKMETLTCTICODLLHDCVSLQCMHTFCAACYSQWNRSSLCPTCRCPV ERICKHILNKLVEAYLIQHPDKSRSEDVQMDARKITODMLQPKVRRSFSEBGS SEDLLESDVSESISQPVYVCRQCPVEYRQAAQPHCPAPBPQAPQALQEGS TSVLTAVQDLYVCPQLGSHALCTCCFPQPDRAERQDPRVAPQCAVCLQFPCHL YWGTRTCYQGLAPFCFLNKLKDLGVNNDNYESDLKNTYKATLWNLMTES LVALQGVLLSDYVLTGDTLVLCYCCGLSRFELTYQYRQNPISAPSELPVAVTSRDCY WGRNCRCTQVKAHAMKENHICQTRFXN"

CDS
3
/note="unnamed protein product"

ORIGIN

Db 425 TGGCATACCTCTATGAATCTTTAAGTGAAGAAAGAGGCATGACACAGAAATCCTTT----- 480
Qy 497 CTAACAAGGAAATGTGTTCCATGGACCAAGATACCTCAGTGCAGGTGCAGGCGAG 556
Db 481 -----GATACCTCAGGTGCAGGTGCAGGCGAG 508
Qy 557 GGGCCGATCCCGGTCCTTCGTCGTCGCCCGCCACTCAGGTGCTTTGAGGAACAC 616
Db 509 GGGCCGATCCCGGTCCTTCGTCGTCGCCCGCCACTCAGGTGCTTTGAGGAACAC 568
Qy 617 AGCCATCAACATCGAGCTCAGACCTCTTCCACAGCCTCGGCCCTTCCACGAGCCTT 676
Db 569 AGCCATCAACATCGAGCTCAGACCTCTTCCACAGCCTCGGCCCTTCCACGAGCCTT 628
Qy 677 CTCCTCGAGGCGAGAGGCTTCCTCAGTTGTGGTCTGGGGTGTGGCATCTCCCTTA 736
Db 629 CTCCTCGAGGCGAGAGGCTTCCTCAGTTGTGGTCTGGGGTGTGGCATCTCCCTTA 688
Qy 737 AAGGAGTGTCTCCTGTGGCAAGTGATGAAGTCTCAGCTTTGGCTCAGCTCTCCAC 796
Db 689 AAGGAGTGTCTCCTGTGGCAAGTGATGAAGTCTCAGCTTTGGCTCAGCTCTCCAC 748
Qy 797 ACAGAAAGATGCGTCTTCTGTCGTTGGAACCCAGGATCAGGAGGATTTGGAGCCG 856
Db 749 ACAGAAAGATGCGTCTTCTGTCGTTGGAACCCAGGATCAGGAGGATTTGGAGCCG 808
Qy 857 TGAAGAGAAATGAGAGGATGGGACCTTGACCTGAACGGGAGTTGTTGTCGCAC 916
Db 809 TGAAGAGAAATGAGAGGATGGGACCTTGACCTGAACGGGAGTTGTTGTCGCAC 868
Qy 917 AACCGGTGAGAAATGCCAAACCGTCCAGAGGACGTCAAGAGCGGCTGGGAAGCCAG 976
Db 869 AACCGGTGAGAAATGCCAAACCGTCCAGAGGACGTCAAGAGCGGCTGGGAAGCCAG 928
Qy 977 ACAAGATGGAGGAGAGCTGACATGATCATCTGCCAGGACCTGCTGACGAGCTGGTGA 1036
Db 929 ACAAGATGGAGGAGAGCTGACATGATCATCTGCCAGGACCTGCTGACGAGCTGGTGA 988
Qy 1037 GTTTGAGCCCTCATGACACAGCTTCTGCGGCTTGTCTACTCGGCTGATGGAGCGCT 1096
Db 989 GTTTGAGCCCTCATGACACAGCTTCTGCGGCTTGTCTACTCGGCTGATGGAGCGCT 1048
Qy 1097 CGTCCCTGTGCTACTCGGCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 1156
Db 1049 CGTCCCTGTGCTACTCGGCTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTC 1108
Qy 1157 ACACCTCGTGGAGATACCTCATCCAGCATCCAGAGAGTTCGAGTGAAGAAGATG 1216
Db 1109 ACACCTCGTGGAGAGATACCTCATCCAGCATCCAGAGAGTTCGAGTGAAGAAGATG 1168
Qy 1217 TGCAAGATATGGATGTCAGGAATAAATCACTCAAGCATGTCGAGGAGTTCGAGTGA 1276
Db 1169 TGCAAGATATGGATGTCAGGAATAAATCACTCAAGCATGTCGAGGAGTTCGAGTGA 1228
Qy 1277 GGTCTTTTCTGATGAAGAGGAGTTTCAGAGACCTGTCGAGCTGTGAGAGTTGACA 1336
Db 1229 GGTCTTTTCTGATGAAGAGGAGTTTCAGAGACCTGTCGAGCTGTGAGAGTTGACA 1288
Qy 1337 GTGAGTCTCAGACATTAAGCCAGCATACCTGTCGTCGTCGTCGTCGTCGTCGTCGTC 1396
Db 1289 GTGAGTCTCAGACATTAAGCCAGCATACCTGTCGTCGTCGTCGTCGTCGTCGTCGTC 1348
Qy 1397 GGCAGGCGGCGAGCTCCCACTGCCAGCACCCGAGGCGGAGCCAGGAGCCCAAGG 1456
Db 1349 GGCAGGCGGCGAGCTCCCACTGCCAGCACCCGAGGCGGAGCCAGGAGCCCAAGG 1408
Qy 1457 CCCTGGGGGATGACCCCTCCAGTCCGTCAGCTGACGACAGCAGTCCAGGATTAAGTGT 1516
Db 1409 CCCTGGGGGATGACCCCTCCAGTCCGTCAGCTGACGACAGCAGTCCAGGATTAAGTGT 1468
Qy 1517 GCCCTCTGCAAGGAGCAGCCCTGTGCACTGCTGCTTCCAGCCCTGCGGAGCGGA 1576

Db 1469 GCCCTCTGCAAGGAAGCCAGCCCTGTGACCTGTGCTTCCAGCCCATGCCGACCGGA 1528
Qy 1577 GAGCGAGCCGAGCAGGACCCGCTGTGCCCTCAGCAGTGTGGGTCTGCTCCTCAGC 1636
Db 1529 GAGCGAGCCGAGCAGGACCCGCTGTGCCCTCAGCAGTGTGGGTCTGCTCCTCAGC 1588
Qy 1637 CTTTCTCCCACTGTACTGGGGTGCACCCGACCCGCTGTCTACGGCTGCTGCCGCCGT 1696
Db 1589 CTTTCTCCCACTGTACTGGGGTGCACCCGACCCGCTGTCTACGGCTGCTGCCGCCGT 1648
Qy 1697 TTTGTAGCTCAACCTGGGTGACAGTGTCTGACCGGCTGTGAACAACAAGCTACG 1756
Db 1649 TTTGTAGCTCAACCTGGGTGACAGTGTCTGACCGGCTGTGAACAACAAGCTACG 1708
Qy 1757 AGTCAGACATCTCTGAGAAATTTACCTGCAACACAGAGTTTGAATGAAAAAATGTTGA 1816
Db 1709 AGTCAGACATCTCTGAGAAATTTACCTGCAACACAGAGTTTGAATGAAAAAATGTTGA 1768
Qy 1817 CCGAGAGCTCTGTCGCTCTCCAGCGGGAGTGTCTGCTGTCTGATTACAGAGTCAAG 1876
Db 1769 CCGAGAGCTCTGTCGCTCTCCAGCGGGAGTGTCTGCTGTCTGATTACAGAGTCAAG 1828
Qy 1877 GAGACCCGCTCTGTCGCTCTGTCGCTGCGCAGCTTCCGTCAGCTGACCTATCAGT 1936
Db 1829 GAGACCCGCTCTGTCGCTCTGTCGCTGCGCAGCTTCCGTCAGCTGACCTATCAGT 1888
Qy 1937 ATCCGAGAAATCTCTGCTTCCAGTTCGAGTGGCGGTAAATCCCGTCTCTGACTGCT 1996
Db 1889 ATCCGAGAAATCTCTGCTTCCAGTTCGAGTGGCGGTAAATCCCGTCTCTGACTGCT 1948
Qy 1997 ACTGGGCGCTAAGTCCGCACTCAGGTGAAGCTCACCGCATCAAAATTCATCATATA 2056
Db 1949 ACTGGGCGCTAAGTCCGCACTCAGGTGAAGCTCACCGCATCAAAATTCATCATATA 2008
Qy 2057 TCTGTGAACAGACAAGTTCAAAAATTAAGCATCCAGAGCCCTGAGCAGCTTTCAGCAC 2116
Db 2009 TCTGTGAACAGACAAGTTCAAAAATTAAGCATCCAGAGCCCTGAGCAGCTTTCAGCAC 2068
Qy 2117 TGGAGTGAAGAGAGCTGTTTTTAAATACAGAGACAAGCAGCTCAAGGTGTTTTACA 2176
Db 2069 TGGAGTGAAGAGAGCTGTTTTTAAATACAGAGACAAGCAGCTCAAGGTGTTTTACA 2128
Qy 2177 GCCCCTCAGGGAAGGAGCAGGCTCTCCAGACAGGTCTCTGGGTGACTTCTCTGTGG 2236
Db 2129 GCCCCTCAGGGAAGGAGCAGGCTCTCCAGACAGGTCTCTGGGTGACTTCTCTGTGG 2188
Qy 2237 AGCTTTTACCTCTGAGTGAGACCTCCCGAGAGCCCGGGGCGCCAGCGCCCTCC 2296
Db 2189 AGCTTTTACCTCTGAGTGAGACCTCCCGAGAGCCCGGGGCGCCAGCGCCCTCC 2248
Qy 2297 TGCTGAGCGCTGGCAGGCTCTGCTGGCATCAGCAGCAGAGACGAGCTTCTGTAA 2356
Db 2249 TGCTGAGCGCTGGCAGGCTCTGCTGGCATCAGCAGCAGAGACGAGCTTCTGTAA 2308
Qy 2357 CATCGGCGCTCCCGAGAGGCGCAGTTTGTCTTTTGTACATTTTCGAAACTACA 2416
Db 2309 CATCGGCGCTCCCGAGAGGCGCAGTTTGTCTTTTGTACATTTTCGAAACTACA 2368
Qy 2417 GTTAAAGCAGAGTCTGTTTTTCAGAAAAAGTTTCAAGGAGAGGCGCAAGTTTATCAAAA 2476
Db 2369 GTTAAAGCAGAGTCTGTTTTTCAGAAAAAGTTTCAAGGAGAGGCGCAAGTTTATCAAAA 2428
Qy 2477 ACATTTTTCAGGAGAGGAGCATAAGTTTACAGCTTACAGGCTGACACAATATCTGT 2536
Db 2429 ACATTTTTCAGGAGAGGAGCATAAGTTTACAGCTTACAGGCTGACACAATATCTGT 2488
Qy 2537 CTGCTGGGAAAAACACAGCATTTTATCTATTTTTTTTATTTTATAGGTTGCTTATCT 2596
Db 2489 CTGCTGGGAAAAACACAGCATTTTATCTATTTTTTTTATTTTATAGGTTGCTTATCT 2548
Qy 2597 TCTAATAAGATTAAATCTCAGAACTGTAGCAGAAAAATATATATTTTATATTTTACAAA 2656
Db 2549 TCTAATAAGATTAAATCTCAGAACTGTAGCAGAAAAATATATATTTTATATTTTACAAA 2608

JOURNAL Nature 406 (6794), 430-435 (2000)
MEDLINE 2038685
PUBMED 10935642
REFERENCE 2 (bases 1 to 2679)
AUTHORS Halazonetis, T.D. and Scolnick, D.M.
TITLE Direct Submission
JOURNAL Submitted (21-JUL-1999) Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
FEATURES Location/Qualifiers
source 1..2679
organism="Homo sapiens"
mol_type="mRNA"
db_xref="taxon:9606"
91..2085
/notes="contains FHA domain and ring finger"
/codon_start=1
/product="cell cycle checkpoint protein CHFR"
protein_id="AAF91084.1"
/db_xref="GI:96511170"

CDS

/translations="MRPSEKGGPPQPGWRLRLRLGABEGPHVLLKREWTIGRRR
GCLSPSPNKLVLGSDHCRIVVDESKQGVLEDTSTGTVINLKVTKQTCPLQGDV
IYLVRNKEPHNAVLYLESLSKQGVLEDTSTGTVINLKVTKQTCPLQGDV
VPSSPATQVCPPEPQPSISLDFPTASASSTERSPAGRESSSCGSGGGLSPKGS
GPSVDEVSPASALPDRKTASFSLEPQDDLPVKKMRGDDLDLNLQQLVQA
PRNAQTVHEDVFAAAGKDPKMBEETLTCIQDLDLHCVSLQPCMHFCACTYGMWE
RSLCTCRCPVERIKNHLINLVEAYLIQHPKRSSEEDVQSDARNKIYDMLQIP
KVRSPSDEGSSEDLLELDVDSSESDISQPVVCRQCPYERQAAQPHCPAPEGE
PGAQALGDAPSTVSLTAVQVCPLOGSHALCTCCFPMPDRAREQDPVAPQ
OCACLOPFCHELVGTRTCVGLAFCELNGLDKLQGLVNNNSVESDILKNVLA
RGUTWKNMLESILVALQGVFLSDYRVGTDLVLCYCGILRSFRELTYVRQNIASE
LPVAVTSRSPDCVGRNCRITQVKAHAKFNHICEQTRFN"

ORIGIN

Query Match		100.0%; Score 2679; DB 9; Length 2679;
Best Local Similarity		100.0%; Pred. No. 0;
Matches 2679; Conservative		0; Mismatches 0; Indels 0; Gaps 0;
QY	1	AAGAATTCGACGAGCGCCGATGCTCTGTGACGCGCGCGCGCGCGCGGTTCCGG 60
DB	1	AAGAATTCGACGAGCGCCGATGCTCTGTGACGCGCGCGCGCGCGCGGTTCCGG 60
QY	61	GTTTCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 120
DB	61	GTTTCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 120
QY	121	CCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 180
DB	121	CCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 180
QY	181	GTCTCTCTGAGGAAGCGGAGTGACCATCGGCGGAGACGAGGTTGCGACCTTCCTTC 240
DB	181	GTCTCTCTGAGGAAGCGGAGTGACCATCGGCGGAGACGAGGTTGCGACCTTCCTTC 240
QY	241	CCGAGCAATAAATCTGTTCTGAGATCACTGTAGATTTAGTGGATGAAAATCAGGT 300
DB	241	CCGAGCAATAAATCTGTTCTGAGATCACTGTAGATTTAGTGGATGAAAATCAGGT 300
QY	301	CAGTGACCTGGAAGATACAGCAGCAGTGAACAGTGAATTAACAGCTGAAGGTTGTT 360
DB	301	CAGTGACCTGGAAGATACAGCAGCAGTGAACAGTGAATTAACAGCTGAAGGTTGTT 360
QY	361	AAGAAGCAGACATGCCCTTTACAGACTGGGATGTATCTATCTGTTGTACAGGAAGAT 420
DB	361	AAGAAGCAGACATGCCCTTTACAGACTGGGATGTATCTATCTGTTGTACAGGAAGAT 420
QY	421	GAACCGGAAACACACGAGGCGATACCTCTATGAATCTTTAGTGAAGCAAGGCGATGACA 480
DB	421	GAACCGGAAACACACGAGGCGATACCTCTATGAATCTTTAGTGAAGCAAGGCGATGACA 480
QY	481	CAAGAATCCTTTGAAGCTAAACAGGAATAATGTGTTCCATGGGACCAAGATACCTCAGGT 540
DB	481	CAAGAATCCTTTGAAGCTAAACAGGAATAATGTGTTCCATGGGACCAAGATACCTCAGGT 540

QY	541	GCAGTGCAGGCGGAGGCGGATCCCGGGTCCCTCCGTCGTCCGCGCCGACCTCAGGTG 600
DB	541	GCAGTGCAGGCGGAGGCGGATCCCGGGTCCCTCCGTCGTCCGCGCCGACCTCAGGTG 600
QY	601	TGCTTTGAGGAACACAGGCCATCAACATCGACGTGACACCTCTTCCCGACAGCCTCGGCC 660
DB	601	TGCTTTGAGGAACACAGGCCATCAACATCGACGTGACACCTCTTCCCGACAGCCTCGGCC 660
QY	661	TCTTCCACGAGCCTTCTCTCTGAGGCGGAGAGGTTCTCCAGTCTGGGTCTGGGGGT 720
DB	661	TCTTCCACGAGCCTTCTCTCTGAGGCGGAGAGGTTCTCCAGTCTGGGTCTGGGGGT 720
QY	721	GCTGCATCTCCCTTAAAGGAAGTGGTCTCTCTGCAAGTGTGCAAGTGTGAAGTCTCCAGCTTT 780
DB	721	GCTGCATCTCCCTTAAAGGAAGTGGTCTCTCTGCAAGTGTGCAAGTGTGAAGTCTCCAGCTTT 780
QY	781	GCCTCAGCTCTCCAGACAGAAAGTCCGTCCTTTTCGTCGTTGGAAACCCACAGATCAG 840
DB	781	GCCTCAGCTCTCCAGACAGAAAGTCCGTCCTTTTCGTCGTTGGAAACCCACAGATCAG 840
QY	841	GAGGATTTGGAGCCCGTGAAGAAATAAGAGAGATGGGACCTTGACCTGAACCGG 900
DB	841	GAGGATTTGGAGCCCGTGAAGAAATAAGAGAGATGGGACCTTGACCTGAACCGG 900
QY	901	CAGTTGTTGGTGCACACACCCGCTAGAAATCCCAACCCGTCACAGGAGGTGACAGCA 960
DB	901	CAGTTGTTGGTGCACACACCCGCTAGAAATCCCAACCCGTCACAGGAGGTGACAGCA 960
QY	961	GCGCTGGAAGCCAGACAAAGATGGAGAGACGTGCATCATCATCTGCGCAGACCTG 1020
DB	961	GCGCTGGAAGCCAGACAAAGATGGAGAGACGTGCATCATCATCTGCGCAGACCTG 1020
QY	1021	CTGCAAGCATCGGTGAGTTTGAGCCCTGTCATGACAGTCTCTGCGGGCTTGTACTCG 1080
DB	1021	CTGCAAGCATCGGTGAGTTTGAGCCCTGTCATGACAGTCTCTGCGGGCTTGTACTCG 1080
QY	1081	GGCTGATGAGCGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1140
DB	1081	GGCTGATGAGCGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1140
QY	1141	AAAAACCATCTCTCAACAACTCGTGGAGCATACCTCATCAGCATCCAGACAGT 1200
DB	1141	AAAAACCATCTCTCAACAACTCGTGGAGCATACCTCATCAGCATCCAGACAGT 1200
QY	1201	CGCAGTGAAGAGATGTGCAAGTATGATGCCAGGAATAAATCACTCAAGACATGCTG 1260
DB	1201	CGCAGTGAAGAGATGTGCAAGTATGATGCCAGGAATAAATCACTCAAGACATGCTG 1260
QY	1261	CAGCCCAAGTCAAGCGGTCTTTTCTGATGAAGAAGGAGTTTCAAGGACCTCTCTGAG 1320
DB	1261	CAGCCCAAGTCAAGCGGTCTTTTCTGATGAAGAAGGAGTTTCAAGGACCTCTCTGAG 1320
QY	1321	CTGTCAAGCTTGAAGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1380
DB	1321	CTGTCAAGCTTGAAGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1380
QY	1381	TGTCCTGATGACAGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGAG 1440
DB	1381	TGTCCTGATGACAGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGAG 1440
QY	1441	CCAGAGCGCCACAGGCGCTGGGGATGCACTCTCCAGTCTCGTCAGCTCAGCTCAGCAGCA 1500
DB	1441	CCAGAGCGCCACAGGCGCTGGGGATGCACTCTCCAGTCTCGTCAGCTCAGCTCAGCAGCA 1500
QY	1501	GTCCAGGATTAAGTGTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1560
DB	1501	GTCCAGGATTAAGTGTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1560
QY	1561	CCCATGCCGAGCCGAGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGTGT 1620
DB	1561	CCCATGCCGAGCCGAGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGTGT 1620
QY	1621	GCGGTCTGCTGACGCTTTCTGCAACCTGTACTGGGGCTGCAACCCGAGCGGCTGTCTAC 1680

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

OM nucleic - nucleic search, using sw model

Run on: May 14, 2004, 11:30:48 ; Search time 16426 Seconds
(without alignments)
7069.036 Million cell updates/sec

Title: US-10-048-046-1
Perfect score: 2679
Sequence: 1 aagaattcgacagaggccg.....acaaaaaaaaaaaaaaaa 2679

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 2167151695 residues
Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl.*

- 1: gb_ba.*
- 2: gb_hcg.*
- 3: gb_in.*
- 4: gb_cm.*
- 5: gb_ov.*
- 6: gb_pat.*
- 7: gb_ph.*
- 8: gb_pl.*
- 9: gb_pr.*
- 10: gb_ro.*
- 11: gb_sts.*
- 12: gb_sy.*
- 13: gb_un.*
- 14: gb_vi.*
- 15: em_ba.*
- 16: em_fun.*
- 17: em_hum.*
- 18: em_in.*
- 19: em_mu.*
- 20: em_om.*
- 21: em_or.*
- 22: em_ov.*
- 23: em_pat.*
- 24: em_ph.*
- 25: em_pl.*
- 26: em_ro.*
- 27: em_sts.*
- 28: em_un.*
- 29: em_vi.*
- 30: em_hcg_hum.*
- 31: em_hcg_inv.*
- 32: em_hcg_other.*
- 33: em_hcg_mus.*
- 34: em_hcg_pln.*
- 35: em_hcg_rod.*
- 36: em_hcg_man.*
- 37: em_hcg_vrt.*
- 38: em_sy.*
- 39: em_hgtgo_hum.*
- 40: em_hgtgo_mus.*
- 41: em_hgtgo_other.*

Pred. No. is the number of results predicted by chance to have a

Result No.	Score	Query Match	Length	DB ID	Description
1	2679	100.0	2679	9	AF170724 Homo sapi
2	2566.4	95.8	2639	6	AX877194 Sequence
3	2566.4	95.8	2639	6	BD156534 Primer fo
4	2566.4	95.8	2639	9	AX027887 Homo sapi
5	2497.2	93.2	3189	9	BC012072 Homo sapi
6	2262.4	84.4	3138	6	AX877222 Sequence
7	2262.4	84.4	3138	6	BD156548 Primer fo
8	2262.4	84.4	3138	9	AK001658 Homo sapi
9	2244.6	83.8	3181	6	AX405642 Sequence
10	1919.4	71.6	2448	6	AX834949 Sequence
11	1919.4	71.6	2448	9	AX097671 Homo sapi
12	1500.4	56.0	2297	9	AL337561 Homo sapi
13	1491	55.7	3194	10	BC049792 Mus muscu
14	1279.8	47.8	6235	6	BD183291 Novel gen
15	961.8	35.9	2257	9	AK090948 Homo sapi
16	876.2	32.7	2186	6	AX713476 Sequence
17	876.2	32.7	2186	9	AK054917 Homo sapi
18	727	27.1	816	6	AX868758 Sequence
19	727	27.1	816	6	BD148820 Primer fo
20	608.4	22.7	181012	9	AC127070 Homo sapi
21	608.4	22.7	181438	2	AC023047 Homo sapi
22	583	21.8	824	6	AX868776 Sequence
23	583	21.8	824	6	BD148838 Primer fo
24	488.8	18.2	518	6	AX873789 Sequence
25	488.8	18.2	518	6	BD153851 Primer fo
26	440.8	16.5	151210	2	AC139591 Rattus no
27	440.8	16.5	273812	2	AC106441 Rattus no
28	430.4	16.1	236751	2	AC128407 Rattus no
29	416	15.5	61779	2	AC126301 Rattus no
30	218	8.1	181438	2	AC023047 Homo sapi
31	142.4	5.3	202792	2	AC125898 Rattus no
32	139.2	5.2	158897	2	AC118260 Mus muscu
33	93.4	3.5	173911	9	AC092490 Homo sapi
34	85.2	3.2	338116	2	AC087159 Mus muscu
35	82.8	3.1	321708	2	AC087142 Mus muscu
36	82.2	3.1	617	6	AX385952 Sequence
37	69.4	2.6	601	11	BV02855 S208P6639
38	64.4	2.4	165089	9	AC021646 Homo sapi
39	55.6	2.1	125020	9	AF429315 Homo sapi
40	55.4	2.1	14923	3	AE001394 Plasmodi
41	54.8	2.0	125020	9	AF429315 Homo sapi
42	53.4	2.0	61052	2	AC123513 Dictyoste
43	53.4	2.0	136240	3	AC117070 Dictyoste
44	52.6	2.0	110000	3	AC116957_2 Continuation (3 of
45	52.4	2.0	2000	6	AX655393 Sequence

ALIGNMENTS

RESULT 1
AF170724
LOCUS AF170724 2679 bp mRNA linear PRI 03-AUG-2000
DEFINITION Homo sapiens cell cycle checkpoint protein CHFR mRNA, complete cds.
ACCESSION AF170724
VERSION AF170724.1 GI:96511169
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2679)
AUTHORS Scolnick,D.M. and Halazonetis,T.D.
TITLE Chfr defines a mitotic stress checkpoint that delays entry into metaphase

This Page Blank (uspto)

Query Match 8.7%; Score 82.5; DB 5; Length 1023;
 Best Local Similarity 29.7%; Pred. No. 4.1; Mismatches 27; Indels 17; Gaps 1;
 Matches 22; Conservative 8;
 QY 31 APOQCAVCLQPFCHLYMGCTGTCYGCIAAPFCE-----LNLGDKCLDG 73
 DB 950 APNSCMGCKGPFLLHVMKARVCHCCGKIFCESCTSHKPIKKYINTPRVRCDFND 1009
 QY 74 VLNNNSYESDILKN 87
 DB 1010 LQSNPSSNSFLND 1023

RESULT 15

Q810G8 PRELIMINARY; PRT; 523 RA.
 AC Q810G8.
 DT 01-MAR-2003 (TRENBLrel. 23, Created)
 DT 01-MAR-2003 (TRENBLrel. 23, Last sequence update)
 DE 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
 DE CG32018-PG (Zyx102.6 isoform).
 GN CG32018 OR ZYX102EF.
 OS Drosophila melanogaster (Fruit fly).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
 OC Ephydroidea; Drosophilidae; Drosophila.
 OX NCBI_TaxID=7227;
 RN [1]
 RN SEQUENCE FROM N.A.
 RP MEDLINE=20196006; PubMed=10731132;
 RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
 RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
 RA Sutton G.G., Wortman J.R., Bland J.M., Zhang Q., Chen L.X.,
 RA Brandon R.C., Rogers Y.H., Blazer V., Hughes R., Breen D.,
 RA Wan K.H., Doyle C., Baxter E.G., Heit G., Nelson C.R., Gabor G.L.,
 RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
 RA Beeson K.V., Benos P.V., Bereman B.P., Bhandari D., Bolshakov S.,
 RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,
 RA Burtis K.C., Buesam D.A., Butler H., Cadiou E., Center A., Chandra I.,
 RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
 RA de Pablo B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
 RA Dodson K., Dou P.L., Downes M., Dunagan-Rocha S., Dunkov B.C., Dunn P.,
 RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
 RA Folsler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
 RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
 RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
 RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,
 RA Jaali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
 RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
 RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
 RA Liu X., Mattel B., McIntosh T.C., McLeod M.P., McPherson D.,
 RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
 RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacieb J.M.,
 RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
 RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
 RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
 RA Shue B.C., Siden-Kimons I., Simpson M., Skupski M.P., Smith T.,
 RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
 RA Svirska R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
 RA Wang Z.Y., Wasserman D.A., Weinstock G.M., Weissbach J.,
 RA Williams S.M., Woodger, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
 RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
 RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
 RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.,
 RT "The genome sequence of Drosophila melanogaster."
 RL Science 287:2185-2195(2000).
 RN [2]
 RN SEQUENCE FROM N.A.
 RP Celniker S.E., Adams M.D., Kronmiller B., Wan K.H., Holt R.A.,
 RA Evans C.A., Gocayne J.D., Amanatides P.G., Brandon R.C., Rogers Y.,

RA Banzon J., An H., Baldwin D., Banzon J., Beeson K.Y., Buesam D.A.,
 RA Carlson J.W., Center A., Champe M., Davenport L.B., Dietz S.M.,
 RA Dodson K., Dorsett V., Dou P.L., Doyle C., Dreanek D., Farfan D.,
 RA Ferreira S., Frise E., Galle R.F., Garg N.S., George R.A.,
 RA Gonzalez M., Hock J., Hoskins R.A., Hostin D., Howland T.J.,
 RA Ibegwam C., Jalali M., Kruse D., Li P., Mattel B., Moshrefi A.,
 RA McIntosh T.C., Moy M., Murphy B., Nelson C., Nelson K.A., Nunoo J.,
 RA Pacieb J., Paragas V., Park S., Patel S., Pfeiffer B.,
 RA Phouanavong S., Pittman G.S., Puri V., Richards S., Scheeler F.,
 RA Stapleton M., Strong R., Svirska R., Tector C., Tyler D.,
 RA Williams S.M., Zaveri J.S., Smith H.O., Venter J.C., Rubin G.M.,
 RT "Sequencing of Drosophila melanogaster genome."
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RN SEQUENCE FROM N.A.
 RP Misra S., Crosby M.A., Matthews B.B., Bayraktaroglu L., Campbell K.,
 RA Hradecky P., Huang Y., Kaminker J.S., Prochnik S.E., Smith C.D.,
 RA Tupy J.L., Bergman C., Berman B., Carlson J.W., Celniker S.E.,
 RA Clamp M., Drysdale R., Emmert D., Frise E., de Grey A., Harris N.,
 RA Kronmiller B., Marshall B., Millburn G., Richter J., Russo S.,
 RA Seale S.W.J., Smith E., Shu S., Smutniak P., Whitfield E.,
 RA Ashburner M., Gelbart W.M., Rubin G.M., Mungall C.J., Lewis S.E.,
 RT "Annotation of Drosophila melanogaster genome."
 RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 RN [4]
 RN SEQUENCE FROM N.A.
 RP Adams M.D., Celniker S.E., Gibbs R.A., Rubin G.M., Venter C.J.,
 RA Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
 RN [5]
 RN SEQUENCE FROM N.A.
 RP Flybase;
 RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
 RN [6]
 RN SEQUENCE FROM N.A.
 RP Stonach B.E., Siegrist S., Renfranz P.J., Macalima T., Beckerle M.C.,
 RT "The Zyx102 gene of Drosophila melanogaster."
 RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AE003846; AA006571.1; -
 DR EMBL; AF219947; AA085868.1; -
 DR InterPro; IPR001781; LIM.
 DR Pfam; PF00412; LIM; 3.
 DR ProDom; PD000094; LIM; 3.
 DR SMART; SM00132; LIM; 3.
 DR PROSITE; PS00478; LIM DOMAIN 1; 2.
 DR PROSITE; PS00223; LIM DOMAIN 2; 1.
 SQ SEQUENCE 523 AA; 5908 MW; 79B2A099F8D7890 CRC64;
 Query Match 8.6%; Score 81.5; DB 5; Length 523;
 Best Local Similarity 24.9%; Pred. No. 2.4;
 Matches 44; Conservative 17; Mismatches 63; Indels 53; Gaps 10;
 QY 7 HALTCC-----FQPNP-----DRAERQDPFVAPQCAVCLQPFCHLYMGCT-----RT 52
 DB 348 HIFCTTDCQINLQKPFVALDGKPYCEYDYLQTLKSCVCEPILRILRATKPYHP 407
 QY 53 GCYGCIAAPFCHLYMGCTGTCYGCIAAPFCE-----LNLGDKCLDG----- 100
 DB 408 QCFTCVV--C--GKSLDGLFTVDATNQNYCIIDFHKKE-APRCVCVKQPIMPDPGQ 459
 QY 101 --TESLVALOR-----GVLLSDYRTVG-----DTVLVCYCGCLRSFREL 138
 DB 460 EETIRVALDRSFLECYCKCEDCGLLSSEAGEGCGYPLDDHVLCKSCNAKRVQALT 516

Search completed: May 7, 2004, 14:49:06
 Job time : 26.0148 secs

```
DR InterPro; IPR001304; Lectin_C.
DR InterPro; IPR000436; Sushi_SCR_CCP.
DR Pfam; PF00008; EGF; 7.
DR Pfam; PF02494; HVR; 1.
DR Pfam; PF00057; ldl_recept_a; 1.
DR Pfam; PF00059; lectin_C; 1.
DR Pfam; PF00084; sushi; 3.
DR PRINTS; PR00011; EGF_LAMININ.
DR SMART; SM00032; CCP; 3.
DR SMART; SM00034; CLECT; 1.
DR SMART; SM00181; EGF; 13.
DR SMART; SM00192; LDLA; 1.
DR PROSITE; PS00010; ASX_HYDROXYL; 1.
DR PROSITE; PS00041; C_TYPE_LECTIN_2; 1.
DR PROSITE; PS00022; EGF_1; 8.
DR PROSITE; PS01186; EGF_2; 4.
DR PROSITE; PS01187; EGF_CA; 1.
DR PROSITE; PS00068; LDLFA_2; 1.
KW EGF-like domain.
SQ SEQUENCE 2972 AA; 329457 MW; 87D7BA80562F4C74 CRC64;

Query Match 8.9%; Score 83.5; DB 5; Length 2972;
Best Local Similarity 27.1%; Pred. No. 11;
Matches 55; Conservative 12; Mismatches 51; Indels 85; Gaps 15;

QY 10 CTCCTCFP-----MPDRAERQDPRAVAPQCAVCLQ-----P 41
Db 1407 CLCNPPCPSTELLQR--DQIGDCTLNSCQGVCLQWNGXHDCAENYFIVDRENGTP 1464

QY 42 FCH-----LWGCRTTCYGC-----LAPCELN-LGDKC-LDGVLNNSYE---SD 83
Db 1465 FCKPNHCLFTNQRNSGYDCGTRENAFLCP--NLNFEFGDFQYEGQLYNNSYTILSA 1522

QY 84 ILKNYLATRLGTLWKMLTSLVALQGVFLSDYRTGDTVLVCYCGGLRSFRELTYQVQR 143
Db 1523 GIENATATN-----LCESLDLT-----YAVPN-----TFCV-----Q 1549

QY 144 NIPASELPVAVTSRPPCYWGRNC 166
Db 1550 N-PTSTTP-SIHRCDFCYGENC 1570

RESULT 13
ID 016004 PRELIMINARY; PRT; 2531 AA.
AC 016004;
DT 01-JAN-1998 (T-EMBLrel. 05, Created)
DT 01-JAN-1998 (T-EMBLrel. 05, Last sequence update)
DT 01-OCT-2003 (T-EMBLrel. 25, Last annotation update)
DE Notch homolog.
OC Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinzoa;
OC Echinoidea; Euechinoidea; Echinacea; Temnopleuroidea; Tokopneustidae;
OC Lytechinus.
OX NCBI_TaxID=7654;
[1]
RN SEQUENCE FROM N.A.
RX MEDLINE=97454256; PubMed=9310331;
RA Sherwood D.R., McClay D.R.;
RT "Identification and localization of a sea urchin Notch homologue:
RT insights into vegetal plate regionalization and Notch receptor
RT regulation."
RL Development 124:3363-3374 (1997).
DR EMBL; AF000634; AA82088.1; -.
DR HSP; P01132; IEGF.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005509; F:calcium ion binding; IEA.
DR GO; GO:0030154; P:cell differentiation; IEA.
DR InterPro; IPR002110; ANK.
DR InterPro; IPR00152; Asx_hydroxyl_S.
DR InterPro; IPR000742; EGF_2.
DR InterPro; IPR001881; EGF_CA.
DR InterPro; IPR001438; EGF_II.
```

```
DR InterPro; IPR006209; EGF like.
DR InterPro; IPR008297; Notch_dom.
DR Pfam; PF00023; ank; 6.
DR Pfam; PF00008; EGF; 34.
DR Pfam; PF00066; notch; 3.
DR PRINTS; PR00010; EGFBLCOO.
DR PRINTS; PR001452; NOTCH.
DR SMART; SM00248; ANK; 5.
DR SMART; SM00179; EGF_CA; 23.
DR SMART; SM00004; NL; 3.
DR PROSITE; PS00088; ANK_REPEAT; 5.
DR PROSITE; PS0297; ANK_REPEAT_REGION; 1.
DR PROSITE; PS00010; ASX_HYDROXYL; 21.
DR PROSITE; PS00022; EGF_1; 33.
DR PROSITE; PS01186; EGF_2; 25.
DR PROSITE; PS01187; EGF_CA; 20.
DR PIRSF; PIRSF002279; Notch; 1.
KW ANK repeat; EGF-like domain; Repeat.
SQ SEQUENCE 2531 AA; 273982 MW; 5BF42BEC627CA303 CRC64;

Query Match 8.8%; Score 83; DB 5; Length 2531;
Best Local Similarity 28.6%; Pred. No. 11;
Matches 30; Conservative 9; Mismatches 40; Indels 26; Gaps 6;

QY 5 GSHALCTCCFOP--MPDRAERQDPRAVAPQCAVCLQPECHLYWGCTR-TGCVGCL--- 58
Db 840 GYSCRTSGFGNFCDDRNE-----CLFSPCRNGGCTNLEGSFECSCLP 885

QY 59 ---APFCELNLDGKLDGVLNNSYESDILKNYLAT--RGLTWKN 98
Db 886 GYDGPICEINI-DECAAGPCTNGICITLDDIFCSCQORGTGKN 929

RESULT 14
Q9XYD4 PRELIMINARY; PRT; 1023 AA.
ID Q9XYD4
AC Q9XYD4;
DT 01-NOV-1999 (T-EMBLrel. 12, Created)
DT 01-NOV-1999 (T-EMBLrel. 12, Last sequence update)
DT 01-OCT-2003 (T-EMBLrel. 25, Last annotation update)
DE Sterol glucosyltransferase (EC 2.4.1.173).
GN UGT52.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyostellida; Dictyostelium.
OX NCBI_TaxID=44689;
[1]
RN SEQUENCE FROM N.A.
RX STRAIN=AX4;
RX MEDLINE=99240683; PubMed=10224056;
RA Warnecke D., Erdmann R., Fahl A., Hube B., Muller F., Zank T.,
RA Zahring U., Heinz E.;
RT "Cloning and functional expression of UGT genes encoding sterol
RT glucosyltransferases from Saccharomyces cerevisiae, Candida albicans,
RT Pichia pastoris, and Dictyostelium discoideum."
RL J. Biol. Chem. 274:13048-13059 (1999).
DR EMBL; AF098916; AAD28546.1; -.
DR GO; GO:0016906; F:sterol 3-beta-glucosyltransferase activity; IEA.
DR GO; GO:0016758; F:transferase activity; transferring hexosyl . . . ; IEA.
DR GO; GO:0008270; F:zinc ion binding; IEA.
DR GO; GO:0005975; P:carbohydrate metabolism; IEA.
DR GO; GO:0030259; P:lipid glycosylation; IEA.
DR InterPro; IPR004276; Glyco_trans_28.
DR InterPro; IPR004182; GRAM_dom.
DR InterPro; IPR00306; Znf_FYVE.
DR Pfam; PF01363; FYVE; 1.
DR Pfam; PF03033; Glyco_transf_28; 1.
DR Pfam; PF02893; GRAM; 2.
DR SMART; SM00064; FYVE; 1.
DR SMART; SM00568; GRAM; 1.
DR PROSITE; PS0178; ZF_FYVE; 1.
KW Glycosyltransferase; Transferase.
SQ SEQUENCE 1023 AA; 114366 MW; 0E3C8C556C5D3709 CRC64;
```

```

DR InterPro; IPR001870; B302.
DR InterPro; IPR006574; PRY.
DR InterPro; IPR003877; SPRY_receptor.
DR InterPro; IPR000315; Znf_Box.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00622; SPRY; 1.
DR Pfam; PF00643; zf-B_box; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR Pfam; PF00036; BBOX; 1.
DR SMART; SM00369; PRY; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS01119; ZF_BOX; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
DR Hypothetical protein_Metal-binding; Zinc; Zinc-finger.
KW NON_TER
SQ
SEQUENCE 504 AA; 57735 MW; E0B377F32A36D1B9 CRC64;

Query Match 9.0%; Score 85; DB 4; Length 504;
Best Local Similarity 24.8%; Pred. No. 0.91;
Matches 34; Conservative 15; Mismatches 58; Indels 30; Gaps 7;

16 PMDPRRA-BEQDPRVAPQ-----CAVCLQPFCH-LYWGCTRTGYCGLAPPCELNL 66
5 PEPAARAMERSPDVSPGSRSPKEILLCAVCYDPRDAVTLRCGHNFRCGVCRCMEVQV 64
67 GDKCLDGLVNNNSYESDILKNYL-----ATRGLTWKNMLTESLVALORG---VF 112
65 SPTC--PVCKDRASPADLTNTLNLLVEKLLREAEAGARTSYRFSRVCELHREGQLSLF 122
113 LLSDYRVGTGTVLCYCC 129
123 CLED-----KELLCCSC 134

RESULT 12
P90891 PRELIMINARY; PRT; 2972 AA.
ID P90891
AC P90891;
DT 01-MAY-1997 (TrEMBLrel. 03, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE F55H12.3 protein.
DE F55H12.3.
GN Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderinae; Caenorhabditis.
NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RA Dobson R.;
RR Submitted (OCT-1996) to the EMBL/GenBank/DBJ databases.
RS [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=99069613; PubMed=9851916;
RA none;
RT "Genome sequence of the nematode C.elegans: A platform for
RT investigating biology.";
RT Science 282:2012-2018(1998).
DR EMBL; Z81091; CAB03143.2; -.
DR PIR; T22759; T22759.
DR HSSP; P00740; IEDM.
DR WormPep; F55H12.3; CE25008.
DR GO; GO:0005509; F:calcium ion binding; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR GO; GO:0005529; F:sugar binding; IEA.
DR InterPro; IPR000152; Asx_hydroxyl_S.
DR InterPro; IPR001881; EGF_Ca.
DR InterPro; IPR006209; EGF-like.
DR InterPro; IPR003410; HyalIn.
DR InterPro; IPR006210; IEGF.
DR InterPro; IPR002172; LDL receptor A.

```

Q7T3P2;	01-OCT-2003 (TrEMBLrel. 25, Created)	Query Match	95.5%;	Score 901;	DB 11;	Length 663;
DT	01-OCT-2003 (TrEMBLrel. 25, Last sequence update)	Best Local Similarity	93.4%;	Pred. No. 3.2e-92;		
DE	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)	Matches	155;	Conservative	9;	Mismatches 2; Indels 0; Gaps 0;
DE	Hypothetical protein.					
OS	Brachydanio rerio (Zebrafish) (Danio rerio).	QY	1	CPLQGSALCTCCFQMPDRAAREODPRVAPQCAVCLQPPCHLYWGCTRGCGCLAP	60	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	DB	475	CPLQGSALCTCCFQMPDRAAREODPRVAPQCAVCLQPPCHLYWGCTRGCGCLAP	534	
OC	Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;					
OC	Cyprinidae; Danio.	QY	61	FCELNLGDKCLDGLVNNNSYESDILKNYLATRLGTWKMLTSLVALQGVFLLSDYRVT	120	
OX	NCBI_TaxID=7955;	DB	535	FCELNLGDKCLDGLVNNNSYESDILKNYLATRLGTWKMLTSLVALQGVFLLSDYRVT	594	
RN	[1]					
RP	SEQUENCE FROM N.A.	QY	121	GDTVLCYCGCLRSFRLTYQYQNIIPASELPVAVTSRPPCYGGRNC	166	
RC	TISSUE=Embryo;	DB	595	GNTVLCYCGCLRSFRLTYQYQNIIPASELPVAVTSRPPCYGGRNC	640	
RX	MEDLINE=2238257; PubMed=12477932;					
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,					
RA	Klauser R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,					
RA	Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,					
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,					
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,					
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,					
RA	Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,					
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,					
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,					
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,					
RA	Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,					
RA	Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,					
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,					
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,					
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield V.S.,					
RA	Krzywinski M.I., Skalska U., Smallus D.E., Scherch A., Schein J.B.,					
RA	Jones S.J., Marra M.A.;					
RT	"Generation and initial analysis of more than 15,000 full-length human					
RT	and mouse cDNA sequences."					
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).					
RN	[2]					
RP	SEQUENCE FROM N.A.					
RC	TISSUE=Embryo;					
RA	Strausberg R.;					
RL	Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.					
DR	EMBL; BC053142; AAHS3142.1; -					
KW	Hypothetical protein.					
SQ	SEQUENCE 292 AA; 31678 MW; 5BBA8E434A66287C CRC64;					
		Query Match	9.7%;	Score 91.5;	DB 13;	Length 292;
		Best Local Similarity	23.2%;	Pred. No. 0.089;		
		Matches	35;	Conservative	20;	Mismatches 67; Indels 29; Gaps 7;
QY	1	CPLQGSALCTCCFQMPDRAAREODPRVAP-----OQCAVCLQPPCHLY----	46			
DB	125	CPVQCT-VFCCCRSPWSDGHSLSLQQLPMPPLPDGALSDDTEAALKQCPVCGVIERN	183			
QY	47	WGCTRTGCGCLAPFCELNLDKCLDGLVNNNSYESDILKNYL--ATRGLTWN-----	98			
DB	184	QCCAQLCKSKCHTFWCYCLQN--LDGDIPLRHVDKGCPCNKLGHSRASVMNRVTQVGI	241			
QY	99	MLTESLVALQGVFLLSDYRVTGDTVLCYCC	129			
DB	242	LVGASIIIVLTSPLLL-----LASPCILCCVC	268			
		RESULT 10				
Q9N9P8		PRELIMINARY;	PRT;	806 AA.		
ID	Q9N9P8					
AC	Q9N9P8;					
DT	01-OCT-2000 (TrEMBLrel. 15, Created)					
DT	01-OCT-2000 (TrEMBLrel. 15, Last sequence update)					
DE	Hypothetical protein.					
GN	L2802.02.					
OS	Leishmania major.					
OC	Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.					
OX	NCBI_TaxID=5664;					
RN	[1]					

```
Matches 165; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 CPLQSHALCTCCQPMEDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
DB 435 CPLQSHALCTCCQPMEDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 494
QY 61 FCELNIGDKLDGVLNNNSYSDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVT 120
DB 495 FCELNIGDKLDGVLNNNSYSDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVT 554
QY 121 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 166
DB 555 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 600

RESULT 5
Q96EP1 PRELIMINARY; PRT; 652 AA.
AC Q96EP1,
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC Tissue-Placenta;
RA Strausberg R.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; BC012072; AAH12072.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 652 AA; 72058 MW; 1A50773CEA679F07 CRC64;

Query Match 99.6%; Score 939; DB 4; Length 652;
Best Local Similarity 99.4%; Pred. No. 1.7e-96;
Matches 165; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CPLQSHALCTCCQPMEDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
DB 464 CPLQSHALCTCCQPMEDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 523
QY 61 FCELNIGDKLDGVLNNNSYSDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVT 120
DB 524 FCELNIGDKLDGVLNNNSYSDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVT 583
QY 121 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 166
DB 584 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 629

RESULT 6
Q810L3 PRELIMINARY; PRT; 664 AA.
AC Q810L3,
DT 01-JUN-2003 (TREMBLrel. 24, Created)
DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE RIKEN cDNA 5730484M20 Gene.
OS Mus musculus (Mouse).
```

```
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC Tissue=Limb;
RA Strausberg R.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC049792; AAH49792.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; ZF-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
SQ SEQUENCE 664 AA; 73871 MW; D651BE3E463DEBB6 CRC64;

Query Match 96.5%; Score 910; DB 11; Length 664;
Best Local Similarity 94.0%; Pred. No. 3.1e-93;
Matches 156; Conservative 1; Mismatches 9; Indels 0; Gaps 0;
QY 1 CPLQSHALCTCCQPMEDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
DB 476 CPLQSHALCTCCQPMEDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 535
QY 61 FCELNIGDKLDGVLNNNSYSDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVT 120
DB 536 FCELNIGDKLDGVLNNNSYSDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVT 595
QY 121 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 166
DB 596 GNTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 641

RESULT 7
Q8BJZ9 PRELIMINARY; PRT; 663 AA.
AC Q8BJZ9,
DT 01-MAR-2003 (TREMBLrel. 23, Created)
DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Similar to cell cycle checkpoint protein CHFR.
GN 5730484M20RIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Body;
RX MEDLINE=22354683; PubMed=12466851;
RA The PANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573(2002).
DR EMBL; AK077629; BAC36912.1; -.
DR MGD; MGI:2444898; 5730484M20RIK.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; ZF-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
SQ SEQUENCE 663 AA; 73855 MW; 42BD653DCB4ADF45 CRC64;
```

CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AF170724; AAF91084.1; -.
DR PDB; ILGP; 07-AUG-02.
DR PDB; ILGQ; 07-AUG-02.
DR Genew; HGNC:20455; CHFR.
DR GO; GO:0007033; P:mitotic checkpoint; TAS.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 664 AA; 73386 MW; 141A1E7FEFAE36A2 CRC64;

Query Match 100.0%; Score 943; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 6.1e-97;
Matches 166; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CPLOGSHALCTCCFQPMDDRAEREQDPVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
DB 476 CPLOGSHALCTCCFQPMDDRAEREQDPVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 535

QY 61 FCEINLGDKCLDGVNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYRVT 120
DB 536 FCEINLGDKCLDGVNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYRVT 595

QY 121 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSPDCYWGRC 166
DB 596 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSPDCYWGRC 641

RESULT 4
Q9NVD5 PRELIMINARY; PRT; 623 AA.
ID Q9NVD5
AC Q9NVD5
DT 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Hypothetical protein FLJ10796.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Isogai T., Ota T., Hayaishi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Aotsuka S., Yoshikawa Y.,
RA Matsumura H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,
RA Nakamura Y., Nagahari K., Masuho Y., Sasaki N.,
RT "NEDO human cDNA sequencing project."
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AK001658; BAA91817.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 623 AA; 69204 MW; 45186D3DAE52711 CRC64;

Query Match 99.6%; Score 939; DB 4; Length 623;
Best Local Similarity 99.4%; Pred. No. 1.6e-96;

CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AK027687; BAB55297.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 652 AA; 72030 MW; 572F2CE6D1743D80 CRC64;

Query Match 100.0%; Score 943; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 6e-97;
Matches 166; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CPLOGSHALCTCCFQPMDDRAEREQDPVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
DB 464 CPLOGSHALCTCCFQPMDDRAEREQDPVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 523

QY 61 FCEINLGDKCLDGVNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYRVT 120
DB 524 FCEINLGDKCLDGVNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYRVT 593

QY 121 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSPDCYWGRC 166
DB 584 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSPDCYWGRC 629

RESULT 3
Q9NRT4 PRELIMINARY; PRT; 664 AA.
ID Q9NRT4
AC Q9NRT4
DT 01-OCT-2000 (TREMBlrel. 15, Created)
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Cell cycle checkpoint protein CHFR.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxId=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Sculnick D.M., Halazonetis T.D.;
RT "Chfr defines a mitotic stress checkpoint that delays entry into
RT metaphase."
RL Nature 406:430-435 (2000).

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:40:47 ; Search time 24.0148 Seconds
(without alignments)
2180.991 Million cell updates/sec

Title: US-10-048-046-2_COPY_476_641
Perfect score: 943
Sequence: 1 CPQQSHALCTCCQPMFDR.....ASELPVATSRPDCYGRNC 166

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL 25:

- 1: sp_archaea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp_human:*
- 5: sp_invertebrate:*
- 6: sp_mammal:*
- 7: sp_mhc:*
- 8: sp_organelle:*
- 9: sp_phage:*
- 10: sp_plant:*
- 11: sp_rodent:*
- 12: sp_virus:*
- 13: sp_vertebrate:*
- 14: sp_unclassified:*
- 15: sp_virus:*
- 16: sp_bacteriap:*
- 17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	943	100.0	306	4 Q9NT32	Q9nt32 homo sapien
2	943	100.0	652	4 Q96SL3	Q96sl3 homo sapien
3	943	100.0	664	4 Q9NRT4	Q9nrt4 homo sapien
4	939	99.6	623	4 Q9NVD5	Q9nvd5 homo sapien
5	939	99.6	652	4 Q96EP1	Q96ep1 homo sapien
6	910	96.5	664	11 Q810L3	Q810l3 mus musculus
7	901	95.5	663	11 Q8BJZ9	Q8bjz9 mus musculus
8	137.5	14.6	473	10 Q9SX88	Q9sxd8 arabidopsis
9	91.5	9.7	292	13 Q7T3P2	Q7t3f2 brachydanio
10	88.5	9.4	806	5 Q9N9P8	Q9n9p8 leishmania
11	85	9.0	504	4 Q9UPQ4	Q9upq4 homo sapien
12	83.5	8.9	2972	5 P90891	P90891 caenorhabdi
13	83	8.8	2531	5 O16004	O16004 lytechinus
14	82.5	8.7	1023	5 Q9XYD4	Q9xyd4 dictyosteli
15	81.5	8.6	523	5 Q810G8	Q810g8 drosophila
16	81.5	8.6	564	5 Q8T0F5	Q8t0f5 drosophila

17	81.5	8.6	585	5 Q9N675	Q9n675 drosophila
18	81.5	8.6	1056	11 Q8COP7	Q8cop7 mus musculu
19	81	8.6	551	2 Q8L172	Q8l172 desulfitoba
20	81	8.6	551	2 Q8GJ31	Q8gj31 desulfitoba
21	81	8.6	551	2 Q8GJ27	Q8gj27 dehalobacte
22	80.5	8.5	274	12 Q7TS17	Q7ts17 cryptosporid
23	80.5	8.5	336	2 Q69207	Q69207 actinosynne
24	80	8.5	302	10 Q64762	Q64762 arabidopsis
25	80	8.5	530	5 Q9VTV3	Q9vzv3 drosophila
26	80	8.5	628	13 Q7ZVC1	Q7zvc1 brachydanio
27	79	8.4	1532	4 Q9P2K1	Q9p2k1 homo sapien
28	78.5	8.3	206	4 Q8WVA4	Q8wva4 homo sapien
29	78.5	8.3	493	4 Q86XQ0	Q86xq0 homo sapien
30	78	8.3	310	11 Q8CPU8	Q8cpu8 mus musculu
31	78	8.3	500	11 Q99PN4	Q99pn4 mus musculu
32	78	8.3	639	11 Q8K450	Q8k450 mus musculu
33	77.5	8.2	446	13 Q8Q3L6	Q8q3l6 brachydanio
34	77.5	8.2	601	13 Q8JH43	Q8jh43 brachydanio
35	77.5	8.2	1060	3 Q8TFW3	Q8tfw3 aspergillus
36	77.5	8.2	2215	5 Q81BW9	Q81bw9 plasmodium
37	77	8.2	303	4 Q7Z419	Q7z419 homo sapien
38	77	8.2	1533	11 Q8CFW7	Q8cfw7 mus musculu
39	76.5	8.1	1358	5 Q960D5	Q960d5 drosophila
40	76.5	8.1	1515	13 Q9DE37	Q9de37 brachydanio
41	76.5	8.1	1700	5 Q9VVA9	Q9vva9 drosophila
42	76.5	8.1	2841	5 Q8MLU9	Q8mlu9 drosophila
43	76.5	8.1	2931	5 Q9W2C6	Q9w2c6 drosophila
44	76	8.1	120	2 Q8GHL2	Q8ghl2 serratia ma
45	76	8.1	181	10 Q9AWV5	Q9awv5 cryza sativ

ALIGNMENTS

RESULT 1

Q9NT32	PRELIMINARY;	PRT;	306 AA.
ID	Q9NT32		
AC	Q9NT32;		
DT	01-OCT-2000 (TREMBlrel. 15, Created)		
DT	01-OCT-2000 (TREMBlrel. 15, Last sequence update)		
DT	01-JUN-2003 (TREMBlrel. 24, Last annotation update)		
DE	Hypothetical protein (Fragment).		
GN	DKFP434N2420.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.		
OX	NCBI_TaxID=9606;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	TISSUE=Testis;		
RA	Ottewaelder B., Obermaier B., Mewes H.W., Gassenhuber J., Wiemann S.;		
RL	Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.		
DR	EMBL; AL137561; CAB70812.1; -.		
DR	PIR; T46399; T46399.		
KW	Hypothetical protein.		
FT	NON TER		
SQ	SEQUENCE 306 AA; 34501 MW; 6B50F04601FB2939 CRC64;		

Query Match	100.0%;	Score 943;	DB 4;	Length 306;
Best Local Similarity	100.0%;	Pred. No. 2.4e-97;		
Matches 166;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	CPQQSHALCTCCQPMFDRAREODPRVAPQCCAVCLQPFCHLYWGCTRTGCYCCLAP	60	
Db	118	CPQQSHALCTCCQPMFDRAREODPRVAPQCCAVCLQPFCHLYWGCTRTGCYCCLAP	177	
Qy	61	FCELNLGDKLCLDGLVNNNSVESDILKNYLATRLGLTWKMLTESLVALQRGVFLLSDYRT	120	
Db	178	FCELNLGDKLCLDGLVNNNSVESDILKNYLATRLGLTWKMLTESLVALQRGVFLLSDYRT	237	
Qy	121	GDTVLCYCCGLRSFRLTYQYQNIPASELPVATSRPDCYGRNC	166	
Db	238	GDTVLCYCCGLRSFRLTYQYQNIPASELPVATSRPDCYGRNC	283	

DR PROSITE; PS50023; LIM DOMAIN 2; 4.
KW Repeat; LIM domain; Metal-binding; Zinc; Zinc-finger.
FT ZN FING 7 31 GATA-LIKE (POTENTIAL).
FT DOMAIN 40 92 LIM 1.
FT DOMAIN 101 153 LIM 2.
FT DOMAIN 162 212 LIM 3.
FT DOMAIN 221 275 LIM 4.
SQ SEQUENCE 279 AA; 32072 MW; 6D8CB4B4424BFF2 CRC64;

Query Match 8.0%; Score 75; DB 1; Length 279;
Best Local Similarity 23.6%; Pred. No. 3.2; Mismatches 12; Indels 34; Gaps 6;
Matches 29; Conservative 12; Mismatches 48; Indels 34; Gaps 6;

QY 9 LCTCCFQMPDRR-AAREQDPVAPQCAVCLOPFCHLYWGCTRTGCGYCLAPFCELNLG 67
Db 187 VCTACKQLSGQRTARDEFP-----YCLTCFCDLY-----AKKAGCTNPFISGLG-G 233
QY 68 DKCLDGLVNNNSVESDILKNYLATRGITWKNMLTESLVALQGVFLSDYRVGTGTVLCY 127
Db 234 TKYIS--FEERQWHDNCFNCKGSLVGRGFLTER-----DDILCP 273
QY 128 CCG 130
Db 274 DCG 276

RESULT 14
SLI3_RAT STANDARD; PRT; 279 AA.
AC O35115; 2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE Skeletal muscle LIM-protein 3 (SLIM 3) (LIM-domain protein DRAL)
DE (Four and a half LIM domains protein 2) (FHL-2).
GN FHL2 OR SLIM3 OR DRAL.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
[1]
RN SEQUENCE FROM N.A.
RP STRAIN=Wistar; TISSUE=Brain;
RA Tanahashi H.;
RL Submitted (NOV-1997) to the EMBL/GenBank/DBJ databases.
CC -!- SIMILARITY: Contains 4 LIM zinc-binding domains.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AB008571; BAA23357.1; -
CC InterPro; IPR001781; LIM.
CC Pfam; PF00412; LIM; 4.
CC ProDom; PD000094; LIM; 4.
CC SMART; SM00132; LIM; 4.
DR PROSITE; PS50023; LIM DOMAIN 2; 4.
DR PROSITE; PS50023; LIM DOMAIN 2; 4.
KW Repeat; LIM domain; Metal-binding; Zinc; Zinc-finger.
FT ZN FING 7 31 GATA-LIKE (POTENTIAL).
FT DOMAIN 40 92 LIM 1.
FT DOMAIN 101 153 LIM 2.
FT DOMAIN 162 212 LIM 3.
FT DOMAIN 221 275 LIM 4.
SQ SEQUENCE 279 AA; 32086 MW; 9A9D8E5935034173 CRC64;

Query Match 8.0%; Score 75; DB 1; Length 279;
Best Local Similarity 23.6%; Pred. No. 3.2;
Matches 29; Conservative 12; Mismatches 48; Indels 34; Gaps 6;

QY 9 LCTCCFQMPDRR-AAREQDPVAPQCAVCLOPFCHLYWGCTRTGCGYCLAPFCELNLG 67
Db 187 VCTACKQLSGQRTARDEFP-----YCLTCFCDLY-----AKKAGCTNPFISGLG-G 233
QY 68 DKCLDGLVNNNSVESDILKNYLATRGITWKNMLTESLVALQGVFLSDYRVGTGTVLCY 127
Db 234 TKYIS--FEERQWHDNCFNCKGSLVGRGFLTER-----DDILCP 273
QY 128 CCG 130
Db 274 DCG 276

RESULT 15
ID_OPCA_NOSPU STANDARD; PRT; 465 AA.
AC P48971;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Putative OXPP cycle protein opca.
GN OPCA.
OS Nostoc punctiforme.
OC Bacteria; Cyanobacteria; Nostocales; Nostocaceae; Nostoc.
OX NCBI_TaxID=63737;
[1]
RN SEQUENCE FROM N.A.
RP STRAIN=ATCC 29133 / PCC 73102;
RX MEDLINE=95175603; PubMed=7870816;
RA Summers M.L., Meeks J.C., Chu S., Wolf R.E. Jr.;
RT "Nucleotide sequence of an operon in Nostoc sp. strain ATCC 29133
RT encoding four genes of the oxidative pentose phosphate cycle.";
RL Plant Physiol. 107:267-268 (1995).
CC -!- FUNCTION: MAY BE INVOLVED IN THE FUNCTIONAL ASSEMBLY OF GLUCOSE
CC 6-PHOSPHATE DEHYDROGENASE.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; L32796; AAA50771.1; -
CC InterPro; IPR004555; OPCA.
CC InterPro; IPR002477; PG binding.
CC Pfam; PF01471; PG binding_1; 1.
CC TIGRFAMs; TIGR00534; OPCA; 1.
SQ SEQUENCE 465 AA; 50627 MW; 2E2D080D90E23931 CRC64;

Query Match 8.0%; Score 75; DB 1; Length 465;
Best Local Similarity 22.8%; Pred. No. 5.6;
Matches 38; Conservative 19; Mismatches 68; Indels 42; Gaps 7;

QY 1 CPL--QGSALCTCCFQMPDRRAREQDPVAPQCAVCLOPFCHLYWGCT---RTGCV 55
Db 183 CPIQKSSSTLICCEYITLSGTAALERIGGMIPALLIGGLPKF--LWKATPDNNGLF 240
QY 56 GCLAPFCELNLGDKCLDGLVNNNSVESDILK-NYLATRGL-----TWKNMLTES 103
Db 241 KSLAALCNVIVDSC-----NFNEPESDLRLLEELVEAGVPLADLNRRRLASWQELTA 295
QY 104 LVALQGVFLSDYRVGTGTVLCYCCGLRSFELTYQYRQNPASEL 150
Db 296 YDSPKRR-----AALREIDRVTDYKGNPAQAL 324

Search completed: May 7, 2004, 14:46:34
Job time : 6.60929 secs

QY 135 RELTYQYRONIP 146
DB 64 RELTYQYRONIP 75

RESULT 13

SLI3 MOUSE STANDARD; PRT; 279 AA.
AC 070433; P97448;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Skeletal muscle LIM-protein 3 (SLIM 3) (LIM-domain protein DRAL)
DE (Four and a half LIM domains protein 2) (FHL-2).
GN FHL2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Brain;
RA Chan K.K., Tsui S.K.W., Lee C.Y., Fung K.P., Waye M.M.Y.;
RT "The cloning, sequencing and characterization of a mouse FHL2, which
RT contains four and a half LIM domains."
RL Submitted (MAR-1998) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Skeletal muscle;
RX MEDLINE=99160848; PubMed=10049693;
RA Morgan M.J., Madgwick A.J.A.;
RT "The LIM proteins FHL1 and FHL3 are expressed differently in skeletal
RT muscle."
RL Biochem. Biophys. Res. Commun. 255:245-250(1999).
RN [3]
RP SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RX MEDLINE=20368180; PubMed=10906474;
RA Chu P.-H., Ruiz-Lozano P., Zhou Q., Cai C., Chen J.;
RT "Expression patterns of FHL/SLIM family members suggest important
RT functional roles in skeletal muscle and cardiovascular system."
RL Mech. Dev. 95:259-265(2000).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/c;
RA Starzinski-Powitz A., Martin B., Eckardt F.;
RT "Isolation of the mouse homolog mDRAL from skeletal muscle derived
RT myoblasts."
RL Submitted (JUN-1999) to the EMBL/GenBank/DBJ databases.
CC -1- TISSUE SPECIFICITY: Highly expressed in heart but also detectable
CC in brain and skeletal muscle.
CC -1- SIMILARITY: Contains 4 LIM zinc-binding domains.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC EMBL; AF055889; AAC12770.1; -.
DR EMBL; U77040; AAB19211.2; -.
DR EMBL; AF114381; AAD53230.1; -.
DR EMBL; AF153340; AAD34170.1; -.
DR MGD; MGI:1338762; FHL2.
DR GO; GO:0005634; C:nucleus; IDA.
DR GO; GO:0005515; F:protein binding; IPI.
DR GO; GO:0006357; P:regulation of transcription from Pol II prom. ; IDA.
DR InterPro; IPR001781; LIM.
DR Pfam; PF00412; LIM; 4.
DR ProDom; PD000094; LIM; 4.
DR SMART; SM00132; LIM; 4.
DR PROSITE; PS00478; LIM_DOMAIN_1; 4.

RESULT 12

LPCA YERPE STANDARD; PRT; 193 AA.
AC Q8ZBY7;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Phosphoglycerate isomerase (EC 5.4.2.1).
GN LPCA OR GSHA OR YPO3243 OR Y0947.
OS Yersinia pestis.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Yersinia.
OX NCBI_TaxID=632;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CO-92 / Biovar Orientalis;
RX MEDLINE=21470413; PubMed=11586360;
RA Parkhill J., Wren B.W., Thomson N.R., Titball R.W., Holden M.T.G.,
RA Prentice M.B., Sebatina M., James K.D., Churcher C., Mungall K.L.,
RA Baker S., Basham D., Bentley S.D., Brooks K., Cerdano-Irarraga A.M.,
RA Chillingworth T., Cronin A., Davies R.M., Davis P., Dougan G.,
RA Feltwell T., Hamlin N., Holroyd S., Jagels K., Karlyshev A.V.,
RA Leather S., Moulé S., Oyston P.C.F., Quail M.A., Rutherford K.,
RA Simmonds M., Skelton J., Stevens K., Whitehead S., Barrett B.G.;
RT "Genome sequence of Yersinia pestis, the causative agent of plague."
RL Nature 413:523-527(2001).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=KIM5 / Biovar Mediaevalis;
RX MEDLINE=22137863; PubMed=12142430;
RA Deng W., Burland V., Plunkett G. III, Boutin A., Mayhew G.F., Liss P.,
RA Perna N.T., Rose D.J., Mau B., Zhou S., Schwartz D.C.,
RA Fetherston J.D., Lindler L.E., Brubaker R.R., Plano G.V.,
RA Straley S.C., McDonough K.A., Nilles M.D., Matson J.S., Blattner F.R.,
RA Perry R.D.;
RT "Genome sequence of Yersinia pestis KIM5."
RL J. Bacteriol. 184:4601-4611(2002).
CC -1- FUNCTION: Involved in synthesis of glyceromannoheptose 7-phosphate
CC (by similarity).
CC -1- PATHWAY: Inner core lipopolysaccharide biosynthesis.
CC -1- SUBCELLULAR LOCATION: Cytoplasmic (by similarity).
CC -1- SIMILARITY: Belongs to the SIS family. LPCA subfamily.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC EMBL; AJ414156; CAC92478.1; -.
DR EMBL; AF013698; AAM84528.1; -.
DR PIR; AB0394; AB0394.
DR HAMAP; MF_00067; -; 1.
DR InterPro; IPR004515; GSHA.
DR InterPro; IPR001347; SIS.
DR Pfam; PF01380; SIS; 1.
DR TIGRFAMs; TIGR00441; GSHA; 1.
KW Isomerase, Lipopolysaccharide biosynthesis; Complete proteome.
FT CONFLICT 109 109 D -> G (IN REF. 2).
SQ SEQUENCE 193 AA; -20987 MW; 643E9E0C34452D79 CRC64;
Query Match 8.0%; Score 75; DB 1; Length 193;
Best Local Similarity 29.2%; Pred. No. 2.1;
Matches 21; Conservative 16; Mismatches 27; Indels 8; Gaps 3;
QY 83 DILKNYLTGRLTWKMLTE--SLVALQGVFLISD-YRVTDIVLC-----YCCGLRSF 134
DB 4 DLIRESLNEADTLANFLKDSNIDATQRAILLADSFKAGGKVLSCNGSGHCDAMHFA 63

[9] MEDLINE=92184750; PubMed=1544894;
Harris R.J., Ling V.T., Spellman M.W.;
"O-linked fucose is present in the first epidermal growth factor domain of factor XII but not protein C";
J. Biol. Chem. 267:5102-5107 (1992).
[10]
VARIANT WASHINGTON D.C. SER-590.
MEDLINE=90046788; PubMed=2510163;
Miyata T., Kawabata S.-I., Iwanaga S., Takahashi I., Alving B., Saito H.;
"Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571-->Ser substitution";
Proc. Natl. Acad. Sci. U.S.A. 86:8319-8322 (1989).
[11]
VARIANT LOCARNO PRO-372.
MEDLINE=94325559; PubMed=8049433;
Hovinga J.K., Schaller J., Stricker H., Wuillemin W.A., Furlan M., Laemmle B.;
"Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg-353-->Pro leading to loss of a kallikrein cleavage site";
Blood 84:1173-1181 (1994).
[12]
VARIANT TENRI CVS-53.
MEDLINE=9290785; PubMed=10361128;
Kondo S., Tokunaga F., Kawano S., Ono Y., Kumagai S., Koide T.;
"Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation";
Blood 93:4300-4308 (1999).
-!- FUNCTION: Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin.
-!- CATALYTIC ACTIVITY: Cleaves selectively Arg-Ile bonds in factor VII to form factor VIIa and factor XI to form factor Xla.
-!- PTM: O- AND N-GLYCOSYLATED.
-!- DISEASE: Defects in F12 do not cause any clinical symptoms. The sole effect is that whole-blood clotting time is prolonged.
-!- MISCELLANEOUS: Factor XII, prekallikrein, and HMW kininogen form a complex bound to an anionic surface. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor Xla and then to beta-factor Xla. Alpha-factor Xla activates factor XI to factor Xla.
-!- SIMILARITY: Belongs to peptidase family S1.
-!- SIMILARITY: Contains 2 EGF-like domains.
-!- SIMILARITY: Contains 1 fibronectin type I domain.
-!- SIMILARITY: Contains 1 fibronectin type II domain.
-!- SIMILARITY: Contains 1 kringle domain.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

EMBL; M31315; AAA70225.1; -
EMBL; AF538691; AAM97932.1; -
EMBL; M11723; AAA51986.1; -
EMBL; M17466; AAB59490.1; -
EMBL; M17464; AAB59490.1; JOINED.
EMBL; M17465; AAB59490.1; JOINED.
EMBL; M13147; AAA70224.1; -
EMBL; U71274; AAB51203.1; -
PIR; A29411; KFHU12.
HSSP; P00763; IDPO.
MEOSPS; S01-211; -
Genew; HGNC:3530; F12.
MIM; 234000; -
GO; GO:0003805; F: blood coagulation factor XI activity; TAS.
GO; GO:0003806; F: blood coagulation factor XII activity; TAS.

DR GO; GO:0008236; F: serine-type peptidase activity; TAS.
DR GO; GO:0007596; F: blood coagulation; TAS.
DR InterPro; IPR009003; Cys_Ser_trypsin.
DR InterPro; IPR006209; EGF_like.
DR InterPro; IPR000083; Fibrinctn1.
DR InterPro; IPR000562; FN_Type_II.
DR InterPro; IPR006210; IEGF.
DR InterPro; IPR000001; Kringle.
DR InterPro; IPR001254; Peptidase_S1.
DR InterPro; IPR001314; Peptidase_S1A.
DR Pfam; PF00008; EGF; 2.
DR Pfam; PF00039; fn1; 1.
DR Pfam; PF00040; fn2; 1.
DR Pfam; PF00051; kringle; 1.
DR Pfam; PF00089; trypsin; 1.
DR PRINTS; PRO00722; CHYMOTRYPsin.
DR PRINTS; PRO0013; FNTYPEII.
DR PRINTS; PRO0018; KRINGLE.
DR ProDom; PD000995; FN_Type_II; 1.
DR ProDom; PD000395; Kringle; 1.
DR SMART; SM00181; EGF; 2.
DR SMART; SM00053; FN1; 1.
DR SMART; SM00059; FN2; 1.
DR SMART; SM00130; KR; 1.
DR SMART; SM00020; Tryp_SPC; 1.
DR PROSITE; PS00022; EGF_1; 2.
DR PROSITE; PS01186; EGF_2; 1.
DR PROSITE; PS00266; EGF_3; 2.
DR PROSITE; PS01253; FIBRONECTIN_1; 1.
DR PROSITE; PS00023; FIBRONECTIN_2; 1.
DR PROSITE; PS00021; KRINGLE_1; 1.
DR PROSITE; PS00020; KRINGLE_2; 1.
DR PROSITE; PS00240; TRYPSIN_DOM; 1.
DR PROSITE; PS00134; TRYPSIN_HIS; 1.
DR PROSITE; PS00135; TRYPSIN_SER; 1.
KW Glycoprotein; Blood coagulation; plasma; Kringle; Serine protease;
KW Hydrolase; Fibrinolysis; Signal; EGF-like domain; Repeat; Zymogen;
KW Polymorphism; Disease mutation.
FT SIGNAL 1 19
FT CHAIN 20 372 ALPHA-FACTOR XIIA HEAVY CHAIN.
FT CHAIN 373 615 ALPHA-FACTOR XIIA LIGHT CHAIN.
FT CHAIN 354 362 BETA-FACTOR XIIA PART 1.
FT CHAIN 373 615 BETA-FACTOR XIIA PART 2.
FT DOMAIN 47 88 FIBRONECTIN TYPE-II.
FT DOMAIN 94 131 EGF-LIKE 1.
FT DOMAIN 133 173 FIBRONECTIN TYPE-I.
FT DOMAIN 174 210 EGF-LIKE 2.
FT DOMAIN 217 295 KRINGLE.
FT DOMAIN 296 349 PRO-RICH.
FT DOMAIN 373 615 SERINE PROTEASE.
FT CARBOHYD 109 109 O-LINKED (FUC).
FT CARBOHYD 249 249 N-LINKED (GLCNAC...).
FT CARBOHYD 299 299 O-LINKED (POTENTIAL).
FT CARBOHYD 305 305 O-LINKED (POTENTIAL).
FT CARBOHYD 308 308 O-LINKED (POTENTIAL).
FT CARBOHYD 328 328 O-LINKED (POTENTIAL).
FT CARBOHYD 329 329 O-LINKED (POTENTIAL).

Query Match 8.0%; Score 75.5; DB 1; Length 615;
Best Local Similarity 20.7%; Pred. No. 6.9;
Matches 29; Conservative 13; Mismatches 35; Indels 63; Gaps 6;

QY 1 CP--LQSHALCTCCFQPM-----PDRAREQDPVPAP 32
DB 121 CPCHLTGNHCQKCFEQLLFFHKNELWYRTEQAARCOCKGPDACQ-----RLAS 175
QY 33 QCAV-----CLQPFCHLYWGCTRTGCGCLAPFCELNLDGKLDGLVNNNSYSDI 84
DB 176 QACRTNPLHGGRCLVEGHRLCHCP----VGVTGFCVDVDTKASCYDG----- 220
QY 85 LKNYLATRLGLTWKNMLTSL 104
DB 221 -----RGLSYRGLARTIL 233

RESULT 11

FA12	HUMAN	STANDARD;	PRT;	615 AA.
ID	FA12 HUMAN			
AC	P00748; P78339;			
DT	21-JUL-1986 (Rel. 01, Created)			
DD	01-OCT-1989 (Rel. 12, Last sequence update)			
DE	28-FEB-2003 (Rel. 41, Last annotation update)			
DE	Coagulation factor XII precursor (EC 3.4.21.38) (Hageman factor) (HAP).			
GN	P12.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
OX	[1]			
RP	SEQUENCE FROM N.A.			
RP	MEDLINE=88007593; PubMed=2888762;			
RP	Cool D.E., McGillivray R.T.A.;			
RA	"Characterization of the human blood coagulation factor XII gene.			
RA	Intron/exon gene organization and analysis of the 5'-flanking			
RT	region.";			
RT	J. Biol. Chem. 262:13662-13673(1987).			
RL	[2]			
RP	SEQUENCE FROM N.A., AND VARIANTS ALA-207; ASP-545 AND HIS-605.			
RP	Rieder M.J., Amel T.Z., Carrington D.P., Ozuna M., Kuldaneck S.A.,			
RA	Rajkumar N., Toth E.J., Yi Q., Nickerson D.A.;			
RA	Submitted (AUG-2002) to the EMBL/GenBank/DBJ databases.			
RL	[3]			
RP	SEQUENCE OF 4-615 FROM N.A.			
RP	MEDLINE=86176794; PubMed=3754331;			
RP	Tripodi M., Citarella F., Guida S., Galeffi P., Fantoni A.,			
RA	Cortese R.;			
RA	"cDNA sequence coding for human coagulation factor XII (Hageman)." ;			
RL	Nucleic Acids Res. 14:3146-3146(1986).			
RL	[4]			
RP	SEQUENCE OF 14-615 FROM N.A.			
RP	MEDLINE=86033830; PubMed=3877053;			
RP	Cool D.E., Edgell C.-J.S., Louie G.V., Zoller M.J., Brayer G.D.,			
RA	McGillivray R.T.A.;			
RA	"Characterization of human blood coagulation factor XII cDNA.			
RT	Prediction of the primary structure of factor XII and the tertiary			
RT	structure of beta-factor XIIa.";			
RL	J. Biol. Chem. 260:13666-13676(1985).			
RL	[5]			
RP	SEQUENCE OF 146-615 FROM N.A.			
RP	MEDLINE=86216049; PubMed=3011063;			
RA	Que B.O., Davie E.W.;			
RA	"Characterization of a cDNA coding for human factor XII (Hageman			
RT	factor)." ;			
RL	Biochemistry 25:1525-1528(1986).			
RL	[6]			
RP	SEQUENCE OF 20-379.			
RP	MEDLINE=85182674; PubMed=3886654;			
RA	McMullen B.A., Fujikawa K.;			
RA	"Amino acid sequence of the heavy chain of human alpha-factor XIIa			
RT	(activated Hageman factor)." ;			
RL	J. Biol. Chem. 260:5328-5341(1985).			
RL	[7]			
RP	SEQUENCE OF 354-362 AND 373-615.			
RP	MEDLINE=83291041; PubMed=6604055;			
RA	Fujikawa K., McMullen B.A.;			
RA	"Amino acid sequence of human beta-factor XIIa." ;			
RL	J. Biol. Chem. 259:10924-10933 (1983).			
RL	[8]			
RP	SEQUENCE OF 561-615 FROM N.A.			
RP	TISSUE=Blood;			
RC	MEDLINE=96133302; PubMed=8528215;			
RA	Schloesser M., Hofferbert S., Bartz U., Lutze G., Lammle B., Engel			
RA	"The novel acceptor splice site mutation 1139(G->A) in the factor			
RT	XII gene causes a truncated transcript in cross-reacting material			
RT	negative patients." ;			
RL	Hum. Mol. Genet. 4:1235-1237(1995).			
RL	[9]			

RESULT 10
ID FAAA_HUMAN STANDARD; PRT; 419 AA.
AC P16930;
DT 01-AUG-1990 (Rel. 15, Created)
DT 01-AUG-1992 (Rel. 23, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Fumarylacetoacetase (EC 3.7.1.2) (Fumarylacetoacetate hydrolase)
DE (Beta-diketone) (FAA).
GN FAH.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP MEDLINE=91150763; PubMed=1998338;
RA Phaneuf D., Labelle Y., Berube D., Arden K., Cavenee W., Gagne R.,
RA Tanguay R.M.;
RT "Cloning and expression of the cDNA encoding human
RT fumarylacetoacetate hydrolase, the enzyme deficient in hereditary
RT tyrosinemia: assignment of the gene to chromosome 15";
RL Am. J. Hum. Genet. 48:525-535(1991).
RN [2]
RP SEQUENCE FROM N.A.
RP TISSUE=Placenta;
RC MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.P., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallaloon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A.C., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [3]
RP SEQUENCE OF 71-419 FROM N.A.
RC TISSUE=Liver;
RA Agatekibbe E., van Faassen H., Hartog M.V., Reversma T.,
RA Taanman J.-W., Pannkoek H., Evers R.F., Welling G.M., Berger R.;
RT "Nucleotide sequence of cDNA encoding human fumarylacetoacetase";
RL Nucleic Acids Res. 18:1887-1887(1990).
RN [4]
RP REVIEW ON VARIANTS.
RX MEDLINE=97255958; PubMed=9101289;
RA St Louis M., Tanguay R.M.;
RT "Mutations in the fumarylacetoacetate hydrolase gene causing
RT hereditary tyrosinemia type I: overview";
RL Hum. Mutat. 9:291-299(1997).
RN [5]
RP VARIANT TYROSINEMIA TYPE I ILR-16.
RX MEDLINE=93016844; PubMed=1401056;
RA Phaneuf D., Lambert M., Laframboise R., Mitchell G., Lettre F.,
RA Tanguay R.M.;
RT "Type I hereditary tyrosinemia. Evidence for molecular heterogeneity
RT and identification of a causal mutation in a French Canadian
RL J. Clin. Invest. 90:1185-1192(1992).
RN [6]
RP VARIANT TYROSINEMIA TYPE I ASP-134.

RX MEDLINE=93372857; PubMed=8364576;
RA Labelle Y., Phaneuf D., Leclerc B., Tanguay R.M.;
RT "Characterization of the human fumarylacetoacetate hydrolase gene and
RT identification of a missense mutation abolishing enzymatic
RL activity";
RN Hum. Mol. Genet. 2:941-946(1993).
RP VARIANT TYROSINEMIA TYPE I GLY-166.
RX MEDLINE=93306316; PubMed=8318997;
RA Grompe M., Al-Dhalimy M.;
RT "Mutations of the fumarylacetoacetate hydrolase gene in four patients
RT with tyrosinemia, type I";
RL Hum. Mutat. 2:85-93(1993).
RN [8]
RP VARIANT TYROSINEMIA TYPE I VAL-233.
RX MEDLINE=95029364; PubMed=7942842;
RA Rootwelt H., Berger R., Gray G., Kelly D.A., Coskun T.,
RA Kvittingen E.A.;
RT "Novel splice, missense, and nonsense mutations in the
RT fumarylacetoacetase gene causing tyrosinemia type 1";
RL Am. J. Hum. Genet. 55:653-658(1994).
RN [9]
RP VARIANT TYROSINEMIA TYPE I TRP-341.
RX MEDLINE=95067974; PubMed=7977370;
RA Rootwelt H., Brodtkorb E., Kvittingen E.A.;
RT "Identification of a frequent pseudodeficiency mutation in the
RT fumarylacetoacetase gene, with implications for diagnosis of
RT tyrosinemia type I";
RL Am. J. Hum. Genet. 55:1122-1127(1994).
RN [10]
RP VARIANTS TYROSINEMIA TYPE I ASP-134 AND LEU-342.
RX MEDLINE=94274193; PubMed=8005583;
RA Rootwelt H., Chou J., Gahl W.A., Berger R., Coskun T., Brodtkorb E.,
RA Kvittingen E.A.;
RT "Two missense mutations causing tyrosinemia type 1 with presence and
RT absence of immunoreactive fumarylacetoacetase";
RL Hum. Genet. 93:615-619(1994).
RN [11]
RP VARIANTS TYROSINEMIA TYPE I SER-337 AND GLY-381.
RX MEDLINE=95276752; PubMed=757089;
RA St Louis M., Poudrier J., Phaneuf D., Leclerc B., Laframboise R.,
RA Tanguay R.M.;
RT "Two novel mutations involved in hereditary tyrosinemia type I";
RL Hum. Mol. Genet. 4:319-320(1995).
RN [12]
RP VARIANT TYROSINEMIA TYPE I GLY-234.
RX MEDLINE=96055520; PubMed=7550234;
RA Hahn S.H., Kraenewich D., Brantly M., Kvittingen E.A., Gahl W.A.;
RT "Heterozygosity for an exon 12 splicing mutation and a W234G missense
RT mutation in an American child with chronic tyrosinemia type 1";
RL Hum. Mutat. 6:66-73(1995).
RN [13]
RP VARIANTS TYROSINEMIA TYPE I ARG-193 AND VAL-369.
RX MEDLINE=96140750; PubMed=8557261;
RA Floos van Amstel J.K., Bergman A.J.I.W., van Beurden E.A.C.M.,
RA Roijers J.F.M., Peelen T., van den Berg I.E.T., Poll-The B.T.,
RA Kvittingen E.A., Berger R.;
RT "Hereditary tyrosinemia type 1: novel missense, nonsense and splice
RT consensus mutations in the human fumarylacetoacetate hydrolase gene;
RT variability of the genotype-phenotype relationship";
RL Hum. Genet. 97:51-59(1996).
RN [14]
RP VARIANTS TYROSINEMIA TYPE I ASP-158; LEU-261; HIS-405 AND SER-366 DEL.
RX MEDLINE=98295572; PubMed=9633815;
RA Bergman A.J.I.W., van den Berg I.E.T., Brink W., Poll-The B.T.,
RA Floos van Amstel J.K., Berger R.;
RT "Spectrum of mutations in the fumarylacetoacetate hydrolase gene of
RT tyrosinemia type 1 patients in northwestern Europe and Mediterranean
RL countries";
RL Hum. Mutat. 12:19-26(1998).
CC -1- CATALYTIC ACTIVITY: 4-fumarylacetoacetate + H(2)O = acetoacetate +
CC fumarate.
CC -1- PATHWAY: Phenylalanine catabolism; sixth step.

```

SEQUENCE OF 1-154 FROM N.A.
MEDLINE=20035825; PubMed=10571048;
Tang W., Bardin S., Bhattacharya S.S., Prescott S.M.;
"Characterization of the human diacylglycerol kinase epsilon gene and its assessment as a candidate for inherited retinitis pigmentosa.";
Gene 239:185-192(1999).
CC CC
-|- FUNCTION: Highly selective for arachidonate-containing species of diacylglycerol (DAG). May terminate signals transmitted through arachidonyl-DAG or may contribute to the synthesis of phospholipids with defined fatty acid composition.
CC CC
-|- CATALYTIC ACTIVITY: ATP + 1,2-diacylglycerol = ADP + 1,2-diacylglycerol 3-phosphate.
CC CC
-|- TISSUE SPECIFICITY: Expressed predominantly in testis.
CC CC
-|- SIMILARITY: Belongs to the eukaryotic diacylglycerol kinase family.
CC CC
-|- SIMILARITY: Contains 2 zinc-dependent phorbol-ester and DAG binding domains.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.ebi.ac.uk/termsandconditions.html) or send an email to license@ebi.ac.uk.
-----
EMBL; U49379; AAC50497.1; -.
EMBL; AF136745; AAD45666.1; -.
Genew; HGNC:2852; DGKE.
MIM; 601440; -.
GO; GO:0005524; P:ATP binding; TAS.
GO; GO:0004143; F:diacylglycerol kinase activity; TAS.
GO; GO:0008654; P:phospholipid biosynthesis; TAS.
InterPro; IPR002219; DAG_PE-bind.
InterPro; IPR000756; DAGKa.
InterPro; IPR01206; DAGKc.
Pfam; PF00130; DAG PE-bind; 2.
Pfam; PF00603; DAGKa; 1.
Pfam; PF00781; DAGKc; 1.
ProDom; PD002939; DAGKa; 1.
ProDom; PD005043; DAGKc; 1.
SMART; SM00109; C1; 2.
SMART; SM00045; DAGKa; 1.
SMART; SM00046; DAGKc; 1.
PROSITE; PS00479; DAG PE BIND DOM 1; 2.
PROSITE; PS00081; DAG PE BIND DOM 2; 2.
Transferrase; Kinase; Phorbol-ester binding; Multigene family; KW
Transmembrane; Repeat. FT
TRANSMEM 22 42 POTENTIAL.
FT TRANSMEM 436 456 POTENTIAL.
FT DOMAIN 60 108 PHORBOL-ESTER AND DAG BINDING 1.
FT DOMAIN 125 177 PHORBOL-ESTER AND DAG BINDING 2.
FT DOMAIN 217 350 CATALYTIC-A (POTENTIAL).
FT DOMAIN 369 524 CATALYTIC-B (POTENTIAL).
SEQUENCE 567 AA; 63927 MW; BC334AD15FE4DB4 CRC64; SQ
Query Match 8.1%; Score 76; DB 1; Length 567;
Best Local Similarity 21.6%; Pred. No. 5.6;
Matches 36; Conservative 21; Mismatches 54; Indels 56; Gaps 10;
QY 3 LOGSHALTCGFQMPD--RRAR-----EODPRVAPQQ-----CAVL 39
Db 82 LQG--AFDCGGLRVDEGCILKKRQCCKIKNKTVDAMPHHWIRGNVPCLSYCM 139
QY 40 QPFCHLYWGCTRCG-YCGLAPCELNIGDKLDGVNNNSYESDLXN-----YLAT- 91
Db 140 --VCQKCGCPKLCDTRCI--WCQKVHDECWKSLNKNEKCDFGEFNLLIPPSYLTSI 195
QY 92 -----RGJTWKMN--LTESLVALORGVFILLSDRYV 119
Db 196 NQMQRDKXTDYEVLASIKLGKWTPPLAILANSRSGETNMNGELLEGFRI 242

```

```
QY 129 CG 130
Db 275 CG 276

RESULT 7
ID T1B MOUSE STANDARD; PRT; 834 AA.
AC Q62318; P70391;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DE 28-FEB-2003 (Rel. 41, Last annotation update)
DE Transcription intermediary factor 1-beta (TIF1-beta) (Tripartite motif
DE protein 28) (KRAB-A interacting protein) (KRIP-1).
GN TRIM28 OR TIF1B OR KRIP1.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RN SEQUENCE FROM N.A.
RP MEDLINE=9713329; PubMed=8978696;
RA le Douarin B., Nielsen A.L., Garnier J.M., Ichinose H., Jeanmougin F.,
RA Lesson R., Chambon P.;
RT "A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic
RT control of transcription by nuclear receptors.";
RL EMBO J. 15:6701-6715(1996).
RN [2]
RN SEQUENCE FROM N.A.
RP TSSUE=Kidney;
RC MEDLINE=97140325; PubMed=8986806;
EX Kim S.-S., Chen Y.-M., O'Leary E., Witzgall R., Vidal M.,
RA Bonventre J.V.;
RT "A novel member of the RING finger family, KRIP-1, associates with
RT the KRAB-A transcriptional repressor domain of zinc finger
RT proteins.";
RL Proc. Natl. Acad. Sci. U.S.A. 93:15299-15304(1996).
RN [3]
RN SEQUENCE FROM N.A.
RP MEDLINE=20400347; PubMed=10940561;
RA Cammas F., Garnier J.-M., Chambon P., Losson R.;
RT "Correlation of the exon/intron organization to the conserved domains
RT of the mouse transcriptional corepressor TIF1beta.";
RL Gene 253:231-235(2000).
CC -1- FUNCTION: Forms a complex with a KRAB-domain transcription factor
CC and increases the efficiency of KRAB-mediated repression by
CC recruiting SETDB1 to histone H3 (By similarity).
CC -1- SUBUNIT: Interacts with SETDB1 and CBX3 (By similarity).
CC -1- SUBCELLULAR LOCATION: Nuclear.
CC -1- SIMILARITY: Contains 1 RING-type zinc finger.
CC -1- SIMILARITY: Contains 2 B box-type zinc fingers.
CC -1- SIMILARITY: Contains 1 PHD-type zinc finger.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X99644; CAA67963.1; -
CC EMBL; U67303; AAB1722.1; -
CC EMBL; AF230878; AAG02638.1; -
CC GGD; MGI:109274; Trim28.
CC GO; GO:0000785; C:chromatin; IDA.
CC InterPro; IPR003649; Bbox_C.
CC InterPro; IPR001487; BboxDomain.
CC InterPro; IPR000315; Znf_Ebox.
CC InterPro; IPR001965; Znf_PHD.
CC InterPro; IPR001841; Znf_Ring.
CC Pfam; PF00628; PHD; 1.

Query Match 8.3%; Score 78; DB 1; Length 834;
Best Local Similarity 19.9%; Pred. No. 5.4;
Matches 40; Conservative 18; Mismatches 59; Indels 84; Gaps 8;

QY 10 CTCFQPMEDRAERBQDPVPOQCAVCLQPFCHLYWGCTRTGTCYGCCLAPFCEINLGD- 68
Db 66 CGVCRE-----RLRPEDPRLLP-----CLHSAC-----SACLOFATFAAANNSGDG 107
QY 69 -KCLDG-----VLNNNSYESDILKNYL-----ATRG 93
Db 108 GSAGGAMVDCPVCKQCYKDIENFMRDGSKASSDSQDANQCCTSCEDNAPATSYC 167
QY 94 LTKRNMLTESLVALQGVFLLSDY--RVTG-----DT 123
Db 168 VECSEPLCETCEAHQRVKYTKDTRVSTGPATKTRDGERIVYCNVHKHEPLVLFCESCDT 227
QY 124 VLYCCGLRSFRELTYQYRON 144
Db 228 LTRCDQLNAHKHQYQFLED 248

RESULT 8
ID DPD2 YEAST STANDARD; PRT; 487 AA.
AC P46957;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE DNA polymerase delta small subunit (EC 2.7.7.7).
DE POL31 OR HYS2 OR HUS2 OR SDP5 OR YJR006W OR J1427 OR YJR83.7.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
RN [1]
RN SEQUENCE FROM N.A.
RA Sugimoto K., Sakamoto Y., Matsumoto K.;
RN Submitted (APR-1995) to the EMBL/GenBank/DBJ databases.
RN [2]
RN SEQUENCE FROM N.A.
RC STRAIN=S288c / FY1679;
RA de Haan M., Smits P.H.M., Grivell L.A.;
RL Submitted (MAY-1995) to the EMBL/GenBank/DBJ databases.
RN [3]
RN PARTIAL SEQUENCE, AND CHARACTERIZATION.
EX MEDLINE=98083176; PubMed=9421503;
RA Hashimoto K., Nakashima N., Ohara T., Maki S., Sugino A.;
RT "The second subunit of DNA polymerase III (delta) is encoded by the
RT HYS2 gene in Saccharomyces cerevisiae.";
```


DR EMBL; AEO16842; AA070124.1; -.
DR StyGene; SG77777; lpcA.
DR HAMAP; MF 00067; -. 1.
DR InterPro; IPR004515; Gnha.
DR InterPro; IPR001347; SIS.
DR Pfam; PF01380; SIS; 1.
DR TIGRFAMs; TIGR00441; gmba; 1.
DR Isomerase; Lipopolysaccharide biosynthesis; Complete proteome.
SQ SEQUENCE 192 AA; 20896 MW; 0ABFCCEBCE6786A4 CRC64;
Query Match 8.5%; Score 80; DB 1; Length 192;
Best Local Similarity 30.6%; Pred. No. 0.66;
Matches 22; Conservative 15; Mismatches 27; Indels 8; Gaps 3;
QY 83 DILKXNYLATGLTWKMLTE--SLVALQGVFLISD-YRVGTDTVLC-----YCCGLRSF 134
DB 4 LLIRNELNEAETLANFLKDDANIHAQRAAVLLADSFKAGGKVLSCNGSGSHCDAMHFA 63
QY 135 RELTYQYRONIP 146
DB 64 EELTGVRNRP 75
RESULT 6
SLI3 HUMAN STANDARD; PRT; 279 AA.
ID SLI3 HUMAN STANDARD; PRT; 279 AA.
AC Q14192; Q13229; Q13644; Q9P294;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Skeletal muscle LIM-protein 3 (SLIM3) (LIM-domain protein DRAL)
DE (Four and a half LIM domains protein 2) (FHL-2).
GN FHL2 OR SLIM3 OR DRAL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A.
RC TISSUE=Skeletal muscle;
RX MEDLINE=97294674; PubMed=9150430;
RA Genini M., Schwabe P., Scholl F.A., Remppis A., Mattei M.-G.,
RA Schaefer B.W.;
RT "Subtractive cloning and characterization of FHL2, a novel LIM-domain
RT protein down-regulated in rhabdomyosarcoma."
RL DNA Cell Biol. 16:433-442(1997).
[2]
SEQUENCE FROM N.A.
RC TISSUE=Heart;
RX MEDLINE=98248917; PubMed=9573400;
RA Chan K.X., Tsui S.K.W., Lee S.M.Y., Luk S.C.W., Liew C.C., Fung K.P.,
RA Waye M.M.Y., Lee C.Y.;
RT "Molecular cloning and characterization of FHL2, a novel LIM domain
RT protein preferentially expressed in human heart."
RL Gene 210:345-350(1998).
[3]
SEQUENCE FROM N.A.
RC TISSUE=Leukocyte;
RX MEDLINE=20458893; PubMed=11001931;
RA Tanahashi H., Tabira T.;
RT "Alzheimer's disease-associated presenilin 2 interacts with DRAL, an
RT LIM-domain protein."
RL Hum. Mol. Genet. 9:2281-2289(2000).
[4]
SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McKean P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny K.C., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[5]
SEQUENCE OF 127-279 FROM N.A.
RP TISSUE=Heart muscle;
RC MEDLINE=96354835; PubMed=8753811;
RX Morgan M.J., Madgwick A.J.A.;
RA "Slim defines a novel family of LIM-proteins expressed in skeletal
RT muscle."
RL Biochem. Biophys. Res. Commun. 225:632-638(1996).
CC -!- TISSUE SPECIFICITY: Expressed only in skeletal muscle.
CC -!- SIMILARITY: Contains 4 LIM zinc-binding domains.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
DR EMBL; L42176; AA85333.1; -.
DR EMBL; U29332; AAC52073.1; -.
DR EMBL; AB038794; BAA92253.1; JOINED.
DR EMBL; AB038991; BAA92253.1; JOINED.
DR EMBL; AB038992; BAA92253.1; JOINED.
DR EMBL; AB038792; BAA92253.1; JOINED.
DR EMBL; AB038793; BAA92253.1; JOINED.
DR EMBL; BC014397; AAH14397.1; -.
DR EMBL; U60117; AAC50794.1; -.
DR PIR; JC6565; JC6565.
DR Genew; HGNC:3703; FHL2.
DR MIM; 602633; -.
DR GO; GO:0005634; C:nucleus; TAS.
DR InterPro; IPR001781; LIM.
DR Pfam; PF0412; LIM; 4.
DR ProDom; PD000094; LIM; 4.
DR SMART; SM00132; LIM; 4.
DR PROSITE; PS00478; LIM DOMAIN 1; 4.
DR PROSITE; PS0023; LIM DOMAIN 2; 4.
KW Repeat; LIM domain; Metal-binding; Zinc; Zinc-finger.
FT ZN FING 7 31 GATA-LIKE (POTENTIAL).
FT DOMAIN 40 92 LIM 1.
FT DOMAIN 101 153 LIM 2.
FT DOMAIN 162 212 LIM 3.
FT DOMAIN 221 275 LIM 4.
FT CONFLICT 167 167 M -> G (IN REF. 1).
FT CONFLICT 167 167 M -> K (IN REF. 3 AND 4).
SQ SEQUENCE 279 AA; 32196 MW; DBDC77C9BD6C4BBA CRC64;
Query Match 8.4%; Score 79; DB 1; Length 279;
Best Local Similarity 23.8%; Pred. No. 1.3;
Matches 29; Conservative 10; Mismatches 51; Indels 32; Gaps 5;
QY 9 LTCFCFQMPDRAREQDPFVAPQCAVCLQPFCHLWGCTRTGCGYGLAPFCEINLGD 68
DB 187 VCTACRKQLSGQRTARD------FAYCLNCFCDLY-----AKCAGCTNFIISGL-GT 234
QY 69 KCLDGLVNNNSYESDLKLYLATGLTWKMLTESLVALQGVFLISDVRVGTDTVLCYC 128
DB 235 KVIS--FERQHNDCFNCKKCSLSIVRGFLTER-----DDILCPD 274

RA	MEDLINE=21156231; PubMed=11258796;	DB	4 DLIRNELNEAETLANFLKDDANIHTQRAAVLLADSKAGGKVLSCNGSGSHCDAMHFA 63
RA	Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,	QY	135 RELTYQYRQNP 146
RA	Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T.,		: :
RA	Iida T., Takami H., Honda T., Sasakawa C., Ogasawara N., Yasunaga T.,	DB	64 BELTGYRENRP 75
RA	Kuhara S., Shiba T., Hattori M., Shinagawa H.,		
RT	"Complete genome sequence of enterohemorrhagic <i>Escherichia coli</i>		
RT	O157:H7 and genomic comparison with a laboratory strain K-12."		
RL	DNA Res. 8:11-22(2001).		
RN	[9]		
RP	SEQUENCE FROM N.A.		
RC	SPECIES=S.flexneri; STRAIN=301 / Serotype 2a;		
RC	MEDLINE=2272406; PubMed=12384590;	AC	Q8XGZ8; STANDARD; PRT; 192 AA.
RA	Jin Q., Yuan X., Xu J., Wang Y., Shen Y., Lu W., Wang J., Liu H.,	DT	28-FEB-2003 (Rel. 41, Created)
RA	Yang J., Yang F., Zhang X., Zhang J., Yang G., Wu H., Qu D., Dong J.,	DT	28-FEB-2003 (Rel. 41, Last sequence update)
RA	Sun L., Xue Y., Zhao A., Gao Y., Zhu J., Kan B., Ding K., Chen S.,	DE	10-OCT-2003 (Rel. 42, Last annotation update)
RA	Cheng H., Yao Z., He B., Chen R., Ma D., Qiang B., Wen Y., Hou Y.,	GN	Phosphoprotein isomerase (EC 5.-.-.-) OR T2540.
RA	Yu J.,	OS	LPCA OR GMAH OR STM0310 OR STY0355 OR T2540.
RT	"Genome sequence of <i>Shigella flexneri</i> 2a: insights into pathogenicity	OS	Salmonella typhimurium, and
RT	through comparison with genomes of <i>Escherichia coli</i> K12 and O157."	OC	Salmonella typhi.
RL	Nucleic Acids Res. 30:4432-4441(2002).	OC	Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
RN	[10]	OC	Enterobacteriaceae; Salmonella.
RP	SEQUENCE FROM N.A.	OX	NCBI_TaxID=602, 601;
RC	SPECIES=S.flexneri; STRAIN=2457T / ATCC 700930 / Serotype 2a;	RN	[1]
RC	MEDLINE=22590274; PubMed=12704152;	RP	SEQUENCE FROM N.A.
RA	Wei J., Goldberg M.B., Burland V., Venkatesan M.M., Deng W.,	RC	SPECIES=S.typhimurium; STRAIN=LT2 / SGSC1412 / ATCC 700720;
RA	Fournier G., Maynew G.F., Plunkett G. III, Rose D.J., Darling A.,	RX	MEDLINE=21534948; PubMed=11677609;
RA	Mau B., Perna N.T., Payne S.M., Runyen-Janecky L.J., Zhou S.,	RA	McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P.,
RA	Schwartz D.C., Blattner F.R.;	RA	Courtney L., Porwollik S., Ali J., Dante M., Du F., Hou S., Layman D.,
RA	"Complete genome sequence and comparative genomics of <i>Shigella</i>	RA	Leonard S., Nguyen C., Scott K., Holmes A., Grewal N., Mulvaney E.,
RT	flexneri genome 2a strain 2457T."	RA	Ryan E., Sun H., Florea L., Miller W., Stenseth T., Nhan M.,
RL	Infect. Immun. 71:2775-2786(2003).	RA	Waterston R., Wilson R.K.;
CC	-1- FUNCTION: Involved in synthesis of glyceromannose 7-	RT	"Complete genome sequence of <i>Salmonella enterica</i> serovar Typhimurium
CC	phosphate.	RT	LT2."
CC	-1- PATHWAY: Inner core lipopolysaccharide biosynthesis.	RL	Nature 413:852-856(2001).
CC	-1- SUBCELLULAR LOCATION: Cytoplasmic.	RP	SEQUENCE FROM N.A.
CC	-1- SIMILARITY: Belongs to the SIS family. Lpca subfamily.	RC	SPECIES=S.typhi; STRAIN=CT18;
CC		RX	MEDLINE=21534947; PubMed=11677608;
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration	RA	Parhill J., Dougan G., James K.D., Thomson N.R., Pickard D., Wain J.,
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -	RA	Churcher C., Mungall K.L., Bentley S.D., Holden M.T.G., Sebaihia M.,
CC	the European Bioinformatics Institute. There are no restrictions on its	RA	Baker S., Basham D., Brooks K., Chillingworth T., Connor P.,
CC	use by non-profit institutions as long as its content is in no way	RA	Cronin A., Davis P., Davies R.M., Dowd L., White N., Farrar J.,
CC	modified and this statement is not removed. Usage by and for commercial	RA	Faltwell T., Hamlin N., Haque A., Hien T.T., Holroyd S., Jagals K.,
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/	RA	Krogh A., Larsen T.S., Leather S., Moule S., O'Gaora P., Parry C.,
CC	or send an email to license@isb-sib.ch).	RA	Quail M.A., Rutherford K., Simmonds M., Skelton J., Stevens K.,
CC		RA	Whitehead S., Barrett B.G.;
DR	EMBL; U32590; AAC43630.1; -	RT	"Complete genome sequence of a multiple drug resistant <i>Salmonella</i>
DR	EMBL; D38582; BAA07584.1; -	RT	enterica serovar Typhi CT18."
DR	EMBL; AE000131; AAC73326.1; -	RL	Nature 413:848-852(2001).
DR	EMBL; D83536; BAA77892.1; -	RN	[3]
DR	EMBL; U70214; AAB08644.1; ALT_INIT.	RP	SEQUENCE FROM N.A.
DR	EMBL; AE016756; AAN78853.1; ALT_INIT.	RC	SPECIES=S.typhi; STRAIN=Ty2 / ATCC 700931;
DR	EMBL; AP005200; AAG54547.1; -	RX	MEDLINE=22531367; PubMed=12644504;
DR	EMBL; AP002551; BAB33672.1; -	RA	Deng W., Liou S.-R., Plunkett G. III, Mayhew G.F., Rose D.J.,
DR	EMBL; AE015082; AAN41932.1; ALT_INIT.	RA	Burland V., Kodyanni V., Schwartz D.C., Blattner F.R.;
DR	EMBL; AE016979; AAP15818.1; -	RT	"Comparative genomics of <i>Salmonella enterica</i> serovar Typhi strains Ty2
DR	PIR; A90660; A90660.	RT	and CT18."
DR	PIR; G64746; G64746.	RL	J. Bacteriol. 185:2330-2337(2003).
DR	PIR; G85510; G85510.	CC	-1- FUNCTION: Involved in synthesis of glyceromannose 7-phosphate
DR	EcoGene; EG13146; lpcA.	CC	(By similarity).
DR	HMAP; MF 00067; -	CC	-1- PATHWAY: Inner core lipopolysaccharide biosynthesis.
DR	InterPro; IPR004515; GmbA.	CC	-1- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
DR	InterPro; IPR001347; SIS.	CC	-1- SIMILARITY: Belongs to the SIS family. Lpca subfamily.
DR	Pfam; PF01380; SIS; 1.	CC	
DR	TIGRFAMs; TIGR00441; GmbA; 1.	CC	This SWISS-PROT entry is copyright. It is produced through a collaboration
DR	Isomerase; Lipopolysaccharide biosynthesis; Complete proteome.	CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -
KW	SEQUENCE 192 AA; 20815 MW; 7A2C05E1079108B4 CRC64;	CC	the European Bioinformatics Institute. There are no restrictions on its
SQ		CC	use by non-profit institutions as long as its content is in no way
		CC	modified and this statement is not removed. Usage by and for commercial
		CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/
		CC	or send an email to license@isb-sib.ch).
		CC	
		CC	EMBL; AE008709; AAL19267.1; -
		CC	EMBL; AL627266; CAD08780.1; -
QY	83 DILKRYLATRGITWKNLITE--SLVALQGVFLSD-YRVYGTDTVLC-----YCCGLRSF 134		: :

Query Match 8.5%; Score 80; DB 1; Length 192;
Best Local Similarity 30.6%; Pred No. 0.66; Mismatches 27; Indels 8; Gaps 3;
Matches 22; Conservative 15

```

RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Pancreas, and Thymus;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaoka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Aeshburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staib F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann S., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-P.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
CC -!- SUBCELLULAR LOCATION: Type III membrane protein (Potential).
CC -!- INDUCTION: By interferons.
CC -!- SIMILARITY: Belongs to the TMEM7 family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AJ251364; CAC13976.1; --
DR EMBL; AK007477; BAB25057.1; --
DR EMBL; AK018021; BAB1041.1; --
DR MGD; MGI:1915025; 5830458KL6R1x.
KW Transmembrane.
FT TRANSMEM 228 248 POTENTIAL.
FT CONFLICT 185 185 K -> N (IN REF. 2; BAB31041).
FT CONFLICT 209 209 F -> L (IN REF. 2; BAB31041).
FT SEQUENCE 249 AA; 283391 MW; 2C79B36ED6F042D4 CRC64;
Query Match 8.6%; Score 81; DB 1; Length 249;
Best Local Similarity 22.2%; Pred. No. 0.7;
Matches 37; Conservative 21; Mismatches 71; Indels 38; Gaps 6;
QY 17 MPDREA---EREQDPRVAPQCAVCLQPF-----CHLY-----WGCTR 51
Db 36 VFDGALGWRHQQTIVLGRFQSCRCRSWTSAQVMILCHMYPDTLKSQGRMRIFQKC 95
QY 52 TGCYGLAPFCNELNGDKLGVLNNSYSDILKNYLATRLGTLWKNMLTSLVALQGV 111
Db 96 QKCFGC--QFEPKPFSTBIKRIILNN-----LVNVIQRYGHRKIALTSNASLGEKV 146
QY 112 FLLSDYRTVGTIVLCYCGCLSGFRLTYQYRQNTIPASELPVAVTSRP 158
Db 147 TLDGPH-----DTRNCEACLSHGRCALAHKVKPPRSPSPKXSSP 189
RESULT 4
LPCA_ECOLI
ID LPCA_ECOLI STANDARD; PRT; 192 AA.
AC F51001;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Phosphoheptose isomerase (EC 5.---).
GN LPCA OR GWHA OR TFRA OR B0222 OR C0372 OR Z0280 OR ECS0249 OR SF0272
CN OR S0293
OS Escherichia coli,

```

```

OS Escherichia coli O6,
OS Escherichia coli O157:H7, and
OS Shigella flexneri.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Escherichia.
CX NCBI_TaxID=562, 217992, 83334, 623;
[1]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli; STRAIN=K12 / W3110;
RC MEDLINE=96216460; PubMed=8631969;
RA Brooke J.S., Valvano M.A.;
RT "Biosynthesis of inner core lipopolysaccharide in enteric bacteria
RT identification and characterization of a conserved phosphoheptose
RT isomerase.";
RL J. Biol. Chem. 271:3608-3614(1996).
[2]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli; STRAIN=K12;
RC Olmori H.;
RA Submitted (OCT-1995) to the EMBL/GenBank/DBJ databases.
[3]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli; STRAIN=K12 / MG1655;
RC MEDLINE=97426617; PubMed=9278503;
RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA Mau B., Shao Y.;
RT "The complete genome sequence of Escherichia coli K-12.";
RL Science 277:1453-1474(1997).
[4]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli; STRAIN=K12 / W3110;
RA Yamamoto K., Mori H., Murayama N., Kataoka K., Yano M., Itoh T.,
RA Yamanoto Y., Inokuchi H., Miki T., Hataeda E., Fukuda R., Ichihara S.,
RA Mizuno T., Makino K., Nakata A., Yura T., Sampei G., Mizobuchi K.;
RT "Systematic sequencing of the Escherichia coli genome: analysis of the
RT 4.0 - 6.0 min (189,987 - 281,416bp) region.";
RL Submitted (FEB-1996) to the EMBL/GenBank/DBJ databases.
[5]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli;
RA Schramm S., Duncan M., Allen E., Araujo R., Aparicio A., Chung E.,
RA Davis K., Federspiel N., Hyman R., Kalman S., Komp C., Kurdi O.,
RA Lashkari D., Lew H., Lin D., Namath A., Oefner P., Roberts D.,
RA Davis R.W.;
RL Submitted (SEP-1996) to the EMBL/GenBank/DBJ databases.
[6]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli; STRAIN=O6:H1 / CFT073 / ATCC 700928;
RC MEDLINE=22388234; PubMed=12471157;
RA Welch R.A., Burland V., Plunkett G. III, Redford P., Roesch P.,
RA Raeko D., Buckles E.L., Liou S.-R., Boutin A., Hackett J., Stroud D.,
RA Mayhew G.F., Rose D.J., Zhou S., Schwartz D.C., Perna N.T.,
RA Mobley H.L.T., Donnenberg M.S., Blattner F.R.;
RT "Extensive mosaic structure revealed by the complete genome sequence
RT of uropathogenic Escherichia coli.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:17020-17024(2002).
[7]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli; STRAIN=O157:H7 / EDL933 / ATCC 700927;
RC MEDLINE=21074935; PubMed=11206551;
RA Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D.,
RA Rose D.J., Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A.,
RA Posfai G., Hackett J., Klink S., Boutin A., Shao Y., Miller L.,
RA Grobeck E.J., Davis N.W., Lim A., Dimalanta E.T., Potamousis K.,
RA Apodaca J., Anantharaman T.S., Lin J., Yen G., Schwartz D.C.,
RA Welch R.A., Blattner F.R.;
RT "Genome sequence of enterohaemorrhagic Escherichia coli O157:H7.";
RL Nature 409:529-533(2001).
[8]
RP SEQUENCE FROM N.A.
RC SPECIES=E.coli; STRAIN=O157:H7 / RIMD 0509952;

```

```
CC ENBL; AF025441; AAC39561.1; ALT_INIT.
DR ENBL; BC015050; AAH15050.1; -.
DR MIM; 606020; -.
DR GO; GO:0005515; P:protein binding; TAS.
DR GO; GO:0007154; P:cell communication; NAS.
SQ SEQUENCE 229 AA; 24691 MW; 0EBD4006193A3106 CRC64;

Query Match          9.0%; Score 85; DB 1; Length 229;
Best Local Similarity 26.6%; Pred. No. 0.25;
Matches 38; Conservative 15; Mismatches 52; Indels 38; Gaps 6;

QY 26 QDPRVAPQOCACV---LQPPCHLYWGCTRTGCGYCLAPFCCLNGLDKCLDGLVNNNSYES 82
DB 71 QPERCAVFQCAQCHAVLADSLVHLAWDLR-----SLGAVVFSRTNNVLEA 117
QY 83 DILKNVLT-RLGTWKML-----TESLVALQGVFLLSDYRTVGTIVLC 126
DB 118 PFLVIGIEGLKSGTY-NLLFCGSGIPGVPHLYSTHAAALAGHFCLS-----SDKMYC 171
QY 127 YCCGLRSFRLTYQYRONIPASE 149
DB 172 YLLKTKVAIVNASEMDIQNVLPSE 194

RESULT 2
Z451_MOUSE          STANDARD;          PRT; 1056 AA.
AC QSC0F7; 2004 (Rel. 43, Created)
DT 15-MAR-2004 (Rel. 43, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Zinc finger protein 451.
GN ZNF451.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Testis;
RX MEDLINE=22354683; PubMed=12466851;
RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA Nikaido I., Osato N., Saito R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,
RA Schirral L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,
RA Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA Kanai A., Kawaji H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,
RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,
RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita K.,
RA Vitaranto R., Wagner L., Wanstedt C., Wang Y., Watanabe Y., Wells C.,
RA Wilming L.G., Wyszynski-Boris A., Yanagisawa M., Yang I., Yang L.,
RA Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA Miyazaki A., Sakai K., Sasaki K., Shibata K., Shinagawa A.,
RA Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA Birney E., Hayashizaki Y.,
RT "Analysis of the mouse transcriptome based on functional annotation of
RL Nature 420:563-573(2002)."
CC -!- FUNCTION: May be involved in transcriptional regulation.
CC -!- SUBCELLULAR LOCATION: Nuclear (Potential).
```

```
CC CC -!- SIMILARITY: BELONGS TO THE KRUEPPEL FAMILY OF C2H2-TYPE ZINC-
CC FINGER PROTEINS.
CC -!- SIMILARITY: Contains 12 C2H2-type zinc fingers.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC ENBL; AK030088; BAC26778.1; -.
DR MGD; MGI:2138298; AI596398.
DR InterPro; IPR007087; Znf_C2H2.
DR Pfam; PF00096; zf_C2H2_7.
DR SMART; SM00355; Znf_C2H2_12.
DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 8.
DR PROSITE; PS50157; ZINC_FINGER_C2H2_2; 5.
DR Transcription regulation; DNA-binding; Zinc-finger; Metal-binding;
KW Nuclear protein; Repeat.
FT ZN_FING 169 195
FT ZN_FING 212 234
FT ZN_FING 253 277
FT ZN_FING 315 338
FT ZN_FING 362 385
FT ZN_FING 494 517
FT ZN_FING 527 550
FT ZN_FING 604 629
FT ZN_FING 634 657
FT ZN_FING 665 688
FT ZN_FING 751 774
FT ZN_FING 787 810
FT ZN_FING 1056 AA; 120069 MW; 7D8FBC0B50ECA622 CRC64;
SQ SEQUENCE 1056 AA; 120069 MW; 7D8FBC0B50ECA622 CRC64;

Query Match          8.6%; Score 81.5; DB 1; Length 1056;
Best Local Similarity 25.0%; Pred. No. 3.1;
Matches 38; Conservative 17; Mismatches 52; Indels 45; Gaps 8;

QY 35 CAVCLQPPC-----HLVWGCTRTG-----CYCLAPFCCLNGLDKCLD 72
DB 214 CAVCYEHFVTOQYKDHLL---LSRTAARDGHSNLLPQITQCYACPOCFLFSTKDECLK 270
QY 73 GVLNNNSYESD--ILKNLYATRLTKNMLTESLVALQGVFLLSDYRTVGTIVLCVCC- 129
DB 271 HMTKKNHFOHFKSLDNKGTARPISFPFAKRLVSLCKDVPF-----QVKCVACH 321
QY 130 -GLRSFRLTYQYR---QNIPASBELPVAVTSR 157
DB 322 QTLRSHMELTAHFVRVRCQAG----PVALAEK 349

RESULT 3
IF28_MOUSE
ID IF28_MOUSE          STANDARD;          PRT; 249 AA.
AC Q9ER80; Q9D3D6;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE 28 kDa interferon responsive protein.
GN IFRG28.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=DBA/2;
RT "Characterization of ifrg28, two newly identified
RL Nature 420:563-573(2002)."
RN [2]
```

34 69.5 7.4 63 1 KURT PARTR
35 69.5 7.4 2139 1 CRB_DROME
36 69 7.3 305 1 FX34_HUMAN
37 68.5 7.3 245 1 YPC2_ECOLI
38 68.5 7.3 456 1 NRI1_CHICK
39 68.5 7.3 491 1 2ASR_MOUSE
40 68.5 7.3 780 1 OSTA_YERPE
41 68.5 7.3 1122 1 TEST_MOUSE
42 68.5 7.3 1341 1 Y178_YEAST
43 68.5 7.3 2715 1 GL56_PAPPR
44 68 7.2 342 1 ARG_CAMJIE
45 68 7.2 550 1 SYM_CHLTR

US-10-046-046-2_COPY_476_641
Title: US-10-046-046-2_COPY_476_641
Perfect score: 943
Sequence: 1 CPGQSHALCTCCFQMPDR.....ASELPVAVTSRDPYWGRC 166
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 141681 seqs, 52070155 residues
Total number of hits satisfying chosen parameters: 141681
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries
Database : SwissProt_42:*

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.
OM protein - protein search, using sw model
Run on: May 7, 2004, 14:37:32 ; Search time 5.60929 Seconds
(without alignments)
1540.951 Million cell updates/sec
Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	85	9.0	229	1 OIP5_HUMAN	O43482 homo sapien
2	81.5	8.6	1056	1 Q8COP7	mus musculus
3	81	8.6	249	1 IF28_MOUSE	Q9er80 mus musculus
4	80	8.5	192	1 LPCA_ECOLI	P51001 escherichia
5	80	8.5	192	1 LPCA_SALTY	Q8Xg28 mus musculus
6	79	8.4	279	1 SLI3_HUMAN	Q14192 homo sapien
7	78	8.3	834	1 TPIB_MOUSE	O62318 mus musculus
8	76.5	8.1	487	1 DP22_YEAST	P46957 saccharomyc
9	76	8.1	567	1 KGE_HUMAN	P52429 homo sapien
10	75.5	8.0	419	1 FAAA_HUMAN	P16930 homo sapien
11	75.5	8.0	615	1 FA12_HUMAN	P00748 homo sapien
12	75	8.0	193	1 LPCA_YERPE	Q82BY7 yersinia pe
13	75	8.0	279	1 SLI3_MOUSE	O70433 mus musculus
14	75	8.0	279	1 SLI3_RAT	O35115 rattus norv
15	75	8.0	465	1 OPCA_NOSPU	P48971 nostoc punc
16	75	8.0	1180	1 RNT1_DROME	Q9VY83 drosophila
17	75	8.0	1458	1 PHIX_RABIT	Q05017 oryctoiaqus
18	74.5	7.9	603	1 FA12_CAVPO	Q04962 cavia porce
19	73.5	7.8	419	1 FAAA_MOUSE	P35505 mus musculus
20	73.5	7.8	419	1 FAAA_RAT	P25093 rattus norv
21	73	7.7	603	1 PGH2_CHICK	T27607 gallus gall
22	72.5	7.7	835	1 TPIB_HUMAN	Q13263 homo sapien
23	72	7.6	193	1 PHOL1_HUMAN	Q7H7F7 photornadu
24	72	7.6	3075	1 LNA1_HUMAN	P25391 homo sapien
25	71.5	7.6	854	1 NAL6_RAT	Q63035 rattus norv
26	71	7.5	450	1 NRI1_HUMAN	Q9BU40 homo sapien
27	71	7.5	485	1 RNI4_MOUSE	Q91190 mus musculus
28	71	7.5	3718	1 LNA5_MOUSE	O61001 mus musculus
29	70.5	7.5	192	1 YD24_AQUAE	O67344 aquifex aeo
30	70.5	7.5	351	1 Y876_METUA	Q58286 methanococc
31	70.5	7.5	387	1 SGCA_MOUSE	P82350 mus musculus
32	70.5	7.5	1135	1 VGLM_TSWV1	P36291 tomato spot
33	70	7.4	1093	1 RNT1_NEUCR	Q9HEH1 neurospora

ALIGNMENTS

RESULT 1
OIP5_HUMAN
ID OIP5_HUMAN STANDARD; PRT; 229 AA.
AC O43482; Q96BX7;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Opa-interacting protein 5.
GN OIP5.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
OX [1]
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98125741; PubMed=9466265;
RA Williams J.M., Chen G.-C., Zhu L., Rest R.F.;
RT "Using the yeast two-hybrid system to identify human epithelial cell
RT proteins that bind gonococcal Opa proteins: intracellular gonococci
RT bind pyruvate kinase via their Opa proteins and require host pyruvate
RT for growth.";
RL Mol. Microbiol. 27:171-186(1998).
RN [2]
RP SEQUENCE FROM N.A.
RX TISSUE=Uterus;
RA MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udgin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McGowan P.J., McKernan K.J., Malek J.A., Gumarstne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield A.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- SUBUNIT: Binds outer membrane protein Opa from Neisseria
CC gonorrhoeae.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).

A:Molecule type: DNA
A:Residues: 1-1101 <GEI>
A:Cross-references: EMBL:U39644; NID:g1049339; PID:g1049343; PIDN:AAA80360.1; CESP:T10E1
A:Experimental source: strain Bristol N2
C:Genetics:
A:Gene: CESP:T10E10.4
A:Introns: 93/2; 152/2; 191/3; 209/2; 283/3; 303/1; 399/3; 421/1; 440/1; 465/1; 547/3; 7
Query Match 8.0%; Score 75.5; DB 2; Length 1101;
Best Local Similarity 20.3%; Pred. No. 54;
Matches 35; Conservative 27; Mismatches 55; Indels 55; Gaps 9;
QY 1 CPLQGSHALCTCCFQMPDRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGYGLAP 60
Db 558 CGVGSYKTKTCQEI---KLPVCSNGMISQKRCIVAAE--CGLNLECSNGGC--CPIP 610
QY 61 FC-----ELN---LGDKCLDGVLNNSYESDILKNVLTATRGLTWKWMLTESLVA 106
Db 611 FCFNGVTARGCSQVNGCPMGQACMEGLC-----CPLPK---CSNGITSLGICITRTLLDC 661
QY 107 LQEGV-----FLLSDYRVRTGDTVLCY-----CCGLRS 133
Db 662 GRIGVDCNNGACCPLETCPNNIASSQRCSGGCTNCCPVGQTCWNGGCCDLPS 713

Search completed: May 7, 2004, 14:50:10
Job time : 11.5404 secs

C>Date: 02-Feb-2001 #sequence_revision 02-Feb-2001 #text_change 02-Feb-2001
 C/Accession: H64724
 R/Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.;
 M.; Fujikawa, K.; Cronin, L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, L.;
 Koo, H.; Moffat, K.S.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter,
 D.; Mierman, W.C.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.;
 Nature 402, 761-768, 1999
 A>Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.
 A/Reference number: A84420; MUID:20083487; PMID:10617197
 A/Accession: H64724
 A/Status: preliminary
 A/Molecule type: DNA
 A/Residues: 1-343 <STO>
 A/Cross-references: GB:AB002093; NID:94887759; PIDN:AA032295.1; GSPDB:GN00139
 C/Genetics:
 A/Gene: At2g31770
 A/Map position: 2

Query Match 8.0%; Score 75.5; DB 2; Length 543;
 Best Local Similarity 25.3%; Pred. No. 27;
 Matches 24; Conservative 10; Mismatches 32; Indels 29; Gaps 5;

QY 10 CTCGQPMPPRAERQDPRAVQCAVCLQPFCHLYW-----GCTRTGCGYC 57
 128 CGICFESY-----TREIARVS-----CGHYCKTWAGYITTKIEDGPGCLRV---KC 173

QY 58 LAPCELNLDGKCLDGLN---NNSYESDILKNYL 89
 DB 174 PEPSCSAAGVGMIEDVPTETKNEKISYILRSYV 208

RESULT 14
 KFHU12
 coagulation factor XIIa (EC 3.4.21.38) precursor [validated] - human
 N/Alternate names: Hageman factor (activated)
 C/Species: Homo sapiens (man)
 C/Date: 27-Nov-1985 #sequence_revision 30-Jun-1991 #text_change 08-Dec-2000
 C/Accession: A29411; A26814; A00930; A25191; A22248; A21037
 R/Cool, D.E.; MacGillivray, R.T.A.
 J. Biol. Chem. 262, 13662-13673, 1987
 A>Title: Characterization of the human blood coagulation factor XII gene. Intron/exon ge
 A/Reference number: A29411; MUID:86007593; PMID:2888762
 A/Accession: A29411
 A/Molecule type: DNA
 A/Residues: 1-615 <COO>
 A/Cross-references: GB:M17466; NID:9180355; PIDN:AA059490.1; PID:g180357
 R/Tripodi, M.; Citarella, F.; Guida, S.; Galeffi, P.; Fantoni, A.; Cortese, R.
 Nucleic Acids Res. 14, 3146, 1986
 A>Title: cDNA sequence coding for human coagulation factor XII (Hageman).
 A/Reference number: A26814; MUID:86176794; PMID:3754331

A/Accession: A26814
 A/Molecule type: mRNA
 A/Residues: 4-615 <TRI>
 A/Cross-references: GB:M31315; NID:g182291; PIDN:AAA70225.1; PID:g182292
 R/Cool, D.E.; Edgell, C.J.; Louis, G.V.; Zoller, M.J.; Brayer, G.D.; MacGillivray, R.T.
 J. Biol. Chem. 260, 13666-13676, 1985
 A>Title: Characterization of human blood coagulation factor XII cDNA. Prediction of the
 A/Reference number: A00930; MUID:86033830; PMID:3877053
 A/Accession: A00930
 A/Molecule type: mRNA
 A/Residues: 14-332, 'S', 334-615 <CO2>
 A/Cross-references: GB:M11723; NID:g180358; PIDN:AAA51986.1; PID:g180359
 R/Que, B.G.; Davie, E.W.
 Biochemistry 25, 1525-1528, 1986
 A>Title: Characterization of a cDNA coding for human factor XII (Hageman factor).
 A/Reference number: A25191; MUID:86216049; PMID:3011063
 A/Accession: A25191
 A/Molecule type: mRNA
 A/Residues: 146-378, 'G', 380-615 <QUE>
 A/Cross-references: GB:M3147; NID:g180360; PIDN:AAA70224.1; PID:g180361
 R/McMullen, B.A.; Fujikawa, K.
 J. Biol. Chem. 260, 5328-5341, 1985
 A>Title: Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Ha
 A/Reference number: A22248; MUID:85182674; PMID:3886654

A/Accession: A22248
 A/Molecule type: protein
 A/Residues: 20-379 <MCM>
 R/Fujikawa, K.; McMullen, B.A.
 J. Biol. Chem. 258, 10924-10933, 1983
 A>Title: Amino acid sequence of human beta-factor XIIa.
 A/Reference number: A21037; MUID:83291041; PMID:6604055
 A/Accession: A21037
 A/Molecule type: protein
 A/Residues: 354-362; 373-615 <FUD>
 R/Harris, R.J.; Ling, V.T.; Spellman, M.W.
 J. Biol. Chem. 267, 5102-5107, 1992
 A>Title: O-linked fucose is present in the first epidermal growth factor domain of factor
 A/Reference number: A44606; MUID:92184750; PMID:1544894
 A/Contents: annotation; carbohydrate binding site
 C/Genetics:
 A/Gene: GDB:F12
 A/Cross-references: GDB:119892; OMIM:234000
 A/Map position: 5q34-5qter
 A/Introns: 19/3; 39/1; 72/2; 96/1; 133/1; 177/1; 212/1; 267/2; 340/1; 417/2; 463/1; 511/1
 C/Complex: factor XII, prekallikrein, and HMW kininogen form a complex bound to anionic s
 C/Function:
 A/Description: factor XIIa catalyzes the proteolytic activation of plasminogen, plasma p
 ikrein
 A/Pathway: blood coagulation; fibrinolysis
 C/Superfamily: coagulation factor XII; EGF homology; fibronectin type I repeat homology;
 C/Keywords: blood coagulation; fibrinolysis; glycoprotein; hydrolase; kringle; plasma; se
 F/1-19/Domain: signal sequence #status predicted <SIG>
 F/20-372,373-615/Product: coagulation factor XIIa, alpha form #status experimental <A12>
 F/47-88/Domain: fibronectin type II repeat homology <F82>
 F/98-130/Domain: EGF homology <EG1>
 F/135-170/Domain: fibronectin type I repeat homology <1F1>
 F/178-209/Domain: EGF homology <EG2>
 F/217-295/Domain: kringle homology <KRG>
 F/238-356/Region: proline-rich
 F/354-362,373-615/Product: coagulation factor XIIa, beta form #status experimental <B12>
 F/373-609/Domain: trypsin homology <TRY>
 F/98-110,104-119,121-130,135-163,161-170,178-189,183-198,200-209,217-295,238-277,266-290,
 F/109/Binding site: carbohydrate (Thr) (covalent) #status experimental
 F/249,433/Binding site: carbohydrate (Asn) (covalent) #status experimental
 F/259,305,328,329,337/Binding site: carbohydrate (Thr) (covalent) #status predicted
 F/308/Binding site: carbohydrate (Ser) (covalent) #status predicted
 F/412,461,563/Active site: His, Asp, Ser #status predicted

Query Match 8.0%; Score 75.5; DB 1; Length 615;
 Best Local Similarity 20.7%; Pred. No. 30;
 Matches 29; Conservative 13; Mismatches 35; Indels 63; Gaps 6;

QY 1 CP--LOGSHALCTCCFQPM-----PDRAEREQDDRVAP 32
 121 CPOHLTGNHCQKCEPEQLLRFHFKNEIWRTEQAAVARCCKGPDACQ-----RLAS 175
 QY 33 QQCAV-----CLOPFCHLYWGCTRTGCGCLAPFCFLNLGDKCLDGLVNNNSYESDI 84
 176 QACRTNPCLHGGRCLEVEGHRLLCHCP---VGTGFCVDVTKASCYDG-----220
 QY 85 LKNYLATRGLTWKNMLTESL 104
 221 -----RGLSVYRGLARTTL 233

RESULT 15
 T16840
 hypothetical protein T10E10.4 - Caenorhabditis elegans
 C/Species: Caenorhabditis elegans
 C/Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999
 C/Accession: T16840
 R/Geisel, C.
 submitted to the EMBL Data Library, October 1995
 A/Description: The sequence of C. elegans cosmid T10E10.
 A/Reference number: Z18588
 A/Accession: T16840
 A/Status: preliminary; translated from GB/EMBL/DD5J

db 258 VFSYQRRMHFSFDCAWSTSC 277

RESULT 10

JC6565
 four-and-a-half LIM-only protein 2 - human
 C/Species: Homo sapiens (man)
 C/Date: 05-Dec-1998 #sequence_revision 05-Dec-1998 #text_change 21-Jul-2000
 C/Accession: JC6565 S.K.W.; Luk, S.M.Y.; Lee, S.C.W.; Fung, K.P.; Waye, M.M.; Chan, K.K.; Tsui, S.K.W., 1998
 Gene 210, 345-350, 1998
 A/Title: Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in muscle
 A/Reference number: JC6565; MUID:98248917; PMID:9573400
 A/Accession: JC6565
 A/Molecule type: mRNA
 A/Residues: 1-279 <GB>
 A/Cross-references: CHA:U29332; NID:gr1845201; PIDN:AAC52073.1; PID:gl377897
 A/Experimental source: heart
 C/Genetics:
 A/Map position: 2q12-2q13
 C/Superfamily: LIM metal-binding repeat homology
 C/Keywords: cardiac muscle; heart; zinc finger
 P:231-375/Domain: LIM metal-binding repeat homology <LIM>

Query Match	8.4%	Score 79	DB 2	Length 279
Best Local Similarity	23.8%	Pred. No. 6.5		
Matches	29	Conservative	10	Mismatches 51
				Indels 32
				Gaps 5

9 LCTCCFQPMDDRAAREQDPRVAPQCAVCLQPFCHLYWGCTRTGCVGCLAPFCCLNLGD 68

Db 187 VCTACRQLSGQRFRTARD-----FAYCLNCFDLY-----AKKACAGTNPISGLG-GT 234

Qy 69 XCLEDGVLNNNSYESDILKNYLATRGLTWKQMLTESIALQRGVFLLSDYRVGTGDTVLQYC 128

Db 235 KYIS--FEERQWHDNCFNCKCSSLVGRGFLTER-----DILCPD 274

QY 129 CG 130

Db 275 CG 276

RESULT 11

S55194
 Saccharomyces cerevisiae
 N:Alternate names: DNA-directed DNA polymerase delta small chain; HUS2 protein; HYS2 protein
 C:Species: Saccharomyces cerevisiae
 C:Date: 30-Oct-1998 #sequence revision 30-Oct-1998 #text_change 21-Jul-2000
 C:Accession: S55194; S57021; S59122
 R:de Haan, M.; Smits, P.H.M.; Grivell, L.A.
 submitted to the EMBL Data Library, May 1995
 A:Reference number: S55183
 A:Accession: S55194
 A:Molecule type: DNA
 A:Residues: 1-487 <DSH>
 A:Cross-references: EMBL:X87611; NID:g854567; PIDN:CAA60928.1; PID:g854579
 R:de Haan, M.; Grivell, L.A.; Smits, P.H.M.
 submitted to the Protein Sequence Database, September 1995
 A:Reference number: S56771
 A:Accession: S57021
 A:Molecule type: DNA
 A:Residues: 1-487 <ZAG>
 A:Cross-references: EMBL:Z49506; NID:g1015629; PIDN:CAA89528.1; PID:g1015630; GSPDB:GN00
 R:Sugimoto, K.; Sakamoto, Y.; Takahashi, O.; Matsumoto, K.
 Nucleic Acids Res. 23, 3493-3500, 1995
 A:Title: HYS2, an essential gene required for DNA replication in Saccharomyces cerevisiae
 A:Reference number: S59122; MUID:96032843; PMID:7567461
 A:Accession: S59122
 A:Status: nucleic acid sequence not shown; translation not shown
 A:Molecule type: DNA
 A:Residues: 1-155, 'H', 157-454, 'N', 466-487 <SUG>
 A:Cross-references: EMBL:D50324; NID:gs987711; PIDN:BA008859.1; PID:gs1256943
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library April 1995

A;Reference number: AB0502; MUID:21534947; PMID:11677608
A;Accession: AD0542
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-192 <PAR>
A;Cross-references: GB:AL513382; PIDN:CAD08780.1; PID:gi6501596; GSPDB:GN00176
C;Genetics:
A;Gene: STY0355
C;Superfamily: phosphoheptose isomerase

Query Match 8.5%; Score 80; DB 2; Length 192;
Best Local Similarity 30.6%; Pred. No. 3.6;
Matches 22; Conservative 15; Mismatches 27; Indels 8; Gaps 3;
QY 83 DILKNYLATRGLTWKNMLTE--SLVALQRGVFLSD-YRVGTGTVLC-----YCCGLRSF 134
DB 4 DLRNENAEATLANFLKDDANIHAIQRAAVLLADSFVAGGKVLSCGSGSHCDAMHFA 63
QY 135 RELTYOYRONIP 146
DB 64 EELTYGRENRP 75

RESULT 9
T00480
probable RING zinc finger protein Ar2g34990 [imported] - Arabidopsis thaliana
N;Alternate names: hypothetical protein F1913.22
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 12-Feb-1999 #sequence_revision 12-Feb-1999 #text_change 23-Mar-2001
C;Accession: T00480; C84763
R;Rounsley, S.D.; Lin, X.; Ketchum, K.A.; Crosby, M.L.; Brandon, R.C.; Sykes, S.
submitted to the EMBL Data Library, April 1998
A;Description: Arabidopsis thaliana chromosome II BAC F1913 genomic sequence.
A;Reference number: Z14160
A;Accession: T00480
A;Status: translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-302 <ROU>
A;Cross-references: EMBL:AC004238; NID:g30333373; PID:g30333394
A;Experimental source: Cultivar Columbia
R;Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii
M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; VanAken, S.E.; Umavam, L.; T
eusa, D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.;
Nature 402, 761-768, 1999
A;Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana
A;Reference number: AB4420; MUID:20083487; PMID:10617197
A;Accession: C84763
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-302 <STO>
A;Cross-references: GB:AE002093; NID:g30333394; PIDN:AAC12838.1; GSPDB:GN00139
C;Genetics:
A;Gene: At2g34990; F1913.22
A;Map position: 2
C;Superfamily: Arabidopsis hypothetical protein F1913.22; RING finger homology

Query Match 8.5%; Score 80; DB 2; Length 302;
Best Local Similarity 22.8%; Pred. No. 5.7;
Matches 45; Conservative 18; Mismatches 53; Indels 84; Gaps 10;
QY 34 QCAVCLQFPF-----CHLY-----WGCTRTGCGYGLAPFCELNLDGKCL--- 71
DB 95 ECAVCIPEDEHETRLMPECCVHFADCVSVWLSDHSTC-----FLCRVDL---CLQPG 146
QY 72 -----DGVLNNSYSDILKNYLATRGLTWKNMLTES-----LVALQRGVFLSD 116
DB 147 ERSYLNPEPDLVESTNSHLFD-----GVTTNRNPRSRWSWTLSCRVSQLISR 197
QY 117 YRVGTGTVLCYCCGLRSF-----RELTYO-----YRONIPASELP 151
DB 198 SHSTGSHVQPLNDLDRFTLRLEPVEVRQLTKXTVDNVAFSQARSSRGVRSAGSERS 257
QY 152 V-----AVTSRPDCYWGRCN 166

A:Accession: C96516
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-473 <STO>
A:Cross-references: GB:AE005173; NID:g5668816; PIDN:ABD46042.1; GSPDB:GN00141
A:Gene: E16N3.15
A:Map position: 1

Query Match 14.6%; Score 137.5; DB 2; Length 473;
Best Local Similarity 25.0%; Pred. No. 4.2e-05;
Matches 45; Conservative 26; Mismatches 88; Indels 21; Gaps 6;

QY 1 CPLQSHALCTCCFQMPDRAERQDPRAVAPQCAVCLQPFCHLYWGCTRTGCGYGLAP 60
Db 275 CEHGHAGLQCHLCQGMWFRANLQ-----VPLHCKGCDRPFCCGAYWS-SENVTGVGSGP 327

QY 61 FCELN-----LQKCLDGV-----LNNNSYSDILKNYLATRLGTWKNMLES-----VAL 107
Db 328 VCVRETRFISERTITRIPIFTHMNRHQDITQRCIAHMEKTVDPVVAEMLRLFNREI 387

QY 108 QGVFLLSYR-VTGTDTLVCYGLRSFRELTVQYRQNPASELPVAVTSRDPDCYWGRC 166
Db 388 DSRMPLNHAETITASTHVNCNDYKLVGFLYWFRLTPRNHLPADVAAREDCWYGAC 447

RESULT 3
T22759
hypothetical protein F55H12.3 - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 18-Aug-2000
C:Accession: T22759
R:Dobson, R.
submitted to the EMBL Data Library, October 1996
A:Reference number: Z19610
A:Accession: T22759
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: DNA
A:Residues: 1-2824 <WIL>
A:Cross-references: EMBL:Z81091; PIDN:CA03143.1; GSPDB:GN00019; CESP:F55H12.3
A:Experimental source: clone F55H12
C:Genetics:
A:Gene: CESP:F55H12.3
A:Map position: 1
A:Introns: 87/1; 98/1; 126/2; 201/3; 343/3; 406/1; 576/3; 656/1; 825/3; 869/1; 909/1; 967/1; 1755/2; 1800/1; 1850/3; 1896/1; 2003/3; 2035/3; 2082/3; 2119/1; 2144/1; 2200/2; 2277/1; 2279/Domain: LDL receptor ligand-binding repeat homology <LDL>
F:243-279/Domain: LDL receptor ligand-binding repeat homology <LDL>

Query Match 8.9%; Score 83.5; DB 2; Length 2824;
Best Local Similarity 27.1%; Pred. No. 26;
Matches 55; Conservative 12; Mismatches 51; Indels 85; Gaps 15;

QY 10 CTCCTCFP-----MPDRAERQDPRAVAPQCAVCLQ-----P 41
Db 1407 CLCNPPCPSTELLQPR--DQIGDCTLNSCQNGVCLQNGMHDCACNEFYFVDRENGTF 1464

QY 42 FCH-----LYWGCTRTGCGY-----LAPCELN-LQDKC-LDGVNNNSYE---SD 83
Db 1465 FCPNHLFTNQTRNSGYDCSTGRENALFLCP--NLNFGDFCPYEGQLYNNSYIVLSA 1522

QY 84 ILKNYLATRLTWNKMLTSLVALQGVFLLSYRVTGTDTLVCYCCGLRSFRELTVQYRQ 143
Db 1523 GIENAIATN-----LCBSLDTL-----YAVPN-----TFCV-----Q 1549

QY 144 NIPASELPVAVTSRDPDCYWGRC 166
Db 1550 N-PTSTTP-SIHRCDFCYGGENC 1570

RESULT 4
T31070
notch homolog - sea urchin (Lytechinus variegatus)

C:Species: Lytechinus variegatus (variegated urchin)
C:Date: 22-Oct-1999 #sequence_revision 22-Oct-1999 #text_change 31-Jan-2000
C:Accession: T31070
R:Sherwood, D.R.; McClay, D.R.
Development 124; 3393-3574, 1997
A:Title: Identification and localization of a sea urchin Notch homologue: insights into
A:Reference number: Z20966; MUID:97454256; PMID:9310331
A:Accession: T31070
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-2531 <SHE>
A:Cross-references: EMBL:AF000634; NID:g2570350; PID:g2570351; PIDN:AA82088.1
C:Superfamily: notch protein; ankyrin repeat homology; EGF homology

Query Match 8.8%; Score 83; DB 2; Length 2531;
Best Local Similarity 28.6%; Pred. No. 25;
Matches 30; Conservative 9; Mismatches 40; Indels 26; Gaps 6;

QY 5 GSHALCTCCFQ--MPDRAERQDPRAVAPQCAVCLQPFCHLYWGCTR-TGCVGCL--- 58
Db 840 GYSCRTSGTGGFQGNFCDDDRNE-----CLFSPCRNGSGCTNLEGSFECSCLP 885

QY 59 ---APFCELNLGDKCLDGVNNNSYSDILKNYLAT--RGLTWKN 98
Db 886 GYDGPICEINI-DECASGPCTNGGICTDLDDYFCSCQRGFTGKN 929

RESULT 5
G64746
phosphoheptose isomerase (EC 5.---) gmbA - Escherichia coli (strain K-12)
C:Species: Escherichia coli
C:Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 01-Mar-2002
C:Accession: G64746
R:Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.; Riley, M.; Co
A.; Rose, D.J.; Mau, B.; Shao, Y.
Science 277; 1453-1462, 1997
A:Title: The complete genome sequence of Escherichia coli K-12.
A:Reference number: A64720; MUID:97426617; PMID:9278503
A:Accession: G64746
A:Status: nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-192 <BLAT>
A:Cross-references: GB:AE000131; GB:U00096; NID:g1786415; PIDN:AACT3326.1; PID:g1786416;
A:Experimental source: strain K-12, substrain MG1655
C:Genetics:
A:Gene: gmbA
C:Function:
A:Description: synthesis of glyceromannoheptose 7-phosphate
A:Pathway: inner core lipopolysaccharide biosynthesis
C:Superfamily: phosphoheptose isomerase
C:Keywords: isomerase

Query Match 8.5%; Score 80; DB 1; Length 192;
Best Local Similarity 30.6%; Pred. No. 3.6;
Matches 22; Conservative 15; Mismatches 27; Indels 8; Gaps 3;

QY 83 DILKNYLATRLTWNKMLTE--SLVALQGVFLLS-YYVTGDTVLC-----YCCGLRSF 134
Db 4 DLIRNELNEAETLANFLKDDANIHAIQRAAVLLADSFKAGGKVLSCNGSGHCDMHFA 63

QY 135 RELTVQYRQNP 146
Db 64 BELTGYRENRP 75

RESULT 6
A90660
phosphoheptose isomerase [imported] - Escherichia coli (strain O157:H7, substrain RMD 0
C:Species: Escherichia coli
C:Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 03-Aug-2001
C:Accession: A90660
R:Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.
gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:41:17 ; Search time 9.29039 Seconds
(without alignments)
1718.743 Million cell updates/sec

Title: US-10-048-046-2_COPY_476_641

Perfect score: 943
Sequence: 1 CPLQGSHALCTCCFQMPDR.....ASLPVAVTSRPPDCYWGRC 166

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: Pir1.*

2: Pir2.*

3: Pir3.*

4: Pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	943	100.0	306	2 T46399	hypothetical prote
2	137.5	14.6	473	2 C96516	F16N3.15 [imported]
3	83.5	8.9	2824	2 T22759	hypothetical prote
4	83	8.8	2531	2 T11070	notch homolog - se
5	80	8.5	192	1 G64746	phosphoheptose iso
6	80	8.5	192	2 A30660	phosphoheptose iso
7	80	8.5	192	2 G85510	phosphoheptose iso
8	80	8.5	192	2 AD0542	phosphoheptose iso
9	80	8.5	302	2 T00480	probable RING zinc
10	79	8.4	279	2 C65855	four-and-a-half LI
11	76.5	8.1	487	1 S55194	DNA-directed DNA p
12	75.5	8.0	419	2 A37926	fumarylacetoacetat
13	75.5	8.0	543	2 H84724	probable ARI-like
14	75.5	8.0	615	1 KFHU12	coagulation factor
15	75.5	8.0	1101	2 T16840	hypothetical prote
16	75	8.0	193	2 A80394	phosphoheptose iso
17	75	8.0	1458	2 A56855	adult-specific bru
18	74.5	7.9	419	2 A56825	fumarylacetoacetat
19	74.5	7.9	603	2 S28941	coagulation factor
20	73.5	7.8	362	2 T02605	hypothetical prote
21	73.5	7.8	406	2 T24021	hypothetical prote
22	73.5	7.8	419	2 A40219	fumarylacetoacetat
23	73.5	7.8	419	2 JH0467	fumarylacetoacetat
24	73.5	7.8	679	2 B96599	protein F20N2.12 [
25	73	7.7	603	2 A38630	prostaglandin-endo
26	72	7.6	3075	2 S14458	laminin alpha-1 ch
27	71.5	7.6	483	2 S27880	Nasopressin recept
28	71.5	7.6	4550	2 T18440	hypothetical prote
29	71	7.5	3635	2 T10053	laminin alpha 5 ch

30	70.5	7.5	192	2 E70414	hypothetical prote
31	70.5	7.5	351	2 D64409	iron(III) dicitrat
32	70.5	7.5	387	2 JCS556	adhalin - mouse
33	70.5	7.5	421	2 AC1096	hypothetical prote
34	70.5	7.5	1135	1 JQ1928	G2-G1 polypeptide
35	70	7.4	661	2 B96596	hypothetical prote
36	70	7.4	802	2 T24293	hypothetical prote
37	70	7.4	949	2 T24294	hypothetical prote
38	69.5	7.4	320	2 T45909	hypothetical prote
39	69.5	7.4	401	2 T02958	ribulose-bisphosph
40	69.5	7.4	2139	2 A35672	crumbs protein - f
41	69	7.3	302	2 AE0645	probable ROK-famil
42	69	7.3	347	2 T33204	hypothetical prote
43	69	7.3	378	2 T00481	probable RING zinc
44	69	7.3	456	2 T19817	hypothetical prote
45	68.5	7.3	444	2 A55071	hydrogen peroxide-

ALIGNMENTS

RESULT 1

T46399
hypothetical protein DKFP434N2420.1 - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 04-Feb-2000 #sequence_revision 04-Feb-2000 #text_change 04-Feb-2000
C;Accession: T46399
R;Ottewaelde, B.; Obermaier, B.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
submitted to the Protein Sequence Database, January 2000
A;Reference number: Z23031
A;Accession: T46399
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-306 <AAA>
A;Cross-references: EMBL:AL137561
A;Experimental source: adult testis; clone DKFP434N2420
C;Genetics:
A;Note: DKFP434N2420.1

Query Match	100.0%;	Score 943;	DB 2;	Length 306;
Best Local Similarity	100.0%;	Pred. No. 7e-80;	Mismatches 0;	Gaps 0;
Matches 166;	Conservative 0;	Indels 0;		
QY	1	CPLQGSHALCTCCFQMPDRRAERQDPRAVAPQCAVCLQPFCHLYWGTRTCGYGCLAP	60	
Db	118	CPLQGSHALCTCCFQMPDRRAERQDPRAVAPQCAVCLQPFCHLYWGTRTCGYGCLAP	177	
QY	61	FCEINLGDKCLDGLVNNNSYESDILKNYLATGLTKWMLTESLVALQGVLLSDYRVT	120	
Db	178	FCEINLGDKCLDGLVNNNSYESDILKNYLATGLTKWMLTESLVALQGVLLSDYRVT	237	
QY	121	GDTVLCYCCGLRSFRELTYQYRQNPASLPVAVTSRPPDCYWGRC	166	
Db	238	GDTVLCYCCGLRSFRELTYQYRQNPASLPVAVTSRPPDCYWGRC	283	

RESULT 2

C96516
F16N3.15 [imported] - Arabidopsis thaliana
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 31-Mar-2001
C;Accession: C96516
R;Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso, Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Dewar, T.H.; Dewart, K.; ansen, N.F.; Hughes, B.; Huizlar, L.
Nature 408, 816-820, 2000
A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.C. C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Lueros, J.S.; Maiti, R.; Marziali, Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A;Authors: Salzberg, S.B.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, I ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A;Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A;Reference number: A86141; MUID:21016719; PMID:11130712

```

; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C30
; CURRENT APPLICATION NUMBER: US/10/123,155
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 495
; LENGTH: 771
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-155-495

Query Match      8.2%; Score 77; DB 14; Length 771;
Best Local Similarity 29.4%; Pred.No. 32;
Matches 20; Conservative 1; Mismatches 29; Indels 18; Gaps 2;

QY      1 CPLQGGSHALCTCCFQMPDRRAEREDPRVAPQCCAVCLQPFCHLYWGCTRTG-CYGCILA 59
Db      98 CCCAGTGGCCCC-----ATGACTCTTACCTGATGCTGTGCCAGCCA 140

QY      60 PFCELNIG 67
Db      141 CACAAGAG 148

Search completed: May 7, 2004, 15:06:52
Job time : 27.2936 secs
```

```

RESULT 12
US-10-425-114-62319
; Sequence 62319, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Jingdong
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K.
; APPLICANT: Screen, Steven E
; APPLICANT: Tabaska, Jack E
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53313)B
; CURRENT APPLICATION NUMBER: US/10/425,114
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 62319
; LENGTH: 216
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: LIB4666-024-H5_FLI.pep
US-10-425-114-62319

Query Match      8.3%; Score 78.5; DB 12; Length 216;
Best Local Similarity 24.8%; Pred. No. 4.4;
Matches 40; Conservative 11; Mismatches 55; Indels 55; Gaps 10;

QY      2  PLOGSHALCTCCFQMPDRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPP 61
Db      74  PTQWSSGICAC-----FDD-----PQSC-----CIGAICP- 98

QY      62  CELNLGDKLDGVLNNNSYSDILKNYLATRGLTWKNMLTESLVALQRGVFLLSYRVVTG 121
Db      99  -----CFLGKNAGFLSGTLAGSCTTHCMLM-GLLT-SLCCVFTGGLVLA---VPG 145

QY      122  DTVLCYCCGLRSFRLTYQYRONIPASELPVA-VTSRPDCY 161
Db      146  SAVACYACGYRSALTRY-----NLP--EAPCGDLTLHLFCH 180

RESULT 13
US-10-108-260A-3965
; Sequence 3965, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1e1 full length cDNA
; FILE REFERENCE: HI-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3965
; LENGTH: 303
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-3965

Query Match      8.2%; Score 77; DB 15; Length 303;
Best Local Similarity 22.3%; Pred. No. 9.9;
Matches 39; Conservative 19; Mismatches 65; Indels 52; Gaps 10;

QY      1  CPLQGS-----ALCTCCFQMPDRAERQDPRVAP----- 32
Db      130  CPVASSDFGQVFLVECPSCHLKFCSCCKDAWHAEVSCDSQPIVLPTEHREALFGTDAEAP 189

QY      33  -QCAVCLQPFCHLYWGCTRTGCGCLAPPCELNGLDKLDGVLNN---NSYSDILKNY 88
Db      190  IKQCPVC-RVYIERNEGCAQWMCNCKXHTFCWY-----CLQNLNDNIFLRYDKGFCRNK 243

RESULT 14
US-10-142-426-495
; Sequence 495, Application US/10142426
; Publication No. US20040048333A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C224
; CURRENT APPLICATION NUMBER: US/10/142,426
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 495
; LENGTH: 771
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-426-495

Query Match      8.2%; Score 77; DB 12; Length 771;
Best Local Similarity 29.4%; Pred. No. 32;
Matches 20; Conservative 1; Mismatches 29; Indels 18; Gaps 2;

QY      1  CPLQGSALCTCCFQMPDRAERQDPRVAPQCAVCLQPFCHLYWGCTRTG-CYGCCLA 59
Db      98  CCACGTGGCCCC-----ATGACTCTTACTGATCTGTGCCAGCCA 140

QY      60  PFCEINLG 67
Db      141  CACAAGAG 148

RESULT 15
US-10-123-155-495
; Sequence 495, Application US/10123155
; Publication No. US20030068794A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Goddard, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
```

US-09-942-052-731

Query Match 9.0%; Score 85; DB 10; Length 229;
Best Local Similarity 26.6%; Pred. No. 0.96;
Matches 38; Conservative 15; Mismatches 52; Indels 38; Gaps 6;

QY 26 QDRVAPQCAVC---LQPFCHLYWGCTRGCGVCLAPFCELNLDGKLDGLVNNNSYES 82
DB 71 QPERCAVFOCAQCHAVLADSVHLADLSR-----SLGAVFSRTNNVVLEA 117
QY 83 DILKNYLAT-RGLTWKNML-----TESLVALQGVFLLSDYRVGTGTVLC 126
DB 118 PFLVGIEGSLKSTY-NLLFCGSGGIPVGFHLYSTHAALALRGHFCLS-----SDKMCV 171
QY 127 YCCGLRSFRELTYQYRQNPASE 149
DB 172 YLLKTKAIVNASEMDIQNVPLSE 194

RESULT 9

US-10-424-599-184701
; Sequence 184701, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424, 599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 184701
; LENGTH: 202
; TYPE: PRT
; ORGANISM: Glycine max
; NAME/KEY: unsure
; LOCATION: (1) (202)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_137800C.1.pap
US-10-424-599-184701

Query Match 8.9%; Score 83.5; DB 12; Length 202;
Best Local Similarity 20.1%; Pred. No. 1.2;
Matches 37; Conservative 19; Mismatches 65; Indels 63; Gaps 7;

QY 4 QGSHALCTCCFQPMDDRAERQDPVAPQCAVCLQPFCHLYWGCTRGCGVCLAPFCE 63
DB 42 QWSSGICACDD-----MQSCMLFPVPTSFXY-----KGCIGCLCP--- 78
QY 64 LNLGDKCLDGLVNNNSYESDILKNYLATRLGTLWKNMLTESLVALQGVFLLSDYRVGTDT 123
DB 79 -----CFLPGKADFLGSGTFLGSCVTHFILM-SVNTACCLLTGLF-----WGLPGCL 127
QY 124 VLYCCGLRSFRELTY-----QYRQ-----NIPASELPVAV 154
DB 128 VSCVACGYRKALRSKYNLPAQCGDFVTHPCCHPCAICQYREIRSRSGDCEATDLKLV 187
QY 155 TSRR 158
DB 188 VTAP 191

RESULT 10

US-10-369-493-5166
; Sequence 5166, Application US/10369493
; Publication No. US20030233675A1
; GENERAL INFORMATION:
; APPLICANT: Cao, Yongwei

; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Goldman, Barry S.
; APPLICANT: Chen, Xianfeng
; TITLE OF INVENTION: EXPRESSION OF MICROBIAL PROTEINS IN PLANTS FOR PRODUCTION OF
; TITLE OF INVENTION: PLANTS WITH IMPROVED PROPERTIES
; FILE REFERENCE: 38-10(52052)B
; CURRENT APPLICATION NUMBER: US/10/369, 493
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/360, 039
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 47374
; SEQ ID NO 5166
; LENGTH: 2824
; TYPE: PRT
; ORGANISM: Caenorhabditis elegans
US-10-369-493-5166

Query Match 8.9%; Score 83.5; DB 15; Length 2824;
Best Local Similarity 27.1%; Pred. No. 34;
Matches 55; Conservative 12; Mismatches 51; Indels 85; Gaps 15;

QY 10 CTCGCFQ-----MPDRRAERQDPVAPQCAVCLQ-----P 41
DB 1407 CLCNPPPCPSTELLPOR--DQIGDTLNSCQNGVCLQMGMDCAENEYFIVDRENGTP 1464
QY 42 FCH-----LYMGCTRTGCGC-----LAPFCELN-LGDKC-LDGLVNNNSYE---SD 83
DB 1465 FCKPNHCLFTQNTNSGYDCSTGRENALFLCP--NLNEFGDFCOYEGOLYNNSTYILSA 1522
QY 84 ILKNYLATRLGTLWKNMLTESLVALQGVFLLSDYRVGTGTVLCVCCGLRSFRELTYQYRQ 143
DB 1523 GIENAIATN-----LCESLDLT-----YAVPN-----TPCV-----Q 1549
QY 144 NIPASELPVAVTSRPPDCVWGRNC 166
DB 1550 N-PTSTTP-SIHRCDPCYGGNC 1570

RESULT 11

US-10-424-599-224914
; Sequence 224914, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424, 599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 224914
; LENGTH: 129
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_45128C.1.pap
US-10-424-599-224914

Query Match 8.7%; Score 82; DB 12; Length 129;
Best Local Similarity 19.1%; Pred. No. 0.97;
Matches 22; Conservative 26; Mismatches 31; Indels 36; Gaps 4;

QY 15 QPMDDRAERQDPVAPQCAVCLQPF-----CHLYWGCTRTGCGY 56
DB 22 KPLKEKQRENDSDK-----SCAILEDPDFNNEVMTFCNNHMFHEDCIVPLTSKQCPV 77
QY 57 CLAPFCELNLDGKLDGLVNNNSYESDILKNYLATRLGTLWKNMLTESLVALQGV 111
DB 78 CRFVICEIRG-----NHSSFNNDIAN-----LEPSNLINGELLSILRAM 118

;; PRIOR APPLICATION NUMBER: 60/228,432
;; PRIOR FILING DATE: 2000-08-28
;; NUMBER OF SEQ ID NOS: 744
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 728
;; LENGTH: 229
;; TYPE: PRT
;; ORGANISM: Unknown Organism
;; FEATURE:
;; OTHER INFORMATION: Description of Unknown Organism: 85P1B3/OIPS
;; OTHER INFORMATION: clone A protein
US-09-942-052-728

Query Match 9.0%; Score 85; DB 10; Length 229;
Best Local Similarity 26.6%; Pred. No. 0.96;
Matches 38; Conservative 15; Mismatches 52; Indels 38; Gaps 6;
QY 26 QDPRVAPQCAVC---LQPFCHLYWGCTRTGCGYCLAPFCEINLGDCKLDGVLNNNSYES 82
DB 71 QPERCAVFQCAQCHAVLADSVHLAWDLR-----SLGAVVFSRVTTNNVLEA 117
QY 83 DILKNYLAT-RGLTWKNNL-----TESVALQRGVFLLSDYRVGTGTVLC 126
DB 118 PFLVIGIEGSLKSTY-NLLFCGSGIPVGFPHLYSTHAALAAALRGHFCLS-----SDKMVC 171
QY 127 YCCGLRSFRELTYQYRONIPASE 149
DB 172 YLLTKAIVNASEMDIQNVPLSE 194

RESULT 6
US-09-942-052-729
;; Sequence 729, Application US/09942052
;; Publication No. US20030170626A1
;; GENERAL INFORMATION:
;; APPLICANT: Raitano, Arthur B.
;; APPLICANT: Paris, Mary
;; APPLICANT: Hubert, Rene S.
;; APPLICANT: Afar, Daniel
;; APPLICANT: Ge, Wangmao
;; APPLICANT: Challita-Bid, Pia M.
;; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 85P1B3
;; FILE REFERENCE: 51158-20028.00
;; CURRENT APPLICATION NUMBER: US/09/942,052
;; PRIOR FILING DATE: 2001-08-28
;; PRIOR APPLICATION NUMBER: 60/228,432
;; PRIOR FILING DATE: 2000-08-28
;; NUMBER OF SEQ ID NOS: 744
;; SOFTWARE: PatentIn ver. 2.1
;; SEQ ID NO 729
;; LENGTH: 229
;; TYPE: PRT
;; ORGANISM: Unknown Organism
;; FEATURE:
;; OTHER INFORMATION: Description of Unknown Organism: 85P1B3/OIPS
;; OTHER INFORMATION: protein sequence
US-09-942-052-729

Query Match 9.0%; Score 85; DB 10; Length 229;
Best Local Similarity 26.6%; Pred. No. 0.96;
Matches 38; Conservative 15; Mismatches 52; Indels 38; Gaps 6;
QY 26 QDPRVAPQCAVC---LQPFCHLYWGCTRTGCGYCLAPFCEINLGDCKLDGVLNNNSYES 82
DB 71 QPERCAVFQCAQCHAVLADSVHLAWDLR-----SLGAVVFSRVTTNNVLEA 117
QY 83 DILKNYLAT-RGLTWKNNL-----TESVALQRGVFLLSDYRVGTGTVLC 126
DB 118 PFLVIGIEGSLKSTY-NLLFCGSGIPVGFPHLYSTHAALAAALRGHFCLS-----SDKMVC 171
QY 127 YCCGLRSFRELTYQYRONIPASE 149

DB 172 YLLTKAIVNASEMDIQNVPLSE 194
RESULT 7
US-09-942-052-730
;; Sequence 730, Application US/09942052
;; Publication No. US20030170626A1
;; GENERAL INFORMATION:
;; APPLICANT: Raitano, Arthur B.
;; APPLICANT: Paris, Mary
;; APPLICANT: Hubert, Rene S.
;; APPLICANT: Afar, Daniel
;; APPLICANT: Ge, Wangmao
;; APPLICANT: Challita-Bid, Pia M.
;; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 85P1B3
;; FILE REFERENCE: 51158-20028.00
;; CURRENT APPLICATION NUMBER: US/09/942,052
;; PRIOR FILING DATE: 2001-08-28
;; PRIOR APPLICATION NUMBER: 60/228,432
;; PRIOR FILING DATE: 2000-08-28
;; NUMBER OF SEQ ID NOS: 744
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 730
;; LENGTH: 229
;; TYPE: PRT
;; ORGANISM: Unknown Organism
;; FEATURE:
;; OTHER INFORMATION: Description of Unknown Organism: 85P1B3 protein
;; OTHER INFORMATION: sequence
US-09-942-052-730

Query Match 9.0%; Score 85; DB 10; Length 229;
Best Local Similarity 26.6%; Pred. No. 0.96;
Matches 38; Conservative 15; Mismatches 52; Indels 38; Gaps 6;
QY 26 QDPRVAPQCAVC---LQPFCHLYWGCTRTGCGYCLAPFCEINLGDCKLDGVLNNNSYES 82
DB 71 QPERCAVFQCAQCHAVLADSVHLAWDLR-----SLGAVVFSRVTTNNVLEA 117
QY 83 DILKNYLAT-RGLTWKNNL-----TESVALQRGVFLLSDYRVGTGTVLC 126
DB 118 PFLVIGIEGSLKSTY-NLLFCGSGIPVGFPHLYSTHAALAAALRGHFCLS-----SDKMVC 171
QY 127 YCCGLRSFRELTYQYRONIPASE 149
DB 172 YLLTKAIVNASEMDIQNVPLSE 194

RESULT 8
US-09-942-052-731
;; Sequence 731, Application US/09942052
;; Publication No. US20030170626A1
;; GENERAL INFORMATION:
;; APPLICANT: Raitano, Arthur B.
;; APPLICANT: Paris, Mary
;; APPLICANT: Hubert, Rene S.
;; APPLICANT: Afar, Daniel
;; APPLICANT: Ge, Wangmao
;; APPLICANT: Challita-Bid, Pia M.
;; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 85P1B3
;; FILE REFERENCE: 51158-20028.00
;; CURRENT APPLICATION NUMBER: US/09/942,052
;; PRIOR FILING DATE: 2001-08-28
;; PRIOR APPLICATION NUMBER: 60/228,432
;; PRIOR FILING DATE: 2000-08-28
;; NUMBER OF SEQ ID NOS: 744
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 731
;; LENGTH: 229
;; TYPE: PRT
;; ORGANISM: Homo sapiens

Db 596 GDTVLVCCGLRSFRLTYQYRQNI PASELPVAVTSRPPDCYWGNC 641

RESULT 2

US-10-094-749-1799
; Sequence 1799, Application US/10094749
; Publication No. US20030219741A1
; GENERAL INFORMATION:
; APPLICANT: ISOGAI, TAKAO
; APPLICANT: SUGIYAMA, TOMOYASU
; APPLICANT: OTSUKI, TETSUJI
; APPLICANT: WAKAMATSU, AI
; APPLICANT: SATO, HIROYUKI
; APPLICANT: ISHII, SHIZUKO
; APPLICANT: YAMAMOTO, JUN-ICHI
; APPLICANT: ISONO, YUUKO
; APPLICANT: HIO, YURI
; APPLICANT: OTSUKA, KAORU
; APPLICANT: NAGAI, KEIICHI
; APPLICANT: IRIE, RYOTARO
; APPLICANT: TAMECHIKA, ICHIRO
; APPLICANT: SEKI, NACHIKO
; APPLICANT: YOSHIKAWA, TSUTOMU
; APPLICANT: OTSUKA, MOTOKYUKI
; APPLICANT: NAGAHARI, KENJI
; APPLICANT: MASUHO, YASUHIKO
; TITLE OF INVENTION: NOVEL FULL-LENGTH cDNA
; FILE REFERENCE: 084335/0160
; CURRENT APPLICATION NUMBER: US/10/094,749
; PRIOR FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/350,435
; PRIOR FILING DATE: 2002-01-24
; PRIOR APPLICATION NUMBER: JP 2001-328381
; PRIOR FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 3381
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1799
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-094-749-1799

Query Match 46.4%; Score 438; DB 15; Length 128;
Best Local Similarity 98.8%; Pred. No. 6.7e-39;
Matches 80; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 86 KNYLATRGLTWKMLTESLVALQGVFLLSYRVGTGTVLCYCCGLRSFRLTYQYRQNI 145
Db 25 QNYLATRGLTWKMLTESLVALQGVFLLSYRVGTGTVLCYCCGLRSFRLTYQYRQNI 84
Qy 146 PASELPVAVTSRPPDCYWGNC 166
Db 85 PASELPVAVTSRPPDCYWGNC 105

RESULT 3

US-10-108-260A-4516
; Sequence 4516, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US20040005560A1el full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5456
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4516
; LENGTH: 349
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-4516

Query Match 39.9%; Score 376; DB 15; Length 349;
Best Local Similarity 98.4%; Pred. No. 1.1e-31;
Matches 61; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CPLOGSHALCTCCQPMPPDRAREQDPVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
Db 276 CPLOGSHALCTCCQPMPPDRAREQDPVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 335

Qy 61 FC 62
Db 336 FC 337

RESULT 4

US-10-424-599-264601
; Sequence 264601, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 264601
; LENGTH: 287
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_80956C.1.pap
US-10-424-599-264601

Query Match 16.0%; Score 150.5; DB 12; Length 287;
Best Local Similarity 25.1%; Pred. No. 1.2e-07;
Matches 46; Conservative 26; Mismatches 84; Indels 27; Gaps 6;

Qy 1 CPLOGSHALCTCCQPMPPDRAREQDPVAPQCAVCLQPFCHLYW---GCTRTGCGYC 57
Db 90 KRYDTVHLQCAQCGGMPSTGFG-----IPQYCGCDRSPCGAYWALGVGTNGSY-- 141
Qy 58 LAPFCELN---LGGKCLDGV---LNNNSVESDILKNYLATRGITWKNMLTESLVALQ- 108
Db 142 --PVCSDTLRISDHSISRIPLLAHEKXKLNITDSCIRQMGRTLPDVISWEIAFEN 199
Qy 109 -----RGVFLLSDYRVGTGTVLCYCCGLRSFRLTYQYRQNI PASELPVAVTSRPPDCYWG 163
Db 200 REIDRRMMLNEAMITARTFVCQDCTYKLVSFLLYWFRLSIPKHLPPDESAREDCWYG 259
Qy 164 RNC 166
Db 260 YAC 262

RESULT 5

US-09-942-052-728
; Sequence 728, Application US/09942052
; Publication No. US20030170626A1
; GENERAL INFORMATION:
; APPLICANT: Raitano, Arthur B.
; APPLICANT: Paris, Mary
; APPLICANT: Hubert, Rene S.
; APPLICANT: Afar, Daniel
; APPLICANT: Ge, Wangmao
; APPLICANT: Challita-Eld, Pia M.
; TITLE OF INVENTION: NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 85P1B3
; TITLE OF INVENTION: USEFUL IN TREATMENT AND DETECTION OF CANCER
; FILE REFERENCE: 51158-20028.00
; CURRENT APPLICATION NUMBER: US/09/942,052
; CURRENT FILING DATE: 2001-08-28

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:49:13 ; Search time 26.2936 Seconds
(without alignments)
1752.371 Million cell updates/sec

Title: US-10-048-046-2_COPY_476_641

Perfect score: 943
Sequence: 1 CFIQSGSHALCTCCFQMPDR.....ASELPVATSRPDCYWGRC 166

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1140673 seqs, 277566755 residues

Total number of hits satisfying chosen parameters: 1140673

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA.*

- 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pap.*
- 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pap.*
- 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pap.*
- 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pap.*
- 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pap.*
- 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pap.*
- 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pap.*
- 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pap.*
- 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pap.*
- 10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pap.*
- 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pap.*
- 12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pap.*
- 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pap.*
- 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pap.*
- 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pap.*
- 16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pap.*
- 17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pap.*
- 18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	943	100.0	664	9	US-09-780-525-2 Sequence 2, Appli
2	438	46.4	128	15	US-10-094-749-1799 Sequence 1799, Ap
3	376	39.9	349	15	US-10-108-260A-4516 Sequence 4516, Ap
4	150.5	16.0	287	12	US-10-424-599-264601 Sequence 264601,
5	85	9.0	229	10	US-09-942-052-728 Sequence 728, App
6	85	9.0	229	10	US-09-942-052-729 Sequence 729, App
7	85	9.0	229	10	US-09-942-052-730 Sequence 730, App
8	85	9.0	229	10	US-09-942-052-731 Sequence 731, App
9	83.5	8.9	202	12	US-10-424-599-184701 Sequence 184701,
10	83.5	8.9	2824	15	US-10-369-493-5166 Sequence 5166, Ap
11	82	8.7	129	12	US-10-424-599-224914 Sequence 224914,
12	78.5	8.3	216	12	US-10-425-114-62319 Sequence 62319, A
13	77	8.2	303	15	US-10-108-260A-3965 Sequence 3965, Ap
14	77	8.2	771	12	US-10-142-426-495 Sequence 495, App
15	77	8.2	771	14	US-10-123-155-495 Sequence 495, App

16	77	8.2	771	14	US-10-146-731-495	Sequence 495, App
17	77	8.2	771	14	US-10-140-472-495	Sequence 495, App
18	77	8.2	771	14	US-10-141-761-495	Sequence 495, App
19	77	8.2	771	14	US-10-142-885-495	Sequence 495, App
20	77	8.2	771	14	US-10-158-790-495	Sequence 495, App
21	77	8.2	771	15	US-10-137-871-495	Sequence 495, App
22	77	8.2	771	15	US-10-140-923-495	Sequence 495, App
23	77	8.2	771	15	US-10-141-756-495	Sequence 495, App
24	77	8.2	771	15	US-10-141-759-495	Sequence 495, App
25	77	8.2	771	15	US-10-140-805-495	Sequence 495, App
26	77	8.2	771	15	US-10-140-864-495	Sequence 495, App
27	76.5	8.1	487	15	US-10-369-493-22178	Sequence 22178, A
28	76	8.1	567	12	US-10-369-022-2	Sequence 2, Appli
29	75.5	8.0	419	14	US-10-354-358-76	Sequence 76, Appli
30	75.5	8.0	615	10	US-09-858-909-2	Sequence 2, Appli
31	75.5	8.0	615	14	US-10-172-712-30	Sequence 30, Appli
32	75.5	8.0	615	16	US-10-449-132-2	Sequence 2, Appli
33	75	8.0	1835	10	US-09-457-571-15	Sequence 15, Appli
34	74.5	7.9	246	15	US-10-104-047-3660	Sequence 3660, Ap
35	74.5	7.9	2849	12	US-10-142-426-371	Sequence 371, App
36	74.5	7.9	2849	14	US-10-123-155-371	Sequence 371, App
37	74.5	7.9	2849	14	US-10-146-731-371	Sequence 371, App
38	74.5	7.9	2849	14	US-10-140-472-371	Sequence 371, App
39	74.5	7.9	2849	14	US-10-141-761-371	Sequence 371, App
40	74.5	7.9	2849	14	US-10-142-885-371	Sequence 371, App
41	74.5	7.9	2849	14	US-10-158-790-371	Sequence 371, App
42	74.5	7.9	2849	15	US-10-137-871-371	Sequence 371, App
43	74.5	7.9	2849	15	US-10-140-923-371	Sequence 371, App
44	74.5	7.9	2849	15	US-10-141-756-371	Sequence 371, App
45	74.5	7.9	2849	15	US-10-141-759-371	Sequence 371, App

ALIGNMENTS

RESULT 1

US-09-780-525-2
; Sequence 2, Application US/09780525
; Patent No. US20020004223A1
; GENERAL INFORMATION:
; APPLICANT: Bin-Bing Zhou
; APPLICANT: Yuan Zhu
; APPLICANT: Priya Chaturvedi
; APPLICANT: Mark R. Hurle
; APPLICANT: Xiaotong Li
; TITLE OF INVENTION: FHAR1, A NEW RING FINGER PROTEIN
; FILE REFERENCE: GP-70668-C1
; CURRENT APPLICATION NUMBER: US/09/780,525
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 09/456,876
; PRIOR FILING DATE: 1999-12-08
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 664
; TYPE: PRT
; ORGANISM: HOMO SAPIENS
US-09-780-525-2

Query Match	100.0%;	Score	943;	DB	9;	Length	664;
Best Local Similarity	100.0%;	Pred. No.	4e-92;				
Matches	166;	Conservative	0;	Mismatches	0;	Indels	0;
QY	1	CPLQSGSHALCTCCFQMPDRRAEREQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP	60				
Db	476	CPLQSGSHALCTCCFQMPDRRAEREQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP	535				
QY	61	FCLENLGDKCLDGLVNNNSYESDILKNYLATRLTGLTWKNNLTESLVALQRGVFLLSDYRVT	120				
Db	536	FCLENLGDKCLDGLVNNNSYESDILKNYLATRLTGLTWKNNLTESLVALQRGVFLLSDYRVT	595				
QY	121	GDTVLCVCCGLRSFRLTYQYRONIPASLPVATSRPDCYWGRC	166				

```
RESULT 15
US-09-798-051-9
; Sequence 9, Application US/09798051
; Patent No. 6632780
; GENERAL INFORMATION:
; APPLICANT: Zhang, Ke
; APPLICANT: Cam, Linh
; APPLICANT: Nakayama, Naoki
; TITLE OF INVENTION: Chordin-Like-2 Molecules and Uses Thereof
; FILE REFERENCE: 01-005
; CURRENT APPLICATION NUMBER: US/09/798,051
; CURRENT FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
; LENGTH: 452
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-798-051-9

Query Match      7.2%; Score 67.5; DB 4; Length 452;
Best Local Similarity 25.0%; Pred. No. 27;
Matches 40; Conservative 18; Mismatches 73; Indels 29; Gaps 9;

QY      4 QGSHALCTCCFQMPDRAEREQDPVAPQCCAVCLQPECHLYWG--CTRTGC--YGCLA 59
Db      23 QVXSETYCMFQDKKYRVGER-WHPYLEPYGLVYCNVICSENGNVLCSSRVCPNVHCLS 81
QY      60 P-----FCEINLGDKCLDGVINNNSYESDILKNYLAIRGLTWKNMLTESLVALQRGVFL 114
Db      82 PVHHPHLCPCPCEDSLPPVNNKVTSKS-----CEYNGTTYQH--GELFVA--EGLF-- 129
QY      115 SDYRVTDGVLCYC-----CGLRSPRELTYYQRNIPAS 148
Db      130 -QNRQPNQCTQCSCSEGNVYGLKTCFKLTCAFPVSVPDS 168

Search completed: May 7, 2004, 14:51:24
Job time : 12.0433 secs
```

```
; Sequence 5, Application US/09798051
; Patent No. 6632780
; GENERAL INFORMATION:
; APPLICANT: Zhang, Ke
; APPLICANT: Cam, Linh
; APPLICANT: Nakayama, Naoki
; TITLE OF INVENTION: Chordin-Like-2 Molecules and Uses Thereof
; FILE REFERENCE: 01-005
; CURRENT APPLICATION NUMBER: US/09/798,051
; CURRENT FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 5
; LENGTH: 429
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-798-051-5

Query Match
Best Local Similarity 24.3%; Pred. No. 22; Length 429;
Matches 25; Conservative 8; Mismatches 46; Indels 24; Gaps 3;

QY 2 PLOGSHALCTCCFOP-----MPDRRAE-----REQDPRVAPQCCAVCLQ 40
Db 84 PVTEPQCCCKVEPHPTPSGLRAPPKSCQNGTMYQHGTEIFSAHELFFSLPQNCVLCSC 143
QY 41 PFCHLYWGCTRTGCGCLAPFCEINLGDKLDGVLNNSYESD 83
Db 144 TEGQIYGLTTCPEPGCAP---LPLPDSCCQACKDEASEQSD 183

RESULT 13
US-08-191-866D-81
; Sequence 81, Application US/08191866D
; Patent No. 5783195
; GENERAL INFORMATION:
; APPLICANT: Cochran, Mark D
; APPLICANT: Macdonald, Richard D.
; TITLE OF INVENTION: Recombinant Infectious Bovine
; TITLE OF INVENTION: Rhinotracheitis Virus S-IBR-052 And Uses Thereof
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John P. White
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/191,866D
; FILING DATE: 4 February 1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 278-0400
; TELEFAX: (212) 391-0525
; TELEX: 422523
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 572 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-191-866D-81

Query Match
7.2%; Score 68; DB 1; Length 572;
Best Local Similarity 20.4%; Pred. No. 32;
Matches 31; Conservative 14; Mismatches 41; Indels 66; Gaps 5;

QY 49 CTRTGCYGCCLAPFC-----ELNLGDKLDGVLNNSYESDILKN----- 87
Db 350 CNTTGCPTQDCNQASYPWFSNRRMWNISIVVDKGDATFSLRVWTIPMSQNWGSE 409
QY 88 -----YLATRLTWNKMLTESLVALQRGVFLSDYRTGTVLCYCCGLRSFREL 137
Db 410 GRLLLGDRIIYIYTRSTSWHS-----KLQLGVIDISDY----- 442
QY 138 TYQYRONIPASELPVAVTSRP---DCYWGRC 166
Db 443 -----NNIRINWTHNVPSRPGNDECPWGHSC 469

RESULT 14
US-08-185-949B-81
; Sequence 81, Application US/08185949B
; Patent No. 5874279
; GENERAL INFORMATION:
; APPLICANT: Mark D. Cochran
; APPLICANT: Richard D. Macdonald
; TITLE OF INVENTION: Recombinant Infectious Bovine
; TITLE OF INVENTION: Rhinotracheitis Virus
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John P. White
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM 330 466 DX2
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/185,949B
; FILING DATE: 03-NOV-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 678
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 278-0400
; TELEFAX: (212) 278-0525
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 572 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-185-949B-81

Query Match
7.2%; Score 68; DB 2; Length 572;
Best Local Similarity 20.4%; Pred. No. 32;
Matches 31; Conservative 14; Mismatches 41; Indels 66; Gaps 5;

QY 49 CTRTGCYGCCLAPFC-----ELNLGDKLDGVLNNSYESDILKN----- 87
Db 350 CNTTGCPTQDCNQASYPWFSNRRMWNISIVVDKGDATFSLRVWTIPMSQNWGSE 409
QY 88 -----YLATRLTWNKMLTESLVALQRGVFLSDYRTGTVLCYCCGLRSFREL 137
Db 410 GRLLLGDRIIYIYTRSTSWHS-----KLQLGVIDISDY----- 442
QY 138 TYQYRONIPASELPVAVTSRP---DCYWGRC 166
Db 443 -----NNIRINWTHNVPSRPGNDECPWGHSC 469
```

Db 904 CHVKGSHSAVCHLETGLDC-----KENVTGQCDQCL-----HGYGL--D 943

QY 53 GCYGCCLAPFCEL--NLGDKOLD 72
: : : : :
Db 944 SGHGCRPCNCVAGSVSDGCTD 965

RESULT 8
US-09-543-681A-5344
; Sequence 5344, Application US/09543681A
; Patent No. 6605709
; GENERAL INFORMATION:
; APPLICANT: GARY BRETON
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PROTEUS MIRABILIS
; FILE REFERENCE: 2709.1002-001
; CURRENT APPLICATION NUMBER: US/09/543,681A
; PRIOR FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/128,706
; PRIOR FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 8344
; SEQ ID NO 5344
; LENGTH: 200
; TYPE: PRT
; ORGANISM: Proteus mirabilis
US-09-543-681A-5344

Query Match 7.5%; Score 71; DB 4; Length 200;
Best Local Similarity 25.3%; Pred. No. 3.6;
Matches 20; Conservative 17; Mismatches 34; Indels 8; Gaps 3;

QY 76 NNNYSIEDILKNYATRLGLTWKNLITE--SLVALQGVFLSLP-YRVGTDTVLG-----Y 127
: : : : :
Db 5 SKNPMYDILRGELTEAATLSRFLQDDANIEAQAIVLLADSPKAGKVLSCGNGGSH 64
: : : : :
QY 128 CGLRSFRELTYQRONIP 146
: : : : :
Db 65 CDAMHFAEELTGRENRP 83
: : : : :

RESULT 9
US-09-328-352-5062
; Sequence 5062, Application US/09328352
; Patent No. 8562958
; GENERAL INFORMATION:
; APPLICANT: Gary L. Breton et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER
; FILE REFERENCE: GTC99-03PA
; CURRENT APPLICATION NUMBER: US/09/328,352
; CURRENT FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 8252
; SEQ ID NO 5062
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Acinetobacter baumannii
US-09-328-352-5062

Query Match 7.5%; Score 71; DB 4; Length 460;
Best Local Similarity 26.1%; Pred. No. 11;
Matches 37; Conservative 22; Mismatches 57; Indels 26; Gaps 9;

QY 26 QDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFCELNGLDKCLDGLVNN---NSYES 82
: : : : :
Db 333 QSPK-STQPDVICTETNFKNYWSNAQQLTHHTIGG-CNVQVGLMGSGTISGSTPDSYGS 390
: : : : :
QY 83 DILKNYATRLGLTWKNMLTSLVALQGVFLSLDYRVGTDTVL-----CYCCGLR-SFREL 137
: : : : :
Db 391 LLELTWNTTKPLTANGET-----RG--FLQD-----GDTLMKGHCENKIRIGFGEV 437
: : : : :
QY 138 TYQYRONIPASELPVAVTSRPD 159
: : : : :
Db 438 R---NTVLPALTFDAETSEPN 456
: : : : :

RESULT 10
US-09-845-583A-2
; Sequence 2, Application US/09845583A
; Patent No. 6635616
; GENERAL INFORMATION:
; APPLICANT: Burgeson, Robert
; APPLICANT: Brunken, William Joseph
; APPLICANT: Champliand, Marie-France
; APPLICANT: Hunter, Dale
; TITLE OF INVENTION: LAMININ 15 AND USES THEREOF
; FILE REFERENCE: 10287-056001
; CURRENT APPLICATION NUMBER: US/09/845,583A
; CURRENT FILING DATE: 2001-04-30
; PRIOR APPLICATION NUMBER: US 60/200,863
; PRIOR FILING DATE: 2000-05-01
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 3635
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-845-583A-2

Query Match 7.5%; Score 71; DB 4; Length 3635;
Best Local Similarity 24.5%; Pred. No. 1.7e+02;
Matches 25; Conservative 9; Mismatches 38; Indels 30; Gaps 6;

QY 1 CPLQGSHAL-----CTCCFOPMPDRRAERQDPRVAPQCAVCLQP 41
: : : : :
Db 1379 CFCRG-HVIGRDCSRCATGYGFCNCRPCDCGARLCLDELGTQCICPRTVPPDCLVC-QP 1436
: : : : :
QY 42 ---FCHLYWGCTRTGCVG-----CLAPFCELNGLD-KCLDGV 74
: : : : :
Db 1437 CSFGCHPLVGCCEGNCSPGVQELTDTCDMDSCQCRPNV 1478
: : : : :

RESULT 11
US-09-798-051-6
; Sequence 6, Application US/09798051
; Patent No. 6632780
; GENERAL INFORMATION:
; APPLICANT: Zhang, Ke
; APPLICANT: Cam, Linh
; APPLICANT: Nakayama, Naoki
; TITLE OF INVENTION: Chordin-Like-2 Molecules and Uses Thereof
; FILE REFERENCE: 01-005
; CURRENT APPLICATION NUMBER: US/09/798,051
; CURRENT FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 408
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-798-051-6

Query Match 7.2%; Score 68; DB 4; Length 408;
Best Local Similarity 24.3%; Pred. No. 20;
Matches 25; Conservative 8; Mismatches 46; Indels 24; Gaps 3;

QY 2 PLQGSHALCTCCFOP-----MPDRRAE-----REQDPRVAPQCAVCLQ 40
: : : : :
Db 63 PYTEFQCCPKCVBPTSPGLRAPPKSCQHGNTWYQGEIFSAHELFPRLPNQCVLCSC 122
: : : : :
QY 41 PFCHLYWGCTRTGCVGCLAPFCELNGLDKCLDGLVNNNSYESD 83
: : : : :
Db 123 TEGQIYCGLTTCPEPGCAP---LPLPDSCCQACKDEASEQSD 162
: : : : :

RESULT 12
US-09-798-051-5


```
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-12650

Query Match      8.5%; Score 80; DB 4; Length 197;
Best Local Similarity 30.6%; Pred. No. 0.34;
Matches 22; Conservative 15; Mismatches 27; Indels 8; Gaps 3;

QY 83 DILKNYLRGLTKQMLTE--SLVALQGVFLLS--YRVTDGTVLC-----YCCGLRSF 134
DB 8 DIRMELNBAETLANFLODEANIHAIQRAVLLADSFAGGKVLSCNGGSHCDAMEHA 67
QY 135 RELTYQYRONIP 146
DB 68 EELTGYRENRP 79

RESULT 3
US-08-841-483-2
; Sequence 2, Application US/08841483B
; Patent No. 5976875
; GENERAL INFORMATION:
; APPLICANT: Prescott, Steven M.
; APPLICANT: Bunting, Michaeline
; APPLICANT: Tang, Wen
; TITLE OF INVENTION: Diacylglycerol Kinase Isoforms Epsilon and Zeta and
; TITLE OF INVENTION: Methods of Use Thereof
; FILE REFERENCE: 2037.2.1a
; CURRENT APPLICATION NUMBER: US/08/841,483B
; CURRENT FILING DATE: 1997-04-22
; EARLIER APPLICATION NUMBER: 60/016,210
; EARLIER FILING DATE: 1996-04-22
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 567
; TYPE: PRT
; ORGANISM: Homo sapiens
US-08-841-483-2

Query Match      8.1%; Score 76; DB 2; Length 567;
Best Local Similarity 21.6%; Pred. No. 3.9;
Matches 36; Conservative 21; Mismatches 54; Indels 56; Gaps 10;

QY 3 LQSHALCTCCFQMPD---RRAER-----EODPRVAPQ-----CAVCL 39
DB 82 LQ--AFDCGGLRVDEGCLRKADRFQCKEIMLKNDTKVLDAMPHHWIRGNVPLCSYCM 139
QY 40 QPFCHLYWGCTRTGC-YGCLAPCELNGLDKLDGVNNNSVESDILKN-----YLAT- 91
DB 140 --VCKQCGGCPKLCYRCI--WCQKTVHDECWNLSKNEKCDGFEKXLIIPPSYLTISI 195
QY 92 -----RGLTWKNN--LTSVLALQGVFLLSDYRV 119
DB 196 NQMRKDKKTDYEVLSKGLGKQWTPFLIILANSRSGTNGEGLGEPRI 242

RESULT 4
US-09-382-911-2
; Sequence 2, Application US/09382911
; Patent No. 6221658
; GENERAL INFORMATION:
; APPLICANT: Prescott, Steven M.
; APPLICANT: Bunting, Michaeline
; APPLICANT: Tang, Wen
; APPLICANT: Topham, Matthew
; TITLE OF INVENTION: Diacylglycerol Kinase Isoforms Epsilon and Zeta and
; TITLE OF INVENTION: Methods of Use Thereof
; FILE REFERENCE: 2037.2.1a
; CURRENT APPLICATION NUMBER: US/09/382,911
; CURRENT FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: 08/841,483
; PRIOR FILING DATE: 1997-04-22

; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-12650

Query Match      8.5%; Score 80; DB 4; Length 197;
Best Local Similarity 30.6%; Pred. No. 0.34;
Matches 22; Conservative 15; Mismatches 27; Indels 8; Gaps 3;

QY 83 DILKNYLRGLTKQMLTE--SLVALQGVFLLS--YRVTDGTVLC-----YCCGLRSF 134
DB 8 DIRMELNBAETLANFLODEANIHAIQRAVLLADSFAGGKVLSCNGGSHCDAMEHA 67
QY 135 RELTYQYRONIP 146
DB 68 EELTGYRENRP 79

RESULT 3
US-08-841-483-2
; Sequence 2, Application US/08841483B
; Patent No. 5976875
; GENERAL INFORMATION:
; APPLICANT: Prescott, Steven M.
; APPLICANT: Bunting, Michaeline
; APPLICANT: Tang, Wen
; TITLE OF INVENTION: Diacylglycerol Kinase Isoforms Epsilon and Zeta and
; TITLE OF INVENTION: Methods of Use Thereof
; FILE REFERENCE: 2037.2.1a
; CURRENT APPLICATION NUMBER: US/08/841,483B
; CURRENT FILING DATE: 1997-04-22
; EARLIER APPLICATION NUMBER: 60/016,210
; EARLIER FILING DATE: 1996-04-22
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 567
; TYPE: PRT
; ORGANISM: Homo sapiens
US-08-841-483-2

Query Match      8.1%; Score 76; DB 2; Length 567;
Best Local Similarity 21.6%; Pred. No. 3.9;
Matches 36; Conservative 21; Mismatches 54; Indels 56; Gaps 10;

QY 3 LQSHALCTCCFQMPD---RRAER-----EODPRVAPQ-----CAVCL 39
DB 82 LQ--AFDCGGLRVDEGCLRKADRFQCKEIMLKNDTKVLDAMPHHWIRGNVPLCSYCM 139
QY 40 QPFCHLYWGCTRTGC-YGCLAPCELNGLDKLDGVNNNSVESDILKN-----YLAT- 91
DB 140 --VCKQCGGCPKLCYRCI--WCQKTVHDECWNLSKNEKCDGFEKXLIIPPSYLTISI 195
QY 92 -----RGLTWKNN--LTSVLALQGVFLLSDYRV 119
DB 196 NQMRKDKKTDYEVLSKGLGKQWTPFLIILANSRSGTNGEGLGEPRI 242

RESULT 4
US-09-382-911-2
; Sequence 2, Application US/09382911
; Patent No. 6221658
; GENERAL INFORMATION:
; APPLICANT: Prescott, Steven M.
; APPLICANT: Bunting, Michaeline
; APPLICANT: Tang, Wen
; APPLICANT: Topham, Matthew
; TITLE OF INVENTION: Diacylglycerol Kinase Isoforms Epsilon and Zeta and
; TITLE OF INVENTION: Methods of Use Thereof
; FILE REFERENCE: 2037.2.1a
; CURRENT APPLICATION NUMBER: US/09/382,911
; CURRENT FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: 08/841,483
; PRIOR FILING DATE: 1997-04-22

; ORGANISM: Homo sapiens
US-09-382-911-2

Query Match      8.1%; Score 76; DB 3; Length 567;
Best Local Similarity 21.6%; Pred. No. 3.9;
Matches 36; Conservative 21; Mismatches 54; Indels 56; Gaps 10;

QY 3 LQSHALCTCCFQMPD---RRAER-----EODPRVAPQ-----CAVCL 39
DB 82 LQ--AFDCGGLRVDEGCLRKADRFQCKEIMLKNDTKVLDAMPHHWIRGNVPLCSYCM 139
QY 40 QPFCHLYWGCTRTGC-YGCLAPCELNGLDKLDGVNNNSVESDILKN-----YLAT- 91
DB 140 --VCKQCGGCPKLCYRCI--WCQKTVHDECWNLSKNEKCDGFEKXLIIPPSYLTISI 195
QY 92 -----RGLTWKNN--LTSVLALQGVFLLSDYRV 119
DB 196 NQMRKDKKTDYEVLSKGLGKQWTPFLIILANSRSGTNGEGLGEPRI 242

RESULT 5
US-08-836-325-15
; Sequence 15, Application US/08836325
; Patent No. 6110672
; GENERAL INFORMATION:
; APPLICANT: Mandel, Gail
; APPLICANT: Halsegoua, Simon
; APPLICANT: Borden, Laurence A.
; TITLE OF INVENTION: Peripheral Nervous System Specific
; TITLE OF INVENTION: Sodium Channels, DNA Encoding Therefor, Crystallization,
; TITLE OF INVENTION: X-ray Diffraction, Computer Molecular Modeling, Rational
; TITLE OF INVENTION: Drug Design, Drug Screening, and Methods of Making and Using
; TITLE OF INVENTION: Thereof
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERN, KESSLER, GOLDSTEIN & FOX P.L.L.C
; STREET: 1100 New York Ave., N. W., Suite 600
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/836,325
; FILING DATE: 2-MAY-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/14251
; FILING DATE: 02-NOV-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/482,401
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/334,029
; FILING DATE: 02-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ludwig, Steven R.
; REGISTRATION NUMBER: 36,203
; REFERENCE/DOCKET NUMBER: 0917.0240002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-371-2600
; TELEFAX: 202-371-2540
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:42:23 ; Search time 11.0433 Seconds
(without alignments)
776.028 Million cell updates/sec

Title: US-10-048-046-2_COPY_476_641
Perfect score: 943
Sequence: 1 CPGQSHALCTCCFQMPDR.....ASELPVAVTSRDPCTYGRNC 166
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues
Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA.*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/PTUS_COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	81	8.6	376	4	US-09-489-039A-11343
2	80	8.5	197	4	US-09-489-039A-12650
3	76	8.1	567	2	US-08-841-483-2
4	76	8.1	567	3	US-09-382-911-2
5	75	8.0	1835	3	US-08-836-325-15
6	72	7.6	3075	2	US-08-460-309-5
7	72	7.6	3075	2	US-08-125-077-5
8	71	7.5	200	4	US-09-543-681A-5344
9	71	7.5	460	4	US-09-328-352-5062
10	71	7.5	3635	4	US-09-843-583A-2
11	68	7.2	408	4	US-09-798-051-6
12	68	7.2	429	4	US-09-798-051-5
13	68	7.2	572	1	US-08-191-866D-81
14	68	7.2	572	2	US-08-185-949B-81
15	67.5	7.2	452	4	US-09-798-051-9
16	67	7.1	174	3	US-09-383-586-12
17	67	7.1	202	4	US-09-489-039A-14068
18	67	7.1	276	2	US-09-786-606-5
19	67	7.1	276	4	US-09-203-258-1027
20	67	7.1	341	4	US-09-203-258-1034
21	67	7.1	441	4	US-08-914-375C-66
22	67	7.1	449	3	US-09-306-593-10
23	67	7.1	503	3	US-09-382-256-10
24	67	7.1	503	3	US-09-395-115-10
25	67	7.1	503	4	US-08-436-265-10
26	67	7.1	503	4	US-09-679-187-10
27	67	7.1	3174	2	US-08-477-451-3

28 66.5 7.1 259 4 US-09-252-991A-29086 Sequence 29086, A
29 66.5 7.1 387 1 US-08-123-161A-12 Sequence 12, Appl
30 66.5 7.1 387 1 US-08-483-278-12 Sequence 12, Appl
31 66 7.0 125 4 US-09-489-039A-10681 Sequence 10681, A
32 66 7.0 330 4 US-09-489-039A-8234 Sequence 8234, Ap
33 66 7.0 515 4 US-09-635-872A-6 Sequence 6, Appl
34 66 7.0 515 4 US-09-636-077A-6 Sequence 6, Appl
35 66 7.0 515 4 US-09-636-060C-6 Sequence 6, Appl
36 66 7.0 515 4 US-09-986-552-6 Sequence 6, Appl
37 65.5 6.9 276 4 US-09-719-402A-782 Sequence 782, App
38 65.5 6.9 324 4 US-09-198-452A-2 Sequence 2, Appl
39 65.5 6.9 539 4 US-09-719-402A-2 Sequence 3, Appl
40 65.5 6.9 1417 4 US-08-900-230-3 Sequence 28511, A
41 65 6.9 177 4 US-09-252-991A-28511 Sequence 5215, Ap
42 65 6.9 212 1 US-09-107-532A-5215 Sequence 1, Appl
43 65 6.9 1015 3 US-08-537-210A-1 Sequence 1, Appl
44 65 6.9 1015 3 US-09-113-825-1 Sequence 2, Appl
45 65 6.9 1165 1 US-08-144-121-2 Sequence 2, Appl

ALIGNMENTS

RESULT 1
US-09-489-039A-11343
; Sequence 11343, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; TITLE OF INVENTION: PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 11343
; LENGTH: 376
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-11343

Query Match 8.6%; Score 81; DB 4; Length 376;
Best Local Similarity 33.7%; Pred. No. 0.62; 32; Indels 18; Gaps 5;
Matches 30; Conservative

QY 32 PQCAVCL-----QPFCHLYWGCTRTGCGCLAPFCELNLGDKCLDGVNNNSYES 82
DB 237 PIAAACTADAVSSTAGKPLKQLFW-C--AGSNGTLTPFGNQNGK---GVIRDSLLS 290
QY 83 DILKNVLAIRGLTWKMLTESLVALORGV 111
DB 291 ARVLAALHRRGLAWKTGSE---AMCRGV 316

RESULT 2
US-09-489-039A-12650
; Sequence 12650, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; TITLE OF INVENTION: PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 12650
; LENGTH: 197
; TYPE: PRT


```

XX WPI: 2000-638211/61.
DR N-PSDB; AAC59810.
XX
XX Novel proteins and polypeptides useful for the treatment of e.g multiple
PT sclerosis, systemic lupus erythematosus, rheumatoid arthritis, cancer,
PT Alzheimer's disease, Parkinson's disease, stroke, anemia and ulcers.
XX
XX Disclosure; Page 480-481; 493pp; English.
XX
XX This invention relates to 59 human secreted proteins and the nucleotide
CC sequences encoding them. Sequences AAC59798-C59846 and AAB34687-B34745
CC represent the proteins and their encoding nucleotide sequences, and
CC sequences AAB34746-B34771 represent fragments of the proteins. Probes for
CC the DNA sequences are represented by sequences AAC59847-C59596. The
CC proteins exhibit neuroprotective, dermatological, immunosuppressive,
CC antiinflammatory, antianaemic, nootropic, antiparkinsonian,
CC cerebroprotective, haemostatic, vulnery, cytostatic, antipsoriatic,
CC antibacterial, virucide, and fungicide activity. The proteins and
CC nucleotide sequences are useful as nutritional sources or supplements and
CC in research. The proteins are useful for treating immune deficiency and
CC disorders, which may be genetic or resulting from infections, autoimmune
CC disorders such as multiple sclerosis, systemic lupus erythematosus,
CC rheumatoid arthritis, and for treating myeloid or lymphoid cell
CC deficiencies such as anaemias by regulating haematopoiesis. The proteins
CC are also useful in compositions for bone, cartilage, tendon, ligament
CC and/or nerve tissue growth or regeneration, for wound healing, tissue
CC repair and replacement and in the treatment of wounds, incisions and
CC ulcers. Other uses include in the treatment of central and peripheral
CC nervous system and neuropathies such as Alzheimer's and Parkinson's
CC diseases and Shy-Drager syndrome, and mechanical and traumatic disorders
CC such as spinal cord disorders, head trauma and stroke. The proteins may
CC also be used as a contraceptive, and for treating coagulation disorders
CC such as haemophilias. The protein and nucleotide sequences with cadherin
CC activity are useful for treating cancer. Other uses for the protein
CC include for inhibiting the growth, infection or function of or killing,
CC infectious agents such as bacteria, virus, fungi and other parasites, for
CC effecting bodily characteristics such as height, weight, hair colour,
CC effecting biorhythms or cardiac cycles or rhythms, effecting metabolism,
CC catabolism, anabolism, processing, utilization, storage or elimination of
CC dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors,
CC effecting behavioural characteristics, providing analgesic effects and
CC for treating hyperproliferative disorders such as psoriasis
XX
XX SQ Sequence 227 AA;
Query Match 9.8%; Score 92.5; DB 3; Length 227;
Best Local Similarity 23.8%; Pred. No. 0.62;
Matches 45; Conservative 21; Mismatches 70; Indels 53; Gaps 10;
QY 2 PLOGSHALTCCTCFMP-----DRAERQDPRVAP-----OQAVC----- 38
Db 19 PVLPSEAL--LFFGLPAGFSRRLUSSNAGPRLLAWLACPLRLACLISVALPGCWA 75
QY 39 ----LQPFCHLYWCGRG--CYGCLAP-FCEINLGDKCLDGVNNSYESILKNYLAT 91
Db 76 LSGRLLPVCFPMWLCLGAPAFSGCLLPVYCHLQSGLLRPTLLH-----LAPFWL-- 126
QY 92 RGLTWKMLTSLVALQGVFLSDVRVTGDTVL---CYCCGLRSFRELTYQVRQNIAS 148
Db 127 ---LAMPNLPACMLELLELFFRGGNRVESGKGLAPKCCCGFFAPS-----KQALPGP 178
QY 149 ELFVAVTSR 157
Db 179 KIQTAVLSK 187
XX
XX RESULT 15
XX AAU56425
XX ID AAU56425 standard; protein; 244 AA.
XX AC
XX AAU56425;
XX

```

PR	28-APR-1999;	99US-0131449P.	PR	21-JUL-1999;	99US-0144814P.
PR	30-APR-1999;	99US-0132048P.	PR	21-JUL-1999;	99US-0145086P.
PR	30-APR-1999;	99US-0132407P.	PR	22-JUL-1999;	99US-0145088P.
PR	04-MAY-1999;	99US-0132484P.	PR	22-JUL-1999;	99US-0145088P.
PR	05-MAY-1999;	99US-0132485P.	PR	22-JUL-1999;	99US-0145089P.
PR	06-MAY-1999;	99US-0132486P.	PR	22-JUL-1999;	99US-0145192P.
PR	06-MAY-1999;	99US-0132487P.	PR	23-JUL-1999;	99US-0145145P.
PR	07-MAY-1999;	99US-0132863P.	PR	23-JUL-1999;	99US-0145218P.
PR	11-MAY-1999;	99US-0134256P.	PR	23-JUL-1999;	99US-0145224P.
PR	14-MAY-1999;	99US-0134218P.	PR	26-JUL-1999;	99US-0145276P.
PR	14-MAY-1999;	99US-0134219P.	PR	27-JUL-1999;	99US-0145913P.
PR	14-MAY-1999;	99US-0134370P.	PR	27-JUL-1999;	99US-0145918P.
PR	14-MAY-1999;	99US-0134768P.	PR	27-JUL-1999;	99US-0145919P.
PR	18-MAY-1999;	99US-0134941P.	PR	28-JUL-1999;	99US-0145951P.
PR	19-MAY-1999;	99US-0135124P.	PR	02-AUG-1999;	99US-0146386P.
PR	21-MAY-1999;	99US-0135353P.	PR	02-AUG-1999;	99US-0146388P.
PR	24-MAY-1999;	99US-0135629P.	PR	03-AUG-1999;	99US-0146388P.
PR	25-MAY-1999;	99US-0136021P.	PR	04-AUG-1999;	99US-0147038P.
PR	27-MAY-1999;	99US-0136392P.	PR	04-AUG-1999;	99US-0147204P.
PR	28-MAY-1999;	99US-0136782P.	PR	05-AUG-1999;	99US-0147302P.
PR	01-JUN-1999;	99US-0137222P.	PR	05-AUG-1999;	99US-0147192P.
PR	03-JUN-1999;	99US-0137528P.	PR	06-AUG-1999;	99US-0147260P.
PR	04-JUN-1999;	99US-0137502P.	PR	06-AUG-1999;	99US-0147303P.
PR	07-JUN-1999;	99US-0137724P.	PR	09-AUG-1999;	99US-0147418P.
PR	08-JUN-1999;	99US-0138094P.	PR	09-AUG-1999;	99US-0147493P.
PR	10-JUN-1999;	99US-0138847P.	PR	10-AUG-1999;	99US-0147935P.
PR	10-JUN-1999;	99US-0139119P.	PR	10-AUG-1999;	99US-0148171P.
PR	14-JUN-1999;	99US-0139452P.	PR	11-AUG-1999;	99US-0148319P.
PR	16-JUN-1999;	99US-0139453P.	PR	12-AUG-1999;	99US-0148341P.
PR	17-JUN-1999;	99US-0139492P.	PR	13-AUG-1999;	99US-0148655P.
PR	18-JUN-1999;	99US-0139454P.	PR	13-AUG-1999;	99US-0148684P.
PR	18-JUN-1999;	99US-0139455P.	PR	16-AUG-1999;	99US-0149368P.
PR	18-JUN-1999;	99US-0139457P.	PR	17-AUG-1999;	99US-0149175P.
PR	18-JUN-1999;	99US-0139458P.	PR	18-AUG-1999;	99US-0149222P.
PR	18-JUN-1999;	99US-0139460P.	PR	18-AUG-1999;	99US-0149426P.
PR	18-JUN-1999;	99US-0139461P.	PR	20-AUG-1999;	99US-0149723P.
PR	18-JUN-1999;	99US-0139462P.	PR	20-AUG-1999;	99US-0149723P.
PR	18-JUN-1999;	99US-0139463P.	PR	23-AUG-1999;	99US-0149929P.
PR	18-JUN-1999;	99US-0139750P.	PR	23-AUG-1999;	99US-0149930P.
PR	18-JUN-1999;	99US-0139763P.	PR	25-AUG-1999;	99US-0150566P.
PR	21-JUN-1999;	99US-0139817P.	PR	26-AUG-1999;	99US-0150884P.
PR	22-JUN-1999;	99US-0139899P.	PR	27-AUG-1999;	99US-0151065P.
PR	23-JUN-1999;	99US-0140353P.	PR	27-AUG-1999;	99US-0151066P.
PR	24-JUN-1999;	99US-0140695P.	PR	27-AUG-1999;	99US-0151080P.
PR	28-JUN-1999;	99US-0140823P.	PR	30-AUG-1999;	99US-0151303P.
PR	29-JUN-1999;	99US-0140991P.	PR	31-AUG-1999;	99US-0151438P.
PR	30-JUN-1999;	99US-0141287P.	PR	07-SEP-1999;	99US-0151930P.
PR	01-JUL-1999;	99US-0141842P.	PR	07-SEP-1999;	99US-0152363P.
PR	01-JUL-1999;	99US-0142154P.	PR	10-SEP-1999;	99US-0153070P.
PR	02-JUL-1999;	99US-0142055P.	PR	13-SEP-1999;	99US-0153758P.
PR	06-JUL-1999;	99US-0142390P.	PR	15-SEP-1999;	99US-0154018P.
PR	08-JUL-1999;	99US-0142803P.	PR	16-SEP-1999;	99US-0154039P.
PR	09-JUL-1999;	99US-0142920P.	PR	20-SEP-1999;	99US-0154779P.
PR	12-JUL-1999;	99US-0142977P.	PR	22-SEP-1999;	99US-0155139P.
PR	13-JUL-1999;	99US-0143542P.	PR	23-SEP-1999;	99US-0155486P.
PR	14-JUL-1999;	99US-0143624P.	PR	24-SEP-1999;	99US-0155659P.
PR	15-JUL-1999;	99US-0144005P.	PR	28-SEP-1999;	99US-0156458P.
PR	16-JUL-1999;	99US-0144085P.	PR	29-SEP-1999;	99US-0156596P.
PR	16-JUL-1999;	99US-0144086P.	PR	04-OCT-1999;	99US-0157117P.
PR	19-JUL-1999;	99US-0144325P.	PR	06-OCT-1999;	99US-0157753P.
PR	19-JUL-1999;	99US-0144331P.	PR	07-OCT-1999;	99US-0157865P.
PR	19-JUL-1999;	99US-0144332P.	PR	08-OCT-1999;	99US-0158029P.
PR	19-JUL-1999;	99US-0144333P.	PR	12-OCT-1999;	99US-0158232P.
PR	19-JUL-1999;	99US-0144334P.	PR	13-OCT-1999;	99US-0158369P.
PR	19-JUL-1999;	99US-0144335P.	PR	13-OCT-1999;	99US-0159293P.
PR	20-JUL-1999;	99US-0144336P.	PR	13-OCT-1999;	99US-0159294P.
PR	20-JUL-1999;	99US-0144337P.	PR	13-OCT-1999;	99US-0159295P.
PR	20-JUL-1999;	99US-0144338P.	PR	14-OCT-1999;	99US-0159329P.
PR	20-JUL-1999;	99US-0144339P.	PR	14-OCT-1999;	99US-0159330P.
PR	20-JUL-1999;	99US-0144340P.	PR	14-OCT-1999;	99US-0159331P.
PR	20-JUL-1999;	99US-0144341P.	PR	14-OCT-1999;	99US-0159637P.
PR	20-JUL-1999;	99US-0144342P.	PR	14-OCT-1999;	99US-0159638P.
PR	20-JUL-1999;	99US-0144884P.			

PR	21-JUL-1999;	99US-0145086P.
PR	21-JUL-1999;	99US-0145088P.
PR	22-JUL-1999;	99US-0145085P.
PR	22-JUL-1999;	99US-0145087P.
PR	22-JUL-1999;	99US-0145089P.
PR	22-JUL-1999;	99US-0145122P.
PR	23-JUL-1999;	99US-0145145P.
PR	23-JUL-1999;	99US-0145218P.
PR	23-JUL-1999;	99US-0145224P.
PR	26-JUL-1999;	99US-0145276P.
PR	27-JUL-1999;	99US-0145913P.
PR	27-JUL-1999;	99US-0145918P.
PR	27-JUL-1999;	99US-0145919P.
PR	28-JUL-1999;	99US-0145951P.
PR	02-AUG-1999;	99US-0146386P.
PR	02-AUG-1999;	99US-0146388P.
PR	03-AUG-1999;	99US-0147038P.
PR	04-AUG-1999;	99US-0147204P.
PR	04-AUG-1999;	99US-0147302P.
PR	05-AUG-1999;	99US-0147192P.
PR	05-AUG-1999;	99US-0147260P.
PR	06-AUG-1999;	99US-0147303P.
PR	06-AUG-1999;	99US-0147416P.
PR	09-AUG-1999;	99US-0147493P.
PR	09-AUG-1999;	99US-0147935P.
PR	10-AUG-1999;	99US-0148171P.
PR	11-AUG-1999;	99US-0148319P.
PR	12-AUG-1999;	99US-0148341P.
PR	13-AUG-1999;	99US-0148565P.
PR	13-AUG-1999;	99US-0148684P.
PR	16-AUG-1999;	99US-0149368P.
PR	17-AUG-1999;	99US-0149175P.
PR	18-AUG-1999;	99US-0149426P.
PR	20-AUG-1999;	99US-0149722P.
PR	20-AUG-1999;	99US-0149723P.
PR	20-AUG-1999;	99US-0149929P.
PR	23-AUG-1999;	99US-0149930P.
PR	23-AUG-1999;	99US-0150566P.
PR	25-AUG-1999;	99US-0150884P.
PR	26-AUG-1999;	99US-0151065P.
PR	27-AUG-1999;	99US-0151066P.
PR	27-AUG-1999;	99US-0151080P.
PR	30-AUG-1999;	99US-0151303P.
PR	31-AUG-1999;	99US-0151438P.
PR	01-SEP-1999;	99US-0151910P.
PR	07-SEP-1999;	99US-0152363P.
PR	10-SEP-1999;	99US-0153070P.
PR	13-SEP-1999;	99US-0153758P.
PR	15-SEP-1999;	99US-0154018P.
PR	16-SEP-1999;	99US-0154779P.
PR	20-SEP-1999;	99US-0155139P.
PR	22-SEP-1999;	99US-0155486P.
PR	23-SEP-1999;	99US-0155565P.
PR	24-SEP-1999;	99US-0156458P.
PR	28-SEP-1999;	99US-0156596P.
PR	28-SEP-1999;	99US-0157117P.
PR	04-OCT-1999;	99US-0157753P.
PR	05-OCT-1999;	99US-0157865P.
PR	06-OCT-1999;	99US-0158029P.
PR	07-OCT-1999;	99US-0158232P.
PR	08-OCT-1999;	99US-0158369P.
PR	12-OCT-1999;	99US-0159293P.
PR	13-OCT-1999;	99US-0159294P.
PR	13-OCT-1999;	99US-0159295P.
PR	13-OCT-1999;	99US-0159329P.
PR	14-OCT-1999;	99US-0159330P.
PR	14-OCT-1999;	99US-0159331P.
PR	14-OCT-1999;	99US-0159637P.
PR	14-OCT-1999;	99US-0159638P.
PR	18-OCT-1999;	99US-0159584P.
PR	18-OCT-1999;	99US-0159584P.
PR	21-OCT-1999;	99US-0160741P.
PR	21-OCT-1999;	99US-0160767P.
PR	21-OCT-1999;	99US-0160768P.
PR	21-OCT-1999;	99US-0160770P.
PR	21-OCT-1999;	99US-0160814P.
PR	21-OCT-1999;	99US-0160815P.
PR	22-OCT-1999;	99US-0160980P.
PR	22-OCT-1999;	99US-0160981P.
PR	22-OCT-1999;	99US-0160989P.
PR	25-OCT-1999;	99US-0161404P.
PR	25-OCT-1999;	99US-0161405P.
PR	25-OCT-1999;	99US-0161406P.
PR	26-OCT-1999;	99US-0161359P.
PR	26-OCT-1999;	99US-0161360P.
PR	26-OCT-1999;	99US-0161361P.
PR	28-OCT-1999;	99US-0161920P.
PR	28-OCT-1999;	99US-0161932P.
PR	28-OCT-1999;	99US-0161993P.
PR	29-OCT-1999;	99US-0162142P.
PR	29-OCT-1999;	99US-0162142P.
Query Match 14.6%; Score 137.5; DB 3; Length 453;		
Best Local Similarity 25.0%; Pred. No. 4.9e-05;		
Matches 45; Conservative 26; Mismatches 88; Indels 21; Gaps 6;		
QY	1	CPLOGSHALCTCCQPNPDRAREQDPRAVAPQCAVLCLOPFCHLYWGCTTCYGCGLAP 60
Db	255	CEHGAHLQCHLCQGMPPFRANLQ-----VPLHCKGCDRPFCCAYMS-SENVTQVSGP 307
QY	61	FCELN----LQDKCLDGV---LNNNSYESDILKNYLATRLTKNNMLTESL-----VAL 107
Db	308	VCVRETFPISERTITRIPITHEMREHODITQRCIAHMEKIVPDVVAEWLRLFNREI 367
QY	108	QRGVFLLSDYR-VTGDVTLCYCCGLRSFRLEITQYRONIFASBLPVAVTSRPPCYWGRNC 166
Db	368	DRSRPLNHAEMITASTHVCNDCYDKLVGLFYWFRITLPRNHLPAVAAEDCWYGYAC 427
RESULT 13		
AAG37658		
ID AAG37658 standard; protein; 453 AA.		
XX		
AC	AAG37658;	
XX		
DT	18-OCT-2000 (first entry)	
XX		
DE	Arabidopsis thaliana protein fragment SEQ ID NO: 46342.	
KW	Protein identification; signal transduction pathway; metabolic pathway;	
KW	hybridisation assay; genetic mapping; gene expression control; promoter;	
KW	termination sequence.	
XX		
OS	Arabidopsis thaliana.	
XX		
PN	EP1033405-A2.	
XX		
PD	06-SEP-2000.	
XX		
PF	25-FEB-2000; 2000EP-00301439.	
XX		
PR	25-FEB-1999;	99US-0121825P.
PR	05-MAR-1999;	99US-0123180P.
PR	09-MAR-1999;	99US-0123548P.
PR	23-MAR-1999;	99US-0125788P.
PR	25-MAR-1999;	99US-0126264P.
PR	29-MAR-1999;	99US-0126785P.
PR	01-APR-1999;	99US-0127462P.
PR	08-APR-1999;	99US-0128234P.
PR	08-APR-1999;	99US-0128714P.
PR	16-APR-1999;	99US-0129845P.
PR	19-APR-1999;	99US-0130077P.
PR	21-APR-1999;	99US-0130449P.
PR	23-APR-1999;	99US-0130510P.
PR	23-APR-1999;	99US-0130891P.

PR	21-OCT-1999;	99US-0160767P.	PR	30-APR-1999;	99US-0132048P.
PR	21-OCT-1999;	99US-0160768P.	PR	30-APR-1999;	99US-0132407P.
PR	21-OCT-1999;	99US-0160770P.	PR	04-MAY-1999;	99US-0132484P.
PR	21-OCT-1999;	99US-0160814P.	PR	05-MAY-1999;	99US-0132485P.
PR	21-OCT-1999;	99US-0160815P.	PR	06-MAY-1999;	99US-0132486P.
PR	22-OCT-1999;	99US-0160840P.	PR	06-MAY-1999;	99US-0132487P.
PR	22-OCT-1999;	99US-0160881P.	PR	07-MAY-1999;	99US-0132863P.
PR	22-OCT-1999;	99US-0160898P.	PR	11-MAY-1999;	99US-0134256P.
PR	22-OCT-1999;	99US-0160981P.	PR	14-MAY-1999;	99US-0134218P.
PR	25-OCT-1999;	99US-0161404P.	PR	14-MAY-1999;	99US-0134219P.
PR	25-OCT-1999;	99US-0161406P.	PR	14-MAY-1999;	99US-0134221P.
PR	25-OCT-1999;	99US-0161359P.	PR	18-MAY-1999;	99US-0134370P.
PR	26-OCT-1999;	99US-0161360P.	PR	19-MAY-1999;	99US-0134768P.
PR	26-OCT-1999;	99US-0161361P.	PR	20-MAY-1999;	99US-0135124P.
PR	26-OCT-1999;	99US-0161920P.	PR	21-MAY-1999;	99US-0135353P.
PR	28-OCT-1999;	99US-0161922P.	PR	21-MAY-1999;	99US-0135629P.
PR	28-OCT-1999;	99US-0161931P.	PR	24-MAY-1999;	99US-0136021P.
PR	29-OCT-1999;	99US-0162142P.	PR	25-MAY-1999;	99US-0136392P.
Query Match 14.6%; Score 137.5; DB 3; Length 426;					99US-0136782P.
Best Local Similarity 25.0%; Pred. No. 4.6e-05;					99US-0137222P.
Matches 45; Conservative 26; Mismatches 88; Indels 21; Gaps 6;					99US-0137528P.
Qy	1	CPLOGSHALCTCCQPMPPDRRAEREQDPVAPQOCACVLCQPFCHLYWGCRTGCGCLAP 60	PR	04-JUN-1999;	99US-0137502P.
Db	228	CEHGAHLQHLCOGMPPFRANLQ-----VPLCKGCDRPFCCAYWS-SENVTQGVSGP 280	PR	07-JUN-1999;	99US-0137724P.
Qy	61	FCELN----LGDKCLDGV----LNNNSYESDILKNYLATRLGLTWKMLTSL-----VAL 107	PR	08-JUN-1999;	99US-0138094P.
Db	281	VCVRETPRISERTITRIPPTHEMNRHEQDITQCIAMKTVDPVVAEWLRLFNREI 340	PR	10-JUN-1999;	99US-0138540P.
Qy	108	QRGVFLSDYR-VTGDTVLCVCCGLRFRELTVOYRONIPASELPVAVTSRPPCYWGRNC 166	PR	10-JUN-1999;	99US-0138847P.
Db	341	DRSRPLNHAETITASTHVCNDCYKLVGELLYWFRITLPRNHLDPADVAAREDCWGIYAC 400	PR	14-JUN-1999;	99US-0139119P.
RESULT 12					99US-0139452P.
AAG20352					99US-0139453P.
ID	AAG20352 standard; protein; 453 AA.				99US-0139453P.
XX					99US-0139461P.
AC	AAG20352;				99US-0139462P.
XX					99US-0139463P.
DT	17-OCT-2000 (first entry)				99US-0139750P.
XX					99US-0139763P.
DE	Arabidopsis thaliana protein fragment SEQ ID NO: 22505.				99US-0139817P.
XX					99US-0139899P.
KW	Protein identification; signal transduction pathway; metabolic pathway;				99US-0140353P.
KW	hybridisation assay; genetic mapping; gene expression control; promoter;				99US-0140354P.
KW	termination sequence.				99US-0140695P.
XX					99US-0140823P.
OS	Arabidopsis thaliana.				99US-0140991P.
XX					99US-0141287P.
FN	EPI033405-A2.				99US-0141424P.
XX					99US-0142154P.
PD	06-SEP-2000.				99US-0142055P.
XX					99US-0142390P.
XX	25-FEB-2000; 2000EP-00301439.				99US-0142803P.
PR	25-FEB-1999;	99US-0121825P.	PR	08-JUL-1999;	99US-0142920P.
PR	05-MAR-1999;	99US-0123180P.	PR	09-JUL-1999;	99US-0142977P.
PR	09-MAR-1999;	99US-0123548P.	PR	12-JUL-1999;	99US-0143542P.
PR	23-MAR-1999;	99US-0125788P.	PR	13-JUL-1999;	99US-0143542P.
PR	25-MAR-1999;	99US-0126264P.	PR	14-JUL-1999;	99US-0144005P.
PR	29-MAR-1999;	99US-0126785P.	PR	15-JUL-1999;	99US-0144085P.
PR	01-APR-1999;	99US-0127462P.	PR	16-JUL-1999;	99US-0144085P.
PR	06-APR-1999;	99US-0128234P.	PR	19-JUL-1999;	99US-0144325P.
PR	08-APR-1999;	99US-0128714P.	PR	19-JUL-1999;	99US-0144332P.
PR	16-APR-1999;	99US-0129845P.	PR	19-JUL-1999;	99US-0144333P.
PR	19-APR-1999;	99US-0130077P.	PR	19-JUL-1999;	99US-0144334P.
PR	21-APR-1999;	99US-0130449P.	PR	19-JUL-1999;	99US-0144335P.
PR	23-APR-1999;	99US-0130510P.	PR	20-JUL-1999;	99US-0144352P.
PR	23-APR-1999;	99US-0130891P.	PR	20-JUL-1999;	99US-0144884P.
PR	28-APR-1999;	99US-0131449P.	PR	21-JUL-1999;	99US-0144884P.

PR	30-APR-1999;	99US-0132407P.	PR	21-JUL-1999;	99US-0145088P.
PR	04-MAY-1999;	99US-0132484P.	PR	22-JUL-1999;	99US-0145085P.
PR	05-MAY-1999;	99US-0132485P.	PR	22-JUL-1999;	99US-0145087P.
PR	06-MAY-1999;	99US-0132486P.	PR	22-JUL-1999;	99US-0145089P.
PR	06-MAY-1999;	99US-0132487P.	PR	22-JUL-1999;	99US-0145192P.
PR	07-MAY-1999;	99US-0132863P.	PR	23-JUL-1999;	99US-0145145P.
PR	11-MAY-1999;	99US-0134256P.	PR	23-JUL-1999;	99US-0145218P.
PR	14-MAY-1999;	99US-0134218P.	PR	23-JUL-1999;	99US-0145244P.
PR	14-MAY-1999;	99US-0134219P.	PR	26-JUL-1999;	99US-0145276P.
PR	14-MAY-1999;	99US-0134370P.	PR	27-JUL-1999;	99US-0145913P.
PR	18-MAY-1999;	99US-0134768P.	PR	27-JUL-1999;	99US-0145918P.
PR	19-MAY-1999;	99US-0134941P.	PR	27-JUL-1999;	99US-0145919P.
PR	20-MAY-1999;	99US-0135124P.	PR	28-JUL-1999;	99US-0145951P.
PR	21-MAY-1999;	99US-0135353P.	PR	02-AUG-1999;	99US-0146386P.
PR	24-MAY-1999;	99US-0135629P.	PR	02-AUG-1999;	99US-0146388P.
PR	25-MAY-1999;	99US-0136021P.	PR	02-AUG-1999;	99US-0146389P.
PR	27-MAY-1999;	99US-0136392P.	PR	03-AUG-1999;	99US-0147038P.
PR	28-MAY-1999;	99US-0136782P.	PR	04-AUG-1999;	99US-0147204P.
PR	01-JUN-1999;	99US-0137222P.	PR	04-AUG-1999;	99US-0147302P.
PR	03-JUN-1999;	99US-0137528P.	PR	05-AUG-1999;	99US-0147192P.
PR	04-JUN-1999;	99US-0137724P.	PR	06-AUG-1999;	99US-0147260P.
PR	07-JUN-1999;	99US-0138094P.	PR	06-AUG-1999;	99US-0147303P.
PR	08-JUN-1999;	99US-0138540P.	PR	09-AUG-1999;	99US-0147416P.
PR	10-JUN-1999;	99US-0138847P.	PR	09-AUG-1999;	99US-0147493P.
PR	14-JUN-1999;	99US-0139119P.	PR	10-AUG-1999;	99US-0147935P.
PR	16-JUN-1999;	99US-0139452P.	PR	11-AUG-1999;	99US-0148171P.
PR	17-JUN-1999;	99US-0139453P.	PR	12-AUG-1999;	99US-0148319P.
PR	18-JUN-1999;	99US-0139454P.	PR	12-AUG-1999;	99US-0148341P.
PR	18-JUN-1999;	99US-0139455P.	PR	13-AUG-1999;	99US-0148665P.
PR	18-JUN-1999;	99US-0139456P.	PR	13-AUG-1999;	99US-0148684P.
PR	18-JUN-1999;	99US-0139457P.	PR	16-AUG-1999;	99US-0149368P.
PR	18-JUN-1999;	99US-0139458P.	PR	17-AUG-1999;	99US-0149175P.
PR	18-JUN-1999;	99US-0139459P.	PR	18-AUG-1999;	99US-0149426P.
PR	18-JUN-1999;	99US-0139460P.	PR	20-AUG-1999;	99US-0149722P.
PR	18-JUN-1999;	99US-0139461P.	PR	20-AUG-1999;	99US-0149723P.
PR	18-JUN-1999;	99US-0139462P.	PR	20-AUG-1999;	99US-0149823P.
PR	18-JUN-1999;	99US-0139463P.	PR	23-AUG-1999;	99US-0149902P.
PR	18-JUN-1999;	99US-0139750P.	PR	23-AUG-1999;	99US-0149930P.
PR	18-JUN-1999;	99US-0139763P.	PR	25-AUG-1999;	99US-0150566P.
PR	21-JUN-1999;	99US-0139817P.	PR	26-AUG-1999;	99US-0150884P.
PR	22-JUN-1999;	99US-0139899P.	PR	27-AUG-1999;	99US-0151065P.
PR	23-JUN-1999;	99US-0140353P.	PR	27-AUG-1999;	99US-0151066P.
PR	23-JUN-1999;	99US-0140354P.	PR	27-AUG-1999;	99US-0151080P.
PR	24-JUN-1999;	99US-0140695P.	PR	30-AUG-1999;	99US-0151303P.
PR	28-JUN-1999;	99US-0140823P.	PR	31-AUG-1999;	99US-0151438P.
PR	29-JUN-1999;	99US-0140991P.	PR	01-SEP-1999;	99US-0151930P.
PR	30-JUN-1999;	99US-0141287P.	PR	07-SEP-1999;	99US-0152363P.
PR	01-JUL-1999;	99US-0141842P.	PR	10-SEP-1999;	99US-0153070P.
PR	01-JUL-1999;	99US-0142154P.	PR	13-SEP-1999;	99US-0153758P.
PR	02-JUL-1999;	99US-0142055P.	PR	13-SEP-1999;	99US-0154018P.
PR	06-JUL-1999;	99US-0142330P.	PR	16-SEP-1999;	99US-0154039P.
PR	08-JUL-1999;	99US-0142803P.	PR	20-SEP-1999;	99US-0154779P.
PR	09-JUL-1999;	99US-0142940P.	PR	23-SEP-1999;	99US-0155139P.
PR	12-JUL-1999;	99US-0142977P.	PR	23-SEP-1999;	99US-0155486P.
PR	13-JUL-1999;	99US-0143542P.	PR	24-SEP-1999;	99US-0155659P.
PR	14-JUL-1999;	99US-0143624P.	PR	26-SEP-1999;	99US-0156458P.
PR	15-JUL-1999;	99US-0144005P.	PR	29-SEP-1999;	99US-0158596P.
PR	16-JUL-1999;	99US-0144085P.	PR	04-OCT-1999;	99US-0157117P.
PR	16-JUL-1999;	99US-0144325P.	PR	05-OCT-1999;	99US-0157533P.
PR	19-JUL-1999;	99US-0144331P.	PR	06-OCT-1999;	99US-0157865P.
PR	19-JUL-1999;	99US-0144332P.	PR	07-OCT-1999;	99US-0158029P.
PR	19-JUL-1999;	99US-0144333P.	PR	08-OCT-1999;	99US-0158232P.
PR	19-JUL-1999;	99US-0144334P.	PR	12-OCT-1999;	99US-0158363P.
PR	19-JUL-1999;	99US-0144335P.	PR	13-OCT-1999;	99US-0159293P.
PR	20-JUL-1999;	99US-0144352P.	PR	13-OCT-1999;	99US-0159294P.
PR	20-JUL-1999;	99US-0144632P.	PR	13-OCT-1999;	99US-0159295P.
PR	20-JUL-1999;	99US-0144684P.	PR	14-OCT-1999;	99US-0159329P.
PR	21-JUL-1999;	99US-0144814P.	PR	14-OCT-1999;	99US-0159330P.
PR	21-JUL-1999;	99US-0145086P.	PR	14-OCT-1999;	99US-0159331P.
PR			PR	14-OCT-1999;	99US-0159637P.
PR			PR	18-OCT-1999;	99US-0159638P.
PR			PR	21-OCT-1999;	99US-0159584P.
PR			PR		99US-0160741P.


```
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 22-OCT-1999; 99US-0161404P.
PR 22-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 25-OCT-1999; 99US-0161559P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 26-OCT-1999; 99US-0161320P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 14.6%; Score 137.5; DB 3; Length 350;
Best Local Similarity 25.0%; Pred. No. 3.6e-05;
Matches 45; Conservative 26; Mismatches 88; Indels 21; Gaps 6;

QY 1 CPLQGSALCTCCQPMPPRAAREQDPVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
Db 152 CEHGHGALQCHLCQGMPPFRANLQ-----VPLHCKGCDRPFCAWWS-SENVTQGVSGP 204
QY 61 FCELN----LGDKCLGV-----LNNNSYSDILKNVLTATGLTWKMLTESL-----VAL 107
Db 205 VCVRETRFRISERTITRIPIFTHMNRHEQDITQRCIAHMEKTVPDVAEWLRLFNREI 264
QY 108 QRGVFLLSDYR-VTGDTVLCYCGCLRSFRELTYQYRONIPASELPVAVTSRDPDCYWGRC 166
Db 265 DRSNPFNHAETTTASTHVCNDCYDKLVGFLLYWFRITLPRNHLPADVAAREDCWGYAC 324

RESULT 10
AAG20353
ID AAG20353 standard; protein; 426 AA.
AC AAG20353;
XX
XX
DT 17-OCT-2000 (first entry)
DE
DE Arabidopsis thaliana protein fragment SEQ ID NO: 22506.
XX
XX Protein identification; signal transduction pathway; metabolic pathway;
XX hybridisation assay; genetic mapping; gene expression control; promoter;
XX termination sequence.
XX
XX Arabidopsis thaliana.
XX
XX EP1033405-A2.
XX
PD 06-SEP-2000.
XX
XX 25-FEB-2000; 2000EP-00301439.
XX
XX 25-FEB-1999; 99US-0121825P.
XX 05-MAR-1999; 99US-0123180P.
PR 05-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.

PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-01324256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137232P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 17-JUN-1999; 99US-0139453P.
PR 18-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 02-JUL-1999; 99US-0142154P.
PR 06-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
```

PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 07-MAY-1999; 99US-0132487P.
PR 08-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0133456P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 19-MAY-1999; 99US-0134768P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 17-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139452P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139876P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144311P.
PR 19-JUL-1999; 99US-0144312P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.

PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146393P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149173P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155133P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 05-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157665P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.

PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
XX WPI; 2003-395539/38.
DR N-PSDB; ADA52592.
XX New polynucleotides encoding full-length polypeptides, e.g. secretory
PT and/or membrane proteins useful for developing medicines for diseases in
PT which the gene is involved, or as target molecules for gene therapy.
XX
PS Claim 14; SEQ ID NO 1799; 205pp; English.
XX
CC The present invention relates to novel human secretory or membrane
CC proteins (ADA54072-ADA55710) and their coding sequences (ADA52433-
CC ADA54071). The coding sequences are useful in the gene therapy of
CC diseases caused by abnormalities of the proteins, e.g. cancer,
CC inflammatory diseases, osteoporosis or neurological disease.
XX
SQ Sequence 128 AA;

Query Match 46.4%; Score 438; DB 6; Length 128;
Best Local Similarity 98.8%; Pred. No. 2.1e-35;
Matches 80; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 86 KNYLATRGLTWKMLTESLVALQGVFLSDYRTGDTVLCCGGLSPRELTYYQRNI 145
:|||||
Db 25 QNYLATRGLTWKMLTESLVALQGVFLSDYRTGDTVLCCGGLSPRELTYYQRNI 84

QY 146 PASELPVAVTSRDCYWGRCN 166
85 PASELPVAVTSRDCYWGRCN 105

RESULT 8
AAG20354
ID AAG20354 standard; protein; 350 AA.
AC AAG20354;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 22507.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
DN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0130891P.
PR 30-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 04-MAY-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.

06-MAY-1999; 99US-0132486P.
07-MAY-1999; 99US-0132487P.
07-MAY-1999; 99US-0132863P.
11-MAY-1999; 99US-0134256P.
14-MAY-1999; 99US-0134218P.
14-MAY-1999; 99US-0134219P.
14-MAY-1999; 99US-0134221P.
14-MAY-1999; 99US-0134370P.
18-MAY-1999; 99US-0134768P.
19-MAY-1999; 99US-0134941P.
20-MAY-1999; 99US-0135124P.
21-MAY-1999; 99US-0135353P.
24-MAY-1999; 99US-0135623P.
25-MAY-1999; 99US-0136021P.
27-MAY-1999; 99US-0136392P.
28-MAY-1999; 99US-0136782P.
01-JUN-1999; 99US-0137222P.
03-JUN-1999; 99US-0137528P.
04-JUN-1999; 99US-0137502P.
07-JUN-1999; 99US-0137724P.
08-JUN-1999; 99US-0138094P.
10-JUN-1999; 99US-0138540P.
10-JUN-1999; 99US-0138847P.
14-JUN-1999; 99US-0139119P.
16-JUN-1999; 99US-0139452P.
16-JUN-1999; 99US-0139453P.
17-JUN-1999; 99US-0139492P.
18-JUN-1999; 99US-0139454P.
18-JUN-1999; 99US-0139455P.
18-JUN-1999; 99US-0139456P.
18-JUN-1999; 99US-0139457P.
18-JUN-1999; 99US-0139458P.
18-JUN-1999; 99US-0139459P.
18-JUN-1999; 99US-0139460P.
18-JUN-1999; 99US-0139461P.
18-JUN-1999; 99US-0139462P.
18-JUN-1999; 99US-0139463P.
18-JUN-1999; 99US-0139750P.
18-JUN-1999; 99US-0139763P.
21-JUN-1999; 99US-0139817P.
22-JUN-1999; 99US-0139899P.
23-JUN-1999; 99US-0140353P.
23-JUN-1999; 99US-0140354P.
24-JUN-1999; 99US-0140695P.
28-JUN-1999; 99US-0140823P.
29-JUN-1999; 99US-0140991P.
30-JUN-1999; 99US-0141287P.
01-JUL-1999; 99US-0141842P.
01-JUL-1999; 99US-0142154P.
02-JUL-1999; 99US-0142055P.
06-JUL-1999; 99US-0142390P.
08-JUL-1999; 99US-0142803P.
09-JUL-1999; 99US-0142920P.
12-JUL-1999; 99US-0142977P.
13-JUL-1999; 99US-0143542P.
14-JUL-1999; 99US-0143624P.
15-JUL-1999; 99US-0144005P.
16-JUL-1999; 99US-0144085P.
18-JUL-1999; 99US-0144086P.
18-JUL-1999; 99US-0144325P.
19-JUL-1999; 99US-0144331P.
19-JUL-1999; 99US-0144332P.
19-JUL-1999; 99US-0144333P.
19-JUL-1999; 99US-0144334P.
19-JUL-1999; 99US-0144335P.
20-JUL-1999; 99US-0144352P.
20-JUL-1999; 99US-0144632P.
20-JUL-1999; 99US-0144884P.
21-JUL-1999; 99US-0144814P.
21-JUL-1999; 99US-0145086P.
21-JUL-1999; 99US-0145088P.
22-JUL-1999; 99US-0145085P.
22-JUL-1999; 99US-0145087P.

length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.

Claim 8; SEQ ID NO 12128; 2537pp + Sequence Listing; English.

The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesising polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention

Sequence 623 AA;

Query Match 99.6%; Score 939; DB 4; Length 623;
Best Local Similarity 99.4%; Pred. No. 3.5e-84;
Matches 165; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 CPLQSHALCTCCFQMPDRRAERQDPRAVQCCAVCLQPFCHLYWGCTRTGCGCLAP 60
DB 435 CPLQSHALCTCCFQMPDRRAERQDPRAVQCCAVCLQPFCHLYWGCTRTGCGCLAP 494
QY 61 FCELNLDGKCLDGVNNSYESDILKNYLATRLGTWKNNMLTESLVALQRGVFLLSDYRVT 120
DB 495 FCELNLDGKCLDGVNNSYESDILKNYLATRLGTWKNNMLTESLVALQRGVFLLSDYRVT 554
QY 121 GDTVLCYCCGLRSFRELTYQYQNIPASELPVAVTSRPPDCYGRNC 166
DB 555 GDTVLCYCCGLRSFRELTYQYQNIPASELPVAVTSRPPDCYGRNC 600

RESULT 6

ABB97233
ID ABB97233 standard; protein; 623 AA.
AC ABB97233;
XX ABB97233;
XX 27-JUN-2002 (first entry)
DE Novel human protein SEQ ID NO: 501.
XX Human; antianaemic; vulnary; antiinflammatory; immunomodulator;
XX antiinfertility; cerebroprotective; cytosstatic; rheumatic; gene therapy;
KW neuroprotective; antiaparkinsonian; protein therapy; EST;
KW expressed sequence tag.
XX Homo sapiens.
OS WO200222660-A2.
XX 21-MAR-2002.
XX 10-SEP-2001; 2001WO-US026015.
XX 11-SEP-2000; 2000US-00659671.
XX

(HYSE-) HYSEQ INC.

PA Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI Xue AJ, Yang Y, Wehrman T, Drmanac RT;
XX WPI: 2002-292408/33.
DR N-PSDB; ABN32419.
XX

An isolated polynucleotide for treating diseases associated with its encoded polypeptide such as cancer and multiple sclerosis.

Example 2; SEQ ID NO 501; 509pp; English.

The present invention provides the protein and coding sequences of 444 novel human proteins. These were isolated from expressed sequences tags (ESTs). They can be used to stimulate cell growth, to regulate haematopoiesis e.g. to treat aplastic anaemia, to help tissue regrowth e.g. in burn treatment, to regulate the immune system e.g. to treat multiple sclerosis, to regulate activin or inhibin e.g. to treat infertility, to regulate haemostasis or thrombolysis e.g. to treat stroke and cancer, to screen for drugs, to treat inflammatory conditions e.g. rheumatoid arthritis, and to treat nervous system disorders e.g. Parkinson's disease. The present sequence is a protein of the invention

Sequence 623 AA;

Query Match 99.6%; Score 939; DB 5; Length 623;
Best Local Similarity 99.4%; Pred. No. 3.5e-84;
Matches 165; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 CPLQSHALCTCCFQMPDRRAERQDPRAVQCCAVCLQPFCHLYWGCTRTGCGCLAP 60
DB 435 CPLQSHALCTCCFQMPDRRAERQDPRAVQCCAVCLQPFCHLYWGCTRTGCGCLAP 494
QY 61 FCELNLDGKCLDGVNNSYESDILKNYLATRLGTWKNNMLTESLVALQRGVFLLSDYRVT 120
DB 495 FCELNLDGKCLDGVNNSYESDILKNYLATRLGTWKNNMLTESLVALQRGVFLLSDYRVT 554
QY 121 GDTVLCYCCGLRSFRELTYQYQNIPASELPVAVTSRPPDCYGRNC 166
DB 555 GDTVLCYCCGLRSFRELTYQYQNIPASELPVAVTSRPPDCYGRNC 600

RESULT 7

ADA54231
ID ADA54231 standard; protein; 128 AA.
XX ADA54231;
XX 20-NOV-2003 (first entry)
DE Human protein, SEQ ID 1799.
XX Cytostatic; Anti-inflammatory; Osteopathic; Neuroprotective; Nootropic;
KW Gene Therapy; human; secretory protein; membrane proteins; cancer;
KW inflammatory disease; osteoporosis; neurological disease.
XX Homo sapiens.
OS EP1293569-A2.
XX 19-MAR-2003.
XX 21-MAR-2002; 2002EP-00006586.
XX 14-SEP-2001; 2001JP-00328391.
XX 24-JAN-2002; 2002US-0350435P.
XX (HELI-) HELIX RES INST.
PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;

CC prophase to metaphase during mitosis. It has ubiquitin-protein ligase
CC activity. The Chfr checkpoint was evident in primary human cells, but was
CC inactivated in 4 of 8 human cancer cell lines. In U2OS cells, a mutation
CC was identified that caused a Val to Met amino acid substitution in the
CC highly conserved C-terminal Cys-rich region of the Chfr protein. In the
CC absence of the Chfr checkpoint, cells subjected to mitotic stress
CC condensed their chromosomes despite failing to separate their
CC chromosomes. Chfr may monitor centrosome separation. Inactivation of the
CC Chfr gene (see AAF3035) in human cancer is theorized to underlie the
CC increased sensitivity of cancer cells to antimitotic drugs. Polypeptides
CC comprising the present sequence, or sequences comprising at least amino
CC acids 31-103, 303-346 and/or 476-641 of this sequence, are claimed
CC Claimed methods of determining the tumorigenic potential of a cell
CC comprise examining the cell for the presence of Chfr expression or for
CC the presence of Chfr-mediated ubiquitin-protein ligase activity (in both
CC cases, absence of Chfr expression indicating predisposition to tumorigenesis
CC upon exposure to mitotic stress). A diagnostic kit for detecting the
CC tumorigenic potential of cell cells comprises may comprise a ligand that
CC binds to Chfr, such as an antibody or its fragment. Inhibitors of Chfr
CC are identified by monitoring their effect on Chfr expression, and are
CC used to retard the growth of cancer cells
XX
SQ Sequence 564 AA;

Query Match 100.0%; Score 943; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 1.5e-84;
Matches 166; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CPLQSHALCTCCFQMPDRRAERQDPRVAPQCAVCLQPFCHLYMGCTRTGCGCLAP 60
Db 476 CPLQSHALCTCCFQMPDRRAERQDPRVAPQCAVCLQPFCHLYMGCTRTGCGCLAP 535
QY 61 FCEINLGDKCLDGVLNNSYESDILKNYLATRGLTWKMLTESLVALQGVFLLSDYRVT 120
Db 536 FCEINLGDKCLDGVLNNSYESDILKNYLATRGLTWKMLTESLVALQGVFLLSDYRVT 595
QY 121 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 166
Db 596 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 641

RESULT 4
AAO08972
ID AAO08972 standard; protein; 269 AA.
XX
AC AAO08972;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 22864.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation.
XX
OS Homo sapiens.
XX
FN WO200164835-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US004927.
XX
PR 28-FEB-2000; 2000US-00515126.
PR 18-MAY-2000; 2000US-00577409.
XX
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Drmanac RT;
XX
XX WPI: 2001-514838/56.
XX N-PSDB; AAI8903.
XX
XX
XX

XX Isolated nucleic acids and polypeptides, useful for preventing diagnosing
PT and treating e.g. leukemia, inflammation and immune disorders.
XX
XX Claim 20; SEQ ID NO 22864; 1399pp + Sequence Listing; English.
XX
XX The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC polynucleotides and polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ffp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 269 AA;

Query Match 99.7%; Score 940; DB 4; Length 269;
Best Local Similarity 99.4%; Pred. No. 1e-84;
Matches 165; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 CPLQSHALCTCCFQMPDRRAERQDPRVAPQCAVCLQPFCHLYMGCTRTGCGCLAP 60
Db 81 CPLQSHALCTCCFQMPDRRAERQDPRVAPQCAVCLQPFCHLYMGCTRTGCGCLAP 140
QY 61 FCEINLGDKCLDGVLNNSYESDILKNYLATRGLTWKMLTESLVALQGVFLLSDYRVT 120
Db 141 FCEINLGDKCLDGVLNNSYESDILKNYLATRGLTWKMLTESLVALQGVFLLSDYRVT 200
QY 121 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 166
Db 201 GDTVLCYCCGLRSFRELTYQYRONIPASELPVATSRPDCYWGRC 246

RESULT 5
AAB93182
ID AAB93182 standard; protein; 623 AA.
XX
AC AAB93182;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:12128.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
FN EPI074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-00116126.
XX
PR 29-JUL-1999; 99JP-00248036.
PR 27-AUG-1999; 99JP-00300253.
PR 11-JAN-2000; 2000JP-00118776.
PR 02-MAY-2000; 2000JP-00183767.
PR 09-JUN-2000; 2000JP-00241899.
XX
XX (HELI-) HELIX RES INST.
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Iehii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
XX WPI: 2001-318749/34.
XX
XX Primer sets for synthesizing polynucleotides, particularly the 5602 full-
PT

CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in the
CC specification. The primer sets can be used in antisense therapy and in
CC gene therapy. The primers are useful for synthesizing polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAH02446 to AAH95893
CC represent human amino acid sequences; and AAH13629 to AAH13632 represent
CC oligonucleotides, all of which are used in the exemplification of the
CC present invention

XX
SQ Sequence 652 AA;

Query Match 100.0%; Score 943; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 1.5e-84; Indels 0; Gaps 0;
Matches 166; Conservative 0; Mismatches 0;

QY 1 CPLQSGHALCTCCFQMPDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
Db 464 CPLQSGHALCTCCFQMPDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 523
QY 61 FCELNLDGKCLDGLVNNNSYESDILKNYLATRLTGWKMLTSLVALQRGVFLSDYRVT 120
Db 524 FCELNLDGKCLDGLVNNNSYESDILKNYLATRLTGWKMLTSLVALQRGVFLSDYRVT 583
QY 121 GDTVLCYCCGLRSFRELTYQYRQNPASELPVAVTSRPPDCYWGRC 166
Db 584 GDTVLCYCCGLRSFRELTYQYRQNPASELPVAVTSRPPDCYWGRC 629

RESULT 2
AAB83843
ID AAB83843 standard; protein; 664 AA.
XX AAB83843;
AC AAB83843;
XX
XX 22-AUG-2001 (first entry)
DT Amino acid sequence of a human ring finger protein designated FHAR1.
DE FHAR1; RING finger protein; cancer; vaccine.
XX
KW Homo sapiens.
XX
OS WO200142430-A1.
XX
XX 14-JUN-2001.
XX
XX 07-DEC-2000; 2000WO-US033094.
XX
XX 08-DEC-1999; 99US-00456876.
XX (SMIK) SMITHKLINE BEECHAM CORP.
XX
XX Zhou B, Zhu Y, Chaturvedi P, Hurler MR, Li X;
PI WPI; 2001-381663/40.
XX N-PSDB; AAF89709.
XX

XX New FHAR1 polypeptide, a member of the RING finger protein family for
XX diagnosing and treating cancer, and for use in anti-cancer vaccines.
XX
XX Claim 1; Page 19; 28pp; English.
XX
XX The present sequence represents a FHAR1 polypeptide, which is a member of
XX the RING finger protein family. FHAR1 is useful in the treatment of
XX cancer, and as a vaccine for inducing an immunological response in a
XX mammal. FHAR1 polynucleotides may also be used as a diagnostic reagent
XX through detection of mutations in the associated gene, and for chromosome

CC localization studies, and tissue expression studies. FHAR1 antibodies are
CC useful to isolate and to identify clones expressing the polypeptides, or
CC to purify the polypeptides by affinity chromatography and to treat cancer

XX
SQ Sequence 664 AA;

Query Match 100.0%; Score 943; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 1.5e-84; Indels 0; Gaps 0;
Matches 166; Conservative 0; Mismatches 0;

QY 1 CPLQSGHALCTCCFQMPDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 60
Db 476 CPLQSGHALCTCCFQMPDRAEREDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAP 535
QY 61 FCELNLDGKCLDGLVNNNSYESDILKNYLATRLTGWKMLTSLVALQRGVFLSDYRVT 120
Db 536 FCELNLDGKCLDGLVNNNSYESDILKNYLATRLTGWKMLTSLVALQRGVFLSDYRVT 595
QY 121 GDTVLCYCCGLRSFRELTYQYRQNPASELPVAVTSRPPDCYWGRC 166
Db 596 GDTVLCYCCGLRSFRELTYQYRQNPASELPVAVTSRPPDCYWGRC 641

RESULT 3
AAB20219
ID AAB20219 standard; protein; 664 AA.
XX AAB20219;
AC AAB20219;
XX
XX 14-MAY-2001 (first entry)
DT Human Chfr (checkpoint with FHA and ring finger) protein.
DE Checkpoint with forkhead associated domain and ring finger; Chfr; human;
KW mitosis; cell cycle; tumour; diagnosis; antitumour; drug screening;
KW ubiquitin-protein ligase.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH Domain 31..103
FT Domain /label= Forkhead-associated_domain
FT Domain 303..346
FT Domain /label= Ring_finger_domain
FT Region 476..641
FT Misc-difference 580 /note= "cysteine-rich region"
FT /note= "Met in U2OS cells"

XX WO200109150-A2.
XX
XX 08-FEB-2001.
XX
XX 14-JUN-2000; 2000WO-US016391.
XX
XX 29-JUL-1999; 99US-0146194P.
XX (WIST-) WISTAR INST ANATOMY & BIOLOGY.
XX Halazonetis T, Scolnick D;
XX
XX WPI; 2001-182927/18.
XX N-PSDB; AAF30352.
XX
XX Novel nucleic acid sequence of mitotic checkpoint gene encoding a
XX checkpoint with forkhead-associated domain and ring finger protein, for
XX diagnosing tumorigenic cells and in screening for anticancer drugs.

XX Claim 8(a); Fig 4A-C; 85pp; English.
XX
XX The present sequence is that of human mitotic checkpoint protein Chfr.
XX having a forkhead associated domain (FHA) and a ring finger domain. The
XX protein is required for regulation of the transition of cells from

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:36:57 ; Search time 34.0063 Seconds
(without alignments)
1379.240 Million cell updates/sec

Title: US-10-048-046-2_COPY_476_641

Perfect score: 943
Sequence: 1 CPGQSHALCTCCQPMFDR.....ASELPVAVTSPDCYWGRC 166

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_25Jan04.*

- 1: Geneseqp1980s.*
- 2: Geneseqp1990s.*
- 3: Geneseqp2000s.*
- 4: Geneseqp2001s.*
- 5: Geneseqp2002s.*
- 6: Geneseqp2003as.*
- 7: Geneseqp2003bs.*
- 8: Geneseqp2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	943	100.0	652	4	AAB93168 Human pro
2	943	100.0	664	4	AAB83843 Amino aci
3	943	100.0	664	4	AAB20219 Human Chf
4	940	99.7	269	4	AAO08972 Human pol
5	939	99.6	623	4	AAB93182 Human pro
6	939	99.6	623	5	ABB97233 Novel hum
7	438	46.4	128	6	ADA54231 Human pro
8	137.5	14.6	350	3	AAG20354 Arabidops
9	137.5	14.6	350	3	AAG37660 Arabidops
10	137.5	14.6	426	3	AAG20353 Arabidops
11	137.5	14.6	426	3	AAG37659 Arabidops
12	137.5	14.6	453	3	AAG20352 Arabidops
13	137.5	14.6	453	3	AAG37658 Arabidops
14	92.5	9.8	227	3	AAB34759 Human sec
15	85.5	9.1	244	4	AAU54425 Propionib
16	85.5	9.1	244	6	ABM52944 Propionib
17	85	9.0	229	4	AAW40223 Human pol
18	85	9.0	229	5	ABG34856 Human can
19	85	9.0	231	4	AAW42009 Human pol
20	85	9.0	504	4	AAE02617 Human hae
21	84	8.9	232	6	ABG73844 Mutant hu
22	82.5	8.7	1023	6	ABG73844 D. discoi
23	81	8.6	551	5	ABW01436 Desulfito
24	80	8.5	192	6	ABR55481 Amino aci
25	80	8.5	302	3	AAG47210 Arabidops

ALIGNMENTS

RESULT 1

AAB93168
ID AAB93168 standard; protein; 652 AA.
XX
AC AAB93168;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:12100.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-00116126.
XX
PR 29-JUL-1999; 99JP-00248036.
PR 27-AUG-1999; 99JP-00300253.
PR 11-JAN-2000; 2000JP-00118776.
PR 02-MAY-2000; 2000JP-00183767.
PR 09-JUN-2000; 2000JP-00241899.
XX
(HELI-) HELIX RES INST.

Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

WPI; 2001-318749/34.

Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.

Claim 8; SEQ ID NO 12100; 2537pp + Sequence Listing; English.

The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dr primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the polynucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end

Aag47209 Arabidops
Abb71303 Drosophil
Abg18306 Novel hum
Abg28511 Novel hum
Abg96264 Human imm
Ade07954 Novel pro
Abb97437 Novel hum
Aae02618 Human hae
Abg73838 Mutant hu
Abu92033 Human pro
Aab93353 Human pro
Abb64608 Drosophil
Abb68229 Rice prot
Ada48586 Rice prot
Ada47952 Rice prot
Aay54838 Human dia
Aae01864 Human dia
Aae36090 Human dia
Aae36089 Human dia
Adc77639 Human 994

26 80 8.5 324 3 AAG47209
27 80 8.5 530 4 ABB71303
28 80 8.5 725 4 ABG18306
29 80 8.5 725 4 ABG28511
30 79.5 8.4 577 5 ABG96264
31 79 8.4 317 7 ADE07954
32 79 8.4 1561 5 ABB97437
33 78.5 8.3 493 4 AAE02618
34 77 8.2 232 6 ABG73838
35 77 8.2 303 6 ABU92033
36 76.5 8.1 418 4 AAB93353
37 76.5 8.1 1700 4 ABB64608
38 76.5 8.1 2931 4 ABB68229
39 76 8.1 185 6 ADA48586
40 76 8.1 185 6 ADA47952
41 76 8.1 567 3 AAY54838
42 76 8.1 567 4 AAE01864
43 76 8.1 567 6 AAE36090
44 76 8.1 567 6 AAE36089
45 76 8.1 567 7 ADC77639

Search completed: May 7, 2004, 14:49:04
Job time : 8.36536 secs

OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eucosids II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Haas B.J., Volkovsky N., Town C.D., Trukhan M., Alexandrov N.,
RA Feldmann K.A., Flavell R.B., White O., Salzberg S.L.;
RT "Full-length messenger RNA sequences greatly improve genome
RT annotation."
RL Genome Biol. 0:0-0(2002).
RN [2]
RP SEQUENCE FROM N.A.
RA Brover V., Trukhan M., Alexandrov N., Lu Y.-P., Flavell R.,
RA Feldmann K.;
RT "Full-length cDNA from Arabidopsis thaliana."
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AY087766; AAM65302.1; Znf_ring.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 426 AA; 47807 MW; 48974F27881BB833 CRC64;

Query Match 42.7%; Score 113.5; DB 10; Length 426;
Best Local Similarity 46.5%; Pred. No. 5.3e-07;
Matches 20; Conservative 4; Mismatches 18; Indels 1; Gaps 1;

QY 2 CIIQDLHDCVSLQPCMHHTFCAACYSGWMERSSLCPTCRCPV 44
DB 365 CAIQCKMHTPILLR-CKHMFCDVSEWFERETCPLCALV 406

RESULT 13
O8L610 PRELIMINARY; PRT; 426 AA.
ID O8L610;
AC O8L610;
DT 01-OCT-2002 (TRENBLrel. 22, Created)
DT 01-OCT-2002 (TRENBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE Hypothetical protein.
GN AT5G01960.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eucosids II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RA Nguyen M., Karlin-Neumann G., Southwick A., Lam B., Miranda M.,
RA Palm C.J., Bowser L., Jones T., Banh J., Carninci P., Chen H.,
RA Cheuk R., Chung M.K., Hayashizaki Y., Ishida J., Kamiya A., Kawai J.,
RA Kim C., Lin J., Liu S.X., Narusaka M., Pham P.K., Sakano H.,
RA Sakurai T., Satou M., Seki M., Shinn P., Yamada K., Shinozaki K.,
RA Ecker J., Theologis A., Davis R.W.;
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Nguyen M., Karlin-Neumann G., Southwick A., Tripp M., Miranda M.,
RA Palm C.J., Bowser L., Jones T., Banh J., Carninci P., Chen H.,
RA Cheuk R., Chung M.K., Hayashizaki Y., Ishida J., Kamiya A., Kawai J.,
RA Kim C., Lin J., Liu S.X., Narusaka M., Pham P.K., Sakano H.,
RA Sakurai T., Satou M., Seki M., Shinn P., Yamada K., Shinozaki K.,
RA Ecker J., Theologis A., Davis R.W.;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AY099711; AAM20562.1; -;
DR EMBL; BT000282; AAN15601.1; -;
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.

DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 426 AA; 47791 MW; B245F521B9F663D1 CRC64;

Query Match 42.7%; Score 113.5; DB 10; Length 426;
Best Local Similarity 46.5%; Pred. No. 5.3e-07;
Matches 20; Conservative 4; Mismatches 18; Indels 1; Gaps 1;

QY 2 CIIQDLHDCVSLQPCMHHTFCAACYSGWMERSSLCPTCRCPV 44
DB 365 CAIQCKMHTPILLR-CKHMFCDVSEWFERETCPLCALV 406

RESULT 14
O37928 PRELIMINARY; PRT; 498 AA.
ID O37928;
AC O37928;
DT 01-JAN-1998 (TRENBLrel. 05, Created)
DT 01-JAN-1998 (TRENBLrel. 05, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE Immediate early protein.
OS Feline herpesvirus (Feline herpesvirus 1).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Varicellovirus.
OX NCBI_TaxID=10334;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C-27;
RA Sussman M.D., Maes R.K.;
RT "Nucleotide sequence and characterization of feline herpesvirus 1
RT homologs for ICP0, glycoprotein gL and uracil DNA glycosylase."
RL Submitted (SEP-1997) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AF022391; AAB80763.1; -;
DR HSPSP; P28990; ICHC.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 498 AA; 55012 MW; 68C58DED3B9C58C8 CRC64;

Query Match 41.4%; Score 110; DB 12; Length 498;
Best Local Similarity 39.5%; Pred. No. 1.8e-06;
Matches 17; Conservative 8; Mismatches 18; Indels 0; Gaps 0;

QY 2 CIIQDLHDCVSLQPCMHHTFCAACYSGWMERSSLCPTCRCPV 44
DB 8 CPICLDMNDLTFTMPLCHKFCYSLRWVGLNNKCLCKTSV 50

RESULT 15
O13628 PRELIMINARY; PRT; 304 AA.
ID O13628;
AC O13628;
DT 01-JAN-1998 (TRENBLrel. 05, Created)
DT 01-JAN-1998 (TRENBLrel. 05, Last sequence update)
DT 01-MAR-2003 (TRENBLrel. 23, Last annotation update)
DE PAS4 protein.
GN P1036.
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
OX NCBI_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=972 h-;
RX MEDLINE=20089027; PubMed=10620777;
RA Machida M., Yamazaki S., Kunihiro S., Tanaka T., Kushida N., Jinno K.,
RA Haikawa Y., Yamazaki J., Yamamoto S., Sekine M., Oguchi A., Nagai Y.,

DR PROSITE; PS0089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 829 AA; 91849 MW; 5C5B74906E2E621D CRC64;

Query Match 44.4%; Score 118; DB 3; Length 829;
Best Local Similarity 41.1%; Pred.No.2.4e-07;
Matches 23; Conservative

QY 1 TCIIQCPLL-----HDCVSLQ-----PCWHTFCACACYGWMERSLCTCRCPV 44
||| ||| : : : : :
DB 340 TCIICREMPDPHPDLRERFAKLPCHILHQCLKSWLBRQQVCPTCRPV 395
||| ||| : : : : :

RESULT 9
Q8BTQ Q8BTQ PRELIMINARY; PRT; 178 AA.

AC Q8BTQ; AC Q8BTQ; 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE RING finger protein homolog.
GN 2310035N15Rik.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
NCBI_TaxID=10090;
[1]
RN RNP SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Cecum;
RC MEDLINE=22354683; PubMed=12466851;
RX The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."
RL NCBI accession number: 2310035N15Rik.
RM ENBL; AKO33609; BAC28388.1; -;
DR MGD; MGI:1916837; 2310035N15Rik.
DR InterPro; IPRO01841; ZnF_Ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SMO0184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS0089; ZF_RING_2; 1.
SQ SEQUENCE 178 AA; 20842 MW; 792FB74D2F0938A1 CRC64;

Query Match 43.2%; Score 115; DB 11; Length 178;
Best Local Similarity 41.5%; Pred.No.1.6e-07;
Matches 17; Conservative 9; Mismatches 15; Indels 0; Gaps 0;

QY 1 TCIIQCPLLHDCVSLQPCWHTFCACACYGWMERSLCTPCR 41
||| ||| : : : : :
DB 16 TCRUCSYLLDATVTTCGLHFCSRCLVKYLENNTPCTCR 56
||| ||| : : : : :

RESULT 10
Q8BTQ Q8BTQ PRELIMINARY; PRT; 241 AA.

AC Q8BTQ; AC Q8BTQ; 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE RING finger protein homolog (Similar to ring finger protein 3).
GN 2310035N15Rik.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
NCBI_TaxID=10090;
[1]
RN RNP SEQUENCE FROM N.A.
RP STRAIN=NOD; TISSUE=Thymus;
RC MEDLINE=22354683; PubMed=12466851;
RX The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."

OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20388685; PubMed=10935642;
RA Scolnick D.M., Halazonetis T.D.;
RT "Chr1 defines a mitotic stress checkpoint that delays entry into
RT metaphase";
RL Nature 406:430-435(2000).
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AF170724; AAF91084.1; -.
DR PDB; 1LGP; 07-AUG-02.
DR PDB; 1LGO; 07-AUG-02.
DR Genes; HGNC:20455; CHFR.
DR GO; GO:0007093; P:mitotic checkpoint; TAS.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS50006; FHA DOMAIN; 1.
DR PROSITE; PS00538; ZF_RING_1; 1.
DR PROSITE; PS50089; ZF_RING_2; 1.
DR PROSITE; PS50089; ZF_RING_2; 1.
KW Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 664 AA; 73386 MW; 141A1E7FEFAE36A2 CRC64;

Query Match 100.0%; Score 266; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 5.1e-27;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIQDQLHDCVSLQPCMTTFCACYSGWMSRLCPTCRCPV 44
DB 303 TCIIQDQLHDCVSLQPCMTTFCACYSGWMSRLCPTCRCPV 346

RESULT 6
Q810L3 PRELIMINARY; PRT; 664 AA.
ID Q810L3;
AC Q810L3;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE RIKEN cDNA 573048420 gene.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Limb;
RA Strausberg R.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC049792; AAF49792.1; -.
DR InterPro; IPR00253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS50006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS50089; ZF_RING_2; 1.
SQ SEQUENCE 664 AA; 73871 MW; D651BE3B463DEB56 CRC64;

Query Match 100.0%; Score 266; DB 11; Length 664;
Best Local Similarity 100.0%; Pred. No. 5.1e-27;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIQDQLHDCVSLQPCMTTFCACYSGWMSRLCPTCRCPV 44
DB 302 TCIIQDQLHDCVSLQPCMTTFCACYSGWMSRLCPTCRCPV 345

RESULT 7
Q9SX88 PRELIMINARY; PRT; 473 AA.
ID Q9SX88;
AC Q9SX88;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE F16N3.15.
GN F16N3.15.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RA Vysotskaia V.S., Schwartz J.R., Yu G., Toriumi M., Lenz C., Liu S.,
RA Lee J., Liu A., Li J., Kremenetskaia I., Gonzalez A., Altafi H.,
RA Araujo R., Brooks S., Buehler E., Chao Q., Conn L., Conway A.B.,
RA Dunn P., Hansen N., Huizar L., Khan S., Kim C., Palm C., Rowley D.,
RA Shinn P., Walker M., Davis R.W., Ecker J.R., Federspiel N.A.,
RA Theologis A.;
RT "Arabidopsis thaliana chromosome 1 BAC F16N3 sequence.";
RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AC007519; AAD46042.1; -.
DR PIR; C96516; C96516.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS50089; ZF_RING_2; 1.
DR PROSITE; PS50089; ZF_RING_2; 1.
KW Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 473 AA; 53874 MW; D17217493A81C991 CRC64;

Query Match 50.8%; Score 135; DB 10; Length 473;
Best Local Similarity 46.9%; Pred. No. 8.3e-10;
Matches 23; Conservative 5; Mismatches 15; Indels 6; Gaps 1;

QY 2 CIIICDQLHDCVSLQPCMTTFCACYSGWMSRLCPTCRCPV 44
DB 145 CSICLNIWHDVVVTAAPCLHNFNGCFSEMMRSEKHKHVLCPQCRTPV 193

RESULT 8
Q8NJ06 PRELIMINARY; PRT; 829 AA.
ID Q8NJ06;
AC Q8NJ06;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Conserved hypothetical protein.
GN SP3.020.
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RA Schulte U., Aign V., Hoheisel J., Brandt P., Fartmann B., Holland R.,
RA Nyakatura G., Mewes H.W., Mannhaupt G.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA German Neurospora genome project;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
ENBL; AL807371; CAD37003.1; -.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.

```
QY 1 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 44
DB 262 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 305

RESULT 2
Q96SL3 PRELIMINARY; PRT; 652 AA.
AC Q96SL3;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein FLJ14781.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Aotsuka S., Yoshikawa Y.,
RA Matsunawa H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,
RA Nakamura Y., Nagahari K., Masuho Y., Sasaki N.;
RT "NEDO human cDNA sequencing project.";
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
CC 1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AK027687; BAB5297.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA_DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS0089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 652 AA; 72030 MW; 572F2CB6D1743D80 CRC64;

Query Match 100.0%; Score 266; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 5.1e-27;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 44
DB 291 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 334

RESULT 3
Q96EP1 PRELIMINARY; PRT; 652 AA.
AC Q96EP1;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
CC 1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; BC012072; AAH12072.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.

Query Match 100.0%; Score 266; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 5.1e-27;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 44
DB 291 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 334

RESULT 3
Q96EP1 PRELIMINARY; PRT; 652 AA.
AC Q96EP1;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
CC 1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; BC012072; AAH12072.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
```

```
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA_DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS0089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 652 AA; 72058 MW; 1A50773CEA679F07 CRC64;

Query Match 100.0%; Score 266; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 5.1e-27;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 44
DB 291 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 334

RESULT 4
Q8BJZ9 PRELIMINARY; PRT; 663 AA.
ID Q8BJZ9
AC Q8BJZ9;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Similar to cell cycle checkpoint protein CHFR.
GN 5730484M20RIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Body;
RA MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573(2002).
DR EMBL; AK077629; BAC36912.1; -.
DR MGD; MGI:2444898; 5730484M20RIK.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS00006; FHA_DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS0089; ZF_RING_2; 1.
SQ SEQUENCE 663 AA; 73855 MW; 42BD653DCB4ADF45 CRC64;

Query Match 100.0%; Score 266; DB 11; Length 663;
Best Local Similarity 100.0%; Pred. No. 5.1e-27;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 44
DB 302 TCIIQDILLHDCVSLQPCMHFTFCAACYSYSGWMSRSLCPTCRCPV 345

RESULT 5
Q9NRT4 PRELIMINARY; PRT; 664 AA.
ID Q9NRT4
AC Q9NRT4;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Cell cycle checkpoint protein CHFR.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

Q08109 saccharomyc
Q961u7 arabidopsis
Q20798 caenorhabdi
Q80318 brachydanio
Q21641 caenorhabdi
Q72x20 xenopus lae
Q8teh6 homo sapien
Q80t88 mus musculu
Q961l5 homo sapien
Q96b5 mus musculu
Q96b1 mus musculu
Q96b1 mus musculu
Q8n3k3 homo sapien
Q96p33 homo sapien
Q8n6e8 homo sapien
Q86tm6 homo sapien
Q9viw5 drosophila
Q9nxf3 arabidopsis
Q9nfs8 arabidopsis
Q96a37 homo sapien
Q7za17 yarrowia li
Q9d612 mus musculu
Q96182 plasmodium
Q9m0r7 arabidopsis
Q80106 schizosacch
Q9855 arabidopsis
Q86y15 homo sapien
Q67469 feldmannia
Q75162 homo sapien
Q8qld7 mamestra co

17 107 40.2 551 3 Q08109
18 105.5 39.7 515 10 Q961u7
19 104 39.1 610 5 Q20798
20 104 39.1 618 13 Q80318
21 104 39.1 639 5 Q21641
22 103.5 38.9 540 13 Q72x20
23 103 38.7 298 4 Q8teh6
24 103 38.7 575 11 Q80t88
25 103 38.7 579 4 Q96b5
26 103 38.7 612 11 Q96b1
27 103 38.7 612 11 Q96b1
28 103 38.7 616 4 Q8n3k3
29 103 38.7 616 4 Q96p33
30 103 38.7 617 4 Q8n6e8
31 103 38.7 617 4 Q86tm6
32 102 38.3 328 5 Q9viw5
33 102 38.3 351 5 Q9nxf3
34 101.5 38.2 161 10 Q9nfs8
35 101.5 38.2 237 4 Q96a37
36 101.5 38.2 459 3 Q7za17
37 101 38.0 496 11 Q9d612
38 101 38.0 587 5 Q96182
39 100.5 37.8 132 10 Q9m0r7
40 100.5 37.8 486 3 Q80106
41 100.5 37.8 496 10 Q9855
42 100.5 37.8 652 4 Q86y15
43 100.5 37.8 673 12 Q67469
44 100.5 37.8 1208 4 Q75162
45 100 37.6 168 12 Q8qld7

ALIGNMENTS

RESULT 1
Q9NVD5 PRELIMINARY; PRT; 623 AA.
ID Q9NVD5
AC Q9NVD5; 01-OCT-2000 (TREMBLrel. 15, Created)
DT 01-OCT-2000 (TREMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Hypothetical protein FLJ10796.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Aotsuka S., Yoshikawa Y.,
RA Matsunawa H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,
RA Nakamura Y., Nagahari K., Masuho Y., Sasaki N.;
RT "NEDO human cDNA sequencing project."
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR ENBL: AK001658; BAA91817.1; -
DR InterPro: IPR000253; FHA.
DR InterPro: IPR008984; SMAD_FHA.
DR Pfam: PF00498; FHA; 1.
DR Pfam: PF00097; zf-C3HC4; 1.
DR SMART: SM00240; FHA; 1.
DR SMART: SM00184; RING; 1.
DR PROSITE: PS00066; FHA_DOMAIN; 1.
DR PROSITE: PS00518; ZF_RING_1; 1.
DR PROSITE: PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 623 AA; 69204 MW; 45186D33DAE52711 CRC64;

Query Match 100.0%; Score 266; DB 4; Length 623;
Best Local Similarity 100.0%; Pred. No. 4, 9e-27;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model
Run on: May 7, 2004, 14:40:47 ; Search time 6.36536 Seconds
(without alignments)
2180.991 Million cell updates/sec

Title: US-10-048-046-2_COPY_303_346
Perfect score: 266
Sequence: 1 TCICQDLLHDCVSLQPCMH.....ACYSGMWERSLCLPTCRCPV 44

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

- Database : SPTREMBL 25;*
- 1: sp_archea:*
 - 2: sp_bacteria:*
 - 3: sp_fungi:*
 - 4: sp_human:*
 - 5: sp_invertebrate:*
 - 6: sp_mammal:*
 - 7: sp_mhc:*
 - 8: sp_organelle:*
 - 9: sp_phase:*
 - 10: sp_plant:*
 - 11: sp_rodent:*
 - 12: sp_virus:*
 - 13: sp_vertebrate:*
 - 14: sp_unclassified:*
 - 15: sp_virus:*
 - 16: sp_bacteriap:*
 - 17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	266	100.0	623	4	Q9NVD5	Q9nvd5 homo sapien
2	266	100.0	652	4	Q96SL3	Q96sl3 homo sapien
3	266	100.0	652	4	Q96EP1	Q96ep1 homo sapien
4	266	100.0	663	11	Q8BJZ9	Q8bjz9 mus musculu
5	266	100.0	664	4	Q9NRT4	Q9nrt4 homo sapien
6	266	100.0	664	11	Q810L3	Q810l3 mus musculu
7	135	50.8	473	10	Q9SX88	Q9sx88 arabidopsis
8	118	44.4	829	3	Q9NJ06	Q9nj06 neurospora
9	115	43.2	178	11	Q8BZT0	Q8bzt0 mus musculu
10	115	43.2	241	11	Q8BCT0	Q8bct0 mus musculu
11	115	43.2	247	4	O15262	O15262 homo sapien
12	113.5	42.7	426	10	Q8LAK0	Q8lak0 arabidopsis
13	113.5	42.7	426	10	Q8L610	Q8l610 arabidopsis
14	110	41.4	498	12	O37928	O37928 feline herp
15	107.5	40.4	304	3	O13628	O13628 schizosacch
16	107.5	40.4	306	3	Q9UUF0	Q9uuf0 schizosacch

Matches 16; Conservative 6; Mismatches 21; Indels 2; Gaps 1;
 ID TRM3_MOUSE STANDARD; PRT; 744 AA.
 AC Q9R1R2;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 15-MAR-2004 (Rel. 43, Last annotation update)
 DE Tripartite motif protein 3 (RING finger protein 22) (RING finger
 protein HACL1).
 GN TRM3 OR RNF22 OR HACL1.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Liver;
 RA Yanai K., Shimamoto Y., Hirota K., Fukamizu A.;
 RT "Cloning of a new co-activator with ring finger motif.";
 RL Submitted (AUG-1999) to the EMBL/GenBank/DBJ databases.
 RW [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21231161; PubMed=11331580;
 RA Raymond A., Meroni G., Pantozzi A., Merla G., Cairo S., Luzi L.,
 RA Riganelli D., Zanaria E., Messali S., Calnarca S., Guffanti A.,
 RA Minucci S., Pelicci P.G., Ballabio A.;
 RT "The tripartite motif family identifies cell compartments.";
 RL EMO J. 20:2140-2151(2001).
 RW [3]
 RP SEQUENCE FROM N.A.
 RX STRAIN=C57BL/6J; TISSUE=Embryo;
 RC MEDLINE=21085660; PubMed=11217851;
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaoka I.,
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 RA Fleischmann W., Gaasterland T., Glissi C., King B., Kochiwa H.,
 RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,
 RA Schriml L.M., Staib F., Suzuki R., Tonita M., Wagner L., Washio T.,
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
 RA Wyshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
 RA Hayashizaki Y.;
 RT "Functional annotation of a full-length mouse cDNA collection.";
 RN Nature 409:685-690(2001).
 RW [4]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Retina;
 RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grove L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahey J., Helton B., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,
 RA Whiting M., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalius D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 CC -1- SUBUNIT: Associates with myosin V and alpha-actinin-4 (By
 similarity).
 CC -1- SIMILARITY: Contains 1 RING-type zinc finger.
 CC -1- SIMILARITY: Contains 1 B box-type zinc finger.
 CC -1- SIMILARITY: Contains 1 filament repeat.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).
 EMBL; AB030312; BAA83343.1; -;
 EMBL; AP220019; AAG53473.1; -;
 EMBL; AK019165; BAB31580.1; -;
 EMBL; BC034263; AAB34263.1; -;
 DR HSSP; P29590; 1EOR.
 DR MGD; MGI:1860040; Trim3.
 DR GO; GO:0005737; C:cytoplasm; IDA.
 DR GO; GO:0005515; F:protein binding; IPI.
 DR InterPro; IPR003649; Bbox_C.
 DR InterPro; IPR001298; Filamin.
 DR InterPro; IPR007110; IG-like.
 DR InterPro; IPR001258; NHL.
 DR InterPro; IPR000315; Znf_Bbox.
 DR InterPro; IPR001841; Znf_Ring.
 DR Pfam; PF00630; Filamin; 1.
 DR Pfam; PF01436; NHL; 6.
 DR Pfam; PF00643; Zf-B_box; 1.
 DR Pfam; PF00097; Zf-C3HC4; 1.
 DR SMART; SM00502; BBC; 1.
 DR SMART; SM00336; BBOX; 1.
 DR SMART; SM00557; IG_FLMN; 1.
 DR SMART; SM00184; RING; 1.
 DR PROSITE; PS00194; FILAMIN_REPEAT; 1.
 DR PROSITE; PS00119; ZF_BBOX; 1.
 DR PROSITE; PS00518; ZF_RING_1; 1.
 DR PROSITE; PS00089; ZF_RING_2; 1.
 KW Zinc-finger; Coiled Coil.
 FT ZN FING 22 63 RING-TYPE.
 FT ZN FING 110 151 B_BOX-TYPE.
 FT DOMAIN 153 224 COILED COIL (POTENTIAL).
 FT REPEAT 317 418 FILAMIN.
 FT SEQUENCE 744 AA; 80774 MW; D9AEF4FA264BA168 CRC64;
 Query Match 36.1%; Score 96; DB 1; Length 744;
 Best Local Similarity 41.9%; Pred. No. 0.00078;
 Matches 18; Conservative 5; Mismatches 16; Indels 4; Gaps 2;
 Qy 2 CIIQCQLLHDCVSLQPCMHFTFCACACVSGWMSRL---CPTCR 41
 Db 22 CSICLD-RYRCPKVLPCILHTFCERCLQNYTPQSLTSLSCPVC 63
 Search completed: May 7, 2004, 14:46:33
 Job time : 2.4868 secs

ID AC Q9YK7; Q9E011; STANDARD; PRT; 154 AA.
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE RING finger protein 11 (Sidi669) (Nedd4 WW domain-binding protein 2).
GN RNF11 OR N4WBP2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20135600; PubMed=10673045;
RA Seki N., Hattori A., Hayashi A., Kozuma S., Sasaki M., Suzuki Y.,
RA Sugano S., Muramatsu M., Saito T.,
RT "Cloning and expression profile of mouse and human genes, Rnf11/RNF11,
RT encoding a novel RING-H2 finger protein";
RL Biochim. Biophys. Acta 1489:421-427(1999).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=20498735; PubMed=11042109;
RA Jolliffe C.N., Harvey K.F., Haines B.P., Parasivam G., Kumar S.;
RT "Identification of multiple proteins expressed in murine embryos as
RT binding partners for the WW domains of the ubiquitin-protein ligase
RT Nedd4";
RL Biochem. J. 351:557-565 (2000).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22389257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gnaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S., Krywinski W.I., Skalska U., Smalusz D.E.,
RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -1- SUBUNIT: Interacts with NEDD4.
CC -1- SIMILARITY: Contains 1 RING-type zinc finger.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AB024427; BA94682.1; -
CC EMBL; AF220206; AAG44245.1; ALT_INIT.
CC EMBL; BC010299; AAH10299.1; -
CC GGD; MGI:135759; Rnf11.
CC GO; GO:000151; C:ubiquitin ligase complex; IPI.
CC GO; GO:0005515; F:protein binding; IPI.
CC GO; GO:0006511; P:ubiquitin-dependent protein catabolism; IPI.
CC InterPro; IPR001841; Znf_ring.
CC Pfam; PF00097; zf-C3HC4; 1.
CC SMART; SM00184; RING; 1.
CC PROSITE; PS00518; ZF_RING_1; FALSE_NEG.
CC PROSITE; PS50089; ZF_RING_2; 1.

KW Zinc-finger.
FT ZN_FING 99 140 RING-TYPE.
SQ SEQUENCE 154 AA; 17458 MW; EF192AB0C2D4BF87 CRC64;

Query Match 36.5%; Score 97; DB 1; Length 154;
Best Local Similarity 40.0%; Pred. No. 0.00015;
Matches 18; Conservative 7; Mismatches 18; Indels 2; Gaps 2;

QY 2 CIIIC-QDLH-DCVSLQFCMHTFCAACYSGWMERSLCTPCRPV 44
DB 99 CVICWMDFFVGDPIRFLPCMHYHLDICDDLMRSLFTCPSCMBPV 143

RESULT 14
ICP0_HSV2H
ID ICP0_HSV2H STANDARD; PRT; 825 AA.
AC P28284;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Trans-acting transcriptional protein ICP0 (VMW118 protein).
GN RL2.
OS Herpes simplex virus (type 2 / strain HG52).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Simplexvirus.
OX NCBI_TaxID=10315;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92113549; PubMed=1662697;
RA McGeoch D.J., Cunningham C., McIntyre G., Dolan A.;
RT "Comparative sequence analysis of the long repeat regions and
RT adjoining parts of the long unique regions in the genomes of herpes
RT simplex viruses types 1 and 2";
RL J. Gen. Virol. 72:3057-3075(1991).
RN [2]
RP SEQUENCE FROM N.A.
RA Dolan A.;
RL Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: Contains 1 RING-type zinc finger.
CC -1- SIMILARITY: TO OTHER HERPESVIRUSES ICP0 PROTEIN.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; D10471; BAA23427.1; -
CC EMBL; Z86099; CAB06760.1; -
CC PIR; JQ1501; EDBEXD.
CC HSP; P28990; 1CHC.
CC InterPro; IPR001841; Znf_ring.
CC Pfam; PF00097; zf-C3HC4; 1.
CC SMART; SM00184; RING; 1.
CC PROSITE; PS00518; ZF_RING_1; 1.
CC PROSITE; PS50089; ZF_RING_2; 1.
KW Transcription regulation; Trans-acting factor; Activator; Zinc-finger;
KW DNA-binding.
FT DOMAIN 120 123 POLY-GLY.
FT ZN_FING 126 167 RING-TYPE.
FT DOMAIN 266 271 POLY-GLY.
FT DOMAIN 292 295 POLY-SER.
FT DOMAIN 342 345 POLY-ALA.
FT DOMAIN 386 389 POLY-SER.
FT DOMAIN 395 400 POLY-GLY.
FT DOMAIN 425 428 POLY-ALA.
FT DOMAIN 530 627 POLY-SER.
SQ SEQUENCE 825 AA; 81986 MW; 5CEB15858553A274 CRC64;

Query Match 36.5%; Score 97; DB 1; Length 825;
Best Local Similarity 35.6%; Pred. No. 0.00066;

[3] STRUCTURE BY NMR OF 1-63.
 RX MEDLINE=941172642; PubMed=9126734;
 RA Barlow P.N., Luisi B., Milner A., Elliott M., Everett R.D.;
 RT "Structure of the C3HC4 domain by 1H-nuclear magnetic resonance
 spectroscopy. A new structural class of zinc-finger.";
 RL J. Mol. Biol. 237:201-211(1994).
 CC -1- SIMILARITY: Contains 1 RING-type zinc finger.
 CC -1- SIMILARITY: TO OTHER HERPESVIRUSES ICP0 PROTEIN.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).
 CC ENBL; M86664; AAB02498.1; --
 DR PIR; I36801; WZBEP5.
 DR PDB; 1CHC; 30-APR-94.
 DR InterPro; IPR001841; Znf_ring.
 DR Pfam; PF00097; zf-C3HC4; 1.
 DR SMART; SM00184; RING; 1.
 DR PROSITE; PS00518; ZF_RING_1; 1.
 DR PROSITE; PS00089; ZF_RING_2; 1.
 DR Transcription regulation; Trans-acting factor; Activator; Zinc-finger;
 KW DNA-binding; 3D-structure.
 FT ZN FING 8 47 RING-TYPE.
 FT METAL 8 47 ZINC 1.
 FT METAL 11 11 ZINC 1.
 FT METAL 24 24 ZINC 2.
 FT METAL 26 26 ZINC 1.
 FT METAL 29 29 ZINC 1.
 FT METAL 32 32 ZINC 1.
 FT METAL 43 43 ZINC 2.
 FT METAL 46 46 ZINC 2.
 FT METAL 210 217 POLY-SER.
 FT DOMAIN 19 21 STRAND
 FT TURN 22 25
 FT STRAND 26 28
 FT TURN 30 31
 FT TURN 32 39
 FT HELIX 43 46
 FT TURN 43 46
 FT STRAND 53 54
 SQ SEQUENCE 532 AA; 58629 MW; B4CB7E16FA26FDFA CRC64;
 Query Match 36.8%; Score 98; DB 1; Length 532;
 Best Local Similarity 34.9%; Pred. No. 0.00034;
 Matches 15; Conservative 8; Mismatches 20; Indels 0; Gaps 0;
 QY 2 CIIICDILLHDCVSLQPCWHFTCAACYSGWMSRLCFTCRCPV 44
 Db 8 CPICLEDPSNYSMALPCLHAFYCYVITRWIRQNPTCLKVPV 50
 RESULT 12
 RN11 HUMAN
 ID RN11 HUMAN STANDARD; PRT; 154 AA.
 AC Q9Y3C5;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE RING finger protein.11 (Sld1669) (CGI-123).
 GN RN11.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20135600; PubMed=10673045;
 RA Seki N., Hattori A., Hayashi A., Kozuma S., Sasaki M., Suzuki Y.,

RA Sugano S., Muramatsu M., Saito T.;
 RT "Cloning and expression profile of mouse and human genes. Rnf11/RNF11,
 encoding a novel RING-H2 finger protein.";
 RL Biochim. Biophys. Acta 1489:421-427(1999).
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20272150; PubMed=10810093;
 RA Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.;
 RT "Identification of novel human genes evolutionarily conserved in
 Caenorhabditis elegans by comparative proteomics.";
 RL Genome Res. 10:703-713(2000).
 CC -1- SIMILARITY: TO OTHER HERPESVIRUSES ICP0 PROTEIN.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).
 CC ENBL; AB024703; BAA84683.1; --
 DR ENBL; AF151881; AAD34118.1; --
 DR ENBL; BC020964; AAH20964.1; --
 DR ENBL; BC047654; AAH47654.1; --
 DR Genew; HGNC:10056; RNF11.
 DR GO; GO:0003677; P.DNA binding; TAS.
 DR GO; GO:0008270; P.zinc ion binding; TAS.
 DR InterPro; IPR001841; Znf_ring.
 DR Pfam; PF00097; zf-C3HC4; 1.
 DR SMART; SM00184; RING; 1.
 DR PROSITE; PS00518; ZF_RING_1; FALSE_NEG.
 DR PROSITE; PS00089; ZF_RING_2; 1.
 KW Zinc-finger.
 FT ZN FING 99 140 RING-TYPE
 FT SEQUENCE 154 AA; 17444 MW; C36E38148FC1D0D CRC64;
 Query Match 36.5%; Score 97; DB 1; Length 154;
 Best Local Similarity 40.0%; Pred. No. 0.00015;
 Matches 18; Conservative 7; Mismatches 18; Indels 2; Gaps 2;
 QY 2 CIIICDILLHDCVSLQPCWHFTCAACYSGWMSRLCFTCRCPV 44
 Db 99 CVICMMDFTVIGDPIFLPCWHYHLDICDDWLMRSFTFCSCMEPV 143
 RESULT 13
 RN11 MOUSE

FT SQ SEQUENCE 744 AA; 80836 MW; 3338151B7368B37E CRC64; /FTID=VSP_005759.

Query Match 37.2%; Score 99; DB 1; Length 744;
Best Local Similarity 41.9%; Pred. No. 0.00036;
Matches 18; Conservative 5; Mismatches 16; Indels 4; Gaps 2;

OY 2 CIIQDLHDCVSLQPCVHTFCACACYSQWMSRL---CPTCR 41
DB 22 CSICLD-RYQCKVLPCLTFCERCLQNVIPAQSILTSQPCVR 63

RESULT 10

CBLC HUMAN STANDARD; PRT; 474 AA.

AC Q9ULV8; Q9Y5Z2; Q9Y5Z3;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DE 15-MAR-2004 (Rel. 43, Last annotation update)
DE Signal transduction protein CBL-C (SH3-binding protein CBL-C) (CBL-3).
GN CBL3 OR CBL3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A. (ISOFORM LONG).
RP MEDLINE=20035621; PubMed=10571044;
RA Kim M., Tezuka T., Suzuki Y., Sugano S., Hirai M., Yamamoto T.;
RX "Molecular cloning and characterization of a novel cbl-family gene,
RT cbl-c".
RL Gene 239:145-154 (1999).
[2]
SEQUENCE FROM N.A. (ISOFORMS LONG AND SHORT).
RP TISSUE=Pancreatic adenocarcinoma;
RC MEDLINE=99289203; PubMed=10362357;
RA Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M.,
RA Penninger J., Lipkowitz S.;
RT "Cbl-3: a new mammalian cbl family protein.";
RL Oncogene 18:3365-3375 (1999).
CC -1- FUNCTION: Regulator of EGFR mediated signal transduction.
CC -1- SUBUNIT: Interacts with a restricted range of SH3 domain proteins.
CC -1- SUBCELLULAR LOCATION: Nuclear (Potential).
CC -1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=Long;
CC IsoId=Q9ULV8-1; Sequence=Displayed;
CC Name=Short;
CC IsoId=Q9ULV8-2; Sequence=VSP_005732;
CC TISSUE SPECIFICITY: Ubiquitous.
CC -1- DOMAIN: The N-terminus is composed of the phosphotyrosine binding
CC (PTB) domain, a short linker region and the RING-type zinc finger.
CC The PTB domain, which is also called TKB (tyrosine kinase binding)
CC domain, is composed of three different subdomains: a four-helix
CC bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
CC -1- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC ubiquitin-conjugating enzyme (By similarity).
CC -1- PTM: Phosphorylated on tyrosines by EGFR.
CC -1- MISCELLANEOUS: This protein has one functional calcium-binding
CC site (By similarity).
CC -1- SIMILARITY: Contains 2 EF-hand-like calcium-binding domains.
CC -1- SIMILARITY: Contains 1 RING-type zinc finger.
CC -1- SIMILARITY: Contains 1 SH2 domain.
CC -1- DATABASE: NAME=Atlas Genet. Cytogenet. Oncol. Haematol.;
CC WWW="http://www.infobiogen.fr/services/Chromancer/Genes/CBLCID194.html".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>)
CC or send an email to license@isb-sib.ch.

CC EMBL; AB028645; BAA86298.1; --
DR EMBL; AF117646; AAD34341.1; --
DR EMBL; AF117647; AAD34342.1; --
DR HSSP; P22681; 1B47.
DR Genew; HGNC:15961; CBLC.
DR GO; GO:0005515; F:protein binding; TAS.
DR GO; GO:0008270; F:zinc ion binding; TAS.
DR GO; GO:0007175; P:negative regulation of EGF receptor activity; TAS.
DR GO; GO:0006468; P:protein amino acid phosphorylation; TAS.
DR InterPro; IPR003153; Cbl_N.
DR InterPro; IPR000980; SH2.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF02761; Cbl_N2; 1.
DR Pfam; PF02762; Cbl_N3; 1.
DR Pfam; PF02862; Cbl_N; 1.
DR Pfam; PF02862; Cbl_N; 1.
DR SMART; SM00184; RING; 1.
DR SMART; SM00252; SH2; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
DR Nuclear protein; Zinc-finger; Phosphorylation; Alternative splicing;
KW SH2 domain; Calcium-binding. PTB.
FT DOMAIN 8 327
FT DOMAIN 8 147
FT DOMAIN 182 190
FT CA_BIND 199 210
FT CA_BIND 237 311
FT DOMAIN 312 350
FT ZN_FING 351 390
FT DOMAIN 89 92
FT BINDING 264 264
FT VARSPLIC 261 306
FT CONFLICT 234 234
FT SEQUENCE 474 AA; 52468 MW; 91013DDF12828242 CRC64;
T -> N (IN REF. 2).
Query Match 36.8%; Score 98; DB 1; Length 474;
Best Local Similarity 38.6%; Pred. No. 0.00031;
Matches 17; Conservative 6; Mismatches 19; Indels 2; Gaps 2;

OY 2 CIIQDLHDCVSLQPCVHTFCACACYSQWMSRL---CPTCR 44
DB 351 CKIAESNKD-VKIEPCGHLCLCCLAAWQHSQTCFCRCI 393

RESULT 11

ICP0_HSVEB STANDARD; PRT; 532 AA.

AC P28950.
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Trans-acting transcriptional protein ICP0.
GN ICP0.
OS Equine herpesvirus type 1 (strain Ab4p) (EHV-1).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Varicellovirus.
OX NCBI_TaxID=31520;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92295566; PubMed=1318606;
RA Telford E.A.R., Watson M.S., McBride K., Davison A.J.;
RT "The DNA sequence of equine herpesvirus-1";
RL Virology 189:304-316 (1992).
RN [2]
RP STRUCTURE BY NMR OF 1-63.
RX MEDLINE=94087718; PubMed=8263911;
RA Everett R.D., Barlow P.N., Milner A., Luisi B., Orr A., Hope G.,
RA Lyon D.;
RT "A novel arrangement of zinc-binding residues and secondary structure
RT in the C3HC4 motif of an alpha herpes virus protein family";
RL J. Mol. Biol. 234:1038-1047 (1993).

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.P., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldi M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gurnaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Kzywinski M.I., Skalska U., Smalish D.E.,
RA Schnarch A., Schein J.E., Jones S.J.M., Marra M.A.,
RA RT and mouse cDNA sequences.
RT generation and initial analysis of more than 15,000 full-length human
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: Functions as a ubiquitin ligase protein in vitro.
CC -!- SUBUNIT: Homodimer and heterodimer. Can heterodimerize with DTX1,
CC enhancing its ubiquitin ligase activity in vitro. Interacts with
CC BAL. Found in a complex with MYO6.
CC -!- SIMILARITY: Belongs to the Deltex family.
CC -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF484416; AAL90859.1; -;
DR EMBL; AC042191; AAL42191.1; -;
DR InterPro; IPR002350; kazal.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS30089; ZF_RING_2; 1.
KW Metal-binding; Zinc; Zinc-finger.
FT ZN FING 561 600 RING-TYPE.
FT ZN FING 740 AA; 83554 MW; C413BB744CBE6223 CRC64;
SQ
Query Match 37.2%; Score 99; DB 1; Length 740;
Best Local Similarity 40.0%; Pred.No. 0.00035;
Matches 16; Conservative 6; Mismatches 18; Indels 0; Gaps 0;
QY 2 CIIICDILHDCVSLQPCWHFCAACYSGWERSSLCPTCR 41
Db 561 CVICMDTISNKKVLKCKHFEFCAPCINKMSYKPCPTCQ 600
RESULT 9
TM3 HUMAN STANDARD; PRT; 744 AA.
AC Q53382; Q9C038; Q9C039;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Tripartite motif protein 3 (RING finger protein 22) (Brain-expressed
DE ring finger protein).
GN TRIM3 OR RNF22 OR BERP.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM ALPHA).
RT TISSUE=Brain;

RX MEDLINE=211100911; PubMed=11170753;
RA El-Husseini A.E.-D., Fretier P., Vincent S.R.;
RT "Cloning and characterization of a gene (RNF22) encoding a novel brain
RT expressed ring finger protein (BERP) that maps to human chromosome
RT 11p15.5".
RL Genomics 71:363-367(2001).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORMS ALPHA; BETA AND GAMMA).
RX MEDLINE=21231161; PubMed=11331580;
RA Raymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L.,
RA Rignelli D., Zanaria E., Messali S., Cainarca S., Guffanti A.,
RA Minucci S., Pellicci P.G., Ballabio A.;
RT "The tripartite motif family identifies cell compartments.";
RL EMBO J. 20:2140-2151(2001).
CC -!- SUBUNIT: Associates with myosin V and alpha-actinin-4 (By
CC similarity).
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=Alpha;
CC IsoId=075382-1; Sequence=Displayed;
CC Name=Beta;
CC IsoId=075382-2; Sequence=VSP_005758;
CC Name=Gamma;
CC IsoId=075382-3; Sequence=VSP_005759;
CC -!- TISSUE SPECIFICITY: Expressed in brain, heart, uterus and testis.
CC -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC -!- SIMILARITY: Contains 1 B-box-type zinc finger.
CC -!- SIMILARITY: Contains 1 filamin repeat.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF045239; AAC34809.1; -;
DR EMBL; AF220020; AAG53474.1; -;
DR EMBL; AF220021; AAG53475.1; -;
DR EMBL; AF220022; AAG53476.1; -;
DR HSP; P29590; IBOR.
DR Genew; HGNC:10064; TRIM3.
DR MIM; 605493; -;
DR GO; GO:0005737; C:cytoplasm; TAS.
DR GO; GO:0008022; F:protein C-terminus binding; TAS.
DR GO; GO:0007393; P:neurogenesis; TAS.
DR InterPro; IPR003649; Bbox_C.
DR InterPro; IPR001298; Filamin.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR001258; NHL.
DR InterPro; IPR000315; Znf_Bbox.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00630; Filamin; 1.
DR Pfam; PF01436; NHL; 6.
DR Pfam; PF00643; ZF-B_Box; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00502; BBC; 1.
DR SMART; SM00336; BBOX; 1.
DR SMART; SM00557; IG_FLN; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00194; FILAMIN_REPEAT; 1.
DR PROSITE; PS00119; ZF_BBOX; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Zinc-finger; Coiled coil; Alternative splicing.
FT ZN FING 22 63 RING-TYPE.
FT ZN FING 110 151 B_BOX-TYPE.
FT ZN FING 153 224 COILED COIL (POTENTIAL).
FT DOMAIN 317 418 FILAMIN.
FT REPEAT 146 156 Missing (in isoform Beta).
FT VARSPLIC 224 302 /FTID=VSP_005758.
FT VARSPLIC 224 302 Missing (in isoform Gamma).

CC -1- SIMILARITY: Contains 1 RING-type zinc finger.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC -----

CC EMBL; U23511; AAC6798.2; -

CC DR WormPep; C32D5.10; CE29688.

CC DR InterPro; IPR001841; Znf_fing.

CC DR Pfam; PF00097; zf-C3HC4; 1.

CC DR SMART; SM00184; RING; 1.

CC DR PROSITE; PS00518; ZF_RING_1; 1.

CC DR PROSITE; PS00089; ZF_RING_2; 1.

CC KW Hypothetical protein; Zinc-finger.

CC FT ZN_FING 41 82 RING-TYPE.

CC FT DOMAIN 451 499 ASFP-RICH.

CC SQ SEQUENCE 610 AA; 68276 MW; 60166BSPD59AE806F CRC64;

Query Match 41.4%; Score 110; DB 1; Length 610;

Best Local Similarity 40.0%; Pred. No. 1.7e-05;

Matches 18; Conservative 7; Mismatches 18; Indels 2; Gaps 1;

CC

QY 2 CIIQDILLHDCVSLQPCWHTFCAACYSGWMSRSLCPTCR 44

DB 41 CSVKCKEIIITSLSCCHEFCYDCIVGLTWLTKSGGFFPCMKPTPV 95

RESULT 5

ID RNFB HUMAN STANDARD; PRT; 485 AA.

AC C76084; DB 1; Length 485;

DT 28-FEB-2003 (Rel. 41, Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE RING finger protein 8.

GN RNFB OR KIA00646.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.

OX NCBI_TaxID=9606;

[1] SEQUENCE FROM N.A.

RN TISSUE=Brain;

RP "Isolation and chromosomal assignment of the gene for a novel zinc

RT finger protein."

RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.

RL [2] SEQUENCE FROM N.A.

RP TISSUE=Brain;

RC MEDLINE=98403880; PubMed=9734811;

RX Ishikawa K.-I., Nagase T., Suyama M., Miyajima N., Tanaka A.,

RA Kotani H., Nomura N., Ohara O.;

RA "Prediction of the coding sequences of unidentified human genes. X.

RT The complete sequences of 100 new cDNA clones from brain which can

RT code for large proteins in vitro."

RL DNA Res. 5:169-176(1998).

[3] SEQUENCE FROM N.A.

RN Tracey A.;

RP Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.

RL [4] SEQUENCE FROM N.A.

RP TISSUE=Muscle;

RC MEDLINE=22388257; PubMed=12477932;

RX Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

RA Altschul S.F., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA

Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,

RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Villalón D.K., Muzny K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Richardson D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,

RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;

RT "Generation and initial analysis of more than 15,000 full-length

RT human and mouse cDNA sequences."

RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

CC -1- SIMILARITY: Contains 1 FHA domain.

CC -1- SIMILARITY: Contains 1 RING-type zinc finger.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC -----

CC EMBL; AB012770; BAA33557.1; -

CC DR EMBL; AB014546; BAA31621.1; -

CC DR EMBL; AL096712; CAB75689.1; -

CC DR EMBL; BC007517; AAH07517.1; -

CC DR Genew; HGNC:10071; RNFB.

CC DR InterPro; IPR000253; FFA.

CC DR InterPro; IPR008384; SMAD FFA.

CC DR InterPro; IPR001841; Znf_fing.

CC DR Pfam; PF00498; FFA; 1.

CC DR Pfam; PF00097; ZF-C3HC4; 1.

CC DR SMART; SM00184; RING; 1.

CC DR SMART; SM00184; RING; 1.

CC DR PROSITE; PS00006; FFA DOMAIN; 1.

CC DR PROSITE; PS00518; ZF_RING_1; 1.

CC DR PROSITE; PS00089; ZF_RING_2; 1.

CC KW Zinc-finger.

CC FT DOMAIN 38 92 FFA.

CC FT DOMAIN 276 345 GLN-RICH.

CC FT ZN_FING 403 441 RING-TYPE.

CC SQ SEQUENCE 485 AA; 55517 MW; 54650B2FFC9948B1 CRC64;

Query Match 40.8%; Score 108.5; DB 1; Length 485;

Best Local Similarity 45.0%; Pred. No. 2e-05;

Matches 18; Conservative 7; Mismatches 14; Indels 1; Gaps 1;

QY 2 CIIQDILLHDCVSLQPCWHTFCAACYSGWMSRSLCPTCR 41

DB 403 CIISEYFIEAVTLN-CAHSFCSYCNEMWKRKIECPICR 441

RESULT 6

ID RNFB MOUSE STANDARD; PRT; 488 AA.

AC Q8VC56; DB 1; Length 488;

DT 28-FEB-2003 (Rel. 41, Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE RING finger protein 8.

GN RNFB.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN [1] SEQUENCE FROM N.A.

RP TISSUE=Kidney;

RA

QY 1 TCICQDLHDCVSLQPCMTFCACYSGWMSRLCPTCRCPV 44
DB 18 TCTICMTSVSLGKTMCLHDFCVCIRAWITSTSVQCPLCRCPV 61

RESULT 2
ICPO_HSVBJ
ID ICPO_HSVBJ STANDARD; PRT; 676 AA.
AC P29128;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Trans-acting transcriptional protein ICPO (P135 protein) (IER 2.9/ER2.6).
GN BICPO.
OS Bovine herpesvirus type 1 (strain Jura).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Varicellovirus.
OX NCBI_TaxID=31518;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92219360; PubMed=1313901;
RA With U.V., Fraefel C., Vogt B., Vlcek C., Paces V., Schwyzer M.;
RT "Immediate-early RNA 2.9 and early RNA 2.6 of bovine herpesvirus 1
are 3' coterminal and encode a putative zinc finger transactivator
protein.";
RL J. Virol. 66:2763-2772(1992).
CC -!- PTM: THE STRONGLY ACIDIC REGION MIGHT SERVE AS A TRANSCRIPTIONAL
ACTIVATION DOMAIN, POSSIBLY REGULATED THROUGH PHOSPHORYLATION BY
CASEIN KINASE II.
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
CC -!- SIMILARITY: TO OTHER HERPESVIRUSES ICPO PROTEIN.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL Outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC
CC EMBL; M84465; AAA46062.1; --
CC PIR; B38209; EDRE23.
CC HSPF; P28990; 1CHC.
CC InterPro; IPR001841; Znf_ring.
CC Pfam; PF00097; zf-C3HC4; 1.
CC SMART; SM00184; RING; 1.
CC PROSITE; PS00518; ZF_RING_1; 1.
CC PROSITE; PS00089; ZF_RING_2; 1.
KW Transcription regulation; Trans-acting factor; Activator; Zinc-finger;
KW DNA-binding; Early protein; Repressor; Phosphorylation.
FT ZNFING 13 52 RING-TYPE.
FT DOMAIN 284 331 ASP/GLU-RICH (ACIDIC).
SQ SEQUENCE 676 AA; 67879 MW; 11B06BA4E5C4EB71 CRC64;
Query Match 44.7%; Score 119; DB 1; Length 676;
Best Local Similarity 40.9%; Pred. No. 1.7e-06;
Matches 18; Conservative 5; Mismatches 21; Indels 0; Gaps 0;
QY 1 TCICQDLHDCVSLQPCMTFCACYSGWMSRLCPTCRCPV 44
DB 12 SCCICLDAITGAARALPCLHAFCLACIRRWLEGRPTCLCAPV 55

RESULT 3
ICPO_HSVBK
ID ICPO_HSVBK STANDARD; PRT; 676 AA.
AC P29836;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Trans-acting transcriptional protein ICPO (P135 protein) (IER

DE 2.9/ER2.6).
GN BICPO.
OS Bovine herpesvirus type 1 (strain K22).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Varicellovirus.
OX NCBI_TaxID=31519;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92219360; PubMed=1313901;
RA With U.V., Fraefel C., Vogt B., Vlcek C., Paces V., Schwyzer M.;
RT "Immediate-early RNA 2.9 and early RNA 2.6 of bovine herpesvirus 1
are 3' coterminal and encode a putative zinc finger transactivator
protein.";
RL J. Virol. 66:2763-2772(1992).
CC -!- PTM: THE STRONGLY ACIDIC REGION MIGHT SERVE AS A TRANSCRIPTIONAL
ACTIVATION DOMAIN, POSSIBLY REGULATED THROUGH PHOSPHORYLATION BY
CASEIN KINASE II.
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
CC -!- SIMILARITY: TO OTHER HERPESVIRUSES ICPO PROTEIN.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL Outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC
CC EMBL; M84464; AAA46061.1; --
CC PIR; A38209; EDSE22.
CC HSPF; P28990; 1CHC.
CC InterPro; IPR001841; Znf_ring.
CC Pfam; PF00097; zf-C3HC4; 1.
CC SMART; SM00184; RING; 1.
CC PROSITE; PS00518; ZF_RING_1; 1.
CC PROSITE; PS00089; ZF_RING_2; 1.
KW Transcription regulation; Trans-acting factor; Activator; Zinc-finger;
KW DNA-binding; Early protein; Repressor; Phosphorylation.
FT ZNFING 13 52 RING-TYPE.
FT DOMAIN 284 331 ASP/GLU-RICH (ACIDIC).
SQ SEQUENCE 676 AA; 67701 MW; 9BB0683C9BFC65D CRC64;
Query Match 44.7%; Score 119; DB 1; Length 676;
Best Local Similarity 40.9%; Pred. No. 1.7e-06;
Matches 18; Conservative 5; Mismatches 21; Indels 0; Gaps 0;
QY 1 TCICQDLHDCVSLQPCMTFCACYSGWMSRLCPTCRCPV 44
DB 12 SCCICLDAITGAARALPCLHAFCLACIRRWLEGRPTCLCAPV 55

RESULT 4
YQDA_CAEEL
ID YQDA_CAEEL STANDARD; PRT; 610 AA.
AC Q03268;
DT 01-NOV-1997 (Rel. 35, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Hypothetical RING finger protein C32D5.10 in chromosome II.
GN C32D5.10
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditidae;
OC Rhabditidae; Peleodermidae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Miller N.;
RL Submitted (JUL-1995) to the EMBL/GenBank/DBJ databases.
RN [2]
RP REVISIONS.
RA Waterston R.;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:37:32 ; Search time 1.4868 Seconds
(without alignments)
1540.951 Million cell updates/sec

Title: US-10-048-046-2_COPY_303_346

Perfect score: 266
Sequence: 1 TCTICQDILLHDCVSLQPCMH.....ACVSGHMERSSLCPTCRCPV 44

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	129	48.5	467	1	ICP0_VZVD
2	119	44.7	676	1	ICP0_HSVBJ
3	119	44.7	676	1	ICP0_HSVBK
4	110	41.4	610	1	YODA_CAEEL
5	108.5	40.8	485	1	RNF8_HUMAN
6	108.5	40.8	488	1	RNF8_MOUSE
7	103.5	38.9	564	1	VFES_CAEEL
8	99	37.2	740	1	BBAP_HUMAN
9	99	37.2	744	1	TRM3_HUMAN
10	98	36.8	474	1	CBLC_HUMAN
11	98	36.8	532	1	ICP0_HSVBB
12	97	36.5	154	1	RN11_HUMAN
13	97	36.5	154	1	RN11_MOUSE
14	97	36.5	825	1	ICP0_HSV2H
15	96	36.1	744	1	TRM3_MOUSE
16	96	36.1	744	1	TRM3_RAT
17	96	36.1	906	1	CSL_HUMAN
18	96	36.1	913	1	CSL_MOUSE
19	96	36.1	982	1	CSLE_HUMAN
20	95.5	35.9	643	1	AMF2_HUMAN
21	95.5	35.9	643	1	AMF2_MOUSE
22	95	35.7	410	1	ICP0_PRVIF
23	95	35.7	775	1	ICP0_HSV11
24	94	35.3	324	1	BM11_MOUSE
25	94	35.3	326	1	BM11_FELCA
26	94	35.3	326	1	BM11_HUMAN
27	93.5	35.2	407	1	RP12_HUMAN
28	92.5	34.8	387	1	RH18_SCHPO
29	92	34.6	488	1	RN23_MOUSE
30	92	34.6	518	1	RN23_HUMAN
31	91.5	34.4	605	1	RN23_MOUSE
32	91.5	34.4	643	1	PJAI_HUMAN
33	90.5	34.0	161	1	YODA_CAEEL

34	89.5	33.6	377	1	RNGL_HUMAN
35	88.5	33.3	443	1	UVSH_EMENI
36	88.5	33.3	493	1	TRM5_HUMAN
37	88.5	33.3	501	1	UVS2_NEUCR
38	88	33.1	342	1	ME18_MOUSE
39	88	33.1	344	1	ME18_HUMAN
40	87.5	32.9	337	1	PEXA_YEAST
41	87	32.7	481	1	RNF9_PANTR
42	87	32.7	482	1	RNF9_HUMAN
43	87	32.7	511	1	TRM7_HUMAN
44	87	32.7	1603	1	PSC_DROME
45	85.5	32.1	115	1	YBR2_YEAST

ALIGNMENTS

RESULT 1

ID	ICP0_VZVD	STANDARD;	PRT;	467 AA.
AC	P09309;			
DT	01-VAR-1989 (Rel. 10, Created)			
DT	01-VAR-1989 (Rel. 10, Last sequence update)			
DT	16-OCT-2001 (Rel. 40, Last annotation update)			
DE	Trans-acting transcriptional protein ICP0.			
GN	61.			
OS	Varicella-zoster virus (strain Dumas) (VZV).			
OC	Viruses; dsDNA viruses, no RNA stage; Herpesviridae;			
OC	Alphaherpesvirinae; Varicellovirus.			
OX	NCBI_TaxID=10338;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RX	MEDLINE=86306657; PubMed=3018124;			
RA	Davidson A.J., Scott J.E.;			
RT	"The complete DNA sequence of varicella-zoster virus.";			
RL	J. Gen. Virol. 67:1759-1816(1986).			
RN	[2]			
RP	CHARACTERIZATION.			
RX	MEDLINE=93059681; PubMed=1366099;			
RA	Moriuchi H., Moriuchi M., Smith H.A., Straus S.E., Cohen J.I.;			
RT	"Varicella-zoster virus open reading frame 61 protein is functionally homologous to herpes simplex virus type 1 ICP0.";			
RL	J. Virol. 66:7303-7308(1992).			
CC	-I- FUNCTION: REPRSES THE EXPRESSION OF VIRAL IE, EARLY, AND LATE GENE PROMOTERS.			
CC	-I- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.			
CC	-I- SIMILARITY: TO OTHER HERPESVIRUSES ICP0 PROTEIN.			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).			
CC	EMBL; X04370; CAA27944.1; -			
DR	PR; 127215; WZEE1.			
DR	HSP; P28990; ICHC.			
DR	InterPro; IPR001841; Znf_ring.			
DR	Pfam; PF00097; zf-C3HC4; 1.			
DR	SMART; SMC0184; RING; 1.			
DR	PROSITE; PS00518; ZF_RING_1; 1.			
DR	PROSITE; PS00089; ZF_RING_2; 1.			
KW	Transcription regulation; Trans-acting factor; Repressor; Zinc-finger; DNA-binding.			
FT	ZN FING 19 58			
SQ	SEQUENCE 467 AA; 50916 MW; 25EFA697EA6994C CRC64;			

Query Match 48.5%; Score 129; DB 1; Length 467;
Best Local Similarity 45.5%; Pred. No. 8.9e-08;
Matches 20; Conservative 2; Mismatches 22; Indels 0; Gaps 0;

A:Molecule type: DNA
A:Residues: 1-551 <HUG>
A:Cross-references: EMBL:Z74755; NID:G1419784; PID:e252259; PID:G1419785; MIPS:YOL013c
A:Experimental source: strain S288C
C:Genetics:
A:Gene: SGD:HRD1
A:Cross-references: SGD:S0005373; MIPS:YOL013c
A:Map position: 15L
A:Superfamily: RING finger homology
C:Keywords: transmembrane protein
F:10-26/Domain: transmembrane #status predicted <TM1>
F:46-62/Domain: transmembrane #status predicted <TM2>
F:105-121/Domain: transmembrane #status predicted <TM3>
F:144-160/Domain: transmembrane #status predicted <TM4>
F:185-201/Domain: transmembrane #status predicted <TM5>
F:345-405/Domain: RING finger homology <RRN>
Query Match 40.2%; Score 107; DB 2; Length 551;
Best Local Similarity 40.0%; Pred. No. 0.00097;
Matches 22; Conservative 2; Mismatches 19; Indels 12; Gaps 1;
QY 2 CIIICQDLHDCVSIQ-----PCMHFTCAACYSGWMERSLLCPTCRCPV 44
Db 349 CIIICWDELHSPNQTKWKNKPKRLPCGHILSLCKNWMERSQTCPIRLPV 403
RESULT 8
F84591
hypothetical protein At2g20650 [imported] - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C:Date: 02-Feb-2001 #sequence_revision 02-Feb-2001 #text_change 02-Feb-2001
C:Accession: F84591
R:Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.;
M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.A.; Vanaken, S.E.; Umayam, L.; Tallon, L.;
euss, D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter, J.
Nature 402, 761-768, 1999
A:Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.
A:Reference number: A84420; MUID:20083487; PMID:10617197
A:Accession: F84591
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-276 <STO>
A:Cross-references: GB:AB002093; NID:94512649; PIDN:AA021704.1; GSPDB:GN00139
C:Genetics:
A:Gene: At2g20650
A:Map position: 2
Query Match 39.7%; Score 105.5; DB 2; Length 276;
Best Local Similarity 42.9%; Pred. No. 0.00086;
Matches 21; Conservative 6; Mismatches 15; Indels 7; Gaps 3;
QY 2 CIIICQ---DLAH---DCVSLQPCMHFTCAACYSGWMERSLLCPTCRCPV 44
Db 226 CVICWTTIDLRINDCM-VTPCEHIFHSGCLQRMWDIKMECPTCRRL 273
RESULT 9
T22687
hypothetical protein F55A11.3 - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 02-Sep-2000
C:Accession: T22687
R:Kershaw, J.
submitted to the EMBL Data Library, May 1996
A:Reference number: Z19600
A:Accession: T22687
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-610 <WIL>
A:Cross-references: EMBL:Z72511; PIDN:CAA96657.1; GSPDB:GN00023; CESP:F55A11.3
A:Experimental source: clone F55A11
C:Genetics:
A:Gene: CESP:F55A11.3

A:Map position: 5
A:Introns: 76/3; 221/1; 275/2; 338/1; 424/3
A:Superfamily: RING finger homology
F:288-338/Domain: RING finger homology <RRN>
Query Match 39.1%; Score 104; DB 2; Length 610;
Best Local Similarity 41.3%; Pred. No. 0.0021;
Matches 19; Conservative 6; Mismatches 19; Indels 2; Gaps 1;
QY 1 TCIIICQDLHDCVSIQ---PCMHFTCAACYSGWMERSLLCPTCRCPV 44
Db 291 TCIIICREMTVDASPKRLPCSHVFAHCLRSWFORQOTCPTCRTDI 336
RESULT 10
T16648
hypothetical protein R02E12.4 - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 02-Sep-2000
C:Accession: T16648
R:Leimbach, D.
submitted to the EMBL Data Library, April 1996
A:Description: The sequence of C. elegans cosmid R02E12.
A:Reference number: Z18554
A:Accession: T16648
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-639 <LEI>
A:Cross-references: EMBL:U53337; NID:G1255833; PIDN:AAA96184.1; GSPDB:GN000
A:Experimental source: strain Bristol N2; clone R02E12
C:Genetics:
A:Gene: CESP:R02E12.4
A:Map position: X
A:Introns: 63/3; 90/1; 136/2; 177/1; 220/2; 242/3; 294/2; 427/2; 464/3; 505/3; 580/1
A:Superfamily: RING finger homology
F:22-70/Domain: RING finger homology <RRN>
Query Match 39.1%; Score 104; DB 2; Length 639;
Best Local Similarity 39.5%; Pred. No. 0.0022;
Matches 17; Conservative 6; Mismatches 20; Indels 0; Gaps 0;
QY 2 CIIICQDLHDCVSIQPCMHFTCAACYSGWMERSLLCPTCRCPV 44
Db 26 CHICFQVNHPEVTFITCKHSICAGCAGRWLSSCVCPMCRIV 68
RESULT 11
T21423
hypothetical protein F26E4.11 - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 29-Oct-1999
C:Accession: T21423; T21749
R:Lightning, J.
submitted to the EMBL Data Library, October 1996
A:Reference number: Z19419
A:Accession: T21423
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-564 <WIL>
A:Cross-references: EMBL:Z81070; PIDN:CAB03009.1; GSPDB:GN00019; CESP:F26E4.11
A:Experimental source: clone F26E4
R:Baynes, C.
submitted to the EMBL Data Library, October 1996
A:Reference number: Z19468
A:Accession: T21749
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-564 <WI2>
A:Cross-references: EMBL:Z81075; PIDN:CAB03049.1; GSPDB:GN00019; CESP:F26E4.11
A:Experimental source: clone F35C12
C:Genetics:
A:Gene: CESP:F26E4.11
A:Map position: 1

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:41:17 ; Search time 2.46251 Seconds
(without alignments)
1718.743 Million cell updates/sec

Title: US-10-048-046-2_COPY_303_346

Perfect score: 266
Sequence: 1 TCIIICDLDHDCVSLQPCVH.....ACVSGWMERSLLCPTCRCPV 44

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_78:*

- 1: Pir1:*
- 2: Pir2:*
- 3: Pir3:*
- 4: Pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	135	50.8	473	2 C96516	Fl6N3.15 [imported]
2	129	48.5	467	1 WZBE61	gene 61 protein -
3	119	44.7	676	1 EDBE22	immediate-early pr
4	119	44.7	676	1 EDBE23	immediate-early pr
5	110	41.4	621	2 T15741	hypothetical prote
6	107.5	40.4	306	2 T39702	probable peroxisom
7	107	40.2	551	2 S66695	probable membrane
8	105.5	39.7	276	2 P84591	hypothetical prote
9	104	39.1	610	2 T22687	hypothetical prote
10	104	39.1	639	2 T16648	hypothetical prote
11	103.5	38.9	564	2 T21423	hypothetical prote
12	101	38.0	568	2 P71614	chromatinic RING f
13	100.5	37.8	132	2 B85092	hypothetical prote
14	100.5	37.8	486	2 T39456	zinc finger protei
15	100.5	37.8	496	2 B96674	hypothetical prote
16	100.5	37.8	1208	2 T00362	hypothetical prote
17	100	37.6	222	2 JC4296	ring finger protei
18	99.5	37.4	1375	2 T37672	probable DNA repai
19	98	36.8	230	2 JC7972	spermatogenesis-re
20	98	36.8	532	1 WZBEF5	59K transcription
21	98	36.8	536	2 T42606	probable transcrip
22	97	36.5	410	2 A40505	early protein EF0
23	97	36.5	825	1 EDBEXD	immediate-early pr
24	96.5	36.3	409	2 T25935	hypothetical prote
25	96	36.1	906	2 A43817	transforming prote
26	95.5	35.9	245	2 T45652	RNA binding-like p
27	95	35.7	315	2 D48560	immediate-early pr
28	95	35.7	775	1 EDBE11	immediate-early pr
29	94	35.3	118	2 T01883	hypothetical prote

transforming prote
transforming prote
proto-oncogene bmi
related to COP1-in
hypothetical prote
hypothetical prote
hypothetical prote
hypothetical prote
hypothetical prote
probable DNA repai
hypothetical prote
testis-abundant fi
hypothetical prote
hypothetical prote
probable RING zinc
hypothetical prote
hypothetical prote
hypothetical prote

30 94 35.3 324 2 A39523
31 94 35.3 326 2 I51694
32 94 35.3 326 2 I54339
33 94 35.3 532 2 T49467
34 93.5 35.2 242 2 T48173
35 93.5 35.2 1331 2 T04938
36 93.5 35.2 1495 2 A85240
37 93.5 35.2 1495 2 T10649
38 92.5 34.8 387 2 T39653
39 92 34.6 273 2 T47692
40 92 34.6 518 2 JC7387
41 91.5 34.4 302 2 C85092
42 91.5 34.4 327 2 D86474
43 91.5 34.4 345 2 D85092
44 91.5 34.4 836 2 T18460
45 91.5 34.4 2447 2 T16870

ALIGNMENTS

RESULT 1
C96516
Fl6N3.15 [imported] - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cross)
C>Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 31-Mar-2001
C:Accession: C96516
R:Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,
Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;
ansen, N.F.; Hughes, B.; Huizar, L.
Nature 408, 816-820, 2000
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.;
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziali,
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, I
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Davis, R.W.
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A:Reference number: A86141; MUID:21016719; PMID:11130712
A:Accession: C96516
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-473 <STO>
A:Cross-references: GB:AE005173; NID:G5668816; PIDN:AAD46042.1; GSPDB:GN00141
C:Genetics:
A:Gene: Fl6N3.15
A:Map position: 1

Query Match 50.8%; Score 135; DB 2; Length 473;
Best Local Similarity 46.9%; Pred. No. 1.3e-06;
Matches 23; Conservative 5; Mismatches 15; Indels 6; Gaps 1;

QY 2 CIIICDLDHDCVSLQPCVHPTCAACVSGWMERS-----LCPTCRCPV 44
Db 145 CSICLINIHVDVTAAPCLHFNFCNGCFSEWMRSEKHKHVLCPQCRITV 193

RESULT 2

WZBE61
gene 61 protein - human herpesvirus 3
C:Species: human herpesvirus 3, varicella-zoster virus
C>Date: 30-Sep-1988 #sequence_revision 30-Sep-1988 #text_change 17-Mar-2000
C:Accession: I27215
R:Davidson, A.J.; Scott, J.E.
J. Gen. Virol. 67, 1759-1816, 1986
A:Title: The complete DNA sequence of varicella-zoster virus.
A:Reference number: A27345; MUID:86306657; PMID:3018124
A:Accession: I27215
A:Molecule type: DNA
A:Residues: 1-467 <DAV>
A:Cross-references: EMBL:X04370; NID:G59989; PIDN:CAA27944.1; PID:G60050
C:Genetics:
A:Gene: 61
C:Superfamily: varicella-zoster virus gene 61 protein; RING finger homology

```

; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (358)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (494)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (504)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (505)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-833-245-808

```

```

Query Match      38.7%; Score 103; DB 11; Length 505;
Best Local Similarity 39.5%; Pred. No. 0.0035;
Matches 17; Conservative 5; Mismatches 21; Indels 0; Gaps 0;

```

```

QY      2 CIIICDLDHDCVSLQPCMHFTCAACYSQWMSRSSLCPTCRCPV 44
DB      291 CIIICREMYTGAKRLPCNHFHTSCLRSWFQRTCTCTCRMDV 333

```

```

RESULT 15
US-09-833-245-810
; Sequence 810, Application US/09833245
; Publication No. US20040010134A1
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc.
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PF546PCT
; CURRENT APPLICATION NUMBER: US/09/833,245
; CURRENT FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: 60/229,358
; PRIOR FILING DATE: 2000-04-12
; PRIOR APPLICATION NUMBER: 60/256,931
; PRIOR FILING DATE: 2000-12-21
; PRIOR APPLICATION NUMBER: 60/199,384
; PRIOR FILING DATE: 2000-04-25
; NUMBER OF SEQ ID NOS: 2267
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 810
; LENGTH: 617
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-833-245-810

```

```

Query Match      38.7%; Score 103; DB 11; Length 617;
Best Local Similarity 39.5%; Pred. No. 0.0041;
Matches 17; Conservative 5; Mismatches 21; Indels 0; Gaps 0;

```

```

QY      2 CIIICDLDHDCVSLQPCMHFTCAACYSQWMSRSSLCPTCRCPV 44
DB      291 CIIICREMYTGAKRLPCNHFHTSCLRSWFQRTCTCTCRMDV 333

```

```

Search completed: May 7, 2004, 15:06:51
Job time : 7.96938 secs

```

```

; APPLICANT:  Cao Yongwei
; TITLE OF INVENTION:  Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
; FILE REFERENCES:  38-21(53223)B
; CURRENT APPLICATION NUMBER:  US/10/424,599
; CURRENT FILING DATE:  2003-04-28
; NUMBER OF SEQ ID NOS:  285684
; SEQ ID NO 235446
; LENGTH:  216
; TYPE:  PRT
; ORGANISM:  Glycine max
; FEATURE:
; OTHER INFORMATION:  Clone ID:  PAT_MRT3847_54635C.1.pep
US-10-424-599-235446

```

```
Query Match      41.2%; Score 109.5; DB 12; Length 216;
Best Local Similarity 39.1%; Pred. No. 0.00033;
Matches 18; Conservative 6; Mismatches 19; Indels 3; Gaps 1;
```

QY 2 CIIQCDDLHD--CVSIQPCMHITFCAACYSGWMERSSLCPTCRCPV 44
 |::| | | : | | | | | | | | : | : | | | | |
D6 139 CVVCLEDAFHNAOWCKLAAAGHVHRTCTVDTWLLKVAACPTCTPV 184

```

RESULT 11
US-10-424-599-250642
; Sequence 250642, Application US/10424599
; Publication NO. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 250642
; LENGTH: 242
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_6835C.1.pep
US-10-424-599-250642

```

Query Match 40.8%; Score 108.5; DB 12; Length 242;
Best Local Similarity 39.1%; Pred. No. 0.00047;
Matches 18; Conservative 6; Mismatches 19; Indels 3; Gaps 1;

Qy 2 CIIQDILLHD---CVSIQPCMHIFCAACVSGWMERSLCPTRCPV 44
|::| | : | | | | | : : | | | | |
Db 165 CWYCLDAFHNAOWCRKLAACGHVFRRCVDTWLLKVAACPTCTPV 210

RESULT 12
US-10-425-114-49876
; Sequence 49876, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Jingdong
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovacic, David K.
; APPLICANT: Screen, Steven E
; APPLICANT: Tabaska, Jack E
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53313) B
; CURRENT APPLICATION NUMBER: US/10/425,114
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128

```

; SEQ ID NO 49876
; LENGTH: 234
; TYPE: PRT
; ORGANISM: Gly
; FEATURE:
; OTHER INFORMATION:
US-10-425-114-498

```

Query Match 39.3%; Score 104.5; DB 12; Length 234;
Best Local Similarity 44.2%; Pred. No. 0.0012;
Matches 19; Conservative 3; Mismatches 20; Indels 1;

Qy	2	CIICQDLLHDCVSLQPCMH	TFCAACVSGWMERS	SLCPTCRCPV	44
		:			
		:			
Db	173	CAICQEKMQAPILLS-	CKHMFCEECVSEWF	ERTCPLCRALV	214

```

RESULT 13
US-10-424-599-154629
; Sequence 154629, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 154629
; LENGTH: 393
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(393)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_110651C.1.pep
US-10-424-599-154629

```

Query Match	39.3%;	Score 104.5;	DB 12;	Length 393;
Best Local Similarity	44.2%;	Pred. No. 0.0019;		
Matches 19;	Conservative 3;	Mismatches 20;	Indels 1;	Gaps 1;

Qy 2 CIIICQDLLHDCVSLQPCHMTFCAACYSGMWERSLCPTRCPV 44
| | | | : : | | | | | | | | | |
Db 332 CAICOEKMOAPILLS-CKHMFCCECVSWFERTECPLCRALV 373

```

RESULT 14
US-09-833-245-808
? Sequence 808, Application US/09833245
? Publication NO. US20040010134A1
? GENERAL INFORMATION:
? APPLICANT: Human Genome Sciences, Inc.
? TITLE OF INVENTION: Albumin Fusion Proteins
? FILE REFERENCE: PF546PCT
? CURRENT APPLICATION NUMBER: US/09/833,245
? CURRENT FILING DATE: 2001-04-12
? PRIOR APPLICATION NUMBER: 60/229, 358
? PRIOR FILING DATE: 2000-04-12
? PRIOR APPLICATION NUMBER: 60/256, 931
? PRIOR FILING DATE: 2000-12-21
? PRIOR APPLICATION NUMBER: 60/199, 384
? PRIOR FILING DATE: 2000-04-25
? NUMBER OF SEQ ID NOS: 2267
? SOFTWARE: Patent In Ver. 2.1
? SEQ ID NO 808
? LENGTH: 505
?

```

```

US-10-001-885-150
; Sequence 150, Application US/10001885
; Publication No. US20040058319A1
; GENERAL INFORMATION:
; APPLICANT: Salceda, Susana
; APPLICANT: Macina, Roberto
; APPLICANT: Recipon, Herve
; APPLICANT: Cafferkey, Robert
; APPLICANT: Sun, Yongming
; APPLICANT: Liu, Chenghua
; TITLE OF INVENTION: Compositions and Methods Relating to Ovary Specific Genes and Pro
; FILE REFERENCE: DEX-0279
; CURRENT APPLICATION NUMBER: US/10/001,885
; PRIOR FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 60/252,061
; PRIOR FILING DATE: 2000-11-20
; PRIOR APPLICATION NUMBER: 60/253,257
; PRIOR FILING DATE: 2000-11-27
; NUMBER OF SEQ ID NOS: 167
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 150
; LENGTH: 254
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-001-885-150

Query Match 43.2%; Score 115; DB 12; Length 254;
Best Local Similarity 41.5%; Pred. No. 9.8e-05;
Matches 17; Conservative 9; Mismatches 15; Indels 0; Gaps 0;

QY 1 TCIIQDILLHDCVSLQPCMHHTFCAACYSYSGWMSRLCPTCR 41
DB 21 TCRLCGYLDATTVTECLHTFCSRCLVKYLEENNTCPTCR 61

RESULT 7
US-10-425-114-40033
; Sequence 40033, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Jingdong
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K.
; APPLICANT: Screen, Steven E
; APPLICANT: Tabaska, Jack E
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53313)B
; CURRENT APPLICATION NUMBER: US/10/425,114
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 40033
; LENGTH: 183
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: 700962291_FLI.pep
US-10-425-114-40033

Query Match 42.3%; Score 112.5; DB 12; Length 183;
Best Local Similarity 46.5%; Pred. No. 0.00014;
Matches 20; Conservative 4; Mismatches 18; Indels 1; Gaps 1;

QY 2 CIIICDILLHDCVSLQPCMHHTFCAACYSYSGWMSRLCPTCR 44
DB 122 CAICQKMHAPILLR-CXHIFFCDVSEWFERTCPLCALV 163

RESULT 8
US-10-424-599-277916
; Sequence 277916, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 277916
; LENGTH: 257
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_92981C.1.pep
US-10-424-599-277916

Query Match 42.3%; Score 112.5; DB 12; Length 257;
Best Local Similarity 46.5%; Pred. No. 0.00018;
Matches 20; Conservative 4; Mismatches 18; Indels 1; Gaps 1;

QY 2 CIIICDILLHDCVSLQPCMHHTFCAACYSYSGWMSRLCPTCR 44
DB 196 CAICQKMHAPILLR-CXHIFFCDVSEWFERTCPLCALV 237

RESULT 9
US-10-425-114-51122
; Sequence 51122, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K.
; APPLICANT: Screen, Steven E
; APPLICANT: Tabaska, Jack E
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; FILE REFERENCE: 38-21(53313)B
; CURRENT APPLICATION NUMBER: US/10/425,114
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 51122
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: 700083617_FLI.pep
US-10-425-114-51122

Query Match 42.3%; Score 112.5; DB 12; Length 327;
Best Local Similarity 48.8%; Pred. No. 0.00023;
Matches 21; Conservative 3; Mismatches 18; Indels 1; Gaps 1;

QY 2 CIIICDILLHDCVSLQPCMHHTFCAACYSYSGWMSRLCPTCR 44
DB 266 CAICQKMHAPILLR-CXHIFFCDVSEWFERTCPLCALV 307

RESULT 10
US-10-424-599-235446
; Sequence 235446, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
```

```

; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 809
; LENGTH: 426
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (414)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (415)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (420)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-809

Query Match
Best Local Similarity 100.0%; Score 266; DB 9; Length 426;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCICQDLHDCVSLQPCMTFCAACYSYGMWERSLCTCRCPV 44
Db 213 TCICQDLHDCVSLQPCMTFCAACYSYGMWERSLCTCRCPV 256

RESULT 3
US-09-780-525-2
; Sequence 2, Application US/09780525
; Patent No. US2002004223A1
; GENERAL INFORMATION:
; APPLICANT: Bin-Bing Zhou
; APPLICANT: Yuan Zhu
; APPLICANT: Priya Chaturvedi
; APPLICANT: Mark R. Hurie
; APPLICANT: Xiaotong Li
; TITLE OF INVENTION: FHAR1, A NEW RING FINGER PROTEIN
; FILE REFERENCE: GP-70668-C1
; CURRENT APPLICATION NUMBER: US/09/780,525
; CURRENT FILING DATE: 2001-02-09
; PRIOR FILING DATE: 1999-12-08
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 664
; TYPE: PRT
; ORGANISM: HOMO SAPIENS
US-09-780-525-2

Query Match
Best Local Similarity 100.0%; Score 266; DB 9; Length 664;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCICQDLHDCVSLQPCMTFCAACYSYGMWERSLCTCRCPV 44
Db 303 TCICQDLHDCVSLQPCMTFCAACYSYGMWERSLCTCRCPV 346

RESULT 4
US-09-764-864-1270
; Sequence 1270, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0

```

```

; SEQ ID NO 1270
; LENGTH: 230
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (4)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (189)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (192)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (193)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (194)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (213)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (223)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (229)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (230)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1270

Query Match
Best Local Similarity 100.0%; Score 176; DB 9; Length 230;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 17 POMTFCAACYSYGMWERSLCTCRCPV 44
Db 5 POMTFCAACYSYGMWERSLCTCRCPV 32

RESULT 5
US-09-919-039-285
; Sequence 285, Application US/09919039
; Publication No. US20030108871A1
; GENERAL INFORMATION:
; APPLICANT: Kaser, Matthew R.
; TITLE OF INVENTION: GENES EXPRESSED IN TREATED HUMAN C3A LIVER CELL CULTURES
; FILE REFERENCE: PA-0035 US
; CURRENT APPLICATION NUMBER: US/09/919,039
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: 60/222,113
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 401
; SOFTWARE: PERL Program
; SEQ ID NO 285
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. US20030108871A1 1427459CD1
US-09-919-039-285

Query Match
Best Local Similarity 43.2%; Score 115; DB 10; Length 247;
Matches 17; Conservative 9; Mismatches 15; Indels 0; Gaps 0;

QY 1 TCICQDLHDCVSLQPCMTFCAACYSYGMWERSLCTCR 41
Db 21 TCICQDLHDCVSLQPCMTFCAACYSYGMWERSLCTCR 61

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:49:13 ; Search time 6.96938 Seconds
(without alignments)
1752.371 Million cell updates/sec

Title: US-10-048-046-2_COPY_303_346
Perfect score: 266
Sequence: 1 TCIIQDLHDCVSLQPCMH.....ACYSGWMSRSLCPTCRCPV 44

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1140673 seqs, 277566755 residues

Total number of hits satisfying chosen parameters: 1140673

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:

- 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
- 17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
- 18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	266	100.0	349	15	US-10-108-260A-4516
2	266	100.0	426	9	US-09-764-864-809
3	266	100.0	684	9	US-09-780-525-2
4	176	66.2	230	9	US-09-764-864-1270
5	115	43.2	247	10	US-09-919-039-285
6	115	43.2	254	12	US-10-001-885-150
7	112.5	42.3	183	12	US-10-425-114-40033
8	112.5	42.3	257	12	US-10-424-599-277916
9	112.5	42.3	327	12	US-10-425-114-51122
10	109.5	41.2	216	12	US-10-424-599-235446
11	108.5	40.8	242	12	US-10-424-599-250642
12	104.5	39.3	234	12	US-10-425-114-49876
13	104.5	39.3	393	12	US-10-424-599-154629
14	103	38.7	505	11	US-09-833-245-808
15	103	38.7	617	11	US-09-833-245-810

16	103	38.7	617	12	US-10-470-360-17	Sequence 17, Appl
17	100.5	37.8	185	12	US-10-425-114-40364	Sequence 40364, A
18	99.5	37.4	165	12	US-10-424-599-170452	Sequence 170452,
19	99.5	37.4	169	12	US-10-424-599-170451	Sequence 170451,
20	99.5	37.4	176	12	US-10-425-114-49027	Sequence 49027, A
21	99.5	37.4	163	12	US-10-424-599-180706	Sequence 180706,
22	99	37.2	206	9	US-09-764-864-845	Sequence 845, App
23	99	37.2	218	9	US-09-764-864-1300	Sequence 1300, App
24	99	37.2	218	14	US-10-106-698-6052	Sequence 6052, Ap
25	99	37.2	356	15	US-10-136-728-18	Sequence 18, Appl
26	99	37.2	404	15	US-10-094-749-1721	Sequence 1721, Ap
27	99	37.2	568	12	US-10-126-103-112	Sequence 112, App
28	99	37.2	739	9	US-09-957-635-2	Sequence 2, Appl
29	98.5	37.0	48	14	US-10-283-500-14	Sequence 14, Appl
30	98.5	37.0	113	12	US-10-424-599-158001	Sequence 158001,
31	98.5	37.0	486	12	US-10-425-114-40759	Sequence 40759, A
32	98.5	37.0	575	12	US-10-424-599-157327	Sequence 157327,
33	98	36.8	131	15	US-10-264-049-2856	Sequence 2856, Ap
34	98	36.8	158	9	US-09-764-864-1304	Sequence 1304, App
35	98	36.8	230	15	US-10-295-027-702	Sequence 702, App
36	98	36.8	439	9	US-09-764-864-849	Sequence 849, App
37	98	36.8	439	15	US-10-264-049-1081	Sequence 1081, Ap
38	98	36.8	474	14	US-10-157-031-251	Sequence 251, App
39	97.5	36.7	331	12	US-10-425-114-37376	Sequence 37376, A
40	97.5	36.7	353	12	US-10-424-599-187936	Sequence 187936,
41	97.5	36.7	420	12	US-10-424-599-160966	Sequence 160966,
42	97.5	36.7	424	12	US-10-425-114-70107	Sequence 70107, A
43	97	36.5	154	12	US-10-231-625-105	Sequence 105, App
44	97	36.5	207	9	US-09-925-302-638	Sequence 638, App
45	97	36.5	207	12	US-09-925-302-638	Sequence 638, App

ALIGNMENTS

RESULT 1
US-10-108-260A-4516
; Sequence 4516, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1 full length cdna
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4516
; LENGTH: 349
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-108-260A-4516

Query Match 100.0%; Score 266; DB 15; Length 349;
Best Local Similarity 100.0%; Pred. No. 8.2e-21;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TCIIQDLHDCVSLQPCMHITCAACYSGWMSRSLCPTCRCPV 44
Db 103 TCIIQDLHDCVSLQPCMHITCAACYSGWMSRSLCPTCRCPV 146

RESULT 2
US-09-764-864-809
; Sequence 809, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper

FILING DATE: 31-Mar-1998
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-198 CIP 1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-487-5800
TELEFAX: 201-343-1684
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 47 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
FRAGMENT TYPE: internal
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-052-089A-12
Query Match 36.1%; Score 96; DB 4; Length 47;
Best Local Similarity 38.8%; Pred. No. 0.00032;
Matches 17; Conservative 6; Mismatches 19; Indels 2; Gaps 2;
QY 2 CIIICODLLHDCVSLQPCNHTTFCACYSGWMMERSL-CPTCRCPV 44
DB 4 CKICAENDND-VKIEPCGHLMTCTSLTWSOESGQCGPCFRCBEI 46
RESULT 14
US-07-945-283-6
Sequence 6, Application US/07945283
Patent No. 5352596
GENERAL INFORMATION:
APPLICANT: Cheung, Andrew K.
APPLICANT: Wesley, Ronald D.
TITLE OF INVENTION: Pseudorabies Virus Deletion Mutants
TITLE OF INVENTION: Involving the EP0 and LIT Genes
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESS: Curtis P. Ribando
STREET: 1815 No. 5352596th University Street
CITY: Peoria
STATE: IL
COUNTRY: USA
ZIP: 61604
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/945,283
FILING DATE: 19920911
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Ribando, Curtis P
REGISTRATION NUMBER: 27976
TELECOMMUNICATION INFORMATION:
TELEPHONE: 309-685-4011 ext.513
TELEFAX: 309-685-4128
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 69 amino acids
TYPE: AMINO ACID
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: Herpes simplex virus
US-07-945-283-6

Query Match 35.7%; Score 95; DB 1; Length 69;
Best Local Similarity 39.0%; Pred. No. 0.00058;
Matches 16; Conservative 4; Mismatches 19; Indels 2; Gaps 1;
QY 2 CIIICODLLHDCVSLQPCNHTTFCACYSGWMMERSL-CPTC 40
DB 6 CAVCTDEIAPHLRCDTFPCNHRFCIPCKMTWMOIRNTCPCLC 46
RESULT 15
US-07-945-283-4
Sequence 4, Application US/07945283
Patent No. 5352596
GENERAL INFORMATION:
APPLICANT: Cheung, Andrew K.
APPLICANT: Wesley, Ronald D.
TITLE OF INVENTION: Pseudorabies Virus Deletion Mutants
TITLE OF INVENTION: Involving The EP0 and LIT Genes
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESS: Curtis P. Ribando
STREET: 1815 No. 5352596th University Street
CITY: Peoria
STATE: IL
COUNTRY: USA
ZIP: 61604
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/945,283
FILING DATE: 19920911
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Ribando, Curtis P
REGISTRATION NUMBER: 27976
TELECOMMUNICATION INFORMATION:
TELEPHONE: 309-685-4011 ext.513
TELEFAX: 309-685-4128
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 410 amino acids
TYPE: AMINO ACID
TOPOLOGY: linear
MOLECULE TYPE: protein
US-07-945-283-4
Query Match 35.7%; Score 95; DB 1; Length 410;
Best Local Similarity 39.5%; Pred. No. 0.003;
Matches 17; Conservative 2; Mismatches 24; Indels 0; Gaps 0;
QY 2 CIIICODLLHDCVSLQPCNHTTFCACYSGWMMERSL-CPTCRCPV 44
DB 46 CPICLDVAATEAQTLPCNHRFCICIQRWTLTSTACPLCNARV 88
Search completed: May 7, 2004, 14:51:23
Job time : 3.92714 secs

OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patin (Genentech)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/06639
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/250858
 FILING DATE: 27-MAY-1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/331394
 FILING DATE: 28-OCT-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Dreger, Ginger R.
 REGISTRATION NUMBER: 33,055
 REFERENCE/DOCKET NUMBER: 897P2PCT
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415/225-3216
 TELEFAX: 415/952-9881
 TELEX: 910/371-7168
 INFORMATION FOR SEQ ID NO: 14:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 48 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 PCT-US95-06639-14

Query Match 37.0%; Score 98.5; DB 5; Length 48;
 Best Local Similarity 42.2%; Pred. No. 0.00017;
 Matches 19; Conservative 5; Mismatches 16; Indels 5; Gaps 2;

QY 2 CIIQDILLHDCVSLQPCMTFCAACVSGWMMER-SSLCPTCRC 42
 DB 4 CXICAENDKD-VKIEPCGHLMTCSLTLSWQSEGGSGGCPFCR 47

RESULT 11
 US-07-945-283-5
 Sequence 5, Application US/07945283
 Patent No. 5352596
 GENERAL INFORMATION:
 APPLICANT: Cheung, Andrew K.
 APPLICANT: Wesley, Ronald D.
 TITLE OF INVENTION: Pseudorabies Virus Deletion Mutants
 TITLE OF INVENTION: Involving The EPO and LIT Genes
 NUMBER OF SEQUENCES: 7
 CORRESPONDENCE ADDRESS:
 ADDRESSES: Curtis P. Ribando
 STREET: 1815 No. 5352596th University Street
 CITY: Peoria
 STATE: IL
 COUNTRY: USA
 ZIP: 61604
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/945,283
 FILING DATE: 19920911
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: Ribando, Curtis P.
 REGISTRATION NUMBER: 27976
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 309-685-4011 ext.513
 TELEFAX: 309-685-4128
 INFORMATION FOR SEQ ID NO: 5:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 67 amino acids
 TYPE: AMINO ACID
 TOPOLOGY: linear

MOLECULE TYPE: peptide
 HYPOTHEICAL: NO
 FRAGMENT TYPE: internal
 ORIGINAL SOURCE:
 ORGANISM: Pseudorabies virus
 US-07-945-283-5
 Query Match 36.5%; Score 97; DB 1; Length 67;
 Best Local Similarity 39.5%; Pred. No. 0.00034;
 Matches 17; Conservative 3; Mismatches 23; Indels 0; Gaps 0;
 QY 2 CIIQDILLHDCVSLQPCMTFCAACVSGWMMERSSLCPTCRCPV 44
 DB 6 CPICLDVAATEAQTLPCKMKFCLDCIQRFWTLTSTACPLCKARV 48
 RESULT 12
 US-09-894-998A-47
 Sequence 47, Application US/09894998A
 Patent No. 6537555
 GENERAL INFORMATION:
 APPLICANT: Hosken, Nancy Ann
 APPLICANT: Craig H. Day
 APPLICANT: Davin C. Dillon
 APPLICANT: McGowan, Patrick
 APPLICANT: Sleath, Paul R.
 TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
 TITLE OF INVENTION: TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
 FILE REFERENCE: 210121.538
 CURRENT APPLICATION NUMBER: US/09/894,998A
 CURRENT FILING DATE: 2001-06-28
 NUMBER OF SEQ ID NOS: 64
 SOFTWARE: FastSeq for Windows Version 4.0
 SEQ ID NO 47
 LENGTH: 826
 TYPE: PRT
 ORGANISM: HSV-2
 US-09-894-998A-47

Query Match 36.5%; Score 97; DB 4; Length 826;
 Best Local Similarity 35.6%; Pred. No. 0.0034;
 Matches 16; Conservative 6; Mismatches 21; Indels 2; Gaps 1;

QY 2 CIIQDILLHDCVSLQ-PCMTFCAACVSGWMMERSSLCPTCRCPV 44
 DB 126 CAVCTDEIAPFLRCQSFCLHPFCIPCKMTWIPURNTCPLCNTFV 170
 RESULT 13
 US-09-052-089A-12
 Sequence 12, Application US/09052089A
 Patent No. 6346605
 GENERAL INFORMATION:
 APPLICANT: Lee, Soo Y.
 APPLICANT: Choi, Yongwon
 TITLE OF INVENTION: SIGNAL TRANSDUCER FOR THE TNF RECEPTOR SUPER
 TITLE OF INVENTION: FAMILY, AND USES THEREOF
 NUMBER OF SEQUENCES: 16
 CORRESPONDENCE ADDRESS:
 ADDRESSES: David A. Jackson, Esq.
 STREET: 411 Hackensack Ave, Continental Plaza, 4th
 Floor
 CITY: Hackensack
 STATE: New Jersey
 COUNTRY: USA
 ZIP: 07601
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/052,089A

FILING DATE: 27-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/331394
FILING DATE: 28-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: 897P2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/225-3216
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 48 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-446-915-14

Query Match 37.0%; Score 98.5; DB 1; Length 48;
Best Local Similarity 42.2%; Pred. No. 0.00017;
Matches 19; Conservative 5; Mismatches 16; Indels 5; Gaps 2;

Qy 2 CIIICODLLHDCVSLQPCMHFTCAACYSGWMER-----SSLCPTRC 42
Db 4 CKICAENDKD-VKIEPCGHLMTCLTSWQSEGGSGGCGPCRC 47

RESULT 8
US-08-744-139-14
Sequence 14, Application US/08744139
Patent No. 5869612
GENERAL INFORMATION:
APPLICANT: Goeddel, David V
APPLICANT: Rothe, Mike
TITLE OF INVENTION: TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESS: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/744,139
FILING DATE: 31-Oct-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/250858
FILING DATE: 05/27/1994
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P0897C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/225-3216
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 48 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-744-139-14

Query Match 37.0%; Score 98.5; DB 2; Length 48;
Best Local Similarity 42.2%; Pred. No. 0.00017;

Matches 19; Conservative 5; Mismatches 16; Indels 5; Gaps 2;
Qy 2 CIIICODLLHDCVSLQPCMHFTCAACYSGWMER-----SSLCPTRC 42
Db 4 CKICAENDKD-VKIEPCGHLMTCLTSWQSEGGSGGCGPCRC 47

RESULT 9
US-08-779-599-14
Sequence 14, Application US/08779599
Patent No. 6500922
GENERAL INFORMATION:
APPLICANT: Goeddel, David V.
APPLICANT: Rothe, Mike
TITLE OF INVENTION: Tumor Necrosis Factor Receptor-Associated Factors
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESS: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA: US/08/779,599
FILING DATE: 07-Jan-1997
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: P0897C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/225-3216
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 48 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-779-599-14

Query Match 37.0%; Score 98.5; DB 4; Length 48;
Best Local Similarity 42.2%; Pred. No. 0.00017;
Matches 19; Conservative 5; Mismatches 16; Indels 5; Gaps 2;

Qy 2 CIIICODLLHDCVSLQPCMHFTCAACYSGWMER-----SSLCPTRC 42
Db 4 CKICAENDKD-VKIEPCGHLMTCLTSWQSEGGSGGCGPCRC 47

RESULT 10
PCT-US95-06639-14
Sequence 14, Application PC/TUS9506639
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
TITLE OF INVENTION: Tumor Necrosis Factor Receptor-Associated Factors
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESS: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb disk
COMPUTER: IBM PC compatible

APPLICANT: Rothe, Mike
TITLE OF INVENTION: Tumor Necrosis Factor Receptor-Associated Factors
NUMBER OF SEQUENCES: 62
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
CITY: 460 Point San Bruno Blvd
STATE: South San Francisco
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: patin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/250.858
FILING DATE: 27-May-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Dregler, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: 897.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/225-3216
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 48 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-250-858-14

Query Match 37.0%; Score 98.5; DB 1; Length 48;
Best Local Similarity 42.2%; Pred. No. 0.00017; Indels 5; Gaps 2;
Matches 19; Conservative 5; Mismatches 16;

QY 2 CIIQDLHDCVSLQPCMHFTFCAACYSQWMSRSLCPTCPC 42
DB 4 CKICAENDKD-VKIEPCGHLMTCLTSQWSEGGSGCPCPC 47

RESULT 7
US-08-446-915-14
Sequence 14, Application US/08446915
Patent No. 5741667
GENERAL INFORMATION:
APPLICANT: Goeddel, David V.
APPLICANT: Rothe, Mike
TITLE OF INVENTION: Tumor Necrosis Factor Receptor-Associated Factors
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
CITY: 460 Point San Bruno Blvd
STATE: South San Francisco
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: patin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/446,915
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/250858

TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: polypeptide
US-09-628-133-25

Query Match 40.2%; Score 107; DB 4; Length 551;
Best Local Similarity 40.0%; Pred. No. 0.00018; Indels 12; Gaps 1;
Matches 22; Conservative 2; Mismatches 19;

QY 2 CIIQDLHDCVSLQPCMHFTFCAACYSQWMSRSLCPTCPC 44
DB 349 CIIQDLHDCVSLQPCMHFTFCAACYSQWMSRSLCPTCPC 403

RESULT 5
US-08-331-394-14
Sequence 14, Application US/08331394
Patent No. 5670319
GENERAL INFORMATION:
APPLICANT: Goeddel, David V.
APPLICANT: Rothe, Mike
TITLE OF INVENTION: Tumor Necrosis Factor Receptor-Associated Factors
NUMBER OF SEQUENCES: 66
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
CITY: 460 Point San Bruno Blvd
STATE: South San Francisco
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: patin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/331.394
FILING DATE:
CLASSIFICATION: 436
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/250858
FILING DATE: 27-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Dregler, Ginger R.
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: 897P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/225-3216
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 48 amino acids
TYPE: amino acid
TOPOLOGY: linear
US-08-331-394-14

Query Match 37.0%; Score 98.5; DB 1; Length 48;
Best Local Similarity 42.2%; Pred. No. 0.00017; Indels 5; Gaps 2;
Matches 19; Conservative 5; Mismatches 16;

QY 2 CIIQDLHDCVSLQPCMHFTFCAACYSQWMSRSLCPTCPC 42
DB 4 CKICAENDKD-VKIEPCGHLMTCLTSQWSEGGSGCPCPC 47

RESULT 6
US-08-250-858-14
Sequence 14, Application US/08250858
Patent No. 5708142
GENERAL INFORMATION:
APPLICANT: Goeddel, David V.

RESULT 2

US-08-699-103B-25
; Sequence 25, Application US/08699103B
; Patent No. 6107462
; GENERAL INFORMATION:
; APPLICANT: Rine, Jasper D.
; APPLICANT: Hampton, Randolph
; TITLE OF INVENTION: GENES AND PROTEINS CONTROLLING
; TITLE OF INVENTION: CHOLESTEROL SYNTHESIS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: 16-AUG-1996
; PRIOR APPLICATION NUMBER: US/08/699.103B
; FILING DATE: 16-AUG-1996
; APPLICATION NUMBER: 60/002.581
; FILING DATE: 17-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Green, Grant D.
; REGISTRATION NUMBER: 31,259
; REFERENCE/DOCKET NUMBER: 09272/005001
; TELEPHONE: 650/322-5070
; TELEFAX: 650/854-0875
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 551 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: polypeptide
US-08-699-103B-25

Query Match 40.2%; Score 107; DB 3; Length 551;
Best Local Similarity 40.0%; Pred.No.0.00018;
Matches 22; Conservative 2; Mismatches 19; Indels 12; Gaps 1;

QY 2 CIIICDILLHDCVSLQ-----PCMHFFCAACYSGWMMSSSLCPTCRCPV 44
DB 349 CIIICWDELHSPNQOTWKNKKPKRLPCGHILHLSCLKNNMERSQTCPCICRLPV 403

RESULT 3

US-09-229-059-25
; Sequence 25, Application US/09229059
; Patent No. 6333172
; GENERAL INFORMATION:
; APPLICANT: Rine, Jasper D.
; APPLICANT: Hampton, Randolph
; TITLE OF INVENTION: GENES AND PROTEINS CONTROLLING
; TITLE OF INVENTION: CHOLESTEROL SYNTHESIS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/229,059
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/699,103
; FILING DATE: 16-AUG-1996
; APPLICATION NUMBER: 60/002,581
; FILING DATE: 17-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Green, Grant D.
; REGISTRATION NUMBER: 31,259
; REFERENCE/DOCKET NUMBER: 09272/005001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/322-5070
; TELEFAX: 650/854-0875
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 551 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: polypeptide
US-09-229-059-25

Query Match 40.2%; Score 107; DB 4; Length 551;
Best Local Similarity 40.0%; Pred.No.0.00018;
Matches 22; Conservative 2; Mismatches 19; Indels 12; Gaps 1;

QY 2 CIIICDILLHDCVSLQ-----PCMHFFCAACYSGWMMSSSLCPTCRCPV 44
DB 349 CIIICWDELHSPNQOTWKNKKPKRLPCGHILHLSCLKNNMERSQTCPCICRLPV 403

RESULT 4

US-09-628-133-25
; Sequence 25, Application US/09628133
; Patent No. 6531292
; GENERAL INFORMATION:
; APPLICANT: Rine, Jasper D.
; APPLICANT: Hampton, Randolph
; TITLE OF INVENTION: GENES AND PROTEINS CONTROLLING
; TITLE OF INVENTION: CHOLESTEROL SYNTHESIS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/628,133
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/699,103
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Green, Grant D.
; REGISTRATION NUMBER: 31,259
; REFERENCE/DOCKET NUMBER: 09272/005001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/322-5070
; TELEFAX: 650/854-0875
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 551 amino acids


```
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 25-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161320P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 50.8%; Score 135; DB 3; Length 453;
Best Local Similarity 46.9%; Pred. No. 1.2e-06;
Matches 23; Conservative 5; Mismatches 15; Indels 6; Gaps 1;

QY 2 CIIQDILLHDCVSLQPCMHFTFCAACYSGWNERSS-----LCPTCRCPV 44
Db 125 CSICLNHWHDVVTAAAPCLHNFNGCFSEWNRSEKHKHYLCPCQRTTV 173
```

Search completed: May 7, 2004, 14:45:48
Job time : 11.2637 secs

PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 07-MAY-1999; 99US-0134256P.
PR 11-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 14-MAY-1999; 99US-0134768P.
PR 18-MAY-1999; 99US-0134941P.
PR 19-MAY-1999; 99US-0135124P.
PR 20-MAY-1999; 99US-0135153P.
PR 21-MAY-1999; 99US-0135629P.
PR 24-MAY-1999; 99US-0136021P.
PR 25-MAY-1999; 99US-0136392P.
PR 27-MAY-1999; 99US-0136782P.
PR 28-MAY-1999; 99US-0137222P.
PR 01-JUN-1999; 99US-0137528P.
PR 03-JUN-1999; 99US-0137502P.
PR 04-JUN-1999; 99US-0137724P.
PR 07-JUN-1999; 99US-0138094P.
PR 08-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 10-JUN-1999; 99US-0139119P.
PR 14-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 16-JUN-1999; 99US-0139492P.
PR 17-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139464P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139751P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 28-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 28-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 02-AUG-1999; 99US-0147038P.
PR 03-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 04-AUG-1999; 99US-0147204P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149928P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151080P.
PR 27-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.

PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 03-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142202P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 18-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 08-AUG-1999; 99US-0147493P.
PR 08-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.

PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156598P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157533P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161922P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 50.8%; Score 135; DB 3; Length 453;
Best Local Similarity 46.9%; Pred. No. 1.2e-06;
Matches 23; Conservative 5; Mismatches 15; Indels 6; Gaps 1;

QY 2 CIIICODLLHDCVSLQPCMHPTCAACYSQWMSRSS-----LCPTCRCPV 44
DB 125 CSICLINIWDVVTAAPCLHNFNCGFSQWMSRSEKHKHVLCPQCRITV 173

RESULT 15

AAG37658
ID AAG37658 standard; protein; 453 AA.
XX
AC AAG37658;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 46342.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.

XX KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; Genetic mapping; gene expression control; promoter;
XX termination sequence.
XX OS Arabidopsis thaliana.
XX PN EP1033405-A2.
XX PD 06-SEP-2000.
XX PF 25-FEB-2000; 2000EP-00301439.
XX PR 25-FEB-1999; 99US-0121825P.
XX PR 05-MAR-1999; 99US-0123180P.
XX PR 09-MAR-1999; 99US-0123548P.
XX PR 23-MAR-1999; 99US-0125788P.
XX PR 25-MAR-1999; 99US-0126264P.
XX PR 29-MAR-1999; 99US-0126785P.
XX PR 01-APR-1999; 99US-0127482P.
XX PR 06-APR-1999; 99US-0128234P.
XX PR 08-APR-1999; 99US-0128714P.
XX PR 16-APR-1999; 99US-0129845P.
XX PR 19-APR-1999; 99US-0130077P.
XX PR 21-APR-1999; 99US-0130449P.
XX PR 23-APR-1999; 99US-0130510P.
XX PR 23-APR-1999; 99US-0130831P.
XX PR 28-APR-1999; 99US-0131449P.
XX PR 30-APR-1999; 99US-0132048P.
XX PR 30-APR-1999; 99US-0132407P.
XX PR 04-MAY-1999; 99US-0132484P.
XX PR 05-MAY-1999; 99US-0132485P.
XX PR 06-MAY-1999; 99US-0132486P.
XX PR 06-MAY-1999; 99US-0132487P.
XX PR 07-MAY-1999; 99US-0132863P.
XX PR 11-MAY-1999; 99US-0134256P.
XX PR 14-MAY-1999; 99US-0134218P.
XX PR 14-MAY-1999; 99US-0134219P.
XX PR 14-MAY-1999; 99US-0134221P.
XX PR 14-MAY-1999; 99US-0134370P.
XX PR 18-MAY-1999; 99US-0134768P.
XX PR 18-MAY-1999; 99US-0134941P.
XX PR 20-MAY-1999; 99US-0135134P.
XX PR 21-MAY-1999; 99US-0135353P.
XX PR 24-MAY-1999; 99US-0135629P.
XX PR 25-MAY-1999; 99US-0136021P.
XX PR 27-MAY-1999; 99US-0136392P.
XX PR 28-MAY-1999; 99US-0136782P.
XX PR 01-JUN-1999; 99US-0137222P.
XX PR 03-JUN-1999; 99US-0137528P.
XX PR 04-JUN-1999; 99US-0137502P.
XX PR 07-JUN-1999; 99US-0137724P.
XX PR 08-JUN-1999; 99US-0138094P.
XX PR 10-JUN-1999; 99US-0138540P.
XX PR 10-JUN-1999; 99US-0138847P.
XX PR 14-JUN-1999; 99US-0139119P.
XX PR 16-JUN-1999; 99US-0139452P.
XX PR 16-JUN-1999; 99US-0139453P.
XX PR 17-JUN-1999; 99US-0139492P.
XX PR 18-JUN-1999; 99US-0139454P.
XX PR 18-JUN-1999; 99US-0139455P.
XX PR 18-JUN-1999; 99US-0139456P.
XX PR 18-JUN-1999; 99US-0139457P.
XX PR 18-JUN-1999; 99US-0139458P.
XX PR 18-JUN-1999; 99US-0139459P.
XX PR 18-JUN-1999; 99US-0139460P.
XX PR 18-JUN-1999; 99US-0139461P.
XX PR 18-JUN-1999; 99US-0139462P.
XX PR 18-JUN-1999; 99US-0139463P.
XX PR 18-JUN-1999; 99US-0139750P.
XX PR 18-JUN-1999; 99US-0139763P.
XX PR 21-JUN-1999; 99US-0139817P.
XX PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.

PR	18-JUN-1999;	99US-0139461P.
PR	18-JUN-1999;	99US-0139462P.
PR	18-JUN-1999;	99US-0139463P.
PR	18-JUN-1999;	99US-0139750P.
PR	18-JUN-1999;	99US-0139763P.
PR	21-JUN-1999;	99US-0139817P.
PR	21-JUN-1999;	99US-0139899P.
PR	22-JUN-1999;	99US-0140353P.
PR	23-JUN-1999;	99US-0140695P.
PR	24-JUN-1999;	99US-0140823P.
PR	28-JUN-1999;	99US-0140991P.
PR	29-JUN-1999;	99US-0141287P.
PR	30-JUN-1999;	99US-0141842P.
PR	01-JUL-1999;	99US-0142255P.
PR	01-JUL-1999;	99US-0142390P.
PR	06-JUL-1999;	99US-0142803P.
PR	08-JUL-1999;	99US-0142920P.
PR	12-JUL-1999;	99US-0142977P.
PR	13-JUL-1999;	99US-0143542P.
PR	14-JUL-1999;	99US-0143624P.
PR	15-JUL-1999;	99US-0144005P.
PR	16-JUL-1999;	99US-0144085P.
PR	16-JUL-1999;	99US-0144086P.
PR	19-JUL-1999;	99US-0144325P.
PR	19-JUL-1999;	99US-0144331P.
PR	19-JUL-1999;	99US-0144332P.
PR	19-JUL-1999;	99US-0144333P.
PR	19-JUL-1999;	99US-0144334P.
PR	19-JUL-1999;	99US-0144335P.
PR	20-JUL-1999;	99US-01443352P.
PR	20-JUL-1999;	99US-0144632P.
PR	20-JUL-1999;	99US-0144884P.
PR	21-JUL-1999;	99US-0144814P.
PR	21-JUL-1999;	99US-0145086P.
PR	21-JUL-1999;	99US-0145088P.
PR	22-JUL-1999;	99US-0145087P.
PR	22-JUL-1999;	99US-0145087P.
PR	22-JUL-1999;	99US-0145089P.
PR	22-JUL-1999;	99US-0145192P.
PR	23-JUL-1999;	99US-0145145P.
PR	23-JUL-1999;	99US-0145218P.
PR	23-JUL-1999;	99US-0145224P.
PR	26-JUL-1999;	99US-0145276P.
PR	27-JUL-1999;	99US-0145913P.
PR	27-JUL-1999;	99US-0145918P.
PR	27-JUL-1999;	99US-0145919P.
PR	28-JUL-1999;	99US-0145951P.
PR	02-AUG-1999;	99US-0146388P.
PR	02-AUG-1999;	99US-0146389P.
PR	02-AUG-1999;	99US-0147038P.
PR	04-AUG-1999;	99US-0147204P.
PR	04-AUG-1999;	99US-0147302P.
PR	05-AUG-1999;	99US-0147192P.
PR	05-AUG-1999;	99US-0147260P.
PR	06-AUG-1999;	99US-0147303P.
PR	06-AUG-1999;	99US-0147416P.
PR	09-AUG-1999;	99US-0147493P.
PR	09-AUG-1999;	99US-0147935P.
PR	10-AUG-1999;	99US-0148171P.
PR	11-AUG-1999;	99US-0148319P.
PR	12-AUG-1999;	99US-0148341P.
PR	13-AUG-1999;	99US-0148565P.
PR	13-AUG-1999;	99US-0148684P.
PR	16-AUG-1999;	99US-0149368P.
PR	17-AUG-1999;	99US-0149175P.
PR	18-AUG-1999;	99US-0149426P.
PR	20-AUG-1999;	99US-0149722P.
PR	20-AUG-1999;	99US-0149723P.
PR	20-AUG-1999;	99US-0149929P.
PR	23-AUG-1999;	99US-0149902P.
PR	23-AUG-1999;	99US-0149930P.
PR	25-AUG-1999;	99US-0150566P.
PR	26-AUG-1999;	99US-0150884P.
PR	27-AUG-1999;	99US-0151065P.
PR	27-AUG-1999;	99US-0151066P.
PR	27-AUG-1999;	99US-0151080P.
PR	27-AUG-1999;	99US-0151303P.
PR	31-AUG-1999;	99US-0151438P.
PR	01-SEP-1999;	99US-0151930P.
PR	07-SEP-1999;	99US-0152363P.
PR	10-SEP-1999;	99US-0153070P.
PR	13-SEP-1999;	99US-0153758P.
PR	15-SEP-1999;	99US-0154018P.
PR	16-SEP-1999;	99US-0154039P.
PR	20-SEP-1999;	99US-0154779P.
PR	22-SEP-1999;	99US-0155139P.
PR	23-SEP-1999;	99US-0155486P.
PR	24-SEP-1999;	99US-0155659P.
PR	28-SEP-1999;	99US-0156458P.
PR	29-SEP-1999;	99US-0156596P.
PR	04-OCT-1999;	99US-0157117P.
PR	05-OCT-1999;	99US-0157753P.
PR	07-OCT-1999;	99US-0157865P.
PR	07-OCT-1999;	99US-0158029P.
PR	08-OCT-1999;	99US-0158232P.
PR	12-OCT-1999;	99US-0158369P.
PR	13-OCT-1999;	99US-0159293P.
PR	13-OCT-1999;	99US-0159294P.
PR	14-OCT-1999;	99US-0159295P.
PR	14-OCT-1999;	99US-0159330P.
PR	14-OCT-1999;	99US-0159331P.
PR	14-OCT-1999;	99US-0159637P.
PR	14-OCT-1999;	99US-0159638P.
PR	18-OCT-1999;	99US-0159584P.
PR	21-OCT-1999;	99US-0160741P.
PR	21-OCT-1999;	99US-0160767P.
PR	21-OCT-1999;	99US-0160768P.
PR	21-OCT-1999;	99US-0160770P.
PR	21-OCT-1999;	99US-0160814P.
PR	21-OCT-1999;	99US-0160815P.
PR	22-OCT-1999;	99US-0160980P.
PR	22-OCT-1999;	99US-0160981P.
PR	22-OCT-1999;	99US-0160989P.
PR	25-OCT-1999;	99US-0161404P.
PR	25-OCT-1999;	99US-0161405P.
PR	25-OCT-1999;	99US-0161408P.
PR	26-OCT-1999;	99US-0161359P.
PR	26-OCT-1999;	99US-0161360P.
PR	26-OCT-1999;	99US-0161361P.
PR	28-OCT-1999;	99US-0161920P.
PR	28-OCT-1999;	99US-0161992P.
PR	28-OCT-1999;	99US-0161993P.
PR	29-OCT-1999;	99US-0162142P.
PR	29-OCT-1999;	99US-0162143P.
Query Match 50.8%; Score 135; DB 3; Length 426;		
Best Local Similarity 46.9%; Pred. No. 1.2e-06;		
Matches 23; Conservative 5; Mismatches 15; Indels 6; Gaps 1;		
QY	2	CIICODLLHDCVSLQPCVHTFCAACVSGWMERSS-----LCPTCRCPV 44
Db	98	CSICLNHEDVVTAAAPCLHNFNCGCFSEWMRSEEEKHKHVLCPQCRITV 146
RESULT 13		
AAG37659		
ID	AAG37659 standard; protein; 426 AA.	
XX	AAG37659;	
AC	(first entry)	
XX	18-OCT-2000	
DT	Arabidopsis thaliana protein fragment SEQ ID NO: 46343.	
XX		
DE		

PR	16-AUG-1999;	99US-0149358P.	ID	XX	AAG20353 standard; protein; 426 AA.
PR	17-AUG-1999;	99US-01491175P.	XX	AC	AAG20353;
PR	18-AUG-1999;	99US-0149426P.	XX	XX	17-OCT-2000 (first entry)
PR	20-AUG-1999;	99US-0149723P.	DT	XX	Arabidopsis thaliana protein fragment SEQ ID NO: 22506.
PR	20-AUG-1999;	99US-0149929P.	XX	DE	Protein identification; signal transduction pathway; metabolic pathway;
PR	23-AUG-1999;	99US-0149902P.	XX	KW	hybridisation assay; genetic mapping; gene expression control; promoter;
PR	23-AUG-1999;	99US-0150566P.	XX	KW	termination sequence.
PR	25-AUG-1999;	99US-0150884P.	XX	OS	Arabidopsis thaliana.
PR	26-AUG-1999;	99US-0151065P.	XX	PN	EP1033405-A2.
PR	27-AUG-1999;	99US-0151066P.	XX	XX	06-SEP-2000.
PR	27-AUG-1999;	99US-0151080P.	XX	XX	25-FEB-2000; 2000EP-00301439.
PR	30-AUG-1999;	99US-0151303P.	XX	XX	25-FEB-1999; 99US-0121025P.
PR	31-AUG-1999;	99US-0151438P.	PR	PR	05-MAR-1999; 99US-0123180P.
PR	01-SEP-1999;	99US-0151930P.	PR	PR	09-MAR-1999; 99US-0123548P.
PR	07-SEP-1999;	99US-0152363P.	PR	PR	23-MAR-1999; 99US-0125788P.
PR	10-SEP-1999;	99US-0153070P.	PR	PR	23-MAR-1999; 99US-0126264P.
PR	13-SEP-1999;	99US-0153758P.	PR	PR	23-MAR-1999; 99US-0126785P.
PR	15-SEP-1999;	99US-0154018P.	PR	PR	01-APR-1999; 99US-0127462P.
PR	16-SEP-1999;	99US-0154039P.	PR	PR	06-APR-1999; 99US-0128234P.
PR	20-SEP-1999;	99US-0154775P.	PR	PR	08-APR-1999; 99US-0128714P.
PR	22-SEP-1999;	99US-0155138P.	PR	PR	16-APR-1999; 99US-0129845P.
PR	23-SEP-1999;	99US-0155486P.	PR	PR	19-APR-1999; 99US-0130077P.
PR	24-SEP-1999;	99US-0155659P.	PR	PR	21-APR-1999; 99US-0130449P.
PR	28-SEP-1999;	99US-0156458P.	PR	PR	23-APR-1999; 99US-0130510P.
PR	29-SEP-1999;	99US-0156596P.	PR	PR	23-APR-1999; 99US-0130891P.
PR	04-OCT-1999;	99US-0157117P.	PR	PR	30-APR-1999; 99US-0132407P.
PR	05-OCT-1999;	99US-0157753P.	PR	PR	04-MAY-1999; 99US-0132484P.
PR	06-OCT-1999;	99US-0157865P.	PR	PR	05-MAY-1999; 99US-0132485P.
PR	07-OCT-1999;	99US-0158029P.	PR	PR	06-MAY-1999; 99US-0132486P.
PR	08-OCT-1999;	99US-0158232P.	PR	PR	06-MAY-1999; 99US-0132863P.
PR	12-OCT-1999;	99US-0158369P.	PR	PR	11-MAY-1999; 99US-0134256P.
PR	13-OCT-1999;	99US-0159293P.	PR	PR	14-MAY-1999; 99US-0134218P.
PR	13-OCT-1999;	99US-0159294P.	PR	PR	14-MAY-1999; 99US-0134219P.
PR	13-OCT-1999;	99US-0159295P.	PR	PR	14-MAY-1999; 99US-0134221P.
PR	14-OCT-1999;	99US-0159322P.	PR	PR	14-MAY-1999; 99US-0134370P.
PR	14-OCT-1999;	99US-0159330P.	PR	PR	18-MAY-1999; 99US-0134768P.
PR	14-OCT-1999;	99US-0159331P.	PR	PR	19-MAY-1999; 99US-0134941P.
PR	14-OCT-1999;	99US-0159637P.	PR	PR	20-MAY-1999; 99US-0135124P.
PR	14-OCT-1999;	99US-0159638P.	PR	PR	21-MAY-1999; 99US-0135353P.
PR	18-OCT-1999;	99US-0159584P.	PR	PR	24-MAY-1999; 99US-0135629P.
PR	21-OCT-1999;	99US-0160741P.	PR	PR	25-MAY-1999; 99US-0136021P.
PR	21-OCT-1999;	99US-0160767P.	PR	PR	27-MAY-1999; 99US-0136392P.
PR	21-OCT-1999;	99US-0160768P.	PR	PR	28-MAY-1999; 99US-0136782P.
PR	21-OCT-1999;	99US-0160770P.	PR	PR	01-JUN-1999; 99US-0137222P.
PR	21-OCT-1999;	99US-0160814P.	PR	PR	03-JUN-1999; 99US-0137528P.
PR	21-OCT-1999;	99US-0160815P.	PR	PR	04-JUN-1999; 99US-0137502P.
PR	22-OCT-1999;	99US-0160980P.	PR	PR	07-JUN-1999; 99US-0137724P.
PR	22-OCT-1999;	99US-0160981P.	PR	PR	08-JUN-1999; 99US-0138094P.
PR	22-OCT-1999;	99US-0160982P.	PR	PR	10-JUN-1999; 99US-0138540P.
PR	22-OCT-1999;	99US-0160983P.	PR	PR	10-JUN-1999; 99US-0138647P.
PR	25-OCT-1999;	99US-0161404P.	PR	PR	14-JUN-1999; 99US-0139119P.
PR	25-OCT-1999;	99US-0161406P.	PR	PR	16-JUN-1999; 99US-0139452P.
PR	25-OCT-1999;	99US-0161359P.	PR	PR	16-JUN-1999; 99US-0139453P.
PR	26-OCT-1999;	99US-0161360P.	PR	PR	17-JUN-1999; 99US-0139492P.
PR	26-OCT-1999;	99US-0161361P.	PR	PR	18-JUN-1999; 99US-0139454P.
PR	26-OCT-1999;	99US-0161362P.	PR	PR	18-JUN-1999; 99US-0139455P.
PR	28-OCT-1999;	99US-0161920P.	PR	PR	18-JUN-1999; 99US-0139456P.
PR	28-OCT-1999;	99US-0161992P.	PR	PR	18-JUN-1999; 99US-0139457P.
PR	28-OCT-1999;	99US-0161993P.	PR	PR	18-JUN-1999; 99US-0139458P.
PR	29-OCT-1999;	99US-0162142P.	PR	PR	18-JUN-1999; 99US-0139459P.
PR	29-OCT-1999;	99US-0162143P.	PR	PR	18-JUN-1999; 99US-0139460P.

Query Match 50.8%; Score 135; DB 3; Length 350;
Best Local Similarity 46.9%; Pred. No. 9.9e-07;
Matches 23; Conservative 5; Mismatches 15; Indels 6; Gaps 1;
QY 2 CIIICQDLHDCVSLQFCMHTFCAACYSGWMMRSS-----LCPTCRCPV 44
DB 22 CSICLINIWHDVVTAAPCLINFCNGCFSEWMMRSSEKHKHVLCPQCRTTV 70

PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 24-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142300P.
PR 08-JUL-1999; 99US-0142803P.
PR 08-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 20-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.

PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 11-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 13-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 23-AUG-1999; 99US-0150566P.
PR 23-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 08-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161952P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 50.8%; Score 135; DB 3; Length 350;
Best Local Similarity 46.9%; Pred. No. 9.9e-07;
Matches 23; Conservative 5; Mismatches 15; Indels 6; Gaps 1;

26-JUL-2000; 2000US-0220964P.
14-AUG-2000; 2000US-0224518P.
14-AUG-2000; 2000US-0224519P.
14-AUG-2000; 2000US-0225267P.
14-AUG-2000; 2000US-0225270P.
14-AUG-2000; 2000US-0225447P.
14-AUG-2000; 2000US-0225757P.
14-AUG-2000; 2000US-0225758P.
22-AUG-2000; 2000US-0226688P.
22-AUG-2000; 2000US-0226924P.
30-AUG-2000; 2000US-0229287P.
01-SEP-2000; 2000US-0229343P.
01-SEP-2000; 2000US-0229344P.
01-SEP-2000; 2000US-0229345P.
05-SEP-2000; 2000US-0229509P.
08-SEP-2000; 2000US-0229513P.
08-SEP-2000; 2000US-0231413P.
21-SEP-2000; 2000US-0234223P.
21-SEP-2000; 2000US-0234274P.
25-SEP-2000; 2000US-0234997P.
27-SEP-2000; 2000US-0235834P.
29-SEP-2000; 2000US-0236327P.
29-SEP-2000; 2000US-0236367P.
29-SEP-2000; 2000US-0236368P.
29-SEP-2000; 2000US-0236369P.
29-SEP-2000; 2000US-0236370P.
02-OCT-2000; 2000US-0236802P.
02-OCT-2000; 2000US-0237037P.
02-OCT-2000; 2000US-0237038P.
02-OCT-2000; 2000US-0237039P.
02-OCT-2000; 2000US-0237040P.
13-OCT-2000; 2000US-0239335P.
20-OCT-2000; 2000US-0240960P.
20-OCT-2000; 2000US-0241785P.
20-OCT-2000; 2000US-0241809P.
01-NOV-2000; 2000US-0244617P.
18-NOV-2000; 2000US-0249239P.
08-DEC-2000; 2000US-0251856P.
08-DEC-2000; 2000US-0251868P.
08-DEC-2000; 2000US-0251869P.

(ROSE/) ROSEN C A.
(RUBE/) RUBEN S M.
(BARA/) BARASH S C.

Rosen CA, Ruben SM, Barash SC;
WPI; 2003-147444/14.
N-PSDB; ABX73645.

New polypeptides and nucleic acids, useful in gene therapy for treating, inhibiting or preventing e.g. neural, immune system, muscular, respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or renal disorders.

Claim 11; SEQ ID NO 1270; 402pp; English.

The invention relates to human novel polypeptides and their associated polynucleotides. The polypeptides and polynucleotides are useful in gene therapy for treating, inhibiting or preventing neural disorders, immune system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis), muscular disorders, respiratory diseases (e.g. nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left heart syndrome), renal disorders (e.g. acute kidney failure and end-stage renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and leukemia), inflammatory diseases (e.g. septic shock, bursitis and appendicitis), allergic reactions and conditions (e.g. asthma), blood related disorders (e.g. thrombosis, atherosclerosis and myocardial infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and ABU55748 represent human novel polypeptides of the invention

XX SQ Sequence 230 AA;
Query Match 66.2%; Score 176; DB 6; Length 230;
Best Local Similarity 100.0%; Pred. No. 2,7e-11;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 17 PMETFCACYSGWMSRSSLCPTCRCPV 44
DB 5 PMETFCACYSGWMSRSSLCPTCRCPV 32

RESULT 10
AAG20354
ID AAG20354 standard; protein; 350 AA.
XX
AC AAG20354;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 22507.
XX
KW Protein identification; signal transduction pathway; metabolic pathway; hybridisation assay; genetic mapping; gene expression control; promoter; termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 09-MAR-1999; 99US-0123180P.
PR 05-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 06-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 28-APR-1999; 99US-0130891P.
PR 30-APR-1999; 99US-0131443P.
PR 30-APR-1999; 99US-0132048P.
PR 04-MAY-1999; 99US-0132407P.
PR 05-MAY-1999; 99US-0132484P.
PR 06-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 07-MAY-1999; 99US-0132487P.
PR 11-MAY-1999; 99US-0132863P.
PR 14-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135623P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.

PT	used as food additives or preservatives.	PT	used as food additives or preservatives.
XX	Claim 11; SEQ ID NO 1270; 980pp; English.	XX	Claim 11; SEQ ID NO 1270; 980pp; English.
PS	The invention relates to isolated nucleic acid molecules and their	PS	The invention relates to isolated nucleic acid molecules and their
XX	encoded secreted proteins. The nucleic acids and proteins are used to	XX	encoded secreted proteins. The nucleic acids and proteins are used to
CC	prevent, treat or ameliorate a medical condition in e.g. humans, mice,	CC	prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC	rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used	CC	rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC	in diagnosing a pathological condition or susceptibility to a	CC	in diagnosing a pathological condition or susceptibility to a
CC	pathological condition. Antibodies to the proteins can also be used in	CC	pathological condition. Antibodies to the proteins can also be used in
CC	alleviating symptoms associated with the disorders and in diagnostic	CC	alleviating symptoms associated with the disorders and in diagnostic
CC	immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays	CC	immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC	(ELISA). Disorders which are diagnosed or treated include autoimmune	CC	(ELISA). Disorders which are diagnosed or treated include autoimmune
CC	diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.	CC	diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC	neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac	CC	neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC	arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,	CC	arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC	nervous system disorders e.g. Alzheimer's disease, infections caused by	CC	nervous system disorders e.g. Alzheimer's disease, infections caused by
CC	bacteria, viruses and fungi and ocular disorders e.g. corneal infection,	CC	bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC	and many other disorders listed in the specification. The polypeptides	CC	and many other disorders listed in the specification. The polypeptides
CC	can also be used to aid wound healing and epithelial cell proliferation,	CC	can also be used to aid wound healing and epithelial cell proliferation,
CC	to prevent skin aging due to sunburn, to maintain organs before	CC	to prevent skin aging due to sunburn, to maintain organs before
CC	transplantation, for supporting cell culture of primary tissues, to	CC	transplantation, for supporting cell culture of primary tissues, to
CC	regenerate tissues and in chemotaxis. The polypeptides can also be used	CC	regenerate tissues and in chemotaxis. The polypeptides can also be used
CC	as a food additive or preservative to increase or decrease storage	CC	as a food additive or preservative to increase or decrease storage
CC	capabilities, fat content, lipid, protein, carbohydrate, vitamins,	CC	capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC	minerals, cofactors and other nutritional components. The present	CC	minerals, cofactors and other nutritional components. The present
CC	sequence represents a novel secreted protein of the invention. Note: The	CC	sequence represents a novel secreted protein of the invention. Note: The
CC	sequence data for this patent did not form part of the printed	CC	sequence data for this patent did not form part of the printed
Query Match 66.2%; Score 176; DB 4; Length 230;			
Best Local Similarity 100.0%; Pred. No. 2.7e-11;			
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	17 PCWHFTCAACYSYSGWERSLCTCRCPV 44	QY	17 PCWHFTCAACYSYSGWERSLCTCRCPV 44
Db	5 PCWHFTCAACYSYSGWERSLCTCRCPV 32	Db	5 PCWHFTCAACYSYSGWERSLCTCRCPV 32
RESULT 9			
ABU55386	ID ABU55386 standard; protein; 230 AA.	ABU55386	ID ABU55386 standard; protein; 230 AA.
XX	ABU55386;	XX	ABU55386;
AC	18-MAR-2003 (first entry)	AC	18-MAR-2003 (first entry)
XX	Human novel polypeptide #473.	XX	Human novel polypeptide #473.
DE	Human; neural disorder; immune system disorder; renal disorder;	DE	Human; neural disorder; immune system disorder; renal disorder;
XX	muscular disorder; respiratory disease; reproductive disorder;	XX	muscular disorder; respiratory disease; reproductive disorder;
KW	gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;	KW	gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW	hyperproliferative disorder; inflammatory disease; allergic reaction;	KW	hyperproliferative disorder; inflammatory disease; allergic reaction;
KW	blood related disorder; cancer; immunosuppressive; antiinflammatory;	KW	blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW	cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;	KW	cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW	haemostatic; antiarteriosclerotic.	KW	haemostatic; antiarteriosclerotic.
XX	Homo sapiens.	XX	Homo sapiens.
OS	US2002132753-A1.	OS	US2002132753-A1.
XX	19-SEP-2002.	XX	19-SEP-2002.
PN	17-JAN-2001; 2001US-00764864.	PN	17-JAN-2001; 2001US-00764864.
PD	31-JAN-2000; 2000US-0179065P.	PD	31-JAN-2000; 2000US-0179065P.
PF	04-FEB-2000; 2000US-0180628P.	PF	04-FEB-2000; 2000US-0180628P.
XX	28-JUN-2000; 2000US-0214886P.	XX	28-JUN-2000; 2000US-0214886P.
PR	07-JUL-2000; 2000US-0216647P.	PR	07-JUL-2000; 2000US-0216647P.
PR	07-JUL-2000; 2000US-0216800P.	PR	07-JUL-2000; 2000US-0216800P.
PR	11-JUL-2000; 2000US-0217487P.	PR	11-JUL-2000; 2000US-0217487P.
PR	11-JUL-2000; 2000US-0217496P.	PR	11-JUL-2000; 2000US-0217496P.
PR	14-JUL-2000; 2000US-0218290P.	PR	14-JUL-2000; 2000US-0218290P.
PR	26-JUL-2000; 2000US-0220963P.	PR	26-JUL-2000; 2000US-0220963P.
PA	(HUMA-) HUMAN GENOME SCI INC.	PA	(HUMA-) HUMAN GENOME SCI INC.
XX	Rosen CA, Barash SC, Ruben SM;	XX	Rosen CA, Barash SC, Ruben SM;
PI	WPI; 2001-488783/53.	PI	WPI; 2001-488783/53.
XX	N-PSDB; AAS26304.	XX	N-PSDB; AAS26304.
DR	New nucleic acid molecules encoding 461 human secreted proteins for	DR	New nucleic acid molecules encoding 461 human secreted proteins for
PT	diagnosing, preventing, treating or ameliorating medical conditions and	PT	diagnosing, preventing, treating or ameliorating medical conditions and

DR WPI: 2001-182927/18.
DR N-PSDB; AAF30352.
XX Novel nucleic acid sequence of mitotic checkpoint gene encoding a
PT checkpoint with forkhead-associated domain and ring finger protein, for
PT diagnosing tumorigenic cells and in screening for anticancer drugs.
XX
XX
PS Claim 8(a); Fig 4A-C; 85pp; English.
XX
CC The present sequence is that of human mitotic checkpoint protein Chfr,
CC having a forkhead associated domain (FHA) and a ring finger domain. The
CC protein is required for regulation of the transition of cells from
CC prophase to metaphase during mitosis. It has ubiquitin-protein ligase
CC activity. The Chfr checkpoint was evident in primary human cells, but was
CC inactivated in 4 of 8 human cancer cell lines. In U2OS cells, a mutation
CC was identified that caused a Val to Met amino acid substitution in the
CC highly conserved C-terminal Cys-rich region of the Chfr protein. In the
CC absence of the Chfr checkpoint, cells subjected to mitotic stress
CC condensed their chromosomes despite failing to separate their
CC chromosomes. Chfr may monitor centrosome separation. Inactivation of the
CC Chfr gene (see AAF30352) in human cancer is theorized to underlie the
CC increased sensitivity of cancer cells to antimetabolic drugs. Polypeptides
CC comprising the present sequence, or sequences comprising at least amino
CC acids 31-103, 303-345 and/or 476-641 of this sequence, are claimed.
CC Claimed methods of determining the tumorigenic potential of a cell
CC comprise examining the cell for the presence of Chfr expression or for
CC the presence of Chfr-mediated ubiquitin-protein ligase activity (in both
CC cases, absence of expression indicating predisposition to tumorigenesis
CC upon exposure to mitotic stress). A diagnostic kit for detecting the
CC tumorigenic potential of cell cells comprises may comprise a ligand that
CC binds to Chfr, such as an antibody or its fragment. Inhibitors of Chfr
CC are identified by monitoring their effect on Chfr expression, and are
CC used to retard the growth of cancer cells
XX
SQ Sequence 664 AA;
Query Match 100.0%; Score 266; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 1.3e-20;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TCICODLLHDCVSLQPCMHHTCAACYSGWMMERSLCPTRCPV 44
DB 303 TCICODLLHDCVSLQPCMHHTCAACYSGWMMERSLCPTRCPV 346
RESULT 8
AAU16317
XX ID AAU16317 standard; protein; 230 AA.
XX AC AAU16317;
XX DT 07-NOV-2001 (first entry)
XX DE Human novel secreted protein, Seq ID 1270.
XX Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX
XX Homo sapiens.
XX WO20015322-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001341.
XX
XX

PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 17-MAR-2000; 2000US-0189874P.
PR 16-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 14-JUL-2000; 2000US-0217966P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226688P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.

PR 29-JUL-1999; 99JP-00248036.
 PR 27-AUG-1999; 99JP-00300253.
 PR 11-JAN-2000; 2000JP-00118776.
 PR 03-MAY-2000; 2000JP-00183767.
 PR 09-JUN-2000; 2000JP-00241899.
 XX (HELI-) HELIX RES INST.
 PA Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
 PI Iehli S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
 XX WPI; 2001-318749/34.
 DR
 XX
 XX Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
 XX
 PS Claim 8; SEQ ID NO 12100; 2537pp + Sequence Listing; English.
 XX
 CC The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises:
 CC (a) an oligo-dT primer and an oligonucleotide complementary to the
 CC complementary strand of a polynucleotide which comprises one of the 5602
 CC nucleotide sequences defined in the specification, where the
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
 CC of an oligonucleotide comprising a sequence complementary to the
 CC complementary strand of a polynucleotide which comprises a 5'-end
 CC sequence and an oligonucleotide comprising a sequence complementary to a
 CC polynucleotide which comprises a 3'-end sequence, where the
 CC oligonucleotide comprises at least 15 nucleotides and the combination of
 CC the 5'-end sequence/3'-end sequence is selected from those defined in the
 CC specification. The primer sets can be used in antisense therapy and in
 CC gene therapy. The primers are useful for synthesizing polynucleotides,
 CC particularly full-length cDNAs. The primers are also useful for the
 CC detection and/or diagnosis of the abnormality of the proteins encoded by
 CC the full-length cDNAs. The primers allow obtaining of the full-length
 CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
 CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893
 CC represent human amino acid sequences; and AAH13629 to AAH13632 represent
 CC oligonucleotides, all of which are used in the exemplification of the
 CC present invention
 XX
 XX Sequence 652 AA;
 Query Match 100.0%; Score 266; DB 4; Length 652;
 Best Local Similarity 100.0%; Pred. No. 1.3e-20;
 Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 TCIIQDLHDCVSLQPCMTFCAACYSYSGWMSRLCPTCRCPV 44
 Db 291 TCIIQDLHDCVSLQPCMTFCAACYSYSGWMSRLCPTCRCPV 334
 RESULT 6
 AAB33843
 ID AAB33843 standard; protein; 664 AA.
 XX
 AC AAB33843;
 XX
 XX 22-AUG-2001 (first entry)
 DT
 XX
 DE Amino acid sequence of a human ring finger protein designated FHAR1.
 KW FHAR1; RING finger protein; cancer; vaccine.
 OS Homo sapiens.
 XX
 XX WO200142430-A1.
 PN
 XX
 XX 14-JUN-2001.
 PD
 XX
 XX 07-DEC-2000; 2000WO-US033094.

XX
 PR 08-DEC-1999; 99US-00456876.
 XX (SMIK) SMITHKLINE BEECHAM CORP.
 PA
 XX Zhou B, Zhu Y, Chaturvedi P, Hurler MR, Li X;
 PI
 XX WPI; 2001-381663/40.
 DR N-PSDB; AAF89709.
 DR
 XX New FHAR1 polypeptide, a member of the RING finger protein family for
 PT diagnosing and treating cancer, and for use in anti-cancer vaccines.
 PT
 XX
 PS Claim 1; Page 19; 28pp; English.
 XX
 CC The present sequence represents a FHAR1 polypeptide, which is a member of
 CC the RING finger protein family. FHAR1 is useful in the treatment of
 CC cancer, and as a vaccine for inducing an immunological response in a
 CC mammal. FHAR1 polynucleotides may also be used as a diagnostic reagent
 CC through detection of mutations in the associated gene, and for chromosome
 CC localization studies, and tissue expression studies. FHAR1 antibodies are
 CC useful to isolate and to identify clones expressing the polypeptides, or
 CC to purify the polypeptides by affinity chromatography and to treat cancer
 XX
 SQ Sequence 664 AA;
 Query Match 100.0%; Score 266; DB 4; Length 664;
 Best Local Similarity 100.0%; Pred. No. 1.3e-20;
 Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 TCIIQDLHDCVSLQPCMTFCAACYSYSGWMSRLCPTCRCPV 44
 Db 303 TCIIQDLHDCVSLQPCMTFCAACYSYSGWMSRLCPTCRCPV 346
 RESULT 7
 AAB20219
 ID AAB20219 standard; protein; 664 AA.
 XX
 AC AAB20219;
 XX
 XX 14-MAY-2001 (first entry)
 DT
 XX
 DE Human Chfr (checkpoint with FHA and ring finger) protein.
 XX
 KW Checkpoint with forkhead associated domain and ring finger; Chfr; human;
 KW mitosis; cell cycle; tumour; diagnosis; antitumour; drug screening;
 KW ubiquitin-protein ligase.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Domain 31..103
 FT /label= Forkhead-associated_domain
 FT Domain 303..346
 FT /label= Ring_finger-domain
 FT Region 476..641
 FT /note= "cysteine-rich region"
 FT Misc-difference 580
 FT /note= "Met in U2OS cells"
 FT
 XX WO200109150-A2.
 PN
 XX
 XX 08-FEB-2001.
 PD
 XX
 XX 14-JUN-2000; 2000WO-US016391.
 PF
 XX
 XX 29-JUL-1999; 99US-0146194P.
 PR
 XX (WIST-) WISTAR INST ANATOMY & BIOLOGY.
 PA
 XX Halazonetis T, Scolnick D;
 PI
 XX

DE Human protein sequence SEQ ID NO:12128.
XX Human; primer; detection; diagnosis; antisense therapy; gene therapy.
KW Homo sapiens.
OS Homo sapiens.
XX EP1074617-A2.
XX 07-FEB-2001.
XX 28-JUL-2000; 2000EP-00116126.
XX 29-JUL-1999; 99JP-00248036.
XX 27-AUG-1999; 99JP-00300253.
XX 11-JAN-2000; 2000JP-00118776.
XX 02-MAY-2000; 2000JP-00183767.
XX 09-JUN-2000; 2000JP-00241899.
XX (HELI-) HELIX RES INST.
XX Ota T, Isogai T, Nishikawa T, Hayaashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX WPI; 2001-318749/34.
XX Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
XX Claim 8; SEQ ID NO 12128; 2537pp + Sequence Listing; English.
XX The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises:
CC (a) an oligo-dT primer and an oligonucleotide complementary to the
CC complementary strand of a polynucleotide which comprises one of the 5602
CC nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in the
CC specification. The primer sets can be used in antisense therapy and in
CC gene therapy. The primers are useful for synthesizing polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAH92445 to AAH95893
CC represent human amino acid sequences; and AAH13629 to AAH13632 represent
CC oligonucleotides, all of which are used in the exemplification of the
CC present invention
XX Sequence 623 AA;
XX Query Match 100.0%; Score 266; DB 4; Length 623;
XX Best Local Similarity 100.0%; Pred. No. 1.3e-20;
XX Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TCIIQDILLHDCVSLQPCMTFFCAACYSYGMWERSLLCPTCRCPV 44
DB 262 TCIIQDILLHDCVSLQPCMTFFCAACYSYGMWERSLLCPTCRCPV 305
RESULT 4
ABB97233
ID ABB97233 standard; protein; 623 AA.
XX AC ABB97233;
XX DT 27-JUN-2002 (first entry)

XX Novel human protein SEQ ID NO: 501.
XX Human; antinaemic; vulnary; antiinflammatory; immunomodulator;
KW antifertility; cerebroprotective; cytosatic; rheumatic; gene therapy;
KW neuroprotective; antiparkinsonian; protein therapy; EST;
XX expressed sequence tag.
XX Homo sapiens.
XX WO200222560-A2.
XX 21-MAR-2002.
XX 10-SEP-2001; 2001WO-US026015.
XX 11-SEP-2000; 2000US-00659671.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI Xue AJ, Yang Y, Wehrman T, Drmanac RT;
XX WPI; 2002-292408/33.
XX N-PSDB; AEN32419.
XX An isolated polynucleotide for treating diseases associated with its
PT encoded polypeptide such as cancer and multiple sclerosis.
XX Example 2; SEQ ID NO 501; 509pp; English.
XX The present invention provides the protein and coding sequences of 444
CC novel human proteins. These were isolated from expressed sequences tags
CC (ESTs). They can be used to stimulate cell growth, to regulate
CC haematopoiesis e.g. to treat aplastic anaemia, to help tissue regrowth
CC e.g. in burn treatment, to regulate the immune system e.g. to treat
CC multiple sclerosis, to regulate activin or inhibin e.g. to treat
CC infertility, to regulate haemostasis or thrombolysis e.g. to treat stroke
CC and cancer, to screen for drugs, to treat inflammatory conditions e.g.
CC rheumatoid arthritis, and to treat nervous system disorders e.g.
CC Parkinson's disease. The present sequence is a protein of the invention
XX Sequence 623 AA;
XX Query Match 100.0%; Score 266; DB 5; Length 623;
XX Best Local Similarity 100.0%; Pred. No. 1.3e-20;
XX Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TCIIQDILLHDCVSLQPCMTFFCAACYSYGMWERSLLCPTCRCPV 44
DB 262 TCIIQDILLHDCVSLQPCMTFFCAACYSYGMWERSLLCPTCRCPV 305
RESULT 5
AAB93168
ID AAB93168 standard; protein; 652 AA.
XX AC AAB93168;
XX DT 26-JUN-2001 (first entry)
XX Human protein sequence SEQ ID NO:12100.
XX Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX Homo sapiens.
XX EP1074617-A2.
XX 07-FEB-2001.
XX 28-JUL-2000; 2000EP-00116126.

CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed

Query Match 100.0%; Score 266; DB 4; Length 426;
Best Local Similarity 100.0%; Pred. No. 9.2e-21;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIICDILLHDCVSLQPCMTTFCACYSYGMWSSSLCPTCRCPV 44
DB 213 TCIIICDILLHDCVSLQPCMTTFCACYSYGMWSSSLCPTCRCPV 256

RESULT 2
ABU54925
ID ABU54925 standard; protein; 426 AA.

AC ABU54925;
DT 18-MAR-2003 (first entry)
DE Human novel polypeptide #12.

XX Human; neural disorder; immune system disorder; renal disorder;
XX muscular disorder; respiratory disease; reproductive disorder;
XX gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
XX hyperproliferative disorder; inflammatory disease; allergic reaction;
XX blood related disorder; cancer; immunosuppressive; antiinflammatory;
XX cardiovascular; nephrotropic; cycostatic; antiallergic; thrombolytic;
XX haemostatic; antiarteriosclerotic.

XX Homo sapiens.

OS Homo sapiens.

XX US2002132753-A1.

XX 19-SEP-2002.

XX 17-JAN-2001; 2001US-00764864.

XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0216847P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220984P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 22-AUG-2000; 2000US-0226868P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.

PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251869P.

XX (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
XX (BARA/) BARASH S C.

XX Rosen CA, Ruben SM, Barash SC;

XX WPI; 2003-147444/14.
XX N-PSDB; ABX73184.

XX New polypeptides and nucleic acids, useful in gene therapy for treating,
PT inhibiting or preventing e.g. neural, immune system, muscular,
PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
PT renal disorders.

XX Claim 11; SEQ ID NO 809; 402pp; English.

XX The invention relates to human novel polypeptides and their associated
CC polynucleotides. The polypeptides and polynucleotides are useful in gene
CC therapy for treating, inhibiting or preventing neural disorders, immune
CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
CC leukemia), inflammatory diseases (e.g. septic shock, bursitis and
CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
CC infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
CC ABU55748 represent human novel polypeptides of the invention

XX Sequence 426 AA;

Query Match 100.0%; Score 266; DB 6; Length 426;
Best Local Similarity 100.0%; Pred. No. 9.2e-21;
Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCIIICDILLHDCVSLQPCMTTFCACYSYGMWSSSLCPTCRCPV 44
DB 213 TCIIICDILLHDCVSLQPCMTTFCACYSYGMWSSSLCPTCRCPV 256

RESULT 3
AAB93182
ID AAB93182 standard; protein; 623 AA.

XX AAB93182;
XX 26-JUN-2001 (first entry)

PR	14-AUG-2000;	2000US-02252113P.	PR	08-NOV-2000;	2000US-0246523P.
PR	14-AUG-2000;	2000US-0225214P.	PR	08-NOV-2000;	2000US-0246524P.
PR	14-AUG-2000;	2000US-0225266P.	PR	08-NOV-2000;	2000US-0246525P.
PR	14-AUG-2000;	2000US-0225267P.	PR	08-NOV-2000;	2000US-0246526P.
PR	14-AUG-2000;	2000US-0225268P.	PR	08-NOV-2000;	2000US-0246527P.
PR	14-AUG-2000;	2000US-0225270P.	PR	08-NOV-2000;	2000US-0246528P.
PR	14-AUG-2000;	2000US-0225447P.	PR	08-NOV-2000;	2000US-0246532P.
PR	14-AUG-2000;	2000US-0225757P.	PR	08-NOV-2000;	2000US-0246609P.
PR	14-AUG-2000;	2000US-0225759P.	PR	08-NOV-2000;	2000US-0246610P.
PR	14-AUG-2000;	2000US-0226279P.	PR	08-NOV-2000;	2000US-0246611P.
PR	22-AUG-2000;	2000US-0226681P.	PR	08-NOV-2000;	2000US-0246613P.
PR	22-AUG-2000;	2000US-0226686P.	PR	17-NOV-2000;	2000US-0249207P.
PR	22-AUG-2000;	2000US-0227182P.	PR	17-NOV-2000;	2000US-0249208P.
PR	23-AUG-2000;	2000US-0227009P.	PR	17-NOV-2000;	2000US-0249210P.
PR	30-AUG-2000;	2000US-0228924P.	PR	17-NOV-2000;	2000US-0249211P.
PR	01-SEP-2000;	2000US-0229287P.	PR	17-NOV-2000;	2000US-0249212P.
PR	01-SEP-2000;	2000US-0229343P.	PR	17-NOV-2000;	2000US-0249213P.
PR	01-SEP-2000;	2000US-0229344P.	PR	17-NOV-2000;	2000US-0249214P.
PR	01-SEP-2000;	2000US-0229345P.	PR	17-NOV-2000;	2000US-0249215P.
PR	05-SEP-2000;	2000US-0229509P.	PR	17-NOV-2000;	2000US-0249216P.
PR	06-SEP-2000;	2000US-0229513P.	PR	17-NOV-2000;	2000US-0249217P.
PR	06-SEP-2000;	2000US-0230437P.	PR	17-NOV-2000;	2000US-0249218P.
PR	08-SEP-2000;	2000US-0230438P.	PR	17-NOV-2000;	2000US-0249219P.
PR	08-SEP-2000;	2000US-0231243P.	PR	17-NOV-2000;	2000US-0249220P.
PR	08-SEP-2000;	2000US-0231243P.	PR	17-NOV-2000;	2000US-0249221P.
PR	08-SEP-2000;	2000US-0231244P.	PR	17-NOV-2000;	2000US-0249221P.
PR	08-SEP-2000;	2000US-0231413P.	PR	17-NOV-2000;	2000US-0249224P.
PR	08-SEP-2000;	2000US-0231414P.	PR	17-NOV-2000;	2000US-0249245P.
PR	08-SEP-2000;	2000US-0232080P.	PR	17-NOV-2000;	2000US-0249245P.
PR	08-SEP-2000;	2000US-0232081P.	PR	17-NOV-2000;	2000US-0249264P.
PR	12-SEP-2000;	2000US-0231968P.	PR	17-NOV-2000;	2000US-0249265P.
PR	14-SEP-2000;	2000US-0232397P.	PR	17-NOV-2000;	2000US-0249265P.
PR	14-SEP-2000;	2000US-0232398P.	PR	17-NOV-2000;	2000US-0249297P.
PR	14-SEP-2000;	2000US-0232399P.	PR	17-NOV-2000;	2000US-0249299P.
PR	14-SEP-2000;	2000US-0232400P.	PR	17-NOV-2000;	2000US-0249300P.
PR	14-SEP-2000;	2000US-0232401P.	PR	01-DEC-2000;	2000US-0250160P.
PR	14-SEP-2000;	2000US-0233063P.	PR	01-DEC-2000;	2000US-0250391P.
PR	14-SEP-2000;	2000US-0233064P.	PR	05-DEC-2000;	2000US-0251030P.
PR	14-SEP-2000;	2000US-0233065P.	PR	05-DEC-2000;	2000US-0251988P.
PR	14-SEP-2000;	2000US-0233065P.	PR	05-DEC-2000;	2000US-0251988P.
PR	21-SEP-2000;	2000US-0234223P.	PR	05-DEC-2000;	2000US-0255671P.
PR	21-SEP-2000;	2000US-0234223P.	PR	05-DEC-2000;	2000US-0255671P.
PR	21-SEP-2000;	2000US-0234997P.	PR	05-DEC-2000;	2000US-0255671P.
PR	25-SEP-2000;	2000US-0234998P.	PR	05-DEC-2000;	2000US-0255671P.
PR	25-SEP-2000;	2000US-0234998P.	PR	05-DEC-2000;	2000US-0255671P.
PR	25-SEP-2000;	2000US-0235484P.	PR	05-DEC-2000;	2000US-0255671P.
PR	25-SEP-2000;	2000US-0235834P.	PR	05-DEC-2000;	2000US-0255671P.
PR	27-SEP-2000;	2000US-0235836P.	PR	05-DEC-2000;	2000US-0255671P.
PR	29-SEP-2000;	2000US-0236327P.	PR	05-DEC-2000;	2000US-0255671P.
PR	29-SEP-2000;	2000US-0236367			

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:36:57 ; Search time 9.01373 Seconds
(without alignments)
1379.240 Million cell updates/sec

Title: US-10-048-046-2_COPY_303_346

Perfect score: 266
Sequence: 1 TCICQDLHDCVSLQCMH.....ACVSGWMSRLSPTCRCPV 44

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_29Jan04:*
1: Geneseq1980s:*
2: Geneseq1990s:*
3: Geneseq2000s:*
4: Geneseq2001s:*
5: Geneseq2002s:*
6: Geneseq2003as:*
7: Geneseq2003bs:*
8: Geneseq2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	266	100.0	426	AAU15856	Aau15856 Human nov
2	266	100.0	426	ABU54925	Abu54925 Human nov
3	266	100.0	623	AAU93182	Aau93182 Human pro
4	266	100.0	623	ABU97233	Abu97233 Novel hum
5	266	100.0	652	AAU93168	Aau93168 Human pro
6	266	100.0	664	AAU83843	Aau83843 Amino aci
7	266	100.0	664	AAU20219	Aau20219 Human Chf
8	176	66.2	230	AAU16317	Aau16317 Human nov
9	176	66.2	230	ABU53386	Abu53386 Human nov
10	135	50.8	350	AAU20354	Aau20354 Arabidops
11	135	50.8	350	AAU37660	Aau37660 Arabidops
12	135	50.8	426	AAU20353	Aau20353 Arabidops
13	135	50.8	426	AAU37659	Aau37659 Arabidops
14	135	50.8	453	AAU20352	Aau20352 Arabidops
15	135	50.8	453	AAU37658	Aau37658 Arabidops
16	129	48.5	67	AAU60624	Aau60624 Varicella
17	115	43.2	242	AAU39926	Aau39926 Human pol
18	115	43.2	247	AAU77120	Aau77120 Human pro
19	115	43.2	254	AAU79353	Aau79353 Human ova
20	115	43.2	261	AAU41712	Aau41712 Human pol
21	113.5	42.7	251	AAU06408	Aau06408 Arabidops
22	113.5	42.7	322	AAU06407	Aau06407 Arabidops
23	113.5	42.7	426	AAU06406	Aau06406 Arabidops
24	112	42.1	242	AAU79067	Aau79067 Human pro
25	111	41.7	495	ABR56805	Abu56805 Human sec

26	110	41.4	498	2	AAW80439	Aaw80439 Feline he
27	108.5	40.8	485	2	AAU95017	Aau95017 Human pro
28	107	40.2	551	2	AAW27150	Aaw27150 HMG-CoA r
29	104	39.1	330	4	AAE01417	Aae01417 Human sec
30	103	38.7	328	4	AAE01418	Aae01418 Human alb
31	103	38.7	489	5	ABG64061	Abg64061 Human alb
32	103	38.7	505	4	AAE01380	Aae01380 Human gen
33	103	38.7	616	5	ABU83078	Abu83078 Synovioli
34	103	38.7	617	5	AAE01355	Aae01355 Human gen
35	103	38.7	617	5	ABG79641	Abg79641 Human nov
36	103	38.7	617	5	ABG64063	Abg64063 Human alb
37	103	38.7	617	5	ABU83074	Abu83074 Synovioli
38	103	38.7	617	6	AAE37275	Aae37275 Human gen
39	102	38.3	328	4	ABU64164	Abu64164 Drosophi
40	101	38.0	568	3	AAU18230	Aau18230 Plasmodiu
41	100.5	37.8	499	5	AAO22598	Aao22598 499-mer S
42	100.5	37.8	1208	4	AAU95252	Aau95252 Human pro
43	100.5	37.8	1213	5	AAO22597	Aao22597 1213-mer
44	100	37.6	222	4	ABU60472	Abu60472 Drosophi
45	100	37.6	356	6	ABU65227	Abu65227 Novel hum

ALIGNMENTS

RESULT 1
AAU15856
ID AAU15856 standard; protein; 426 AA.
XX
AC AAU15856;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human novel secreted protein, Seq ID 809.
XX
KW Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX
OS Homo sapiens.
XX
PN WO200155322-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001341.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.

RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold B.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Ustin T.B., Toshiruki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young J.W., Green E.D., Dickson M.C.,
 RA Blakesley R.W., Touchan J.A., Shevchenko Y., Bouffard G.G.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
 RA Krzywinski M.I., Skalka B., Skalka U., Smallus D.E., Schnerch A., Schein J.E.,
 RA Jones S.J., Marra M.A.;
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=FVB/N; TISSUE=Colon;
 RA Strausberg R.;
 RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF076687; AAD20943.1; -
 DR EMBL; BC055061; AAH55061.1; -
 DR MGD; NGI-1351625; Nbn.
 DR GO; GO:0005634; C:nucleus; IDA.
 DR InterPro; IPR001357; BRCT.
 DR InterPro; IPR00253; FHA.
 DR InterPro; IPR008984; SMAD_FHA.
 DR Pfam; PF00533; BRCT; 1.
 DR Pfam; PF00498; FHA; 1.
 DR SMART; SM00292; BRCT; 1.
 DR SMART; SM00240; FHA; 1.
 DR PROSITE; PS00006; FHA_DOMAIN; 1.
 KW Hypothetical protein.
 SQ SEQUENCE 751 AA; 83794 MW; C9F597CC08227B2C CRC64;

Query Match 23.0%; Score 87; DB 11; Length 751;
 Best Local Similarity 26.6%; Pred. No. 0.15;
 Matches 21; Conservative 21; Mismatches 27; Indels 10; Gaps 2;
 Qy 2 LLRKREWTIGRRCCDLSFSPNKLVSGDHCRIVVD-----EKSGQVLTEDTSTSGT 52
 Db 18 LLAGEYVVG-RKNCGLIENDQSIERNHVLTVNFFVTSLSQDTDEIPTLTIKDMSKYGT 76
 Qy 53 VINKLVKKQTCPLQTGD 71
 Db 77 FVNEEKVQTGLSLTKYGD 95

RESULT 15
 Q8G6Q4 PRELIMINARY; PRT; 176 AA.
 ID Q8G6Q4
 AC Q8G6Q4
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Hypothetical protein with FHA domain.
 GN BL0584.
 OS Bifidobacterium longum.
 OC Bacteria; Actinobacteria; Actinobacteridae; Bifidobacteriales;
 OC Bifidobacteriaceae; Bifidobacterium.
 CX NCBI_TaxID=216816;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NCC 2705;
 RX MEDLINE=22294977; PubMed=12381787;
 RA Schell M.A., Karmirantzou M., Snel B., Vilanova D., Berger B.,
 RA Pessi G., Zwahlen M.-C., Desiere P., Bork P., Delley M.,

RA Pridmore R.D., Arigoni F.;
 RT "The genome sequence of Bifidobacterium longum reflects its adaptation
 RT to the human gastrointestinal tract";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:14422-14427(2002).
 DR EMBL; AB014680; AAN24408.1; -
 DR InterPro; IPR000253; FHA.
 DR InterPro; IPR008984; SMAD_FHA.
 DR Pfam; PF00498; FHA; 1.
 DR SMART; SM00240; FHA; 1.
 DR PROSITE; PS00006; FHA_DOMAIN; 1.
 KW Hypothetical protein; Complete proteome.
 SQ SEQUENCE 176 AA; 19530 MW; 1612CDF9C9A93CF6 CRC64;
 Query Match 22.8%; Score 86; DB 16; Length 176;
 Best Local Similarity 32.8%; Pred. No. 0.035;
 Matches 22; Conservative 15; Mismatches 28; Indels 2; Gaps 2;
 Qy 1 VLLRKREWTIGRRCCDLSFSPNKLVSGDHCRIVVDKSGQVLTED-TSTSGTVINKLV 59
 Db 96 VPLAADIITLGRAASNTVVL--DDEFVSSHARVYRDRSGQWAIEDLNSTNGTVVNOQRI 154
 Qy 60 VKKQTCPL 66
 Db 155 NRPTILP 161
 Search completed: May 7, 2004, 14:49:02
 Job time : 11.5607 secs

Query Match 23.0%; Score 87; DB 11; Length 751;
Best Local Similarity 26.6%; Pred. No. 0.15;

SEQUENCE FROM N.A.
STRAIN=FVB/N; TISSUE=Colon;

```
ID Q87PUO PRELIMINARY; PRT; 504 AA.
AC Q87PUO;
DT 01-JUN-2003 (TREMBLrel. 24, Created)
DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Hypothetical protein.
GN VPL111.
OS Vibrio parahaemolyticus.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Vibrionales;
OC Vibrionaceae; Vibrio.
OX NCBI_TaxID=670;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=RIMD 2210633 / Serotype O3:k6;
RX MEDLINE=22508454; PubMed=12620739;
RA Makino K., Oshima K., Kurokawa K., Yokoyama K., Uda T., Tagomori K.,
RA Iijima Y., Najima M., Nakano M., Yamashita A., Kubota Y., Kimura S.,
RA Yasunaga T., Honda T., Shinagawa H., Hattori M., Iida T.;
RA "Genome sequence of Vibrio parahaemolyticus: a pathogenic mechanism
RT distinct from that of V. cholerae.";
RL Lancet 361:743-749(2003).
DR EMBL; AP005078; BAC59674.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00498; FHA; 1.
DR PROSITE; PS50006; FHA_DOMAIN; 1.
KW Hypothetical protein: Complete proteome.
SQ SEQUENCE 504 AA; 55469 MW; 2F96C75A4F83648E CRC64;

Query Match 28.4%; Score 107.5; DB 16; Length 504;
Best Local Similarity 36.4%; Pred. No. 0.00034;
Matches 24; Conservative 12; Mismatches 27; Indels 3; Gaps 2;

QY 9 TIGRRGCDLSPS-NKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVKVKQTCPL 67
DB 31 SVGRASCTLSLHDHNFISGTHCLISV--YGTFFISDVSTGTVWNGKILKNQPISI 88
QY 68 QTGDVI 73
DB 89 VEGDGV 94

RESULT 9
Q97LQO PRELIMINARY; PRT; 159 AA.
AC Q97LQO;
DT 01-OCT-2001 (TREMBLrel. 18, Created)
DT 01-OCT-2001 (TREMBLrel. 18, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE FHA-domain containing secreted protein.
GN CAC0504.
OS Clostridium acetobutylicum.
OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC Clostridium.
OX NCBI_TaxID=1488;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 824 / DSM 792 / VKM B-1787;
RX MEDLINE=21359325; PubMed=11456286;
RA Neelling J., Berton G., Onelchenko M.V., Makarova K.S., Zeng Q.,
RA Gibson R., Lee H.M., Dubois J., Qiu D., Hitti J., Wolf Y.I.,
RA Tatusov R.L., Sabathe B., Doucette-Stamm L., Soucaille P., Daly M.J.,
RA Bennett G.N., Koonin E.V., Smith D.R.;
RA "Genome sequence and comparative analysis of the solvent-producing
RT bacterium Clostridium acetobutylicum.";
RL J. Bacteriol. 183:4823-4838(2001).
DR EMBL; AB007565; AAK78484.1; -.
DR PIR; A96962; A96962.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00498; FHA; 1.
DR SMART; SM00240; FHA; 1.
DR PROSITE; PS50006; FHA_DOMAIN; 1.
```

```
KW Complete proteome.
SQ SEQUENCE 159 AA; 17667 MW; F4P44A3D3BF05AA1 CRC64;

Query Match 23.3%; Score 88; DB 16; Length 159;
Best Local Similarity 41.4%; Pred. No. 0.018;
Matches 29; Conservative 12; Mismatches 21; Indels 8; Gaps 5;

QY 6 REWTIGRRGCDLSPS-NKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVKVKQ 63
DB 85 REITIGRKD--DNSIMLNQGVSGHARVYL--RNNQYILEDLNSGTIVLNQKI--KS 138
QY 64 TCPLQTGDVI 73
DB 139 KAVIKSGDEI 148

RESULT 10
Q8CCYO PRELIMINARY; PRT; 546 AA.
AC Q8CCYO;
DT 01-MAR-2003 (TREMBLrel. 23, Created)
DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Nibrin (Fragment).
GN NBN.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Medulla oblongata;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RL Nature 420:563-573(2002).";
DR EMBL; AK031933; BAC27610.1; -.
DR MGD; MGI:1351625; Nbn.
DR GO; GO:0005634; C:nucleus; IDA.
DR InterPro; IPR001357; BRCT.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00533; BRCT; 1.
DR Pfam; PF00498; FHA; 1.
DR SMART; SM00240; FHA; 1.
DR PROSITE; PS50006; FHA_DOMAIN; 1.
FT NON_TER 546 546
SQ SEQUENCE 546 AA; 60269 MW; 69394A2537EPEF20 CRC64;

Query Match 23.0%; Score 87; DB 11; Length 546;
Best Local Similarity 26.6%; Pred. No. 0.1;
Matches 21; Conservative 21; Mismatches 27; Indels 10; Gaps 2;

QY 2 LLRKEWTIGRRGCDLSPS-NKLVSGDHCRIVVD-----EKSGQVLTSTSGT 52
DB 18 LLAGVEYVVG-RKNGGILIENDQISRNHAILVTNFPVTSLSQDTEIPTLTIKD 76
QY 53 VINKLVKVKQTCPLQTGD 71
DB 77 FVNEEKMQTGLSCLTKTGD 95

RESULT 11
Q88981 PRELIMINARY; PRT; 751 AA.
AC Q88981;
DT 01-NOV-1998 (TREMBLrel. 08, Created)
DT 01-NOV-1998 (TREMBLrel. 08, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Nibrin.
GN NBN.
```


Db 31 VLLKREWTIGRRGCDLSFPSNKLVSQDHCRIVVDEKSGQVLTEDTSTSGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
Db 91 KKQTCPLQTGDVI 103

RESULT 5
Q8BWH4 PRELIMINARY; PRT; 254 AA.
ID Q8BWH4
AC Q8BWH4
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Similar to cell cycle checkpoint protein CHFR (Fragment).
GN 5730484M2ORIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Lung;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."
RL Nature 420:563-573(2002).
DR MGD; MGI:2444898; BAC35008.1; -.
DR EMBL; AK052473; BAC35008.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00498; FHA; 1.
DR SMART; SM00240; FHA; 1.
DR PROSITE; PS00006; FHA_DOMAIN; 1.
FT NON TER 254 254
SQ SEQUENCE 254 AA; 27819 MW; 0340571A2BAEB6EF CRC64;

Query Match 86.2%; Score 326; DB 11; Length 254;
Best Local Similarity 83.6%; Pred. No. 1.6e-30;
Matches 61; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

QY 1 VLLKREWTIGRRGCDLSFPSNKLVSQDHCRIVVDEKSGQVLTEDTSTSGTVINKLVV 60
Db 31 ILLWKREWTIGRRGCDLSFPSNKLVSQDHCKLTVDISGEVLTEDTSTNGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
Db 91 KKQTYPLQSGDII 103

RESULT 6
Q810L3 PRELIMINARY; PRT; 664 AA.
ID Q810L3
AC Q810L3
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE RIKEN CDNA 5730484M20 gene.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Limb;
RA Strausberg R.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC049792; AAH49792.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.

DR Pfam; PF00498; FHA; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS00006; FHA_DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
SQ SEQUENCE 664 AA; 73871 MW; D651BE3E463DBE86 CRC64;

Query Match 86.2%; Score 326; DB 11; Length 664;
Best Local Similarity 83.6%; Pred. No. 4.9e-30;
Matches 61; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

QY 1 VLLKREWTIGRRGCDLSFPSNKLVSQDHCRIVVDEKSGQVLTEDTSTSGTVINKLVV 60
Db 31 ILLWKREWTIGRRGCDLSFPSNKLVSQDHCKLTVDISGEVLTEDTSTNGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
Db 91 KKQTYPLQSGDII 103

RESULT 7
Q8BJZ9 PRELIMINARY; PRT; 663 AA.
ID Q8BJZ9
AC Q8BJZ9
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Similar to cell cycle checkpoint protein CHFR.
GN 5730484M2ORIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Body;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."
RL Nature 420:563-573(2002).
DR EMBL; AK077629; BAC36912.1; -.
DR MGD; MGI:2444898; 5730484M2ORIK.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; ZF-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS00006; FHA_DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
SQ SEQUENCE 663 AA; 73855 MW; 42BD653DCB4ADF45 CRC64;

Query Match 84.9%; Score 321; DB 11; Length 663;
Best Local Similarity 82.2%; Pred. No. 1.9e-29;
Matches 60; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

QY 1 VLLKREWTIGRRGCDLSFPSNKLVSQDHCRIVVDEKSGQVLTEDTSTSGTVINKLVV 60
Db 31 ILLWKREWTIGRRGCDLSFPSNKLVSQDHCKLTVDISGEVLTEDTSTNGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
Db 91 KKQTYPLHSGDII 103

RESULT 8
Q87PU0

QY 1 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 60
DB 31 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
DB 91 KKQTCPLQTGDVI 103

RESULT 2
ID Q96SL3 PRELIMINARY; PRT; 652 AA.
AC Q96SL3; 2001 (T-REMBLrel. 19, Created)
DT 01-DEC-2001 (T-REMBLrel. 19, Last sequence update)
DT 01-DEC-2003 (T-REMBLrel. 25, Last annotation update)
DE Hypothetical protein FLJ14781.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]

SEQUENCE FROM N.A.
RA Isegai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Aotaka S., Yoshikawa Y.,
RA Matsunawa H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,
RA Nakamura Y., Nagahara K., Masuho Y., Sasaki N.;
RA "REDO human cDNA sequencing project.";
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AK027687; BA555297.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
DR Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
KW Tissue=Placenta;
SQ SEQUENCE 652 AA; 72030 MW; 572F2CE6D1743D80 CRC64;

Query Match 100.0%; Score 378; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 3.1e-36;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 60
DB 31 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
DB 91 KKQTCPLQTGDVI 103

RESULT 3
ID Q96EP1 PRELIMINARY; PRT; 652 AA.
AC Q96EP1;
DT 01-DEC-2001 (T-REMBLrel. 19, Created)
DT 01-DEC-2003 (T-REMBLrel. 19, Last sequence update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]

SEQUENCE FROM N.A.
RA Strausberg R.;
RL Tissue=Placenta;
SQ SEQUENCE 652 AA; 72030 MW; 572F2CE6D1743D80 CRC64;

Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
-1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; BC012072; AAH12072.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
DR Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 652 AA; 72058 MW; 1A50773CEA679F07 CRC64;

Query Match 100.0%; Score 378; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 3.1e-36;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 60
DB 31 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
DB 91 KKQTCPLQTGDVI 103

RESULT 4
ID Q9NRT4 PRELIMINARY; PRT; 664 AA.
AC Q9NRT4;
DT 01-OCT-2000 (T-REMBLrel. 15, Created)
DT 01-OCT-2003 (T-REMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (T-REMBLrel. 25, Last annotation update)
DE Cell cycle checkpoint protein CHFR.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]

SEQUENCE FROM N.A.
RA MEDLINE=20388685; PubMed=10935642;
RA Scolnick D.M., Halazonetis T.D.;
RT "Chfr defines a mitotic stress checkpoint that delays entry into
RT metaphase.";
RL Nature 406.430-435(2000).
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AF10724; AAF91084.1; -.
DR PDB; ILGP; 07-AUG-02.
DR PDB; ILGQ; 07-AUG-02.
DR Genes; HGNC:20455; CHFR.
DR GO; GO:0007093; P:mitotic checkpoint; TAS.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
DR Metal-binding; Zinc; Zinc-finger.
KW Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 664 AA; 73386 MW; 141A1E7FEFAE36A2 CRC64;

Query Match 100.0%; Score 378; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 3.2e-36;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 60
DB 31 VLLRKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTDTSGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
DB 91 KKQTCPLQTGDVI 103

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:40:47 ; Search time 10.5607 Seconds
(without alignments)
2180.991 Million cell updates/sec

Title: US-10-048-046-2_COPY_31_103
Perfect score: 378
Sequence: 1 VLLKREWTIGRRGGDLSP.....INKLKVVKQTCPLQGDVI 73

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL 25:**

- 1: sp_archaea:**
- 2: sp_bacteria:**
- 3: sp_fungi:**
- 4: sp_human:**
- 5: sp_invertebrate:**
- 6: sp_mammal:**
- 7: sp_mhc:**
- 8: sp_organelle:**
- 9: sp_phase:**
- 10: sp_plant:**
- 11: sp_rodent:**
- 12: sp_virus:**
- 13: sp_vertebrate:**
- 14: sp_unclassified:**
- 15: sp_rvirus:**
- 16: sp_bacteriap:**
- 17: sp_archaeap:**

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	378	100.0	623	4 Q9NVD5	Q9NVD5 homo sapien
2	378	100.0	652	4 Q96SL3	Q96SL3 homo sapien
3	378	100.0	652	4 Q96EP1	Q96EP1 homo sapien
4	378	100.0	664	4 Q9NRT4	Q9NRT4 homo sapien
5	326	86.2	254	11 Q8BWH4	Q8BWH4 mus musculus
6	326	86.2	664	11 Q810L3	Q810L3 mus musculus
7	321	84.9	663	11 Q8BZ29	Q8BZ29 mus musculus
8	107.5	28.4	504	16 Q87PU0	Q87PU0 vibrio para
9	88	23.3	159	16 Q97LQ0	Q97LQ0 clostridium
10	87	23.0	546	11 Q8CCY0	Q8CCY0 mus musculus
11	87	23.0	751	11 Q88981	Q88981 mus musculus
12	87	23.0	751	11 Q9R1X1	Q9R1X1 mus musculus
13	87	23.0	751	11 Q811I6	Q811I6 mus musculus
14	87	23.0	751	11 Q9R207	Q9R207 mus musculus
15	86	22.8	176	16 Q8G5Q4	Q8G5Q4 bifidobacte
16	83	22.0	243	16 Q7UWU2	Q7UWU2 rhodopirell

17	82.5	21.8	729	10 Q9FMB8	Q9fmb8 arabidopsis
18	79.5	21.0	497	16 Q9I751	Q9i751 pseudomonas
19	79.5	21.0	1236	5 Q9NED7	Q9ned7 leishmania
20	79	20.9	250	16 Q7UGY0	Q7ugy0 rhodopirell
21	79	20.9	345	4 Q9UBH7	Q9ubh7 homo sapien
22	79	20.9	345	4 Q9Y242	Q9y242 homo sapien
23	79	20.9	345	4 Q9BUM2	Q9bum2 homo sapien
24	79	20.9	345	6 Q7YR48	Q7yr48 pan troglod
25	79	20.9	359	4 Q13176	Q13176 homo sapien
26	79	20.9	359	16 Q98IK6	Q98ik6 thizobium 1
27	77.5	20.5	460	16 Q98P85	Q98p85 bradyrhizob
28	77.5	20.5	528	3 Q874N8	Q874n8 candida gla
29	76.5	20.2	517	13 Q918V3	Q918v3 xenopus lae
30	76	20.1	2541	5 Q19663	Q19663 caenorhabdi
31	74.5	19.7	263	11 Q99KJ5	Q99kj5 mus musculu
32	74.5	19.7	263	11 Q8BPA3	Q8bpa3 mus musculu
33	74.5	19.7	517	13 Q98TW0	Q98tw0 xenopus lae
34	74.5	19.7	689	10 Q9FN27	Q9fn27 oryza sativ
35	73.5	19.4	526	3 Q874M7	Q874m7 kluveromyc
36	73	19.3	144	16 Q990Y0	Q990y0 clostridium
37	73	19.3	503	13 Q90ZY5	Q90zy5 brachydanio
38	71.5	18.9	398	16 Q87HC2	Q87hc2 vibrio para
39	71	18.8	503	13 Q803B2	Q803e2 brachydanio
40	70.5	18.7	168	5 Q86DY9	Q86dy9 schistosoma
41	70.5	18.7	230	16 Q9KBZ7	Q9kbz7 bacillus ha
42	70.5	18.7	301	3 Q74388	Q74388 schizosacch
43	70	18.5	254	2 Q9S475	Q9s475 myxococcus
44	70	18.5	388	2 Q52176	Q52176 myxococcus
45	68.5	18.1	157	16 P74513	P74513 synectocyst

ALIGNMENTS

RESULT 1

Q9NVD5	PRELIMINARY;	PRT;	623 AA.
AC	Q9NVD5		
DT	01-OCT-2000 (TREMBLrel. 15, Created)		
DT	01-OCT-2000 (TREMBLrel. 15, Last sequence update)		
DE	01-OCT-2003 (TREMBLrel. 25, Last annotation update)		
DE	Hypothetical protein FLJ10796.		
OS	Homo sapiens (Human)		
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
OX	NCBI_TaxID=9606;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RA	Isegai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,		
RA	Nishikawa T., Nagai K., Sugano S., Aotsuka S., Yoshikawa Y.,		
RA	Matsumura H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,		
RA	Nakamura Y., Nagahara K., Masuho Y., Sasaki N.,		
RT	"NEDO human cDNA sequencing project."		
RL	Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.		
CC	-1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.		
DR	EMBL; AK001658; BAA91817.1; -		
DR	InterPro; IPR000253; FHA.		
DR	InterPro; IPR008984; SMAD FHA.		
DR	InterPro; IPR001841; Znf_Fing.		
DR	Pfam; PF00498; FHA; 1.		
DR	Pfam; PF00097; zf-C3HC4; 1.		
DR	SMART; SM00240; FHA; 1.		
DR	SMART; SM00184; RING; 1.		
DR	PROSITE; PS00006; FHA DOMAIN; 1.		
DR	PROSITE; PS00518; ZF_RING_1; 1.		
DR	PROSITE; PS00899; ZF_RING_2; 1.		
DR	Hypothetical protein; Metal-binding; Zinc; Zinc-finger.		
SQ	SEQUENCE 623 AA; 69204 MW; 45186D33DAE52711 CRC64;		

Query Match 100.0%; Score 378; DB 4; Length 623;
Best Local Similarity 100.0%; Pred. No. 3e-36;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 T-----SGTVI-----NKLKVVKKQTC 65
 Db 129 TNHFEIAGTTVKSQWFKSTTYITLDTQC 156

RESULT 14

TMU CORGL STANDARD; PRT; 365 AA.

AC Q8NR24;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Probable tRNA (5-methylaminomethyl-2-thiouridylylate)-methyltransferase
 DE (EC 2.1.1.61).
 GN TRMU OR CGL1240.
 OS Corynebacterium glutamicum (Brevibacterium flavum).
 CC Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
 CC Corynebacterineae; Corynebacteriaceae; Corynebacterium.
 CC NCBI_TaxID=1718;
 CC [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ATCC 13032 / DSM 20300 / NCIB 10025;
 RA Nakagawa S.;
 RT "Complete genomic sequence of Corynebacterium glutamicum ATCC 13032.";
 RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
 CC -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + tRNA = S-adenosyl-L-homocysteine + tRNA containing 5-methylaminomethyl-2-thiouridylylate.
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -!- SIMILARITY: Belongs to the tmU family.

 This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

DR EMBL; AP005277; BAB98633.1; -;
 DR HAMAP; MF 00144; -; 1.
 DR InterPro; IPR004506; TmU.
 DR Pfam; PF03054; tRNA.Me.trans; 1.
 DR TIGRFAMs; TIGR00420; tmU; 1.
 KW Transferase; Methyltransferase; tRNA processing; Complete proteome.
 SQ SEQUENCE 365 AA; 39237 MW; 21F8EE1B2B3BDC63 CRC64;

Query Match 16.0%; Score 60.5; DB 1; Length 365;
 Best Local Similarity 29.6%; Pred. No. 18;
 Matches 21; Conservative 14; Mismatches 23; Indels 13; Gaps 4;

QY 7 EWTGRRRGCDLSPSKNLVSGDHCRIV--VDEKSGQVTL---EDTSTSGTVINKLVKVK 61
 Db 237 EFTIGQRKGLDIKAPA----ADGRPRYVTDIDAKGTVTGVTRENLIKSTIHADRLKPLH 292

QY 62 KQTCPLQGTGV 72
 Db 293 ----PAMDQOI 299

RESULT 15

Y634 CHLMU STANDARD; PRT; 353 AA.

AC Q9PK39;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Hypothetical protein TC0634 precursor.
 GN TC0634.
 OS Chlamydia muridarum.
 CC Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.
 CC NCBI_TaxID=83560;
 RN [1]

RP SEQUENCE FROM N.A.
 RC STRAIN=MoPn / NiSG;
 RX MEDLINE=20150255; PubMed=10684935;
 RA Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F.,
 RA White O., Hickey E.K., Peterson J., Utterback T., Berry K., Bass S.,
 RA Linher K., Weidman J., Khouri H., Craven B., Bowman C., Dodson R.,
 RA Gwin M., Nelson W., DeBoy R., Kolonay J., McClarty G., Salzberg S.L.,
 RA Eisen J., Fraser C.M.;
 RT "Genome sequences of Chlamydia trachomatis MoPn and Chlamydia
 RT pneumoniae AR39.";
 RT Nucleic Acids Res. 28:1397-1406(2000).
 CC -!- SIMILARITY: BELONGS TO THE CHLAMYDIAL CPN1058/CT355/TC0634
 CC FAMILY.

 This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

DR EMBL; AE002332; AAF39463.1; -;
 DR PIR; E81680; E81680.
 DR TIGR; TC0634; -;
 KW Hypothetical protein; Signal; Complete proteome.
 FT SIGNAL 1 24
 FT CHAIN 25 353 HYPOTHETICAL PROTEIN TC0634.
 SQ SEQUENCE 353 AA; 39840 MW; 3048C59F5B7BB90E CRC64;

Query Match 15.9%; Score 60; DB 1; Length 353;
 Best Local Similarity 32.2%; Pred. No. 20;
 Matches 19; Conservative 10; Mismatches 16; Indels 14; Gaps 3;

QY 15 GCDLSPSKNLVSGD-----HCRIV--VDEKSGQVLTSTSGTVINKLVKVKQTC 66
 Db 24 GYEGSPSSLEQNPQSGVAIHNRVLFKIDETVVTLD-----VIHKLNIIFYSTCP 75

Search completed: May 7, 2004, 14:46:32
 Job time : 4.46674 secs

```
Matches 22; Conservative 9; Mismatches 34; Indels 12; Gaps 3;
QY 8 WTGRRGCDLSPFNK-----VGDHCRIVD-----EKSQVTLDTSTSGVINK 56
Db 118 W-FGRDKSCYCFDGLLRTDXYRTYKFKFRIFREMGPKNCYIIVIEDHSGNGTFVNT 176
QY 57 LKVVKQTCPLQGDVI 73
Db 177 ELGKGKRCPLSNSEI 193
RESULT 12
VGLM_BUNYW STANDARD; PRT; 1433 AA.
AC P04505;
DT 13-AUG-1987 (Rel. 05, Created)
DT 13-AUG-1987 (Rel. 05, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE M polyprotein precursor [Contains: Glycoprotein G2; Nonstructural
DE protein NS-M; Glycoprotein G1].
GN M.
OS Bunyamwera virus.
OC Viruses; ssRNA negative-strand viruses; Bunyaviridae; Orthobunyavirus.
OX NCBI_TaxID=35304;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=86098655; PubMed=3753629;
RA Lees J.F., Pringle C.R., Elliott R.M.;
RT "Nucleotide sequence of the Bunyamwera virus M RNA segment:
RT conservation of structural features in the Bunyamwera glycoprotein
RT gene product.";
RL Virology 148:11-14 (1986).
CC -1- PTM: Specific enzymatic cleavages in vivo yield mature proteins
CC including nonstructural protein NS-M, glycoprotein G1, and
CC glycoprotein G2.
CC -1- SIMILARITY: Belongs to the bunyaviruses M polyprotein family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; M11852; AAA42777.1; -.
DR PIR; A04101; GNVUBW.
DR InterPro; IPR005167; Bunya_G1.
DR InterPro; IPR005168; Bunya_G2.
DR Pfam; PF03557; Bunya_G1; 1.
DR Pfam; PF03563; Bunya_G2; 1.
DR Polyprotein; Glycoprotein; Transmembrane; Nonstructural protein;
DR Signal.
FT SIGNAL.
FT CHAIN 1 16 M POLYPROTEIN.
FT CHAIN 17 1433 GLYCOPROTEIN G2.
FT CHAIN 17 302 NONSTRUCTURAL PROTEIN NS-M.
FT CHAIN 303 477 GLYCOPROTEIN G1.
FT CHAIN 478 1433 POTENTIAL.
FT TRANSMEM 1382 1409 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 60 60 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 248 248 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 624 624 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1169 1169 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 1433 AA; 162077 MW; CD61ABDE782018E0 CRC64;
Query Match 16.1%; Score 61; DB 1; Length 1433;
Best Local Similarity 23.9%; Pred. No. 70;
Matches 21; Conservative 9; Mismatches 30; Indels 28; Gaps 3;
QY 6 RWTIGRRRC-----DLSPFNKLVSGDHCRIVVDEKSGV-----T 43
Db 72 RHWITDKACNPVVTAGSINVIKLVNLTNRVVTGDCITVDRKNAIIFQTDK 131
```

```
QY 44 LEDTSTSGTVI-----NKLKVVKKQTC 65
Db 132 LNHEFVGTGTTISTGWFKSKASVTLDRIC 159
RESULT 13
VGLM_BUNL7 STANDARD; PRT; 1441 AA.
ID VGLM_BUNL7
AC P09612;
DT 01-NAR-1989 (Rel. 10, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE M polyprotein precursor [Contains: Glycoprotein G2; Nonstructural
DE protein NS-M; Glycoprotein G1].
GN M.
OS Bunyavirus La Crosse (isolate L74).
OC Viruses; ssRNA negative-strand viruses; Bunyaviridae; Orthobunyavirus.
OX NCBI_TaxID=11578;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88089508; PubMed=3694177;
RA Grady L.J., Sanders M.L., Campbell W.P.;
RT "The sequence of the M RNA of an isolate of La Crosse virus.";
RL J. Gen. Virol. 68:3057-3071 (1987).
RN [2]
RP SEQUENCE OF 1-46 FROM N.A.
RX MEDLINE=82216937; PubMed=7086954;
RA Clerx-Van Haaster C.M., Akashi H., Auperin D.D., Bishop D.H.L.;
RT "Nucleotide sequence analyses and predicted coding of bunyavirus
RT genome RNA species.";
RL J. Virol. 41:119-128 (1982).
CC -1- PTM: Specific enzymatic cleavages in vivo yield mature proteins
CC including nonstructural protein NS-M, glycoprotein G1, and
CC glycoprotein G2.
CC -1- SIMILARITY: Belongs to the bunyaviruses M polyprotein family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
CC EMBL; D10370; BAA01201.1; -.
DR EMBL; J0231; -; NOT_ANNOTATED_CDS.
DR PIR; A29377; GNVULC.
DR InterPro; IPR005167; Bunya_G1.
DR InterPro; IPR005168; Bunya_G2.
DR Pfam; PF03557; Bunya_G1; 1.
DR Pfam; PF03563; Bunya_G2; 1.
DR Polyprotein; Glycoprotein; Transmembrane; Nonstructural protein;
DR Signal.
FT SIGNAL.
FT CHAIN 1 13 M POLYPROTEIN.
FT CHAIN 14 1441 GLYCOPROTEIN G2.
FT CHAIN 22 299 NONSTRUCTURAL PROTEIN NS-M.
FT CHAIN 300 473 GLYCOPROTEIN G1.
FT CHAIN 474 1441 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 57 57 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 245 245 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 490 490 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 1177 1177 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CONFLICT 40 40 C -> S (IN REF. 2).
SQ SEQUENCE 1441 AA; 162540 MW; 50973CE30973C55B CRC64;
Query Match 16.1%; Score 61; DB 1; Length 1441;
Best Local Similarity 22.7%; Pred. No. 70;
Matches 20; Conservative 12; Mismatches 28; Indels 28; Gaps 3;
QY 6 RWTIGRRRC-----DLSPFNKLVSGDHCRIVVDEKSGV-----T 48
Db 69 RKWLVDHDCRPKXIVGSHINVIKLVNLTNRVVTGDCITVDRKNAIIFQTDK 128
```

```
CC -!- SIMILARITY: Contains 1 fork-head domain.
CC -!- SIMILARITY: Contains 1 FHA domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; L38848; AAA60938.1; -
DR EMBL; Z38059; CA86147.1; -
DR PIR; S48403; S48403.
DR HSSP; Q63245; 2HPH.
DR GernOnline; L39666; -.
DR TRANSFAC; T03303; -.
DR SGD; S0001393; FKH1.
DR GO; GO:0005634; C:nucleus; IDA.
DR GO; GO:0006347; P:chromatin silencing at HML and HMR (sensu S. . .); IGI.
DR GO; GO:0007124; P:pseudohyphal growth; IGI.
DR GO; GO:0000074; P:regulation of cell cycle; IGI.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SWAD_FHA.
DR InterPro; IPR001766; TF_Fork_head.
DR Pfam; PF00498; FHA; 1
DR PRINTS; PR00053; FORKHEAD.
DR PRODOM; PD000425; TF_Fork_head; 1.
DR SMART; SM00339; FH; 1.
DR SMART; SM00240; FHA; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00657; FORK HEAD 1; 1.
DR PROSITE; PS00658; FORK HEAD 2; 1.
DR PROSITE; PS00039; FORK HEAD 3; 1.
DR DNA-BINDING; Nuclear protein.
DR DOMAIN 76 142
FT DNA BIND 302 393 FORK-HEAD.
SQ SEQUENCE 484 AA; 53490 MW; 7159073EB979C489 CRC64;

Query Match 16.1%; Score 61; DB 1; Length 484;
Best Local Similarity 24.7%; Pred. No. 21;
Matches 22; Conservative 15; Mismatches 34; Indels 18; Gaps 2;

QY 3 LRKREWTIGR-----RRGCDLSPFNKLVSGDHCRIVVDEKSGQVLEDT 47
DB 71 VQKLEVTIGRNTDSLNLNAVPGTVVKKNIDIDLGPAKIVSRKHAIRFNLESQSWELQIF 130

QY 48 STSGTVINKLVKKQTGP----LQGDVI 73
DB 131 GRNGAKVNFRIPTGPDSPPTVLSGCII 159

RESULT 11
CHK2_MOUSE
ID CHK2_MOUSE STANDARD; PRT; 546 AA.
AC Q94265;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Serine/threonine-protein kinase Chk2 (EC 2.7.1.37).
GN CHK2 OR CHK2 OR RAD53.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93055399; PubMed=9836640;
RA Matsuo S., Huang M., Ellledge S.J.;
RL "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.";
RT Science 282:1893-1897(1998).
RN [2]
```

```
RP SEQUENCE FROM N.A.
RC STRAIN=NMRI; TISSUE=Mammary gland;
RX MEDLINE=22388557; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fanev J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalios D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC -!- FUNCTION: CONTROLS CELL CYCLE CHECKPOINT. MAY PARTICIPATE IN
CC TRANSDUCTION OF THE DNA DAMAGE AND REPLICATIONAL STRESS SIGNALS.
CC INHIBITS CDC25 PHOSPHATASE BY PHOSPHORYLATING IT, PREVENTING THE
CC ENTRY INTO MITOSIS. MAY HAVE A ROLE IN MEIOSIS AS WELL.
CC -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC -!- ENZYME REGULATION: KINASE ACTIVITY IS UPREGULATED BY
CC AUTOPHOSPHORYLATION. RAPIDLY PHOSPHORYLATED IN RESPONSE TO DNA
CC DAMAGE AND TO REPLICATION BLOCK (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Nuclear.
CC -!- SIMILARITY: Belongs to the Ser/Thr family of protein kinases. CDS1
CC subfamily.
CC -!- SIMILARITY: Contains 1 FHA domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AF086905; AAC83694.1; -
DR EMBL; BC056617; AAH56617.1; -
DR HSSP; Q63450; 1A06.
DR MSD; MGI:1355321; Chk2.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR000719; Prot_kinase.
DR InterPro; IPR008271; Ser_thr_pkin_AS.
DR InterPro; IPR002230; Ser_thr_pkinase.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00458; FHA; 1.
DR Pfam; PF00069; pkinase; 1.
DR PRODOM; PD000001; Prot_kinase; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00220; S_TKC; 1.
DR PROSITE; PS00107; PROTEIN KINASE ATP; FALSE_NEG.
DR PROSITE; PS00108; PROTEIN KINASE ST; 1.
DR PROSITE; PS00011; PROTEIN KINASE_DOM; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
KW transferase, Serine/threonine-protein kinase; ATP-binding;
KW Cell cycle; Phosphorylation; Nuclear protein.
FT DOMAIN 117 179
FT DOMAIN 224 490
FT NP BIND 230 238 ATP (BY SIMILARITY).
FT BINDING 253 253 ATP (BY SIMILARITY).
FT ACT SITE 351 351 BY SIMILARITY.
SQ SEQUENCE 546 AA; 61088 MW; A7949EFB5572CDA4 CRC64;

Query Match 16.1%; Score 61; DB 1; Length 546;
Best Local Similarity 28.6%; Pred. No. 24;
```

RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA Palazzolo M., Pittman G.S., Pan S.S., Pollard J., Puri V., Reese M.G.,
RA Rainert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Swirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wasserman D.A., Weinstein G.M., Weissenbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RA "The genome sequence of *Drosophila melanogaster*.";
RL Science 287:2185-2195(2000).
RN [4]
RP REVISIONS, AND ALTERNATIVE SPLICING.
RX MEDLINE=22426069; PubMed=12537572;
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochuk S.E.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Betencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RA "Annotation of the *Drosophila melanogaster* euchromatic genome: a
RT systematic review.";
RL Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN [5]
RP SEQUENCE FROM N.A. (ISOFORM SHORT).
RC STRAIN=Berkeley; TISSUE=Embryo;
RX MEDLINE=22426066; PubMed=12537569;
RA George R.A., Guarini H., Kronmiller B., Pacleb J.M., Park S., Wan K.H.,
RA Rubin G.M., Celniker S.E.;
RA "A *Drosophila* full-length cDNA resource.";
RL Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002).
CC -!- FUNCTION: May have a role in germ line establishment.
CC -!- SUBCELLULAR LOCATION: Nuclear; speckled subnuclear compartment.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=Long;
CC IsoId=061267-1; Sequence=Displayed;
CC Name=Short;
CC IsoId=061267-2; Sequence=VSP 004865;
CC -!- TISSUE SPECIFICITY: In stage 3 embryos, both isoforms are
CC expressed in both somatic and pole cell nuclei. Expression in pole
CC cell nuclei is sustained until stage 9 and weakly expressed after
CC pole cell invagination into the abdominal cavity.
CC -!- DEVELOPMENTAL STAGE: Expressed both maternally and zygotically in
CC adult females. Levels of the long isoform remain fairly constant
CC from ovaries to embryos, the levels of short isoform decrease
CC dramatically.
CC -!- SIMILARITY: Belongs to the Ser/Thr family of protein kinases. CDS1
CC subfamily.
CC -!- SIMILARITY: Contains 1 FHA domain.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@sib-sib.ch).
CC
CC EMBL: AB007821; BAA28755.1; -
CC EMBL: AB007822; BAA28756.1; -
CC EMBL: U87984; AAB49642.1; -
CC EMBL: AE003665; AAF33867.2; -
CC EMBL: AE003665; AAN1062.1; -
CC EMBL: AY070549; AAL48020.1; -
CC HSP: Q63450.1A06.
CC FlyBase: FBgn019686; lok.
CC GO: GO:0005634; C:nucleus; IEP.

GO: GO:0004674; P:protein serine/threonine kinase activity; NAS.
GO: GO:0008630; P:DNA damage response, signal transduction re.; IMP.
GO: GO:0000077; P:DNA damage response, signal transduction re.; IMP.
GO: GO:0007281; P:germ-cell development; IEP.
GO: GO:0006468; P:protein amino acid phosphorylation; NAS.
InterPro: IPR000253; FHA.
DR InterPro: IPR000719; Prot_kinase.
DR InterPro: IPR008271; Ser_Thr_kinase.
DR InterPro: IPR002290; Ser_Thr_kinase.
DR InterPro: IPR008984; SMAD_FHA.
DR Pfam: PF00498; FHA; 1.
DR Pfam: PF00069; pkinase; 1.
DR ProDom: PD000001; Prot_kinase; 1.
DR SMART: SM00220; FHA; 1.
DR SMART: SM00220; S_TRK; 1.
DR PROSITE: PS50006; FHA_DOMAIN; 1.
DR PROSITE: PS00107; PROTEIN KINASE ATP; 1.
DR PROSITE: PS50011; PROTEIN KINASE DOM; 1.
DR PROSITE: PS00108; PROTEIN KINASE ST; 1.
KW Transferase; Serine/threonine-protein kinase; ATP-binding;
KW Nuclear protein; Alternative splicing.
FT DOMAIN 69 129 FHA
FT DOMAIN 174 441 PROTEIN KINASE
FT NP_BIND 180 188 ATP (BY SIMILARITY).
FT BINDING 203 203 ATP (BY SIMILARITY).
FT ACT_SITE 303 303 BY SIMILARITY.
FT VARSPLIC 46 62 Missing (in isoform Short).
FT /FTID=VSP 004865.
SQ SEQUENCE 476 AA; 54261 MW; 58D583E015C4E626 CRC64;

Query Match 16.3%; Score 61.5; DB 1; Length 476;
Best Local Similarity 25.9%; Pred. No. 18;
Matches 22; Conservative 11; Mismatches 33; Indels 19; Gaps 2;

QY 3 LKREWTIGRRGCDLSPSNKL-----VSGDHCRIVWDEKSGQVLEDTLS 48
DB 64 LANDEFTAGRGANDLILTLNLPKILTRISKVFIKRCNC-----ELTNPVVIQDLS 118
QY 49 TSGTIVINKLVYKQKTCPLQTGQVI 73
DB 119 RGTGFVYNEKIGTNRMRILKNDVI 143

RESULT 10
FKH1 YEAST STANDARD; PRT; 484 AA.
AC P40456;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Fork head protein homolog 1.
GN FKH1 OR YIL131C.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
OX [1]
RN SEQUENCE FROM N.A.
RP STRAIN=S288C;
RC Zhu G., Davis T.N.;
RA Submitted (XXX-1995) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C / AB972;
RX MEDLINE=97313266; PubMed=9169870;
RA Churcher C.M., Bowman S., Badcock K., Bankier A., Brown D.,
RA Chillingworth T., Connor R., Devlin K., Gentles S., Hamlin N.,
RA Harris D.E., Horsnell T., Hunt S., Jagels K., Jones M., Lye G.,
RA Moule S., Odell C., Pearson D., Rajadream M.A., Rice P., Rowley N.,
RA Skelton J., Smith V., Walsh S., Whitehead S., Barrell B.G.;
RT "The nucleotide sequence of *Saccharomyces cerevisiae* chromosome IX.";
RL Nature 387:84-87(1997).
CC -!- SUBCELLULAR LOCATION: Nuclear (Potential).

RA Lyne M.H., Bryant J.A., Aves S.J.,
 RL Submitted (JUL-1996) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=972;
 RX MEDLINE=21848401; PubMed=11859360;
 RA Wood V.J., Gilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
 RA Sgourou J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
 RA Brooks K., Brown D., Brown S., Chillingworth J., Churcher C.M.,
 RA Collins M., Connor R., Cronin A., Davis P., Feltham T., Fraser A.,
 RA Gents J., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
 RA Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
 RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
 RA Mooney P., Moutle S., Mungall K., Murphy L., Niblett D., Odell C.,
 RA Oliver K., O'Neil S., Pearson D., Quail M.A., Rabinowitsch E.,
 RA Rutherford K., Rutter S., Saunders R., Squares S., Stevens K.,
 RA Skellerton J., Simmonds M., Squares R., Squares S., Warren T., Whitehead S.,
 RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whittaker S.,
 RA Woodward J., Volckaert G., Aert R., Robben J., Grymonprez B.,
 RA Weltjens I., Vanstreels E., Rieger M., Schaefer M., Mueller-Auer S.,
 RA Gabeli C., Fuchs M., Fritze C., Holzer E., Mosel D., Hilbert H.,
 RA Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R., Pohl T.M.,
 RA Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
 RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaure V., Mottier S.,
 RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
 RA Lucas M., Rochet M., Gaillardin C., Tallada V.A., Garzon A., Thode G.,
 RA Daga R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
 RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forebush S.L.,
 RA Cerretti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
 RA Shpakovski G.V., Uessery D., Barrrell B.G., Nurse P.;
 RT "The genome sequence of Schizosaccharomyces pombe";
 RL Nature 415:871-880 (2002).
 CC -!- FUNCTION: Probable protein kinase required for meiotic
 CC recombination.
 CC -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
 CC -!- SIMILARITY: Belongs to the Ser/Thr family of protein kinases.
 CC -!- SIMILARITY: Contains 1 FHA domain.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announcement/>
 CC or send an email to license@sib-sib.ch).
 CC -----
 CC EMBL; Z71478; CAA96101.1; -;
 CC EMBL; Z98596; CAB11196.1; -;
 CC FIR; T43420; T43420.
 CC HSSP; P00519; 1PHK.
 CC GeneDB; SFombe; SPAC14C4.03; -;
 CC InterPro; IPR000253; FHA.
 CC InterPro; IPR000719; Prot_kinase.
 CC InterPro; IPR008271; Ser_thr_pkin_AS.
 CC InterPro; IPR002290; Ser_thr_pkinase.
 CC InterPro; IPR069384; SMAD_FHA.
 CC InterPro; IPR001245; Tyr_pkinase.
 CC Pfam; PF00498; FHA; 1.
 CC Pfam; PF00069; pkinase; 1.
 CC PRINTS; PR00109; TYRKINASE.
 CC ProDom; PD000001; Prot_kinase; 1.
 CC SMART; SM00240; FHA; 1.
 CC SMART; SM00220; S_TKC; 1.
 CC PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
 CC PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
 CC PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
 CC PROSITE; PS50006; FHA_DOMAIN; 1.
 CC Transferase; Serine/threonine-protein kinase; ATP-binding; Meiosis.
 KW DOMAIN 62 116 FHA
 FT DOMAIN 160 421 PROTEIN_KINASE
 FT NP_BIND 166 174 ATP (BY SIMILARITY).
 FT ACT_SITE 281 281 BY SIMILARITY.
 FT BINDING 189 189 ATP (BY SIMILARITY).
 FT FT

SQ SEQUENCE 445 AA; 51151 MW; 6D62D79E9A1B45B0 CRC64;
 Query Match 16.8%; Score 63.5; DB 1; Length 445;
 Best Local Similarity 27.8%; Pred.No.10;
 Matches 20; Conservative 14; Mismatches 27; Indels 11; Gaps 3;
 QY 9 TIGRRGCD--LSFSPSKLVSGDHCR1---VVDKSGQVLTEDTSTGTVINKLKVX 61
 DB 63 SVGRSNTCNQLQFTA---SVKHPRVSVLIDDDMDPLVYCDQSSNGTFLNRLIGK 118
 QY 62 KQTCPLQTGDVI 73
 DB 119 GNSVLLSDGDIL 130
 RESULT 9
 LOK DROME STANDARD; PRT; 476 AA.
 AC Q61267; Q61268; P91876; Q8S2S3;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Ovarian-specific serine/threonine-protein kinase Lok (EC 2.7.1.-) (Loki protein) (dMNM).
 DE LOK OR G010895.
 OS Drosophila melanogaster (Fruit fly).
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
 OC Ephydroidea; Drosophilidae; Drosophila.
 ON NCBI_TaxID=7227;
 RX [1]
 RP SEQUENCE FROM N.A. (ISOFORMS LONG AND SHORT), FUNCTION, SUBCELLULAR
 RP LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
 RC STRAIN=Ganton-S; TISSUE=Embryo;
 RC MEDLINE=98175876; PubMed=9507063;
 RA Oishi I., Sugiyama S., Ocami H., Yamamura H., Nishida Y., Minami Y.;
 RT "A novel Drosophila nuclear protein serine/threonine kinase expressed
 RT in the germline during its establishment."; Mech. Dev. 71:49-63(1998).
 RN [2]
 RP SEQUENCE FROM N.A. (ISOFORM SHORT).
 RC STRAIN=Oregon-R; TISSUE=Ovary;
 RA Larochele S., Suter B.;
 RT "Identification of a novel ovarian specific protein kinase."; Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Berkelley;
 RC MEDLINE=20196086; PubMed=10731132;
 RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
 RA Ananthanathan P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
 RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
 RA Brannon R.C., Rogers Y.-H.C., Blazer R.G., Champagne M., Pfeiffer B.D.,
 RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
 RA Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
 RA Beeson K.Y., Berens P.V., Bernier B.P., Bhandari D., Bolshakov S.,
 RA Borkova D., Botchan M.R., Bouck J., Brockstein P., Brotter P.,
 RA Burks K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
 RA Chert J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
 RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
 RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
 RA Durbin K.J., Evangelista C.C., Ferraz C., Ferrier S., Fleischmann W.,
 RA Foele C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
 RA Glodde A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
 RA Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
 RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
 RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
 RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
 RA Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
 RA Liu X., Mattvei B., McIntosh T.C., McLeod M.P., McPherson D.,
 RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,

CC Name=3; Sequences=VSP_006007, VSP_006008;
CC ISOIDS=P97836-3; Expressed in brain and testis.
CC TISSUE SPECIFICITY: Expressed in brain and testis.
CC -1- SIMILARITY: BELONGS TO THE SAPAP FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; U67987; AAC3054.1; -
CC EMBL; AB003594; BAA24265.1; -
CC EMBL; U67137; AAB48587.1; -
CC InterPro; IPR005026; GKAP.
CC Pfam; PF03359; GKAP; 1.
CC Membrane; Alternative splicing.
CC VARSPLIC 1 298
CC VARSPLIC 299 324
CC VARSPLIC 325 325
CC VARSPLIC 547 574
CC MUTAGEN 990 990
CC MUTAGEN 992 992
CC CONFLICT 636 636
CC SEQUENCE 992 AA; 110177 MW; 44BAF9BC0C14C099 CRC64;
Query Match 17.5%; Score 66; DB 1; Length 992;
Best Local Similarity 26.9%; Pred. No. 13;
Matches 21; Conservative 11; Mismatches 30; Indels 16; Gaps 1;
QY 7 EWITGRRGCDLSPFNKLVSGDHCHRVVDEKSG-----QVLEDTST 50
Db 330 EWGTYPRGDDIPICRMWRSYIKAMGDESDSTSPKSPKVAARRESLYKATQPS 389
QY 51 GTVINKLVKVKQTCPLQ 68
Db 390 LTELTTIKISNEHSPKIQ 407
RESULT 7
VGLM BUNSH STANDARD; PRT; 1441 AA.
AC P04875;
DT 13-AUG-1987 (Rel. 05, Created)
DT 13-AUG-1987 (Rel. 05, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE M polyprotein precursor [Contains: Glycoprotein G2; Nonstructural
DE protein NS-M; Glycoprotein G1].
GN M.
OS Bunyavirus snowshoe hare.
OC Viruses; ssRNA negative-strand viruses; Bunyaviridae; Orthobunyavirus.
OX NCBI_TaxID=11580;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=85018241; PubMed=6091326;
RA Eshita Y., Bishop D.H.L.;
RT "The complete sequence of the M RNA of snowshoe hare bunyavirus
RT reveals the presence of internal hydrophobic domains in the viral
RT glycoprotein."
RL Virology 137:227-240 (1984).
RN [2]
RP SEQUENCE OF 1-46 FROM N.A.
RX MEDLINE=82216937; PubMed=7086954;
RA Clerx-Van Haaster C.M., Akashi H., Auperin D.D., Bishop D.H.L.;

RT "Nucleotide sequence analyses and predicted coding of bunyavirus
RT genome RNA species."
RL J. Virol. 41:119-128 (1982).
RN [3]
RP PROCESSING.
RX MEDLINE=89073745; PubMed=2974218;
RA Fazakerley J.K., Gonzalez-Scarano F., Strickler J., Dietz-Schold B.,
RA Karush F., Nathanson N.;
RT "Organization of the middle RNA segment of snowshoe hare bunyavirus."
RL Virology 167:428-432 (1988).
CC -1- PTM: Specific enzymatic cleavages in vivo yield mature proteins
CC including nonstructural protein NS-M, glycoprotein G1, and
CC glycoprotein G2.
CC -1- SIMILARITY: Belongs to the bunyaviruses M polyprotein family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; K02539; AAA47827.1; -
CC EMBL; J02392; -; NOT_ANNOTATED_CDS.
CC PIR; A04102; GNVUSV.
CC InterPro; IPR005167; Bunya_G1.
CC InterPro; IPR005168; Bunya_G2.
CC Pfam; PF03557; Bunya_G1; 1.
CC Pfam; PF03563; Bunya_G2; 1.
CC Polyprotein; Glycoprotein; Transmembrane; Nonstructural protein;
CC SIGNAL.
CC CHAIN 1 13
CC CHAIN 14 1441 M POLYPROTEIN.
CC CHAIN 14 299 GLYCOPROTEIN G2.
CC CHAIN 300 473 NONSTRUCTURAL PROTEIN NS-M.
CC CHAIN 474 1441 GLYCOPROTEIN G1.
CC CARBOHYD 57 57 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC CARBOHYD 245 245 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC CARBOHYD 490 490 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC CARBOHYD 1177 1177 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC SEQUENCE 1441 AA; 162389 MW; 51F01DB268D1A08B CRC64;
Query Match 15.9%; Score 64; DB 1; Length 1441;
Best Local Similarity 22.7%; Pred. No. 32;
Matches 20; Conservative 13; Mismatches 27; Indels 28; Gaps 3;
QY 6 REWTIGRRRG-----DLSPFNKLVSGDHCHRVVDEKSGQVLEDTST 48
Db 69 RKMLVSDWHDRCPPKKTGGHINVEVGDLSLHTESVVCSADCTIGVDKETAQVRLQDT 128
QY 49 T-----SCTVI-----NKLKVKKQTC 65
Db 129 TNHFEIAGTIIVKSGWFKSTTYITLDQTC 156
RESULT 8
MEKL SCHPO STANDARD; PRT; 445 AA.
AC Q10292;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Meiosis-specific serine/threonine-protein kinase mekl (EC 2.7.1.37).
GN MEKL OR SPAC14C4.03.
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
OX NCBI_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=972;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
NCBI_TaxID=10116;
[1]
SEQUENCE FROM N.A. (ISOFORM 2).
RC
TISSUE=Brain;
RX MEDLINE=97177144; PubMed=9024696;
RX Kim E., Naibitt S., Haueh Y.-P., Rao A., Rothschild A., Craig A.M.,
RA Sheng M.;
RT "GKAP, a novel synaptic protein that interacts with the guanylate
RT kinase-like domain of the PSD-95/SAP90 family of channel clustering
RL molecules.";
RL J. Cell Biol. 136:669-678(1997).
[2]
SEQUENCE FROM N.A. (ISOFORM 3).
RX MEDLINE=98089008; PubMed=9428732;
RX Kawashima N., Takamiya K., Sun J., Kitabatake A., Sobue K.;
RA "Differential expression of isoforms of PSD-95 binding protein
RT (GKAP/SAPAP1) during rat brain development.";
RT FEBS Lett. 418:301-304(1997).
[3]
SEQUENCE FROM N.A. (ISOFORM 1).
TX TISSUE=Brain;
RC MEDLINE=97277335; PubMed=9115257;
RX Takeuchi M., Hata Y., Hirao K., Toyoda A., Irie M., Takai Y.;
RA "SAPAPs. A family of PSD-95/SAP90-associated proteins localized at
RT postsynaptic density.";
RT J. Biol. Chem. 272:11943-11951(1997).
[4]
INTERACTION WITH DLG4 AND SHANK PROTEINS.
RX MEDLINE=99458653; PubMed=10527873;
RX Boeckers T.M., Winter C., Smalla K.-H., Kreutz M.R., Bockmann J.,
RA Seidenbecher C., Garner C.C., Gundelfinger E.D.;
RA "proline-rich synapse-associated proteins ProsAP1 and ProsAP2 interact
RT with synaptic proteins of the SAPAP/GKAP family.";
RL Biochem. Biophys. Res. Commun. 264:247-252(1999).
[5]
INTERACTION WITH DLG4 AND SHANK1.
TX TISSUE=Brain;
RC MEDLINE=99419021; PubMed=10488079;
RX Yao I., Hata Y., Hirao K., Deguchi M., Ide N., Takeuchi M., Takai Y.;
RA "Synonin, a novel neuronal protein interacting with synapse-associated
RT protein 90/postsynaptic density-95-associated protein.";
RL J. Biol. Chem. 274:27463-27466(1999).
[6]
INTERACTION WITH SHANK PROTEINS, AND MUTAGENESIS ALA-990 AND ALA-992.
RX MEDLINE=99360650; PubMed=10432368;
RX Naibitt S., Kim E., Tu J.C., Xiao B., Sala C., Valtchanoff J.,
RA Weinberg R.J., Worley P.F., Sheng M.;
RA "Shank, a novel family of postsynaptic density proteins that binds to
RT the NMDA receptor/PSD-95/GKAP complex and cortactin.";
RL Neuron 23:569-582(1999).
[7]
INTERACTION WITH AIPI1.
RX MEDLINE=98361985; PubMed=9694864;
RX Hirao K., Hata Y., Ide N., Takeuchi M., Irie M., Yao I., Deguchi M.,
RA Toyoda A., Sudhof T.C., Takai Y.;
RA "A novel multiple PDZ domain-containing molecule interacting with
RT N-methyl-D-aspartate receptors and neuronal cell adhesion proteins.";
RL J. Biol. Chem. 273:21105-21110(1998).
CC -!- FUNCTION: May play a role in the molecular organization of
CC synapses and neuronal cell signaling. Could be an adapter protein
CC linking ion channel to the subsynaptic cytoskeleton. May induce
CC enrichment of PSD-95/SAP90 at the plasma membrane.
CC -!- SUBUNIT: Interacts with DLG1, DLG4/PSD-95, APC and AIPI1. The C-
CC terminus binds the PDZ domain of the SHANK1, SHANK2 and SHANK3. Is
CC part of a complex with DLG4/PSD-95 and SHANK1, SHANK2 or SHANK3.
CC -!- SUBCELLULAR LOCATION: Membrane-associated.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=p97836-1; Sequence=Displayed;
CC Name=2;
CC IsoId=p97836-2; Sequence=VSP_006007, VSP_006008, VSP_006009,
CC

DR HSP; Q63450; 1A06.
DR Germline; 140343; -.
DR SGD; S0002259; DUN1.
DR GO; GO:0004672; P:DNA damage response, signal transduction re. .; IMP.
DR GO; GO:0000077; P:DNA damage response, signal transduction re. .; IMP.
DR GO; GO:0004668; P:protein amino acid phosphorylation; IDA.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR000719; Prot_kinase.
DR InterPro; IPR008271; Ser_thr_kinase.
DR InterPro; IPR002230; Ser_thr_kinase.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00069; pkinase; 1.
DR ProDom; PD000001; Prot_kinase; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00220; S_TKC; 1.
DR PROSITE; PS00107; PROTEIN KINASE ATP; 1.
DR PROSITE; PS00108; PROTEIN KINASE ST; 1.
DR PROSITE; PS00111; PROTEIN KINASE DOM; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR Transferase; Serine/threonine-protein kinase; ATP-binding;
KW Nuclear protein; Serine/threonine-protein kinase; DNA damage.
FT DOMAIN 56 112 FHA.
FT DOMAIN 200 480 PROTEIN KINASE.
FT NP_BIND 206 214 ATP (BY SIMILARITY).
FT BINDING 229 229 ATP (BY SIMILARITY).
FT ACT_SITE 328 328 BY SIMILARITY.
FT MUTAGEN 229 328 K-R: LOSS OF KINASE FUNCTION.
FT MUTAGEN 328 328 D-A: LOSS OF KINASE FUNCTION.
FT SEQUENCE 513 AA; 58632 MW; 4990F24F024702D7 CRC64;
Query Match 19.0%; Score 72; DB 1; Length 513;
Best Local Similarity 35.7%; Pred. No. 1.3;
Matches 25; Conservative 10; Mismatches 29; Indels 6; Gaps 3;
QY 9 TIGRRCDD--LAPPSNKLVSVDHCRIVDEKSGQ---VLEDTSTGTINKLVKVKQ 63
DB 57 TIGRSCDVLSEPDISTFHAFLQMDVDFQRLNIVDKSNGFINGRLVKD 116
QY 64 TGPLQGDVI 73
DB 117 YI-LKNGDRI 125
RESULT 4
ID PGK MYCPN STANDARD; PRT; 409 AA.
AC P78018;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Phosphoglycerate kinase (EC 2.7.2.3).
GN PGK OR MPN429 OR MP412.
OS Mycoplasma pneumoniae.
OC Bacteria; Firmicutes; Mollicutes; Mycoplasmataceae; Mycoplasma.
OX NCBI_TaxID=2104;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 3).
RC STRAIN=ATCC 29342 / M129;
RA MEDLINE=97105885; PubMed=8948633;
RA Himmelfreich R., Hilbert H., Plagens H., Pirkel E., Li B.-C.,
RA Herrmann R.;
RT "Complete sequence analysis of the genome of the bacterium Mycoplasma
RT pneumoniae"; Res. 24:4420-4449 (1996).
RL Nucleic Acids Res. 24:4420-4449 (1996).
CC -1- CATALYTIC ACTIVITY: ATP + 3-phospho-D-glycerate = ADP + 3-
CC phospho-D-glyceroyl phosphate.
CC -1- PATHWAY: Second phase of glycolysis; second step.
CC -1- SUBUNIT: Monomer (By similarity).
CC -1- SUBCELLULAR LOCATION: Cytoplasmic.
CC -1- SIMILARITY: Belongs to the phosphoglycerate kinase family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AE000040; AAB96060.1; -.
DR PIR; S73738; S73738.
DR HSP; P36204; 1YPE.
DR HAMAP; MF_00145; 1.
DR InterPro; IPR001576; PGK.
DR Pfam; PF00162; PGK; 1.
DR PRINTS; PR00477; PEGLYCKINASE.
DR PROSITE; PS00111; POLYGLYCERATE KINASE; 1.
KW Transferase; Kinase; Glycolysis; Complete proteome.
SQ SEQUENCE 409 AA; 44212 MW; 6AF230188D398731 CRC64;
Query Match 18.8%; Score 71; DB 1; Length 409;
Best Local Similarity 29.2%; Pred. No. 1.3;
Matches 19; Conservative 14; Mismatches 20; Indels 12; Gaps 2;
QY 19 SFPSNKLVSVDHCRIV-----VDEKSGQVLEDTSTGTINKLVKVKQTCLQ 68
DB 41 SLDITKVLGHNCIKVLLSHLSRVKSLDDKKGKSLQPVASA--LQNLKNTKVFHCPEN 98
QY 69 TGDVI 73
DB 99 TGDKV 103
RESULT 5
ID DLPI HUMAN STANDARD; PRT; 977 AA.
AC O14490; O14489; P78335;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Disks large-associated protein 1 (DAP-1) (guanylate kinase-associated
DE protein) (hgkxap) (SAP90/PSD-95-associated protein 1) (SAPAP1) (PSD-
DE 95/SAP90 binding protein 1).
GN DLGAP1 OR GKAP OR DAP1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RC TISSUE=Brain;
RX MEDLINE=97431353; PubMed=9286858;
RA Satoh K., Yanai H., Senda T., Kohu K., Nakamura T., Okumura N.,
RA Matsumine A., Kobayashi S., Toyoshima K., Akiyama T.;
RT "DAP-1, a novel protein that interacts with the guanylate kinase-like
RT domains of hDLG and PSD-95";
RL Genes Cells 2:415-424 (1997).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM 3).
RX MEDLINE=97177144; PubMed=9024696;
RA Kim E., Naisbitt S., Hsueh Y.-P., Rao A., Rothschild A., Craig A.M.,
RA Sheng M.;
RT "GKAP, a novel synaptic protein that interacts with the guanylate
RT kinase-like domain of the PSD-95/SAP90 family of channel clustering
RT molecules";
RL J. Cell Biol. 136:669-678 (1997).
CC -1- FUNCTION: May play a role in the molecular organization of
CC synapses and neuronal cell signaling. Could be an adapter protein
CC linking ion channel to the subsynaptic cytoskeleton. May induce
CC enrichment of PSD-95/SAP90 at the plasma membrane.
CC -1- SUBUNIT: Interacts with DLG1, DLG4/PSD-95, APC and AIP1 (By
CC similarity). Isoform 1 and isoform 2 C-terminus bind the PDZ
CC domain of SHANK1, SHANK2 and SHANK3 (By similarity). Is part of a
CC complex with DLG4/PSD-95 and SHANK1, SHANK2 or SHANK3 (By
CC similarity).
CC

RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Money P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinowitsch E.,
RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
RA Skellton J., Simmonds M., Squares R., Squares S., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA Woodward J., Volckaert G., Aert R., Robben J., Grymonprez B.,
RA Weltjens I., Vanstreels E., Rieger M., Schaefer M., Mueller-Auer S.,
RA Gabel C., Fuchs M., Fritzc C., Holzer E., Moestl D., Hilbert H.,
RA Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R., Pohl T.M.,
RA Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaure V., Mottier S.,
RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas M., Rochet M., Gaillardin C., Tallada V.A., Garzon A., Thode G.,
RA Daga R.R., Cruzado L., Jinenz J., Sanchez M., del Rey F., Benito J.,
RA Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L.,
RA Cerrutti L., Lowe J., McCombie W.R., Paulsen I., Potashkin J.,
RA Sipakovski G.V., Ussery D., Barrell B.G., Nurse P.,
RA "The genome sequence of *Schizosaccharomyces pombe*.";
RA Nature 415:871-880(2002).
CC -1- FUNCTION: Has a role in the DNA replication-monitoring S/G2
CC checkpoint system. It is responsible for blocking mitosis in the
CC S phase. It monitors DNA synthesis by interacting with DNA
CC polymerase alpha and sends a signal to block the onset of mitosis
CC while DNA synthesis is in progress.
CC -1- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC -1- SUBUNIT: Interacts with rad26.
CC -1- PTM: Autophosphorylated.
CC -1- SIMILARITY: Belongs to the Ser/Thr family of protein kinases. CDS1
CC subfamily.
CC -1- SIMILARITY: Contains 1 FHA domain.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; X85040; CAA59410.1; -;
CC EMBL; AJ222869; CAA11019.1; -;
CC EMBL; AL109736; CAB52158.1; -;
CC PIR; S58882; S58882.
CC HSRP; Q00534; 1E17.
CC GeneDB SPombe; SPCC18B5.11c; -;
CC InterPro; IPR000253; FHA.
CC InterPro; IPR000719; Prot kinase.
CC InterPro; IPR008271; Ser Thr pkin AS.
CC InterPro; IPR002290; Ser Thr pkinase.
CC InterPro; IPR008984; SMAD FHA.
CC InterPro; IPR001245; Tyr pkinase.
CC Pfam; PF00498; FHA; 1.
CC Pfam; PF00069; pkinase; 1.
CC PRINTS; PR00109; TYRKINASE.
CC ProDom; PDC00001; Prot kinase; 1.
CC SMART; SM00240; FHA; 1.
CC SMART; SM00220; S_TKC; 1.
CC PROSITE; PS00107; PROTEIN KINASE ATP; 1.
CC PROSITE; PS00108; PROTEIN KINASE-ST; 1.
CC PROSITE; PS00011; PROTEIN KINASE DOM; 1.
CC PROSITE; PS00006; FHA DOMAIN; 1.
CC Transferase; Serine/threonine-protein kinase; ATP-binding;
CC Cell cycle; Phosphorylation.
CC DOMAIN 60 116 FHA.
CC DOMAIN 167 433 PROTEIN KINASE.
CC NP_BIND 173 181 ATP (BY SIMILARITY).
CC BINDING 196 196 ATP (BY SIMILARITY).
CC ACT_SITE 294 294 BY SIMILARITY.
CC CONFLICT 61 61 R -> G (IN REF. 1).
CC CONFLICT 238 238 F -> C (IN REF. 1).
CC

SQ SEQUENCE 460 AA; 52014 MW; 4CEB963D3376DB54 CRC64;
Query Match 20.5%; Score 77.5; DB 1; Length 460;
Best Local Similarity 30.6%; Pred. No. 0.27;
Matches 22; Conservative 34; Indels 7; Gaps 2;
QY 8 WTIGRRGCDLSFSPNKLVSQDHRIV-----VDEKSGQVLTETSGTVINKLKVVK 61
DB 60 WFFGHHKCEVVL-NGPRVSNFHFYIYQGHNRNDSSENVLHDHSSNGTFLNPERLAK 118
QY 62 KQTCPLQTQGDVI 73
DB 119 NSRTILSNGDEI 130
RESULT 3
DUNI_YEAST
ID DUNI_YEAST STANDARD; PRT; 513 AA.
AC P39009;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 30-MAY-2000 (Rel. 39, Last annotation update)
DE DNA damage response protein kinase DUNI (EC 2.7.1.-).
GN DUNI OR YDL101C OR D2370.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94084787; PubMed=8261511;
RA Zhou Z., Elledge S.J.;
RT "DUNI encodes a protein kinase that controls the DNA damage response
RT in yeast.";
RL Cell 75:1119-1127(1993).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN=S288C / FY1679;
RC MEDLINE=97051597; PubMed=8896274;
RA Saiz J.E., Butrago M.J., Garcia R., Revuelta J.L., del Rey F.;
RT "The sequence of a 20.3 kb DNA fragment from the left arm of
RT Saccharomyces cerevisiae chromosome IV contains the KIN28, MSS2,
RT PHO2, POL3 and DUNI genes, and six new open reading frames.";
RN Yeast 12:1077-1084(1996).
RN [3]
RP SEQUENCE FROM N.A.
RX STRAIN=S288C / FY1679;
RC MEDLINE=97082507; PubMed=8923743;
RA Boskovic J., Saiz J.E., Soler-Mira A., Garcia-Cantalejo J.M.,
RA Ballesta J.P.G., Jimenez A., Remacha M.;
RT "The sequence of a 16,691 bp segment of Saccharomyces cerevisiae
RT chromosome IV identifies the DUNI1, PMT1, PMT5, SRP14 and DPR1 genes,
RT and five new open reading frames.";
RL Yeast 12:1377-1384(1996).
CC -1- FUNCTION: Transducer of the DNA damage signal.
CC -1- SUBCELLULAR LOCATION: Nuclear.
CC -1- PTM: Autophosphorylation increases in response to DNA damage.
CC -1- SIMILARITY: Belongs to the Ser/Thr family of protein kinases. CDS1
CC subfamily.
CC -1- SIMILARITY: Contains 1 FHA domain.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; L25549; AAA16324.1; -;
CC EMBL; X95644; CAA64912.1; -;
CC EMBL; Z74149; CAA98668.1; -;
CC PIR; S43941; S43941.
CC

```

InterPro: IPR001245; Tyr_pkinase.
Pfam: PF00498; FHA; 2.
Pfam: PF00089; Pkinase; 1.
PRINTS: PR00109; TYRKINASE.
ProDom: PD00001; Prot_kinase; 1.
SMART: SM00240; FHA; 2.
SMART: SM00220; S_TKG; 1.
PROSITE: PS00107; PROTEIN_KINASE_ATP; 1.
PROSITE: PS00108; PROTEIN_KINASE_ST; 1.
PROSITE: PS00011; PROTEIN_KINASE_DOM; 1.
PROSITE: PSS0006; FHA_DOMAIN; 2.
Transfaser: Serine/threonine-protein kinase; ATP-binding;
Tyrosine-protein kinase; Nuclear protein; Repeat; DNA damage;
Cell cycle; Phosphorylation; 3D-structure.
DOMAIN 66 116 FHA 1.
DOMAIN 198 466 PROTEIN_KINASE.
DOMAIN 601 664 FHA 2.
NP_BIND 204 212 ATP (BY SIMILARITY).
BINDING 227 227 ATP (BY SIMILARITY).
ACT_SITE 319 319 BY SIMILARITY.
SEQUENCE 821 AA; 91962 MW; 84A961229CA72D1 CRC64;

Query Match 28.4%; Score 107.5; DB 1; Length 821;
Best Local Similarity 37.7%; Pred. No. 0.0002;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;

QY 5 KRWTIGRRGGDGLFFPSNKLVSQDHCIVVDEKSGQVLTEDTSTGTVINKLVKKQT 64
DDB 63 KKYVTFGRNPACDYLGNISRLSNKHFQILLGE-DGNLLINDISTNGTWNGKRVKNSN 121

QY 65 CPLQGTGQVVI 73
DDB 122 QLLSQGDEI 130

RESULT 2
CDSI SCHPO
IID CDSI SCHPO STANDARD; PRT; 460 AA.
Q09170; O42642;
01-NOV-1995 (Rel. 32, Created)
16-OCT-2001 (Rel. 40, Last sequence update)
10-OCT-2003 (Rel. 42, Last annotation update)
Protein kinase cds1 (EC 2.7.1.37) (Checkpoint kinase cds1).
CDSI OR SPCC185.11C.
Schizosaccharomyces pombe (Fission yeast).
Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
Schizosaccharomycetales; Schizosaccharomycetaceae;
Schizosaccharomycetes.
NCBI_TaxID=4896;
[1]
SEQUENCE FROM N.A., AND FUNCTION.
MEDLINE=95240713; PubMed=7723827;
Murakami H., Okayama H.;
"A kinase from fission yeast responsible for blocking mitosis in S
phase.";
Nature 374:817-819(1995).
[2]
SEQUENCE FROM N.A., FUNCTION, SUBUNIT, AND PHOSPHORYLATION.
STRAIN=972;
MEDLINE=98119835; PubMed=9450932;
Lindsay J.D., Griffiths D.G.F., Edwards R.J., Christensen P.U.,
Murray J.M., Oman F., Walworth N., Carr A.M.;
"S-phase-specific activation of Cds1 kinase defines a subpathway of
the checkpoint response in Schizosaccharomyces pombe.";
Genes Dev. 12:382-395(1998).
[3]
SEQUENCE FROM N.A.
STRAIN=972;
MEDLINE=21848401; PubMed=11859360;
Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
Sgourou J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
Collins M., Connor R., Cronin A., Davis P., Feltwell T., Fraser A.,
[4]

```

P16715 vaccinia vi
P33817 variola vir
P41846 caenorhabdi
P34631 caenorhabdi
Q9nsd9 homo sapien
P35172 saccharomyc
P25155 gallus gall
P39521 saccharomyc
Q9zou5 rattus norv
Q8tr33 methanosarc
P49305 rhizobium m
Q9rug2 deinococcus

34 58 15.3 891 1 VP4A VACCV
35 58 15.3 892 1 VP4A VARV
36 58 15.3 1009 1 WS14 CAEEL
37 57.5 15.2 469 1 Y0J8 CAEEL
38 57.5 15.2 589 1 SYFB HUMAN
39 57.5 15.2 780 1 TREB YEAST
40 57 15.1 475 1 FA10 CHICK
41 57 15.1 936 1 FHL1 YEAST
42 57 15.1 1333 1 ADO RAT
43 56.5 14.9 215 1 KAD METAC
44 56.5 14.9 334 1 YNO1 RHIME
45 56.5 14.9 376 1 DNJ4 DEIRA

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model
Run on: May 7, 2004, 14:37:32 ; Search time 2.46674 Seconds
(without alignments)
1540.951 Million cell updates/sec

Title: US-10-046-046-2_COPY_31_103
Perfect score: 378
Sequence: 1 VLLKREWTIGRRGCDLSP.....INKLKVVKKQTCLPTQGDVI 73

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues
Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	107.5	28.4	821	1	SPK1 YEAST
2	77.5	20.5	460	1	CS1 SCHPO
3	72	19.0	513	1	DUN1 YEAST
4	71	18.8	409	1	PGK MYCPN
5	66	17.5	977	1	DLF1 HUMAN
6	66	17.5	992	1	DLF1 RAT
7	64	16.9	1441	1	VGLM BUNGH
8	63.5	16.8	445	1	MEK1 SCHPO
9	61.5	16.3	476	1	LOK DROME
10	61	16.1	484	1	FKH1 YEAST
11	61	16.1	546	1	CHK2 MOUSE
12	61	16.1	1433	1	VGLM BUNL7
13	61	16.1	1441	1	VGLM BUNL7
14	60.5	16.0	365	1	TRMU CORGL
15	60	15.9	353	1	Y634 CHLMU
16	60	15.9	403	1	GST1 MOUSE
17	60	15.9	952	1	YK15 CAEEL
18	60	15.9	969	1	UVRA MYCLE
19	59.5	15.7	465	1	TM15 HUMAN
20	59.5	15.7	485	1	RNF8 HUMAN
21	59.5	15.7	809	1	CDML OLICA
22	59	15.6	592	1	YTPF PSEPU
23	59	15.6	1045	1	KMD2 YEAST
24	58.5	15.5	181	1	HAD MYCTU
25	58.5	15.5	209	1	CPMA RHET
26	58.5	15.5	523	1	P60 LISSE
27	58.5	15.5	814	1	SLA1 BACAA
28	58	15.3	497	1	MEK1 YEAST
29	58	15.3	522	1	YNL6 YEAST
30	58	15.3	524	1	HUNB TRICA
31	58	15.3	746	1	TAGF BACSU
32	58	15.3	888	1	SYA ZYMO
33	58	15.3	891	1	VP4A VACCC

ALIGNMENTS

SPK1_YEAST	STANDARD;	PRT;	821 AA.
AC P22216;			
DT 01-AUG-1991 (Rel. 19, Created)			
DT 01-AUG-1991 (Rel. 19, Last sequence update)			
DT 10-OCT-2003 (Rel. 42, Last annotation update)			
DE Protein kinase SPK1 (EC 2.7.1.-) (Serine-protein kinase 1).			
GN SPK1 OR SADI OR RAD53 OR MEC2 OR YPL153C OR P2568.			
OS Saccharomyces cerevisiae (Baker's yeast).			
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;			
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.			
OX NCBI_TaxID=4932;			
RN [1]			
RP SEQUENCE FROM N.A.			
RX MEDLINE=91117267; PubMed=1899289;			
RA Stern D.F., Zheng P., Beidler D.R., Zerillo C.;			
RT "Spk1, a new kinase from Saccharomyces cerevisiae, phosphorylates			
RT proteins on serine, threonine, and tyrosine."			
RL Mol. Cell. Biol. 11:987-1001(1991).			
RN [2]			
RP SEQUENCE FROM N.A.			
RC STRAIN=S288C / AB972;			
RX MEDLINE=97103777; PubMed=8948103;			
RA Purnelle B., Coster F., Goffeau A.;			
RT "The sequence of 55 kb on the left arm of yeast chromosome XVI			
RT identifies a small nuclear RNA, a new putative protein kinase and two			
RT new putative regulators."			
RL Yeast 12:1483-1492(1996).			
RN [3]			
RP SEQUENCE FROM N.A.			
RC STRAIN=S288C / AB972;			
RX MEDLINE=97133271; PubMed=9169875;			
RA Bussey H., Storms R.K., Ahmed A., Albermann K., Allen E., Ansoerge W.,			
RA Araujo R., Aparicio A., Barrall B.G., Badcock K., Benes V.,			
RA Botstein D., Bowman S., Bruckner M., Carpenter J., Cherry J.M.,			
RA Chung E., Churcher C.M., Coster F., Davis K., Davis R.W.,			
RA Dietrich F.S., Delius H., DiPaolo T., Dubois E., Duesterhoeft A.,			
RA Duncan M., Floeth M., Fortin N., Friesen J.D., Fritz C., Goffeau A.,			
RA Hall J., Hebling U., Heumann K., Hilbert H., Hillier L.W.,			
RA Hunicke-Smith S., Hyman R., Johnston M., Kalman S., Kleine K.,			
RA Kemp C., Kurdi O., Lashkari D., Lew H., Lin A., Lin D., Louis E.J.,			
RA Marathe R., Messenguy F., Mewes H.-W., Mirtipati S., Moestl D.,			
RA Mueller-Auer S., Namath A., Newnich U., Oefner P., Pearson D.,			
RA Petel F.X., Pohl T.M., Purnelle D., Schafer M., Scharfe M.,			
RA Scherens B., Schramm S., Schroeder M., Sdicu A.M., Tettelin H.,			
RA Urrestarazu L.A., Ushinsky S., Vierdeels F., Viessers S., Voes H.,			
RA Walsh S.V., Wambolt R., Wang Y., Wedler E., Wedler H., Winnett E.,			
RA Zhong W., Zollner A., Vo D.H., Hani J.;			
RT "The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI."			
RL Nature 387:103-105(1997).			
RN [4]			
RP FUNCTION.			
RX MEDLINE=95047382; PubMed=7958905;			
RA Allen J.B., Zhou Z., Siede W., Friedberg E.C., Elledge S.J.;			
RT "The SADI/RAD53 protein kinase controls multiple checkpoints and DNA			

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 14, 2004, 20:06:30 ; Search time 1483 Seconds

(without alignments)
7674.257 Million cell updates/sec

Title: US-10-048-046-1

Perfect score: 2679

Sequence: 1 aagaattcgcacgagggccg.....acaaaaaaaaaaaaaaaaa 2679

Scoring table: OLIGO NUC

Gapop 60.0, Gapext 60.0

Searched: 3373863 seqs, 2124099041 residues

Word size: 0

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database: N Geneseq 29Jan04.*

- 1: Geneseqn1980s.*
- 2: Geneseqn1990s.*
- 3: Geneseqn2000s.*
- 4: Geneseqn2001as.*
- 5: Geneseqn2001bs.*
- 6: Geneseqn2002s.*
- 7: Geneseqn2003as.*
- 8: Geneseqn2003bs.*
- 9: Geneseqn2003cs.*
- 10: Geneseqn2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2679	100.0	2679	5 AAF30352	AAF30352 Human chf
2	2133	79.6	2639	4 AAh14542	AAh14542 Human cDN
3	1995	74.5	1995	5 AAt89709	AAt89709 Nucleotid
4	1618	60.4	3181	6 ABs59646	ABs59646 Novel hum
5	1465	54.7	3138	4 AAh14556	AAh14556 Human cDN
6	1024	38.2	2259	4 AAI88903	AAI88903 Human pol
7	765	28.6	1311	4 ABx25843	ABx25843 Human cDN
8	765	28.6	1311	7 ABx73184	ABx73184 Human nov
9	633	23.6	2186	7 ADa52592	ADa52592 Human cod
10	478	17.8	816	4 AAh06828	AAh06828 Human cDN
11	468	17.5	824	4 AAh06846	AAh06846 Human cDN
12	455	17.0	693	4 AAs26304	AAs26304 Human nov
13	455	17.0	693	7 ABx73645	ABx73645 Human cDN
14	426	15.9	518	4 AAH11859	AAH11859 Human sec
15	286	10.7	575	3 AAa44336	AAa44336 Human cDN
16	267	10.0	357	4 AAs26143	AAs26143 Human nov
17	267	10.0	357	7 ABx73484	ABx73484 Human nov
18	238	8.9	354	4 AAs26563	AAs26563 Human cDN
19	238	8.9	354	4 AAs26144	AAs26144 Human cDN
20	238	8.9	354	7 ABx73904	ABx73904 Human nov
21	238	8.9	354	7 ABx73485	ABx73485 Human nov
22	217	8.1	449	8 ACh26450	ACh26450 Human adu
23	169	6.3	13836	5 ABA16633	ABA16633 Human ner

ALIGNMENTS

RESULT 1

AAF30352
ID AAF30352 standard; cDNA; 2679 BP.

XX AAF30352;

DT 14-MAY-2001 (first entry)

XX Human chfr cDNA encoding checkpoint with FHA and ring finger protein.

DE Checkpoint with forkhead associated domain and ring finger; Chfr; human;

KW mitosis; cell cycle; tumour; diagnosis; antitumour; drug screening;

KW ubiquitin-protein ligase; ss.

XX Homo sapiens.

OS Homo sapiens.

XX Key Location/Qualifiers

FT CDS 91..2085

FT /*tag= a

FT mutation replace(1828,A)

FT /*tag= b

FT /*note= "alters codon GTG (Val) to ATG (Met) in chfr from human cancer cell line U2OS"

XX WO200109150-A2.

XX 08-FEB-2001.

XX 14-JUN-2000; 2000WO-US016391.

XX 29-JUL-1999; 99US-0146194P.

XX (WIST-) WISTAR INST ANATOMY & BIOLOGY.

XX Halazonetis T, Scolnick D;

XX WPI; 2001-182927/18.

XX P-PSDB; AAB20219.

XX Novel nucleic acid sequence of mitotic checkpoint gene encoding a checkpoint with forkhead-associated domain and ring finger protein, for diagnosing tumorigenic cells and in screening for anticancer drugs.

XX Claim 2(a); Fig 4A-D; 85pp; English.

XX The present sequence is that of cDNA encoding the human mitotic

CC checkpoint protein Chfr (see AAB20219) having a forkhead associated
 CC domain (FHA) and a ring finger domain. The protein is required for
 CC regulation of the transition of cells from prophase to metaphase during
 CC mitosis. It has ubiquitin-protein ligase activity. The Chfr checkpoint
 CC was evident in primary human cells, but was inactivated in 4 of 8 human
 CC cancer cell lines. In U2OS cells, a mutation was identified, which caused
 CC a Val to Met amino acid substitution in the highly conserved C-terminal
 CC Cys-rich region of the Chfr protein. In the absence of the Chfr
 CC checkpoint, cells subjected to mitotic stress condensed their chromosomes
 CC despite failing to separate their chromosomes. Chfr may monitor
 CC centrosome separation. Inactivation of the Chfr gene in human cancer is
 CC theorized to underlie the increased sensitivity of cancer cells to
 CC antimitotic drugs. Nucleic acids comprising the present sequence, or
 CC sequences encoding at least amino acids 31-103 303-346, 476-641 (or
 CC their antisense sequences) are claimed. The Chfr cDNA was isolated from
 CC an expressed sequence tag database sequence for cDNAs with FHA motifs.
 CC Claimed methods of determining the tumorigenic potential of a cell
 CC comprise examining the cell for the presence of Chfr nucleic acid
 CC (absence or mutation indicating predisposition to tumorigenesis upon
 CC exposure to mitotic stress). Also claimed is a diagnostic agent, e.g. an
 CC antisense fragment of the present sequence, that binds to the Chfr
 CC nucleic acid, and a diagnostic kit for detecting tumorigenic potential
 CC of a cell. A composition which inhibits the biological activity of Chfr
 CC may comprise a ligand selected from an antibody or its fragment. The Chfr
 CC inhibitor is used in a claimed method of retarding the growth of a cancer
 CC cells. Chfr polypeptides are useful in screening for drugs which can
 CC inhibit the activity of Chfr in a cancer cell, rendering the cell more
 CC sensitive to additional antitumor therapies

XX Sequence 2679 BP; 650 A; 715 C; 764 G; 550 T; 0 U; 0 Other;

Query Match 100.0%; Score 2679; DB 5; Length 2679;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AAGATTCCGACAGCGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGCGCGTTCGG 60
 DB 1 AAGATTCCGACAGCGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGCGTTCGG 60

QY 61 GTTCGCGCGCGCGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGCGCGTTCGG 120
 DB 61 GTTCGCGCGCGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGCGTTCGG 120

QY 121 CGCGCGCGCGCGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGCGCGTTCGG 180
 DB 121 CGCGCGCGCGCGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGCGTTCGG 180

QY 181 GTTCCTCTGAGGAAGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGCGTTCGG 240
 DB 181 GTTCCTCTGAGGAAGCGGAGTGTGAATCCCGATGAGCGCGCGCGCGCGTTCGG 240

QY 241 CCAGCGATTAATCTGCTCTGAGATCACTGTAGATTTAGTGGATGAATAATCAGGT 300
 DB 241 CCAGCGATTAATCTGCTCTGAGATCACTGTAGATTTAGTGGATGAATAATCAGGT 300

QY 301 CAGGTGACACTGGAAGATACCAAGCACCAGTGGAAAGTGAATTAACAAGCTGAAGTTGTT 360
 DB 301 CAGGTGACACTGGAAGATACCAAGCACCAGTGGAAAGTGAATTAACAAGCTGAAGTTGTT 360

QY 361 AAGAGCGACATGCGCTTACAGATCGGAGTGTCACTTACTTGGTGTACAGAGAAAT 420
 DB 361 AAGAGCGACATGCGCTTACAGATCGGAGTGTCACTTACTTGGTGTACAGAGAAAT 420

QY 421 GAACCGGAACACACGCTGGCATACCTCTATGAATCTTTAAGTGAAGAAAGCAAGCATGACA 480
 DB 421 GAACCGGAACACACGCTGGCATACCTCTATGAATCTTTAAGTGAAGAAAGCAAGCATGACA 480

QY 481 CAGAGATCTTTGAGCTTAAACAGGAAATGTGTTCATGGACCAAGATACCTCAGGT 540
 DB 481 CAGAGATCTTTGAGCTTAAACAGGAAATGTGTTCATGGACCAAGATACCTCAGGT 540

QY 541 GCAGGTGACAGGCGGAGCGGATCCCGGGTCCCTCGCTCGCGCGCGCGCTCAGGTG 600

DB 541 GCAGGTGACAGGCGGAGCGGCGGATCCCGGGTCCCTCGTCTCGCGCGCATCAGGTG 600
 QY 601 TCGTTTGGAGAACACACAGCCATCAACATCGAGTTCAGACTCTTCCCAACAGCTCGGCC 660
 DB 601 TCGTTTGGAGAACACACAGCCATCAACATCGAGTTCAGACTCTTCCCAACAGCTCGGCC 660
 QY 661 TCTTCCACGAGGCGCTTCTCTGACAGGCGGAGCGGTTCCTCCAGTTCGTGGGTCTGGGGT 720
 DB 661 TCTTCCACGAGGCGCTTCTCTGACAGGCGGAGCGGTTCCTCCAGTTCGTGGGTCTGGGGT 720

QY 721 GTGCGATCTCTCCCTAAAGAAAGTGGTCCCTCTCTGCGAAGTGAAGTCTCCAGCTTT 780
 DB 721 GTGCGATCTCTCCCTAAAGAAAGTGGTCCCTCTCTGCGAAGTGAAGTCTCCAGCTTT 780

QY 781 GCGTCAGTCTCTCCACACAGAAAGACTCGTCCGTCCTTTTCGTGTGGAAACCCAGGATCAG 840
 DB 781 GCGTCAGTCTCTCCACACAGAAAGACTCGTCCGTCCTTTTCGTGTGGAAACCCAGGATCAG 840

QY 841 GAGGATTTGGAGCCCGGTGAAGAAATGAGAGGATGGGACCTTGACCTTGAAACGGG 900
 DB 841 GAGGATTTGGAGCCCGGTGAAGAAATGAGAGGATGGGACCTTGACCTTGAAACGGG 900

QY 901 CAGTTTGTGGTTCGACAAACCCGTAAGAAATGCCAAACCGTCCACAGGAGCGTCAGAGCA 960
 DB 901 CAGTTTGTGGTTCGACAAACCCGTAAGAAATGCCAAACCGTCCACAGGAGCGTCAGAGCA 960

QY 961 GCGGCTGGAAAGCGACAGAAATGAGAGGAGCGCTGACATGATCATCTGCCAGGACCTG 1020
 DB 961 GCGGCTGGAAAGCGACAGAAATGAGAGGAGCGCTGACATGATCATCTGCCAGGACCTG 1020

QY 1021 CTGACAGCACTCGTGTGAGTTTTCAGCCCTGATGCACACAGTTTCTGCGCGGTGCTACTCG 1080
 DB 1021 CTGACAGCACTCGTGTGAGTTTTCAGCCCTGATGCACACAGTTTCTGCGCGGTGCTACTCG 1080

QY 1081 GCGTGGATGGAGCGCTCGTCTGTCTTACCTGCGCGTGTCCCGTGGAGCGGATCTGT 1140
 DB 1081 GCGTGGATGGAGCGCTCGTCTGTCTTACCTGCGCGTGTCCCGTGGAGCGGATCTGT 1140

QY 1141 AAAAACCACATCTCTCAACAACTCGTGGAAAGCATACCTCATCCAGCATCCAGCAAGAGT 1200
 DB 1141 AAAAACCACATCTCTCAACAACTCGTGGAAAGCATACCTCATCCAGCATCCAGCAAGAGT 1200

QY 1201 CGCATGGAGAGATGTGAAAGTATGGATGCCAGGATTAATCACTCAAGACATGCTG 1260
 DB 1201 CGCATGGAGAGATGTGAAAGTATGGATGCCAGGATTAATCACTCAAGACATGCTG 1260

QY 1261 CAGCCCAAGTCAAGCGCGTCTTTTCTGATGAAGAGGAGTTTCAGAGACCTGCTGGAG 1320
 DB 1261 CAGCCCAAGTCAAGCGCGTCTTTTCTGATGAAGAGGAGTTTCAGAGACCTGCTGGAG 1320

QY 1321 CTGTCAAGCTTGTGACATGAGTCTCTAGACATTAGCCAGCCATACGTCGTGTCGCGGAG 1380
 DB 1321 CTGTCAAGCTTGTGACATGAGTCTCTAGACATTAGCCAGCCATACGTCGTGTCGCGGAG 1380

QY 1381 TGTCTGAGTACAGAGGCGGCGGCGAGCTTCCCACTGCGCCAGCACCCGAGGCGGAG 1440
 DB 1381 TGTCTGAGTACAGAGGCGGCGGCGAGCTTCCCACTGCGCCAGCACCCGAGGCGGAG 1440

QY 1441 CCAGAGCGCCACAGGCGCTGGGGGATGACCCCTCCAGCTCCCTGAGCTGACAGCA 1500
 DB 1441 CCAGAGCGCCACAGGCGCTGGGGGATGACCCCTCCAGCTCCCTGAGCTGACAGCA 1500

QY 1501 GTCCAGGATTAACGTGTGCTTGTGCAAGGAGCGACGCCCTGTGCACTGCTGCTCCAG 1560
 DB 1501 GTCCAGGATTAACGTGTGCTTGTGCAAGGAGCGACGCCCTGTGCACTGCTGCTCCAG 1560

QY 1561 CCCATGCCGACCGGAGCGGAGCGAGCGCGGAGCGCGGCTGCTGCCCTCAGCAGGTGT 1620
 DB 1561 CCCATGCCGACCGGAGCGGAGCGGAGCGGAGCGCGGCTGCTGCCCTCAGCAGGTGT 1620

QY 1621 CGGTCTCTCTGACGCTTTCTGCCACCTGTACTGGGGTGTGACCCCGGACCGGCTGCTAC 1680
 DB 1621 CGGTCTCTCTGACGCTTTCTGCCACCTGTACTGGGGTGTGACCCCGGACCGGCTGCTAC 1680

QY 1681 GGTCGCTGGCCCGCTTTGTGAGCTCAACCTGGGTGACAGAGTCTCGAGCGCGTCTG 1740
Db 1681 GGTCGCTGGCCCGCTTTGTGAGCTCAACCTGGGTGACAGAGTCTCGAGCGCGTCTG 1740
QY 1741 AACAACAAGCTACAGGTGACAGATCTGGAAGATTTACCTGGCAACAGAGGTTTGACA 1800
Db 1741 AACAACAAGCTACAGGTGACAGATCTGGAAGATTTACCTGGCAACAGAGGTTTGACA 1800
QY 1801 TGGAAAAACATGTTGACCGAGAGCTCGTGGCTCTCCAGCGGGAGTGTCTTCTGTCT 1860
Db 1801 TGGAAAAACATGTTGACCGAGAGCTCGTGGCTCTCCAGCGGGAGTGTCTTCTGTCT 1860
QY 1861 GATTACAGAGTCAAGGAGACACCGTCTGTGTGTTACTGCTGTGGCTCGGCAAGCTTCCGT 1920
Db 1861 GATTACAGAGTCAAGGAGACACCGTCTGTGTGTTACTGCTGTGGCTCGGCAAGCTTCCGT 1920
QY 1921 GAGCTGACCTATCAGTATCGGAGAACATTTCTGCTTCCGAGTTCGAGTGGCCGTAAACA 1980
Db 1921 GAGCTGACCTATCAGTATCGGAGAACATTTCTGCTTCCGAGTTCGAGTGGCCGTAAACA 1980
QY 1981 TCCCGTCTGACTGCTACTGCGGCGCTAACTGCGCACTCAGGTGAAGCTCACCAGCC 2040
Db 1981 TCCCGTCTGACTGCTACTGCGGCGCTAACTGCGCACTCAGGTGAAGCTCACCAGCC 2040
QY 2041 ATGAATTCATATCATATCTGTGACAGACAGGTTCAAAATCTAAGCATCCAGAGGCCCT 2100
Db 2041 ATGAATTCATATCATATCTGTGACAGACAGGTTCAAAATCTAAGCATCCAGAGGCCCT 2100
QY 2101 GAGCAGCTTTTCAGCACTGGAGGTGAAGAGAGCGTGTGTTTAAATAACAGAGCAAGCAG 2160
Db 2101 GAGCAGCTTTTCAGCACTGGAGGTGAAGAGAGCGTGTGTTTAAATAACAGAGCAAGCAG 2160
QY 2161 TCAAGTGTTTTCACAGCCCTTGGAGGAGGAGCGAGGCTCCGACAGTGTCTCTGG 2220
Db 2161 TCAAGTGTTTTCACAGCCCTTGGAGGAGGAGCGAGGCTCCGACAGTGTCTCTGG 2220
QY 2221 GGTGACTCTTCTGAGAGCTTTTACCTCTGAGTGAGACCTTCCCGAGAGCCCGCGGG 2280
Db 2221 GGTGACTCTTCTGAGAGCTTTTACCTCTGAGTGAGACCTTCCCGAGAGCCCGCGGG 2280
QY 2281 CCGCAGCCCGCCCTCTGAGCGCTGGGAGGAGGAGCGGCTCCGACAGTGTCTCTGG 2340
Db 2281 CCGCAGCCCGCCCTCTGAGCGCTGGGAGGAGGAGCGGCTCCGACAGTGTCTCTGG 2340
QY 2341 CGAAGCTTTTCTTAACATGCGCCCTTCCCGAGAGGAGGAGGAGGAGGAGGAGGAG 2400
Db 2341 CGAAGCTTTTCTTAACATGCGCCCTTCCCGAGAGGAGGAGGAGGAGGAGGAGGAG 2400
QY 2401 ATTTTCGAAACTACAGTTAAAGCAGAGTCTGTTTTCAGGAAAGTTTCAAGGGAGAG 2460
Db 2401 ATTTTCGAAACTACAGTTAAAGCAGAGTCTGTTTTCAGGAAAGTTTCAAGGGAGAG 2460
QY 2461 GGCAGTTTATCAAAACATGTTTTCAGGAGAGGAGGAGGAGGAGGAGGAGGAGGAG 2520
Db 2461 GGCAGTTTATCAAAACATGTTTTCAGGAGAGGAGGAGGAGGAGGAGGAGGAGGAG 2520
QY 2521 CGTACAAATATCTGCTGCGGAGAAACACAGCAGATTTATCTATTTTATTTTAAATA 2580
Db 2521 CGTACAAATATCTGCTGCGGAGAAACACAGCAGATTTATCTATTTTATTTTAAATA 2580
QY 2581 GGTGTTGCTTATCTTCTTAATAGATTTAAATGTCAAACTGTAGCAATATATATA 2640
Db 2581 GGTGTTGCTTATCTTCTTAATAGATTTAAATGTCAAACTGTAGCAATATATATA 2640
QY 2641 ATTTTATATTTTACAAATTTGACAAAAAATAAAAAA 2679
Db 2641 ATTTTATATTTTACAAATTTGACAAAAAATAAAAAA 2679

RESULT 2
AAH14542
ID AAH14542 standard; cDNA; 2639 BP.

XX AAH14542;
AC 26-JUN-2001 (first entry)
DE Human cDNA sequence SEQ ID NO:12099.
XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX Homo sapiens.
XX EP1074617-A2.
XX 07-FEB-2001.
XX 28-JUL-2000; 2000EP-00116126.
XX 29-JUL-1999; 99JP-00248036.
XX 27-AUG-1999; 99JP-00300253.
XX 11-JAN-2000; 2000JP-00118776.
XX 02-MAY-2000; 2000JP-00183767.
XX 09-JUN-2000; 2000JP-00241899.
XX (HELI-) HELIX RES INST.
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX WPI; 2001-318749/34.
XX Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
XX Claim 8; SEQ ID NO 12099; 2537pp + Sequence Listing; English.
XX The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesizing polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to AAH95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention
XX Sequence 2639 BP; 620 A; 706 C; 760 G; 553 T; 0 U; 0 Other;
Query Match 79.6%; Score 2133; DB 4; Length 2639;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 529 GATACCTCAGGTGCGAGGTGCGAGGCGCGAGTCCCGGGTCCCTCCGTCGTCGCC 588
Db 481 GATACCTCAGGTGCGAGGTGCGAGGCGCGAGTCCCGGGTCCCTCCGTCGTCGCC 540
QY 589 GCCACTCAGGTGCTTTGAGGAGACCCAGCCATCAGCATCAGCTCTTCCCTTCC 648
Db 541 GCCACTCAGGTGCTTTGAGGAGACCCAGCCATCAGCATCAGCTCTTCCCTTCC 600

QY 649 ACAGCTCGGCTCTTCCACGAGGCTTCTCCTCAGGCGGAGAGCGTTCTCTCCAGTTGT 708
Db 601 ACAGCTCGGCTCTTCCACGAGGCTTCTCCTCAGGCGGAGAGCGTTCTCTCCAGTTGT 660
QY 709 GGGTCTGGGGTGTGGGATCTCCCTAAAGGAAAGTGTCTCCTCTGGGCAAGTATGAA 768
Db 661 GGGTCTGGGGTGTGGGATCTCCCTAAAGGAAAGTGTCTCCTCTGGGCAAGTATGAA 720
QY 769 GTCTCCAGCTTTGGCTCAGCTCTCCAGACAGAAAGACTCGTCCCTTTTCTCGTTGGAA 828
Db 721 GTCTCCAGCTTTGGCTCAGCTCTCCAGACAGAAAGACTCGTCCCTTTTCTCGTTGGAA 780
QY 829 CCCAGGATCAGGAGGATTTGGAGCCCTGGAAGAAATGAGAGAGATGGGAGCCTT 888
Db 781 CCCAGGATCAGGAGGATTTGGAGCCCTGGAAGAAATGAGAGAGATGGGAGCCTT 840
QY 889 GACCTGAACGGGCACTGTCTGTGCGACAAACCGGCTGAAATGCCAAACCGTCCACGAG 948
Db 841 GACCTGAACGGGCACTGTCTGTGCGACAAACCGGCTGAAATGCCAAACCGTCCACGAG 900
QY 949 GACGTACAGACAGCGGCTGGAGAGCCAGACAAAGATGGAGGAGAGCTGACATGATCATC 1008
Db 901 GACGTACAGACAGCGGCTGGAGAGCCAGACAAAGATGGAGGAGAGCTGACATGATCATC 960
QY 1009 TGCCAGGACCTGCTGCACAGACTCGGTGAGTTTGAGCCCTGCATGCACACGTTCTGGCGG 1068
Db 961 TGCCAGGACCTGCTGCACAGACTCGGTGAGTTTGAGCCCTGCATGCACACGTTCTGGCGG 1020
QY 1069 GCTTCTACTCGGCTGAGATGAGGCGCTGCTCCCTGTGTCTACTGCGCGCTGTCCGCTG 1128
Db 1021 GCTTCTACTCGGCTGAGATGAGGCGCTGCTCCCTGTGTCTACTGCGCGCTGTCCGCTG 1080
QY 1129 GAGCGGATCTGTAACCAACATCTCAACACCTCGTGAAGCATACCTCATCCAGCAT 1188
Db 1081 GAGCGGATCTGTAACCAACATCTCAACACCTCGTGAAGCATACCTCATCCAGCAT 1140
QY 1189 CCAGACAGAGTCGAGTGAAGAGATGTCAAGATATGATGATGATGATGATGATGATGATGAT 1248
Db 1141 CCAGACAGAGTCGAGTGAAGAGATGTCAAGATATGATGATGATGATGATGATGATGATGAT 1200
QY 1249 CAAGCATGCTGCAGCCCAAGTCAAGGCGCTCTTTTCTGATGAAGAGGAGTTCAGAG 1308
Db 1201 CAAGCATGCTGCAGCCCAAGTCAAGGCGCTCTTTTCTGATGAAGAGGAGTTCAGAG 1260
QY 1309 GACCTGCTGGAGCTGTACAGACGTTGACAGTGTCTCTCAGACATTPAGCCAGCCATAGCTC 1368
Db 1261 GACCTGCTGGAGCTGTACAGACGTTGACAGTGTCTCTCAGACATTPAGCCAGCCATAGCTC 1320
QY 1369 GTGTCCGCGAGTGTCTGAGTACAGAGGCGAGGCGGAGCCCTCCCACTGCCCAGCA 1428
Db 1321 GTGTCCGCGAGTGTCTGAGTACAGAGGCGAGGCGGAGCCCTCCCACTGCCCAGCA 1380
QY 1429 CCGAGGCGAGCCAGGAGCCCAAGGCGCTGGGGGATGCACCCCTCCACGCTCCGTCCAGC 1488
Db 1381 CCGAGGCGAGCCAGGAGCCCAAGGCGCTGGGGGATGCACCCCTCCACGCTCCGTCCAGC 1440
QY 1489 CTGACACAGCATGTCAGGATTAAGTGTGCTCTGTGAGGAGGAGCCAGCCCTGTGACCC 1548
Db 1441 CTGACACAGCATGTCAGGATTAAGTGTGCTCTGTGAGGAGGAGCCAGCCCTGTGACCC 1500
QY 1549 TGTCTGCTCCAGCCATGCTCCGAGCGAGCGGAGCGGAGCAGACCCGCGTGTGCGC 1608
Db 1501 TGTCTGCTCCAGCCATGCTCCGAGCGGAGCGGAGCGGAGCAGACCCGCGTGTGCGC 1560
QY 1609 CTTACAGAGTGTGGGTCTGCTGACAGCTTTCTGCCACTGTACTGCGGCTGCAACCCGG 1668
Db 1561 CTTACAGAGTGTGGGTCTGCTGACAGCTTTCTGCCACTGTACTGCGGCTGCAACCCGG 1620
QY 1669 ACCGGTGTACGGCTGCTGCGCCCGCTTTGTGAGCTCAACCTGGGTGACAGTGTCTG 1728
Db 1621 ACCGGTGTACGGCTGCTGCGCCCGCTTTGTGAGCTCAACCTGGGTGACAGTGTCTG 1680

QY 1729 GAGCGCTGCTGAAACAACAAGCTACGAGTCAGATCCTGAAAGATTACTGGCAACC 1788
Db 1681 GAGCGGTGCTGAAACAACAAGCTACGAGTCAGATCCTGAAAGATTACTGGCAACC 1740
QY 1789 AGAGGTTTGACATGGAAGAAACATGTTGACCGAGAGCCCTGCTGCTCCAGCGGGAGTG 1848
Db 1741 AGAGGTTTGACATGGAAGAAACATGTTGACCGAGAGCCCTGCTGCTCCAGCGGGAGTG 1800
QY 1849 TTTCTGCTGCTGATTTACAGACTCAGGGAGACACGCTTCTGTTACTGCTGTGGCCTG 1908
Db 1801 TTTCTGCTGCTGATTTACAGACTCAGGGAGACACGCTTCTGTTACTGCTGTGGCCTG 1860
QY 1909 CGCAGCTTCCGTGAGCTGACCTTATCAGTATCGGCAAGAACATTCCTGCTTCCAGTTGCCA 1968
Db 1861 CGCAGCTTCCGTGAGCTGACCTTATCAGTATCGGCAAGAACATTCCTGCTTCCAGTTGCCA 1920
QY 1969 GTGGCGGTAACATCCGCTCTGACTGCTACTGGGCGCTTACTGCGGCACTCAGGTGAAA 2028
Db 1921 GTGGCGGTAACATCCGCTCTGACTGCTACTGGGCGCTTACTGCGGCACTCAGGTGAAA 1980
QY 2029 GTTCACACAGCCCATGAAATTCATATCATATCTGTAACAGAGGTTCAAAAACCTAAGCA 2088
Db 1981 GTTCACACAGCCCATGAAATTCATATCATATCTGTAACAGAGGTTCAAAAACCTAAGCA 2040
QY 2089 TCCAGAGGCGCTGAGCAGCTTTTACGACTGAGAGTGAAGAGAGCGGTTTTTAAATACA 2148
Db 2041 TCCAGAGGCGCTGAGCAGCTTTTACGACTGAGAGTGAAGAGAGCGGTTTTTAAATACA 2100
QY 2149 GAGACAAGCAGCTCAAGGTGTTTTTACAGCCCTTGGAGGAAAGGAGCGAGGCTTCCGA 2208
Db 2101 GAGACAAGCAGCTCAAGGTGTTTTTACAGCCCTTGGAGGAAAGGAGCGAGGCTTCCGA 2160
QY 2209 CAGGTCTCTGGGGTGACTCTTCTGTGAGGCTTTTTTACCTCTGAGTGAAGCCCTCCCA 2268
Db 2161 CAGGTCTCTGGGGTGACTCTTCTGTGAGGCTTTTTTACCTCTGAGTGAAGCCCTCCCA 2220
QY 2269 GAGCCCGGGGCGCAGCCGCTCCTGTGTGAGCGTGGCAGGCGCTCGTGTGGCAT 2328
Db 2221 GAGCCCGGGGCGCAGCCGCTCCTGTGTGAGCGTGGCAGGCGCTCGTGTGGCAT 2280
QY 2329 CAGCAGCAGAGACGAAGCCTTTCTGTAAACATGCGGCGCTCCGCGCAGAGGGGCGAGTTT 2388
Db 2281 CAGCAGCAGAGACGAAGCCTTTCTGTAAACATGCGGCGCTCCGCGCAGAGGGGCGAGTTT 2340
QY 2389 GCTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAACTGTGTTTTTTCAGGAAAAGTT 2448
Db 2341 GCTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAACTGTGTTTTTTCAGGAAAAGTT 2400
QY 2449 TCAAGGAGAGAGGCGCAAGTTTATCAAAAACATTTTTCAGGAGAGGGAGCATAGTTTA 2508
Db 2401 TCAAGGAGAGAGGCGCAAGTTTATCAAAAACATTTTTCAGGAGAGGGAGCATAGTTTA 2460
QY 2509 CAGCCTACAGAGCTACACAAATATCCTGCTGTGGGAAACCCACAGCATTTTATCTATT 2568
Db 2461 CAGCCTACAGAGCTACACAAATATCCTGCTGTGGGAAACCCACAGCATTTTATCTATT 2520
QY 2569 TTTATTTTAAATAGGTTTGTGCTTATCTCTTAATAAGATTTTAAATCTCAAACTGTAGC 2628
Db 2521 TTTATTTTAAATAGGTTTGTGCTTATCTCTTAATAAGATTTTAAATCTCAAACTGTAGC 2580
QY 2629 ACAAAATAATAATTTATTAATTTTACAATTTGAC 2661
Db 2581 ACAAAATAATAATTTATTAATTTTACAATTTGAC 2613

RESULT 3
AAF89709
ID AAF89709 standard; DNA; 1995 BP.
XX
AC AAF89709;
XX
DT 22-AUG-2001 (first entry)
XX

DE	Nucleotide sequence of a human ring finger protein designated FHAR1.
KX	FHAR1; RING finger protein; cancer; vaccine; ss.
XX	
OS	Homo sapiens.
FH	Location/Qualifiers
FT	1..1995
FT	/*tag= a
FT	/product= "ring finger protein FHAR1"
XX	
XX	WO200142430-A1.
PN	
XX	
PD	14-JUN-2001.
XX	
PF	07-DEC-2000; 2000WO-US033094.
XX	
PR	08-DEC-1999; 99US-00456876.
XX	
PA	(SMIK) SMITHKLINE BEECHAM CORP.
XX	
PI	Zhou B, Zhu Y, Chaturvedi P, Hurle MR, Li X;
XX	
XX	WPI; 2001-381663/40.
DR	P-PSDB; AAB83843.
XX	
PT	New FHAR1 polypeptide, a member of the RING finger protein family for
PT	diagnosing and treating cancer, and for use in anti-cancer vaccines.
XX	
PS	Claim 2; Page 18-19; 28pp; English.
XX	
CC	The present sequence encodes a FHAR1 polypeptide, which is a member of
CC	the RING finger protein family. FHAR1 is useful in the treatment of
CC	cancer, and as a vaccine for inducing an immunological response in a
CC	mammal. FHAR1 polynucleotides may also be used as a diagnostic reagent
CC	through detection of mutations in the associated gene, and for chromosome
CC	localization studies, and tissue expression studies. FHAR1 antibodies are
CC	useful to isolate and to identify clones expressing the polypeptides, or
CC	to purify the polypeptides by affinity chromatography and to treat cancer
XX	
SQ	Sequence 1995 BP; 465 A; 563 C; 580 G; 387 T; 0 U; 0 Other;
Query Match 74.5%; Score 1995; DB 5; Length 1995;	
Best Local Similarity 100.0%; Pred. No. 0;	
Matches 1995; Conservative 0; Mismatches 0; Indels 0; Gaps 0	
QY	91 ATGGAGCGGCCGAGGAAGGCAAGTCGCGCGCGCGAGCGCCTGGGACGGCTCTCTG 150
DB	1 ATGGAGCGGCCGAGGAAGGCAAGTCGCGCGCGCGAGCGCCTGGGACGGCTCTCTG 60
QY	151 CGTCTGGCGCGGAGGCGGAGCGCGCACGTCTCTCTGAGGAAGCGGGAGTGGACATC 210
DB	61 CGTCTGGCGCGGAGGCGGAGCGCGCACGTCTCTCTGAGGAAGCGGGAGTGGACATC 120
QY	211 GGGCGGAGACGAGGTGGAGCCTTCTCTTCCCGAGCAATAAATCTGCTCTCTGGAGATCAC 270
DB	121 GGGCGGAGACGAGGTGGAGCCTTCTCTTCCCGAGCAATAAATCTGCTCTCTGGAGATCAC 180
QY	271 TGTAGAATTTGTAGTGGATGAATAAATCAGGTGAGTGCACCTGGAGAATACCAAGCACCAAT 330
DB	181 TGTAGAATTTGTAGTGGATGAATAAATCAGGTGAGTGCACCTGGAGAATACCAAGCACCAAT 240
QY	331 GGAACAGTGATTAACAGCTGAAGTTGTTTAAGAGCAGACATGCCCTTTTACAGATCTGGG 390
DB	241 GGAACAGTGATTAACAGCTGAAGTTGTTTAAGAGCAGACATGCCCTTTTACAGATCTGGG 300
QY	391 GATGTCATCTACTTGTGTGTAAGGAAGATGAACCGGAACAACACGCTGGGATACCTCTAT 450
DB	301 GATGTCATCTACTTGTGTGTAAGGAAGATGAACCGGAACAACACGCTGGGATACCTCTAT 360
QY	451 GAACTCTTTAAGTGAAAGCAAGGCATGACACAAGAATCTCTTTGAAGCTACAGAGAAAT 510
DB	361 GAATCTTTAAGTGAAAGCAAGGCATGACACAAGAATCTCTTTGAAGCTACAGAGAAAT 420

Db	2449	TTTATTTTAATAGCTTTGGTCTTATCTTCTTAATAAGATTAAATGTCACAAACTGAGC	2500
Qy	2629	ACAAATATATAATTTTATATATTTTACAAATGAC	2661
Db	2509	ACAAATATATAATTTTATATATTTTACAAATGAC	2541
RESULT 5			
ID	AAH14556		
XX	AAH14556 standard; cDNA; 3138 BP.		
AC	AAH14556;		
DT	26-JUN-2001 (first entry)		
XX	Human cDNA sequence SEQ ID NO:12127.		
DE	Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.		
KW	Homo sapiens.		
OS	EP1074617-A2.		
PN	07-FEB-2001.		
XX	28-JUL-2000; 2000EP-00116126.		
PD	29-JUL-1999; 99JP-00248036.		
XX	27-AUG-1999; 99JP-00300253.		
PR	11-JAN-2000; 2000JP-00118776.		
PR	02-MAY-2000; 2000JP-00183767.		
PR	09-JUN-2000; 2000JP-00241899.		
XX	(HELI-) HELIX RES INST.		
XX	Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;		
PI	Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;		
XX	WPI; 2001-318749/34.		
DR	Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.		
XX	Claim 8; SEQ ID NO 12127; 2537pp + Sequence Listing; English.		
CC	The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of oligonucleotides comprises at least 15 nucleotides from those defined in the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesising polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention		
XX	Sequence 3138 BP; 738 A; 824 C; 873 G; 703 T; 0 U; 0 Other;		
SQ	Query Match 54.7%; Score 1465; DB4; Length 3138;		

Best Local Similarity 99.6%; Pred. No. 0;			
Matches 1945; Conservative 0; Mismatches 6; Indels 2; Gaps 1;			
QY	709	GGGCTGGGGTGGTGGCATCTCCCTTAAGGAAGTGGTCCCTGTGGCAAGTATGAA	768
Db	560	GGGCTGGGGTGGTGGCATCTCCCTTAAGGAAGTGGTCCCTGTGGCAAGTATGAA	619
QY	769	GTCTCCAGCTTTGCTCAGCTCTCCAGACAGAAAGACTGGTCCCTTTTGTCTTGGAA	828
Db	620	GTCTCCAGCTTTGCTCAGCTCTCCAGACAGAAAGACTGGTCCCTTTTGTCTTGGAA	679
QY	829	CCCCAGATCAGGAGATTTGGAGCCGTGAAGAAAGAAATGAGAGAGATGGGACCTT	888
Db	680	CCCCAGATCAGGAGATTTGGAGCCGTGAAGAAAGAAATGAGAGAGATGGGACCTT	739
QY	889	GACCTGAACGGGAGTGTGTGTGCACAAACCGGTGAGAAATGCCAAACCGTCCACGAG	948
Db	740	GACCTGAACGGGAGTGTGTGTGCACAAACCGGTGAGAAATGCCAAACCGTCCACGAG	799
QY	949	GACGTTCAGAGCAGCGGCTGGGAAGCAGACAAAGATGGAGGAGAGCGTGAACATCATC	1008
Db	800	GACGTTCAGAGCAGCGGCTGGGAAGCAGACAAAGATGGAGGAGAGCGTGAACATCATC	859
QY	1009	TGCCAGGACCTGCTGCAGACTGGGTGAGTTTGCAGCCCTGCATGCAACAGCTTCTGGCG	1068
Db	860	TGCCAGGACCTGCTGCAGACTGGGTGAGTTTGCAGCCCTGCATGCAACAGCTTCTGGCG	919
QY	1069	GCTTCTACTCGGGCTGGATGAGCGCTCGTCCCTGTGTCTTACTCGCCGTGTCCTGGT	1128
Db	920	GCTTCTACTCGGGCTGGATGAGCGCTCGTCCCTGTGTCTTACTCGCCGTGTCCTGGT	979
QY	1129	GAGCGGATCTGTAAACCAACATCTTCAACACCTCTGGAAGCATCTCATCAGCAT	1188
Db	980	GAGCGGATCTGTAAACCAACATCTTCAACACCTCTGGAAGCATCTCATCAGCAT	1039
QY	1189	CCAGACAGAGTCGAGTGAAGAGATGTGCAAGTATGGATGCCAGGAATAAAATCACT	1248
Db	1040	CCAGACAGAGTCGAGTGAAGAGATGTGCAAGTATGGATGCCAGGAATAAAATCACT	1099
QY	1249	CAAGACATCTGCAGCCCAAGTCAAGCGGTCTTTTCTGATGAAGAGGAGTTCAGAG	1308
Db	1100	CAAGACATCTGCAGCCCAAGTCAAGCGGTCTTTTCTGATGAAGAGGAGTTCAGAG	1159
QY	1309	GACCTGCTGAGCTGCAGACGTTGACAGTGTCTCAGACATTCAGCAGCCATACATC	1368
Db	1160	GACCTGCTGAGCTGCAGACGTTGACAGTGTCTCAGACATTCAGCAGCCATACATC	1219
QY	1369	GTGTGCGGCACTGCTCAGTACAGAAAGCGAGGCGGCGAGCCCTCCCACTGCGCCAGCA	1428
Db	1220	GTGTGCGGCACTGCTCAGTACAGAAAGCGAGGCGGCGAGCCCTCCCACTGCGCCAGCA	1279
QY	1429	CCGAGGCGGAGCCAGGAGCCCAAGGCGCTGGGGGATGCAACCTCCACGTCCTCAGC	1488
Db	1280	CCGAGGCGGAGCCAGGAGCCCAAGGCGCTGGGGGATGCAACCTCCACGTCCTCAGC	1339
QY	1489	CTGACACAGCAGTCCAGGATTCAGTGTGCTCCCTCTGCAAGGAAGCCAGCCCTGTGCAC	1548
Db	1340	CTGACACAGCAGTCCAGGATTCAGTGTGCTCCCTCTGCAAGGAAGCCAGCCCTGTGCAC	1399
QY	1549	TGCTGCTTCAGCCCATGTCGACGAGGCGGAGCGGAGCAGCAGCCGCTGTGCGC	1608
Db	1400	TGCTGCTTCAGCCCATGTCGACGAGGCGGAGCGGAGCAGCAGCCGCTGTGCGC	1459
QY	1609	CCTCAGCAGTGTGGGTCTGCTCTGCAAGCTTTTCTGCACTGTGCTGAGGCTGCAACCGG	1668
Db	1460	CCTCAGCAGTGTGGGTCTGCTCTGCAAGCTTTTCTGCACTGTGCTGAGGCTGCAACCGG	1519
QY	1669	ACCGGTGTACGGCTGCTGCGCCCGGTTTGTGAGCTCAACCTGGTGACAAAGTGTCTG	1728
Db	1520	ACCGGTGTACGGCTGCTGCGCCCGGTTTGTGAGCTCAACCTGGTGACAAAGTGTCTG	1579
QY	1729	GACGGGCTGTGAAACAAACACAGTACAGATCAGATCAGACATCTGAGAAATTTACCTGGCAAC	1788

Db	1580	GACGGCGTCTGAAACAACAACAGCTACGAGTCAGACATCCCTGAAGAAATTAACCTGCAACC	1639
QY	1789	AGAGGTTTGGACATGGAATAAACAATGTTGACCGAGAGCCTCTGCTGCTCTCCAGCGGAGTG	1848
Db	1640	AGAGGTTTGGACATGGAATAAACAATGTTGACCGAGAGCCTCTGCTGCTCTCCAGCGGAGTG	1699
QY	1849	TTTCTGCTGCTGATTAACAGAGTCAGGGAGACACGCTCTCTGTGTTACTGCTGCTGCTG	1908
Db	1700	TTTCTGCTGCTGATTAACAGAGTCAGGGAGACACGCTCTCTGTGTTACTGCTGCTGCTG	1759
QY	1909	CGCAGCTTCCGCTGAGCTGACCTATCAGTATCGGCAAGAAATTCCTGCTTCCGAGTTGCCA	1968
Db	1760	CGCAGCTTCCGCTGAGCTGACCTATCAGTATCAGAGAAATTCCTGCTTCCGAGTTGCCA	1819
QY	1969	GTGGCGTAACTCCCGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	2028
Db	1820	GTGGCGTAACTCCCGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1879
QY	2029	GCTCACCAGCCCATGAAATTCATATCTGTGAACAGCAAGGTTCAAAACTAAGCA	2088
Db	1880	GCTCACCAGCCCATGAAATTCATATCTGTGAACAGCAAGGTTCAAAACTAAGCA	1939
QY	2089	TCCAGAGGCGCTGAGCAGCTTTTTCAGCCTGAGAGTGAAGAGAGCGTGTGTTTAAATACA	2148
Db	1940	TCCAGAGGCGCTGAGCAGCTTTTTCAGCCTGAGAGTGAAGAGAGCGTGTGTTTAAATACA	1999
QY	2149	GAGCAGCAGCTCAAGGTGTTTTCACGCCCTGAGGAAAGGAGCGAGGCTCTCCCA	2208
Db	2000	GAGCAGCAGCTCAAGGTGTTTTCACGCCCTGAGGAAAGGAGCGAGGCTCTCCCA	2059
QY	2209	CAGGTGCTCTGGGCTGACTCTTCTGTGAGCTTTTACCTCTGAGTGAAGACCTCTCCCA	2268
Db	2060	CAGGTGCTCTGGGCTGACTCTTCTGTGAGCTTTTACCTCTGAGTGAAGACCTCTCCCA	2117
QY	2269	GAGCAGCAGCTCAAGGTGTTTTCACGCCCTGAGGAAAGGAGCGAGGCTCTCCCA	2328
Db	2118	GAGCAGCAGCTCAAGGTGTTTTCACGCCCTGAGGAAAGGAGCGAGGCTCTCCCA	2177
QY	2329	CAGCAGCAGAGCAGAGCCTTTCTGTAAACATGCGGCGCTCCCGCCGAGAGGCGAGTTT	2388
Db	2178	CAGCAGCAGAGCAGAGCCTTTCTGTAAACATGCGGCGCTCCCGCCGAGAGGCGAGTTT	2237
QY	2389	GCTCTTTTGTACATTTTCGAAACTACAGTTAAAGCAGAGTCTGTTTTCAGGAAAGTT	2448
Db	2238	GCTCTTTTGTACATTTTCGAAACTACAGTTAAAGCAGAGTCTGTTTTCAGGAAAGTT	2297
QY	2449	TCAAGGAGAGGCGCAAGTTTATCAAAAACATTTTTCAGGAGAGGAGGAGCATAGTTTA	2508
Db	2298	TCAAGGAGAGGCGCAAGTTTATCAAAAACATTTTTCAGGAGAGGAGGAGCATAGTTTA	2357
QY	2509	CAGCTACAGGAGCTACACATATCTGCTGCTGCGGAAACCAACAGCATTTTATCTATTT	2568
Db	2358	CAGCTACAGGAGCTACACATATCTGCTGCTGCGGAAACCAACAGCATTTTATCTATTT	2417
QY	2569	TTTATTTTATAGGTTTGGTCTTATCTTCTAATAAGATTAAATGTCAAAACTGTAGC	2628
Db	2418	TTTATTTTATAGGTTTGGTCTTATCTTCTAATAAGATTAAATGTCAAAACTGTAGC	2477
QY	2629	ACAAATAATAATTTTAAATTTTCAAAATGAC	2661
Db	2478	ACAAATAATAATTTTAAATTTTCAAAATGAC	2510

RESULT 6
AAI88903/c
ID AAI88903 standard; cDNA; 2259 BP.
XX
AC AAI88903;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 8963.
XX

Human; cytokine; cell proliferation; cell differentiation; gene therapy; vaccine; peptide therapy; stem cell growth factor; haematopoiesis; tissue growth factor; immunomodulatory; cancer; leukaemia; nervous system disorders; arthritis; inflammation; ss.	Human sapiens.	OS
	WO200164835-A2.	XX
	07-SEP-2001.	XX
	26-FEB-2001; 2001WO-US004927.	XX
	28-FEB-2000; 2000US-00515126.	XX
	18-MAY-2000; 2000US-00577409.	XX
	(HYSE-) HYSEQ INC.	XX
	Tang YT, Liu C, Drmanac RT;	XX
	WPI; 2001-514838/56.	XX
	P-PSDB; AA008972.	XX
Isolated nucleic acids and polypeptides, useful for preventing diagnosing and treating e.g. leukemia, inflammation and immune disorders.		XX
Claim 1; SEQ ID NO 8963; 1399pp + Sequence Listing; English.		XX
The invention relates to human polynucleotides (AA179941-AA193841) and the encoded proteins (AA00010-AA01910) that exhibit activity elating to cytokine, cell proliferation or cell differentiation or which may induce production of other cytokines in other cell populations. The polynucleotides and polypeptides are useful in gene therapy, vaccines or peptide therapy. The polypeptides have various cytokine-like activities, e.g. stem cell growth factor activity, haematopoiesis regulating activity, tissue growth factor activity, immunomodulatory activity and activin/inhibin activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences		XX
Sequence 2259 BP; 531 A; 612 C; 615 G; 501 T; 0 U; 0 Other;		XX
Query Match	38.2%; Score 1024; DB 4; Length 2259;	
Best Local Similarity	99.7%; Pred. No. 0;	
Matches 1304; Conservative	0; Mismatches 2; Indels 2; Gaps 1;	
QY	1354 AGCCAGCCATAGTCGTGTGTCGGCGAGTGTCTGAGTACAGAGGCGAGCGGCGAGCCT 1413	
Db	1965 AGCCAGCCATACGTGTGTGTCGGCGAGTGTCTGAGTACAGAGGCGAGCGGCGAGCCT 1906	
QY	1414 CCCCACTGCCAGCACCCGAGGGCGAGCCAGGAGCCCCACAGCCCTTGGGGGATGCACC 1473	
Db	1905 CCCCACTGCCAGCACCCGAGGGCGAGCCAGGAGCCCCACAGCCCTTGGGGGATGCACC 1846	
QY	1474 TCACAGTCGTGACCTGACGACGACGAGTCCAGATACGTGTGCCCTCTGTCAGGAGAGC 1533	
Db	1845 TCCACGTCCGTGACCTGACGACGACGAGTCCAGATACGTGTGCCCTCTGTCAGGAGAGC 1786	
QY	1534 CAGCCCTGTGACCTGTCTGCTTCCAGCCCATGCCGACCCGAGAGCGGAGCCGAGCAG 1593	
Db	1785 CAGCCCTGTGACCTGTCTGCTTCCAGCCCATGCCGACCCGAGAGCGGAGCGGAGCAG 1726	
QY	1594 GACCCCGGTGTGCCCTCTACGAGTGTGCGGTCTGCTGTGACGCTTCTGCGACCTGTAC 1653	
Db	1725 GACCCCGGTGTGCCCTCTACGAGTGTGCGGTCTGCTGTGACGCTTCTGCGACCTGTAC 1666	
QY	1654 TGGGGGTGACCCCGGACCCGCTGCTACGGCTGCTGCGCCCGCTTTGTGTAGCTCAACCTG 1713	
Db	1665 TGGGGGTGACCCCGGACCCGCTGCTACGGCTGCTGCGCCCGCTTTGTGTAGCTCAACCTG 1606	
QY	1714 GGTGACAGGTGTCTGGAGCGCGGTGCTGAAACAACAGACTACGAGTCAGATTCCTGGAAG 1773	

1605	GGTGCAAGTGCTCTGGAGCGGCTGCTGAACAACAACAGCTACGAGTCTAGACATCTCTGAAG	1546
1774	AATTACCTGGCAACACGAGAGTTTGACATGGAAACAAACATGTTGACCGAGAGCCTCGTGCT	1833
1545	AATTACCTGGCAACACGAGAGTTTGACATGGAAACAAACATGTTGACCGAGAGCCTCATGGCT	1486
1834	CTCCAGCGGGGAGTGTTTTCTGCTGCTGATTTACAGAGTCAAGGAGACACCGTTCTGTGT	1893
1485	CTCCAGCGGGGAGTGTTTTCTGCTGCTGATTTACAGAGTCAAGGAGACACCGTTCTGTGT	1426
1894	TACTGCTGTGGCCTGGCGAGCTTCGGTGAGCTGACCTATCATGTATCGCAGACAATTCCT	1953
1425	TACTGCTGTGGCCTGGCGAGCTTCGGTGAGCTGACCTATCATGTATCGCAGACAATTCCT	1366
1954	GCTTCCGAGTTGCCAGTGGCCGTAACATCCCGTCTCTGACTCTACTCTGGGGCCGTAACTGC	2013
1365	GCTTCCGAGTTGCCAGTGGCCGTAACATCCCGTCTCTGACTCTACTCTGGGGCCGTAACTGC	1306
2014	CGCACTCAGGTGAAGCTCAACAAGCCATGAATTCATCATATCTGTGAACAGACAAG	2073
1305	CGCACTCAGGTGAAGCTCAACAAGCCATGAATTCATCATATCTGTGAACAGACAAG	1246
2074	TTCAAAAATAAGCATCCAGAGGCCCTCAGCAGAGCTTTTCAAGCATCTGGAGGTGAAGAGCG	2133
1245	TTCAAAAATAAGCATCCAGAGGCCCTCAGCAGAGCTTTTCAAGCATCTGGAGGTGAAGAGCG	1186
2134	TGTTTTTAAATACAGACAAGCAAGCTCAAGTGTGTTTCAAGCCCTCTGAGGGAAGGG	2193
1185	TGTTTTTAAATACAGACAAGCAAGCTCAAGTGTGTTTCAAGCCCTCTGAGGGAAGGG	1126
2194	ACGAGGGTCTCCGACAGGTGCTCTGGGGTGACTCTTCTGTGGAGCTTTTAACTCTGA	2253
1125	ACGAGGGTCTCCGACAGGTGCTCTGGGGTGACTCTTCTGTGGAGCTTTTAACTCTGA	1068
2254	GTGAGACCTCCCGAGAGCCCGGGGGCGCAGCCGCGCTCTGCTGAGCGCTGGGAG	2313
1067	GTGAGACCTCCCGAGAGCCCGGGGGCGCAGCCGCGCTCTGCTGAGCGCTGGGAG	1008
2314	GGCTCGTGGTGGCATCAGCAGCAGAGACGAAGCCTTCTGTAAATGCGGCGCTCCCGCC	2373
1007	GGCTCGTGGTGGCATCAGCAGCAGAGACGAAGCCTTCTGTAAATGCGGCGCTCCCGCC	948
2374	GAGAGGGCAGTTTGCTCTTTTGTTACATTTTCCGAACTACAGTTTAAAGCAGAACTCTG	2433
947	GAGAGGGCAGTTTGCTCTTTTGTTACATTTTCCGAACTACAGTTTAAAGCAGAACTCTG	888
2434	TTTTTCAGGAAAGTTTCAAGGGAGAGGCGCAAGTTTATCAAAAACATTTGTTTCAGGAGAA	2493
887	TTTTTCAGGAAAGTTTCAAGGGAGAGGCGCAAGTTTATCAAAAACATTTGTTTCAGGAGAA	828
2494	GGGACATAAGTTTACAGCTACAGACGTACACAATATCCTGCTGCTGGGAAAACCA	2553
827	GGGACATAAGTTTACAGCTACAGACGTACACAATATCCTGCTGCTGGGAAAACCA	768
2554	GCATTTTATCTATTTTATTTTAAATAGTTTGGTCTTATCTTCTAATAAGATTAAAT	2613
767	GCATTTTATCTATTTTATTTTAAATAGTTTGGTCTTATCTTCTAATAAGATTAAAT	708
2614	GTCCAAACTGTAGCACAAAATAATATTTATTAATTTCAAAATTGAC	2661
707	GTCCAAACTGTAGCACAAAATAATATTTAATTTTCAAAATTGAC	660

RESULT 7

AAS25843

ID AAS25843 standard; cDNA; 1311 bp.

XX AC AAS25843;

XX AC AAS25843;

XX AC AAS25843;

DT DT

DE Human cDNA encoding a novel secreted protein, Seq ID 22.

07-NOV-2001 (first entry)

RESULT 7	
AAS25843	
ID	AAS25843 standard; cDNA; 1311 BP.
XX	
XX	AAS25843;
XX	
XX	07-NOV-2001 (first entry)
DT	
DT	
XX	
DE	Human cDNA encoding a novel secret

Human cDNA encoding a novel secreted protein, Seq ID 22.

XX Human; immunosuppressive; antiarthritic; ss; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
XX preservative; antiproliferative.
OS Homo sapiens.
XX
XX WO20015322-A2.
XX
XX PD 02-AUG-2001.
XX
XX
XX 17-JAN-2001; 2001WO-US001341.
XX
XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216547P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 23-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0228242P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 23-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249246P.
PR 17-NOV-2000; 2000US-0249247P.
PR 17-NOV-2000; 2000US-0249257P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.

PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA
PA Rosen CA, Barash SC, Ruben SM;
PI
XX
XX WPI; 2001-488783/53.
DR
DR P-PSDB; AAUI5856.
XX
XX New nucleic acid molecules encoding 461 human secreted proteins for
PT diagnosing, preventing, treating or ameliorating medical conditions and
PT used as food additives or preservatives.
XX
XX Claim 1; SEQ ID NO 22; 980pp; English.
XX
XX The invention relates to isolated nucleic acid molecules and their
CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence encodes a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed
Query Match 28.6%; Score 765; DB 4; Length 1311;
Best Local Similarity 100.0%; Pred. No. 2.2e-273;
Matches 765; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 710 GGTCTGGGGTGGTGGCATCTCCCTTAAGGAGTGGTCCCTCTGTGGCAAGTGATGAG 769
DB 383 GGTCTGGGGTGGTGGCATCTCCCTTAAGGAGTGGTCCCTCTGTGGCAAGTGATGAG 442
QY 770 TCTCCAGCTTTGCTCAGCTCTCCACAGACAAGACTGGCTCTTTTCTGTGGTGGAA 829
DB 443 TCTCCAGCTTTGCTCAGCTCTCCACAGACAAGACTGGCTCTTTTCTGTGGTGGAA 502
QY 830 CCCAGGATCAGGAGGATTGGAGCCCGTGAAGAAATGAGAGAGATGGGACCTTG 889
DB 503 CCCAGGATCAGGAGGATTGGAGCCCGTGAAGAAATGAGAGAGATGGGACCTTG 562
QY 890 ACCTGAACGGCGAGTTGTTGGTGGCAACACCGGCTAGAAATGCCAAACCGTCCACGAGG 949
DB 563 ACCTGAACGGCGAGTTGTTGGTGGCAACACCGGCTAGAAATGCCAAACCGTCCACGAGG 622
QY 950 ACGTCAGAGCAGCGGCTGGGAAGCCAGCAAGATGGAGGAGCGCTGACATCATCT 1009
DB 623 ACGTCAGAGCAGCGGCTGGGAAGCCAGCAAGATGGAGGAGCGCTGACATCATCT 682
QY 1010 GCCAGGACCTGCTCAGCACTGGCTGAGTTTGCAGGCCCTGCATGCACACGTTCTGCGCG 1069

DB 683 GCCAGGACCTGCTCAGCACTGGCTGAGTTTGCAGCCCTGCATGCACACGTTCTGCGCGG 742
QY 1070 CTTGCTACTCGGGCTGGATGGAGGCTGCTCCCTGTGTCTTACCTGCGGTGTCCCGTGG 1129
DB 743 CTTGCTACTCGGGCTGGATGGAGGCTGCTCCCTGTGTCTTACCTGCGGTGTCCCGTGG 802
QY 1130 AGCGGATCTGTAAACCAACATCTCAACCTCTGTTGGGAAGCATACCTATCCAGCATC 1189
DB 803 AGCGGATCTGTAAACCAACATCTCAACCTCTGTTGGGAAGCATACCTATCCAGCATC 862
QY 1190 CAGACAGAGTCGCGAGTGAGAGAGATGTGCAAAAGTATGGATGCCAGGAATAAAATCACTC 1249
DB 863 CAGACAGAGTCGCGAGTGAGAGAGATGTGCAAAAGTATGGATGCCAGGAATAAAATCACTC 922
QY 1250 AAGCATCTGTCAGCCCAAAAGTTCAGGCGGTCTTTTCTGATGAAGAGGGAGTTTCAGAGG 1309
DB 923 AAGCATCTGTCAGCCCAAAAGTTCAGGCGGTCTTTTCTGATGAAGAGGGAGTTTCAGAGG 982
QY 1310 ACCTGCTGGAGCTGTGACGTTGACAGTGTGCTCAGACATTTAGCCAGCCATACCTCG 1369
DB 983 ACCTGCTGGAGCTGTGACGTTGACAGTGTGCTCAGACATTTAGCCAGCCATACCTCG 1042
QY 1370 TGTGCCGCGCAGTGTCTCAGTACAGAAAGGAGGCGGCGCAGCTTCCCCTGCCCCAGCAC 1429
DB 1043 TGTGCCGCGCAGTGTCTCAGTACAGAAAGGAGGCGGCGCAGCTTCCCCTGCCCCAGCAC 1102
QY 1430 CCGAGGCGGAGCCAGAGAGCCCCCAGAGCCCTTGGGGGATGCACCT 1474
DB 1103 CCGAGGCGGAGCCAGAGAGCCCCCAGAGCCCTTGGGGGATGCACCT 1147
RESULT 8
ABX73184
XX ABX73184 standard; DNA; 1311 BP.
ID
XX AEX73184;
AC
XX
DT 18-MAR-2003 (first entry)
XX
DE Human novel polynucleotide #12.
XX
XX Human; gene; ds; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.
XX
XX Homo sapiens.
XX
XX US2002132753-A1.
XX
XX 19-SEP-2002.
XX
XX 17-JAN-2001; 2001US-00764864.
XX
XX 31-JAN-2000; 2000US-0179085P.
PR 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0218290P.
PR 14-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.

14-AUG-2000; 2000US-0225447P.
14-AUG-2000; 2000US-0225757P.
14-AUG-2000; 2000US-0225758P.
22-AUG-2000; 2000US-0228686P.
30-AUG-2000; 2000US-0228924P.
01-SEP-2000; 2000US-0229287P.
01-SEP-2000; 2000US-0229343P.
01-SEP-2000; 2000US-0229344P.
01-SEP-2000; 2000US-0229345P.
05-SEP-2000; 2000US-0229503P.
05-SEP-2000; 2000US-0229513P.
08-SEP-2000; 2000US-0231413P.
21-SEP-2000; 2000US-0234223P.
21-SEP-2000; 2000US-0234274P.
25-SEP-2000; 2000US-0234997P.
27-SEP-2000; 2000US-0235834P.
29-SEP-2000; 2000US-0236327P.
29-SEP-2000; 2000US-0236367P.
29-SEP-2000; 2000US-0236369P.
29-SEP-2000; 2000US-0236369P.
02-OCT-2000; 2000US-0236802P.
02-OCT-2000; 2000US-0237037P.
02-OCT-2000; 2000US-0237038P.
02-OCT-2000; 2000US-0237039P.
02-OCT-2000; 2000US-0237040P.
13-OCT-2000; 2000US-0239335P.
20-OCT-2000; 2000US-0240960P.
20-OCT-2000; 2000US-0241785P.
20-OCT-2000; 2000US-0241809P.
01-NOV-2000; 2000US-0244617P.
17-NOV-2000; 2000US-0249299P.
08-DEC-2000; 2000US-0251856P.
08-DEC-2000; 2000US-0251868P.
08-DEC-2000; 2000US-0251869P.

(ROSE/) ROSEN C A.
(RUBE/) RUBEN S M.
(BARA/) BARASH S C.

Rosen CA, Ruben SM, Barash SC;
WPI; 2003-147444/14.
P-PSDB; ABU54924.

New polypeptides and nucleic acids, useful in gene therapy for treating, inhibiting or preventing e.g. neural, immune system, muscular, respiratory, reproductive, Gastrointestinal, pulmonary, cardiovascular or renal disorders.

Claim 1; SEQ ID NO 22; 402pp; English.

The invention relates to human novel polypeptides and their associated polynucleotides. The polypeptides and polynucleotides are useful in gene therapy for treating, inhibiting or preventing neural disorders, immune system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis), muscular disorders, respiratory diseases (e.g. nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left heart syndrome), renal disorders (e.g. acute kidney failure and end-stage renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and leukaemia), inflammatory diseases (e.g. septic shock, bursitis and appendicitis), allergic reactions and conditions (e.g. asthma), blood related disorders (e.g. thrombosis, atherosclerosis and myocardial infarction) and cancerous diseases. Sequences ABX73173-ABX74167 represent human novel polynucleotides of the invention

Query Match 28.6%; Score 765; DB 7; Length 1311;
Best Local Similarity 100.0%; Pred. No. 2.2e-273;
Matches 765; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 710 GGTCTGGGGTGGTGGCATCTCCCTAAAGAGTGGTCCCTCTGTGGCAAGTGAAG 769
DB 383 GGTCTGGGGTGGTGGCATCTCCCTAAAGAGTGGTCCCTCTGTGGCAAGTGAAG 442
QY 770 TCTCCAGCTTTGGCTCAGCTCTCCAGACAGAAAGACTCGCTCTTTCGTGGTGAAC 829
DB 443 TCTCCAGCTTTGGCTCAGCTCTCCAGACAGAAAGACTCGCTCTTTCGTGGTGAAC 502
QY 830 CCCAGGATCAGGAGGATTTGGAGCCCGTGAAGAGAAATGAGAGAGATGGGACCTTG 889
DB 503 CCCAGGATCAGGAGGATTTGGAGCCCGTGAAGAGAAATGAGAGAGATGGGACCTTG 562
QY 890 ACCTGAACCGGAGCTTTGGTGGCAAAACCCGGTAGAAATGCCAAACCCGTCACGAGG 949
DB 563 ACCTGAACCGGAGCTTTGGTGGCAAAACCCGGTAGAAATGCCAAACCCGTCACGAGG 622
QY 950 ACCTGAACCGGAGCTTTGGTGGCAAAACCCGGTAGAAATGCCAAACCCGTCACGAGG 1009
DB 623 ACCTGAACCGGAGCTTTGGTGGCAAAACCCGGTAGAAATGCCAAACCCGTCACGAGG 582
QY 1010 GCCAGGACCTGTGACGACGCTGCTGAGTTTTCAGCCCTGCATGCACAGCTTCTGGCGG 1069
DB 683 GCCAGGACCTGTGACGACGCTGCTGAGTTTTCAGCCCTGCATGCACAGCTTCTGGCGG 742
QY 1070 CTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGCTTACCTGCGCTGTCGGTGG 1129
DB 743 CTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGCTTACCTGCGCTGTCGGTGG 802
QY 1130 AGCGGATCTGTAACCAACCATCTCTCAACAACTCGTGAAGCATACCTCATCCAGCATC 1189
DB 803 AGCGGATCTGTAACCAACCATCTCTCAACAACTCGTGAAGCATACCTCATCCAGCATC 862
QY 1190 CAGACAGAGTGCAGTGAAGAGATGTGCAAGTATGATGCCAGGAATAAATCAGTTC 1249
DB 863 CAGACAGAGTGCAGTGAAGAGATGTGCAAGTATGATGCCAGGAATAAATCAGTTC 922
QY 1250 AAGACATGTCTGAGCCCAAGTTCAGCGGCTCTTTTCTGATGAAGAGGAGTTCAGAGG 1309
DB 923 AAGACATGTCTGAGCCCAAGTTCAGCGGCTCTTTTCTGATGAAGAGGAGTTCAGAGG 982
QY 1310 ACCTGTGAGAGTGTGACAGCTTGAAGTTCAGTTCCTCAGACATTAGCCAGCCATAGTCG 1369
DB 983 ACCTGTGAGAGTGTGACAGCTTGAAGTTCAGTTCCTCAGACATTAGCCAGCCATAGTCG 1042
QY 1370 TGTGCGGCGAGTGTCTCTGAGTACAGAGGCGCGCGCAGCGCTCCCTCCACTGCCCCAGCAC 1429
DB 1043 TGTGCGGCGAGTGTCTCTGAGTACAGAGGCGCGCGCAGCGCTCCCTCCACTGCCCCAGCAC 1102
QY 1430 CCGAGGCGGAGCCAGAGGCCCAACAGGCGCTGGGGGATGACCCCT 1474
DB 1103 CCGAGGCGGAGCCAGAGGCCCAACAGGCGCTGGGGGATGACCCCT 1147

RESULT 9
ADA52592
ID ADA52592 standard; cDNA; 2186 BP.
XX
AC ADA52592;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human coding sequence, SEQ ID 160.
XX
KW Cytostatic; Anti-inflammatory; Osteopathic; Neuroprotective; Nootropic;
KW Gene Therapy; human; secretory protein; membrane proteins; cancer;
KW inflammatory disease; osteoporosis; neurological disease; gene; ss.
OS Homo sapiens.
XX
FN EPI293569-A2.
XX
PD 19-MAR-2003.

Qy	2396	TGTAACATTTTCGGAACACTACAGTTAAAGCAGAGTCTGTTTTTCAGGAAAAGTTTCAAGGG	2455
Db	1293	TGTAACATTTTCGGAACACTACAGTTAAAGCAGAGTCTGTTTTTCAGGAAAAGTTTCAAGGG	1352
Qy	2456	AGAAGGGCAAGTTTATCAAAAAACATTGTTTTCAGGAGAGGGAGCATAAAGTTTACAGCCTA	2515
Db	1353	AGAAGGGCAAGTTTATCAAAAAACATTGTTTTCAGGAGAGGGAGCATAAAGTTTACAGCCTA	1412
Qy	2516	CAGGACGTACACAATATCTGCTGCTGGGAAAACACACACATTTTATCTATTTTTTATTT	2575
Db	1413	CAGGACGTACACAATATCTGCTGCTGGGAAAACACACACATTTTATCTATTTTTTATTT	1472
Qy	2576	TAATAGGTTTGGTGCCTTATCTTCTTAATAAGATTTAAATGTCACAACTGAGCACAAATA	2635
Db	1473	TAATAGGTTTGGTGCCTTATCTTCTTAATAAGATTTAAATGTCACAACTGAGCACAAATA	1532
Qy	2636	ATATAATTTTATAATTTTACAAATTGAC	2661
Db	1533	ATATAATTTTATAATTTTACAAATTGAC	1558

RESULT 10
 AAH06828
 ID AAH06828 standard; cDNA; 816 BP.
 XX
 XX AAH06828;
 XX
 XX
 DT 26-JUN-2001 (first entry)
 XX
 XX Human cDNA clone (5'-primer) SEQ ID NO:3663.
 DE Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
 XX
 XX Homo sapiens.
 XX
 XX EF1074617-A2.
 XX
 XX 07-FEB-2001.
 XX
 XX 28-JUL-2000; 2000EP-00116126.
 PF
 XX
 XX 29-JUL-1999; 99JP-00248036.
 PR
 XX 27-AUG-1999; 99JP-00300253.
 PR
 XX 11-JAN-2000; 2000JP-00118776.
 PR
 XX 02-MAY-2000; 2000JP-00183767.
 PR
 XX 09-JUN-2000; 2000JP-00241899.
 XX
 XX (HELI-) HELIX RES INST.
 PA
 XX
 XX Ota T, Isogai T, Nishikawa T, Hayaashi K, Saito K, Yamamoto J;
 PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
 PI
 XX
 DR WPI; 2001-318749/34.
 XX
 XX
 XX Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
 PT
 PT
 PT
 PT
 XX
 XX
 XX Claim 1; SEQ ID NO 3663; 2537pp + Sequence Listing; English.
 PS
 XX
 XX The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises:
 CC (a) an oligo-dT primer and an oligonucleotide complementary to the
 CC complementary strand of a polynucleotide which comprises one of the 5602
 CC nucleotide sequences defined in the specification, where the
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
 CC of an oligonucleotide comprising a sequence complementary to the
 CC complementary strand of a polynucleotide which comprises a 5'-end
 CC sequence and an oligonucleotide comprising a sequence complementary to a
 CC polynucleotide which comprises a 3' end sequence, where the
 CC oligonucleotide comprises at least 15 nucleotides and the combination of

Db 361 TGGGGATGTCATCTACTTGGTGTACAGGAAGATGAACGGGAACACAAACGTCGCATACCT 420
QY 447 CTATGAATCTTTAAGTGAAGCAAGCGCATGACACAAAGATCCTTTGA 494
Db 421 CTATGAATCTTTAAGTGAAGCAAGCGCATGACACAAAGATCCTTTGA 469

RESULT 12
AAS26304
ID AAS26304 standard; cDNA; 693 BP.
XX
AC AAS26304;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human cDNA encoding a novel secreted protein. Seq ID 483.
XX
KW Human; immunosuppressive; antiarthritic; ss; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; nontropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX
OS Homo sapiens.
XX
PN WO200155322-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001341.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226688P.
PR 23-AUG-2000; 2000US-0227182P.
PR 30-AUG-2000; 2000US-0227009P.
PR 01-SEP-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232050P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233083P.
PR 14-SEP-2000; 2000US-0233084P.
PR 14-SEP-2000; 2000US-0233085P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234957P.
PR 25-SEP-2000; 2000US-0234958P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241211P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246537P.
PR 08-NOV-2000; 2000US-0246538P.
PR 08-NOV-2000; 2000US-0246539P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.

PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
XX
PA (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
XX
PI Rosen CA, Ruben SM, Barash SC;
PI
XX WPI; 2003-147444/14.
DR P-PSDB; ABUS5385.
XX
XX New polypeptides and nucleic acids, useful in gene therapy for treating,
PT inhibiting or preventing e.g. neural, immune system, muscular,
PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
PT renal disorders.
XX
PS Claim 1; SEQ ID NO 483; 402pp; English.
XX
XX The invention relates to human novel polypeptides and their associated
CC polynucleotides. The polypeptides and polynucleotides are useful in gene
CC therapy for treating, inhibiting or preventing neural disorders, immune
CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
CC leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
CC infarction) and cancerous diseases. Sequences ABX73173-ABX74167 represent
CC human novel polynucleotides of the invention.
XX
SQ Sequence 693 BP; 145 A; 214 C; 197 G; 123 T; 0 U; 14 Other;
Query Match 17.0%; Score 455; DB 7; Length 693;
Best Local Similarity 100.0%; Pred. NO. 1.3e-158;
Matches 455; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1044 GCCCTGATGCACACGTTCTGCCGGCTTCTACTCGCGCTGATGAGCGGCTCGCCCT 1103
Db 14 GCCCTGATGCACACGTTCTGCCGGCTTCTACTCGCGCTGATGAGCGGCTCGCCCT 73

QY 1104 GTGTCCTACTGCGCGCTGTCCCGTGGAGCGGATCTGTAAAAACACATCTCTCAACACCT 1163
DB 74 GTGTCCTACTGCGCGCTGTCCCGTGGAGCGGATCTGTAAAAACACATCTCTCAACACCT 133
QY 1164 COTGGAAGCATACCTCTCATCCAGCATCCAGACAAGATCGCAGTGAAGAAGATGTGCAAG 1223
DB 134 COTGGAAGCATACCTCTCATCCAGCATCCAGACAAGATCGCAGTGAAGAAGATGTGCAAG 193
QY 1224 TATGATGCCAGGAATAAATCACTCAAGACATCTCTGAGGCCCAAGTCAGGCGGTCTTT 1283
DB 194 TATGATGCCAGGAATAAATCACTCAAGACATCTCTGAGGCCCAAGTCAGGCGGTCTTT 253
QY 1284 TTCTGATGAAGAAGAGGAGTTTCAGAGGAGCTCTCTGAGCTGTGACAGTGTGACAGTGC 1343
DB 254 TTCTGATGAAGAAGAGGAGTTTCAGAGGAGCTCTCTGAGCTGTGACAGTGTGACAGTGC 313
QY 1344 CTCAGACATTAGCCAGCATACGTCGTGTCGCGGAGTGTCTCTGAGTACAGAGGAGGC 1403
DB 314 CTCAGACATTAGCCAGCATACGTCGTGTCGCGGAGTGTCTCTGAGTACAGAGGAGGC 373
QY 1404 GCGCAGGCTCCCGACCTGCCAGCAGCCGAGGCGGAGCCAGAGGCCCCACAGGCCCTGGG 1463
DB 374 GCGCAGGCTCCCGACCTGCCAGCAGCCGAGGCGGAGCCAGAGGCCCCACAGGCCCTGGG 433
QY 1464 GGATGCACCCCTCCAGCTCCGTCAGCTGACGACAG 1498
DB 434 GGATGCACCCCTCCAGCTCCGTCAGCTGACGACAG 468

RESULT 14
AAH11859/c
ID AAH11859 standard; cDNA; 518 BP.
XX AC AAH11859;
XX DT 26-JUN-2001 (first entry)
XX DE Human cDNA clone (3'-primer) SEQ ID NO:8694.
XX KW Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX OS Homo sapiens.
XX FN EP1074617-A2.
XX PD 07-FEB-2001.
XX PF 28-JUL-2000; 2000EP-00116126.
XX PR 29-JUL-1999; 93JP-00248036.
XX PR 27-AUG-1999; 93JP-00300253.
XX PR 11-JAN-2000; 2000JP-00118776.
XX PR 02-MAY-2000; 2000JP-00183767.
XX PR 09-JUN-2000; 2000JP-00241899.
XX (HELI-) HELIX RES INST.
XX PA Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
XX PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX WPI; 2001-318749/34.
XX PT Primer sets for synthesizing polynucleotides, particularly the 5602 full-
XX length cDNAs defined in the specification, and for the detection and/or
XX diagnosis of the abnormality of the proteins encoded by the full-length
XX cDNAs.
XX PS Claim 3; SEQ ID NO 8694; 2537pp + Sequence Listing; English.
XX CC The present invention describes primer sets for synthesizing 5602 full-
XX length cDNAs defined in the specification. Where a primer set comprises:
XX (a) an oligo-dT primer and an oligonucleotide complementary to the

complementary strand of a polynucleotide which comprises one of the 5602
nucleotide sequences defined in the specification, where the
oligonucleotide comprises at least 15 nucleotides; or (b) a combination
of an oligonucleotide comprising a sequence complementary to the
complementary strand of a polynucleotide which comprises a 5'-end
sequence and an oligonucleotide comprising a sequence complementary to a
polynucleotide which comprises a 3'-end sequence, where the
oligonucleotide comprises at least 15 nucleotides and the combination of
the 5'-end sequence/3'-end sequence is selected from those defined in the
specification. The primer sets can be used in antisense therapy and in
gene therapy. The primers are useful for synthesising polynucleotides,
particularly full-length cDNAs. The primers are also useful for the
detection and/or diagnosis of the abnormality of the proteins encoded by
the full-length cDNAs. The primers allow obtaining of the full-length
cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to AAH95893
represent human amino acid sequences; and AAH13629 to AAH13632 represent
oligonucleotides, all of which are used in the exemplification of the
present invention

XX SQ Sequence 518 BP; 142 A; 127 C; 108 G; 136 T; 0 U; 5 Other;

Query Match 15.9%; Score 426; DB 4; Length 518;
Best Local Similarity 99.8%; Pred. No. 7.2e-148; Indels 0; Gaps 0;
Matches 476; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2185 AGGGAAGGACGAGGGTCTCCGACAGGTGCTCTGGGGTGAATCTTCTGTGAGCTTTT 2244
DB 503 AGGGAAGGACGAGGGTCTCCGACAGGTGCTCTGGGGTGAATCTTCTGTGAGCTTTT 444
QY 2245 ACCCTCTGAGTGAGACCTTCCGACAGCCCGGGGGCCGAGCCGCTCTGTGAGC 2304
DB 443 ACCCTCTGAGTGAGACCTTCCGACAGCCCGGGGGCCGAGCCGCTCTGTGAGC 384
QY 2305 GCTGGGCGAGGGCTCGTGGTGGCATCAGCAGCAGAGCAAGCTTTCTGTAACTGCGGC 2364
DB 383 GCTGGGCGAGGGCTCGTGGTGGCATCAGCAGCAGAGCAAGCTTTCTGTAACTGCGGC 324
QY 2365 CGTCCCGCCGAGAGGGGAGTTTGTCTTTGTGTACATTTCCGAAACACAGTTAAAGC 2424
DB 323 CGTCCCGCCGAGAGGGGAGTTTGTCTTTGTGTACATTTCCGAAACACAGTTAAAGC 264
QY 2425 AGAAGTCTGTTTTCAGGAAAGTTTCAAGGAGAGGCAAGTTATCAAAACATTTGT 2484
DB 263 AAAAGTCTGTTTTCAGGAAAGTTTCAAGGAGAGGCAAGTTATCAAAACATTTGT 204
QY 2485 TCAGGAGAGGGAGCAATAGTTTACAGCCTACAGGACGTACACAATATCTCTGCTGGG 2544
DB 203 TCAGGAGAGGGAGCAATAGTTTACAGCCTACAGGACGTACACAATATCTCTGCTGGG 144
QY 2545 AAAACACACAGCATTTATCTATTTTATTTTAAATAGTTTGTGCTTATCTCTTAATAA 2604
DB 143 AAAACACACAGCATTTATCTATTTTATTTTAAATAGTTTGTGCTTATCTCTTAATAA 84
QY 2605 GATTTAAATCTCAAACTGTAGCACAATAATATAATTTATTAATTTACAAATTGAC 2661
DB 83 GATTTAAATCTCAAACTGTAGCACAATAATATAATTTATTAATTTACAAATTGAC 27

RESULT 15
AAA44336
ID AAA44336 standard; cDNA; 575 BP.

XX AC AAA44336;

XX DT 21-AUG-2000 (first entry)

XX XX Human secreted expressed sequence tag SEQ ID NO:911.

XX Human; mouse; chicken; rat; secreted expressed sequence tag; sEST;
XX expressed sequence tag; EST; probe; chemotactic; proliferative;
KW immunomodulatory; haematopoietic; chemokinetic; analgesic; haemostatic;
KW thrombolytic; antiinflammatory; cytostatic; antibacterial; antifungal;

KW antiviral; antidiabetic; antiasthmatic; vulnary; antiparkinsonian;
KW antitumor; osteopathic; neuroprotective; nootropic; antipsoriatic;
KW cerebrotective; anticonvulsant; antidepressant; gene therapy; vaccine;
KW autoimmune disorder; multiple sclerosis; allergic condition;
KW insulin dependent diabetes; asthma; myeloid cell deficiency; ulcer;
KW lymphoid cell deficiency; burn; osteoporosis; osteoarthritis;
KW central nervous system disorder; Alzheimer's disease; stroke;
KW Parkinson's disease; Huntington's disease; coagulation disorder;
KW haemophilia; thrombosis; inflammatory disorder; Crohn's disease; tumour;
KW infection; depression; psoriasis; ss.

XX Homo sapiens.

OS WO200021991-A1.

XX 20-APR-2000.

XX 15-OCT-1999; 99WO-US024206.

XX 15-OCT-1998; 98US-0104436P.

XX (GEMY) GENETICS INST INC.

XX Jacobs K, McCoy JM, Lavallie ER, Collins-Racie LA, Evans C;

XX Werberg D, Treacy M, Bowman MR;

XX WPI; 2000-317938/27.

DR Isolated polynucleotides, and encoded proteins, comprising secreted
PT expressed sequence tags (sESTs), useful for treating various disorders
PT such as autoimmune, infectious, and central nervous system disorders.

XX Claim 1; Page 437; 803pp; English.

XX AAA43426 to AAA45925 represent specifically claimed secreted expressed
CC sequence tags (sESTs), isolated from human, mouse, chicken and rat tissue
CC sources. The sESTs can have a range of activities depending on the
CC tissues they were isolated from. The activities include: chemotactic;
CC proliferative; immunomodulatory; haematopoietic; chemokinetic; analgesic;
CC haemostatic; thrombolytic; antiinflammatory; cytostatic; antibacterial;
CC antifungal; antiviral; antidiabetic; antiasthmatic; vulnary; antitumor;
CC osteopathic; neuroprotective; nootropic; antiparkinsonian; antipsoriatic;
CC cerebrotective; anticonvulsant; and antidepressant. The sESTs can be
CC used for gene therapy and in vaccines. The sESTs are useful as probes for
CC the identification and isolation of full-length cDNAs and genomic DNA
CC molecules which correspond to the sESTs. Proteins encoded by the sESTs
CC are useful in assays for determining biological activity and raising
CC antibodies. They may be useful for treatment of autoimmune disorders
CC (multiple sclerosis, insulin dependent diabetes), allergic conditions
CC (asthma), myeloid or lymphoid cell deficiencies, wounds, burns, ulcers,
CC osteoporosis, osteoarthritis, central nervous system disorders
CC (Alzheimer's, Parkinson's, Huntington's disease, stroke), coagulation
CC disorders (haemophilia, thrombosis), inflammatory disorders (Crohn's
CC disease), tumours, bacterial, fungal or viral infections, depression and
CC psoriasis. AAA45926 to AAA45931 represent linker variants which are given
CC in the exemplification of the present invention

XX Sequence 575 BP; 124 A; 168 C; 165 G; 118 T; 0 U; 0 Other;

Query Match 10.7%; Score 286; DB 3; Length 575;
Best Local Similarity 100.0%; Pred. No. 4.5e-96;
Matches 286; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 876 AGATGGGACCTTGACCTGAACGGGCGAGTTGTGTCGCACACCGCGTAGAATGCCA 935

DB 285 AGATGGGACCTTGACCTGAACGGGCGAGTTGTGTCGCACACCGCGTAGAATGCCA 344

QY 936 AACGCTCCACGAGGACGTGACAGCAGCGGCTGGGAAGCCAGACAGATGGAGAGCGCT 995

DB 345 AACGCTCCACGAGGACGTGACAGCAGCGGCTGGGAAGCCAGACAGATGGAGAGCGCT 404

QY 996 GACATGCATCATCTCTCCAGGACCTGCTGCACGACTGCTGAGTTTGAGCCCTCAGTCA 1055

Db 405 GACATGCATCATCTGCCAGGACCTCTGCACGACTGCGTGAGTTTGCAGCCCTGCATGCA 464
Qy 1056 CACGTTCTGCGCGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGTCTTACCTG 1115
Db 465 CACGTTCTGCGCGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGTCTTACCTG 524
Qy 1116 CCGCTGTCCCGTGGAGCGGATCTGTAAAAACCAACATCCTCAACAC 1161
Db 525 CCGCTGTCCCGTGGAGCGGATCTGTAAAAACCAACATCCTCAACAC 570

Search completed: May 15, 2004, 00:35:33
Job time : 1488 secs

OM nucleic - nucleic search, using sw model

Run on: May 14, 2004, 23:43:56 ; Search time 214 Seconds
(without alignments)
6947.259 Million cell updates/sec

Title: US-10-048-046-1
Perfect score: 2679
Sequence: 1 aagaattggcagcgccg.....acaabaaaaaaaaaaaaa 2679

Scoring table: OLIGO_NUC
Gapop 60.0 , Gapext 60.0

Searched: 682709 seqs, 277475446 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : Issued Patents NA.*
1: /cgn2_6/prodata/2/ina/5A COMB.seq.*
2: /cgn2_6/prodata/2/ina/5B COMB.seq.*
3: /cgn2_6/prodata/2/ina/6A COMB.seq.*
4: /cgn2_6/prodata/2/ina/6B COMB.seq.*
5: /cgn2_6/prodata/2/ina/6CTUS COMB.seq.*
6: /cgn2_6/prodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	26	1.0	860	1	US-07-847-010-18
2	25	0.9	1085	4	Sequence 18, Appl
3	24	0.9	3157	6	Sequence 15, Appl
4	23	0.9	443	4	Patent No. 5198347
5	23	0.9	1185	4	Sequence 17572, A
6	23	0.9	1347	3	Sequence 161, App
7	23	0.9	1347	3	Sequence 1, Appl
8	23	0.9	2405	1	Sequence 1, Appl
9	23	0.9	2405	1	Sequence 35, Appl
10	23	0.9	2405	3	Sequence 49, Appl
11	23	0.9	2405	3	Sequence 35, Appl
12	22	0.8	277	1	Sequence 18, Appl
13	22	0.8	424	4	Sequence 159, App
14	22	0.8	786	4	Sequence 172, App
15	22	0.8	906	4	Sequence 190, App
16	22	0.8	914	3	Sequence 24, Appl
17	22	0.8	914	4	Sequence 24, Appl
18	22	0.8	1019	4	Sequence 19, Appl
19	22	0.8	1019	4	Sequence 19, Appl
20	22	0.8	1019	4	Sequence 19, Appl
21	22	0.8	1019	4	Sequence 19, Appl
22	22	0.8	1019	4	Sequence 19, Appl
23	22	0.8	1019	4	Sequence 19, Appl
24	22	0.8	1173	3	Sequence 50, Appl
25	22	0.8	1173	4	Sequence 50, Appl
26	22	0.8	1173	4	Sequence 50, Appl
27	22	0.8	1173	4	Sequence 50, Appl

28	22	0.8	1287	4	US-09-064-411A-35	Sequence 35, Appl
29	22	0.8	1404	4	US-08-979-608A-10	Sequence 10, Appl
30	22	0.8	1404	4	US-09-517-849-10	Sequence 10, Appl
31	22	0.8	1404	4	US-09-616-289-10	Sequence 10, Appl
32	22	0.8	1557	4	US-09-347-650-15	Sequence 15, Appl
33	22	0.8	2339	3	US-09-268-140-11	Sequence 11, Appl
34	22	0.8	2422	1	US-07-867-106-5	Sequence 5, Appl
35	22	0.8	2505	3	US-09-268-140-1	Sequence 1, Appl
36	22	0.8	2517	3	US-09-268-140-7	Sequence 7, Appl
37	22	0.8	2533	4	US-09-604-605-1	Sequence 1, Appl
38	22	0.8	2608	1	US-08-160-861-1	Sequence 4, Appl
39	22	0.8	3138	1	US-07-867-106-4	Sequence 1, Appl
40	22	0.8	5852	1	US-07-867-106-2	Sequence 2, Appl
41	22	0.8	5852	1	US-07-867-106-2	Sequence 2, Appl
42	22	0.8	19307	3	US-08-836-022A-10	Sequence 10, Appl
43	22	0.8	19307	3	US-09-427-048A-10	Sequence 10, Appl
44	22	0.8	26664	4	US-09-564-805-28	Sequence 28, Appl
45	22	0.8	55827	4	US-09-813-133A-3	Sequence 3, Appl

ALIGNMENTS

RESULT 1
US-07-847-010-18/c
; Sequence 18, Application US/07847010
; Patent No. 5693495
; GENERAL INFORMATION:
; APPLICANT: Breitenbach, Michael
; APPLICANT: Reiterstorfer, Arnold
; APPLICANT: Valentia, Rudolf
; APPLICANT: Hoffmann - Sommergruber, Karin
; APPLICANT: Breitenbach, Michael
; APPLICANT: Kraft, Dietrich
; APPLICANT: Rumpold, Helmut
; APPLICANT: Scheiner, Otto
; APPLICANT: Ebner, Christof
; APPLICANT: Ferreira, Fatima
; TITLE OF INVENTION: Allergens of Alder Pollen and
; TITLE OF INVENTION: Applications Thereof
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 01-JUN-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jones III, Harry C
; REGISTRATION NUMBER: 20,280
; REFERENCE/DOCKET NUMBER: 6530-010
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-9741/8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 860 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO

ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: hazel (Corylus sp.)
IMMEDIATE SOURCE:
LIBRARY: POLLEN FROM ALLERSON AB, ENGELHOLM, SWEDEN
US-07-847-010-18

Query Match
Best Local Similarity 1.0%; Score 26; DB 1; Length 860;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2654 AATTGACAAAAA 2679
DB 754 AATTGACAAAAA 729

RESULT 2

US-09-522-714-15
Sequence 15, Application US/09522714

Patent No. 6563020

GENERAL INFORMATION:

APPLICANT: Simmons, Carl R.

APPLICANT: Valpani, Nasser

TITLE OF INVENTION: Maize Chitinases and Their Use in

FILE REFERENCE: 1100

CURRENT APPLICATION NUMBER: US/09/522,714

CURRENT FILING DATE: 2000-03-10

EARLIER APPLICATION NUMBER: 60/125,915

EARLIER FILING DATE: 1999-03-24

NUMBER OF SEQ ID NOS: 32

SOFTWARE: PastSeq for Windows Version 3.0

SEQ ID NO 15

LENGTH: 1085

TYPE: DNA

ORGANISM: Zea mays

FEATURE:

NAME/KEY: CDS

LOCATION: (46)....(966)

US-09-522-714-15

Query Match
Best Local Similarity 0.9%; Score 25; DB 4; Length 1085;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2655 AATTGACAAAAA 2679
DB 1061 AATTGACAAAAA 1085

RESULT 3

5198347-3

Patent No. 5198347

APPLICANT: Miller, Louis H.; Adams, John H.; Kaslow,

DAVID C.; Fang, Xianguo

TITLE OF INVENTION: DNA ENCODING PLASMODIUM VIVAX AND

PLASMODIUM KNOWLES DUFFY RECEPTOR

NUMBER OF SEQUENCES: 27

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/554,837

FILING DATE: 20-JUL-1990

SEQ ID NO: 3

LENGTH: 3157

5198347-3

Query Match
Best Local Similarity 0.9%; Score 24; DB 6; Length 3157;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2656 ATTGACAAAAA 2679
DB 3088 ATTGACAAAAA 3111

RESULT 4

US-09-621-976-17572

Sequence 17572, Application US/09621976

Patent No. 6639063

GENERAL INFORMATION:

APPLICANT: Dumas Milne Edwards, J.B.

APPLICANT: Jobert, S.

APPLICANT: Giordano, J.Y.

TITLE OF INVENTION: ESTs and Encoded Human Proteins.

FILE REFERENCE: GENSET 054PR2

CURRENT APPLICATION NUMBER: US/09/621,976

CURRENT FILING DATE: 2000-07-21

NUMBER OF SEQ ID NOS: 19335

SOFTWARE: Patent.pm

SEQ ID NO 17572

LENGTH: 443

TYPE: DNA

ORGANISM: Homo sapiens

US-09-621-976-17572

Query Match
Best Local Similarity 0.9%; Score 23; DB 4; Length 443;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2657 TTGACAAAAA 2679
DB 420 TTGACAAAAA 442

RESULT 5

US-09-614-912-161

Sequence 161, Application US/09614912

Patent No. 667502

GENERAL INFORMATION:

APPLICANT: Allen, Steve

APPLICANT: Rafalski, Antoni

APPLICANT: Orozco, Buddy

APPLICANT: Miao, Gou-Hau

APPLICANT: Pamodu, Omolayo O.

APPLICANT: Lee, Jian Ming

APPLICANT: Sakai, Hajime

APPLICANT: Weng, Zude

APPLICANT: Caimi, Perry G

APPLICANT: Anderson, Shawn

TITLE OF INVENTION: Plant Metabolism Genes

FILE REFERENCE: BB1378 US NA

CURRENT APPLICATION NUMBER: US/09/614,912

CURRENT FILING DATE: 2000-07-12

PRIOR APPLICATION NUMBER: 60/143,401

PRIOR FILING DATE: 1999-07-12

PRIOR APPLICATION NUMBER: 60/143,412

PRIOR FILING DATE: 1999-07-12

PRIOR APPLICATION NUMBER: 60/146,650

PRIOR FILING DATE: 1999-07-30

PRIOR APPLICATION NUMBER: 60/170,906

PRIOR FILING DATE: 1999-12-15

PRIOR APPLICATION NUMBER: 60/172,959

PRIOR FILING DATE: 1999-12-21

PRIOR APPLICATION NUMBER: 60/172,946

PRIOR FILING DATE: 1999-12-21

NUMBER OF SEQ ID NOS: 204

SOFTWARE: Microsoft Office 97

SEQ ID NO 161

LENGTH: 1185

TYPE: DNA

ORGANISM: Glycine max

US-09-614-912-161

Query Match
Best Local Similarity 0.9%; Score 23; DB 4; Length 1185;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2657 TTGACAAAAA 2679
Db 1163 TTGACAAAAA 1185

RESULT 6
US-09-412-102-1
; Sequence 1, Application US/09412102
; Patent No. 6228932
; GENERAL INFORMATION:
; APPLICANT: JESSEN, HOLLY J
; APPLICANT: MEYER, TERRY E
; TITLE OF INVENTION: GENES AND METHODS FOR CONTROL OF
; TITLE OF INVENTION: NEMATODES IN PLANTS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: W. Murray Spruill (Alston & Bird, LLP)
; STREET: 3605 Glenwood Ave. Suite 310
; CITY: Raleigh
; STATE: NC
; COUNTRY: US
; ZIP: 27622
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/412,102
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/217,787
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Spruill, W. Murray
; REGISTRATION NUMBER: 32,943
; REFERENCE/DOCKET NUMBER: 5718-18P1
; TELEPHONE: 919 420 2202
; TELEFAX: 919 881 3175
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1347 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; ORIGINAL SOURCE:
; ORGANISM: Zea mays
; CLONE: P12217
; IMMEDIATE SOURCE:
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 146..994
US-09-412-102-1

Query Match 0.9%; Score 23; DB 3; Length 1347;
Best Local Similarity 100.0%; Pred. No. 2.9;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2657 TTGACAAAAA 2679
Db 1325 TTGACAAAAA 1347

RESULT 7
US-09-217-787-1
; Sequence 1, Application US/09217787
; Patent No. 6284948
; GENERAL INFORMATION:
; APPLICANT: JESSEN, HOLLY J
; APPLICANT: MEYER, TERRY E

; TITLE OF INVENTION: GENES AND METHODS FOR CONTROL OF
; TITLE OF INVENTION: NEMATODES IN PLANTS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: W. Murray Spruill (Alston & Bird, LLP)
; STREET: 3605 Glenwood Ave. Suite 310
; CITY: Raleigh
; STATE: NC
; COUNTRY: US
; ZIP: 27622
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/217,787
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Spruill, W. Murray
; REGISTRATION NUMBER: 32,943
; REFERENCE/DOCKET NUMBER: 5718-18P1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919 420 2202
; TELEFAX: 919 881 3175
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1347 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; ORIGINAL SOURCE:
; ORGANISM: Zea mays
; IMMEDIATE SOURCE:
; CLONE: P12217
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 146..994
US-09-217-787-1

Query Match 0.9%; Score 23; DB 3; Length 1347;
Best Local Similarity 100.0%; Pred. No. 2.9;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2657 TTGACAAAAA 2679
Db 1325 TTGACAAAAA 1347

RESULT 8
US-08-484-101B-35
; Sequence 35, Application US/08484101B
; Patent No. 5824868
; GENERAL INFORMATION:
; APPLICANT: California Institute of Technology
; TITLE OF INVENTION: PLANTS HAVING MODIFIED RESPONSE TO
; TITLE OF INVENTION: ETHYLENE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard F. Trecartin
; STREET: 3400 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

```

; APPLICATION NUMBER: US/08/484,101B
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA: PCT/US94/
; FILING DATE: 01-JUL-1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/086,555
; FILING DATE: 01-JUL-1993
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Trecartin, Richard F.
; REGISTRATION NUMBER: 31,801
; REFERENCE/DOCKET NUMBER: A-57515-2/RFT
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2405 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 288..2196
; US-08-484-101B-35
;
; Query Match 0.9%; Score 23; DB 1; Length 2405;
; Best Local Similarity 100.0%; Pred. No. 2.8;
; Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 2657 TTGACAAAAA 2679
Db 2378 TTGACAAAAA 2400

RESULT 9
US-08-484-101B-49
; Sequence 49, Application US/08/484101B
; Patent No. 5824868
; GENERAL INFORMATION:
; APPLICANT: California Institute of Technology
; TITLE OF INVENTION: PLANTS HAVING MODIFIED RESPONSE TO
; TITLE OF INVENTION: ETHYLENE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard F. Trecartin
; STREET: 3400 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,101B
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/
; FILING DATE: 01-JUL-1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/086,555
; FILING DATE: 01-JUL-1993
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Trecartin, Richard F.
;
; APPLICATION NUMBER: 31,801
; REFERENCE/DOCKET NUMBER: A-57515-2/RFT
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2405 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 288..2196
; US-08-484-101B-49
;
; Query Match 0.9%; Score 23; DB 1; Length 2405;
; Best Local Similarity 100.0%; Pred. No. 2.8;
; Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 2657 TTGACAAAAA 2679
Db 2378 TTGACAAAAA 2400

RESULT 10
US-08-714-524D-35
; Sequence 35, Application US/08/714524D
; Patent No. 6294716
; GENERAL INFORMATION:
; APPLICANT: Meyerowitz, Elliott M
; APPLICANT: Chang, Caren
; APPLICANT: Blecker, Anthony B
; TITLE OF INVENTION: PLANTS HAVING MODIFIED RESPONSE TO ETHYLENE
; FILE REFERENCE: a-57515-4
; CURRENT APPLICATION NUMBER: US/08/714,524D
; CURRENT FILING DATE: 1996-09-16
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 35
; LENGTH: 2405
; TYPE: DNA
; ORGANISM: Lycopersicon esculentum
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (288)..(2195)
; US-08-714-524D-35
;
; Query Match 0.9%; Score 23; DB 3; Length 2405;
; Best Local Similarity 100.0%; Pred. No. 2.8;
; Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 2657 TTGACAAAAA 2679
Db 2378 TTGACAAAAA 2400

RESULT 11
US-08-714-524D-49
; Sequence 49, Application US/08/714524D
; Patent No. 6294716
; GENERAL INFORMATION:
; APPLICANT: Meyerowitz, Elliott M
; APPLICANT: Chang, Caren
; APPLICANT: Blecker, Anthony B
; TITLE OF INVENTION: PLANTS HAVING MODIFIED RESPONSE TO ETHYLENE
; FILE REFERENCE: a-57515-4
; CURRENT APPLICATION NUMBER: US/08/714,524D
; CURRENT FILING DATE: 1996-09-16
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 49
; LENGTH: 2405

```

; TYPE: DNA
; ORGANISM: Lycopersicon esculentum
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (288)..(2195)
US-08-714-524D-49

Query Match 0.9%; Score 23; DB 3; Length 2405;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2657 TTGACAAAAA 2679
DB 2378 TTGACAAAAA 2400

RESULT 12

US-08-244-113-18
; Sequence 18, Application US/08244113
; Patent No. 5455181

GENERAL INFORMATION:

; APPLICANT: Strube, Karl-Hermann

; APPLICANT: Bialojan, Siegfried

; APPLICANT: Kzoeger, Burkhard

; APPLICANT: Friedrich, Thomas

; TITLE OF INVENTION: No. 5455181el thrombin-inhibitory proteins from terrestrial

; TITLE OF INVENTION: leeches.

; NUMBER OF SEQUENCES: 23

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Keil & Weinkauff

; STREET: 1101 Connecticut Avenue

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20036

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb storage

; COMPUTER: IBM AT-compatible, 80486 processor

; OPERATING SYSTEM: MS-DOS version 6.0

; SOFTWARE: WordPerfect version 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/244,113

; FILING DATE:

; CLASSIFICATION: 530

; CLASSIFICATION: C07K 73/10

; CLASSIFICATION: A61K 37/64

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/EP92/02661

; FILING DATE: 19-NOV-1992

; INFORMATION FOR SEQ ID NO: 18:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 277 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-244-113-18

Query Match 0.8%; Score 22; DB 1; Length 277;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2658 TGACAAAAA 2679
DB 224 TGACAAAAA 245

RESULT 13

US-09-280-116-159/c

; Sequence 159, Application US/09280116A

; Patent No. 6331427

; GENERAL INFORMATION:

; APPLICANT: Robison, Keith E.

; TITLE OF INVENTION: Nucleic Acid Molecules Encoding Human Protease Homologs

; FILE REFERENCE: 5800-24, 035800/176965
; CURRENT APPLICATION NUMBER: US/09/280,116A
; CURRENT FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 268
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 159
; LENGTH: 424
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Lon family of ATP-dependent proteases
US-09-280-116-159

Query Match 0.8%; Score 22; DB 4; Length 424;
Best Local Similarity 100.0%; Pred. No. 8.2;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2658 TGACAAAAA 2679
DB 22 TGACAAAAA 1

RESULT 14

US-09-205-258-172

; Sequence 172, Application US/09205258

; Patent No. 6525174

; GENERAL INFORMATION:

; APPLICANT: Young et al.

; TITLE OF INVENTION: 207 Human Secreted Proteins

; FILE REFERENCE: P2007P1

; CURRENT APPLICATION NUMBER: US/09/205,258

; CURRENT FILING DATE: 1998-12-04

; EARLIER APPLICATION NUMBER: PCT/US98/11422

; EARLIER FILING DATE: 1998-06-04

; EARLIER APPLICATION NUMBER: 60/048,885

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/049,375

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,881

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,880

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,896

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/049,020

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,876

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,895

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,884

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,894

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,971

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,964

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,882

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,899

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,893

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,900

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,901

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,892

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/048,915

; EARLIER FILING DATE: 1997-06-06

; EARLIER APPLICATION NUMBER: 60/049,019

EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,970
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,972
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,916
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,373
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,875
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,374
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,917
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,949
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,974
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,883
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,897
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,898
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,962
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,963
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,877
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,878
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/070,923
EARLIER FILING DATE: 1997-12-18
EARLIER APPLICATION NUMBER: 60/048,895
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,375
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,891

Query Match 0.8%; Score 22; DB 4; Length 786;
Best Local Similarity 100.0%; Pred. No. 7.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2658 TCACAAAAA 2679
DB 760 TCACAAAAA 781

RESULT 15
US-09-205-258-190/c
Sequence 190; Application US/09205258
Patent No. 6525174
GENERAL INFORMATION:
APPLICANT: Young et al.
TITLE OF INVENTION: 207 Human Secreted Proteins
FILE REFERENCE: P2007P1
CURRENT APPLICATION NUMBER: US/09/205,258
CURRENT FILING DATE: 1998-12-04
EARLIER APPLICATION NUMBER: PCT/US98/11422
EARLIER FILING DATE: 1998-06-04
EARLIER APPLICATION NUMBER: 60/048,895
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,375
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,891

EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,880
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,896
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,020
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,876
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,895
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,884
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,894
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,971
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,964
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,882
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,899
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,893
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,900
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,901
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,892
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,915
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,019
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,970
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,972
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,916
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,373
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,875
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/049,374
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,917
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,949
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,974
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,883
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,897
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,898
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,962
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/048,963
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/070,923
EARLIER FILING DATE: 1997-12-18
EARLIER APPLICATION NUMBER: 60/092,921
EARLIER FILING DATE: 1998-07-15
EARLIER APPLICATION NUMBER: 60/094,657
EARLIER FILING DATE: 1998-07-30
NUMBER OF SEQ ID NOS: 1227
SEQ ID NO 172
LENGTH: 786
TYPE: DNA
ORGANISM: Homo sapiens
US-09-205-258-172

```
; NUMBER OF SEQ ID NOS: 1227
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 190
; LENGTH: 906
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (144)
; OTHER INFORMATION: n equals a,t,g, or c
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (145)
; OTHER INFORMATION: n equals a,t,g, or c
US-09-205-258-190

Query Match      0.8%; Score 22; DB 4; Length 906;
Best Local Similarity 100.0%; Pred. No. 7.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2657 TTGACAAAAA 2678
      |||||
Db      843 TTGACAAAAA 822

Search completed: May 15, 2004, 08:02:31
Job time : 216 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:49:13 ; Search time 11.5628 Seconds
(without alignments)
1752.371 Million cell updates/sec

Title: US-10-048-046-2_COPY_31_103

Perfect score: 378
Sequence: 1 VLLRKEWTIGRRGCDLSF.....INLKVVKQTCPLQGTGVI 73

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1140673 seqs, 277566755 residues

Total number of hits satisfying chosen parameters: 1140673

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep.*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	378	100.0	426	9	US-09-764-864-809
2	378	100.0	664	9	US-09-780-525-2
3	304	80.4	92	9	US-09-764-864-1109
4	275	72.8	99	9	US-09-764-864-1110
5	275	72.8	99	9	US-09-764-864-1529
6	107.5	28.4	822	9	US-09-740-627-11
7	107.5	28.4	821	14	US-10-081-119-16
8	99	26.2	699	14	US-10-032-585-7635
9	81	21.4	445	12	US-10-424-599-178873
10	81	21.4	1082	12	US-10-425-114-56100
11	78.5	20.8	175	9	US-09-867-550-1026
12	78.5	20.8	244	9	US-09-764-864-1111
13	77.5	20.5	460	9	US-09-740-627-10
14	76.5	20.2	517	15	US-10-618-173-2
15	74.5	19.7	229	12	US-10-424-599-187236

16	74.5	19.7	376	12	US-10-424-599-233512	Sequence 233512, App
17	74	19.6	250	12	US-10-424-599-269525	Sequence 269525, App
18	72	19.0	513	15	US-10-369-493-1578	Sequence 1578, App
19	71	18.8	409	12	US-10-282-122A-64192	Sequence 64192, A
20	70.5	18.7	874	12	US-10-282-122A-45185	Sequence 45185, A
21	67	17.7	481	14	US-10-156-761-12906	Sequence 12906, A
22	66.5	17.6	288	9	US-09-738-626-3552	Sequence 3552, App
23	66	17.5	435	12	US-10-424-599-276420	Sequence 276420, App
24	64	16.9	545	14	US-10-142-356-6	Sequence 6, Appli
25	63.5	16.8	474	15	US-10-369-493-2299	Sequence 2299, App
26	63.5	16.8	492	15	US-10-369-493-3607	Sequence 3607, App
27	63	16.7	138	14	US-10-238-075-1035	Sequence 1035, App
28	62.5	16.5	527	9	US-09-712-363-156	Sequence 156, App
29	62.5	16.5	527	14	US-10-080-170-348	Sequence 348, App
30	62	16.4	467	12	US-10-406-031-5	Sequence 5, Appli
31	62	16.4	1724	12	US-10-276-774-2176	Sequence 2176, App
32	61.5	16.3	207	12	US-10-382-122A-49959	Sequence 49959, A
33	61.5	16.3	459	9	US-09-740-627-9	Sequence 9, Appli
34	61.5	16.3	488	14	US-10-080-170-4	Sequence 4, Appli
35	61	16.1	1055	12	US-10-282-122A-57704	Sequence 57704, A
36	61	16.1	1056	12	US-10-282-122A-57499	Sequence 57499, A
37	60.5	16.0	365	9	US-09-738-636-4872	Sequence 4872, App
38	60.5	16.0	397	12	US-10-389-647-430	Sequence 430, App
39	60	15.9	939	12	US-10-282-122A-47696	Sequence 47696, A
40	60	15.9	969	12	US-10-282-122A-63852	Sequence 63852, A
41	59.5	15.7	804	12	US-10-282-122A-42499	Sequence 42499, A
42	59.5	15.7	820	9	US-09-815-242-10771	Sequence 10771, A
43	59	15.6	601	12	US-10-257-502-367	Sequence 367, App
44	59	15.6	1045	12	US-10-041-018-199	Sequence 199, App
45	59	15.6	1045	12	US-10-041-018-218	Sequence 218, App

ALIGNMENTS

RESULT 1
US-09-764-864-809
; Sequence 809, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 809
; LENGTH: 426
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (414)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (415)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (420)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; US-09-764-864-809

Query Match 100.0%; Score 378; DB 9; Length 426;
Best Local Similarity 100.0%; Pred. No. 6.9e-39;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VLLRKEWTIGRRGCDLSFPSNKLVSGDHCRIVVDEKSGGVTLSDTSGTVINKLV 60
DB 33 VLLRKEWTIGRRGCDLSFPSNKLVSGDHCRIVVDEKSGGVTLSDTSGTVINKLV 92
QY 61 KKQTCPLQGTGVI 73

not 102?
(date of 2000)
601

Db 93 KKQTCPLQTGDVI 105

RESULT 2

US-09-780-525-2

; Sequence 2, Application US/09780525

; Patent No. US20020004223A1

; GENERAL INFORMATION:

; APPLICANT: Bin-Bing Zhou

; APPLICANT: Yuan Zhu

; APPLICANT: Priya Chaturvedi

; APPLICANT: Mark R. Hurler

; APPLICANT: Xiaotong Li

; TITLE OF INVENTION: FHAR1, A NEW RING FINGER PROTEIN

; FILE REFERENCE: GP-70668-C1

; CURRENT APPLICATION NUMBER: US/09/780,525

; CURRENT FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 09/456,876

; PRIOR FILING DATE: 1999-12-08

; NUMBER OF SEQ ID NOS: 2

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 2

; LENGTH: 664

; TYPE: PRT

; ORGANISM: HOMO SAPIENS

US-09-780-525-2

Query Match 100.0%; Score 378; DB 9; Length 664;

Best Local Similarity 100.0%; Pred. No. 1.2e-38;

Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIIVVDEKSGQVLTDTSGTVINKLVV 60

Db 31 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIIVVDEKSGQVLTDTSGTVINKLVV 90

Qy 61 KKQTCPLQTGDVI 73

Db 91 KKQTCPLQTGDVI 103

RESULT 3

US-09-764-864-1109

; Sequence 1109, Application US/09764864

; Patent No. US20020132753A1

; GENERAL INFORMATION:

; APPLICANT: Rosen et al.

; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies

; FILE REFERENCE: PT223

; CURRENT APPLICATION NUMBER: US/09/764,864

; CURRENT FILING DATE: 2001-01-17

; Prior application data removed - consult PALM or file wrapper

; NUMBER OF SEQ ID NOS: 1792

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1109

; LENGTH: 92

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: SITE

; LOCATION: (80)

; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids

US-09-764-864-1109

Query Match 80.4%; Score 304; DB 9; Length 92;

Best Local Similarity 98.3%; Pred. No. 2.1e-30;

Matches 59; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIIVVDEKSGQVLTDTSGTVINKLVV 60

Db 33 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIIVVDEKSGQVLTDTSGTVINKLVV 92

RESULT 4

US-09-764-864-1110

; Sequence 1110, Application US/09764864

; Patent No. US20020132753A1

; GENERAL INFORMATION:

; APPLICANT: Rosen et al.

; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies

; FILE REFERENCE: PT223

; CURRENT APPLICATION NUMBER: US/09/764,864

; CURRENT FILING DATE: 2001-01-17

; Prior application data removed - consult PALM or file wrapper

; NUMBER OF SEQ ID NOS: 1792

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1110

; LENGTH: 99

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: SITE

; LOCATION: (17)

; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids

US-09-764-864-1110

Query Match 72.8%; Score 275; DB 9; Length 99;

Best Local Similarity 90.3%; Pred. No. 1e-26;

Matches 56; Conservative 1; Mismatches 3; Indels 2; Gaps 1;

Qy 12 RRRGCDLSPFNKLVSGDHCRIIVVDEKSGQVLTDTSGTVINKLVVKKQTCPLQTGD 71

Db 9 RDKGPD--FPNKLVS GDHCRIIVVDEKSGQVLTDTSGTVINKLVVKKQTCPLQTGD 66

Qy 72 VI 73

Db 67 VI 68

RESULT 5

US-09-764-864-1529

; Sequence 1529, Application US/09764864

; Patent No. US20020132753A1

; GENERAL INFORMATION:

; APPLICANT: Rosen et al.

; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies

; FILE REFERENCE: PT223

; CURRENT APPLICATION NUMBER: US/09/764,864

; CURRENT FILING DATE: 2001-01-17

; Prior application data removed - consult PALM or file wrapper

; NUMBER OF SEQ ID NOS: 1792

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1529

; LENGTH: 99

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: SITE

; LOCATION: (17)

; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids

US-09-764-864-1529

Query Match 72.8%; Score 275; DB 9; Length 99;

Best Local Similarity 90.3%; Pred. No. 1e-26;

Matches 56; Conservative 1; Mismatches 3; Indels 2; Gaps 1;

Qy 12 RRRGCDLSPFNKLVSGDHCRIIVVDEKSGQVLTDTSGTVINKLVVKKQTCPLQTGD 71

Db 9 RDKGPD--FPNKLVS GDHCRIIVVDEKSGQVLTDTSGTVINKLVVKKQTCPLQTGD 66

QY 72 VI 73
Db 67 VI 68

US-09-740-627-11
; Sequence 11, Application US/09740627
; Patent No. US20020012964A1
; GENERAL INFORMATION:
; APPLICANT: Nakanishi, Makoto
; TITLE OF INVENTION: CELL CYCLE REGULATING FACTOR
; FILE REFERENCE: 06501-071001
; CURRENT APPLICATION NUMBER: US/09/740,627
; PRIOR FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: PCT/JP99/03350
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: JP 10/192467
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 522
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-740-627-11

Query Match 28.4%; Score 107.5; DB 9; Length 522;
Best Local Similarity 37.7%; Pred. No. 0.0001;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;

QY 5 KREWTIGRRGCDLSPSPNKLVSQDHCRIIVVDEKSGQVLEDTSTGTVINKLVKKQT 64
Db 63 KKVWTFGRNPACDYHLGNISRLSNKHFQILLGE-DGNLLINDISTNGTWLNGQKVEKSN 121

QY 65 CPLQTGDVI 73
Db 122 QLLSQGDEI 130

US-10-081-119-16
; Sequence 16, Application US/10081119
; Publication No. US20030045491A1
; GENERAL INFORMATION:
; APPLICANT: Reinhard, Christoph
; APPLICANT: Jefferson, Anne B.
; APPLICANT: Chan, Vivien W.
; TITLE OF INVENTION: TTK in Diagnosis and as a Therapeutic
; FILE REFERENCE: 16932.002
; CURRENT APPLICATION NUMBER: US/10/081,119
; PRIOR FILING DATE: 2002-02-21
; PRIOR APPLICATION NUMBER: 60/289,813
; PRIOR FILING DATE: 2001-02-21
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 821
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-10-081-119-16

Query Match 28.4%; Score 107.5; DB 14; Length 821;
Best Local Similarity 37.7%; Pred. No. 0.00018;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;

QY 5 KREWTIGRRGCDLSPSPNKLVSQDHCRIIVVDEKSGQVLEDTSTGTVINKLVKKQT 64
Db 63 KKVWTFGRNPACDYHLGNISRLSNKHFQILLGE-DGNLLINDISTNGTWLNGQKVEKSN 121

QY 65 CPLQTGDVI 73

Db 122 QLLSQGDEI 130

RESULT 8
US-10-032-585-7635
; Sequence 7635, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7635
; LENGTH: 699
; TYPE: PRT
; ORGANISM: Candida albicans
US-10-032-585-7635

Query Match 26.2%; Score 99; DB 14; Length 699;
Best Local Similarity 33.3%; Pred. No. 0.0017;
Matches 23; Conservative 12; Mismatches 34; Indels 0; Gaps 0;

QY 5 KREWTIGRRGCDLSPSPNKLVSQDHCRIIVVDEKSGQVLEDTSTGTVINKLVKKQT 64
Db 59 KQWYFGRDPSNDLQVASSRSISNKHQFQIWLNFNDKSLWIKDTSTNGTHLNSRLVKGSN 118

QY 65 CPLQTGDVI 73
Db 119 YLLNQGDEI 127

RESULT 9
US-10-424-599-178873
; Sequence 178873, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 178873
; LENGTH: 445
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_132539C.1.pep
US-10-424-599-178873

Query Match 21.4%; Score 81; DB 12; Length 445;
Best Local Similarity 29.6%; Pred. No. 0.18;
Matches 24; Conservative 10; Mismatches 27; Indels 20; Gaps 2;

QY 13 RRGCDLSPSPNKLVSQDHCRIIVVDEKSGQVLEDTSTGTVINKLV 59
Db 29 RRGCDVITTKDQVSRVHAEIVNTVNPVPLNERSHLSSIIHRCDSKYGTINKNGG 88

QY 60 VKKQT-----CPLQTGDVI 73
Db 89 AKKQVHELPNKETALENGDLV 109

```
RESULT 10
US-10-425-114-56100
; Sequence 56100, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Jingdong
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K.
; APPLICANT: Screen, Steven E
; APPLICANT: Tabaska, Jack E
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53)313B
; CURRENT APPLICATION NUMBER: US/10/425,114
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 56100
; LENGTH: 1082
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: JC-GMLE01810018D04_FLI.psp
US-10-425-114-56100

Query Match      21.4%; Score 81; DB 12; Length 1082;
Best Local Similarity 33.8%; Pred. No. 0.55;
Matches 23; Conservative 12; Mismatches 27; Indels 6; Gaps 4;

QY 10 IGRRGCDLSPSPN-KLVSGDHCRIVVDEKSGQ--VTLEDTSSTGTV-INKLKVVKQTC 65
DB 1 IGSNRSC--NFFPLNDQTSIGNLKIKHTQGDGSAVAVLESMGSGSVLVNGTHVKQNTSC 58
QY 66 PLOTGQDVI 73
DB 59 VLNSGDEV 66

RESULT 11
US-09-867-550-1026
; Sequence 1026, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Mehraban, Fuad,
; APPLICANT: Conley, Pamela
; APPLICANT: Law, Debbie
; APPLICANT: Topper, James
; TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and
; TITLE OF INVENTION: Thereby
; FILE REFERENCE: 21402-013 (Cura-313)
; CURRENT APPLICATION NUMBER: US/09/867,550
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: USSN 60/208,427
; PRIOR FILING DATE: 2000-05-30
; NUMBER OF SEQ ID NOS: 2125
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1026
; LENGTH: 175
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-867-550-1026

Query Match      20.8%; Score 78.5; DB 9; Length 175;
Best Local Similarity 32.7%; Pred. No. 0.12;
Matches 18; Conservative 15; Mismatches 17; Indels 5; Gaps 2;

QY 24 KLVSGDHCRIVVDEKSGQVTLTDT-STSGTVINKLVKVK----KQTCPLQTGDVI 73
DB 49 KVLNRNALVWFDHKTGYLQDTKSSNGTFINSQRLSGSESPPCILSGDII 103

RESULT 12
US-09-867-550-1026
; Sequence 1026, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Mehraban, Fuad,
; APPLICANT: Conley, Pamela
; APPLICANT: Law, Debbie
; APPLICANT: Topper, James
; TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and
; TITLE OF INVENTION: Thereby
; FILE REFERENCE: 21402-013 (Cura-313)
; CURRENT APPLICATION NUMBER: US/09/867,550
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: USSN 60/208,427
; PRIOR FILING DATE: 2000-05-30
; NUMBER OF SEQ ID NOS: 2125
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1026
; LENGTH: 175
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-867-550-1026

Query Match      20.8%; Score 78.5; DB 9; Length 175;
Best Local Similarity 32.7%; Pred. No. 0.12;
Matches 18; Conservative 15; Mismatches 17; Indels 5; Gaps 2;

QY 24 KLVSGDHCRIVVDEKSGQVTLTDT-STSGTVINKLVKVK----KQTCPLQTGDVI 73
DB 49 KVLNRNALVWFDHKTGYLQDTKSSNGTFINSQRLSGSESPPCILSGDII 103
```

```
US-09-764-864-1111
; Sequence 1111, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1111
; LENGTH: 244
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (74)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (159)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (203)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (229)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1111

Query Match      20.8%; Score 78.5; DB 9; Length 244;
Best Local Similarity 32.7%; Pred. No. 0.18;
Matches 18; Conservative 15; Mismatches 17; Indels 5; Gaps 2;

QY 24 KLVSGDHCRIVVDEKSGQVTLTDT-STSGTVINKLVKVK----KQTCPLQTGDVI 73
DB 77 KVLNRNALVWFDHKTGYLQDTKSSNGTFINSQRLSGSESPPCILSGDII 131

RESULT 13
US-09-740-627-10
; Sequence 10, Application US/09740627
; Patent No. US20020012964A1
; GENERAL INFORMATION:
; APPLICANT: Nakanishi, Makoto
; TITLE OF INVENTION: CELL CYCLE REGULATING FACTOR
; FILE REFERENCE: 06501-071001
; CURRENT APPLICATION NUMBER: US/09/740,627
; CURRENT FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: PCT/JP99/03350
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: JP 10/192467
; PRIOR FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Schizosaccharomyces pombe
US-09-740-627-10

Query Match      20.5%; Score 77.5; DB 9; Length 460;
Best Local Similarity 30.8%; Pred. No. 0.52;
Matches 22; Conservative 9; Mismatches 34; Indels 7; Gaps 2;

QY 8 WTIGRRRGCDLSPSPNKLVSQDHCRIIV-----VDEKSGQVTLTDTSTSGTVINKLVKVK 61
DB 60 WRFGRHKSCEVVL-NGPRVSNFHFYIYQGRNDSDESNVFLHDHSSNGTFLNFERLAK 118
QY 62 KQTCPLQTGDVI 73
DB 119 NSRTILSNGDEI 130
```

QY 59 VVKQTCTPLQTGDVI 73
DB 154 VERNTYVDLHVGDVI 168
Search completed: May 7, 2004, 15:06:50
Job time : 12.5628 secs

RESULT 14
US-10-618-173-2
; Sequence 2, Application US/10618173
; Publication No. US20040018603A1
; GENERAL INFORMATION:
; APPLICANT: CALIFORNIA INSTITUTE OF TECHNOLOGY
; APPLICANT: GUO, Zijian
; APPLICANT: DUNPHY, William
; TITLE OF INVENTION: CHECKPOINT-ACTIVATING OLIGONUCLEOTIDES
; FILE REFERENCE: CITI350-1
; CURRENT APPLICATION NUMBER: US/10/618,173
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: US/09/849,617
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: US 60/202,028
; PRIOR FILING DATE: 2000-05-04
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 517
; TYPE: PRT
; ORGANISM: Xenopus laevis
US-10-618-173-2

Query Match 20.2%; Score 76.5; DB 15; Length 517;
Best Local Similarity 31.9%; Pred. No. 0.81;
Matches 23; Conservative 9; Mismatches 29; Indels 11; Gaps 2;
QY 7 EWTIGRRRGCDLSF-----PSNKLVSGDHCRIVVDEKSGQ---VTLEDTSTSGTVIN 55
DB 84 EYVFGDRKKCDYTFDIPVLNQTDYKTSKRHFRIQELGHHGHSRVANTIEDLSGNGTFVN 143
QY 56 KLVVKKQTCTPL 67
DB 144 KEIIGKRTLPL 155

RESULT 15
US-10-424-599-187236
; Sequence 187236, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 187236
; LENGTH: 229
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(229)
; OTHER INFORMATION: unsure at all xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_140086C.1.pap
US-10-424-599-187236

Query Match 19.7%; Score 74.5; DB 12; Length 229;
Best Local Similarity 36.0%; Pred. No. 0.52;
Matches 27; Conservative 9; Mismatches 32; Indels 7; Gaps 4;
QY 2 LLKREWTIGRRGCD--LSFPNKLVSGDHCRIVVDEKSGQVLEDT-STSGTVINKLK 58
DB 98 VFKEGAYMFGRLDLCDFVLEHPT---ISRPHA-WQFKRSGDAYLYDLGSTGTFLNKNQ 153

	1	1995	74.5	1995	9	US-09-780-525-1	Sequence 1, Appl
	2	1919.4	71.6	2448	16	US-10-108-260A-2073	Sequence 273, App
	3	945	32.3	1311	9	US-09-764-864-22	Sequence 22, Appl
	4	876.2	35.7	1886	16	US-10-094-749-160	Sequence 160, App
	5	536.6	20.0	693	9	US-09-764-864-483	Sequence 483, App
	6	394.4	14.7	476	10	US-09-918-995-2180	Sequence 2180, App
	7	310.2	11.6	357	9	US-09-764-864-322	Sequence 322, App
	8	273.6	10.2	449	10	US-09-918-995-13662	Sequence 13662, App
	9	256.4	9.6	354	9	US-09-764-864-323	Sequence 323, App
	10	256.4	9.6	354	9	US-09-764-864-742	Sequence 742, App
	11	60	2.2	60	10	US-09-908-975-6220	Sequence 6220, App
	12	51.4	1.9	1255	13	US-10-424-599-95539	Sequence 95539, App
	13	51	1.9	383	10	US-09-814-593-18006	Sequence 18006, App
	14	51	1.9	411	13	US-10-424-599-127666	Sequence 127666, App

Db 121 GGGCGAGAGCGAGTTGCGACCTTTCTTCCCGCAGCAATAAATGGTCTCTGAGATCAC 180
Qy 271 TGTAGAAATTTAGTGTGATGAATAATCAGGTGAGTGACACTGGAAGATACACGACCACTG 330
Db 181 TGTAGAAATTTAGTGTGATGAATAATCAGGTGAGTGACACTGGAAGATACACGACCACTG 240
Qy 331 GGAACAGTGAATTAACAGCTGAAGTTGTTAAGAGCAGACATGCCCTTTACAGACTGGG 390
Db 241 GGAACAGTGAATTAACAGCTGAAGTTGTTAAGAGCAGACATGCCCTTTACAGACTGGG 300
Qy 391 GATGTGATCTACTGTGTGATGACAGAGAAATGAACCCGGAACACAACTGGGATACCTCTAT 450
Db 301 GATGTGATCTACTGTGTGATGACAGAGAAATGAACCCGGAACACAACTGGGATACCTCTAT 360
Qy 451 GAATCTTTAAGTGAAGCAGGACATGACACAGAAATCTTTGAAGCTAACAGAGAAAT 510
Db 361 GAATCTTTAAGTGAAGCAGGACATGACACAGAAATCTTTGAAGCTAACAGAGAAAT 420
Qy 511 GTGTTCATGGGACCAAGATACCTCAGGTGAGGTGACAGGGGAGGGGCGCATGCCCGG 570
Db 421 GTGTTCATGGGACCAAGATACCTCAGGTGAGGTGACAGGGGAGGGGCGCATGCCCGG 480
Qy 571 GTCCCTCCGTGTCGCCCGCATCTCAGGTGAGGTGACAGGGGAGGGGCGCATGCCCGG 630
Db 481 GTCCCTCCGTGTCGCCCGCATCTCAGGTGAGGTGACAGGGGAGGGGCGCATGCCCGG 540
Qy 631 ACCTCAGACCTCTTCCCGCAGGCTCGGCCCTTTCCACGAGGCTTCTCCTGACGGGCGA 690
Db 541 ACCTCAGACCTCTTCCCGCAGGCTCGGCCCTTTCCACGAGGCTTCTCCTGACGGGCGA 600
Qy 691 GAGGTTCTCCAGTTGTGGGTCTGGGGTGTGGGATCTCCCGCTAAAGGAAGTGTCTCC 750
Db 601 GAGGTTCTCCAGTTGTGGGTCTGGGGTGTGGGATCTCCCGCTAAAGGAAGTGTCTCC 660
Qy 751 TCTGTGCAAGTGAAGTCTCCAGCTTTGCTCAGCTCTCCAGCAGAGAAAGTGTGG 810
Db 661 TCTGTGCAAGTGAAGTCTCCAGCTTTGCTCAGCTCTCCAGCAGAGAAAGTGTGG 720
Qy 811 TCCTTTTCGTGTTGGAACCCCGAGTACAGAGGATTTGAGCCCGTGAAGAGAAATG 870
Db 721 TCCTTTTCGTGTTGGAACCCCGAGTACAGAGGATTTGAGCCCGTGAAGAGAAATG 780
Qy 871 AGAGGATGAGGACCTTGACCTGGAACGGGAGTTGTTGTTGCTCCACAAACCGCGTAGAAAT 930
Db 781 AGAGGATGAGGACCTTGACCTGGAACGGGAGTTGTTGTTGCTCCACAAACCGCGTAGAAAT 840
Qy 931 GCCCAAACCGTCCACGAGGACGTACAGAGCCGCTGGGAAGCCAGACAGATGGAGGAG 990
Db 841 GCCCAAACCGTCCACGAGGACGTACAGAGCCGCTGGGAAGCCAGACAGATGGAGGAG 900
Qy 991 ACCTGACATGATCTATCTGCCAGGACCTGTCAGACAGTCTGAGTTTGACAGCCCTGC 1050
Db 901 ACCTGACATGATCTATCTGCCAGGACCTGTCAGACAGTCTGAGTTTGACAGCCCTGC 960
Qy 1051 ATGCACACGTTCTCGCGGGTTGCTACTCGGGGTGAGTGGAGCGCTGCTCCCTGTGTCT 1110
Db 961 ATGCACACGTTCTCGCGGGTTGCTACTCGGGGTGAGTGGAGCGCTGCTCCCTGTGTCT 1020
Qy 1111 ACCTGCGGCTGTCCTGGAGCGGATCTGTAATAACCAATCTCAACACCTCGTGGAA 1170
Db 1021 ACCTGCGGCTGTCCTGGAGCGGATCTGTAATAACCAATCTCAACACCTCGTGGAA 1080
Qy 1171 GCATACCTCATCCAGCATCCAGACAGAGTCGAGTGAAGAGATGTGCAAGATGGAT 1230
Db 1081 GCATACCTCATCCAGCATCCAGACAGAGTCGAGTGAAGAGATGTGCAAGATGGAT 1140
Qy 1231 GCCAGGAATAAATCATCTAAGACATGTGTCAGGCCCAAGTCAAGCGGCTTTTCTGAT 1290
Db 1141 GCCAGGAATAAATCATCTAAGACATGTGTCAGGCCCAAGTCAAGCGGCTTTTCTGAT 1200
Qy 1291 GAAGAAGGAGTTTCAGAGGACCTGCTGAGCTGTCAGAGTTGACAGTGTCTCTCAGAC 1350

Db 1201 GAAGAAGGAGTTTCAGAGGACCTGCTGGAGCTGTACAGCGTTGACAGTGTCTCAGAC 1260
Qy 1351 ATTAGCCAGCCATACATGTCGTGTCGGGACAGTGTCTTGTAGTACAGAGGAGCGGCGCAG 1410
Db 1261 ATTAGCCAGCCATACATGTCGTGTCGGGACAGTGTCTTGTAGTACAGAGGAGCGGCGCAG 1320
Qy 1411 CTTCCCACTGCTCCAGCACCCGAGGCGAGCCAGGAGCCCAACAGGCCCTTGGGGGATGCA 1470
Db 1321 CTTCCCACTGCTCCAGCACCCGAGGCGAGCCAGGAGCCCAACAGGCCCTTGGGGGATGCA 1380
Qy 1471 CCCTCCACGCTCCGTCAGCTGACGACAGCAGTCCAGGATTCAGTGTGCCCTCTGTCAAGGA 1530
Db 1381 CCCTCCACGCTCCGTCAGCTGACGACAGCAGTCCAGGATTCAGTGTGCCCTCTGTCAAGGA 1440
Qy 1531 AGCCACGCTGTCGCTGCTTCCAGCCCATGCCCAGCCGAGAGCGGAGCGGAG 1590
Db 1441 AGCCACGCTGTCGCTGCTTCCAGCCCATGCCCAGCCGAGAGCGGAGCGGAG 1500
Qy 1591 CAGGACCGCGTGTGCGCCCTCAGCAGTGTGCGTCTGCTGACAGCCCTTCTGCACTG 1650
Db 1501 CAGGACCGCGTGTGCGCCCTCAGCAGTGTGCGTCTGCTGACAGCCCTTCTGCACTG 1560
Qy 1651 TACTGGGGCTGCACCCGAGACCGGCTGCTACGGTGTGCTGCGCCCGTCTTGTGAGCTCAAC 1710
Db 1561 TACTGGGGCTGCACCCGAGACCGGCTGCTACGGTGTGCTGCGCCCGTCTTGTGAGCTCAAC 1620
Qy 1711 CTGGGTGACAGTGTCTGGAGCGGCTGTGACAAACACAGCTACGAGTACAGATCTCTG 1770
Db 1621 CTGGGTGACAGTGTCTGGAGCGGCTGTGACAAACACAGCTACGAGTACAGATCTCTG 1680
Qy 1771 AAGAAATACCTGGCAACCCAGAGGTTTGACATGGAATAAATGTTGACCGAGAGCTCGTG 1830
Db 1681 AAGAAATACCTGGCAACCCAGAGGTTTGACATGGAATAAATGTTGACCGAGAGCTCGTG 1740
Qy 1831 GCTCTCCAGCGGAGTGTCTGCTGTCTGATTTACAGATCAGGAGACCGGAGACCGGCTCTG 1890
Db 1741 GCTCTCCAGCGGAGTGTCTGCTGTCTGATTTACAGAGTACCGGAGACCGGCTCTG 1800
Qy 1891 TGTTACTGCTGTGCGCTGCGAGCTTCCGTGAGCTGACCTATCAGTATCGGAGAACAT 1950
Db 1801 TGTTACTGCTGTGCGCTGCGAGCTTCCGTGAGCTGACCTATCAGTATCGGAGAACAT 1860
Qy 1951 CTTGCTCCGAGTTGCCAGTGGCCGTAACATCCGCTCTGACTCTACTGGGCGGTAAC 2010
Db 1861 CTTGCTCCGAGTTGCCAGTGGCCGTAACATCCGCTCTGACTCTACTGGGCGGTAAC 1920
Qy 2011 TGCCGCACTCAGGTGAAGCTCACACGCCATGAAATTCATCATATCTGTGAACAGACA 2070
Db 1921 TGCCGCACTCAGGTGAAGCTCACACGCCATGAAATTCATCATATCTGTGAACAGACA 1980
Qy 2071 AGGTTCAAAAACTAA 2085
Db 1981 AGGTTCAAAAACTAA 1995

RESULT 2
US-10-108-260A-2073
; Sequence 2073, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1e1 full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2073
; LENGTH: 2448
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-108-260A-2073

Query Match	71.6%;	Score 1919.4;	DB 16;	Length 2448;
Best Local Similarity	88.5%;	Pred. No. 0;		
Matches 2227;	Conservative	0;	Mismatches	6; Indels 284; Gaps 2;
QY	218	GACGAGTTGCGACCTTTCTCTCCCGAGCAATAAACTGGTCTCTGGAGATCACTGAGAA	277	
DB	83	GACCCCTGTTGGACCTTCTCTCCCGAGCAATAAACTGGTCTCTGGAGATCACTGAGAA	142	
QY	278	TTGTAGTGAATGAATAATCAGGTGACGTGACACTGGAAGATACCAGCACAGTGAACAG	337	
DB	143	TTGTAGTGAATGAATAATCAGGTGACGTGACACTGGAAGATACCAGCACAGTGAACAG	202	
QY	338	TGATTAACAGCTGAAGTTGTTAAGAAGCAGACATGCCCTTTTACAGACTGGGGATGTCA	397	
DB	203	TGATTAACAGCTGAAGTTGTTAAGAAGCAGACATGCCCTTTTACAGACTGGGGATGTCA	262	
QY	398	TCTACTTGTGTTACAGGAAGATGAACCGGAAACAAAGTGGCATACCTCTATGAATCTT	457	
DB	263	TCTACTTGTGTTACAGGAAGATGAACCGGAAACAAAGTGGCATACCTCTATGAATCTT	322	
QY	458	TAAGTGAAGAGCAAGGATGACACAAAGATCCCTTTGAAGCTAAAGGAATAATGTGTCC	517	
DB	323	TAAGTGAAGAGCAAGGATGACACAAAGATCCCTTTGAAGCTAAAGGAATAATGTGTCC	356	
QY	518	ATGGGACCAAGATACCTCAGGTGCAGGTGCAGGGCGAGGGGCGGATGCCCGGGTCCCTC	577	
DB	357	-----	356	
QY	578	CGTCTGCCCGCCACTCAGGTGTCTTTGAGGAACACAGACCATCAACATGACGTGAG	637	
DB	357	-----	356	
QY	638	ACCTCTTCCCCACAGCCTCGGCCTCTTCCAGGAGCCTTCTCCTGCGGGCGAGACGTT	697	
DB	357	-----	356	
QY	698	CCTCCAGTTGTGGGTCTGGGGTGGTGGATCTCCCTAAAGAAAGTGTCCCTCTGTGG	757	
DB	357	-----TGGGTCTGGGGTGGTGGATCTCCCTAAAGAAAGTGTCCCTCTGTGG	406	
QY	758	CAAGTGAATGAAGTCTCCAGCTTTGCCCTCAGCTCTCCAGACAGAAAGACTGCCCTCTTT	817	
DB	407	CAAGTGAATGAAGTCTCCAGCTTTGCCCTCAGCTCTCCAGACAGAAAGACTGCCCTCTTT	466	
QY	818	CGTCTTGGAAACCCAGATCAGAGAGATTGGAGCCCGTGAAGAAATCAGAGGAG	877	
DB	467	CGTCTTGGAAACCCAGATCAGAGAGATTGGAGCCCGTGAAGAAATCAGAGGAG	526	
QY	878	ATGGGACCTTGACCTGAACGGGAGTTGTTGTCGACACACCGCTAGAAATGCCCAA	937	
DB	527	ATGGGACCTTGACCTGAACGGGAGTTGTTGTCGACACACCGCTAGAAATGCCCAA	586	
QY	938	CCGTCCAGAGGAGCTCAGAGACGCGCTGGAGAGCCGTCAGACAGATGAGAGAGCGTGA	997	
DB	587	CCGTCCAGAGGAGCTCAGAGACGCGCTGGAGAGCCGTCAGACAGATGAGAGAGCGTGA	646	
QY	998	CATGATCATCTGCAGGACCTGTCGACGACTGCGTGAGTTGACGCCCTGCATGCACA	1057	
DB	647	CATGATCATCTGCAGGACCTGTCGACGACTGCGTGAGTTGACGCCCTGCATGCACA	706	
QY	1058	CGTTCTCGCGGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTCTACTCGTCC	1117	
DB	707	CGTTCTCGCGGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTCTACTCGTCC	766	
QY	1118	GCTGTCCCGTGGAGCGGATCTGTAAACCAATCCTCAACACCTCGTGGAGCATACC	1177	
DB	767	GCTGTCCCGTGGAGCGGATCTGTAAACCAATCCTCAACACCTCGTGGAGCATACC	826	
QY	1178	TCATCCAGCATCCAGACAGAGTGCAGTGAAGAGATGTGCAAGATATGATGCCAGGA	1237	
DB	827	TCATCCAGCATCCAGACAGAGTGCAGTGAAGAGATGTGCAAGATATGATGCCAGGA	886	
QY	1238	ATAAAATCACTCAAGACATGCTGCAGGCCCAAAAGTCAGGCGGTCTTTTCTGATGAAGAG	1297	

DB	887	ATAAAATCACTCAAGACATGCTGCAGCCCAAAGTCAGGCGGTCTTTTCTGATGAAGAG	946	
QY	1298	GGAGTTCAGAGGACCTCTGGAGCTGTGACGTTGACGTGAGTCTCAGACATTAGCC	1357	
DB	947	GGAGTTCAGAGGACCTCTGGAGCTGTGACGTTGACGTGAGTCTCAGACATTAGCC	1006	
QY	1358	AGCCATACGTCTGTGCGGCGAGTGTCTGAGTACAGAAAGCAGGCGCGCAGCTCCCC	1417	
DB	1007	AGCCATACGTCTGTGCGGCGAGTGTCTGAGTACAGAAAGCAGGCGCGCAGCTCCCC	1066	
QY	1418	ACTGCCAGACCCGAGGGCGAGCAGAGCCCCACAGGCCCTGGGGATGCACCCCTCA	1477	
DB	1067	ACTGCCAGACCCGAGGGCGAGCAGAGCCCCACAGGCCCTGGGGATGCACCCCTCA	1126	
QY	1478	CGTCCGTGAGCTGACGACAGCTCCAGGATTAAGTGTGCCCTCTCTCAAGAAAGCCACG	1537	
DB	1127	CGTCCGTGAGCTGACGACAGCTCCAGGATTAAGTGTGCCCTCTCTCAAGAAAGCCACG	1186	
QY	1538	CCCTGTGCACTGTCTGCTTCCAGCCATGCCCCGAGAGCGGAGCGGCGAGCAGACC	1597	
DB	1187	CCCTGTGCACTGTCTTCCAGCCATGCCCCGAGAGCTGGAGCGGCGAGCAGACC	1246	
QY	1598	CGCGTGTGCGCCCTCAGCAGGTGCGGTCTGCCCTGACGCTTTCTGCCACCTGTACTGG	1657	
DB	1247	CGCGTGTGCGCCCTCAGCAGGTGCGGTCTGCCCTGACGCTTTCTGCCACCTGTACTGG	1306	
QY	1658	GCTGCACCCGACCGGCTGTACCGCTGCCCTGGCCCCGTTTTGT	1701	
DB	1307	GCTGCACCCGACCGGCTGTACCGCTGCCCTGGCCCCGTTTTGTGTGTGTCGGGCGAGACGT	1366	
QY	1702	-----	1709	
DB	1367	GCTTCTTCGCGACATCATTAATAACAGGTAACTTGCCCTTCTCTCGGCGAGCTCA	1426	
QY	1710	CCTGGGTGACAAAGTGTCTGGACGGGCTGTGAAACAAACAGCTACAGTACAGATCCT	1769	
DB	1427	CCTGGGTGACAAAGTGTCTGGACGGGCTGTGAAACAAACAGCTACAGTACAGATCCT	1486	
QY	1770	GAAGAAATTAAGTGGCAACAGAGTTTTCACATGGAATAACATGTTGACCGAGAGCTCGT	1829	
DB	1487	GAAGAAATTAAGTGGCAACAGAGTTTTCACATGGAATAACATGTTGACCGAGAGCTCGT	1546	
QY	1830	GCTCTCCAGCGGGAGTGTCTCTGCTCTGATTAACAGAGTCAAGGAGACACCGCTTCT	1889	
DB	1547	GCTCTCCAGCGGGAGTGTCTCTGCTCTGATTAACAGAGTCAAGGAGACACCGCTTCT	1606	
QY	1890	GTGTTACTGTGTGCGCTGCGCAGCTTCCGTGAGTGAACCTATCAGTATCGGCAGACAT	1949	
DB	1607	GTGTTACTGTGTGCGCTGCGCAGCTTCCGTGAGTGAACCTATCAGTATCGGCAGACAT	1666	
QY	1950	TCCTGCTCCGAGTTGCCAGTGGCGTAAACATCCGCTCTGACTGCTACTTGGGGCCGTAA	2009	
DB	1667	TCCTGCTCCGAGTTGCCAGTGGCGTAAACATCCGCTCTGACTGCTACTTGGGGCCGTAA	1726	
QY	2010	CTGCCGCACTCAGGTGAAGCTCAACGCGCAATGAATTAATCAATCATATCTGTGAACAGAC	2069	
DB	1727	CTGCCGCACTCAGGTGAAGCTCAACGCGCAATGAATTAATCAATCATATCTGTGAACAGAC	1786	
QY	2070	AGGTTCAAAAATAAGCAATCCAGAGGCCCTGAGCAGCTTTTCAGCAGCTGGAGGTGAAGAG	2129	
DB	1787	AGGTTCAAAAATAAGCAATCCAGAGGCCCTGAGCAGCTTTTCAGCAGCTGGAGGTGAAGAG	1846	
QY	2130	AGCGTGTGTTTTTAAATACAGACAAGCAAGTCAAGGTGTTTTTCACAGCCCCCTCAGGGA	2189	
DB	1847	AGCGTGTGTTTTTAAATACAGACAAGCAAGTCAAGGTGTTTTTCACAGCCCCCTCAGGGA	1906	
QY	2190	AGGGACGAGGCTCTCCGACAGGTCTCTGGGTGCACTCTCTCTGTTGGAGCTTTTACCT	2249	
DB	1907	AGGGACGAGGCTCTCCGACAGGTCTCTGGGTGCACTCTCTCTGTTGGAGCTTTTACCT	1966	
QY	2250	CTGAGTGAGACCTTCCACAGAGCCCCGGGGCGCGAGCCGCTCTCTGGTGAGGCTGG	2309	

QY 1436 GCGAGCCAGGAGCCCAACAGCCCTGGGGATGACACCCCTCAGCTCCGTGAGCTGACGA 1495
DB 1109 GCGAGCCAGGAGCCCAACAGCCCTGGGGATGACACCCCTCAGCTCCGTGAGCTGACGA 1168
QY 1496 CAGAGTCCAGGATTAGCTGTCCTCTGCAAGGAGCCAGCCCTGTCACCTGCTGCT 1555
DB 1169 CAGT---CAGGATTAGCTGTCCTCTGCAAGGAGCCAGCCCTGTCACCTGCTGCT 1224
QY 1556 TCCAGCCATGCCCCGAGAGCGGAGCGCGAGCAGGA-CGCGGCTGTCGCCCCCTCAG 1614
DB 1225 T-CAGCCATGCCCCGAGAGCGGAGCGCGAGCAGGA-CGCGGCTGTCGCCCCCTCAG 1283
QY 1615 CA 1616
DB 1284 CA 1285

RESULT 4
US-10-094-749-160
; Sequence 160, Application US/10094749
; Publication No. US20030219741A1
; GENERAL INFORMATION:
; APPLICANT: ISOGAI, TAKAO
; APPLICANT: SUGIYAMA, TOMOYASU
; APPLICANT: OTSUKI, TETSUJI
; APPLICANT: WAKAMATSU, AI
; APPLICANT: SATO, HIROYUKI
; APPLICANT: ISHII, SHIZUKO
; APPLICANT: YAMAMOTO, JUN-ICHI
; APPLICANT: ISONO, YUUKO
; APPLICANT: HIO, YURI
; APPLICANT: OTSUKA, KAORU
; APPLICANT: NAGAI, KEIICHI
; APPLICANT: IRIE, RYOTARO
; APPLICANT: TAMECHIKA, ICHIRO
; APPLICANT: SEKI, NAOHICO
; APPLICANT: YOSHIKAWA, TSUTOMU
; APPLICANT: OTSUKA, MOTOKYUKI
; APPLICANT: NAGAHARI, KENJI
; APPLICANT: MASUHO, YASUHIKO
; TITLE OF INVENTION: NOVEL FULL-LENGTH cDNA
; FILE REFERENCE: 084335/0160
; CURRENT APPLICATION NUMBER: US/10/094, 749
; CURRENT FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/350,435
; PRIOR FILING DATE: 2002-01-24
; PRIOR APPLICATION NUMBER: JP 2001-328381
; PRIOR FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 3381
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 160
; LENGTH: 2186
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-094-749-160

Query Match 32.7%; Score 876.2; DB 16; Length 2186;
Best Local Similarity 99.4%; Pred. No. 7.1e-233;
Matches 890; Conservative 0; Mismatches 3; Indels 2; Gaps 1;
QY 1772 AGAATTACCTGGGACAGAGGTTTGACATGCGAAACATGTTGACCGAGAGCCCTGCTG 1831
DB 671 AGAATTACCTGGGACAGAGGTTTGACATGCGAAACATGTTGACCGAGAGCCCTGCTG 730
QY 1832 CTCTCCAGCGGGAGTGTCTGCTGCTGATTACAGAGTCACGGGAGACACCGTTCTGT 1891
DB 731 CTCTCCAGCGGGAGTGTCTGCTGCTGATTACAGAGTCACGGGAGACACCGTTCTGT 790
QY 1892 GTTACTGCTGGGCTCGGAGCTTCGCTGAGCTGACCTATCAGTACGCAACATTC 1951
DB 791 GTTACTGCTGGGCTCGGAGCTTCGCTGAGCTGACCTATCAGTACGCAACATTC 850
QY 1952 CTGCTCCGAGTTGCCAGTGGCCGTAACATCCCGTCTGACTGCTACTGGGGCCGTAAC 2011

DB 851 CTGCTCCGAGTTCCAGTGGCCGTAACATCCCGTCTGACTGCTACTGGGGCCGTAAC 910
QY 2012 GCGGACCTCAGTGAAGCTCACACGCCATGAATTCATATCATATCTGTGAACAGACAA 2071
DB 911 GCGGACCTCAGTGAAGCTCACACGCCATGAATTCATATCATATCTGTGAACAGACAA 970
QY 2072 GGTCAAAAATAAGCATCCAGAGCCCTGAGAGCTTTTCAGCACTGGAGGTGAAGAG 2131
DB 971 GGTCAAAAATAAGCATCCAGAGCCCTGAGAGCTTTTCAGCACTGGAGGTGAAGAG 1030
QY 2132 CGTGTTTTTAAATACAGAGCAAGCTCAAGGTGTTTTTCAGAGCCCTCGAGGGAAG 2191
DB 1031 CGTGTTTTTAAATACAGAGCAAGCTCAAGGTGTTTTTCAGAGCCCTCGAGGGAAG 1090
QY 2192 GSAAGCGGGTCTCCGACAGGTGCTCTGGGGTGAATCTTCTGTGGAGCTTTTACCTCT 2251
DB 1091 GSAAGCGGGTCTCCGACAGGTGCTCTGGGGTGAATCTTCTGTGGAG- -TTTACCTCT 1148
QY 2252 GAGTGAGACCTCCCGACAGAGCCCGGGGGCGCAGCCCGCTCTGCTGAGCGCTGGGC 2311
DB 1149 GAGTGAGACCTCCCGACAGAGCCCGGGGGCGCAGCCCGCTCTGCTGAGCGCTGGGC 1208
QY 2312 AGGGCTCTGTGGCATCAGCAGCAGAGAGCAAGAGCTTTCTGTAACTGCGGCGCTCCCG 2371
DB 1209 AGGGCTCTGTGGCATCAGCAGCAGAGAGCAAGAGCTTTCTGTAACTGCGGCGCTCCCG 1269
QY 2372 CCGAGAGGGGAGTTTGTCTCTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGTC 2431
DB 1269 CCGAGAGGGGAGTTTGTCTCTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGTC 1328
QY 2432 TGTTTTCAGGAAAAGTTTCAAGGGAGAGGCAAGTTTATCAAAAACATTTGTTTCAGGAG 2491
DB 1329 TGTTTTCAGGAAAAGTTTCAAGGGAGAGGCAAGTTTATCAAAAACATTTGTTTCAGGAG 1388
QY 2492 AAGGAGCATTAAGTTTACAGCTACAGCACTACACATATCTGCTGCGGAAACCA 2551
DB 1389 AAGGAGCATTAAGTTTACAGCTACAGCACTACACATATCTGCTGCGGAAACCA 1448
QY 2552 CAGCATTTTATCTATTTTATTTATAGGTTTGGTGTCTTATCTCTTAATAAGATTAA 2611
DB 1449 CAGCATTTTATCTATTTTATTTATAGGTTTGGTGTCTTATCTCTTAATAAGATTAA 1508
QY 2612 ATGTCACAACTGTAGCACAATAATAATTAATTAATTAATTAATTAATTAATTAATTA 2666
DB 1509 ATGTCACAACTGTAGCACAATAATAATTAATTAATTAATTAATTAATTAATTAATTA 1563

RESULT 5
US-09-764-864-483
; Sequence 483, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 483
; LENGTH: 693
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (11)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: SITE
; LOCATION: (13)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: SITE

LOCATION: (623)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: SITE
LOCATION: (640)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: SITE
LOCATION: (670)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: SITE
LOCATION: (687)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: SITE
LOCATION: (690)
OTHER INFORMATION: n equals a,t,g, or c
US-09-764-864-483

Query Match 20.0%; Score 536.6; DB 9; Length 693;
Best Local Similarity 92.5%; Pred. No. 1.6e-138;
Matches 608; Conservative 7; Mismatches 13; Indels 29; Gaps 4;
QY 1044 GGCCTGCATGACACGTTCTGCGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCT 1103
DB 14 GGCCTGCATGACACGTTCTGCGGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCT 73
QY 1104 GTGTCTACCTGCCCTGTCCTGCGGATCTGTAAACACACATCTCTCAACACCT 1163
DB 74 GTGTCTACCTGCCCTGTCCTGCGGATCTGTAAACACACATCTCTCAACACCT 133
QY 1164 CTTGAAGCATACCTCATCCAGCATCCAGACAGAGTCCGAGTGAAGAAGATGTGCAAG 1223
DB 134 CTTGAAGCATACCTCATCCAGCATCCAGACAGAGTCCGAGTGAAGAAGATGTGCAAG 193
QY 1224 TATGATGCCAGTAATAAATCACTCAAGACATGCTGAGCCCAAGTCAAGCGTCTTT 1283
DB 194 TATGATGCCAGTAATAAATCACTCAAGACATGCTGAGCCCAAGTCAAGCGTCTTT 253
QY 1284 TTCTGATGAAGAGGAGTTTCAAGAGCTGCTGAGCTGTGACAGTGTGACAGTGATC 1343
DB 254 TTCTGATGAAGAGGAGTTTCAAGAGCTGCTGAGCTGTGACAGTGTGACAGTGATC 313
QY 1344 CTCAGACATTAGCCAGCCATACGTCTGTGCGGAGTGTCTGAGTACAGAGCGAGC 1403
DB 314 CTCAGACATTAGCCAGCCATACGTCTGTGCGGAGTGTCTGAGTACAGAGCGAGC 373
QY 1404 GGGGAGCTTCCCTGCTCCAGCAGCCGAGGAGCCAGGAGCCCAAGGCGCTGG 1463
DB 374 GGGGAGCTTCCCTGCTCCAGCAGCCGAGGAGCCAGGAGCCCAAGGCGCTGG 433
QY 1464 GGATGCACCTCCAGCTCCGCTGACGCTGACGACAGTCCAGGATACGTGTGCGCTCT 1523
DB 434 GGATGCACCTCCAGCTCCGCTGACGCTGACGACAGTCCAGGATACGTGTGCGCTCT 489
QY 1524 GCAAGAGCCAGCCCTGTGACCTGTCTTCCAGCCCATGCCGAGCCGAGAGCGGA 1583
DB 490 GCAAGAGCCAGCCCTGTGACCTGTCTTCCAGCCCATGCCGAGCCGAGAGCGGA 548
QY 1584 GCGGAGCAGGACCCGCTGTGCGCCCTCAGCAGTGTGCGGTCTGCTGCTGAGCCCTTTCTG 1643
DB 549 -CGCGARCGAGACCCGCTGKGGCC-----TCAMCWTSTG 584
QY 1644 CCACTGTACTGGGGTGACCCGAGCCGCTGTACGCTGCTGCGCCGCTTTG 1700
DB 585 CCACCTGTACTGGGGTGACCCGAGCCGCTGTACGNTTGTGCGCCGCTTTGNG 641

RESULT 6
US-09-918-995-2180
Sequence 2180, Application US/09918995
Publication No. US20030073623A1
GENERAL INFORMATION:
APPLICANT: Hyseq, Inc.
TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED FROM VARIOUS CDNA LIBRARIES

FILE REFERENCE: 20411-756
CURRENT APPLICATION NUMBER: US/09/918,995
CURRENT FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: US/09/235,076
PRIOR FILING DATE: 1999-01-20
NUMBER OF SEQ ID NOS: 38054
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 2180
LENGTH: 476
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)...(476)
OTHER INFORMATION: n = A,T,C or G
US-09-918-995-2180

Query Match 14.7%; Score 394.4; DB 10; Length 476;
Best Local Similarity 96.7%; Pred. No. 5.5e-99;
Matches 413; Conservative 0; Mismatches 12; Indels 2; Gaps 1;
QY 2046 ATTCAATCATATCTGTGAACACAGAGGTTCAAAAACCTAAGCATCCAGAGCCCTGAGCA 2105
DB 52 ATTCAATCATATCTGTGAACACAGAGGTTCAAAAACCTAAGCATCCAGAGCCCTGAGCA 111
QY 2106 GCTTTTCAGCACTGGAGGTGAAGAGAGCGTGTGTTTAAATACAGACACAGCAAGCAAG 2165
DB 112 GCTTTTCAGCACTGGAGGTGAAGAGAGCGTGTGTTTAAATACAGACACAGCAAGCAAG 171
QY 2166 GTGTTTTTCAGCCCCCTGAGGGAAGGACGAGGCTCTCCGACAGGTGCTCTGGGGTGA 2225
DB 172 GTGTTTTTCAGCCCCCTGAGGGAAGGACGAGGCTCTCCGACAGGTGCTCTGGGGTGA 231
QY 2226 CTCTTCTGTGGAGCTTTTACCTCTGAGTGAAGACCTCCCGAGAGCCCGGGGGCGCA 2285
DB 232 CTCTTCTGTGGAGCT--TTTACCTCTGAGTGAAGACCTCCCGAGAGCCCGGGGGCGCA 289
QY 2286 GCCCGCCCTCTCTGAGGAGGCTGGGAGGCTCTGAGTGAAGACCTCCCGAGAGCCCGGGGGCGCA 2345
DB 290 GACCGCCCTCTCTGAGGAGGCTGGGAGGCTCTGAGTGAAGACCTCCCGAGAGCCCGGGGGCGCA 349
QY 2346 CTTTCTGTAAATGCGGCGCTCCCGAGAGGAGGCTCTGAGTGAAGACCTCCCGAGAGCCCGGGGGCGCA 2405
DB 350 CTTTCTGTAAATGCGGCGCTCCCGAGAGGAGGCTCTGAGTGAAGACCTCCCGAGAGCCCGGGGGCGCA 409
QY 2406 CCGAACTACAGTTAAAGCAGAGTCTGTTTTTTCAGGAAAGTTTCAAGGGAGAGGGCAA 2465
DB 410 CCGAACTACAGTTAAAGCAGAGTCTGTTTTTTCAGGAAAGTTTCAAGGGAGAGGGCTA 469
QY 2466 GTTTATC 2472
DB 470 GTTTATC 476

RESULT 7
US-09-764-864-322
Sequence 322, Application US/09764864
Patent No. US20020132753A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PZ23
CURRENT APPLICATION NUMBER: US/09/764,864
CURRENT FILING DATE: 2001-01-17
Prior application data removed - consult PALM or file wrapper
NUMBER OF SEQ ID NOS: 1792
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 322
LENGTH: 357
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE

```
/ LOCATION: (272)
/ OTHER INFORMATION: n equals a,t,g, or c
/ NAME/KEY: SITE
/ LOCATION: (300)
/ OTHER INFORMATION: n equals a,t,g, or c
US-09-764-864-322

Query Match      11.6%; Score 310.2; DB 9; Length 357;
Best Local Similarity 97.7%; Pred. No. 1.3e-75;
Matches 345; Conservative 0; Mismatches 5; Indels 3; Gaps 3;

QY 56 TCCGGGTTCCGGCGCGGGGGGATGTAATCCCGATGGAGCGCCCGGAGGAGGAGC 115
Db 5 TCCGGGTTCCGGCGCGGGGGGATGTAATCCCGATGGAGCGCCCGGAGGAGGAGC 64

QY 116 ACTCGCGCGCGCGAGCCCTGGGACCGCTCTCGCGCTCTCGCGCGCGGAGGAGGAGC 175
Db 65 ACTCGCGCGCGCGAGCCCTGGGACCGCTCTCGCGCTCTCGCGCGCGGAGGAGGAGC 124

QY 176 CCGAGTCTCTCTGAGGAGCGGGAGTGGACATCGGCGGAGGAGGAGGAGGAGC 235
Db 125 CCGAGTCTCTCTGAGGAGCGGGAGTGGACATCGGCGGAGGAGGAGGAGGAGC 184

QY 236 CTTCCCGGAGCAATAAATCTGGTCTCTGGAGATCACTGTAGAAATGTAGTGATGCAAAAT 295
Db 185 CTTCCCGGAGCAATAAATCTGGTCTCTGGAGATCACTGTAGAAATGTAGTGATGCAAAAT 244

QY 296 CAGGTGAGTGCAGCTGAGGAGTACCAGCACAGTGGAGAGTAAAGAGTGAAG 355
Db 245 CAGGTGAGTGCAGCTGAGGAGTACCAGCACAGTGGAGAGTAAAGAGTGAAG 304

QY 356 TTG-TTAAAGAGCAGACATGCC-TTTACAGACT-GGGGATGTCATCTACTTG 405
Db 305 TTGTTTAAAGAACAGACATGCC-TTTACAGACTGGGGAGTGTCTACTTG 357

RESULT 8
US-09-918-995-13662
; Sequence 13662, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE OF INVENTION: FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 13662
; LENGTH: 449
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)-(449)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-13662

Query Match      10.2%; Score 273.6; DB 10; Length 449;
Best Local Similarity 98.6%; Pred. No. 2.5e-65;
Matches 276; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2387 TTGCTCTTTGTACATTTTCGGAACCTACAGTTAAAGCAGAAGTCTCTTTTCAGGAAAG 2446
Db 34 TCGCTCTTTGTACATTTTCGGAACCTACAGTTAAAGCAGAAGTCTCTTTTCAGGAAAG 93

QY 2447 TTTCAAGGAGGAGGCGCAAGTTTATCAAAAATGTTTTCAGGAGAGGAGGAGGATAGTT 2506
Db 94 TTTCAAGGAGGAGGCGCAAGTTTATCAAAAATGTTTTCAGGAGAGGAGGAGGATAGTT 153
```

```
QY 2507 TACAGCCTACAGGACGTACACAATATCCTGCTGGGAAAAACACAGCATTTTATCTAT 2566
Db 154 TACAGCCTACAGGACGTACACAATATCCTGCTGGGAAAAACACAGCATTTTATCTAT 213
QY 2567 TTTTATTTTAAATAGGTTTGGTCTTATCTCTAATAAGATTTAAATGTCAAACTGTA 2626
Db 214 TTTTATTTTAAATAGGTTTGGTCTTATCTCTAATAAGATTTAAATGTCAAACTGTA 273
QY 2627 GCACAAATAAATAATTTTATATTTTACAAATTTGACAAAA 2666
Db 274 GCACAAATAAATAATTTTATATTTTACAAATTTGACTAAAA 313

RESULT 9
US-09-764-864-323
; Sequence 323, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 323
; LENGTH: 354
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (289)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: SITE
; LOCATION: (313)
; OTHER INFORMATION: n equals a,t,g, or c
US-09-764-864-323

Query Match      9.6%; Score 256.4; DB 9; Length 354;
Best Local Similarity 93.3%; Pred. No. 1.3e-60;
Matches 266; Conservative 1; Mismatches 18; Indels 0; Gaps 0;

QY 221 GAGGTTGCGACCTTCTCCCGCAGCAATAAATGCTCTGAGATCACTGTAGATTG 280
Db 27 GAGATAAGGGACCTGACTTCCCGCAATAAATCTGGTCTCTGAGATCACTGTAGATTG 86
QY 281 TAGTGGATGAAAAATCAGGTGACACTGGAAGATACAGCACAGTGGAGACAGTGA 340
Db 87 TAGTGGATGAAAAATCAGGTGACACTGGAAGATACAGCACAGTGGAGACAGTGA 146
QY 341 TTAACAGCTGAAGTTGTTAAGAGCAGACATGCCCTTTACAGACTGGGGATGTCATCT 400
Db 147 TTAACAGCTGAAGTTGTTAAGAGCAGACATGCCCTTTACAGACTGGGGATGTCATCT 206
QY 401 ACTTGGTGTACAGGAAGATGAACCGGAAACACCACTGGCATACCTCTATGAATCTTAA 460
Db 207 ACTTGGTGTACAGGAAGATGAACCGGAAACACCACTGGCATACCTCTATGAATCTTAA 266
QY 461 GTGAAGAGCAGGATCAGACAGATCTCTTTGAGCTAACAGG 505
Db 267 GTGAAGAGCAGGATCAGACAGATCTCTTTTGATACCTCAGG 311

RESULT 10
US-09-764-864-742
; Sequence 742, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
```

; CURRENT FILING DATE: 2001-01-17
 ; Prior application data removed - consult PALM or file wrapper
 ; NUMBER OF SEQ ID NOS: 1792
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 742
 ; LENGTH: 354
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: SITE
 ; LOCATION: (289)
 ; OTHER INFORMATION: n equals a,t,g, or c
 ; NAME/KEY: SITE
 ; LOCATION: (313)
 ; OTHER INFORMATION: n equals a,t,g, or c
 ; US-09-764-864-742

Query Match 9.6%; Score 256.4; DB 9; Length 354;
 Best Local Similarity 93.3%; Pred. No. 1.3e-60;
 Matches 266; Conservative 1; Mismatches 18; Indels 0; Gaps 0;
 QY 221 GAGGTGGACCTTCCTCCCGCAATAACTGGTCTCTGGAGATCACTAGAAATG 280
 DB 27 GAGATAAGGGACCTGACTTCCCGCAATAACTGGTCTCTGGAGATCACTAGAAATG 86
 QY 281 TAGTGGATGAAAAATCAGGTGACGTGACACTGGAAGATACACGACAGTGGAAACAGTGA 340
 DB 87 TAGTGGATGAAAAATCAGGTGACGTGACACTGGAAGATACACGACAGTGGAAACAGTGA 146
 QY 341 TTAACAGCTGAAGGTTGTTAAGAGCAGACATGCCCTTTACAGATCGGGATGCTACT 400
 DB 147 TTAACAGCTGAAGGTTGTTAAGAGCAGACATGCCCTTTACAGATCGGGATGCTACT 206
 QY 401 ACTTGGTGTACAGGAAGAATGAACCGGAACACACGTCGTCATACCTCTATGAATCTTTAA 460
 DB 207 ACTTGGTGTACAGGAAGAATGAACCGGAACACACGTCGTCATACCTCTATGAATCTTTAA 266
 QY 461 GTGAAGACGACGATACACAGATCCTTTGAGCTACAAGG 505
 DB 267 GTGAAGACGACGATACACAGATCCTTTGAGCTACAAGG 311

RESULT 11
 US-09-908-975-6220
 ; Sequence 6220, Application US/09908975
 ; Publication No. US20030165843A1
 ; GENERAL INFORMATION:
 ; APPLICANT: SHOSHAN, Avi
 ; APPLICANT: WASSERMAN, Alon
 ; APPLICANT: MINTZ, Eli
 ; APPLICANT: MINTZ, Liat
 ; APPLICANT: FAIGLER, Simchon
 ; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
 ; FILE REFERENCE: 36688-0005
 ; CURRENT APPLICATION NUMBER: US/09/908,975
 ; CURRENT FILING DATE: 2001-07-20
 ; PRIOR APPLICATION NUMBER: US 60/287,724
 ; PRIOR FILING DATE: 2001-05-02
 ; PRIOR APPLICATION NUMBER: US 60/221,607
 ; PRIOR FILING DATE: 2000-07-28
 ; NUMBER OF SEQ ID NOS: 32337
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 6220
 ; LENGTH: 60
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-09-908-975-6220

Query Match 2.2%; Score 60; DB 10; Length 60;
 Best Local Similarity 100.0%; Pred. No. 2.3e-06;
 Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1843 GGAGTGTCTTCTGCTGTGATTACAGAGTCACGGGAGACACCGTCTCTGTGTTACTGCTGT 1902
 DB 1 GGAGTGTCTTCTGCTGTGATTACAGAGTCACGGGAGACACCGTCTCTGTGTTACTGCTGT 60
 RESULT 12
 US-10-424-599-95539
 ; Sequence 95539, Application US/10424599
 ; Publication No. US20040031072A1
 ; GENERAL INFORMATION:
 ; APPLICANT: La Rosa, Thomas J
 ; APPLICANT: Kovalic, David K
 ; APPLICANT: Zhou, Yihua
 ; APPLICANT: Cao, Yongwei
 ; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
 ; FILE REFERENCE: 38-21(53223)B
 ; CURRENT APPLICATION NUMBER: US/10/424,599
 ; CURRENT FILING DATE: 2003-04-28
 ; NUMBER OF SEQ ID NOS: 285684
 ; SEQ ID NO 95539
 ; LENGTH: 1255
 ; TYPE: DNA
 ; ORGANISM: Glycine max
 ; FEATURE:
 ; NAME/KEY: unsure
 ; LOCATION: (1)-(1255)
 ; OTHER INFORMATION: unsure at all n locations
 ; OTHER INFORMATION: Clone ID: PAT_MRT3847_57283C.1
 ; US-10-424-599-95539

Query Match 1.9%; Score 51.4; DB 13; Length 1255;
 Best Local Similarity 57.0%; Pred. No. 0.0047;
 Matches 94; Conservative 0; Mismatches 71; Indels 0; Gaps 0;
 QY 2515 ACAGGCGTACACAAATCTCTGCTGGGAAACACACAGCATTTTACTATTTTATT 2574
 DB 858 ACATGGTGGAACTTTAACTTGGCGTTGTAATAAGAACCTTTGATCTCTATTTTC 917
 QY 2575 TTAATAGTTTGTGCTTATCTTCTAATAAGATTTTAAATGTCAAACTGTAGCAAAAT 2634
 DB 918 TTGCTAGTAATAGGATGTTTACTTCTAAAAAATAAAAAAAAAAAAAAAAAAAAA 977
 QY 2635 AATATATTTTAAATTTACAAATTCACAAATAAAAAAAAAAAAAAAAAAAAA 2679
 DB 978 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1022

RESULT 13
 US-09-814-353-18006
 ; Sequence 18006, Application US/09814353
 ; Publication No. US20030165831A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Lee, John
 ; APPLICANT: Thompson, Pamela
 ; APPLICANT: Lillie, James
 ; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR
 ; FILE REFERENCE: MRL-0068
 ; CURRENT APPLICATION NUMBER: US/09/814,353
 ; CURRENT FILING DATE: 2001-03-21
 ; PRIOR APPLICATION NUMBER: US 60/191,031
 ; PRIOR FILING DATE: 2000-03-21
 ; PRIOR APPLICATION NUMBER: US 60/207,124
 ; PRIOR FILING DATE: 2000-05-25
 ; PRIOR APPLICATION NUMBER: US 60/211,940
 ; PRIOR FILING DATE: 2000-06-15
 ; PRIOR APPLICATION NUMBER: US 60/216,820
 ; PRIOR FILING DATE: 2000-07-07
 ; PRIOR APPLICATION NUMBER: US 60/220,661
 ; PRIOR FILING DATE: 2000-07-25

```

; PRIOR APPLICATION NUMBER: US 60/257,672
; PRIOR FILING DATE: 2000-12-21
; NUMBER OF SEQ ID NOS: 22037
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 18006
; LENGTH: 383
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-814-353-18006

Query Match      1.9%; Score 51; DB 10; Length 383;
Best Local Similarity 63.4%; Pred. No. 0.0027;
Matches 78; Conservative 0; Mismatches 45; Indels 0; Gaps 0;

QY 2557 TTTTATCTATTTTATTTTAAATAGGTTTGGTCTTATCTTCTAATAAGATTAAATGTC 2616
    |||||
Db 116 TTTTATCTATTTTATTTTAAATAGGTTTGGTCTTATCTTCTAATAAGATTAAATGTC 175
    |||||

QY 2617 ACAAACTGTAGCACAATAATAATAATTAATAATTTACAATTCACAAAAAATAAAAAA 2676
    |||||
Db 176 AAAAAAATAAAAAAATAATAATAATAATAATAATAATAATAATAATAATAATAATAA 235
    |||||

QY 2677 AAA 2679
    |||
Db 236 AAA 238
    |||

RESULT 14
US-10-424-599-127666/c
; Sequence 127666, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 127666
; LENGTH: 411
; TYPE: DNA
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_86287C.1
US-10-424-599-127666

Query Match      1.9%; Score 51; DB 13; Length 411;
Best Local Similarity 63.4%; Pred. No. 0.0028;
Matches 78; Conservative 0; Mismatches 45; Indels 0; Gaps 0;

QY 2557 TTTTATCTATTTTATTTTAAATAGGTTTGGTCTTATCTTCTAATAAGATTAAATGTC 2616
    |||||
Db 216 TCTTATCAATTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTAACTTTA 157
    |||||

QY 2617 ACAAACTGTAGCACAATAATAATAATTAATAATTTACAATTCACAAAAAATAAAAAA 2676
    |||||
Db 156 AAAAAATTTTAAAAAATAATAATAATAATAATAATAATAATAATAATAATAATAATAA 97
    |||||

QY 2677 AAA 2679
    |||
Db 96 AAA 94
    |||

RESULT 15
US-09-960-352-3525/c
; Sequence 3525, Application US/09960352
; Patent No. US20020137139A1
; GENERAL INFORMATION:
; APPLICANT: Warren, Wesley C.

```

```

; APPLICANT: Tao, Nengbing
; APPLICANT: Byatt, John C.
; APPLICANT: Machilagan, Nagappan
; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND
; FILE REFERENCE: MUSCLE AND FAT DEPOSITION
; FILE REFERENCE: 16511.006/37-21(10298)C
; CURRENT APPLICATION NUMBER: US/09/960,352
; CURRENT FILING DATE: 2001-09-24
; NUMBER OF SEQ ID NOS: 15112
; SEQ ID NO 3525
; LENGTH: 434
; TYPE: DNA
; ORGANISM: Bos taurus
; OTHER INFORMATION: Clone ID: 16-BOVMS1-023-Q1-E1-D11
US-09-960-352-3525

Query Match      1.8%; Score 49; DB 9; Length 434;
Best Local Similarity 55.6%; Pred. No. 0.011;
Matches 94; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 2511 GCCTACAGGACGTACACAATATCCTGTCTGGGAAACACACAGATTCTATTTT 2570
    |||||
Db 211 GCCTTTTGAACAGCCCAATTTTCCCAACCTGGGTTTACCCCTGCCCCTTTTGGCCCGTT 152
    |||||

QY 2571 TATTTTAAATAGTTTGGTCTTATCTTCTAATAAGATTAAATGTCAAAATCTAGCAC 2630
    |||||
Db 151 TGGTTTAAAGGTTTTTGTCTTTTGGCCAAAAAATAAAAAAATAAAAAAATAAAAAA 92
    |||||

QY 2631 AAATAATATAATTTATATAATTTTACAAATTTGACAAAAAATAAAAAAATAAAAAA 2679
    |||||
Db 91 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 43
    |||||

Search completed: May 15, 2004, 00:10:39
Job time : 1598 secs

```


REFERENCE
AUTHORS

3 Shibata, K., Itoh, M., Aizawa, K., Nagao, S., Sasaki, N., Carninci, P., Konno, H., Akiyama, J., Nishi, K., Kitsu, T., Taehiro, H., Itoh, M., Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watahiki, M., Yoneda, Y., Ishikawa, T., Oawa, K., Tanaka, T., Matsuura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A. and Hayashizaki, Y.
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multipillar sequencer
Genome Res. 10 (11), 1757-1771 (2000)

JOURNAL
MEDLINE
PUBMED
REFERENCE

AUTHORS

4 The RIKEN Genome Exploration Research Group Phase II Team and the FANTOM Consortium.
Functional annotation of a full-length mouse cDNA collection
Nature 409, 685-690 (2001)

JOURNAL
REFERENCE
AUTHORS

5 The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team.
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
Nature 420, 563-573 (2002)

JOURNAL
REFERENCE
AUTHORS

6 (bases 1 to 3146)
Adachi, J., Aizawa, K., Akimura, T., Arakawa, T., Bono, H., Carninci, P., Fukuda, S., Furuno, M., Hanagaki, T., Hara, A., Hashizume, W., Hayashida, K., Hayatsu, N., Hiramoto, K., Hiraoka, T., Hirozane, T., Hori, F., Imotani, K., Ishii, Y., Itoh, M., Kagawa, I., Kasukawa, T., Katoh, H., Kawai, J., Kojima, Y., Kondo, S., Konno, H., Kouda, M., Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Murata, M., Nakamura, M., Nishi, K., Nomura, K., Numazaki, R., Ohno, M., Ohsato, N., Okazaki, Y., Saito, R., Saitoh, H., Sakai, C., Sakai, K., Sakazume, N., Sano, H., Sasaki, D., Shibata, K., Shinagawa, A., Shiraki, T., Soabe, Y., Tagami, M., Tagawa, A., Takahashi, F., Takaki-Akahira, S., Takeda, Y., Tanaka, T., Tomaru, A., Toyota, T., Yasunishi, A., Muramatsu, M. and Hayashizaki, Y.
Direct Submission

JOURNAL
REFERENCE
AUTHORS

Submitted (16-APR-2002) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail: genome-res@sc.riken.go.jp, URL: <http://genome.gsc.riken.go.jp/>, Tel: 81-45-503-9222, Fax: 81-45-503-9216)
cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.
Please visit our web site for further details.
URL: <http://genome.gsc.riken.go.jp/>
URL: <http://fantom.gsc.riken.go.jp/>
Location/Qualifiers

FEATURES
source

1. 3146
/organism="Mus musculus"
/mol_type="mRNA"
/strain="CS7BL/6J"
/db_xref="FANTOM,DB:5730484M20"
/db_xref="MGI:2393804"
/db_xref="taxon:10090"
/clone="5730484M20"
/tissue_type="whole body"
/clone_lib="RIKEN full-length enriched mouse cDNA library"
/dev_stage="8 days embryo"
89. 2080
/note="unnamed protein product; putative similar to CELL CYCLE CHECKPOINT PROTEIN CHFR [Homo sapiens] (SPTK1/9NR4, evidence: FASTV, 81.7%id, 100%length, match=1989)"
/codon_start=1
/protein_id="BAC36912.1"
/db_xref="GI:26346522"

CDS

1. 3146
/organism="Mus musculus"
/mol_type="mRNA"
/strain="CS7BL/6J"
/db_xref="FANTOM,DB:5730484M20"
/db_xref="MGI:2393804"
/db_xref="taxon:10090"
/clone="5730484M20"
/tissue_type="whole body"
/clone_lib="RIKEN full-length enriched mouse cDNA library"
/dev_stage="8 days embryo"
89. 2080
/note="unnamed protein product; putative similar to CELL CYCLE CHECKPOINT PROTEIN CHFR [Homo sapiens] (SPTK1/9NR4, evidence: FASTV, 81.7%id, 100%length, match=1989)"
/codon_start=1
/protein_id="BAC36912.1"
/db_xref="GI:26346522"

/translation="MELHGEQPPPPQEPWAGPGLLRLLRGAEDRDEPQILLKRWETIGRR
GCLSPFNKLVSGDHCKLTVDEISGEVTEIDTSTNGTVINKLVQVKKQYELHSGDI
IYLVIRKNEPHVAYLYESLQSLQTSLEANKENFMHVTKQSCGGQDQVVP
LLSPMAQCLLEPQSTSDLLPTASTSTSELTSPACKHSSSGPNTSISPKGR
SSLVANGELSSLPVQDEASPSLSEKHSELEPAKKMGKGDGLDNLQLLVSGQ
RGNACTSSBVDASVKPKMBETLTCIICQLLDHCVSLQPCMTFFCACTSGWNER
SLLCPTCRVERIKCNHILNVLVEALVLPKPSRSDVSMARNTKIDMLQPK
VRSFDESSSLLLELDVPSSESDISQYIVCQCEPEYRQVQSLPCVPSSEL
GATLALGGEAPSTASLPTAPYMCPLQSHACTCCFPMPDRARESDRPAPOQ
CAVLQPFCHLYMGCTKTCFCLAPFELNLDKCLDGLVNNNNYESDILKYLATR
GLTVTSVLTSLALQGVFMLSDRYITNGTVLCYCCGLRSFRLTYQYRNPASEL
FVTWTRPDCYWGRCRTQVYAHAMKFNHICEQTRFN"

polyA_signal

/notes="putative"

polyA_site

/notes="putative"

ORIGIN

Query Match 54.7%; Score 1464.6; DB 11; Length 3146;
Best Local Similarity 74.5%; Pred. No. 2.3e-233;
Matches 2007; Conservative 0; Mismatches 634; Indels 52; Gaps 11;
QY 18 CCGCAATGTCTCTTTGACAGCGCGCGCGCG-----CAGCCGGTTCCGGTTCCGGCGG 71
DB 10 CCGAGATGTCCTTTGACAGCGGTGGCGGACTGTGAAGCCCGTTCCGGATCCGGCAG 69
QY 72 GCGCGGATGTGAATCCCGATGAGCGCGCGGAGGAGCAAGCAGTCCGCCCGCGCA 131
DB 70 GCGTGGGATGTGAGTCTTATGAGCTACACGCGGAGAGCAGCGCGCGCGCGCAGGA 129
QY 132 GCCCTGGGAGCGCTCTCTGCTGGCGCGGAGGAGGCGCGCAGCTCTCTCTGAG 191
DB 130 ACCCTGGGAGCGCTCTCTGCTAGCGCGGAGGAGGAGCGCGCAGATCTCTTTG 189
QY 192 GAGCGGATGAGCAATCGCGCGGAGAGAGGTTGCGACCTTTCTTCCCGCAGCAATAA 251
DB 190 GAAACCGAGTGGACCATCGGAGGAGGAGGCGCTGTGACCTCTCTTCCCGCAGCAATAA 249
QY 252 ACTGCTCTCGGAGATCATCTGTAGATTTAGTGGATGAAATCAGGTGAGTGCACACT 311
DB 250 ACTGCTCTCGGAGATCATCTGTAGATTTAGTGGATGAAATCAGGTGAGTGCACACT 309
QY 312 GGAAGTACCGCAGCAGTGGACAGTGAATTAACAGCTGAAGTGTGAAGAGCAGAC 371
DB 310 GGAAGTACCGCAGCAGTGGACAGTGAATTAACAGCTGAAGTGTGAAGAGCAGAC 369
QY 372 ATGCGCTTTACAGATGCGGAGTGTATCTATCTGTTGTACAGGAAGATGAACCGCAACA 431
DB 370 TTACCTTTACATAGCGGAGTATCATCTATTGTTGTACAGGAAGATGAGCCAGACA 429
QY 432 CAACGTGGCATACCTCTATGAATCTTTAAGTGAAGAGCAGCATGACACAGATCTCTT 491
DB 430 CAATGTGGCATACCTCTATGAATCTTTAAGTGGCAACAGAGCTTAACATCAGACTCCCT 489
QY 492 TGAAGCTTAACAGGAAGATGTTCTCATGGGACCAAGATACCTCAGGTGCGAGGTGCGAGG 551
DB 490 TGAAGCTTAACAGGAAGATGTTCTCATGTGACCAAGATGCT-----CAGGTCCAGG 543
QY 552 GCGAGGGCGGATCCCGGGTCCCTCCGTCGTCGCGCGCGCAGTCAAGTGTGCTTGAGGA 611
DB 544 GCGAGGTGATGATCCCGGTTCCCTATTTGTCACCCATGGCTCAGACATGCTTAGAGGA 603
QY 612 ACCACAGCCATCAACATGACGCTCAGACCTCTTCCCGCAGCAGCTCGGCTCTTCCACCGGA 671
DB 604 ACCACAGCCATCAACATGACGCTCAGACCTCTTCCCGCAGCAGCTCTTCCCTTCTACGGA 663
QY 672 GCC-----TTCTCTGCGAGGCGGAGGTTCTTCCAGTGTGGTGTGGGGTGGTGG 725
DB 664 GCGAGAGTGAACCTCTGCGAGGCAAAAGCATTTCTTCTAGCTCTGAGCAGTGGAAACACAAG 723
QY 726 CATCTCCCTAAAGGAAGTGGTCCCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCTC 785
DB 724 CATCTCCCTAAAGGAAGTGGTTCCTTCTGTTGCAATGCGCAACTCTCTAGCTTTCTCC 783

QY 786 AGCTCTCCAGACAGAAAGACTGCGTCTTTTCGTGCTTGGAAACCCAGGATCAGAGGA 845
Db 784 AGTTTTCCAGACAAAGA---AGCATCTCTTTTCTTGTGCGAAAGTAAGACCATGAGGA 840
QY 846 TTTGGAGCCGCTGAAGAAGAAATGAGAGAGATGGGACCTTGACCTGAACGGCGAGTT 905
Db 841 ATTGGAGCCTGCCAAAAAAGATGAAGAGAGATGGGAACTTGACACGAACTCCAGTT 900
QY 906 GTTGGTCGACAAACCCGCTAGAAATGCCAAACCGTCCACGAGGAGCTCAGAGAGCGGC 965
Db 901 ATTAGTTTCAGGCGAGCTGGAAATGCCAAACCTCAAGTGAAGATGTCAAGAGATGCCTC 960
QY 966 TGGAGAGCAGACAGATGGAGAGAGCTGCATGCTATCTGCGAGGACCTGCTGCA 1025
Db 961 TGTGAAGCCAGACAGATGAGAGAGACATAACCTGTATCATCTGCCAGAGACCTTCTGCA 1020
QY 1026 CGACTGCGTGAAGTTTCAGCCCTGCGATGACACAGTTCTCGCGGCTTGTACTCGGGCTG 1085
Db 1021 CGATTGTGTGAGTTTCGAGCCTTGATGACACATTTTGTGGGCTTGTACTCTGGTTG 1080
QY 1086 GATGGAGCGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1145
Db 1081 GATGGAGCGTTCTCTGTGCGCTTACCTGCCGATGTCAGTGGAGCGAATTGCAAAA 1140
QY 1146 CCACATCTCAACAACTCGTGAAGCATACCTCATCCAGCATCCAGACAGAGTGGCAG 1205
Db 1141 CCACATCTCAACAACTAGTGAAGCATACCTTATCCAGCACCAGATAAAGTGGCAG 1200
QY 1206 TGAAGAGATGTGCAAGATGATGATGCGAGGAATAAAATCACTCAAGATATGCTGCAACC 1265
Db 1201 TGAAGAGATGTGAGAAGTATGATGCAAGGAATAAAATCACTCAAGATATGCTGCAACC 1260
QY 1266 CAAAGTCAGCGCTCTTTCTCATGAAGAGGAGTTCAGAGAGCTCTGCGAGCTGTC 1325
Db 1261 CAAAGTCAGAGGCTCTTCTCATGAAGAGGAGGATTCAGAGAGCTCTGAGAGCTGTC 1320
QY 1326 AGACGTTGACAGTGAAGTCTCAGACATTAAGCCAGCCATAGCTGCTGCGGCGAGTCC 1385
Db 1321 TGATGTCGACAGTGAATCTCTCAGATATCAGTCAAGCCATATGCTGCGAGAGTCTCC 1380
QY 1386 TGAGTACAGAGCAGCGCGCAGCTCCCACTGCCAGCACCCGAGGCGGAGCCAGG 1445
Db 1381 TGAATACAGAGCAAGCGGTGAGTCTCTTCTTCCAGAGTCCAGAGAGTGAAGTGGG 1440
QY 1446 AGCCACAGCGCCTGGGGGATGCACTCCAGTCCGTCAGCTGACGACAGCAGTCCA 1505
Db 1441 AGCTACACTGGCCCTTGTGGGAGGACCTTCAACATCTGCCAGCTTGCCAAACAGCCCC 1500
QY 1506 GGATTAAGTGTGCGCTCTGCAAGAGACCCAGCCCTGTGCACTGCTGCTTCCAGCCCAT 1565
Db 1501 GGATTAAGTGTGCGCTCTTCAAGAGAGCCATGCAATATGCACTGCTGCTTCCAGCCAT 1560
QY 1566 GCCCGACCGGAGAGCGGAGCGGAGGACCCGCGTGTGCGCCCTCAGCAGTGTGCGGT 1625
Db 1561 GCCTGACCGGAGAGCTGAACGGGAGCAGGATCCCGGCTGCCCTCAGCAGTGTGCGGT 1620
QY 1626 CTGCTCGAGCTTTCTGCCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1685
Db 1621 GTGCTCGAGCCCTTCTGCCACCTGTACTGCGGCTGCGAGGAGCTGGCTGCTTTGCTG 1680
QY 1686 CCTGGCCCGCTTTGTGAGCTCAACCTGGGTGCAAGTGTCTGACGCGGTGCTGAACAA 1745
Db 1681 CTTGGCCCGCTTTGTGAGCTCAACCTGGGAGCAGTGTGATGGAGTGTGCTGAACAA 1740
QY 1746 CAACAGCTACGAGTACAGATCTCTGAAGAATTAACCTGGCAACAGAGGTTTGATGGAA 1805
Db 1741 TAACAATTAATCGGACATCTCTGAAGAATTAACCTGGCAACAGAGGTTTGATGGAA 1800
QY 1806 AAACATGTTGACAGAGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1865
Db 1801 AAGTGTGTGACAGAGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1860

QY 1866 CAGAGTCAGCGGAGACACCGTTCTGTGTTACTGCTGTGGCTCGCAGCTTCGTGAGCT 1925
Db 1861 CAGAACTACTGGAAATACTGTGCTGTGTTACTGCTGTGGTCTCGGTAGCTTCGAGAGCT 1920
QY 1926 GACCTATCAGTATCGGAGAACATTTCTGTTTCGAGTTCGAGTTCGCGGTAAACATCCG 1985
Db 1921 GACCTACAGTATCGTCAAGAACATTTCTGTTTCGAGTTCGCGGTAAACATCCG 1980
QY 1986 TCCTGACTGCTACTGCGGCGGTAACTCGCCACTCAGGTGAAGCTCACCACGCCATGAA 2045
Db 1981 TCCTGACTGCTACTGCGGCGGTAACTCGCCACTCAGGTGAAGCTCACCATGCAATGAA 2040
QY 2046 ATTCAATCATATCTGTGAACAGACAGAGTTCAAAATTAAGCATCCAGAGCCCTGAGCA 2105
Db 2041 ATTCAATCATATCTGTGAGCAAAACAAGTTCAAGAACTGAATATTGGAAGAGACACGTGA 2100
QY 2106 GCTTTCAGCACTGAGGTGAAGAGAGCGTGTGTTTAAATATACAGAGACAGACGTCAAG 2165
Db 2101 AACAGTTACAGAGCA-CAGGAGGCAATGTTTTTAAAGGCCCATACAAACATTTGAG 2159
QY 2166 GTGTTTTTACAGTTTTCCCTACGACACTGCGGGTCTGCTCAGGCACTGGGGTGTGG 2219
Db 2160 GGCATTTTACAGTTTTTCCCTACGACACTGCGGGTCTGCTCAGGCACTGGGGTGTGG 2219
QY 2226 CTCTTCGTGAGAGCTTTTACCTCTGAGTGAAGACCTTCCACAGAGCCCGGGGGCGCA 2285
Db 2220 ATTTTCCCTTTGTGAGAGCTCATCTGTCAGTGACACACACACCGTGCCTCAGTAAC-CT 2278
QY 2286 GCCCGCCCTCTGCTGAGCGCTGGGAGGCTCGTGTGGTGGCATCAGCAGCAGAG- 2339
Db 2279 GGGAGGCTCTCTGCCACACACAGCCTTCTAGTGGTGAAGAGGATCAGTAGACTGAGTT 2338
QY 2340 -----ACGAAGCCCTTCTGTAAACATCGCGCGCTCCCGCAGAGTCTGTTTTCAGGAAAG 2446
Db 2339 CTCCCTCCCTCCCACTGGACCGCTCTCCCTCTGCTGTGAGGAGCTGACAGTGCAGGT 2398
QY 2387 TTGCTCTTTTCTACATTTTCCGAACTACAGTTAAAGCAGAGTCTGTTTTCAGGAAAG 2446
Db 2389 TTGACTTTTGTGATCTTTT-----CTACCTTGTACCTTGTACTGTTAAATGGGAG 2452
QY 2447 TTTCAAGGAGAGAGGCGAAGTTTATCAAAACATGTTTTCAGGAG--AAGGAGCATTAAG 2504
Db 2453 CTCATAGAAAGTTGTCAGCTGTGTGAGCGCTTCTCCGGAAGGAAGAGCATACG 2512
QY 2505 TTTACAGCTACAGAGCT-ACACATATCTGCTGCTGGGAAACACACAGATTTTATC 2563
Db 2513 TTTACAGCTCCAGGCGGATACATAGTAGTCTCTCTCTGGAAGACACAGCCTTTTGA 2572
QY 2564 TATTTTTTATTTTATAGTTTGGTCTTA-TCTTCTAATAAGATTTTAAATGTCAAAAC 2622
Db 2573 TATTTTTTATTTAATAAGTTTGGTCTTAGTCTTGTAAATAAGATTTTAAATATTAAC 2632
QY 2623 TGTAGCAAAATATATATTTTATTTTAAATTTGACAAATTTGACTAAATATTAGGAATA 2675
Db 2633 TGTAGCAAAATATATATTTTATTTTAAATTTGACAAATTTGACTAAATATTAGGAATA 2685

RESULT 2
AK048930
LOCUS
DEFINITION
2876 bp mRNA linear HTC 20-SEP-2003
Mus musculus 0 day neonate cerebellum cDNA, RIKEN full-length
enriched library, clone: C230682M18 product: similar to CELL CYCLE
CHECKPOINT PROTEIN CHFR [Homo sapiens], full insert sequence.
AK048930
ACCESSION
AK048930.1 GI:26093209
VERSION
KEYWORDS
HTC; CAP trapper.
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1
Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning

Meth. Enzymol. 303, 19-44 (1999)

9279253
10349636

2
Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M., and Hayashizaki, Y. Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes Genome Res. 10 (10), 1617-1630 (2000)

3
20499374
11042159

3
Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P., Konno, H., Akiyama, J., Nishi, K., Kitsu, T., Tashiro, H., Itoh, M., Sumi, N., Iehi, Y., Nakamura, S., Hazama, M., Nishine, I., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwaka, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watahiki, M., Koneaki, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsuura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A., and Hayashizaki, Y. RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multiplexed capillary sequencer Genome Res. 10 (11), 1757-1771 (2000)

4
20530913
11076861

4
The RIKEN Genome Exploration Research Group Phase II Team and the FANTOM Consortium. Functional annotation of a full-length mouse cDNA collection Nature 409, 685-690 (2001)

5
The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs Nature 420, 563-573 (2002)

6
Nature 420, 563-573 (2002)

6
10 bases 1 to 2876)

6
Adachi, J., Aizawa, K., Akimura, T., Arakawa, T., Bono, H., Carninci, P., Fukuda, S., Furuno, M., Hanagaki, T., Hara, A., Hashizume, W., Hayashida, K., Hayatsu, N., Hiramoto, K., Hiraoka, T., Hirozane, T., Hori, F., Imotani, K., Iehi, Y., Itoh, M., Kagawa, I., Kasukawa, T., Kato, H., Kawai, J., Kojima, Y., Kondo, S., Konno, H., Kouda, M., Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Murata, M., Nakamura, M., Nishi, K., Nomura, K., Numazaki, R., Ohno, M., Ohsato, N., Okazaki, Y., Saito, R., Saitoh, H., Sakai, C., Sakai, K., Sakazume, N., Sano, H., Sasaki, D., Shibata, K., Shinagawa, A., Shiraki, T., Sogabe, Y., Tagami, M., Tagawa, A., Takahashi, F., Takaku-Akahira, S., Takada, Y., Tanaka, T., Tomaru, A., Toya, T., Yasunishi, A., Muramatsu, M., and Hayashizaki, Y. Direct Submission

7
Submitted (16-JUN-2001) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan [E-mail: genome-res@gsc.riken.go.jp, URL: http://genome.gsc.riken.go.jp/, Tel: 81-45-503-9222, Fax: 81-45-503-9216]

8
cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.

9
Please visit our web site for further details.
URL: http://genome.gsc.riken.go.jp/
URL: http://fantom.gsc.riken.go.jp/.
Location/Qualifiers

10
1. -2876
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="FANTOM_DB:C230082M18"
/db_xref="MGI:2416097"
/db_xref="taxon:10090"
/clone="C230082M18"

11
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

12
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

13
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

14
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

15
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

16
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

17
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

18
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

19
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

20
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

21
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

22
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

23
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

24
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

25
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

26
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

27
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

28
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

29
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

30
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

31
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

32
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

33
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

34
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

35
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

36
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

37
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

38
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

39
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

40
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

41
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

42
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

43
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

44
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

45
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

46
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

47
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

48
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

49
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

50
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

51
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

52
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

53
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

54
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

55
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

56
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

57
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

58
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

59
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

60
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

61
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

62
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

63
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

64
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

65
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

66
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

67
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

68
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

69
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

70
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

71
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

72
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

73
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

74
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

75
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

76
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

77
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

78
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

79
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

80
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

81
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

82
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

83
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

84
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

85
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

86
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

87
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

88
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

89
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

90
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

91
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

92
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

93
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

94
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

95
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

96
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

97
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

98
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

99
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

100
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

101
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

102
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

103
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS

104
JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS</

1107 TCCTACTCGCGCTGCTCCCGTGGAGGGATCTCTGTAATAAACCAATCCTCAACACCTCGT 1166
1281 CCCTACTCGCGGATGCTCCAGTGGAGCGGATTTGCAAAAACCAATCCTCAACACCTAGT 1340
1167 GGAGCATACCTCATCCAGCATCCAGACAGATCCAGTGGAGAGATGTCAGAGTAT 1226
1341 GGAAGCATACCTTATCCAGCACCCAGATAAAAGTCGAGTGAAGAAGATGTGAGAAGTAT 1400
1227 GGATGCCAGGAATAAATCACTCAAGACATGCTGCGAGCCCAAAAGTCAGGCGGTCTTTTC 1286
1401 GGATGCAAGGAATAAATCACTCAAGATATGCTGCAACCCAAAGTCAGGAGGTCTTTTC 1460
1287 TGATGAAGAAGGAGTTTCAGAGACCTGCTGGAGCTGTTCAGAGTTGACAGTGTGCTTC 1346
1461 TGATGAAGAGGAGTTTCAGAGACCTGCTAGAGCTGTTCGATGTGACAGTGAATCCTTC 1520
1347 AGACATTAGCCAGCATACCTGCTGCGCGAGTGTCTGAGTACAGAGGCGAGCGCGC 1406
1521 AGATATCAGTCAGCCATACATTGCTGCGACAGTGTCTGATACAGAGGCAAGCGGT 1580
1407 GCGAGCTCCCATGTCGCCAGCAACCGAGGCGAGCGAGAGGCCCAAGGCCCTGGGGGA 1466
1581 GCAGTCTCTTCTTCCCGAGTCCAGAGAGTGTGCTGGAGCTTACACTGCGCCCTTGGTG 1640
1467 TGACACCTCCAGCTCGCTGAGCGCTGAGCAGCAGTCCAGGATTCAGTGTGCTCCTGCA 1526
1641 GGAGGCACCTTCAACATCTCCAGCTTGCACAGCTGTGCCAGCCCGGATTCATGTGCCCTTCA 1700
1527 AGGAAGCCAGCGCTGTGCACTGCTGCTTCCAGCCCATGCTCCGAGCGGAGAGCGAGCG 1586
1701 AGGAAGCCATGCCATATGCACTGCTGCTTCCAGCTATGCTGCTGACCGGAGAGCTGAACG 1760
1587 CGAGCAGGACCGGGTGTGCGCCCTCAGCAGTGTGCGGTGCTGCTGAGCCCTTCTGCCA 1646
1761 GGAGCAGGATCCCGCGGTGCGCCCTCAGCAGTGTGCGGTGCTGCTGAGCCCTTCTGCCA 1820
1647 CTTGTACTGCGGCTGCAACCGGCTGCTACGGCTGCTGCGCCCGCTTTTGTGAGCT 1706
1821 CTTGTACTGCGGCTGCAACCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1880
1707 CAACCTGGGTGCAAGTGTGTGAGCGCGTGTGTAACAAACAAAGCTACAGTACAGTACAGAT 1766
1881 CAACCTGGGGAACAAGTGTGTGATGAGTGTGTAACAAATTAATTAATTAATTAATTAAT 1940
1767 CTTGAAGAAATACCTGCAACAGAGTGTGATGTAAGAAACATGTTGACCGAGAGCT 1826
1941 CTTGAAGAAATACCTGCAACAGAGTGTGATGTAAGAAAGTGTGTTGACAGAGTGT 2000
1827 CGTGGCTCTCCAGCGGGAGTGTCTGCTGTCTGATTACAGATCAAGGACACACCT 1886
2001 CTTGGCTCTCCAGCGAGTGTATTTATGCTGTCTGATTACAGATCACTGGAATACTGT 2060
1887 TCTGTGTACTGCTGCTGCTGCGAGCTTCCGTGAGCTGACCTATCAGTATCGGCAGAA 1946
2061 GCTGTGTACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2120
1947 CATTCCTGCTTCCAGTGTGCGAGTGTGCAATCCCGTCTGCTGCTGCTGCTGCTGCTGCTGCT 2006
2121 CATTCCTGCTTCCAGTGTGCGAGTGTGCAATCCCGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2180
2007 TAACCTGCGCACTCAGTGTGAAGTGTACAGCGCATGAATTCATCATATCTGTGAACA 2066
2181 TAACCTGCGCACTCAGTGTGAAGTGTACAGCGCATGAATTCATCATATCTGTGAGCA 2240
2067 GACAAGGTTCAAAAATCAAGCATCCAGAGCGCTTCCAGCAGCTTTCAGCATCTGGAGGTGA 2126
2241 AACAGGTTCAAGNACTGAATTTGGAGAGACACGTTGAACAGTTCAGAGCA-CAGGA 2299
2127 GAGAGCGTGTTTTAAATACAGACAAGCAGCTCAAGTGTGTTTTCAGAGCCCTGAG 2186
2300 GGCAATGTTTTAAAGAGGCCCATACAAACACTTGAAGGCGCATTTTACAGTTCCTTC 2359
2187 GGAAGGACGACGAGGTCTCCGACAGAGTGTCTCTGCGGTGACTCTCTCTGTGAGCTTTTAC 2246

2360 ACGCAGCACTGGGGTCTCTGGTCAGGCACTGGGGTGTGGATTTTCCCTTTTGTGGAGCTC 2419
2247 CCTCTGAGTGAAGCCCTCCCGCAGAGCCCGGGGCGCGCAGCCCGCTCTCTGTTGAGCGC 2306
2420 ATCTGCTAGTGAACACACACACCGTGCCTCCAGTAC-CTGGGAGGCTCTCTGCGCACACC 2478
2307 TGGGAGGAGCTGCTGGTGGCATCAGCAGCA- - - - -GACGAGCC 2347
2479 AGCCTTCTAGTGGGTGAAGAGGATCAGTACAGTCTCTCCCTCCCTCCACCTGGACC 2538
2348 TTTCTGTAACATGGGCGCTCCCGCAGAGGCGCAGTTTGTCTTTTGTGATACATTTTCC 2407
2539 GCTTCCCTCTGCTGCTGCTGAGGAGTGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2596
2408 GAACTACAGTTAAAGCAGAGTCTGTTTTTTCAGAAAGTTTTCAGGAGGAGGAGGCAAGT 2467
2597 ---CTACCTTGTACCTGATGTTGTTTAAATGCGAAGCTCATAGGAAAAAGTTGTCAGC 2652
2468 TATCAAAAAATGTTTTCAGGAG--RAGGAGCATAGTTTTCAGGCTCAGCCTCAGGAGC-TA 2524
2653 TGTGTCAGACCATCTCTCCGGAAGAAAGGAGCATAGCTTTTTCAGGCTCAGGAGTACA 2712
2525 CACAATATCTCTGCTGCTGGGAAACCAAGCATTTTATCTATTTTATTTTATTTTATTTTATTTT 2584
2713 TAGGATAGTCTCTCTGCTGCTGGAAGACACAGCCTTTTGTATATTTTATTTTATTTTATTTT 2772
2585 TGGTCTTATCTCTTAATAAGATTAAATGTCACAACTGTAGCACAATATATAATTT 2644
2773 TGGTCTTATCTCTTAATAAGATTAAATATTAATACTGTAGCACAATATATAATTT 2832
2645 ATAATTTTCAAAATGACAAAAA 2675
2833 ATAATTTTCAAAATGACTAAATTAGGATA 2863

AL539798 1201 bp mRNA linear EST 31-MAY-2003
AL539798 Homo sapiens FETAL BRAIN Homo sapiens cDNA clone
CS0DF031YA23 5-PRIME, mRNA sequence.
ACCESSION AL539798
VERSION AL539798.2 GI:31264361
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1201)
AUTHORS Li,W.B., Gruber,C., Jessee,J. and Polayes,D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On Feb 15, 2001 this sequence version replaced gi:12869349.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seque@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 6792.r For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DF031YA23&cluster=6792.r. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DF031YA23Q21.
Location/Qualifiers
1 .1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF031YA23"
/tissue_type="FETAL BRAIN"
/dev_stage="fetal"

FEATURES
source

/clone lib="Homo sapiens FETAL BRAIN"
/note="Organ: brain; Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."

ORIGIN		Query Match	34.3%; Score 919; DB 9; Length 1201;
		Best Local Similarity	96.8%; Pred. No. 1.1e-142;
		Matches	959; Conservative 9; Mismatches 19; Indels 4; Gaps 3;
QY	61	GTTCGGCGCGGGGGGGGATGTGAATCCCGATGGAGCGGCCGAGAGGCAAGCAGTCG	120
DB	67	GTTCGGCGCGGGGGGGGATGTGAATCCCGATGGAGCGGCCGAGAGGCAAGCAGTCG	126
QY	121	CGCCGCCCGCAGCCCTGGGGAGCGCTCTCGCTCTGGGCGCGGAGGAGCGGCGCAC	180
DB	127	CGCCGCCCGCAGCCCTGGGGAGCGCTCTCGCTCTGGGCGCGGAGGAGCGGCGCAC	186
QY	181	GTCTCTCTGAGGAAGCGGAGTGGACATCGGGCGGAGAGAGGTGGACCTTCCCTTC	240
DB	187	GTCTCTCTGAGGAAGCGGAGTGGACATCGGGCGGAGAGAGGTGGACCTTCCCTTC	246
QY	241	CCAGCAATAAATGCTCTCTGAGATCACTGTAGAAATTTAGTGTGATGAAATCAAGT	300
DB	247	CCAGCAATAAATGCTCTCTGAGATCACTGTAGAAATTTAGTGTGATGAAATCAAGT	306
QY	301	CAGGTGACACTGGAATACCAAGCACCAGTGAACAGTGAATTAACAGTGAAGTTGTT	360
DB	307	CAGGTGACACTGGAATACCAAGCACCAGTGAACAGTGAATTAACAGTGAAGTTGTT	366
QY	361	AGAAGCAGACATGCCCTTTACAGCTGGGATGATCTACTTCTGGTGTACAGGAGAAAT	420
DB	367	AGAAGCAGACATGCCCTTTACAGCTGGGATGATCTACTTCTGGTGTACAGGAGAAAT	426
QY	421	GAACCGGAACACAACTGGCATACCTCTATGATCTTTAAGTGAAGCAAGGCAATGACA	480
DB	427	GAACCGGAACACAACTGGCATACCTCTATGATCTTTAAGTGAAGCAAGGCAATGACA	486
QY	481	CAAGAAATCTTTGAAGCTAACAGGAATGTTTCCATGGGACCAAGATACCTCAGGT	540
DB	487	CAAGAAATCTTTGAAGCTAACAGGAATGTTTCCATGGGACCAAGATACCTCAGGT	546
QY	541	GCAGGTGCAGGGGAGGGGCGGATCCCCGGGTCCCTCGCTCGGCCGCCCACTCAGGTG	600
DB	547	GCAGGTGCAGGGGAGGGGCGGATCCCCGGGTCCCTCGCTCGGCCGCCCACTCAGGTG	606
QY	601	TGCTTTGAGGAACACAGGCCATCAACATCGACGTGAGCTCTTCCCGACAGCTCGGCC	660
DB	607	TGCTTTGAGGAACACAGGCCATCAACATCGACGTGAGCTCTTCCCGACAGCTCGGCC	666
QY	661	TCTTCCAGGAGCTTCTCTCGAGGCGAGAGCGTTCTCCAGTTGTGGGTCTGGGGT	720
DB	667	TCTTCCAGGAGCTTCTCTCGAGGCGAGAGCGTTCTCCAGTTGTGGGTCTGGGGT	726
QY	721	GGTGGCATCTCCCTAAAGGAAGTGTCCCTCTGTGCGCAAGTGAAGTCTCCAGCTTT	780
DB	727	GGTGGCATCTCCCTAAAGGAAGTGTCCCTCTGTGCGCAAGTGAAGTCTCCAGCTTT	786
QY	781	GCCTCAGCTCTCCAGACAAAGACTGGCTCTTTTCTGCTTGTGAACCCAGAGATCAG	840
DB	787	GCCTCAGCTCTCCAGACAAAGACTGGCTCTTTTCTGCTTGTGAACCCAGAGATCAG	846
QY	841	GAGGATTTGAGCCGCTGAAGAGAAATGAGAGGAGATGGGACCTTGACCTGAACCGG	900
DB	847	GAGGATTTGAGCCGCTGAAGAGAAATGAGAGGAGATGGGACCTTGACCTGAACCGG	906
QY	901	CAGTTGTTGTGCAACCCGCTAGAAATGCCAAACCGTCCACAGAGAGCTCAGAGCA	960
DB	906	CAGTTGTTGTGCAACCCGCTAGAAATGCCAAACCGTCCACAGAGAGCTCAGAGCA	965
QY	961	CGCGCTGGAGGACAGACAGATGGAGGAGACGCTGACATCATCTCTGCCAGGACCTG	1020

966	CGCGCTGGGAGCAAGAAAGATGGAGRG-MSC	1021	CTGCAGCAGTCGCTGAGTTTGTCAGCCCTGCA
1021	CTGCAGCAGTCGCTGAGTTTGTCAGCCCTGCA	1051	CTGCAGCAGTCGCTGAGTTTGTCAGCCCTGCA
1023	CTGCAGCAGTCGCTGAGTTTGTCAGCCCTGCA	1053	CTGCAGCAGTCGCTGAGTTTGTCAGCCCTGCA
RESULT 4			
AL539797/c			
LOCUS		1201 bp	linear EST 31-MAY-2003
DEFINITION		AL539797 Homo sapiens FETAL BRAIN Homo sapiens cDNA Clone	
ACCESSION		AL539797	
VERSION		AL539797.2	
KEYWORDS		GI:31264360	
SOURCE		Homo sapiens (human)	
ORGANISM		Homo sapiens	
REFERENCE		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS		Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
TITLE		1 (bases 1 to 1201)	
JOURNAL		Li, W.B., Gruber, C., Jesse, J. and Polayes, D.	
COMMENT		Full-length cDNA libraries and normalization	
		Unpublished (2001)	
		On Feb 15, 2001 this sequence version replaced gi:12869347.	
		Contact: Genoscope	
		Genoscope - Centre National de Sequencage	
		BP 191 91006 EVRY cedex - France	
		Email: seq@genoscope.cns.fr, Web : www.genoscope.cns.fr	
		Library was constructed by Life Technologies, a division of	
		Invitrogen. This sequence belongs to sequence cluster 6792.r For	
		more information about this cluster, see	
		http://www.genoscope.cns.fr/	
		cgi-bin/cluster.cgi?seq=CS0DF031AA12NP1&cluster=6792.r. Contact :	
		Feng Liang Email : fliang@lifetech.com URL :	
		http://fulllength.invitrogen.com/ invitrogen Corporation 1600	
		Faraday Avenue Genoscope sequence ID : CS0DF031AA12NP1.	
FEATURES		Location/Qualifiers	
		1..1201	
		/organism="Homo sapiens"	
		/mol_type="mRNA"	
		/db_xref="taxon:9606"	
		/clone="CS0DF031YA23"	
		/tissue_type="FETAL BRAIN"	
		/dev_stage="fetal"	
		/clone_lib="Homo sapiens FETAL BRAIN"	
		/note="Organ: brain; Vector: pCMVSPORT 6; 1st strand cDNA	
		was primed with a NotI-oligo(dT) primer. Five prime end	
		enriched, double-strand cDNA was digested with Not I and	
		cloned into the Not I and EcoRV sites of the pCMVSPORT 6	
		vector. Library was not normalized."	
ORIGIN			
		Query Match	34.0%; Score 911.8; DB 9; Length 1201;
		Best Local Similarity	91.2%; Pred. No. 1.8e-141;
		Matches	973; Conservative 41; Mismatches 47; Indels 6; Gaps 5;
QY	1580	CGGAGCGGAGCAGGACCCGGGTGTCGCCCTCAGCAGTGTGCGGTCTGCTGCAGCCTT	1639
DB	1061	CGGAGCGGAGCAGGACCCGGGTGTCGCCCTCAGCAGTGTGCGGTCTGCTGCAGCCT	1002
QY	1640	TCTGCCACCTCTACTTGGGCTGACCGGACCGGCTCTACTCGGCTGCTGCCCGCTTTT	1699
DB	1001	TCTGCCACCTCTACTTGGGCTGACCGGACCGGCTCTACTCGGCTGCTGCCCGCTTTT	945
QY	1700	GTGAGCTCAACCTGGGTGACAGTGTCTGACCGGCTGCTGACCAACAGCTACGAGT	1759
DB	944	GKRGCTCAACCTGGGTGACAGTGTCTGACCGGCTGCTGACCAACAGCTACGAGT	885
QY	1760	CAGCATCTCTGAAGATTTACCTGGCAACCGAGAGTTTGACATGAGAAACATGTTGACCG	1819
DB	884	CAGCATCTCTGAAGATTTACCTGGCAACCGAGAGTTTGACATGAGAAACATGTTGACCG	825

1820	AGAGCCTCGTGGCTCTCCAGCGGGAGTGTTCCTGCTGTCTGATTCACAGAGTCACGGGAG	1879
QY		
824	AGAGCCTCGTGGCTCTCCAGCGGGAGTGTTCCTGCTGTCTGATTCACAGAGTCACGGGAG	765
DB		
1880	ACACCGTTCGTGTACTCTGCTGGCCCTGGCAGCTCCGTGAGCTGACCTACAGTATC	1939
QY		
764	ACACCGTTCGTGTACTCTGCTGGCCCTGGCAGCTCCGTGAGCTGACCTACAGTATC	705
DB		
1940	GGCAGAACATTCCTGCTTCGAGTTCGCCAGTGGCCGTAACTCCGCTCTGACTGTACT	1999
QY		
704	GGCAGAACATTCCTGCTTCGAGTTCGCCAGTGGCCGTAACTCCGCTCTGACTGTACT	645
DB		
2000	GGGGCCGTAACTCCCGCAGCTCAGGTGAAGAGCTCACACGCCATGAATTCATCATATCT	2059
QY		
644	GGGGCCGTAACTCCCGCAGCTCAGGTGAAGAGCTCACACGCCATGAATTCATCATATCT	585
DB		
2060	GTGAACAGACAAGGTTCAAAAATAAGACATCCAGAGGCCCTGAGCAGCTTTCAGCACTGG	2119
QY		
584	GTGAACAGACAAGGTTCAAAAATAAGACATCCAGAGGCCCTGAGCAGCTTTCAGCACTGG	525
DB		
2120	AGGTGAAGAGAGCGTGTTCCTTTAAATAACAGACAAGCAGCGTCAAGGTGTTCACAGCC	2179
QY		
524	AGGTGAAGAGAGCGTGTTCCTTTAAATAACAGACAAGCAGCGTCAAGGTGTTCACAGCC	465
DB		
2180	CCCTGAGGAGGAGCAGGGTCTCCGACAGCTGCTCTGGGGTGACTCTCTGTGTGAGC	2239
QY		
464	CCCTGAGGAGGAGGAGCAGGGTCTCCGACAGCTGCTCTGGGGTGACTCTCTGTGTGAGC	405
DB		
2240	TTTTTACCTCTCAGTGAAGACCCCTCCCGACAGCCCGGGCGCGACGCCGCCCTCTCTG	2299
QY		
404	--TTTACCTCTCAGTGAAGACCCCTCCCGACAGCCCGGGCGCGACGCCGCCCTCTCTG	347
DB		
2300	TGAGCGCTGGCAGGGCTCGTGTGGCATCAGCAGACAGAGACGAGCGTTCCTGTAACT	2359
QY		
346	TGAGCGCTGSGCAGVCGCCCTGGTGGGTCAGCAGCAGAGACGAAACCTTCCTGTACAT	287
DB		
2360	CGCGCCGTCGCCGAGAGGGGAGTTTGCTCTTTTGTACATTTTCGAAACTACAGTT	2419
QY		
286	CGCGCCGTCGCCGAGAGGGGAGTTTGCTCTTTTGTACATTTTCGAAACTACAGTT	227
DB		
2420	AAAGCAGAAGTCTGTTTTTCAGGAAAAGTTTCAGGGGAGAGGCGCAAGTTTATCAAAAACA	2479
QY		
226	AAAGCGAAGTCTGTTTTTCAGGAAWKTTCAGGGGAGAGGCGCAAKTTTTTTAAWACA	167
DB		
2480	TTGTTTTCAGAGAAAGGAGCATTAAGTTTACAGCTACAGGACGTACACATATCCTGCTG	2539
QY		
166	TTGTTTTCAGGAGAGGGKGCATWDGTTTACWGCTTACAGGACGTABACAAATATCCTGCTG	107
DB		
2540	CTGGAAAAACAAGCATTTTATCTATTTTTTTATTTTAAAGCTTTGGTGCTTATCTTCT	2599
QY		
106	CTKGAAGSSACGGGTTTTATSTDTTTTTTATTTTAAAGCTTTGGTGCTTCTTCTCT	47
DB		
2600	AATAAGATTTAAAGTCACAAACTGTAGCACAAATAATAAATTAAT	2646
QY		
46	AATAAGATTTAAATGTCACATATGTA-YACAWTAATAATAAATTAAT	1
DB		

RESULT 5	
BQ876252	
LOCUS	876 bp mRNA linear EST 16-AUG-2002
DEFINITION	AGENCOURT_8681566 NIH_MGC_43 Homo sapiens cDNA clone IMAGE:6376937
	5', mRNA sequence.
ACCESSION	BQ876252
VERSION	BQ876252.1 GI:22268258
KEYWORDS	EST.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 (bases 1 to 876)
AUTHORS	NIH-MGC http://mgc.nci.nih.gov/ .
TITLE	National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL	Unpublished (1999)

Contact: Robert Strausberg, Ph.D.
 Email: cgapbs-remail.nih.gov
 Tissue Procurement: ATCC
 cDNA Library Preparation: Rubin Laboratory
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Agencourt Bioscience Corporation
 Clone distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
 Plate: LLCW2559 row: c column: 18
 High quality location stop: 678.
 Location/Qualifiers
 1..876
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:637693"
 /tissue_type="normal pigmented retinal epithelium"
 /lab_host="DH10B (phage-resistant)"
 /clone_lib="NIH MGC 43"
 /name="Organ: eye; Vector: pOTB7; Site 1: XhoI; Site 2:
 EcORI; cDNA made by oligo-dT priming. Directionally-
 cloned into EcORI/XhoI sites using the following 5'
 adaptor: GGCAACAG(G).. Library constructed by Ling Hong
 in the laboratory of Gerald M. Rubin (University of
 California, Berkeley) using ZAP-cDNA synthesis kit
 (Stratagene) and Superscript II RT (Life Technologies).
 Note: this is a NIH MGC Library."

Query Match	30.7%	Score 822.2	DB 13	Length 876
Best Local Similarity	98.3%	Pred. No. 1.4e-126		
Matches 863	Conservative	0	Mismatches 9	Indels 6
Gaps				
1165	GTGGGAAGCATACCTCATCCAGCATCCAGCAAGAGTGCAGTGAAGAGATGTGCAAGT	1224		
Db	1	GTGGGAAGCATACCTCATCCAGCATCCAGCAAGAGTGCAGTGAAGAGATGTGCAAGT	60	
1225	ATGGATGCCAGGAATATAATCTCAAGACATCTGCAGCCCAAGTTCAGCGGCTCTTTT	1284		
Qy				
Db	61	ATGGATGCCAGGAATATAATCTCAAGACATCTGCAGCCCAAGTTCAGCGGCTCTTTT	120	
1285	TCTGATGAAGAAAGGAGTTTCAGAGACCTGTGTGAGCTGTGCAGACGTTGACAGTGAGTCC	1344		
Qy				
Db	121	TCTGATGAAGAAAGGAGTTTCAGAGACCTGTGTGAGCTGTGCAGACGTTGACAGTGAGTCC	180	
1345	TCAGACATTAGCCAGCCATAGCTCGTGTGCCGCGAGTGTCTCTGAGTACAGAAAGCAGCGC	1404		
Qy				
Db	181	TCAGACATTAGCCAGCCATAGCTCGTGTGCCGCGAGTGTCTCTGAGTACAGAAAGCAGCGC	240	
1405	GGCGAGCCTCCCCACTGGCCAGCACCCGAGGGCGAGCCAGAGGCCCAACAGGCCCTTGGG	1464		
Qy				
Db	241	GGCGAGCCTCCCCACTGGCCAGCACCCGAGGGCGAGCCAGAGGCCCAACAGGCCCTTGGG	300	
1465	GATGACACCTCCACGTCCTGAGCTGACAGCAGCAGTCCAGGATTACGTGTGCCCTCTG	1524		
Qy				
Db	301	GATGACACCTCCACGTCCTGAGCTGACAGCAGTCCAGGATTACGTGTGCCCTCTG	357	
1525	CAAGGAAGCCAAGCCCTGTGCACTGTCTTTCAGCCCATGCCGACCGAGAGCGAG	1584		
Qy				
Db	358	CAAGGAAGCCAAGCCCTGTGCACTGTCTTTCAGCCCATGCCGACCGAGAGCGAG	417	
1585	CGCGACAGCAACCGCGTGTGCCCTCTCAGCAGTGTGGCGTGTGCTTCGACGCTTCTGC	1644		
Qy				
Db	418	CGCGACAGCAACCGCGTGTGCCCTCTCAGCAGTGTGGCGTGTGCTTCGACGCTTCTGC	477	
1645	CACCTGTATCGGGGTGCAACCGGACCGGTGCTACGGTGCCTGGCCCGCTTTGTGAG	1704		
Qy				
Db	478	CACCTGTATCGGGGTGCAACCGGACCGGTGCTACGGTGCCTGGCCCGCTTTGTGAG	537	
1705	CTCAACCTGGGTGCAAAAGTGTCTGCAACGGCGTGTGAAACAAACAGCTACGAGTCAGAC	1764		
Qy				
Db	538	CTCAACCTGGGTGCAAAAGTGTCTGCAACGGCGTGTGAAACAAACAGCTACGAGTCAGAC	597	

QY	1695	GTTTGTGAGCTCAACTGGGTG 1717																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
----	------	----------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

QY	1695	CTTTTGTGAGCTCAACCTGGGTG	1717
DB	778	CTTTTGTGAGCTCAACCTGGGG	800
RESULT 8			
BQ073354			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
COMMENT			
FEATURES			
source			
1..992			
/organism="Homo sapiens"			
/mol_type="mRNA"			
/db_xref="taxon:9606"			
/clone="IMAGE:5806143"			
/tissue_type="epidermoid carcinoma, cell line"			
/lab_host="DH10B (phage-resistant)"			
/clone_lib="NIH_MGC 101"			
/note="Organ: lung; Vector: pOTB7; Site 1: EcoRI; Site 2: XhoI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies). Note: this is a NIH_MGC Library."			
ORIGIN			
Query Match		28.3%; Score 758; DB 13; Length 992;	
Best Local Similarity		96.6%; Pred. No. 6.3e-116;	
Matches 817; Conservative		0; Mismatches 25; Indels 4; Gaps 4;	
QY	551	GGCGAGGGGCGGATCCCGGGTCCCTCGTGTGCGCCGCGCACTCAGGTGCTTTGAGG	610
DB	1	GGCGAGGGGCGGATCCCGGGTCCCTCGTGTGCGCCGCGCACTCAGGTGCTTTGAGG	60
QY	611	AACCAACAGCATCAACATCGAGTCAGACCTCTTCCCAACAGCCTCGGCTTCCACGG	670
DB	61	AACCAACAGCATCAACATCGAGTCAGACCTCTTCCCAACAGCCTCGGCTTCCACGG	120
QY	671	AGCCTTCTCTCAGGGGAGAGCGTTCCTCCAGTGTGGTCTGGGGTGGTGGCATCT	730
DB	121	AGCCTTCTCTCAGGGGAGAGCGTTCCTCCAGTGTGGTCTGGGGTGGTGGCATCT	180
QY	731	CCCTTAAAGGAAGTGGTCCCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCTCAGCTC	790
DB	181	CCCTTAAAGGAAGTGGTCCCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCTCAGCTC	240
QY	791	TCCAGACAGAAAGACTGGTCCCTTTTGTGCTGTTGGAACCCAGGATCAGGAGGATTGG	850

241 TCCAGACAGAAAGAGCTGCTCTCTTTCTGCTGCTGAAACCCAGGATCAGGAGATTGG 300
851 AGCCCGTGAAGAAAGAAATGAGAGAGATGGGACCTTGACTGAAAGGCGACCTTGTGG 910
301 AGCCCGTGAAGAAAGAAATGAGAGAGATGGGACCTTGACTGAAAGGCGAGTGTGG 360
911 TGCGACACCGGCTGAATGAAATGCCAAACCGTCCAGAGGAGCTCAGAGACGCGCTGGGA 970
361 TGCGACACCGGCTGAATGAAATGCCAAACCGTCCAGAGGAGCTCAGAGACGCGCTGGGA 420
971 AGCCAGACAGATGAGAGAGAGCTGATGATGATGATGATGATGATGATGATGATGATGAT 1030
421 AGCCAGACAGATGAGAGAGAGCTGATGATGATGATGATGATGATGATGATGATGATGAT 480
1031 GCGTGAGTTGAGCCCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1090
481 GCGTGAGTTGAGCCCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 540
1091 AGCGTCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1150
541 AGCGTCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 600
1151 TCTTCAACAACTCTGGAAGATACCTTCCAGATCCAGATCCAGATCCAGATCCAGATCCAG 1210
601 TCTTCAACAACTCTGGAAGATACCTTCCAGATCCAGATCCAGATCCAGATCCAGATCCAG 660
1211 AAGATGTGAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1269
661 AAGATGTGAAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 720
1270 GTGAGCGGCTCTTTTCTGATGAAGAGAGGAGTTTCCAGAGACCTGCTGAGTGTGAG- 1327
721 GTGAGCGGCTCTTTTCTGATGAAGAGAGGAGTTTCCAGAGACCTGCTGAGACCTGTGAGA 780
1328 ACGTTGACAGTGAG-TCTTCAAGATGAGCCAGGATACCTGCTGCTGCTGCTGCTGCTGCT 1386
781 ACGTTGACAGTGAGTTCTTCAAGATGAGCCAGGATACCTTCTTGGGCGCGGAGT 840
1387 GAGTAC 1392
841 GGGTCC 846

CD243458 877 bp mRNA linear EST 22-MAY-2003
AGENCY: NIH MGC 180 Homo sapiens cDNA clone
IMAGE: 30383176 5', mRNA sequence.
CD243458
CD243458.1 GI:31003922
EST.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 877)
NIH-MGC http://mhc.nci.nih.gov/
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: rstraus@remail.nih.gov
Tissue Procurement: Dr. Michael Brownstein
cDNA Library Preparation: Invitrogen Corp
DNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: NDAM446 row: j column: 17
High quality sequence stop: 660.
Location/Qualifiers
1. .877
/organism="Homo sapiens"

RESULT 9
CD243458
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

/mol_type="mRNA"
db_xref="taxon:9606"
/lab host="DH10B-Ton A (T1 and T5 phage resistances)"
/clone lib="NIH MGC 180"
/note="Organ: Testis; Vector: pCMV-Sport6.1; Site 1: NotI;
Site 2: EcoRV (destroyed); Library is oligo-dT primed and
directionally cloned (EcoRV site is destroyed upon
cloning). Average insert size 1.68 kb. Library was
constructed by (invitrogen). Note: this is a NIH_MGC
Library."

Query Match 28.3%; Score 757.6; DB 14; Length 877;
Best Local Similarity 96.9%; Pred. No. 7.6e-116;
Matches 772; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 1527 AGGAAGCAGCCCTGTCACCTGCTCTCCAGCCCATGCCCCGAGCGAGAGCGGAGCG 1586
Db 4 AGGAAGCAGCCCTGTCACCTGCTCTCCAGCCCATGCCCCGAGCGAGAGCGGAGCG 63
QY 1587 CGAGCAGGACCCCGCTGTCGCCCTCAGCAGTGTGCGGTGTGCTCAGCCTTTTCGCCA 1646
Db 64 CGAGCAGGACCCCGCTGTCGCCCTCAGCAGTGTGCGGTGTGCTCAGCCTTTTCGCCA 123
QY 1647 CCTGTACTGGGGCTGCAACCGGCTGCTACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1706
Db 124 CCTGTACTGGGGCTGCAACCGGCTGCTACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 183
QY 1707 CAACCTGGGTGACAAAGTGTCTGACCGCGTGTGAAACAACAGCTACAGTTCAGCAT 1766
Db 184 CAACCTGGGTGACAAAGTGTCTGACCGCGTGTGAAACAACAGCTACAGTTCAGCAT 243
QY 1767 CCTGAAGAAATTAACCTGGCAACAGAGTTTGCATGGAAGAAATTAACATGTCAGGAGCT 1826
Db 244 CCTGAAGAAATTAACCTGGCAACAGAGTTTGCATGGAAGAAATTAACATGTCAGGAGCT 303
QY 1827 CGTGGCTCTCCAGCGGGAGTGTCTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1886
Db 304 CGTGGCTCTCCAGCGGGAGTGTCTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 363
QY 1887 TCTGTGTTACTGCTGTGGCTGCGAGCTTCCGTGAGCTGACCTATCAGTATCGGAGAA 1946
Db 364 TCTGTGTTACTGCTGTGGCTGCGAGCTTCCGTGAGCTGACCTATCAGTATCGGAGAA 423
QY 1947 CATTCCTGCTTCCAGGTTCGAGTGGCCCTTAACATCCCTGCTGCTGCTGCTGCTGCTGCTG 2006
Db 424 CATTCCTGCTTCCAGGTTCGAGTGGCCCTTAACATCCCTGCTGCTGCTGCTGCTGCTGCTG 483
QY 2007 TAACTGCGCAGCTCAGTGTGAAGCTCACCAGCCCATGAATTCATCATCTGCTGAGCA 2066
Db 484 TAACTGCGCAGCTCAGTGTGAAGCTCACCAGCCCATGAATTCATCATCTGCTGAGCA 543
QY 2067 GACAAAGTTCAAAAATAAGCATPCCAGAGCCCTGAGCAGCTTTTTCAGCACTGGAGTGA 2126
Db 544 GACAAAGTTCAAAAATAAGCATPCCAGAGCCCTGAGCAGCTTTTTCAGCACTGGAGTGA 603
QY 2127 GAGAGCGTGTGTTTTTAAATAACAGAGACAGCAGCTCAAGGTGTTTTTTCAGAGCCCTGAG 2186
Db 504 GAGAGCGTGTGTTTTTAAATAACAGAGACAGCAGCTCAAGGTGTTTTTTCAGAGCCCTGAG 663
QY 2187 GGAAGGGAACCGAGGTGCTCCGACAGGTGCTCTGGGTGAGCTCTTCTGTGGAGCTTTTAC 2246
Db 664 GGAAGGGAACCGAGGTGCTCCGACAGGTGCTCTGGGTGAGCTCTTCTGTGGAGCTTTTAC 723
QY 2247 CCTCTGAGTGAGACCTCTCCAGAGCCCGGGGGCGGAGCGCCCTCCTGCTGAGCGC 2306
Db 724 CCTCTGAGTGAGACCTCTCCAGAGCCCGGGGGCGGAGCGCCCTCCTGCTGAGCGC 783
QY 2307 TGGGCGAGGGCTCGTGTGT 2323
Db 784 GCGCTTGGGCAAGGCT 800


```
RESULT 10
BUI148471
LOCUS
DEFINITION AGENCOURT 8675647 NIH_MGC_40 Homo sapiens cDNA clone IMAGE:6380102
5' RNA sequence.
ACCESSION BUI148471.1 GI:22662003
VERSION BUI148471.1
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 910)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs@mail.nih.gov
Tissue Procurement: DCTD/DTF
CDNA Library Preparation: Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLCM2568 row: c column: 15
High quality sequence stop: 620.
FEATURES
source
Location/Qualifiers
1..910
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6380102"
/tissue_type="carcinoma, cell line"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH_MGC_40"
/notes="Organ: prostate; Vector: pOTB7; Site:1: XhoI;
Site 2: EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(G). Library constructed by
Ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC Library."
ORIGIN
Query Match 27.68; Score 740.6; DB 13; Length 910;
Best Local Similarity 91.18; Pred. No. 5e-113;
Matches 858; Conservative 0; Mismatches 40; Indels 44; Gaps 5;
Qy 12 ACAGAGCGCGCAATGCTCTTTCACAGCGCGCGCGCGCGCGGTTCCGGTTCCGGCGCG 71
Db 5 AGGAGCGCGCAATGCTCTTTCACAGCGCGCGCGCGCGCGGTTCCGGTTCCGGCGCG 64
Qy 72 GCGCGGATGTGAATCCCGATGGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCA 131
Db 65 GCGCGGATGTGAATCCCGATGGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCA 124
Qy 132 GCGCGGAGCGGCTCTCTGCGTTCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 191
Db 125 GCGCGGAGCGGCTCTCTGCGTTCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 184
Qy 192 GAAGCGGAGTGGACCATCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCA 251
Db 185 GAAGCGGAGTGGACCATCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCA 244
Qy 252 ACTGCTCTCGAGATCACTGTAGAAATGTAGTGGATGAAATCAGGTGAGTGCACCT 311
Db 245 ACTGCTCTCGAGATCACTGTAGAAATGTAGTGGATGAAATCAGGTGAGTGCACCT 304
Qy 312 GGAAGATACCAGCACCAGTGAACAGTGATTAAACAGCTGAAGTCTTTAAGAGCAGAC 371
```

```
Db 305 GGAAGATACCAGCACCAGTGAACAGTGATTAAACAGCTGAAGTGTGTTAAGAGCAGAC 364
Qy 372 ATGCCCTTTACAGACTGGGGATGTCTACTTGGTGTACAGGAAGATGACCGGACACA 431
Db 365 ATGCCCTTTACAGACTGGGGATGTCTACTTGGTGTACAGGAAGATGACCGGACACA 424
Qy 432 CAACGTGGCATACCTCTATGAATCTTTAAGTGAAGCAAGGCATGACACAAGATCCTT 491
Db 425 CAACGTGGCATACCTCTATGAATCTTTAAGTGAAGCAAGGCATGACACAAGATCCTT 484
Qy 492 TGAAGCTAACAGGAAATGTGTTCCATGGACCAAGATACCTCAGGTGAGGTGAGG 551
Db 485 T-----GATACCTCAGGTGAGGTGAGG 508
Qy 552 GCGAGGGCCGATCCCGGGTCCCTCCGTCTCCGCCGCCACTCAGGTGTGCTTTGAGCA 611
Db 509 GCGAGGGCCGATCCCGGGTCCCTCCGTCTCCGCCGCCACTCAGGTGTGCTTTGAGCA 568
Qy 612 ACCCAGGCATCAACATCGACGTGAGCTCTTCCCAACAGCTCGGCTCTTCCACGGA 671
Db 569 ACCCAGGCATCAACATCGACGTGAGCTCTTCCCAACAGCTCGGCTCTTCCACGGA 628
Qy 672 GCCTTCTCTCGAGGGCGAGAGCGTTCTCAGTTGTGGTCTGGGGTGGTGGCATCTC 731
Db 629 GCCTTCTCTCGAGGGCGAGAGCGTTCTCAGTTGTGGTCTGGGGTGGTGGCATCTC 688
Qy 732 CCTAAAGGAAGTGTCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCTCAGCTCT 791
Db 689 CCTAAAGGAAGTGTCTCTGTGGCAAGTGAAGTCTCCAGCTTTGCTCAGCTCT 748
Qy 792 CCCAGACAGAAAGACT-GCGTCCCTTTTCGTGTGGAAACCCAGGATCAGAGGATTTGG 850
Db 749 CCCAAACAGAAAGACTGGGGTCTCTTTCGTGTGGAAACCCAGGATCAGAGGATTTG 808
Qy 851 AGCCCGTGAAGAAAGAAATGA----GAGGAGATGGGGACCTTG--ACCTGAACGGGCGAGT 904
Db 809 GGAGCCCTGTAAGAAAGAAATGACAGAGAGATGGGGACCTTGACCTGAACGGGCGAGT 868
Qy 905 TGTGCTCGCAACAC-CCGTAGAAATCCCAACCCGCTCCAC 945
Db 869 GGTGTTTCCCAACACCGGGGTAGAAATGCCCAACCGGGCCC 910
RESULT 11
BUI148471
LOCUS
DEFINITION mRNA sequence.
ACCESSION BG395714
VERSION BG395714.1 GI:13289162
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 840)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs@mail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Ling Hong/Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov
Plate: LLCM1300 row: a column: 18
High quality sequence stop: 775.
FEATURES
source
Location/Qualifiers
1..840
/organism="Homo sapiens"
/mol_type="mRNA"
```


	QY	345	CAAGCTGAAGGTTGTAAAGAAGCAGACATGCCCTTTTACAGACTGGGGATGTCATCTACTT	404
	Db	301	CAAGCTGAAGGTTGTAAAGAAGCAGACATGCCCTTTTACAGACTGGGGATGTCATCTACTT	360
	QY	405	GCGTGACAGGAAGTAATGAACCGGAACAACAAGTGGCATCCTCTATGAATCTTTAAGTGA	464
	Db	361	GCTGTACAGGAGAAATGNAACCGGAACAACAAGTGGCATCCTCTATGAATCTTTAAGTGA	420
	QY	465	AAAGCAAGGCATGACACAAGAATCTTTTGAAGCTATAAAGGAATAATGTGTTCCATGGGAC	524
	Db	421	AAAGCAAGGCATGACACAAGAATCTTTT-----	448
	QY	525	CAAAGATACCTCAGGTGCAGGTGCAGGGGCGAGGGCGGATCCCCGGGTCCCCTCCGTGCTC	584
	Db	449	----GATTACCTCAGGTGCAGGTGCAGGGGCGAGGGGCGGATCCCCGGGTCCCCTCCGTGCTC	504
	QY	585	GCCGCCCACTCAGGTGTGCTTTTGAGGAACCAACAGCCCATCAACATCGACGTCAAGACTCTT	644
	Db	505	GCCGCCCACTCAGGTGTGCTTTTGAGGAACCAACAGCCCATCAACATCGACGTCAAGACTCTT	564
	QY	645	CCCACACGCTCGCCCTCTTCCACGGAGCCTTCTCCTGCAGGGCGAGAGCGTTTCTCCAG	704
	Db	565	CCCACACGCTCGCCCTCTTCCACGGAGCCTTCTCCTGCAGGGCGAGAGCGTTTCTCCAG	624
	QY	705	TGTGTGGGTCT--GGGGGTGGTGGCATCTCCCTTAAAGAAAGTGGTCCCTCTGTGGCAAGTG	763
	Db	625	TGTGTGGGTCTGGGGGTGGTGGCATCTCCCTTAAAGAAAGTGGTCCCTCTGTGGCAAGTG	684
	QY	764	ATGAAGTCTCAGACTTTGCTCCTCACCTCCACAGACAAAAGACTGGGTCC--TTTTCTGTCG	822
	Db	685	ATGAAGTCTCAGACTTTGCTCCTCACCTCCACAGACAAAAGACTGGGTCCTTTTTCTGTCG	744
	QY	823	TTGGAACCCCAAGGATC--AGGAGGATTTGGAGCCCGTGAAGAAAGAAAAATGACAGAGAGATG	880
	Db	745	TTGGAACCCCAAGGATCAGAGAAAGATTTGGAGCCCGTGAAGAAAGAAAAATGACAGAGATG	804
	QY	881	GGGACCTT--GACCTGAACGGGCAAGTTGTTGG---TGGCACAAACCGCGTAGAAATGCCCCA	935
	Db	805	GGGACCTTTGACCTGGACGGGGCAAGTTGGTGGGTGCGACAAACCGCGCTAGAAATGCCCC	864
	QY	936	AACCG 940	
	Db	865	AACCG 869	
<hr/>				
RESULT	13	BQ924736	938 bp	mRNA linear EST 20-AUG-2002
LOCUS	BQ924736	AGENCOURT_8953777 NIH_MGC_18 Homo sapiens cDNA clone IMAGE:6374110		
DEFINITION	5', mRNA sequence.			
ACCESSION	BQ924736			
VERSION	BQ924736.1	GI:22339767		
KEYWORDS	EST.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
TITLE	N1 (bases 1 to 938)			
JOURNAL	NIH-MGC http://mgc.nci.nih.gov/.			
COMMENT	National Institutes of Health, Mammalian Gene Collection (MGC) Unpublished (1999) Contact: Robert Strausberg, Ph.D. Email: cgapbs-re@mail.nih.gov Tissue Procurement: DCTD/BTP/Gazdar cDNA Library Preparation: Rubin Laboratory cDNA library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Agencourt Bioscience Corporation Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov Plate: LLCN2552 row: i column: 23 High quality sequence stop: 629. Location/Qualifiers			
FEATURES				

1870 GTACGGGAGACACCGTTCTGTGTTTCTGCTGTGGCTGGCAGGCTTCCGTGAGCTGACC 1929
62 GTACGGGAGACACCGTTCTGTGTTTCTGCTGTGGCTGGCAGGCTTCCGTGAGCTGACC 121
1930 TATCAGTATCGGAGAACATTCCTCTCCGAGTTGCCAGTGGCGGTAACTCCCGTCT 1989
122 TATCAGTATCGGAGAACATTCCTCTCCGAGTTGCCAGTGGCGGTAACTCCCGTCT 181
1990 GACTGTCTACTGGGGCGGTAACTGCGGCACTCAGGTGAAAGCTCACACGCCATGAAATTC 2049
182 GACTGTCTACTGGGGCGGTAACTGCGGCACTCAGGTGAAAGCTCACACGCCATGAAATTC 241
2050 AATCATATCTGTGAAACAGAAAGGTTCAAAACTAAGCATCCAGAGGCCCTCAGAGAGCTT 2109
242 AATCATATCTGTGAAACAGAAAGGTTCAAAACTAAGCATCCAGAGGCCCTCAGAGAGCTT 301
2110 TCAGCACTGGAGGTGAAGAGAGCGTGTGTTTAAATACAGACAGCAAGCAAGTCAAGGTGT 2169
302 TCAGCACTGGAGGTGAAGAGAGCGTGTGTTTAAATACAGACAGCAAGCAAGTCAAGGTGT 361
2170 TTTTCAGAGCCCTGAGGAGGAGCGAGGCTCTCCGACAGTGTCTCTGGGCTGACTCT 2229
362 TTTTCAGAGCCCTGAGGAGGAGCGAGGCTCTCCGACAGTGTCTCTGGGCTGACTCT 421
2230 TCTGTGAGAGCTTTTACCCCTCTGAGTGAGACCCCTCCGAGAGCCCGGGGCGGAGCC 2289
422 TCTGTGAGAGCTTTTACCCCTCTGAGTGAGACCCCTCCGAGAGCCCGGGGCGGAGCC 478
2290 GCCTCTCTGAGGCTGGGAGGAGCGAGGCTCTCCGACAGTGTCTCTGGGCTGACTCT 2349
479 GCCTCTCTGAGGCTGGGAGGAGCGAGGCTCTCCGACAGTGTCTCTGGGCTGACTCT 538
2350 TCTGTAACTGCGGCGCTCCGCGGAGAGGCGGAGGCTTTTGTCTCTTTGTACATTTTCCGA 2409
539 TCTGTAACTGCGGCGCTCCGCGGAGAGGCGGAGGCTTTTGTCTCTTTGTACATTTTCCGA 598
2410 AACTACAGTTAAAGCAGAGAGTCTGTTTTCAGG-AAAAGTTTCAGGAGAGAGGCAAGTT 2468
599 AACTACAGTTAAAGCAGAGAGTCTGTTTTCAGGAGAGAGGCAAGTTTTCAGGAGAGGCAAGTT 658
2469 TATCAAAAACATGTTTCAGGAGAGGAGAGTAACTTTACAGCTTAC-AGGACGTACAC 2527
659 TATCAAAAACATGTTTCAGGAGAGGAGAGTAACTTTACAGCTTAC-AGGACGTACAC 717
2528 AATATCTCTGCTGCTGGGAGAGAGAGAGTAACTTTATCTTTTATTTTATAGGTTTG 2587
718 AATATCTCTGCTGCTGGGAGAGAGAGTAACTTTATCTTTTATTTATCTAATA---GGTTGG 773
2588 TGCTTATCTCTTAAAGATTTTAAATGTCACAACTGTAGCACAAATAAT 2637
774 GGCTTATCTCTTAAAGATTTTAAATGTCACAACTGTAGCACAAATAAT 823
RESULT 15
BX409790 944 bp mRNA linear EST 13-MAY-2003
LOCUS BX409790 Homo sapiens FETAL BRAIN Homo sapiens cDNA clone
DEFINITION CS0DF017119 5-PRIME, mRNA sequence.
ACCESSION BX409790
VERSION BX409790.1 GI:30656944
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1. (bases 1 to 944)
Li, W.B., Gruber, C., Jesse, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished (2001)
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr

827 AA-CCCCAGGATCAGGAGATTTCGAGCC------GTCAAGAGAAATGAGAGGATG 880
745 AACCCCCAGATCAGGAGATTTCGAGCCCGGAGAGAAATGANNAGAGATGGG 804
881 GGGACCTTTGACCTGAA-----CGGCGAGTTGTTGGTCGCAACACCGGCTGAGAAATGCCCA 935
805 GGACCTTTGACCTGAAACGGCGAGTTGTTGGTCGCAACACCGGCTGAGAAATGCCCA 864
936 AACCGTCCACGAGG-CCGTCAGAGCAGCGGCTGGGAG-CCAGACAAAGAT-CGAGGAG 990
865 AACCGTCCACGAGGAGACCCAGAGCAACCCGCTGGGAGCCCAAGATGGGAGAG 924
991 ACGCTGACATGCAT 1004
925 ACGCTGACATGCAT 938
RESULT 14
BG831289 824 bp mRNA linear EST 22-MAY-2001
LOCUS 602766120F1 NIH_MGC_42 Homo sapiens cDNA clone IMAGE:4908316 5',
DEFINITION mRNA sequence.
ACCESSION BG831289
VERSION BG831289.1 GI:14178876
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1. (bases 1 to 824)
NIH-MGC http://mgi.mcg.mcg.mcg/
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Ling Hong/Rubin Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLC1814 row: 9 column: 05
High quality sequence stop: 745.
FEATURES
source
1..824
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4908316"
/tissue_type="epithelioid carcinoma cell line"
/lab_host="pH10B (phage-resistant)"
/clone_lib="NIH_MGC_42"
/note="Organ: pancreas; Vector: pOTB7; Site: 1: XhoI;
Site: 2: EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(G). Size-selected >500bp
for average insert size 1.8kb. Library constructed by Ling
Hong in the laboratory of Gerald M. Rubin (University of
California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC library."
ORIGIN
Query Match 26.4%; Score 708.4; DB 12; Length 824;
Best Local Similarity 95.7%; Pred. No. 1.1e-107;
Matches 794; Conservative 0; Mismatches 26; Indels 10; Gaps 6;
1810 ATGTTGACCGAGAGCTCGGTCTCCAGCGGGAGTGTCTGCTGCTGATACAGA 1869
2 ATGTTGACCGAGAGCTCGGTCTCCAGCGGGAGTGTCTGCTGCTGATACAGA 61

Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6792.x For more information about this cluster, see http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CS0BAF014ZC07_AF01300_1&cluster=6792.x. Contact : Feng Liang Email : fliang@lifetech.com URL : <http://fulllength.invitrogen.com/InvitroGen> Corporation 1600 Faraday Avenue Genoscope sequence ID : CS0BAF014ZC07_AF01300_1.

FEATURES
source
1..944
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF017Y119"
/tissue_type="FETAL BRAIN"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL BRAIN"
/note="Organ: brain; Vector: pCMVSPORT_6; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

ORIGIN

Query Match 26.4%; Score 706.2; DB 13; Length 944;
Best Local Similarity 89.7%; Pred. No. 2.5e-107;
Matches 849; Conservative 0; Mismatches 84; Indels 13; Gaps 8;

QY 1578 AGCGAGCGGAGCAGACCCGGCTGCGCCCTCAGCAGTGTGGCTGCTGCTCAGCC 1637
Db 4 AGCGAGCGGAGCAGACCCGGCTGCGCCCT-AGCAGTGTGGCTGCTGCTCAGCC 62
QY 1638 TTTCTGCCACCTGTACTGGGGTGTGACCCCGGACCGGCTGCTACGGCTGCTGGCCCGTT 1697
Db 63 TTTCTGCCACCTGTACTGGGGTGTGACCCCGGACCGGCTGCTACGGCTGCTGGCCCGTT 122
QY 1698 TTGTGAGCTCACTGGGTGTGACAGTGTGTGACGGCGTGTGACACACACAGCTACGA 1757
Db 123 TTGTGAGCTCACTGGGTGTGACAGTGTGTGACGGCGTGTGACACACACAGCTTTC 182
QY 1758 GTCAGACATCTCA-----AGAAATACCTGGCAACCCAGAGGTTTGACATGGAACATG 1812
Db 183 CTCGACATCATTTATAACAGAAATACCTGGCAACCCAGAGGTTTGACATGGAACATG 242
QY 1813 TTGACCGAGAGCTCGTGGCTCTCCAGCGGGAGTGTCTGCTGTCTGATTACAGAGTC 1872
Db 243 TTGACCGAGAGCTCGTGGCTCTCCAGCGGGAGTGTCTGCTGTCTGATTACAGAGTC 302
QY 1873 ACGGGAGACACCTGTTCTGTGTACTGTGCTGCGCAGCTTCCGTGAGCTGACCTAT 1932
Db 303 ACGGGAGACACCTGTTCTGTGTACTGTGCTGCGCAGCTTCCGTGAGCTGACCTAT 362
QY 1933 CAGTATCGGCAGAACATTCCTGCTTCCGAGTTGCCAGTGGCGGTAAACATCCCGTCTGAC 1992
Db 363 CAGTATCGGCAGAACATTCCTGCTTCCGAGTTGCCAGTGGCGGTAAACATCCCGTCTGAC 422
QY 1993 TGCTACTGGGGCGGTAACTGCCGCTCTCAGGTGAAGAGCTCACCAGCCCATGAATTCAT 2052
Db 423 TGCTACTGGGGCGGTAACTGCCGCTCTCAGGTGAAGAGCTCACCAGCCCATGAATTCAT 482
QY 2053 CATATCTGTGAACAGACAGGTTCAAAACTAAGCATCCAGAGGCCCTGAGCAGCTTCA 2112
Db 483 CATATCTGTGAACAGACAGGTTCAAAACTAAGCATCCAGAGGCCCTGAGCAGCTTCA 542
QY 2113 GCACGTGAGGTGAAGAGAGCGTGTTTTAAATACAGACAGACAGCTCAAGGTGTTT 2172
Db 543 GCACGTGAGGTGAAGAGAGCGTGTTTTAAATACAGACAGACAGCTCAAGGTGTTT 602
QY 2173 CACAGCCCCCTGAGGGAGGAGCGAGGGTCTCCGACAGGTGCTCTGGGGTGACTCTTCT 2232
Db 603 CACAGCCCCCTGAGGGAGGAGCGAGGGTCTCCGACAGGTGCTCTGGGGTGACTCTTCT 662
QY 2233 GTGAGAGCTTTTACCCTCTGAGTGAGACCTCCCTCCAGAGCCCCCGGGGGCGGAGCCCGCC 2292

Db 663 GTGAGC--TTTACCCTCTGAGTGAGACCTCCCCAGAG-CCCGGGGGCGCAGCCGCC 719
QY 2293 CTCTGTGTAGCCCTGGGCAAGGCTCGTGTGTCATCAGCAGCAGAGCGAGCCTTCT 2352
Db 720 CTCT-GTGAGCGCTGGGCAAGGCTCGTGTGTCATCAGCAGCAGAG-CTTCT 777
QY 2353 GTAACATGCGGCGCTCCCGCCGAGAGGGGCGAGTTTGTCTTTGTAC-ATTTCCGAAA 2411
Db 778 GTAACATGCGGCGCTCCCGCCGAGAGGGGCGAGTTTGTCTTTGGTCTTTTGGACAATTTCCGAAC 837
QY 2412 CTACAGTTAAA-CCAGAGTCTCTTTTCAGGAAAAGTTTCAAGGGAGAGGCAAGTTTA 2470
Db 838 CTACCGTTAAAGCGGGAAGGTTGGTTTAAAGAAAAGTGTTAAGGAAAAGGGCCAGGTTT 897
QY 2471 TCAGAAAACATTTTTCAGGAGAGGAGGAGCATAAAGTTTACAGCCCTAC 2516
Db 898 ATAAACATTTGTAAAGGAAAAGGGAGCCTTAGTTTTCAGTCCAC 943

Search completed: May 14, 2004, 20:06:21
Job time : 10045 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 14, 2004, 20:10:20 ; Search time 16426 Seconds
(without alignments)
7069.036 Million cell updates/sec

Title: US-10-048-046-1
Perfect score: 2679
Sequence: 1 aagaattcggcagggccg.....acaaaaaaaaaaaaaa 2679

Scoring table: OLIGO NUC
Gapop_60.0 , Gapext 60.0

Searched: 3470272 seqs, 21671516995 residues

Word size : 0

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : GenEmbl.*

- 1: gb.ba.*
- 2: gb.btg.*
- 3: gb.in.*
- 4: gb.om.*
- 5: gb.ov.*
- 6: gb.pat.*
- 7: gb.ph.*
- 8: gb.pl.*
- 9: gb.pr.*
- 10: gb.ro.*
- 11: gb.sts.*
- 12: gb.sy.*
- 13: gb.un.*
- 14: gb.vi.*
- 15: em.ba.*
- 16: em.fun.*
- 17: em.hum.*
- 18: em.in.*
- 19: em.mu.*
- 20: em.om.*
- 21: em.or.*
- 22: em.ov.*
- 23: em.pat.*
- 24: em.ph.*
- 25: em.pl.*
- 26: em.ro.*
- 27: em.sts.*
- 28: em.un.*
- 29: em.vi.*
- 30: em.htg.hum.*
- 31: em.htg.inr.*
- 32: em.htg.other.*
- 33: em.htg.mus.*
- 34: em.htg.pln.*
- 35: em.htg.rod.*
- 36: em.htg.mam.*
- 37: em.htg.vrt.*
- 38: em.sy.*
- 39: em.htgo.hum.*
- 40: em.htgo.mus.*
- 41: em.htgo.other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	2679	100.0	2679	9	AF170724	AF170724 Homo sapi
2	2133	79.6	2639	6	AX877194	AX877194 Sequence
3	2133	79.6	2639	6	BD156534	BD156534 Primer fo
4	2133	79.6	2639	9	AK027687	AK027687 Homo sapi
5	2031	75.8	3189	9	BC012072	BC012072 Homo sapi
6	1818	60.4	3181	6	AX405642	AX405642 Sequence
7	1497	55.9	2297	9	HSN802304	AL137561 Homo sapi
8	1465	54.7	3138	6	AX877222	AX877222 Sequence
9	1465	54.7	3138	6	BD156548	BD156548 Primer fo
10	1465	54.7	3138	9	AK001658	AK001658 Homo sapi
11	944	35.2	2448	6	AX834949	AX834949 Sequence
12	944	35.2	2448	9	AK097671	AK097671 Homo sapi
13	930	34.7	6235	6	BD183291	BD183291 Novel gen
14	909	33.9	2257	9	AK090948	AK090948 Homo sapi
15	633	23.6	2186	6	AX713476	AX713476 Sequence
16	633	23.6	2186	9	AX054917	AK054917 Homo sapi
17	478	17.8	816	6	AX868758	AX868758 Sequence
18	478	17.8	816	6	BD148820	BD148820 Primer fo
19	468	17.5	824	6	AX868776	AX868776 Sequence
20	468	17.5	824	6	BD148838	BD148838 Primer fo
21	426	15.9	518	6	AX873789	AX873789 Sequence
22	426	15.9	518	6	BD153851	BD153851 Primer fo
23	386	14.4	181012	9	AC127070	AC127070 Homo sapi
24	386	14.4	181438	2	AC023047	AC023047 Homo sapi
25	218	8.1	181438	2	AC023047	AC023047 Homo sapi
26	78	2.9	617	6	AX385952	AX385952 Sequence
27	38	1.4	158897	2	AC118260	AC118260 Mus muscu
28	37	1.4	3194	10	BC049792	BC049792 Mus muscu
29	37	1.4	321708	2	AC087142	AC087142 Mus muscu
30	37	1.4	338116	2	AC087159	AC087159 Mus muscu
31	34	1.3	202792	2	AC125898	AC125898 Rattus no
32	32	1.2	601	11	BV002855	BV002855 S208P6639
33	29	1.1	125396	2	AC124951	AC124951 Medicago
34	28	1.0	146516	2	AC079981	AC079981 Homo sapi
35	28	1.0	218226	2	AC126634	AC126634 Rattus no
36	28	1.0	228987	2	AC111838	AC111838 Rattus no
37	28	1.0	274796	2	AC097665	AC097665 Rattus no
38	27	1.0	167166	2	AC117568	AC117568 Mus muscu
39	27	1.0	167904	2	AC115904	AC115904 Mus muscu
40	27	1.0	217842	2	AL929073	AL929073 Mus muscu
41	27	1.0	230221	10	AC123851	AC123851 Mus muscu
42	27	1.0	234393	10	AL772311	AL772311 Mouse DNA
43	27	1.0	236825	2	AC140355	AC140355 Mus muscu
44	27	1.0	239783	2	AC102564	AC102564 Mus muscu
45	27	1.0	266632	2	AC129762	AC129762 Rattus no

ALIGNMENTS

RESULT 1
AF170724
LOCUS AF170724 Homo sapiens cell cycle checkpoint protein CHFR mRNA, complete cds.
DEFINITION AF170724 Homo sapiens cell cycle checkpoint protein CHFR mRNA, complete cds.
ACCESSION AF170724
VERSION AF170724.1 GI:96511169
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 2679)
AUTHORS Scolnick,D.M. and Halazonetis,T.D.
TITLE Chfr defines a mitotic stress checkpoint that delays entry into metaphase

JOURNAL Nature 406 (5794), 430-435 (2000)
 MEDLINE 20388685
 PUBMED 10935542
 REFERENCE 2 (bases 1 to 2679)
 AUTHORS Halazonetis,T.D. and Scolnick,D.M.
 TITLE Direct Submission
 JOURNAL Submitted (21-JUL-1999) Wistar Institute, 3601 Spruce Street,
 Philadelphia, PA 19104, USA
 FEATURES
 source location/Qualifiers
 1..2679
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 91..2085
 /note="contains FHA domain and ring finger"
 /codon_start=1
 /product="cell cycle checkpoint protein CHFR"
 /protein_id="AAF91084.1"
 /db_xref="GI:9651170"
 /translation="MERPEGKQSPPPQPWGRLRLGAEEGEPVLLRKREWTIGRR
 GCDLSPFNKLVDGDCRIVVDEKSGQVLTEDTSTGINKLVKVKQTCPLOTGGV
 IYLVRKNEPEHNVALYVLSLEKQGTQSBPEANKENVFHGTQDTGAGAGADPR
 VPLSPYQCTCFEPEQSTNSDLPTTASASTEPSAGRRSSSCSGGGGSIKPGS
 GPSVASDEVASFASALDRKTAASFSSLEPQDOEDLEPVKKMRGDGLDINGQLLVAQ
 PRNNAQVHEDVRAAAGKQKMEETLCIIQDLDHCKSVLQPCMHFTFCAKSYGWMME
 RSSLCPTCPCEPVRICKNHLINLVEALIQHPDKSSEEDVQSDARNKIQTMDLQF
 KVRFSDEGSSDLELSDVDESDDISQPYVVCQCEPYRRQAQPHPCPAPEGE
 PGAPQALDAPSTSVSLTATVDYVCLQSHALCTCCFQMPDRRAERQDPRVAFQ
 QCAVCLFCHLYGALTRTGCGCLAPFCELNLGDKLDGVLNNNSVESDILKNYLAT
 RGLTKWMLNLSIALVGORFLLSDYRTGDTVLVCYCGGLRSFRELTVQYRQNPITASE
 LPVATSRPDCYMGNGRGTQVKAHAMKFNHICQTQFNK"
 ORIGIN
 Query Match 100.0%; Score 2679; DB 9; Length 2679;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2679; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AAGAAATTCGGACAGAGCCGCAATGTCTCTTCAGACGGCGCGCGCGCGTCCGG 60
 DB 1 AAGAAATTCGGACAGAGCCGCAATGTCTCTTCAGACGGCGCGCGCGTCCGG 60
 QY 61 GTTCGGCGCGCGCGGGGATGTGAATCCCGATGGAGCGGCCGAGGAAGCAAGCAGTCG 120
 DB 61 GTTCGGCGCGCGCGGGATGTGAATCCCGATGGAGCGGCCGAGGAAGCAAGCAGTCG 120
 QY 121 CCGCGCGCGACGCCCTGGGGACCGGTCTCTGGCTCTGGCGCGGGAGGGCGAGCCGAC 180
 DB 121 CCGCGCGCGACGCCCTGGGGACCGGTCTCTGGCTCTGGCGCGGGAGGGCGAGCCGAC 180
 QY 181 GTCTCTCTGAGGAAGCGGGAGTGGACCATCGGGCGGACAGAGTGTGCACTTTCCTTC 240
 DB 181 GTCTCTCTGAGGAAGCGGGAGTGGACCATCGGGCGGACAGAGTGTGCACTTTCCTTC 240
 QY 241 CCCAGCAATAAATCGGTCTCTGGAGATCACTGTGAGATTGTAGTGGATGAATAATCAGGT 300
 DB 241 CCCAGCAATAAATCGGTCTCTGGAGATCACTGTGAGATTGTAGTGGATGAATAATCAGGT 300
 QY 301 CAGGTGACACTGGGAAGATACACAGACACAGTGGACAGTGGATTAAACAAGCTGAAGTTGTT 360
 DB 301 CAGGTGACACTGGGAAGATACACAGACACAGTGGACAGTGGATTAAACAAGCTGAAGTTGTT 360
 QY 361 AAGAGCAGACATGCCCTTTACAGACTGGGATGTCTACTCTTGGTGTACAGGAAGAT 420
 DB 361 AAGAGCAGACATGCCCTTTACAGACTGGGATGTCTACTCTTGGTGTACAGGAAGAT 420
 QY 421 GAAACGGGACACAGCTGGCATACCTCTATGAATCTTTAAGTGAAGAACCAAGGCATGACA 480
 DB 421 GAAACGGGACACAGCTGGCATACCTCTATGAATCTTTAAGTGAAGAACCAAGGCATGACA 480
 QY 481 CAAGAATCTTTGAAGCTAAACAAGGAAATGTGTTCCATGGGACCAAGAATCACTCAGGT 540
 DB 481 CAAGAATCTTTGAAGCTAAACAAGGAAATGTGTTCCATGGGACCAAGAATCACTCAGGT 540

Db	1621	CGCGTCTGCCTCGAGCCCTTTCTGCACCTGTACTGGGGCTGCAACCGCGACCGGCTGCTAC	1680
Qy	1681	GGCTGCTGCCTGCCCGTTTCTGTGAGCTCAACCTCGSGTGTACAAGTGTCTGGACGCGCTGCTG	1740
Db	1681	GGCTGCTGCCTGCCCGTTTCTGTGAGCTCAACCTCGSGTGTACAAGTGTCTGGACGCGCTGCTG	1740
Qy	1741	AACAACAACAGCTACGAGTCAGAGTCAGACATCTCTGAAGAAATPACTGTGCAACACAGAGTTTGACA	1800
Db	1741	AACAACAACAGCTACGAGTCAGAGTCAGACATCTCTGAAGAAATPACTGTGCAACACAGAGTTTGACA	1800
Qy	1801	TGGAAGAAACATGTTGACCGAGAGCCCTGTCGGCTCTCCAGCGGGAGTGTCTTCGTCGTCT	1860
Db	1801	TGGAAGAAACATGTTGACCGAGAGCCCTGTCGGCTCTCCAGCGGGAGTGTCTTCGTCGTCT	1860
Qy	1861	GATTACAGAGTCACGGGAGACACCGTTCTGTGTACTGTCTGTGCGCTGCGCAGCTTCCGT	1920
Db	1861	GATTACAGAGTCACGGGAGACACCGTTCTGTGTACTGTCTGTGCGCTGCGCAGCTTCCGT	1920
Qy	1921	GAGCTGACCTATCAGTATCGGAGAACATTCCTGTCTTCGAGTTCGAGTGGCGCGTAACA	1980
Db	1921	GAGCTGACCTATCAGTATCGGAGAACATTCCTGTCTTCGAGTTCGAGTGGCGCGTAACA	1980
Qy	1981	TCCCGTCTGACTGCTACTCTGGGCGGTAACTGCGGCACCTCAGGTGAAAGCTCAACACGCC	2040
Db	1981	TCCCGTCTGACTGCTACTCTGGGCGGTAACTGCGGCACCTCAGGTGAAAGCTCAACACGCC	2040
Qy	2041	ATGAAATTCATCATATCTGTGAACAGACAGGTTCAAAAATCAAGCATCCAGAGCCCT	2100
Db	2041	ATGAAATTCATCATATCTGTGAACAGACAGGTTCAAAAATCAAGCATCCAGAGCCCT	2100
Qy	2101	GAGCAGCTTTTCAGCACCTGAGAGTGAAGAGACGCTGTTTTTAAAAATCAGAGACAAGCACG	2160
Db	2101	GAGCAGCTTTTCAGCACCTGAGAGTGAAGAGACGCTGTTTTTAAAAATCAGAGACAAGCACG	2160
Qy	2161	TCAAGTGTGTTTTTCACAGCCCTTCAGGGAAGGAGCGCAGGCTCTCCGACAGTGTCTCTGG	2220
Db	2161	TCAAGTGTGTTTTTCACAGCCCTTCAGGGAAGGAGCGCAGGCTCTCCGACAGTGTCTCTGG	2220
Qy	2221	GGTGACTCTTCTGTGAGACTTTTTTACCCCTCTGAGTGAGACCCCTCCCGAGAGCCCGGGGG	2280
Db	2221	GGTGACTCTTCTGTGAGACTTTTTTACCCCTCTGAGTGAGACCCCTCCCGAGAGCCCGGGGG	2280
Qy	2281	CCGAGAGCCGCCCTCTGTGTGAGCGCTGGGCGAGGCTCTGTGGCATCAGCAGCAGAGA	2340
Db	2281	CCGAGAGCCGCCCTCTGTGTGAGCGCTGGGCGAGGCTCTGTGGCATCAGCAGCAGAGA	2340
Qy	2341	CGAAGCCTTTCTGTAAACATCGCGCGCTCCCGCCGAGAGGGGCGAGTTTGTCTCTTTTGTAC	2400
Db	2341	CGAAGCCTTTCTGTAAACATCGCGCGCTCCCGCCGAGAGGGGCGAGTTTGTCTCTTTTGTAC	2400
Qy	2401	ATTTTCGAAACTACAGTTAAAGCAGAGTCTGTTTTTCAGGAAAGTTTCAAGGGAGAG	2460
Db	2401	ATTTTCGAAACTACAGTTAAAGCAGAGTCTGTTTTTCAGGAAAGTTTCAAGGGAGAG	2460
Qy	2461	GGCAAGTTTATCAAAAACATTTTTCAGGAGAGGGAGCATTAAGTTTACAGCCTCACAGGA	2520
Db	2461	GGCAAGTTTATCAAAAACATTTTTCAGGAGAGGGAGCATTAAGTTTACAGCCTCACAGGA	2520
Qy	2521	CGTACAATAATCTGCTGTGGGAAAAACACAGCATTTTTATCTATTTTTTTATTTTAATA	2580
Db	2521	CGTACAATAATCTGCTGTGGGAAAAACACAGCATTTTTATCTATTTTTTTATTTTAATA	2580
Qy	2581	GGTTTGGTGCTTATCTTTCTAATAGATTTAAATGTCACAACTGTAGCAAAATAATATA	2640
Db	2581	GGTTTGGTGCTTATCTTTCTAATAGATTTAAATGTCACAACTGTAGCACAATAATATA	2640
Qy	2641	ATTTTATATTTTACAAATGTGACAAAAAATAAAAAA	2679
Db	2641	ATTTTATATTTTACAAATGTGACAAAAAATAAAAAA	2679

AX877194
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
JOURNAL
FEATURES
source
CDS

AX877194
Sequence 12099 from Patent EP1074617.
AX877194
AX877194.1 GI:40031930
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
1
Ota, T., Isogai, T., Nishikawa, T., Hayashi, K., Saito, K., Yamamoto, J.,
Tahii, S., Sugiyama, T., Wakamatsu, A., Nagai, K. and Otsuki, T.
Primers for synthesising full-length cDNA and their use
Patent: EP 1074617-A 12099 07-FEB-2001;
Research Association for Biotechnology (JP)
Location/Qualifiers
1. .2639
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
79. .2037
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAE89614.1"
/db_xref="GI:40031931"
/translation="MERPEGQSPPPQWGLRLRGAEGEPHVLLRKEWTIGRRR
GDLSPFNKLVEGHVDRHRIVDKSKQVLEDTSGTVINKLVKVKQKCPLOTGDV
ILVYRNKPEHNVAYLYESLSEKQMTSEDTSGTVINKLVKVKQKCPLOTGDV
EPPQSTSDLPFTASSTPEPPAGRSRSCSGGGGIPKSGQSPVASDEVHDF
ASALPRKTAISFSLSEPPQEDLEPVKKRWGDDLDLNGQLVAQPRNAQVHEDV
RAAGPKNNMEETLTCII CODLLHDCVLPQCHTCAACYSGWMSRSLCPTCRCPV
ERICKHNNLEAVLII QHPDKSRSEEDVQSDARNKITQDMLQPKVRSFLSDRGS
SEDLLESDVDSSESDISQVYVCRCPVRRQAAQPHCPAPEGPGPAQALQDAPS
TSVSLTAVQDYVCPQLQSHALTCFCFQPMPPRRAREODPRVAPOQACVLCFFCHL
YNGCTGFGCLAPFCELNGLDKDGLVNNNSYESDILKNYLATRGLTKWMLTES
LVALRGVFLSDRYVTGTVLVCYCGCLSGFRELTYQYQNIPASELPVAVTSRPDCY
WGNCRCTQVKAHAMKFNHICEQTRFN"

ORIGIN
Query Match 79.6%; Score 2133; DB 6; Length 2639;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 529 GATACCTCAGGTGCAGGTGCAGGCGAGGGCGGATCCCGGGTCCCTCGTGGTGGCCC 588
DB 481 GATACCTCAGGTGCAGGTGCAGGCGAGGGCGGATCCCGGGTCCCTCGTGGTGGCCC 540
QY 589 GCACCTCAGGTGCTTTGAGGAACACAGCATCAACATCGACGTCAGACCTCTTCCCC 648
DB 541 GCACCTCAGGTGCTTTGAGGAACACAGCATCAACATCGACGTCAGACCTCTTCCCC 600
QY 649 ACAGCTCGGCTCTTCCAGGAGGCTTCTCTGCGAGGGCGAGGCTTCTCTCGAGTGT 708
DB 601 ACAGCTCGGCTCTTCCAGGAGGCTTCTCTGCGAGGGCGAGGCTTCTCTCGAGTGT 660
QY 709 GGGTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGGTCCCTCTGTGGCAAGTGATGA 768
DB 661 GGGTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGGTCCCTCTGTGGCAAGTGATGA 720
QY 769 GTCTCCAGCTTTGCCTCAGCTCTCCAGACAGAAAGACTCGCTCTTTTCGTGGTGGAA 828
DB 721 GTCTCCAGCTTTGCCTCAGCTCTCCAGACAGAAAGACTCGCTCTTTTCGTGGTGGAA 780
QY 829 CCCAGGATCAGAGGATTTGGAGCCCGTGAAAGAGAAATGAGAGGATGGGACCTT 888
DB 781 CCCAGGATCAGAGGATTTGGAGCCCGTGAAAGAGAAATGAGAGGATGGGACCTT 840
QY 889 GACCTGAACGGGAGTTGTTGGTGGCAGACACCGGTAGAAATGCCAAACCGTCCACGAG 948
DB 841 GACCTGAACGGGAGTTGTTGGTGGCAGACACCGGTAGAAATGCCAAACCGTCCACGAG 900
QY 949 GACGTACAGACGCGGTGGGAAGCCAGACAGATGGAGGAGACGCTGACATGCATCATC 1008

FEATURES	PT	CDS	Location/Qualifiers		Query Match	Best Local Similarity	Matches 2133; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
			Location/Qualifiers	(79) . . (2034) .							
Source			1. .2639								
			/organism="Homo sapiens"								
			/mol_type="genomic DNA"								
			/db_xref="taxon:9606"								
ORIGIN											
Query Match 79.6%; Score 2133; DB 6; Length 2639;											
Best Local Similarity 100.0%; Pred. No. 0;											
Matches 2133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;											
QY	529	GATACCTCAGGTGCGAGTGCAGGCGGAGGGGCGGATCCCGGGTCCCTCCGTCGTCGCC	588								
DB	481	GATACCTCAGGTGCGAGTGCAGGCGGAGGGGCGGATCCCGGGTCCCTCCGTCGTCGCC	540								
QY	589	GCCACTCAGGTGCTTTGAGGAACACAGCCATCAACATGACGTGACAGCTCTTCCCC	648								
DB	541	GCCACTCAGGTGCTTTGAGGAACACAGCCATCAACATGACGTGACAGCTCTTCCCC	600								
QY	649	ACAGCTCGGCTCTTCCAGGAGCTTCTCTGAGGGGAGAGGCTTCCACAGTGT	708								
DB	601	ACAGCTCGGCTCTTCCAGGAGCTTCTCTGAGGGGAGAGGCTTCCACAGTGT	660								
QY	709	GGGTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGGTCCCTCTGTGGCAAGTATGAA	768								
DB	661	GGGTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGGTCCCTCTGTGGCAAGTATGAA	720								
QY	769	GTCTCAGCTTTGCTCCTCAGCTCTCCAGACAGAAAGACGTGCTCTTTGCTGCTGGAA	828								
DB	721	GTCTCAGCTTTGCTCCTCAGCTCTCCAGACAGAAAGACGTGCTCTTTGCTGCTGGAA	780								
QY	829	CCCCAGGATCAGAGGATTTGAGCCCGTGAAGAGAAATCAGAGGAGATGGGACCTT	888								
DB	781	CCCCAGGATCAGAGGATTTGAGCCCGTGAAGAGAAATCAGAGGAGATGGGACCTT	840								
QY	889	GACCTGAACGGGCGAGTTGTTGTCGACAAACCGGTGAGAAATGCCAAACCGTCCACGAG	948								
DB	841	GACCTGAACGGGCGAGTTGTTGTCGACAAACCGGTGAGAAATGCCAAACCGTCCACGAG	900								
QY	949	GAGCTCAGAGCAGCGCTGGGAGCAGACAGAGATGGAGGACGCTGACATGATCATC	1008								
DB	901	GAGCTCAGAGCAGCGCTGGGAGCAGACAGAGATGGAGGACGCTGACATGATCATC	960								
QY	1009	TGCAGGACCTGTGCACGACTGCGTAGTTTGCAGCCCTGCATGCACACAGTTCTCGCG	1068								
DB	961	TGCAGGACCTGTGCACGACTGCGTAGTTTGCAGCCCTGCATGCACACAGTTCTCGCG	1020								
QY	1069	GCTTGCTACTCGGGCTGGATGGAGCGCTCGTCTGTGTCTTACCTGCGCTGTCCGCTG	1128								
DB	1021	GCTTGCTACTCGGGCTGGATGGAGCGCTCGTCTGTGTCTTACCTGCGCTGTCCGCTG	1080								
QY	1129	GAGCGGATCTGTAACCAACATCTCTCAACACCTCGTGGAGGACATCTCATCCAGCAT	1188								
DB	1081	GAGCGGATCTGTAACCAACATCTCTCAACACCTCGTGGAGGACATCTCATCCAGCAT	1140								
QY	1189	CCAGACAGAGTGCAGTGAAGAGATGTGAAATATGATGGATGGACGGAATAAATCACT	1248								
DB	1141	CCAGACAGAGTGCAGTGAAGAGATGTGAAATATGATGGATGGACGGAATAAATCACT	1200								
QY	1249	CAAGACATCTGCAGCCCAAGTCAGCGCTCTTTTCTGATGAAGAGGGAGTTTCAGAG	1308								
DB	1201	CAAGACATCTGCAGCCCAAGTCAGCGCTCTTTTCTGATGAAGAGGGAGTTTCAGAG	1260								
QY	1309	GACCTGCTGGAGTGTTCAGAGTGTGACGTGAGTCTCTCAGACATTTAGCCAGCCATACGTC	1368								
DB	1261	GACCTGCTGGAGTGTTCAGAGTGTGACGTGAGTCTCTCAGACATTTAGCCAGCCATACGTC	1320								
QY	1369	GTGTGCGGCGTGTCTCAGTACAGAGCGGGCGGCGGCTCCCTCCCTCCCTCCCTCCCT	1428								
DB	1321	GTGTGCGGCGTGTCTCAGTACAGAGCGGGCGGCGGCTCCCTCCCTCCCTCCCTCCCT	1380								

QY	1429	CCGAGGGCGAGCCAGGAGCCGCCACAGGCCCTGGGGATGCACCTCCACGTCGTCAGC	1488								
DB	1381	CCGAGGGCGAGCCAGGAGCCGCCACAGGCCCTGGGGATGCACCTCCACGTCGTCAGC	1440								
QY	1489	CTGACGACAGCAGTCCAGGATTTACGTGTGCCCTCTGCAAGAAAGACACGCTGTGACCC	1548								
DB	1441	CTGACGACAGCAGTCCAGGATTTACGTGTGCCCTCTGCAAGAAAGACACGCTGTGACCC	1500								
QY	1549	TGCTGCTTCCAGCCATGCGGACCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG	1608								
DB	1501	TGCTGCTTCCAGCCATGCGGACCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG	1560								
QY	1609	CCTCAGCAGTGTGCGGTCTGCTGACGCTTCTGCGCACCTGTACTGGGGCTGACCCCG	1668								
DB	1561	CCTCAGCAGTGTGCGGTCTGCTGACGCTTCTGCGCACCTGTACTGGGGCTGACCCCG	1620								
QY	1669	ACGGCTGCTACGGCTGCTGCGGCCCGTTTGTGAGCTGAACCTGGGTGACAGTGTCTG	1728								
DB	1621	ACGGCTGCTACGGCTGCTGCGGCCCGTTTGTGAGCTGAACCTGGGTGACAGTGTCTG	1680								
QY	1729	GACGGCTGCTGAACAAACACAGCTACGAGTCAGACATCTCTGAAGAAATTAACCTGGCAACC	1788								
DB	1681	GACGGCTGCTGAACAAACACAGCTACGAGTCAGACATCTCTGAAGAAATTAACCTGGCAACC	1740								
QY	1789	AGAGTTTGAATGGAAGAAACATGTTGAACGAGAGCTCTGCGCTCTCCAGCGGGAGTG	1848								
DB	1741	AGAGTTTGAATGGAAGAAACATGTTGAACGAGAGCTCTGCGCTCTCCAGCGGGAGTG	1800								
QY	1849	TTTCTGCTGCTGATTAACAGGTCAACGAGAGACACGCTTCTGTGTTACTGCTGTGGCTG	1908								
DB	1801	TTTCTGCTGCTGATTAACAGGTCAACGAGAGACACGCTTCTGTGTTACTGCTGTGGCTG	1860								
QY	1909	CGCAGCTTCCGTGAGCTGACCTATCATCTGTCGACAGAACTTCTGCTCCGAGTTGCCA	1968								
DB	1861	CGCAGCTTCCGTGAGCTGACCTATCATCTGTCGACAGAACTTCTGCTCCGAGTTGCCA	1920								
QY	1969	GTGGCCGTAACTCCGCTCTGACTGCTACTGGGGCGGTAACTGCCGACTCAGAGTGA	2028								
DB	1921	GTGGCCGTAACTCCGCTCTGACTGCTACTGGGGCGGTAACTGCCGACTCAGAGTGA	1980								
QY	2029	GCTCACCACGCGCATGAAATTCATATCTGTGAACAGCAAGGTTCAAAAATAAGCA	2088								
DB	1981	GCTCACCACGCGCATGAAATTCATATCTGTGAACAGCAAGGTTCAAAAATAAGCA	2040								
QY	2089	TCCAGAGGCGCTGAGCAGCTTTGAGCCTGAGGTGAGAGAGGCTTTTAAATAACA	2148								
DB	2041	TCCAGAGGCGCTGAGCAGCTTTGAGCCTGAGGTGAGAGAGGCTTTTAAATAACA	2100								
QY	2149	GAGACAAGCAGCTCAAGGTGTTTTCAGCCCTGAGGGAAGGAGCGCAGGCTCTCCGA	2208								
DB	2101	GAGACAAGCAGCTCAAGGTGTTTTCAGCCCTGAGGGAAGGAGCGCAGGCTCTCCGA	2160								
QY	2209	CAGTGTCTCTGGGTGACTCTTCTGTGGAGCTTTTAACTCTGAGTGAAGCCCTCCCA	2268								
DB	2161	CAGTGTCTCTGGGTGACTCTTCTGTGGAGCTTTTAACTCTGAGTGAAGCCCTCCCA	2220								
QY	2269	GAGCCCGGGGGCGCAGCCGCTCTCTGCTGAGCGCTGGGAGGCGCTCGTGGGCAT	2328								
DB	2221	GAGCCCGGGGGCGCAGCCGCTCTCTGCTGAGCGCTGGGAGGCGCTCGTGGGCAT	2280								
QY	2329	CAGCAGCAGAGAGCAAGCCCTTTCTGTAACATGCGGCGCTCCCGCCGAGAGGGGAGTTT	2388								
DB	2281	CAGCAGCAGAGAGCAAGCCCTTTCTGTAACATGCGGCGCTCCCGCCGAGAGGGGAGTTT	2340								
QY	2389	GCTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGTCTGTTTTTTCAGGAAAAGTT	2448								
DB	2341	GCTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGTCTGTTTTTTCAGGAAAAGTT	2400								
QY	2449	TCAAGGAGAGAGGCAAGTTTATCAAAAATTTTTCAGGAGAGAGGAGGAGTAAAGTTTA	2508								
DB	2401	TCAAGGAGAGAGGCAAGTTTATCAAAAATTTTTCAGGAGAGAGGAGGAGTAAAGTTTA	2460								
QY	2509	CAGCTACAGGACGTACACATATCTCTGCTGGGAAAACACACAGCATTTTATCTATT	2568								

Db 2461 CAGCCTACAGGACGTACACATAATCTGCTGCTGGGAACACACAGCATTTATCTATTT 2520
Qy 2569 TTTATTTTAAATAGCTTTGGCTTATCTCTTAATAGATTAATTAATGTCACAACTGTAGC 2628
Db 2521 TTTATTTTAAATAGCTTTGGCTTATCTCTTAATAGATTAATTAATGTCACAACTGTAGC 2580
Qy 2629 ACAATAATATAATTTATATAATTTACAAATTCAC 2661
Db 2581 ACAATAATATAATTTATATAATTTACAAATTCAC 2613

RESULT 4

AK027687

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

FEATURES

source

Location/Qualifiers

1. .2639

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="NT2RP4000455"

/cell_line="NT2"

/cell_type="teratocarcinoma"

/clone_lib="NT2RP4"

/notes="Cloning vector: pME18SFL3-mRNA from NT2 neuronal precursor cells after 2-weeks retinoic acid (RA) induction."

79. .2037

/notes="unnamed protein product"

/codon_start=1

/protein_id="BAB55297.1"

/db_xref="GI:14042553"

/translation="MRPEEGKQSPPPQWGLLLGLABEGEPHVLKRWTTGRR

GCGLSPFNKLVSQDRIIVDEKSGQVLTSTGTVINKLVKKQTCPLQTDV

YLIVYKRNPEFTVAALYSELKQGMTOESFTSGAGAGRGADPRVPSPTQVCF

EEFQPTSTSLDLPFTASSTFSPAGRSRSSCGSGGGISPKSGSPVADSVSFF

ASALPRKTSFSLSPQDEPLEPVKKWRGDLNGLLVAPRNAACTVHEDV

RAAAGKPDMEETLTCIICODLLHDCVLPQWHTFCAACYSGMWRSSLCCTCRCPV

ERICKHLLNLNVEALIOPDKSRSEEDVQSDARKNTODMLQPKVRSFSDGGS

SEDLLESDVDSSEDSISQPYVVCRCQPEYRQAQPHCPAPGEPGAPQALDAPS

TSVSLTAVDQVYCPQGGSHALCTCCFPMPDRARSDQDPAPQCAVCLQPFCHL

YWCTGTGCGCLAPFCELNGLKLDGLVNNNSYSEDLKLYLATRLGLTKWMLTSS

LVALQGVFLSDYRTVLCYCCGLRSFELTYQYRQNIPIASELPVAVTSRDCY

WGRNCRTOVKAHAMFNHCQTRFKN"

ORIGIN

Query Match 79.6%; Score 2133; DB 9; Length 2639;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2133; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 529 GATACTCAGGTGAGGTGAGGGCGAGGGCGAGTCCCGGGTCCCTCCGTCGTCGCC 588
Db 481 GATACTCAGGTGAGGTGAGGGCGAGGGCGAGTCCCGGGTCCCTCCGTCGTCGCC 540

Qy 589 GCCACTCAGGTGAGGTGAGGGCGAGGGCGAGTCCCGGGTCCCTCCGTCGTCGCC 648
Db 541 GCCACTCAGGTGAGGTGAGGGCGAGGGCGAGTCCCGGGTCCCTCCGTCGTCGCC 600

Qy 649 ACAGCTTCGGCCCTCTTCCACGAGGCTTCTCTGAGGGCGAGAGGCTTCTTCCAGTTGT 708
Db 601 ACAGCTTCGGCCCTCTTCCACGAGGCTTCTCTGAGGGCGAGAGGCTTCTTCCAGTTGT 660

Qy 709 GGGTCTGGGGTGGTGGCATCTCCCTTAAGAGAGTGTCTCTTGTGGCAAGTATGAA 768
Db 661 GGGTCTGGGGTGGTGGCATCTCCCTTAAGAGAGTGTCTCTTGTGGCAAGTATGAA 720

Qy 769 GTCTCCAGCTTTTCCCTCAGCTCTCCACAGACAGAAAGATGCTCTTCTTGTGTTGAA 828
Db 721 GTCTCCAGCTTTTCCCTCAGCTCTCCACAGACAGAAAGATGCTCTTCTTGTGTTGAA 780

Qy 829 CCCAGGATCAGAGATTTGGAGCCCTGTAAGAGAGAGAGAGAGAGAGAGAGAGAGAG 888
Db 781 CCCAGGATCAGAGATTTGGAGCCCTGTAAGAGAGAGAGAGAGAGAGAGAGAGAGAG 840

Qy 889 GACCTGAAACGGGCGAGTTGTTGGTGCACACACCGCTAGAAATGCCAACCGTCCACGAG 948
Db 841 GACCTGAAACGGGCGAGTTGTTGGTGCACACACCGCTAGAAATGCCAACCGTCCACGAG 900

Qy 949 GAGCTCAGAGCGAGCTGGGAGCCAGACAGAGTGGAGAGAGAGAGAGAGAGAGAGAGATC 1008
Db 901 GAGCTCAGAGCGAGCTGGGAGCCAGACAGAGTGGAGAGAGAGAGAGAGAGAGAGAGATC 960

Qy 1009 TGCAGGACCTGCTGCACGACTGCTGAGTTTGCAGCCCTGTCATGCACACAGTTTCTGCGG 1068
Db 961 TGCAGGACCTGCTGCACGACTGCTGAGTTTGCAGCCCTGTCATGCACACAGTTTCTGCGG 1020

Qy 1069 GCTTGTCTCTCGGCTGGATGAGGCTGCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTG 1128
Db 1021 GCTTGTCTCTCGGCTGGATGAGGCTGCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080

Qy 1129 GAGCGGATCTGTAATAAACCAATCTCTCAACACCTCTGGAAGCATACCTCATCCAGAT 1188
Db 1081 GAGCGGATCTGTAATAAACCAATCTCTCAACACCTCTGGAAGCATACCTCATCCAGAT 1140

Qy 1189 CCAGACAAGAGTCGAGTGAAGAAGATGCAAGATGATGGATGCCAGGAATAAATCACT 1248
Db 1141 CCAGACAAGAGTCGAGTGAAGAAGATGCAAGATGATGGATGCCAGGAATAAATCACT 1200

Qy 1249 CAAGACATCTCAGCCCAAGTCAAGGCGTCTTTTCTGATGAAGAAGGAGTTCAGAG 1308
Db 1201 CAAGACATCTCAGCCCAAGTCAAGGCGTCTTTTCTGATGAAGAAGGAGTTCAGAG 1260

Qy 1309 GACCTGCTGAGCTGTCAGCTTGCAGTGTGCTCAGACATTTAGCCAGCCATACGTC 1368
Db 1261 GACCTGCTGAGCTGTCAGCTTGCAGCTTGCAGTGTGCTCAGACATTTAGCCAGCCATACGTC 1320

Qy 1369 GTGTGCGGAGTGTCTGAGTACAGAGGCGGCGGCGGCGGCTCCCACTGCCAGCA 1428
Db 1321 GTGTGCGGAGTGTCTGAGTACAGAGGCGGCGGCGGCGGCTCCCACTGCCAGCA 1380

Qy 1429 CCGAGGGCGAGCGAGGAGCCCAAGGCTTGGGGATGCAACCTCCACGCTCCGTCAGC 1488
Db 1381 CCGAGGGCGAGCGAGGAGCCCAAGGCTTGGGGATGCAACCTCCACGCTCCGTCAGC 1440

Qy 1489 CTGACGACAGCAGTCCAGGATTTAGTGTGCTCTGCAAGAGCAAGCCGCTGTGCAAC 1548
Db 1441 CTGACGACAGCAGTCCAGGATTTAGTGTGCTCTGCAAGAGCAAGCCGCTGTGCAAC 1500

QY	1549	TGCTGTTTCCAGCCCATGCCCCGACCGGAGACGGAGCGGACGAGAACCCGCGTGTGCC	1608
DB	1501	TGCTGTTTCCAGCCCATGCCCCGACCGGAGACGGAGCGGAGCGGACGAGAACCCGCGTGTGCC	1560
QY	1609	CCTCAGCAGTGTGGGGTCTGCTGTCAGCCCTTTCTGCACCTGTACTTGGGGGTGCACCCGG	1668
DB	1561	CCTCAGCAGTGTGGGGTCTGCTGTCAGCCCTTTCTGCACCTGTACTTGGGGGTGCACCCGG	1620
QY	1669	ACGGCTGCTAGGCTGCCTGGCCCCGTTTGTGAGCTCAACCTGGGTGACAGTGTCTG	1728
DB	1621	ACGGCTGCTAGGCTGCCTGGCCCCGTTTGTGAGCTCAACCTGGGTGACAGTGTCTG	1680
QY	1729	GACGCGTGTGAACAACAACAGCTACGAGTCAGACATCCTCGAAGATTTACTCTGGCAACC	1788
DB	1681	GACGCGTGTGAACAACAACAGCTACGAGTCAGACATCCTCGAAGATTTACTCTGGCAACC	1740
QY	1789	AGAGGTTTGAATGGAATAAACATGTTGACCGAGAGCCTCGTGCCTCTCCACGCGGGAGTG	1848
DB	1741	AGAGGTTTGAATGGAATAAACATGTTGACCGAGAGCCTCGTGCCTCTCCACGCGGGAGTG	1800
QY	1849	TTTCTGCTGTCTGATTACAGAGTCACGGGAGACACCGTTCTGTGTTACTGTCTGGGCTG	1908
DB	1801	TTTCTGCTGTCTGATTACAGAGTCACGGGAGACACCGTTCTGTGTTACTGTCTGGGCTG	1860
QY	1909	CGCAGCTTCCGTGAGCTGCACCTACAGTATCGCGAGAACATTCCTGCTTCCGAGTTCGCA	1968
DB	1861	CGCAGCTTCCGTGAGCTGCACCTACAGTATCGCGAGAACATTCCTGCTTCCGAGTTCGCA	1920
QY	1969	GTGGCGGTAAACATCCCGTCTGACTGCTACTGGGGCGGTAACTGCCGCACTCAGGTGAAA	2028
DB	1921	GTGGCGGTAAACATCCCGTCTGACTGCTACTGGGGCGGTAACTGCCGCACTCAGGTGAAA	1980
QY	2029	GCTCACACGCGCATGAATTTCAATCATATCTGTGAACAGACAAGGTTCAAAAACATAAGCA	2088
DB	1981	GCTCACACGCGCATGAATTTCAATCATATCTGTGAACAGACAAGGTTCAAAAACATAAGCA	2040
QY	2089	TCCAGAGCCCTGAGCAGCTTTCAGACCTGGAGGTGAGAGAGCGTGTTTTAAANATACA	2148
DB	2041	TCCAGAGCCCTGAGCAGCTTTCAGACCTGGAGGTGAGAGAGCGTGTTTTAAANATACA	2100
QY	2149	GAGACAAGCAGCTCAAGGTTGTTTTACAGCCGCCCTGAGGGAAGGACGACAGGGTCTCCGA	2208
DB	2101	GAGACAAGCAGCTCAAGGTTGTTTTACAGCCGCCCTGAGGGAAGGACGACAGGGTCTCCGA	2160
QY	2209	CAGGTGCTCTGGGGTGACTCTTCTGTGGAGCTTTTTACCTCTGAGTGAGACCTCCCCA	2268
DB	2161	CAGGTGCTCTGGGGTGACTCTTCTGTGGAGCTTTTTACCTCTGAGTGAGACCTCCCCA	2220
QY	2269	GAGCCCCGGGGCCGACGCCGCCCTCCTGGTAGCGTGGCGAGGGCTCGTGTGGCAT	2328
DB	2221	GAGCCCCGGGGCCGACGCCGCCCTCCTGGTAGCGTGGCGAGGGCTCGTGTGGCAT	2280
QY	2329	CAGCAGCAGAGACGAAAGCTTTTCTGTAAACATATGGCGCGTCCCGCCGACAGGGGCGATTTT	2388
DB	2281	CAGCAGCAGAGACGAAAGCTTTTCTGTAAACATATGGCGCGTCCCGCCGACAGGGGCGATTTT	2340
QY	2389	GCTCTTTTGTACATTTTCCGAACCTACAGTTAAAGCAGAGTCTGTTTTTCAGAAAAGTT	2448
DB	2341	GCTCTTTTGTACATTTTCCGAACCTACAGTTAAAGCAGAGTCTGTTTTTCAGAAAAGTT	2400
QY	2449	TCAAGGGAGAAGGCGAAGTTTATCAAAAAACATGTTTTAGCAGAGAGGGAGCATAAAGTTTA	2508
DB	2401	TCAAGGGAGAAGGCGAAGTTTATCAAAAAACATGTTTTAGCAGAGAGGGAGCATAAAGTTTA	2460
QY	2509	GAGCCTACAGACGTACAAATATCTGCTGTGGGAAACCAACAGCATTTTATCTATTTT	2568
DB	2461	GAGCCTACAGACGTACAAATATCTGCTGTGGGAAACCAACAGCATTTTATCTATTTT	2520
QY	2569	TTTATTTTAAATAGGTTTGGTGCTTATCTCTAATAAGATTTAAATGTCCAAACCTGTAGC	2628
DB	2521	TTTATTTTAAATAGGTTTGGTGCTTATCTCTAATAAGATTTAAATGTCCAAACCTGTAGC	2580

QY	2629	ACAATTAATAATTATTTATTAATTTACAAATTGAC	2661
DB	2581	ACAATTAATAATTATTTATTAATTTACAAATTGAC	2613
RESULT 5			
BC012072			
LOCUS	3189 bp	mRNA	linear PRI 04-OCT-2003
DEFINITION	Homo sapiens checkpoint with forkhead and ring finger domains, mRNA (cDNA clone MGC:11963 IMAGE:4650348), complete cds.		
ACCESSION	BC012072		
VERSION	NC_012072.1	GI:15082329	
KEYWORDS	MGC.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 3189)		
AUTHORS	Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G., Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D., Altschul,S.F., Ziegler,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K., Hopkins,R.F., Latorre,H., Moore,T.I., Max,S.I., Wang,J., Haieh,F., Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L., Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L., Scheetz,T.E., Brownstein,M.J., Ustin,T.B., Toshiyuki,S., Carninci,P., France,C., Raha,S.S., Loquellano,N.A., Peters,G.J., Abramson,R.D., Mullany,S.J., Bosak,S.A., McEwan,P.J., McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S., Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W., Villalobio,A.C., Munz,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A., Fahey,J., Helton,E., Kettman,M., Madan,A., Rodrigues,S., Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y., Bouffard,G.G., Blakealey,R.W., Touchman,J.W., Green,E.D., Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M., Buttefield,Y.S., Krzywinski,M.I., Skalska,U., Smalios,D.E., Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.		
TITLE	Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences		
JOURNAL	Proc. Natl. Acad. Sci. U.S.A.	99 (26), 16899-16903	(2002)
MEDLINE	23288257		
PUBMED	12477932		
REFERENCE	2 (bases 1 to 3189)		
AUTHORS	Strausberg,R.		
TITLE	Direct Submission		
JOURNAL	Submitted (02-AUG-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA		
REMARK	NIH-MGC project URL: http://mgc.nci.nih.gov		
COMMENT	Contact: MGC help desk Email: cgaps@mail.nih.gov Tissue Procurement: ARCC cDNA Library Preparation: Ruben Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Genome Sequence Center, BC Cancer Agency, Vancouver, BC, Canada info@bcgsc.bc.ca Steven Jones, Jennifer Asano, Ian Boeder, Yaron Butterfield, Susanna Chan, Readman Chiu, Chris Fjell, Brin Garland, Ran Guin, Leticia Hsiao, Martin krzywinski, Reta Kutsche, Oliver Lee, Soo Sen Lee, Victor Ling, Carrie Mathewson, Candice McLeavy, Steven Ness, Pawan Pandoh, Anna-Liisa Prabhu, Farvanee Saedi, Jacqueline Schein, Duane Smalios, Michael Smith, Corrine Spence, Jeff Scott, Michael Thorne, Miranada Teai, Natasja van den Bosch, Jill Vardy, George Yang, Scott Zuyderduyn, Marco Marra.		
FEATURES	Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov Series: IRAL Plate: 29 Row: n Column: 3 This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 8922674. Location/Qualifiers 1..3189		

/organism="Homo sapiens"
/mol_type="mrna"
/db_xref="taxon:9606"
/clone="MGC:19963 IMAGE:4650348"
/tissue_type="Placenta, chorioncarcinoma"
/clone_lib="NIH MGC 21"
/lab_host="DH10B-R"
/note="Vector: pOTB7"
1. .3189
/gene="CHFR"
/note="synonyms: FLJ10796, RNF116"
/db_xref="LocusID:55743"
/db_xref="MIM:605209"
9. .1967
/codon_start=1
/product="CHFR protein"
/protein_id="AAH12072.1"
/db_xref="GI:15082330"
/db_xref="LocusID:55743"
/translation="MERPEEGKQPPPPQWGRLLRLGAEEGEPHLLRLKREWITGRR
GDLSPFNKLVSQDHCRIVVDEKSGQVLTEDTSGTVINKLVKVPKQCPLOTQGV
IYLVRKNEPHNVAYLVESLSEKQMTQESFTDSGAGARGADPRVPPSPATQVCF
PEPOSTSLDLPASASSTEPSAPGERSSCGSGGGI SPKSGSPVASDRVSF
ASALDRKTAFSLPEQDLELPVKKXRGDGLDLNGQLLVAQPRRNQVTHEDV
RAAGKPKMETLTCIIQDLDHCVSLQPCMETFCAACYSYGMWERSLSUCPTCRCPV
ERICKHILNLNLEAYLIQHPDKSRSEEDVQMDARKNIQTQMLQPKVRSFSDEEGS
SEDLLESDVSESDIQPVVCRQCEYRROAQPHPCEPGEPCAPQALGDAPS
TSVSLTAVQDVVCLPFCNLGHALCTCFQPMFDRVERQDPRVAPQCAVCLQPFCHL
YWGCTRTCYGLAPFLGSLNGLKCLDGLVANNVSVEDILKNYLATRLGLTWKMLTES
LVALQGVFLSLDVRVGTQVLCVCGGLRSFRELTYQVRQNI PASELPVAVTSRPDCY
WGRNCRQVKAHHAWKFNHICEQTRFN"
120. .317
/note="FHA; Region: FHA domain. The FHA
(Forhead-associated) domain is a phosphopeptide binding
motif"
/db_xref="CDD:pfam0498"
879. .1010
/note="HRD1; Region: COG5243, HRD1, HRD ubiquitin ligase
complex, ER membrane component [Posttranslational
modification, protein turnover, chaperones]"
/db_xref="CDD:COG5243"
529 GATACCTCAGGTGACAGTGCAGGGGAGGGGCGGATCCCGGGTCCCTCCGTCGTCGCC 588
411 GATACCTCAGGTGACAGTGCAGGGGAGGGGCGGATCCCGGGTCCCTCCGTCGTCGCC 470
589 GCCACTCAGGTGCTTTGAGGAACCAAGCCATCAACATCGACGTGACCTCTTCCCC 648
471 GCCACTCAGGTGCTTTGAGGAACCAAGCCATCAACATCGACGTGACCTCTTCCCC 530
649 ACAGCTCGGCTCTTCCAGGAGCTTCTCCTCGAGGGCGAGAGCGTTCTCCAGTTGT 708
531 ACAGCTCGGCTCTTCCAGGAGCTTCTCCTCGAGGGCGAGAGCGTTCTCCAGTTGT 590
709 GGGTCGCGGGTGGTGGCACTCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGAA 768
591 GGGTCGCGGGTGGTGGCACTCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGAA 650
769 GTCTCAGCTTTGCTCAGCTCTCCAGACAGAAAGCTCGCTCTTTTCGTCGTTGAA 828
651 GTCTCAGCTTTGCTCAGCTCTCCAGACAGAAAGCTCGCTCTTTTCGTCGTTGAA 710
829 CCCAGGATCAGAGGATTTGAGCCGCTGAAAGAAAGAAATGAGAGGAGATGGGACCTT 888
711 CCCAGGATCAGAGGATTTGAGCCGCTGAAAGAAAGAAATGAGAGGAGATGGGACCTT 770
889 GACCTGAAGCGGAGTGTGTGTCACAAACCGCTAGAAATGCCAAACCGTCCACGAG 948

ORIGIN

Query Match 75.8%; Score 2031; DB 9; Length 3189;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 2131; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 529 GATACCTCAGGTGACAGTGCAGGGGAGGGGCGGATCCCGGGTCCCTCCGTCGTCGCC 588
Db 411 GATACCTCAGGTGACAGTGCAGGGGAGGGGCGGATCCCGGGTCCCTCCGTCGTCGCC 470
Qy 589 GCCACTCAGGTGCTTTGAGGAACCAAGCCATCAACATCGACGTGACCTCTTCCCC 648
Db 471 GCCACTCAGGTGCTTTGAGGAACCAAGCCATCAACATCGACGTGACCTCTTCCCC 530
Qy 649 ACAGCTCGGCTCTTCCAGGAGCTTCTCCTCGAGGGCGAGAGCGTTCTCCAGTTGT 708
Db 531 ACAGCTCGGCTCTTCCAGGAGCTTCTCCTCGAGGGCGAGAGCGTTCTCCAGTTGT 590
Qy 709 GGGTCGCGGGTGGTGGCACTCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGAA 768
Db 591 GGGTCGCGGGTGGTGGCACTCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGAA 650
Qy 769 GTCTCAGCTTTGCTCAGCTCTCCAGACAGAAAGCTCGCTCTTTTCGTCGTTGAA 828
Db 651 GTCTCAGCTTTGCTCAGCTCTCCAGACAGAAAGCTCGCTCTTTTCGTCGTTGAA 710
Qy 829 CCCAGGATCAGAGGATTTGAGCCGCTGAAAGAAAGAAATGAGAGGAGATGGGACCTT 888
Db 711 CCCAGGATCAGAGGATTTGAGCCGCTGAAAGAAAGAAATGAGAGGAGATGGGACCTT 770
Qy 889 GACCTGAAGCGGAGTGTGTGTCACAAACCGCTAGAAATGCCAAACCGTCCACGAG 948

Db 771 GACCTGAAGCGGAGTGTGTGTCGCAAAACCGCTAGAAATGCCAAACCGTCCACGAG 830
Qy 949 GACCTCAGAGCAGCGGCTGGGAAGCCAGACAGATGGAGGAGACGCTGACATGCAATC 1008
Db 831 GACCTCAGAGCAGCGGCTGGGAAGCCAGACAGATGGAGGAGACGCTGACATGCAATC 890
Qy 1009 TGCAGGACCTGCTGCACACTGCGTAGTTTGTGACGCCCTGCTGATGACACAGTTTCTGCGG 1068
Db 891 TGCAGGACCTGCTGCACACTGCGTAGTTTGTGACGCCCTGCTGATGACACAGTTTCTGCGG 950
Qy 1069 GCTTGTACTCGGGCTGGATGAGCGCTGCTCCCTGTGTCTTCTGATGACCGCTGCTCCGCTG 1128
Db 951 GCTTGTACTCGGGCTGGATGAGCGCTGCTCCCTGTGTCTTCTGATGACCGCTGCTCCGCTG 1010
Qy 1129 GAGCGGATCTGTAATAAACCAATCTCAACAACTCTGCTGGAAGCATACCTCATCCAGCAT 1188
Db 1011 GAGCGGATCTGTAATAAACCAATCTCAACAACTCTGCTGGAAGCATACCTCATCCAGCAT 1070
Qy 1189 CCAGACAGAGTGCAGTGAAGAGATGTGCAAGATGATGATGATGATGATGATGATGATGATGAT 1248
Db 1071 CCAGACAGAGTGCAGTGAAGAGATGTGCAAGATGATGATGATGATGATGATGATGATGATGAT 1130
Qy 1249 CAAGACATGCTGCAGCCCAAGATGTCAGGCGCTCTTTTCTGATGAAGAGAGGATTCAGAG 1308
Db 1131 CAAGACATGCTGCAGCCCAAGATGTCAGGCGCTCTTTTCTGATGAAGAGAGGATTCAGAG 1190
Qy 1309 GACCTGCTGAGAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGT 1368
Db 1191 GACCTGCTGAGAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGT 1250
Qy 1369 GTGTGCGGCGAGTCTCTGAGTACAGAGCGAGCGGCGGCGAGCTCCCACTGCCAGCA 1428
Db 1251 GTGTGCGGCGAGTCTCTGAGTACAGAGCGAGCGGCGGCGAGCTCCCACTGCCAGCA 1310
Qy 1429 CCGAGGCGGAGCCAGGAGCCCAAGAGCTGTGGGGATGCACTCCCTCCAGTCCGTCAGC 1488
Db 1311 CCGAGGCGGAGCCAGGAGCCCAAGAGCTGTGGGGATGCACTCCCTCCAGTCCGTCAGC 1370
Qy 1489 CTGACAGCAGCAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGT 1548
Db 1371 CTGACAGCAGCAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGACAGT 1430
Qy 1549 TGCTGCTTCCAGCCCATGCGGACCGGAGCGGAGCGGCGGAGCGGAGCGGAGCGGAGCGGAGCGG 1608
Db 1431 TGCTGCTTCCAGCCCATGCGGACCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG 1490
Qy 1609 CTTGACAGTGTGCGGTGCTGCTGAGCGCTTTCTGCACTGTGACTGGGGCTGCACCCG 1668
Db 1491 CTTGACAGTGTGCGGTGCTGCTGAGCGCTTTCTGCACTGTGACTGGGGCTGCACCCG 1550
Qy 1669 ACCGGTGTCTACGGCTGCTGCGCCCGCTTTGTGAGCTCAACCTGGGTGACAGTGTCTG 1728
Db 1551 ACCGGTGTCTACGGCTGCTGCGCCCGCTTTGTGAGCTCAACCTGGGTGACAGTGTCTG 1610
Qy 1729 GAGCGGCTGTGAACCAACACAGCTACGATCGATCGATCGATCGATCGATCGATCGATCGATCG 1788
Db 1611 GAGCGGCTGTGAACCAACACAGCTACGATCGATCGATCGATCGATCGATCGATCGATCGATCG 1670
Qy 1789 AGAGTTTGTGATGGAAGAAACATGTTGACCGAGAGCTCTGCTGCTCCAGCGGGAGTG 1848
Db 1671 AGAGTTTGTGATGGAAGAAACATGTTGACCGAGAGCTCTGCTGCTCCAGCGGGAGTG 1730
Qy 1849 TTTCTGCTGTCTGATTAAGAGTCAAGGAGACACCGTTCTGTGTGTTACTGCTGTGCTGCTG 1908
Db 1731 TTTCTGCTGTCTGATTAAGAGTCAAGGAGACACCGTTCTGTGTGTTACTGCTGTGCTGCTG 1790
Qy 1909 CGCAGCTTCCGCTGAGCTGACCTATGATCGGCAAGCAATCTCTCTCCAGTGTGCCA 1968
Db 1791 CGCAGCTTCCGCTGAGCTGACCTATGATCGGCAAGCAATCTCTCTCTCCAGTGTGCCA 1850
Qy 1969 GTGGCCGTAACTCCCGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2028
Db 1851 GTGGCCGTAACTCCCGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1910

1549 TGCTGCTTCCAGCCATCCCGACCGAGAGCGGAGCGGAGCAGGACCCCGCTGTGCGC 1608
1431 TGCTGCTTCCAGCCATCCCGACCGAGAGCGGAGCGGAGCAGGACCCCGCTGTGCGC 1490
1609 CCTCAGCAGTGTGGGCTGTGCTGCGAGCGCTTTCTGCGACCTGTACTGTGGGCTGCACCCG 1668
1491 CCTCAGCAGTGTGGGCTGTGCTGCGAGCGCTTTCTGCGACCTGTACTGTGGGCTGCACCCG 1550
1669 ACCGCTGCTAGCGGCTGCTGCGCCCGTTTGTGAGCTCAACCTGGGTGACAACTGTCTG 1728
1551 ACCGCTGCTAGCGGCTGCTGCGCCCGTTTGTGAGCTCAACCTGGGTGACAACTGTCTG 1610
1729 GACGCGTGTCTGAACCAACAGCTACGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 1788
1611 GACGCGTGTCTGAACCAACAGCTACGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 1670
1789 AGAGCTTTGACATGAAACATGTTGACCGAGAGCTGCGCTCTCCAGCGGGAGTG 1848
1671 AGAGCTTTGACATGAAACATGTTGACCGAGAGCTGCGCTCTCCAGCGGGAGTG 1730
1849 TTTCTGCTGTCTGATTACAGAGTCAAGGAGACACCGTTCTGTGTACTGTGTGGCTG 1908
1731 TTTCTGCTGTCTGATTACAGAGTCAAGGAGACACCGTTCTGTGTACTGTGTGGCTG 1790
1909 CGAGCTTCGCTGAGCTGACCTATCAGTATCGGAGACATCTCTGCTTCGAGTTCGCA 1968
1791 CGAGCTTCGCTGAGCTGACCTATCAGTATCAGGAGACATCTCTGCTTCGAGTTCGCA 1850
1969 GTGGCGCTAAACATCCGCTCTGACTGCTACTGGGCGCTGACTGCGCACTCAGTGAAA 2028
1851 GTGGCGCTAAACATCCGCTCTGACTGCTACTGGGCGCTGACTGCGCACTCAGTGAAA 1910
2029 GGTCAACGCGCATGAATTCATATCTGTGTGAACAGACAGGTTCAAAACCTAAGCA 2088
1911 GGTCAACGCGCATGAATTCATATCTGTGTGAACAGACAGGTTCAAAACCTAAGCA 1970
2089 TCCAGAGCGCTGAGCAGCTTTTTCAGCCTGAGGTTGAAGAGAGCTGTTTTTAAATACA 2148
1971 TCCAGAGCGCTGAGCAGCTTTTTCAGCCTGAGGTTGAAGAGAGCTGTTTTTAAATACA 2030
2149 GAGACAGCAGCTCAAGGTGTTTTTCAAGCCCTTGAAGGAGGAGCGAGGCTCTCGCA 2208
2031 GAGACAGCAGCTCAAGGTGTTTTTCAAGCCCTTGAAGGAGGAGCGAGGCTCTCGCA 2090
2209 CAGGTGCTCTGGGTGACTCTCTGAGGCTTTTTTACCTCTGAGTGAGACCTTCCCA 2268
2091 CAGGTGCTCTGGGTGACTCTCTGAGGCTTTTTTACCTCTGAGTGAGACCTTCCCA 2148
2269 GAGCCCGGGGCGCGCAGCGCCCTCTCTGAGTGAAGGAGGAGGCTCTGAGTGGCAT 2328
2149 GAGCCCGGGGCGCGCAGCGCCCTCTCTGAGTGAAGGAGGAGGCTCTGAGTGGCAT 2208
2329 CAGCAGCAGAGCAGAGCCTTTCTGTAATCATCGGCGCTCCCGCAGAGGCGGAGTCTT 2388
2209 CAGCAGCAGAGCAGAGCCTTTCTGTAATCATCGGCGCTCCCGCAGAGGCGGAGTCTT 2268
2389 GCTCTTTTGTACATTTTCCGAACTACAGTAAAGCAGAGTCTGTTTTTACGAGAAAAGT 2448
2269 GCTCTTTTGTACATTTTCCGAACTACAGTAAAGCAGAGTCTGTTTTTACGAGAAAAGT 2328
2449 TCAAGGAGAGAGGCGAAGTTTATCAAAAACATGTTTTCAGGAGAGGAGGAGTATAGTTA 2508
2329 TCAAGGAGAGAGGCGAAGTTTATCAAAAACATGTTTTCAGGAGAGGAGGAGTATAGTTA 2389
2509 CAGCCTACAGGAGTACAGATATCTGCTGCTGGGAGAAACACAGCAGATTTTATCTATT 2568
2389 CAGCCTACAGGAGTACAGATATCTGCTGCTGGGAGAAACACAGCAGATTTTATCTATT 2448
2569 TTTATTTTATAGGTTTGGTGTATCTTCTTAATAGATTTAAATGTCAAACTGTAGC 2628
2449 TTTATTTTATAGGTTTGGTGTATCTTCTTAATAGATTTAAATGTCAAACTGTAGC 2508

QY 2629 ACAATAATATATATTTATTTATTTACAAATTGAC 2661
Db 2509 ACAATAATATATATTTATTTATTTACAAATTGAC 2541
RESULT 7
HSM802304 2297 bp mRNA linear PRI 18-FEB-2000
LOCUS Homo sapiens mRNA; cDNA DKFZp434N2420 (from clone DKFZp434N2420);
DEFINITION partial cds.
ACCESSION AL137561
VERSION AL137561.1 GI:6808265
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2297)
AUTHORS Ottenwälder, B., Obermaier, B., Mewes, H.W., Gassenhuber, J. and
Wiemann, S.
TITLE Direct Submission
JOURNAL Submitted (15-JAN-2000) MIPS, Am Klopferspitz 18a, D-82152
COMMENT Martinsried, GERMANY
Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de;
sequenced by VedicGenomix (Martinsried/Germany) within the cDNA
sequencing consortium of the German Genome Project. This clone
(DKFZp434N2420) is available at the RZPD in Berlin. Please contact
the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059
Berlin-Charlottenburg, GERMANY; Email: clone@rzd.de Further
information about the clone and the sequencing project is available
at http://www.mips.biochem.mpg.de/proj/cDNA/
FEATURES
Location/Qualifiers
source 1..2297
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="DKFZp434N2420"
/issue_type="testis"
/clone_lib="434 (synonym: htes3). Vector pSport1; host
DH10B; sites NotI + SalI"
/dev_stage="adult"
gene 1..2297
/gene="DKFZp434N2420"
CDS <1..921
/gene="DKFZp434N2420"
/notes="unknown"
/codon_start=1
/product="hypothetical protein"
/protein_id="CA570812.1"
/db_xref="GI:6808265"
/translation="VEAYLIQHPDKSRSEEDVQSMARKNIQDMLOPKVRRSFDEE
GSSEDLLELDVDSSESDISQPVVCKQCPEYRQAAQPPHCPAGEPAPALGDA
PSTSVLITTAVDYVCPLOGSHALCTCCQPMPPDRAREQDPRAVAPQCAVCLQFC
HLYMGCTRGVGLAPFCELNIGDKLDGLNNNSYESDILKNVLAETGLTKNMLT
ESLVALQRGVFLSDYRVGTDTVLVCYCCGLRSFRELTYQVRQNPASELPVAVTSRPD
CYWGRNCRQVKAHAWKNHNHCQTRFKN"
polyA_signal 2227..2232
/gene="DKFZp434N2420"
polyA_site 2251
/gene="DKFZp434N2420"
ORIGIN
Query Match 55.9%; Score 1497; DB 9; Length 2297;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1497; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1165 GTGGAAGCATACCTCATCCAGCATCCAGACAGAGTGCAGTGCAGAGATGTGCAAGT 1224
Db 1 GTGGAAGCATACCTCATCCAGCATCCAGACAGAGTGCAGTGCAGAGATGTGCAAGT 60
QY 1225 ATGATGCCAGGAATAAATCACTCAAGACATGCTGCAGCCCAAGTGCAGCGCTCTTT 1284

Db 1141 GCTGGCAGGCGCTGCTGGTGGCATCAGACAGAGAGCGAAGCCCTTTCTGTAAATGCGGC 1200
Qy 2365 CGTCCCGCCGAGAGGGGCGAGTTTGTCTCTTTTGTACATTTTCGAAACTACAGTTAAAGC 2424
Db 1201 CGTCCCGCCGAGAGGGGCGAGTTTGTCTCTTTTGTACATTTTCGAAACTACAGTTAAAGC 1260
Qy 2425 AGAAGTCTGTTTTTCAGAAAAGTTTCAAGGAGAGGAGGCGAAGTTTATCAAAAACATTTGTT 2484
Db 1261 AGAAGTCTGTTTTTCAGAAAAGTTTCAAGGAGAGGAGGCGAAGTTTATCAAAAACATTTGTT 1320
Qy 2485 TCAGAGAGGAGGAGCAATAAGTTTACAGCCTACAGAGCGTACACAATATCTCTGCTGCTGGG 2544
Db 1321 TCAGAGAGGAGGAGCAATAAGTTTACAGCCTACAGAGCGTACACAATATCTCTGCTGCTGGG 1380
Qy 2545 AAAACCCAGCAGATTTTATCTATTTTATTTTAAATAGTTTGGTGTATCTTCTTAATAA 2604
Db 1381 AAAACCCAGCAGATTTTATCTATTTTATTTTAAATAGTTTGGTGTATCTTCTTAATAA 1440
Qy 2605 GATTAAATGTACAACTGTAGCACAATAATATAATTTATAATTTACAATTTGAC 2661
Db 1441 GATTAAATGTACAACTGTAGCACAATAATATAATTTATAATTTACAATTTGAC 1497

RESULT 8
AX877222
LOCUS AX877222 3138 bp DNA linear PAT 17-DEC-2003
DEFINITION Sequence 12127 from Patent EPI074617.
ACCESSION AX877222
VERSION AX877222.1 GI:40031958
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Ota, T., Isogai, T., Nishikawa, T., Hayashi, K., Saito, K., Yamamoto, J.,
Ishii, S., Sugiyama, T., Wakamatsu, A., Nagai, K. and Otsuki, T.
TITLE Primers for synthesising full-length cDNA and their use
JOURNAL Patent: EP 1074617-A 12127 07-FEB-2001;
Research Association for Biotechnology (JP)
FEATURES
source
1. 3138
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
65..1936
/note="unnamed protein product"
/codon_start=1
/protein_id="CAB89626.1"
/translation="MERPEKQSPPPPOPMGRLLRLGAEGBEPHYLLKREWTIGRRV
GCDLSPSPKLVSGDHCHRIIVDEKSGOVLTEDTSTGTVINKLVKKQTCPLQTGDV
TYLVYRNEPHNVAYLYLESXKGMTQESFEMVPCVQAAGLKLGGSDPLEPKKX
SIVITGSGGIGSPNGSGPSVASDEVSPFASALPDKTASFFSLPEQDDELEPKKX
MRGDDLDLNGQLLVAPRRNAQIVHEDVRAAAGKPKDMEETLICIQDILLHDCVSL
QPCMTFCAACYSGMERSLCTPCRCPEVRIKNNHILNNLVEAYLIQHPKSRSEED
VQSDARNKITQDMLQPKVRSFSDDESSDLELSDVDESSESDISQFYVVCRCPE
YRQAAQPHCPAPEGPQALQDAPPTSVSLTAVQDYVCPQGGSHALCTCCFQ
MPDRAREQDPVPAQOCVCLQPFCHLYWGTCTGCGYGLAPFCELNGLDKLDGV
LNNRSSEIDILKNLYATRLGLTKNMLTBSLVALQGVFLSDYRVTVGTVLVCCGLR
SFRELYTQYQNIIPASELPVATSRPDCYWGRCNCTQVKAHAKMFNHCIEQTRFKN"

ORIGIN
Query Match 54.7%; Score 1465; DB 6; Length 3138;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 1945; Conservative 0; Mismatches 6; Indels 2; Gaps 1;
Qy 709 GGGCTGGGGTGGTGGCATCTCCCTAAAGAGAGTGTCCCTCTGTGGCAGTGAATGAA 768
Db 560 GGGCTGGGGTGGTGGCATCTCCCTAAAGAGAGTGTCCCTCTGTGGCAGTGAATGAA 619
Qy 769 GTCTCCAGCTTTGGCTCAGCTCTCCAGACAGAAAGATGGCTCTTTTCGTTGGAA 828

Db 61 ATGGATGCCAGGATTAATCACTCAAGACATGCTGCAGCCCAAGTCAAGCGGCTCTTT 120
Qy 1285 TCTGATGAAGAGAGGAGTTTCAAGAGACCTGCTGGAGCTGTACAGCTTGAAGTGAAGTCC 1344
Db 121 TCTGATGAAGAGAGGAGTTTCAAGAGACCTGCTGGAGCTGTACAGCTTGAAGTGAAGTCC 180
Qy 1345 TCAGACATTAGCAGCAGCATCTGCTGCTGCGGACAGTCTCTGAGTACAGAAAGGAGGCG 1404
Db 181 TCAGACATTAGCAGCAGCATCTGCTGCTGCGGACAGTCTCTGAGTACAGAAAGGAGGCG 240
Qy 1405 GCGCAGCCTCCCACTGCCAGCAGCCAGCGGAGCGAGGAGCGCCCAAGCAGCCTGGGG 1464
Db 241 GCGCAGCCTCCCACTGCCAGCAGCCAGCGGAGCGAGGAGCGCCCAAGCAGCCTGGGG 300
Qy 1465 GATGACCTTCCAGCTCCGTCAGCTGACAGCAGTCCAGGATTAAGTGTGCTGCTG 1524
Db 301 GATGACCTTCCAGCTCCGTCAGCTGACAGCAGTCCAGGATTAAGTGTGCTGCTG 360
Qy 1525 CAAGGAAGCCACGCCCTGTGCTGCTGCTTCCAGCCCACTGCCAGCGGAGCGGAG 1584
Db 361 CAAGGAAGCCACGCCCTGTGCTGCTGCTTCCAGCCCACTGCCAGCGGAGCGGAG 420
Qy 1585 GCGCAGCAGCAGCCGCTGCTGCGCCCTCAGCAGTGTGCGGTCTGCCGTGAGCCTTCTGC 1644
Db 421 GCGCAGCAGCAGCCGCTGCTGCGCCCTCAGCAGTGTGCGGTCTGCCGTGAGCCTTCTGC 480
Qy 1645 CACTGTACTGGGGTGTGACCCGAGCGGCTGTACGGTCTGCTGCGCCCTTTCTGAG 1704
Db 481 CACTGTACTGGGGTGTGACCCGAGCGGCTGTACGGTCTGCTGCGCCCTTTCTGAG 540
Qy 1705 CTCACCTGGGTGACAGTGTCTGAGCGGCTGTGAAACAAACAGCTACAGTACAGAC 1764
Db 541 CTCACCTGGGTGACAGTGTCTGAGCGGCTGTGAAACAAACAGCTACAGTACAGAC 600
Qy 1765 ATCCTGAAGATTAACCTGGCAACAGAGTTTGCATGGAACAACTGTTGACCGAGAGC 1824
Db 601 ATCCTGAAGATTAACCTGGCAACAGAGTTTGCATGGAACAACTGTTGACCGAGAGC 660
Qy 1825 CTCGTGCTCTCCAGCGGGGAGTGTCTGCTGTGATTACAGAGTCAAGGAGACACC 1884
Db 661 CTCGTGCTCTCCAGCGGGGAGTGTCTGCTGTGATTACAGAGTCAAGGAGACACC 720
Qy 1885 GTTCTGTGTACTGCTGTGCTGCGCAGCTTCCGTGAGCTGACCTATCAGTATCGGCG 1944
Db 721 GTTCTGTGTACTGCTGTGCTGCGCAGCTTCCGTGAGCTGACCTATCAGTATCGGCG 780
Qy 1945 AACATTCTGCTTCCGAGTTGCCAGTGGCGGTAAACATCCCGTCTGACTGCTACTGGGC 2004
Db 781 AACATTCTGCTTCCGAGTTGCCAGTGGCGGTAAACATCCCGTCTGACTGCTACTGGGC 840
Qy 2005 CGTAACCTCCGCACTCAGGTGAAGCTCAACAGCCATGAATTCATATCTGTGAA 2064
Db 841 CGTAACCTCCGCACTCAGGTGAAGCTCAACAGCCATGAATTCATATCTGTGAA 900
Qy 2065 CAGCAAGGTTCAAAACTAAGCATCCAGAGGCGCTGAGCAGCTTTTCAGCACTGGAGGTG 2124
Db 901 CAGCAAGGTTCAAAACTAAGCATCCAGAGGCGCTGAGCAGCTTTTCAGCACTGGAGGTG 960
Qy 2125 AAGAGAGCGTGTGTTTTAAATACAGACAGCAGTCAAGGTTGTTTTTCACGCCCTTG 2184
Db 961 AAGAGAGCGTGTGTTTTAAATACAGACAGCAGTCAAGGTTGTTTTTCACGCCCTTG 1020
Qy 2185 AGGAAGGAGCGAGGTTCTCCGAGCTGCTGCTGGGTCGCTCTCTGTGGAGCTTTT 2244
Db 1021 AGGAAGGAGCGAGGTTCTCCGAGCTGCTGCTGGGTCGCTCTCTGTGGAGCTTTT 1080
Qy 2245 ACCCTCTGAGTGAGACCTCTCCAGAGCCCGGGGGCGCAGCGCCCTCTCTGGTGAAG 2304
Db 1081 ACCCTCTGAGTGAGACCTCTCCAGAGCCCGGGGGCGCAGCGCCCTCTCTGGTGAAG 1140
Qy 2305 GCTGGGAGGCGCTGCTGGTGGCATCAGCAGCAGAGAGAGCCCTTTCTGTAAATGCGGC 2364

Db 620 GTCTCAGCTTTGCTCAGCTCTCCAGACAGAAAGACTGGCTCTCTTTTCCTGCTGGAA 679
Qy 829 CCCAGGATCAGGAGATTTGAGCCGCTGAGAGAGAAATGAGAGGAGATGGGACCTT 888
Db 680 CCCAGGATCAGGAGATTTGAGCCGCTGAGAGAGAAATGAGAGGAGATGGGACCTT 739
Qy 889 GACCTGAACGGGACGTTGTTGTCGACAAACCGCTAGAAATGCCAAACCGTCCACGAG 948
Db 740 GACCTGAACGGGACGTTGTTGTCGACAAACCGCTAGAAATGCCAAACCGTCCACGAG 799
Qy 949 GAGCTCAGAGACGGCTGGGAGCCAGACAGATGAGAGAGAGCGCTGACATGCATCATC 1008
Db 800 GAGCTCAGAGACGGCTGGGAGCCAGACAGATGAGAGAGAGCGCTGACATGCATCATC 859
Qy 1009 TGCAGGACCTGCTGACAGCTGCGTGAAGTTGACAGCCCTGATCAGACAGCTTCTGCGCG 1068
Db 860 TGCAGGACCTGCTGACAGCTGCGTGAAGTTGACAGCCCTGATCAGACAGCTTCTGCGCG 919
Qy 1069 GCTTGCTACTCGGGCTGAGATGAGAGCGCTGCTCCCTGCTGTCCTACCTGCTGCTCCCGTG 1128
Db 920 GCTTGCTACTCGGGCTGAGATGAGAGCGCTGCTCCCTGCTGTCCTACCTGCTGCTCCCGTG 979
Qy 1129 GAGCGGATCTGTAAACCAACACATCTCAACACCTCTGGAAGATACCTCATCCAGCAT 1188
Db 980 GAGCGGATCTGTAAACCAACACATCTCAACACCTCTGGAAGATACCTCATCCAGCAT 1039
Qy 1189 CCAGACAGAGTCGACAGTGAAGAAGATGTGAAAGTATGATGCCAGGAATAAATCACT 1248
Db 1040 CCAGACAGAGTCGACAGTGAAGAAGATGTGAAAGTATGATGCCAGGAATAAATCACT 1099
Qy 1249 CAAGACATCTGACAGCCCAAGTCAAGCGCTCTTTCTGATGAGAGAGGAGTTCAAG 1308
Db 1100 CAAGACATCTGACAGCCCAAGTCAAGCGCTCTTTCTGATGAGAGAGGAGTTCAAG 1159
Qy 1309 GACCTCTCGAGCTGTGACAGCTTGACAGTGAAGTCTCTCAGACATTTAGCCAGCCATCCTC 1368
Db 1160 GACCTCTCGAGCTGTGACAGCTTGACAGTGAAGTCTCTCAGACATTTAGCCAGCCATCCTC 1219
Qy 1369 GTGTCGGGAGTCTGAGTACAGAGCAGCGGCGGACGCTCCCACTGCCCCAGCA 1428
Db 1220 GTGTCGGGAGTCTGAGTACAGAGCAGCGGCGGACGCTCCCACTGCCCCAGCA 1279
Qy 1429 CCCAGGGGAGCAGAGAGCCCAAGGCGCTGGGGGATGCACTCTCAAGCTCCGTCAGC 1488
Db 1280 CCCAGGGGAGCAGAGAGCCCAAGGCGCTGGGGGATGCACTCTCAAGCTCCGTCAGC 1339
Qy 1489 CTGACAGCAGCTCCAGGATTAAGTGTGCTCTGCAAGAGAGCGACGCCCTGTGCAAC 1548
Db 1340 CTGACAGCAGCTCCAGGATTAAGTGTGCTCTGCAAGAGAGCGACGCCCTGTGCAAC 1399
Qy 1549 TGCCTGCTCCAGCCATGCGGACGAGAGCGGAGCGAGCGAGCCCGGCTGTGCGC 1608
Db 1400 TGCCTGCTCCAGCCATGCGGACGAGAGCGGAGCGAGCGAGCGCCCGGCTGTGCGC 1459
Qy 1609 CCTCAGCAGTGTGCGTCTGCTGAGCCTTTCTGCACTGATGCGGCTGCAACCGG 1668
Db 1460 CCTCAGCAGTGTGCGTCTGCTGAGCCTTTCTGCACTGATGCGGCTGCAACCGG 1519
Qy 1669 ACCGCTGCTACGCTGCTGCGGCGGCTTTGAGCTCAACTGAGTGAAGTGTCTG 1728
Db 1520 ACCGCTGCTACGCTGCTGCGGCGGCTTTGAGCTCAACTGAGTGAAGTGTCTG 1579
Qy 1729 GACCGGCTGTGAACCAACACAGTACAGTTCAGACATCTGAGAAATTTACTTGCACAC 1788
Db 1580 GACCGGCTGTGAACCAACACAGTACAGTTCAGACATCTGAGAAATTTACTTGCACAC 1639
Qy 1789 AGAGTTTGCATGGAAGAAATGTTGACCGAGAGCTGCTGCTCTCCAGCGGGAGTG 1848
Db 1640 AGAGTTTGCATGGAAGAAATGTTGACCGAGAGCTGCTGCTCTCCAGCGGGAGTG 1699
Qy 1849 TTTCTGCTGTGATACAGAGTCAAGGAGACAGCGTTCTGTGTTACTGCTGTGCGCTG 1908
Db 1700 TTTCTGCTGTGATACAGAGTCAAGGAGACAGCGTTCTGTGTTACTGCTGTGCGCTG 1759

Qy 1909 CGCAGCTTCCGTGAGCTGACCTATCAGTATCGGAGAAATTCCTGCTTCCGAGTTGCCA 1968
Db 1760 CGCAGCTTCCGTGAGCTGACCTATCAGTATCAGGAGAAATTCCTGCTTCCGAGTTGCCA 1819
Qy 1969 GTGGCGTAACTCCGCTGCTGACTGCTACTGGGCGGTAATCTGCCGACTCAGGTGAAA 2028
Db 1820 GTGGCGTAACTCCGCTGCTGACTGCTACTGGGCGGTAATCTGCCGACTCAGGTGAAA 1879
Qy 2029 GCTCACCACGCCATGAAATTCATATCTGTGAACAGACAGGTTCAAAAATCAAGCA 2088
Db 1880 GCTCACCACGCCATGAAATTCATATCTGTGAACAGACAGGTTCAAAAATCAAGCA 1939
Qy 2089 TCAGAGGCGCTCAGCAGCTTTTTCAGCAGCTGAGAGTGAAGAGCGTGTGTTTAAATACA 2148
Db 1940 TCAGAGGCGCTCAGCAGCTTTTTCAGCAGCTGAGAGTGAAGAGCGTGTGTTTAAATACA 1999
Qy 2149 GAGCAAGCAGCTCAAGGTGTTTTCAGCGCCCTCAGGAGAGGAGCGCAGGCTCTCCGA 2208
Db 2000 GAGCAAGCAGCTCAAGGTGTTTTCAGCGCCCTCAGGAGAGGAGCGCAGGCTCTCCGA 2059
Qy 2209 CAGGTGCTGCGGCTGACTCTTCTGTGAGCTTTTACCCCTGTGAGTGAAGCCCTCCCA 2268
Db 2060 CAGGTGCTGCGGCTGACTCTTCTGTGAGC--TTTACCCCTGTGAGTGAAGCCCTCCCA 2117
Qy 2269 GAGCCCGGGGCGCAGCGCCCTCCTGCTGAGCGCTGGGAGGCGCTCGTGTGSCAT 2328
Db 2118 GAGCCCGGGGCGCAGCGCCCTCCTGCTGAGCGCTGGGAGGCGCTCGTGTGSCAT 2177
Qy 2329 CAGCAGCAGAGACGAAAGCTTTCTGTAACATCGGCGCTCCCGCAGAGGGGCGAGTTT 2388
Db 2178 CAGCAGCAGAGACGAAAGCTTTCTGTAACATCGGCGCTCCCGCAGAGGGGCGAGTTT 2237
Qy 2389 GCTCTTTGTGACATTTTCGAAACTCAGTTAAAGCAGAGTCTGTTTTCAGGAAAGATT 2448
Db 2238 GCTCTTTGTGACATTTTCGAAACTCAGTTAAAGCAGAGTCTGTTTTCAGGAAAGATT 2297
Qy 2449 TCAGGAGAGAGGCGCAAGTTTATCAAAAATTTTTCAGGAGAGGAGCGATTAAGTTTA 2508
Db 2298 TCAGGAGAGAGGCGCAAGTTTATCAAAAATTTTTCAGGAGAGGAGCGATTAAGTTTA 2357
Qy 2509 CAGCCTACAGACGTACACAAATATCCTGCTGCTGGGAAACACACAGATTTTATCTATT 2568
Db 2358 CAGCCTACAGACGTACACAAATATCCTGCTGCTGGGAAACACACAGATTTTATCTATT 2417
Qy 2569 TTTATTTTAAATAGTTTGTGCTTATCTTCTAAATAGATTTAAATGTCAAAAATCTGTAGC 2628
Db 2418 TTTATTTTAAATAGTTTGTGCTTATCTTCTAAATAGATTTAAATGTCAAAAATCTGTAGC 2477
Qy 2629 ACAATATATATAATTTATAATTTTACAATTTGAC 2661
Db 2478 ACAATATATATAATTTATAATTTTACAATTTGAC 2510

RESULT 9
BD156548
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD156548 3138 bp DNA linear PAT 17-JAN-2003
Primer for synthesizing full-length cDNA and use thereof.
BD156548
BD156548
GI:27862306
JP 2002191363-A/11391.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 3138)
Ota, T., Isogai, T., Nishikawa, T., Hayashi, K., Saito, K., Yamamoto, J.,
Ishii, S., Sugiyama, T., Wakamatsu, A., Nagai, K., and Otsuki, T.
Primer for synthesizing full-length cDNA and use thereof
Patent: JP 2002191363-A 11391 09-JUL-2002;
HELIUS RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002191363-A/11391

PD 09-JUL-2002
 PF 28-JUL-2000 JP 2000280990
 PI TOSHIO OTA, TAKAO ISOGAI, TETSUO NISHIKAWA, KOJI HAYASHI, KAORU
 PI SAITO,
 PI JUNICHI YAMAMOTO, SHIZUKO ISHII, TOMOYASU SUGIYAMA, AI WAKAMATSU,
 PI KEIICHI NGAI, TETSUJI OTSUKI
 PC
 C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
 10,
 PC C12P21/02, C12Q1/68//C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC
 Primer for synthesizing full-length cDNA and use thereof FH Key
 Location/Qualifiers
 (65). (1933).

FT CDS Location/Qualifiers
 source
 1. .3138
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

ORIGIN

Query Match 54.7%; Score 1465; DB 6; Length 3138;
 Best Local Similarity 99.6%; Pred. No. 0;
 Matches 1945; Conservative 0; Mismatches 6; Indels 2; Gaps 1;
 709 GGGCTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGTCCCTCTGTGGCAAGTATGAA 768
 Db GGGCTCTGGGGTGGTGGCATCTCCCTAAAGGAAGTGTCCCTCTGTGGCAAGTATGAA 619
 769 GTCTCCAGCTTTGCCCTCAGCTCTCCAGACAGAAAGACTGGCTCTTTTCGTTGGAA 828
 Db GTCTCCAGCTTTGCCCTCAGCTCTCCAGACAGAAAGACTGGCTCTTTTCGTTGGAA 679
 829 CCCAGGATCAGAGAGATTGGAGCCGCTGAGAGAAAGAAATGAGAGAGATGGGACCTT 888
 Db CCCAGGATCAGAGAGATTGGAGCCGCTGAGAGAAAGAAATGAGAGAGATGGGACCTT 739
 680 CCCAGGATCAGAGAGATTGGAGCCGCTGAGAGAAAGAAATGAGAGAGATGGGACCTT 948
 889 GACCTGAACCGGCGAGTTGGTGGCAGCAACCGCTGAGAAATGCCAAACCGCTCCACGAG 948
 Db GACCTGAACCGGCGAGTTGGTGGCAGCAACCGCTGAGAAATGCCAAACCGCTCCACGAG 799
 949 GACGTCAGAGACGCGCTGGGAAGCCAGACAAGATGGAGAGACGCTGACATGCATCATC 1008
 Db GACGTCAGAGACGCGCTGGGAAGCCAGACAAGATGGAGAGACGCTGACATGCATCATC 859
 1009 TGCAGAGACCTGTGCACGACTCCGCTGAGTTTGCAGCCCTGATGACACAGCTTCTGGCG 1068
 Db TGCAGAGACCTGTGCACGACTCCGCTGAGTTTGCAGCCCTGATGACACAGCTTCTGGCG 919
 860 TGCAGAGACCTGTGCACGACTCCGCTGAGTTTGCAGCCCTGATGACACAGCTTCTGGCG 919
 1069 GCTTGTCTACTCGGGCTGGATGGAGCGCTGCTCCTGTGCTTACTGCGCGCTGCTCCGCTG 1128
 Db GCTTGTCTACTCGGGCTGGATGGAGCGCTGCTCCTGTGCTTACTGCGCGCTGCTCCGCTG 979
 920 GCTTGTCTACTCGGGCTGGATGGAGCGCTGCTCCTGTGCTTACTGCGCGCTGCTCCGCTG 1188
 1129 GAGGGATCTGTAAGAACCAATCCCTCAACACCTCGTGGAGCATACCTCATCCAGCAT 1188
 Db GAGGGATCTGTAAGAACCAATCCCTCAACACCTCGTGGAGCATACCTCATCCAGCAT 1039
 980 GAGGGATCTGTAAGAACCAATCCCTCAACACCTCGTGGAGCATACCTCATCCAGCAT 1039
 1189 CCAGACAAGAGTCCGAGTGAAGAGATGTGCCAAGTATGGATGCCAGGAATAAATCACT 1248
 Db CCAGACAAGAGTCCGAGTGAAGAGATGTGCCAAGTATGGATGCCAGGAATAAATCACT 1099
 1249 CAAGACATGTCAGCCCAAGTCAGCGCTCTTTCTGATGAAGAAGGAGTTCAGAG 1308
 Db CAAGACATGTCAGCCCAAGTCAGCGCTCTTTCTGATGAAGAAGGAGTTCAGAG 1159
 1100 CAAGACATGTCAGCCCAAGTCAGCGCTCTTTCTGATGAAGAAGGAGTTCAGAG 1159
 1309 GACCTGCTGGAGTGTGACAGCTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGAC 1368
 Db GACCTGCTGGAGTGTGACAGCTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGAC 1219
 1160 GACCTGCTGGAGTGTGACAGCTGTGACAGTGTGACAGTGTGACAGTGTGACAGTGTGAC 1219
 1369 GTGTGCGGCGAGTGTCTGTGATGACAGAGCAGCGCGCGAGCTCCCACTGCCAGCA 1428
 Db GTGTGCGGCGAGTGTCTGTGATGACAGAGCAGCGCGCGAGCTCCCACTGCCAGCA 1279
 1220 GTGTGCGGCGAGTGTCTGTGATGACAGAGCAGCGCGCGAGCTCCCACTGCCAGCA 1279
 1429 CCCGAGGCGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1488

Db CCCGAGGCGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1339
 QY CTGACGACAGCAGTCCAGGATTTACGTGTGCTCTCTGCAAGGAAGGAGGAGGAGGAGGAGGAG 1548
 Db CTGACGACAGCAGTCCAGGATTTACGTGTGCTCTCTGCAAGGAAGGAGGAGGAGGAGGAGGAG 1399
 1340 CTGACGACAGCAGTCCAGGATTTACGTGTGCTCTCTGCAAGGAAGGAGGAGGAGGAGGAGGAG 1399
 1549 TGCTGCTTCAGACCATGCCCCGACCCGAGAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1608
 Db TGCTGCTTCAGACCATGCCCCGACCCGAGAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1459
 1400 TGCTGCTTCAGACCATGCCCCGACCCGAGAGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1459
 1609 CCTCAGCAGTGTGGGTCTGCTGCTCAGCCTTTCTGCAACCTGTACTGCGGGGTGACCCCGG 1668
 Db CCTCAGCAGTGTGGGTCTGCTGCTCAGCCTTTCTGCAACCTGTACTGCGGGGTGACCCCGG 1519
 1460 CCTCAGCAGTGTGGGTCTGCTGCTCAGCCTTTCTGCAACCTGTACTGCGGGGTGACCCCGG 1519
 1669 ACCGGCTGTACGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1728
 Db ACCGGCTGTACGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1579
 1520 ACCGGCTGTACGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1579
 1729 GACGGCTGTGACCAACACAGCTACAGTTCAGACATCTGAGAAATTAACCTGGCAACC 1788
 Db GACGGCTGTGACCAACACAGCTACAGTTCAGACATCTGAGAAATTAACCTGGCAACC 1639
 1580 GACGGCTGTGACCAACACAGCTACAGTTCAGACATCTGAGAAATTAACCTGGCAACC 1639
 1789 AGAGGTTTGACATGGAAAAACATGTTGACCGAGAGCTCTGCTGCTCTCCAGCGGGAGTG 1848
 Db AGAGGTTTGACATGGAAAAACATGTTGACCGAGAGCTCTGCTGCTCTCCAGCGGGAGTG 1699
 1849 TTTCTGCTGTGATTAACAGATCAGCGGAGACACCGTCTGCTGCTGCTGCTGCTGCTGCTGCTG 1908
 Db TTTCTGCTGTGATTAACAGATCAGCGGAGACACCGTCTGCTGCTGCTGCTGCTGCTGCTGCTG 1759
 1700 TTTCTGCTGTGATTAACAGATCAGCGGAGACACCGTCTGCTGCTGCTGCTGCTGCTGCTGCTG 1759
 1909 CGCAGCTTCCGCTGAGCTGACCTATCAGTATCGGAGAACATTCCTGCTTCCGAGTTGCCA 1968
 Db CGCAGCTTCCGCTGAGCTGACCTATCAGTATCGGAGAACATTCCTGCTTCCGAGTTGCCA 1819
 1760 CGCAGCTTCCGCTGAGCTGACCTATCAGTATCGGAGAACATTCCTGCTTCCGAGTTGCCA 1819
 1969 GTGGCGTTAACTCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2028
 Db GTGGCGTTAACTCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1879
 1820 GTGGCGTTAACTCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1879
 2029 GCTCACCACGCGCATGAATTCATCATATCTGCAACAGCAAGGTTCAAAAATAAGCA 2088
 Db GCTCACCACGCGCATGAATTCATCATATCTGCAACAGCAAGGTTCAAAAATAAGCA 1939
 1880 GCTCACCACGCGCATGAATTCATCATATCTGCAACAGCAAGGTTCAAAAATAAGCA 1939
 2089 TCCAGAGCGCTGAGAGCTTTTTCAGACTGAGAGTGAAGAGAGCTGTTTTTAAATACA 2148
 Db TCCAGAGCGCTGAGAGCTTTTTCAGACTGAGAGTGAAGAGAGCTGTTTTTAAATACA 1999
 1940 TCCAGAGCGCTGAGAGCTTTTTCAGACTGAGAGTGAAGAGAGCTGTTTTTAAATACA 1999
 2149 GAGCAAGCAGCTCAAGGTGTTTTTTCAGAGCGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2208
 Db GAGCAAGCAGCTCAAGGTGTTTTTTCAGAGCGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2059
 2000 GAGCAAGCAGCTCAAGGTGTTTTTTCAGAGCGCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2059
 2209 CAGGTGCTCTGGGGTGAATCTTTTTCAGAGCTTTTTCAGAGCGCTGAGGAGGAGGAGGAGGAGGAG 2268
 Db CAGGTGCTCTGGGGTGAATCTTTTTCAGAGCTTTTTCAGAGCGCTGAGGAGGAGGAGGAGGAGGAG 2117
 2060 CAGGTGCTCTGGGGTGAATCTTTTTCAGAGCTTTTTCAGAGCGCTGAGGAGGAGGAGGAGGAGGAG 2117
 2269 GAGCGCGGGGGCGCAGCGCGCTCTGCTGAGCGCTGCGGCGGCTCGTGTGGCAT 2328
 Db GAGCGCGGGGGCGCAGCGCGCTCTGCTGAGCGCTGCGGCGGCTCGTGTGGCAT 2177
 2118 GAGCGCGGGGGCGCAGCGCGCTCTGCTGAGCGCTGCGGCGGCTCGTGTGGCAT 2177
 2329 CAGCAGCAGAGAGCAAGGCTTTTTCAGATCATGCGCGCGCTCCCGCGAGAGGAGGAGGAGGAGGAG 2388
 Db CAGCAGCAGAGAGCAAGGCTTTTTCAGATCATGCGCGCGCTCCCGCGAGAGGAGGAGGAGGAGGAG 2237
 2178 CAGCAGCAGAGAGCAAGGCTTTTTCAGATCATGCGCGCGCTCCCGCGAGAGGAGGAGGAGGAGGAG 2237
 2389 GCTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGCTGTTTTTTCAGGAAAAGTT 2448
 Db GCTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGCTGTTTTTTCAGGAAAAGTT 2297
 2238 GCTCTTTTGTACATTTTCCGAACTACAGTTAAAGCAGAGCTGTTTTTTCAGGAAAAGTT 2297
 2449 TCAAGGGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2508
 Db TCAAGGGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2357
 2298 TCAAGGGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2357
 2509 CAGCCTACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2568

Db 2358 CAGCCTACAGGACGTACCAATATCTCTGCTGCTGGGAAACACAGACATTTTATCTATTT 2417

Qy 2569 TTTATTTTAAATAGGTTTCGTCCTATCTTCTAATAAGATTTTAAATGTCACAACTGTAGC 2628

Db 2418 TTTATTTTAAATAGGTTTCGTCCTATCTTCTAATAAGATTTTAAATGTCACAACTGTAGC 2477

Qy 2629 ACAAATAATATATTTATTAATTTACAAATTCAC 2661

Db 2478 ACAAATAATATATTTATTAATTTACAAATTCAC 2510

RESULT 10

AK001658 3138 bp mRNA linear PRI 01-AUG-2002

LOCUS Homo sapiens CDNA FLJ10796 fis, clone NT2RF4000648, weakly similar

DEFINITION to TRANS-ACTING TRANSCRIPTIONAL PROTEIN ICPO.

ACCESSION AK001658

VERSION oligo capping; fis (full insert sequence).

KEYWORDS Homo sapiens (human)

SOURCE Eukaryota

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Isogai,T., Ota,T., Hayaashi,K., Sugiyama,T., Otsuki,T., Suzuki,Y., Nishikawa,T., Nagai,K., Sugano,S., Aotsuka,S., Yoshikawa,Y., Matsuura,H., Ishii,S., Kawai,Y., Saito,K., Yamamoto,J., Wakamatsu,A., Nakamura,Y., Nagahara,K., Masuho,Y. and Sasaki,N.

TITLE NEDO human cDNA sequencing project

JOURNAL Unpublished

AUTHORS 2 (bases 1 to 3138)

JOURNAL Isogai,T. and Otsuki,T.

COMMENT Submitted (16-FEB-2000) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986) NEDO human cDNA sequencing project supported by Ministry of International Trade and Industry of Japan; cDNA full insert sequencing; Research Association for Biotechnology; cDNA library construction, 5'- & 3'-end one pass sequencing and clone selection; Helix Research Institute (supported by Japan Key Technology Center etc.) and Department of Virology, Institute of Medical Science, University of Tokyo.

FEATURES

Location/Qualifiers

1..3138

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="NT2RF4000648"

/cell_line="NT2"

/cell_type="teratocarcinoma"

/clone_lib="NT2RP4"

/notes="cloning vector: pME18SFL3-mRNA from NT2 neuronal precursor cells after 2-weeks retinoic acid (RA) induction."

65..1936

/note="unnamed protein product"

/codon_start=1

/protein_id="BAA91817.1"

/db_xref="GI:7023051"

CDS

translation="MERPEEGKSPQPPQWGRLLRLGAESEPHVLLKREWTIGRRR

GGDLSPFNKLVGDRHVSQVLEDTISGIVINKLVKKVKTQPLQGDV

IYLVKNEPHNVAYLSESKQMTQESFEMVPCVQAQGLKLLGSDPPTLASQ

SIVITGSGGGGIPKSGSPASDEVSPASALPDKRTASFSLEPODELEPEKQ

MRGDGLDLGQLVAQPRNAQTHVEDVRAAGKPKDMEETLCIIQQDLLHDCVSL

QPMHTFCAACYSWMMESLCTCRCPVERICKHNLNLVEALYIQLPKRSSEED

YQSMARKITQDMLOPKVRSFSDSESSDLELSDVSESSDIQPVVCRQCEP

YRQAQPHCPAPPEGPQALGDAPPTSVLTAQDYVVCPLQSGHALCTQCFOP

MPDRAERQDPRAVQACVCLQPFCHLFWGCTGTGCTGCLAPFCEINLQGLDGV

LNNNSYDILKNYLATRLGVLWKNMLTESLVALQGLFLLSYRTVGTIVLCYCGLR

SFRELTYQONIPASELVAVTSRSDCVWGNCRITQVKAHAKFNHCQTRFNN"

Query Match 54.7%; Score 1465; DB 9; Length 3138;

Best Local Similarity 99.6%; Pred. No. 0;

Matches 1945; Conservative 0; Mismatches 6; Indels 2; Gaps 1;

Qy 709 GGGTCTGGGGGTGGTGGCATCTCCCTTAAAGAAAGTGGTCCCTCTGTGGCAAGTGATGAA 768

Db 560 GGGTCTGGGGGTGGTGGCATCTCCCTTAAAGAAAGTGGTCCCTCTGTGGCAAGTGATGAA 619

Qy 769 GTCTCCAGCTTTTGGCTCAGCTCTCCAGACAGAAAGACTGCGCTCTTTCTGCTGGTGGAA 828

Db 620 GTCTCCAGCTTTTGGCTCAGCTCTCCAGACAGAAAGACTGCGCTCTTTCTGCTGGTGGAA 679

Qy 829 CCCAGAGTCAGAGATTTGGAGCCGCTGAGAGAAATAGAGAGAGATGGGACCTT 888

Db 680 CCCAGAGTCAGAGATTTGGAGCCGCTGAGAGAAATAGAGAGAGATGGGACCTT 739

Qy 889 GACCTCAAGCGGCGAGTTTGGTTCGACCAACCGCTAGAAATGCCCAACCGTCCACGAG 948

Db 740 GACCTCAAGCGGCGAGTTTGGTTCGACCAACCGCTAGAAATGCCCAACCGTCCACGAG 799

Qy 949 GAGCTCAGAGACGCGCTGGGAAGCCAGACAGATGGAGAGACGCTGCATGCATC 1008

Db 800 GAGCTCAGAGACGCGCTGGGAAGCCAGACAGATGGGAAGACGCTGCATGCATC 859

Qy 1009 TGCAGAGACCTGTCACGACTGCGTGGTGGTTCGAGCCCTGTCATGCACACGTTCTCGCG 1068

Db 860 TGCAGAGACCTGTCACGACTGCGTGGTGGTTCGAGCCCTGTCATGCACACGTTCTCGCG 919

Qy 1069 GCTTGTACTCGCGCTGGAGCGCTCGTCCCTGTCTTACCTGCGCTGTCGCGT 1128

Db 920 GCTTGTACTCGCGCTGGAGCGCTCGTCCCTGTCTTACCTGCGCGTCTGTCGCGT 979

Qy 1129 GAGCGATCTGTAATAAACACATCTCTCAACACCTCTGGAAGCATACCTCATCCAGCAT 1188

Db 980 GAGCGATCTGTAATAAACACATCTCTCAACACCTCTGGAAGCATACCTCATCCAGCAT 1039

Qy 1189 CCAGACAAGAGTCCGAGTGAAGAAATGTCAGAAATGATGATGCCAGGAATAAATCACT 1248

Db 1040 CCAGACAAGAGTCCGAGTGAAGAAATGTCAGAAATGATGATGCCAGGAATAAATCACT 1099

Qy 1249 CAGACATCTGTCAGCCCAAGTCAAGCTCTTTTCTGATCAAGAAGGAGTTCAGAG 1308

Db 1100 CAGACATCTGTCAGCCCAAGTCAAGCTCTTTTCTGATGAGAGAGGAGTTCAGAG 1159

Qy 1309 GACCTGCTGAGCTGTACAGCTTGAACAGTGTCTCTAGACATTCAGACCATACGTC 1368

Db 1160 GACCTGCTGAGCTGTACAGCTTGAACAGTGTCTCTAGACATTCAGACCATACGTC 1219

Qy 1369 GTGTGCGGCGAGTCTGTGATACAGAGCGAGCGCGGCGAGCTCCCACTGCCAGCA 1428

Db 1220 GTGTGCGGCGAGTCTGTGATACAGAGCGAGCGCGGCGAGCTCCCACTGCCAGCA 1279

Qy 1429 CCCAGGCGAGCCAGGAGCCCAAGGCTTGGGGATGACCCCTCCAGTCCGTCAGC 1488

Db 1280 CCCAGGCGAGCCAGGAGCCCAAGGCTTGGGGATGACCCCTCCAGTCCGTCAGC 1339

Qy 1489 CTGACGACAGCTCAGGATTAAGTGTGCTCTGACAGAGAGCCAGCCCTGTGCACC 1548

Db 1340 CTGACGACAGCTCAGGATTAAGTGTGCTCTGACAGAGAGCCAGCCCTGTGCACC 1399

Qy 1549 TGCTGCTTCCAGCCCATGCCCGAGAGCGAGCGCGAGAGAGCCAGCCCTGTGCACC 1608

Db 1400 TGCTGCTTCCAGCCCATGCCCGAGAGCGAGCGCGAGAGAGCCAGCCCTGTGCACC 1459

Qy 1609 CCTCAGAGTGTGGGTCTGCTGAGCTTTTCTGCCACTGTACTGGGGCTGCACCCGG 1668

Db 1460 CCTCAGAGTGTGGGTCTGCTGAGCTTTTCTGCCACTGTACTGGGGCTGCACCCGG 1519

Qy 1669 ACCGGCTGTACGGCTGCTGGCCCGTGTGTGAGCTCAACCTGGGTGACAGTGTCTG 1728

Db 1520 ACCGGCTGTACGGCTGCTGGCCCGTGTGTGAGCTCAACCTGGGTGACAGTGTCTG 1579

Qy 1729 GACGGCTGTGCTGAACAAACAGCTACGATCTGAGACATCTGAGAAATTACCTGGCAACC 1788

ORIGIN

1580	DB		GACGGGCTGCTGAACAAACAACAGCTACGAGTCAGACATCCTGAAGAAATTAACCTGGCAAC	1639
1789	QY		AGAGGTTTCACATGGAATAAACAATGTTGACCGAGAGCCTCGTGGCTCTCCAGCGGGAGTG	1848
1640	DB		AGAGGTTTGACATGGAATAAACAATGTTGACCGAGAGCCTCGTGGCTCTCCAGCGGGAGTG	1699
1849	QY		TTTCTGCTGTCTGATTACAGAGTCACGGGAGACACCGTTCCTGTTGTTACTGTTGCGCTG	1908
1700	DB		TTTCTGCTGTCTGATTACAGAGTCACGGGAGACACCGTTCCTGTTGTTACTGTTGCGCTG	1759
1909	QY		CGCAGCTTCGGTGAGCTGACCTATCAGTATCGGCGAGAACATTCCTGCTCCGAGTTGGCA	1968
1760	DB		CGCAGCTTCGGTGAGCTGACCTATCAGTATCAGGAAACATTCCTGCTCCGAGTTGGCA	1819
1969	QY		GTGGCCGTAACTCCCGTCTCTGACTCTACTGGGGCCGTAACTCCGCACACTCAGGTGAAA	2028
1820	DB		GTGGCCGTAACTCCCGTCTCTGACTCTACTGGGGCCGTAACTCCGCACACTCAGGTGAAA	1879
2029	QY		GCTCACACGCCATGAATTCATATCTGTGTAACAGACAAGGTTCAAAAACCTAAGCA	2088
1880	DB		GCTCACACGCCATGAATTCATATCTGTGTAACAGACAAGGTTCAAAAACCTAAGCA	1939
2089	QY		TCCAGAGGCCCTCAGCAGACTTTCAGACACTGGAGTGAAAGAGCGGTGTTTTAAAAATACA	2148
1940	DB		TCCAGAGGCCCTCAGCAGACTTTCAGACACTGGAGTGAAAGAGCGGTGTTTTAAAAATACA	1999
2149	QY		GAGCAAGCACGTCACAGGTTTTCACAGCCCCTCAGGGAAAGGACGACAGGTCCTCCGA	2208
2000	DB		GAGCAAGCACGTCACAGGTTTTCACAGCCCCTCAGGGAAAGGACGACAGGTCCTCCGA	2059
2209	QY		CAGGTGCTGTGGGGTGACTTCTGTGGAGCTTTTACCTCTGTAGTGAGACCCCTCCCA	2268
2060	DB		CAGGTGCTGTGGGGTGACTTCTGTGGAGC--TTTACCTCTGTAGTGAGACCCCTCCCA	2117
2269	QY		GAGCCCCGGGGCCGACGCCGCCCTCTGGTGAGGGCTGGGACAGGGCTCGTGGTGGCAT	2328
2118	DB		GAGCCCCGGGGCCGACGCCGCCCTCTGGTGAGGGCTGGGACAGGGCTCGTGGTGGCAT	2177
2329	QY		CAGCAGCAGAGACGAAGCTTTCGTAAACATCGGGCCGCTCCGCCAGAGGGGACAGTTTT	2388
2178	DB		CAGCAGCAGAGACGAAGCTTTCGTAAACATCGGGCCGCTCCGCCAGAGGGGACAGTTTT	2237
2389	QY		GCTCTTTGTGACATTTCCGAAACTACAGTTAAAGCAGAGAGTCTGTTTTCAGGAAAAGTT	2448
2238	DB		GCTCTTTGTGACATTTTCGAAACTACAGTTAAAGCAGAGAGTCTGTTTTCAGGAAAAGTT	2297
2449	QY		TCAAGGAGAGAGGCAAGTTTATCAAAAACATTTGTTTCAGGAGAAGGAGCATAGTTTA	2508
2298	DB		TCAAGGAGAGAGGCAAGTTTATCAAAAACATTTGTTTCAGGAGAAGGAGCATAGTTTA	2357
2509	QY		CAGCCTACAGGACGTACACAAATATCTGCTGGGNAACACACAGCATTTTATCTATTT	2568
2358	DB		CAGCCTACAGGACGTACACAAATATCTGCTGGGNAACACACAGCATTTTATCTATTT	2417
2569	QY		TTTATTTTAAAGTTTGGTGCTTATCTTCTAATAAGATTTAAATGTCACAAACTGTAGC	2628
2418	DB		TTTATTTTAAAGTTTGGTGCTTATCTTCTAATAAGATTTAAATGTCACAAACTGTAGC	2477
2629	QY		ACAAATAATAATTTATAATTTACAAATGAC	2661
2478	DB		ACAAATAATAATTTATAATTTACAAATGAC	2510

[illegible]

REFERENCE	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.									
AUTHORS	1 Isogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S., Yamamoto,J.I., Isono,Y., Hiko,Y., Otsuka,K., Nagai,K., Irie,R., Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahazi,K. and Masuho Y.									
TITLE	Full-length cDNA sequences									
JOURNAL	Patent: EP 1347046-A 2073 24-SEP-2003;									
FEATURES	Research Association for Biotechnology (JP)									
source	Location/Qualifiers									
	1..2448									
	/organism="Homo sapiens"									
	/mol_type="unassigned DNA"									
	/db_xref="taxon:9606"									
ORIGIN										
	Query Match 35.2%; Score 944; DB 6; Length 2448;									
	Best Local Similarity 99.9%; Pred. No. 0;									
	Matches 994; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	708	TGGGTC	TGGGGTGGTGGCATCTCCCTAAAGAACTGTCCTCTGTGSCAAAGTATGA	767						
DB	357	TGGGTC	TGGGGTGGTGGCATCTCCCTAAAGAACTGTCCTCTGTGSCAAAGTATGA	416						
QY	768	AGTCTCCAGCTTTGCCCTCAGCTCTCCACAGAAAGACTGGTCTCTTTTCGCTGGGA	827							
DB	417	AGTCTCCAGCTTTGCCCTCAGCTCTCCACAGAAAGACTGGTCTCTTTTCGCTGGGA	476							
QY	828	ACCCAGGATCAGGAGGATTTGGAGCCCGTGAGAGAAATAGAGAGGAGATCGGGACCT	887							
DB	477	ACCCAGGATCAGGAGGATTTGGAGCCCGTGAGAGAAATAGAGAGGAGATCGGGACCT	536							
QY	888	TGACCTTGAAACGGGCAGTTGTGTGTCTGCACAAACCGCGTAGAAATGCCAAACCGTCCACGA	947							
DB	537	TGACCTTGAAACGGGCAGTTGTGTGTCTGCACAAACCGCGTAGAAATGCCAAACCGTCCACGA	596							
QY	948	GGACGT	CAGACGACGCGCTGGGAGCCAGACAGATGGAGGAGACCTGCATGCGATCAT	1007						
DB	597	GGACGT	CAGACGACGCGCTGGGAGCCAGACAGATGGAGGAGACCTGCATGCGATCAT	656						
QY	1008	CTGCCAGGACCTGCTGCACGACTCGCTGTGATTTTGCAGCCCTGTGATGCACACGTTCTGCGC	1067							
DB	657	CTGCCAGGACCTGCTGCACGACTCGCTGTGATTTTGCAGCCCTGTGATGCACACGTTCTGCGC	716							
QY	1068	GGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGCTTACTCGCGCTGCCGT	1127							
DB	717	GGCTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGCTTACTCGCGCTGCCGT	776							
QY	1128	GGAGCGGATCTGTAAAAACCAATCTCTCAACACCTCGTGGAAAGCATCCTCATCCAGCA	1187							
DB	777	GGAGCGGATCTGTAAAAACCAATCTCTCAACACCTCGTGGAAAGCATCCTCATCCAGCA	836							
QY	1188	TCAGACAGAGTCGCGATGAGAGATGTGCAAGATGGATGCCAGGATAAATCAC	1247							
DB	837	TCAGACAGAGTCGCGATGAGAGATGTGCAAGATGGATGCCAGGATAAATCAC	896							
QY	1248	TCAAGACATGCTGCAGCCAAAGTCAAGGGGCTCTTTTCTGATGAAGAGGGAGTTTCAGA	1307							
DB	897	TCAAGACATGCTGCAGCCAAAGTCAAGGGGCTCTTTTCTGATGAAGAGGGAGTTTCAGA	956							
QY	1308	GGACCTGTGAGACTGTACAGCTTGACAGTGTGATCTTCAGACATTAGCCAGGCCATACGT	1367							
DB	957	GGACCTGTGAGACTGTACAGCTTGACAGTGTGATCTTCAGACATTAGCCAGGCCATACGT	1016							
QY	1368	CGTGTGCGGCAGTGTCTTGATACAGAGGCGAGGGCGCGCAGCCTCCCTCCCTGCCCAGC	1427							
DB	1017	CGTGTGCGGCAGTGTCTTGATACAGAGGCGAGGGCGCGCAGCCTCCCTCCCTGCCCAGC	1076							
QY	1428	ACCCAGGGCGAGCGCAGGAGCCCAACAGGCCCTGGGGGATGCACCTTCACAGTCCGTCAG	1487							
DB	1077	ACCCAGGGCGAGCGCAGGAGCCCAACAGGCCCTGGGGGATGCACCTTCACAGTCCGTCAG	1136							

QY 1488 CTTGACGACAGCAGTCCAGGATTACGTGTGCTCCCTCTGCAAGGAGCCAGCCCTGTGCAC 1547
DB 1137 CTTGACGACAGCAGTCCAGGATTACGTGTGCTCCCTCTGCAAGGAGCCAGCCCTGTGCAC 1196
QY 1548 CTGCTGCTTCCAGCCATGCGCCGACCGGAGAGCGGAGAGCCCGGCTGTGC 1607
DB 1137 CTGCTGCTTCCAGCCATGCGCCGACCGGAGAGCGGAGAGCCCGGCTGTGC 1256
QY 1608 CCTTCAGCAGTGTGGGGTCTGCTGCGAGCTTTCTGCACTGTACTTGGGGCTGCACCCG 1316
DB 1257 CCTTCAGCAGTGTGGGGTCTGCTGCGAGCTTTCTGCACTGTACTTGGGGCTGCACCCG 1316
QY 1668 GACCGCTGTACGGCTGCTGCGCCCGGCTTTCTGCACTGTACTTGGGGCTGCACCCG 1702
DB 1317 GACCGCTGTACGGCTGCTGCGCCCGGCTTTCTGCACTGTACTTGGGGCTGCACCCG 1351

RESULT 12
AK097671
LOCUS 2448 bp mRNA linear PRI 15-JUL-2002
DEFINITION Homo sapiens cDNA FLJ40352 fis, clone TEST12033505, highly similar to Homo sapiens cell cycle checkpoint protein CHFR mRNA.
ACCESSION AK097671
VERSION AK097671.1 GI:21757518
KEYWORDS oligo capping; fis (full insert sequence).
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS
Oshima, A., Takahashi-Fujii, A., Tanase, T., Imose, N., Takeuchi, K., Arita, M., Mutsaers, K., Yuuki, H., Hara, H., Sugiyama, T., Irie, R., Otsuki, T., Sato, H., Wakamatsu, A., Ishii, S., Yamamoto, J., Isono, Y., Kawai-Hio, Y., Saito, K., Nishikawa, T., Kimura, K., Yamashita, H., Matsuo, K., Nakamura, Y., Sekine, M., Kikuchi, H., Kanda, K., Wagatsuma, M., Murakawa, K., Kanehori, K., Sugiyama, A., Kawakami, B., Suzuki, Y., Sugano, S., Nagahara, K., Masuho, Y., Nagai, K. and Isogai, T.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

FEATURES
source
1. 2448
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="TEST12033505"
/tissue_type="testis"
/clone_lib="TEST12"
/note="cloning vector: pME185FL3"

ORIGIN
Query Match 35.2%; Score 944; DB 9; Length 2448;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 994; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 708 TGGGTCTGGGGGTGGTGGATCTCCCTAAAGGAAGTGTCCCTCTGTGGCAAGTGATGA 767
DB 357 TGGGTCTGGGGGTGGTGGATCTCCCTAAAGGAAGTGTCCCTCTGTGGCAAGTGATGA 416

QY 768 AGTCTCAGAGTTTGCCTCAGCTCTCCAGACAGAAAGACTGGTCTCTTTTCGTGTTGA 827
DB 417 AGTCTCAGAGTTTGCCTCAGCTCTCCAGACAGAAAGACTGGTCTCTTTTCGTGTTGA 476
QY 828 ACCCCAGGATCAGAGGATTTGGAGCCCTGGAAGAAAGAAATCAGAGGAGATGGGACCT 887
DB 477 ACCCCAGGATCAGAGGATTTGGAGCCCTGGAAGAAAGAAATCAGAGGAGATGGGACCT 536
QY 888 TGACCTGAAAGGGGAGTGTGTGTCACACACCGGCTAGAAATGCCAAACCGTCCACGA 947
DB 537 TGACCTGAAAGGGGAGTGTGTGTCACACACCGGCTAGAAATGCCAAACCGTCCACGA 596
QY 948 GGAGCTCAGAGCAGCGGCTGGGAAAGCCAGACAAAGATGGAGGAGAGCGCTGACATCAT 1007
DB 597 GGAGCTCAGAGCAGCGGCTGGGAAAGCCAGACAAAGATGGAGGAGAGCGCTGACATCAT 656
QY 1008 CTGCCAGGACCTGCTGCAAGCTGCTGAGTTTGCAGCCCTGCATGACACAGCTTCTGCG 1067
DB 657 CTGCCAGGACCTGCTGCAAGCTGCTGAGTTTGCAGCCCTGCATGACACAGCTTCTGCG 716
QY 1068 GGCTTGCTACTCGGGTGGATGGAGCGCTGCTCCCTGTGTCTTCTGCTGCTGCTGCTG 1127
DB 717 GGCTTGCTACTCGGGTGGATGGAGCGCTGCTCCCTGTGTCTTCTGCTGCTGCTGCTG 776
QY 1128 GGAGCGGATCTGTAAAGAAACACATCTCAACACCTCGTGGAGGATACCTCATCAGCA 1187
DB 777 GGAGCGGATCTGTAAAGAAACACATCTCAACACCTCGTGGAGGATACCTCATCAGCA 836
QY 1188 TCCAGACAGAGTCGCGAGTGAAGAGATGTGCAAGTATGGATGCCAGGATATAAATCAC 1247
DB 837 TCCAGACAGAGTCGCGAGTGAAGAGATGTGCAAGTATGGATGCCAGGATATAAATCAC 896
QY 1248 TCAGGACATGCTCCAGCCCAAGTTCAGAGCGGCTTTCTTCTGATGAAGAGGAGTTTCA 1307
DB 897 TCAGGACATGCTCCAGCCCAAGTTCAGAGCGGCTTTCTTCTGATGAAGAGGAGTTTCA 956
QY 1308 GGACCTGCTGGAGCTGTCTAGAGCTGTGAGTGTGCTGAGTGTGCTGAGTGTGCTGAG 1367
DB 957 GGACCTGCTGGAGCTGTCTAGAGCTGTGAGTGTGCTGAGTGTGCTGAGTGTGCTGAG 1016
QY 1368 CGTGTGCGGCGAGTGTCTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGT 1427
DB 1017 CGTGTGCGGCGAGTGTCTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1076
QY 1428 ACCCGAGGCGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAGCCAG 1487
DB 1077 ACCCGAGGCGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAGCCAGGAGCCAG 1136
QY 1488 CCTGACGACAGCAGTCCAGGATTTAGTGTGCTTCTGCAAGGAGGAGCCAGGAGCCAG 1547
DB 1137 CCTGACGACAGCAGTCCAGGATTTAGTGTGCTTCTGCAAGGAGGAGCCAGGAGCCAG 1196
QY 1548 CTGCTGCTTCCAGCCCATGCCGAGCCGAGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG 1607
DB 1197 CTGCTGCTTCCAGCCCATGCCGAGCCGAGAGTGGAGCGGAGCGGAGCGGAGCGGAGCGG 1256
QY 1608 CCTTCAGCAGTGTGGGGTCTGCTGCGAGCTTTCTGCCACCTGTACTGGGGTGCACCCG 1667
DB 1257 CCTTCAGCAGTGTGGGGTCTGCTGCGAGCTTTCTGCCACCTGTACTGGGGTGCACCCG 1316
QY 1668 GACCGCTGTGAGGCTGCTGCTGCGCCCGGCTTTGTG 1702
DB 1317 GACCGCTGTGAGGCTGCTGCTGCGCCCGGCTTTGTG 1351

RESULT 13
BD183291
LOCUS 6235 bp DNA linear PAT 17-JUN-2003
DEFINITION Novel genes and proteins encoded by the genes.
ACCESSION BD183291
VERSION BD183291.1 GI:31875491
KEYWORDS JF 2002345492-A/4.
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 6235)
Chara,O., Nagase,I. and Nakajima,D.
Novel genes and proteins encoded by the genes
Patent: JP 2002345492-A 4 03-DEC-2002;
KAZUSA DNA RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002345492-A/4
PD 03-DEC-2002
PF 28-FEB-2002 JP 2002049009
PI OSAMU OHARA,TAKAHIRO NAGASE,DAISUKE NAKAJIMA
PC C12N15/09,C07K14/47//A61K31/711,A61K38/00,A61K48/00,A61P25/00,
PC A61P25/14,
PC A61P25/18,A61P35/00,C12N15/00,A61K37/02
CC Novel genes and proteins encoded by the genes FH Key
Location/Qualifiers
FT CDS (50)..(1414).
Location/Qualifiers
1..6235
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 34.7%; Score 930; DB 6; Length 6235;
Best Local Similarity 99.7%; Pred.No. 0;
Matches 1160; Conservative 0; Mismatches 1; Indels 2; Gaps 1;
QY 1499 CAGTCCAGGATTACGTTGCTCCCTCTGCAAGGAAGCAGCCCTGTCACCTGCTGCTTCC 1558
DB 4447 CAGTCCAGGATTACGTTGCTCCCTCTGCAAGGAAGCAGCCCTGTCACCTGCTGCTTCC 4506
QY 1559 AGCCCATGCCACCGGAGAGCGGAGCGAGCAGAGACCCCGTGTGCGCCCTCAGCAGT 1618
DB 4507 AGCCCATGCCACCGGAGAGCGGAGCGGAGCAGAGACCCCGTGTGCGCCCTCAGCAGT 4565
QY 1619 GTGCGGTCTGCTGCGAGCTTTTCCACCTCTACTGCGGCTGCAACCGGAGCGGCTGCT 1678
DB 4567 GTGCGGTCTGCTGCGAGCTTTTCCACCTCTACTGCGGCTGCAACCGGAGCGGCTGCT 4626
QY 1679 AGCGTCTGCTGCGCCCGCTTTTGTGAGCTCAACCTGGTGACAAAGTGTCTGACGCGCTGC 1738
DB 4627 AGCGTCTGCTGCGCCCGCTTTTGTGAGCTCAACCTGGTGACAAAGTGTCTGACGCGCTGC 4686
QY 1739 TGAACAAACAGTACGATCAGATCAGATCCTCAAGATTTACCTGGCAACCAAGAGTTTGA 1798
DB 4687 TGAACAAACAGTACGATCAGATCAGATCCTCAAGATTTACCTGGCAACCAAGAGTTTGA 4746
QY 1799 CATGGAACAAACATGTTGACCGAGAGCTCTGCTGCTCTCCAGCGGAGTGTTCTGCTGT 1858
DB 4747 CATGGAACAAACATGTTGACCGAGAGCTCTATGCTCTCCAGCGGAGTGTTCTGCTGT 4806
QY 1859 CTGATTACAGATCAGGAGACACCGTTCTGTGTTACTGTGTGCGCTGCGCAGCTTCC 1918
DB 4807 CTGATTACAGATCAGGAGACACCGTTCTGTGTTACTGTGTGCGCTGCGCAGCTTCC 4866
QY 1919 GTGAGTGCACCTATCAGTATCGGAGAACATTCCTGCTTCCAGTGTCCAGTGCGCGCTAA 1978
DB 4867 GTGAGTGCACCTATCAGTATCGGAGAACATTCCTGCTTCCAGTGTCCAGTGCGCGCTAA 4925
QY 1979 CATCCCGTCTGACTCTACTTGGGCGCGTAACCTGCGCACTCAGGTGAAGCTCCACAG 2038
DB 4927 CATCCCGTCTGACTCTACTTGGGCGCGTAACCTGCGCACTCAGGTGAAGCTCCACAG 4986
QY 2039 CCATGAATTCATATCTGTGACACAGCAAGGTTCAAAACCTAAGCATCCAGAGGCC 2098
DB 4987 CCATGAATTCATATCTGTGTAACAGCAAGGTTCAAAACCTAAGCATCCAGAGGCC 5046
QY 2099 CTCAGCAGCTTTTCAGCAGCTGGAGTGGAAGAGCGGTGTTTTTAAATAACAGACAAGCA 2158
DB 5047 CTCAGCAGCTTTTCAGCAGCTGGAGTGGAAGAGCGGTGTTTTTAAATAACAGACAAGCA 5106

QY 2159 CGTCAAGGTGTTTTTCACAGCCCCCTCAGGGAAGGACGAGGCTCTCCGACAGGTGCTCT 2218
DB 5107 CGTCAAGGTGTTTTTCACAGCCCCCTCAGGGAAGGACGAGGCTCTCCGACAGGTGCTCT 5166
QY 2219 GGAGTGACTCTTCTGTGGAGCTTTTACCCCTCTGAGTGAGACCCCTCCCGAGAGCCCGGG 2278
DB 5167 GGAGTGACTCTTCTGTGGAGC--TTTACCCCTCTGAGTGAGACCCCTCCCGAGAGCCCGGG 5224
QY 2279 GGCGGAGAGCCCGCCCTCTGAGCGGCTGGGAGGCGCTCGTGGTGGCATCAGCAGCAGA 2338
DB 5225 GGCGGAGAGCCCGCCCTCTGAGCGGCTGGGAGGCGCTCGTGGTGGCATCAGCAGCAGA 5284
QY 2339 GACGAGAGCTTTCTGTAAACATGCGGCGCTCCCGGAGGAGGCGGAGCTTTTCTCTTTGT 2398
DB 5285 GACGAGAGCTTTCTGTAAACATGCGGCGCTCCCGGAGGAGGCGGAGCTTTTCTCTTTGT 5344
QY 2399 ACATTTTCCGAAACTACAGTTAAAGCAGAGTCTGTTTTTTCAGGAAAGTTTCAAGGAGA 2458
DB 5345 ACATTTTCCGAAACTACAGTTAAAGCAGAGTCTGTTTTTTCAGGAAAGTTTCAAGGAGA 5404
QY 2459 AGGCAAGTTTATCAAAACATTTGTTTTCAGGAGAGGAGCATTAAGTTTACAGCCTACAG 2518
DB 5405 AGGCAAGTTTATCAAAACATTTGTTTTCAGGAGAGGAGCATTAAGTTTACAGCCTACAG 5464
QY 2519 GAGTCACACAATATCTGCTGCTGGGAAACACACAGCATTTTATCTATTTTATTTTAA 2578
DB 5465 GAGTCACACAATATCTGCTGCTGGGAAACACACAGCATTTTATCTATTTTATTTAA 5524
QY 2579 TAGTGTGCTGCTATCTTCTTAATAGATTTAAATGTCACAAACTGTAGCACAATAATA 2638
DB 5525 TAGTGTGCTGCTATCTTCTTAATAGATTTAAATGTCACAAACTGTAGCACAATAATA 5584
QY 2639 TAATTTATTAATTTACAAATTTGAC 2661
DB 5585 TAATTTATTAATTTACAAATTTGAC 5607
RESULT 14
AK090948 2257 bp mRNA linear PRI 15-JUL-2002
LOCUS Homo sapiens cDNA FLJ33629 fis, clone BRAMY2022454, highly similar
DEFINITION to Homo sapiens cell cycle checkpoint protein CHFR mRNA.
AK090948
VERSION AK090948.1 GI:21749208
KEYWORDS oligo capping; fis (full insert sequence).
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
1
AUTHORS Ninomiya,K., Wagatsuma,M., Kanda,K., Kondo,H., Yokoi,T.,
Kodaïra,H., Furuya,T., Takahashi,M., Kikkawa,E., Omura,Y., Abe,K.,
Kamihara,K., Katsuta,N., Sato,K., Tanikawa,M., Yamazaki,M.,
Sugiyama,T., Irie,R., Otsuki,T., Sato,H., Wakamatsu,A., Ishii,S.,
Yamamoto,J., Isono,Y., Kawai-Hio,Y., Saito,K., Nishikawa,T.,
Kimura,K., Yamashita,H., Matsuo,K., Nakamura,Y., Sekine,M.,
Kikuchi,H., Murakawa,K., Kanehori,K., Takahashi-Fujii,A.,
Oshima,A., Sugiyama,A., Kawakami,B., Suzuki,Y., Sugano,S.,
Nagahara,K., Masuko,Y., Nagai,K. and Isogai,T.
Unpublished
2 (bases 1 to 2257)
JOURNAL Isogai,T. and Yamamoto,J.
REFERENCE Direct Submission
AUTHORS Submitted (04-JUL-2002) Takao Isogai, FLJ Project (HRI Team); 2-6-7
TITLE Kazusa-Kamatari, Kisarazu, Chiba 292-0812, Japan
JOURNAL (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
COMMENT NEDO human cDNA sequencing project supported by Ministry of
Economy, Trade and Industry of Japan; cDNA full insert sequencing:
Research Association for Biotechnology (RAB); cDNA library
construction: Helix Research Institute (HRI) (supported by Japan
Key Technology Center etc.); 5'- & 3'-end one pass sequencing: RAB.

QY 2276 GGGGGCCGAGCCGCCCTCCTGGTGAGCGCTGGGCAGGGCTCGTGGTCATCAGCAGC 2335
Db |||||
1173 GGGGGCCGAGCCGCCCTCCTGGTGAGCGCTGGGCAGGGCTCGTGGTCATCAGCAGC 1232
QY 2336 AGAGACGAAGCCCTTCTGTAAACATGCGCGCTCCCGCCGAGAGGGGCAGTTTGTCTTTT 2395
Db |||||
1233 AGAGACGAAGCCCTTCTGTAAACATGCGCGCTCCCGCCGAGAGGGGCAGTTTGTCTTT 1292
QY 2396 TGTACATTTCCGAARACTACAGTTAAAGCAGAGTCTGTTTCAGGAAAGTTTCAAGG 2455
Db |||||
1293 TGTACATTTCCGAARACTACAGTTAAAGCAGAGTCTGTTTCAGGAAAGTTTCAAGG 1352
QY 2456 AGAAGGCCAAGTTTATCAAAAACATTGTTTCAGGAGAGGAGCATAGTTTACAGCCTA 2515
Db |||||
1353 AGAAGGCCAAGTTTATCAAAAACATTGTTTCAGGAGAGGAGCATAGTTTACAGCCTA 1412
QY 2516 CAGGACGTACACAATATCCTGTGCTGGGAAACCAACAGCATTTTATCTATTTTATTT 2575
Db |||||
1413 CAGGACGTACACAATATCCTGTGCTGGGAAACCAACAGCATTTTATCTATTTTATTT 1472
QY 2576 TAATAGTTTGGTGTCTTCTCTTAATAAGATTAAATGTCACAACTGTAGCAAAATA 2635
Db |||||
1473 TAATAGTTTGGTGTCTTCTCTTAATAAGATTAAATGTCACAACTGTAGCAAAATA 1532
QY 2636 ATATAATTATATAATTACAAATTGAC 2661
Db |||||
1533 ATATAATTATATAATTACAAATTGAC 1558

Search completed: May 15, 2004, 05:09:34
Job time : 16432 secs

Query Match 35.2%; Score 944; DB 16; Length 2448;									
Best Local Similarity 99.9%; Pred. No. 0;									
Matches 994; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Qy	708	TGGGTCTGGGGTGGTGGCATCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGA	767						
Db	357	TGGGTCTGGGGTGGTGGCATCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGA	416						
Qy	768	AGTCTCCAGCTTTGGCTCAGCTCTCCACAGACAAAGACTCGCTCCCTTTTCGTGCTTGA	827						
Db	417	AGTCTCCAGCTTTGGCTCAGCTCTCCACAGACAAAGACTCGCTCCCTTTTCGTGCTTGA	476						
Qy	828	ACCCAGGATCAGAGAGATTGGAGCCCGTGAAGAAATGAGAGAGATGGGACCT	887						
Db	477	ACCCAGGATCAGAGAGATTGGAGCCCGTGAAGAAATGAGAGAGATGGGACCT	536						
Qy	888	TGACCTCAACGGGAGTGTGGTTCGCACAAACCGCTAGAAATGCCAAACCGTCCACGA	947						
Db	537	TGACCTCAACGGGAGTGTGGTTCGCACAAACCGCTAGAAATGCCAAACCGTCCACGA	596						
Qy	948	GGAGCTCAGAGACGCGCTGGGAAGCAGACAAAGATGGAGAGACGCTGACATGCATCAT	1007						
Db	597	GGAGCTCAGAGACGCGCTGGGAAGCAGACAAAGATGGAGAGACGCTGACATGCATCAT	656						
Qy	1008	CTGCCAGACCTGCTGCACGACTCGCTGAGTGTGGAGCCCTGCATGCACACGTTCCGCC	1067						
Db	657	CTGCCAGACCTGCTGCACGACTCGCTGAGTGTGGAGCCCTGCATGCACACGTTCCGCC	716						
Qy	1068	GGCTTGCTACTCGGGCTGGAGTGGAGCGCTCGTCCCTGTGTCCTACCTGCGCTGTCCCGT	1127						
Db	717	GGCTTGCTACTCGGGCTGGAGTGGAGCGCTCGTCCCTGTGTCCTACCTGCGCTGTCCCGT	776						
Qy	1128	GGAGCGATCTGTAAACACACATCTCTCAACACCTCGTGGAGAGCATACCTCATCAGCA	1187						
Db	777	GGAGCGATCTGTAAACACACATCTCTCAACACCTCGTGGAGAGCATACCTCATCAGCA	836						
Qy	1188	TCCAGACAAGAGTCGAGTGAAGAAGATGTCAAAGTATGGATGCCAGGAATAAAATCAC	1247						
Db	837	TCCAGACAAGAGTCGAGTGAAGAAGATGTCAAAGTATGGATGCCAGGAATAAAATCAC	896						
Qy	1248	TCAAGACATGCTGCAGCCCAAGTCAAGCGCTCTTTTCTGATGAAGAGGAGTTCAGA	1307						
Db	897	TCAAGACATGCTGCAGCCCAAGTCAAGCGCTCTTTTCTGATGAAGAGGAGTTCAGA	956						
Qy	1308	GGACCTGCTGAGCTGTGACAGCTTGACAGTGTGCTCAGACATAGCCAGCCATACGT	1367						
Db	957	GGACCTGCTGAGCTGTGACAGCTTGACAGTGTGCTCAGACATAGCCAGCCATACGT	1016						
Qy	1368	CGTGTGCGGAGTGCCTGAGTACAGAGGCGGCGCAGCCTCCCACTGCCCAGC	1427						
Db	1017	CGTGTGCGGAGTGCCTGAGTACAGAGGCGGCGCAGCCTCCCACTGCCCAGC	1076						
Qy	1428	ACCCGAGGCGGCGCAGGCGCCACAGGCGCTGGGGGATGCACCTCCACGTCGCTCAG	1487						
Db	1077	ACCCGAGGCGGCGCAGGCGCCACAGGCGCTGGGGGATGCACCTCCACGTCGCTCAG	1136						
Qy	1488	CCTGACACACAGCTCCAGGATACGTGTGCCCTCTGCAAGGAGGACCCCTGTCAC	1547						
Db	1137	CCTGACACACAGCTCCAGGATACGTGTGCCCTCTGCAAGGAGGACCCCTGTCAC	1196						
Qy	1548	CTGCTGCTTCAGCCCATGTCGCGGAGCGGAGCGGAGCGGAGACCCGGGTCTCC	1607						
Db	1197	CTGCTGCTTCAGCCCATGTCGCGGAGCGGAGCGGAGCGGAGACCCGGGTCTCC	1256						
Qy	1608	CCCTCAGCAGTGTGCGGTCTGCTGACGCTTTCTGCGACCTGTACTGGGGCTGCAACCG	1667						
Db	1257	CCCTCAGCAGTGTGCGGTCTGCTGACGCTTTCTGCGACCTGTACTGGGGCTGCAACCG	1316						
Qy	1668	GACCGGTGCTACGGCTGCTGCGCCCGCTGCTTTGTG	1702						
Db	1317	GACCGGTGCTACGGCTGCTGCGCCCGCTTGTG	1351						

Query Match 28.6%; Score 765; DB 9; Length 1311;									
Best Local Similarity 100.0%; Pred. No. 0;									
Matches 765; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
Qy	710	GGTCTGGGGTGGTGGCATCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGAAG	769						
Db	383	GGTCTGGGGTGGTGGCATCTCCCTAAAGAAAGTGGTCCCTCTGTGGCAAGTATGAAG	442						
Qy	770	TCTCCAGCTTTGCCCTCAGCTCTCCACAGACAAAGACTCGCTCTTTTCGTGCTTGAAC	829						
Db	443	TCTCCAGCTTTGCCCTCAGCTCTCCACAGACAAAGACTCGCTCTTTTCGTGCTTGAAC	502						
Qy	830	CCAGGATCAGAGAGATTGGAGCCCGTGAAGAAATGAGAGAGATGGGACCTTG	889						
Db	503	CCAGGATCAGAGAGATTGGAGCCCGTGAAGAAATGAGAGAGATGGGACCTTG	562						
Qy	890	ACCTCAACGGGAGTGTGGTTCGCACAAACCGCTAGAAATGCCAAACCGTCCACGAGG	949						
Db	563	ACCTCAACGGGAGTGTGGTTCGCACAAACCGCTAGAAATGCCAAACCGTCCACGAGG	622						
Qy	950	ACGTGAGAGACGCGCTGGGAAGCAGACAAAGATGGAGAGACGCTGATGCATCATCT	1009						
Db	623	ACGTGAGAGACGCGCTGGGAAGCAGACAAAGATGGAGAGACGCTGATGCATCATCT	682						
Qy	1010	GCCAGACCTGCTGCACGACTCGCTGAGTGTGCGAGCCCTGCATGCACACGTTCTCGCGGG	1069						
Db	683	GCCAGACCTGCTGCACGACTCGCTGAGTGTGCGAGCCCTGCATGCACACGTTCTCGCGGG	742						
Qy	1070	CTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGTCCTACCTGCGCTGTCCCGTGG	1129						
Db	743	CTTGCTACTCGGGCTGGATGGAGCGCTCGTCCCTGTGTCCTACCTGCGCTGTCCCGTGG	802						
Qy	1130	AGCGGATCTGTAAACACACATCTCTCAACACCTCGTGGAGAGCATACCTCATCCAGCATC	1189						
Db	803	AGCGGATCTGTAAACACACATCTCTCAACACCTCGTGGAGAGCATACCTCATCCAGCATC	862						
Qy	1190	CAGACAGAGTCGAGTGAAGAAGATGTGCAAAAGTATGGATGCCAGGAATAAAATCACTC	1249						
Db	863	CAGACAGAGTCGAGTGAAGAAGATGTGCAAAAGTATGGATGCCAGGAATAAAATCACTC	922						
Qy	1250	AAGACATGCTGAGCCCAAGTCTAGGCGGTCTTTTCTGATGAAGAGGAGTTCAGAGG	1309						
Db	923	AAGACATGCTGAGCCCAAGTCTAGGCGGTCTTTTCTGATGAAGAGGAGTTCAGAGG	982						
Qy	1310	ACCTGCTGAGCTGTGAGAGTGTGAGTGTGCTCAGACATAGCCAGGCCATACGTCG	1369						
Db	983	ACCTGCTGAGCTGTGAGAGTGTGAGTGTGCTCAGACATAGCCAGGCCATACGTCG	1042						
Qy	1370	TGTGCGGAGTGTCTCTGAGTACAGAGCGGCGGCGCTCCCACTGCGCCAGCAC	1429						

Db 1043 TGTGCGGCGAGTCTCTGAGTACAGAGGCGGCGGCGAGCCTCCCACTGCGCCAGCAC 1102
QY 1430 CCGAGGGCGGAGCCAGAGCCCCCAGAGCCCTGGGGGATGACACCT 1474
Db 1103 CCGAGGGCGGAGCCAGAGCCCCCAGAGCCCTGGGGGATGACACCT 1147

RESULT 4

US-10-094-749-160

; Sequence 160, Application US/10094749

; Publication No. US20030219741A1

; GENERAL INFORMATION:

; APPLICANT: ISOGAI, TAKAO

; APPLICANT: SUGIYAMA, TOMOYASU

; APPLICANT: OTSUKI, TETSUJI

; APPLICANT: WAKAMATSU, AI

; APPLICANT: SATO, HIROYUKI

; APPLICANT: ISHII, SHIZUKO

; APPLICANT: YAMAMOTO, JUN-ICHI

; APPLICANT: ISONO, YUUKO

; APPLICANT: HIO, YURI

; APPLICANT: OTSUKA, KAORU

; APPLICANT: NAGAI, KEIICHI

; APPLICANT: IRIE, RYOTARO

; APPLICANT: TAMECHIKI, ICHIRO

; APPLICANT: SEKI, NAOHICO

; APPLICANT: YOSHIKAWA, TSUTOMU

; APPLICANT: OTSUKA, MOTOKI

; APPLICANT: NAGAHARI, KENJI

; APPLICANT: MASUHO, YASUHIKO

; TITLE OF INVENTION: NOVEL FULL-LENGTH CDNA

; FILE REFERENCE: 084335/0160

; CURRENT APPLICATION NUMBER: US/10/094,749

; CURRENT FILING DATE: 2002-03-12

; PRIOR APPLICATION NUMBER: 60/350,435

; PRIOR FILING DATE: 2002-01-24

; PRIOR FILING DATE: 2001-09-14

; NUMBER OF SEQ ID NOS: 3381

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 160

; LENGTH: 2186

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-094-749-160

Query Match

Best Local Similarity 23.6%; Score 633; DB 16; Length 2186;

Matches 863; Conservative 0; Mismatches 1; Indels 2; Gaps 1;

QY 1796 TGACATGGAAAACATGTTGACCGAGAGCCCTCGTGGCTCTCCAGCGGGAGTGTCTGC 1855

Db 695 TGACATGGAAAACATGTTGACCGAGAGCCCTCGTGGCTCTCCAGCGGGAGTGTCTGC 754

QY 1856 TGTCTGATTACAGAGTACAGGAGACACCGTTCTGTGTTACTGCTGTGGCCTCGCGAGCT 1915

Db 755 TGTCTGATTACAGAGTACAGGAGACACCGTTCTGTGTTACTGCTGTGGCCTCGCGAGCT 814

QY 1916 TCCGTGAGCTACCTATCAGTATCGGAGACATTCCTGCTCCGAGTTCGAGTGGCG 1975

Db 815 TCCGTGAGCTACCTATCAGTATCGGAGACATTCCTGCTCCGAGTTCGAGTGGCG 874

QY 1976 TAACATCCGCTCTGACTGCTACTGGGCGGTAACTCCGCACCTCAGGTGAAGTCCACC 2035

Db 875 TAACATCCGCTCTGACTGCTACTGGGCGGTAACTCCGCACCTCAGGTGAAGTCCACC 934

QY 2036 ACGCATGAATTCATCATATCTGTGAACAGACAGGTTCAAACTAAGATCCAGAG 2095

Db 935 ACGCATGAATTCATCATATCTGTGAACAGACAGGTTCAAACTAAGATCCAGAG 994

QY 2096 GCCCTGACAGCTTTACAGCACTGGAGGTGAAGAGAGCGTGTCTTTTAAATACAGACAA 2155

Db 995 GCCCTGACAGCTTTACAGCACTGGAGGTGAAGAGAGCGTGTCTTTTAAATACAGACAA 1054

QY 2156 GCAGTCAAGGTGTTTTCACAGCCCTGAGGAGGAGCGAGGCTCTCCGACAGTGC 2215
Db 1055 ACAGTCAAGGTGTTTTCACAGCCCTGAGGAGGAGCGAGGCTCTCCGACAGTGC 1114
QY 2216 TCTGGGTGACTCTTCTGTGGAGCTTTTACCTCTCTGAGTACACCTCCCCAGAGCCCC 2275
Db 1115 TCTGGGTGACTCTTCTGTGGAGC--TTTACCTCTCTGAGTACACCTCCCCAGAGCCCC 1172
QY 2276 GGGGGCGCAGCGCCCTCTGAGGAGGCTGGGAGGAGGCTGGTGGCATCAGCAGC 2335
Db 1173 GGGGGCGCAGCGCCCTCTGAGGAGGCTGGGAGGAGGCTGGTGGCATCAGCAGC 1232
QY 2336 AGAGCAAGGCTTTCTGTAAACATGCGGCGCTCCCGCAGAGGGGAGTGTGCTCTTT 2395
Db 1233 AGAGCAAGGCTTTCTGTAAACATGCGGCGCTCCCGCAGAGGGGAGTGTGCTCTTT 1292
QY 2396 TGTACATTTCCGAAACTACAGTTAAAGCAAGAGTCTGTTTTTCAAGAAAAGTTTCAAGG 2455
Db 1293 TGTACATTTCCGAAACTACAGTTAAAGCAAGAGTCTGTTTTTCAAGAAAAGTTTCAAGG 1352
QY 2456 AGAAGGCAAGTATTATCAAAAAATTTTTCAGGAGGAGGAGCATTAAGTTACAGCCTA 2515
Db 1353 AGAAGGCAAGTATTATCAAAAAATTTTTCAGGAGGAGGAGCATTAAGTTACAGCCTA 1412
QY 2516 CAGGACGTACACATATCTCTGCTGGGAAAACACAGCATTTTATCTATTTTATTT 2575
Db 1413 CAGGACGTACACATATCTCTGCTGGGAAAACACAGCATTTTATCTATTTTATTT 1472
QY 2576 TAATAGTTTGGTCTTATCTTCTAATAAGATTTAAATGTCAAACTGTAGCAGCAATA 2635
Db 1473 TAATAGTTTGGTCTTATCTTCTAATAAGATTTAAATGTCAAACTGTAGCAGCAATA 1532
QY 2636 ATATAATTTTATTAATTTACAAATTTGAC 2661
Db 1533 ATATAATTTTATTAATTTACAAATTTGAC 1558

RESULT 5

US-09-764-864-483

; Sequence 483, Application US/09764864

; Patent No. US20020132753A1

; GENERAL INFORMATION:

; APPLICANT: Rosen et al.

; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies

; FILE REFERENCE: PT223

; CURRENT APPLICATION NUMBER: US/09/764,864

; CURRENT FILING DATE: 2001-01-17

; Prior application data removed - consult PALM or file wrapper

; NUMBER OF SEQ ID NOS: 1792

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 483

; LENGTH: 693

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: SITE

; LOCATION: (11)

; OTHER INFORMATION: n equals a,t,g, or c

; NAME/KEY: SITE

; LOCATION: (13)

; OTHER INFORMATION: n equals a,t,g, or c

; NAME/KEY: SITE

; LOCATION: (623)

; OTHER INFORMATION: n equals a,t,g, or c

; NAME/KEY: SITE

; LOCATION: (640)

; OTHER INFORMATION: n equals a,t,g, or c

; NAME/KEY: SITE

; LOCATION: (670)

; OTHER INFORMATION: n equals a,t,g, or c

; NAME/KEY: SITE

; LOCATION: (687)


```

;
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILER: Patent and Trademark Office
; FILE REFERENCE: PR23
; CURRENT APPLICATION NUMBER: US/09/764,864
; PRIOR FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: Patent Ver. 2.0
;

```

Query Match 8.9%; Score 238; DB 9; Length 354;
Best Local Similarity 100.0%; Pred. No. 4.3e-109;
Matches 238; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

245	Qy	GCATTAATAACTGGTCTCTCGAGATCACTGTGAGAAATTTAGTGGATGGAATAAATCAGGTCAAG	304
51	Db	GCATTAATAACTGGTCTCTCGAGATCACTGTGAGAAATTTAGTGGATGGAATAAATCAGGTCAAG	110
305	Qy	TCACACTCGGAATACACAGACCAGTCAGTGGACAGTGAATTAAACAGCTGGAAGTTGTGTTAAGA	364
111	Db	TGACACTGGAAGATACACAGACCAGTCAGTGGACAGTGAATTAAACAGCTGGAAGTTGTGTTAAGA	170
365	Qy	AGCAGACATGCCCTTTACAGACTCGGGATGTCATCTACTTGGTGTTACAGGAAGAATGAAC	424
171	Db	AGCAGACATGCCCTTTACAGACTCGGGATGTCATCTACTTGGTGTTACAGGAAGAATGAAC	230
425	Qy	CGGAACACACAGTGGCACTCTATGAACTTTTAACTGAAAGAGCGCATGACACA	482
231	Db	CGGAACACACAGTGGCACTCTATGAACTTTTAACTGAAAGAGCGCATGACACA	288

```

RESULT 9
US-09-918-995-13662
; Sequence 13662, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 13662
; LENGTH: 449
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(449)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-13662

```

Query Match	8.1%	Score 217;	DB 10;	Length 449;
Best Local Similarity	100.0%;	Pred. No. 1.7e-99;		
Matches 217;	Conservative	0;	Mismatches 0;	Indels 0;
				Gaps 0;

2445 AGTTTCAGGGGAGAAGGCAAGTTTATCAAAAACATTCTTTTCAGGAGAGGGAGCATTAAG 2504

Db	92	AGTTTCAAGGGGAAGGGGCGAAGTTTATCAAAAACAATTGTTTCAGGAGAAAGGGAGCATAAG	151
Qy	2505	TTTACAGCCTACAGGACGTACACAAATATCTGCTGCTGGGAAAACACACAGCATTTTATCT	2564
Db	152	TTTACAGCCTACAGGACGTACAAATATCTGCTGCTGGGAAAACACACAGCATTTTATCT	211
Qy	2565	ATTTTTATTTTAAATAGGTTGGTGCTTATCTCTTAATAAGATTTTAAATGTCACAAACTG	2624
Db	212	ATTTTTATTTTAAATAGGTTGGTGCTTATCTCTTAATAAGATTTTAAATGTCACAAACTG	271
Qy	2625	TAGCACAATAATATATTTTATATTTTACAAATTGAC	2661
Db	272	TAGCACAATAATATATTTTATATTTTACAAATTGAC	308

```

RESULT 10
US-09-918-995-2180
; Sequence 2180, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hvsseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2180
; LENGTH: 476
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(476)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-2180

```

Query Match 2.9%; Score 77; DB 10; Length 476;
Best Local Similarity 100.0%; Pred. No. 7.5e-28;
Matches 77; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	2046	ATTCAATCATATCTGTGAACAGACAAGGTTCAAAACTAAGCATCCAGAGGCGCTGAGCA	2109
Db	52	ATTCAATCATATCTGTGAACAGACAAGGTTCAAAACTAAGCATCCAGAGGCGCTGAGCA	111
Qy	2106	GCATTCAGCACTGGAGG	2122
Db	112	GCATTCAGCACTGGAGG	128

RESULT 11
US-09-908-975-6220
; Sequence 6220, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: Oligonucleotide library for detecting RNA transcripts and splice
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTOME
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; CURRENT FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6220
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-908-975-6220

Query Match      2.2%; Score 60; DB 10; Length 60;
Best Local Similarity 100.0%; Pred. No. 2.8e-19;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1843 GGAGTGTTCGTCTGTTGATTACAGAGTCACGGGAGACACCGTCTGTGTTACTGCTGT 1902
Db 1 GGAGTGTTCGTCTGTTGATTACAGAGTCACGGGAGACACCGTCTGTGTTACTGCTGT 60

RESULT 12
US-10-304-928-15
; Sequence 15, Application US/10304928
; Publication No. US20030101484A1
; GENERAL INFORMATION:
; APPLICANT: Simmons, Carl R.
; APPLICANT: Yalpani, Nasser
; TITLE OF INVENTION: Maize Chitinases and Their Use in
; TITLE OF INVENTION: Enhancing Disease Resistance in Crop Plants
; FILE REFERENCE: 1100D
; CURRENT APPLICATION NUMBER: US/10/304,928
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: 09/522,714
; PRIOR FILING DATE: 2000-03-10
; PRIOR APPLICATION NUMBER: 60/125,915
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 15
; LENGTH: 1085
; TYPE: DNA
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (46)...(966)
US-10-304-928-15

Query Match      0.9%; Score 25; DB 15; Length 1085;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2655 AATTGACAAAAA 2679
Db 1061 AATTGACAAAAA 1085

RESULT 13
US-09-957-664-1
; Sequence 1, Application US/09957664
; Patent No. US20020123097A1
; GENERAL INFORMATION:
; APPLICANT: Curtis, Rory A. J.
; TITLE OF INVENTION: A NOVEL HUMAN TRANSPORTER AND
; TITLE OF INVENTION: USES THEREFOR
; FILE REFERENCE: MNI-192
; CURRENT APPLICATION NUMBER: US/09/957,664
; CURRENT FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: 60/233,790
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 1963
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
```

```
; LOCATION: (67)...(1491)
US-09-957-664-1

Query Match      0.9%; Score 25; DB 9; Length 1963;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2655 AATTGACAAAAA 2679
Db 1916 AATTGACAAAAA 1940

RESULT 14
US-10-154-419-15
; Sequence 15, Application US/10154419
; Publication No. US20030143675A1
; GENERAL INFORMATION:
; APPLICANT: Curtis, Rory A.J.
; APPLICANT: Gluckman, Maria Alexandra
; APPLICANT: Meyers, Rachel E.
; TITLE OF INVENTION: NOVEL 38594, 57312, 53659, 57250, 63760, 49938, 32146,
; TITLE OF INVENTION: 57259, 67118, 67067, 62952, 8099, 46455, 54144, 53763,
; TITLE OF INVENTION: 67076, 67102, 44181, 67084FL, 67084ALT, FHS8295FL, 57255,
; TITLE OF INVENTION: AND 57255alt MOLECULES AND USES THEREFOR
; FILE REFERENCE: MNI-249
; CURRENT APPLICATION NUMBER: US/10/154,419
; CURRENT FILING DATE: 2002-05-22
; PRIOR APPLICATION REMOVED - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: FastSeq Version 4.0
; SEQ ID NO 15
; LENGTH: 1963
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (67)...(1491)
US-10-154-419-15

Query Match      0.9%; Score 25; DB 15; Length 1963;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2655 AATTGACAAAAA 2679
Db 1916 AATTGACAAAAA 1940

RESULT 15
US-09-938-842A-3337/c
; Sequence 3337, Application US/09938842A
; Patent No. US20020160378A1
; GENERAL INFORMATION:
; APPLICANT: Harper, Jeff
; APPLICANT: Kreps, Joel
; APPLICANT: Wang, Xun
; APPLICANT: Zhu, Tong
; TITLE OF INVENTION: STRESS-REGULATED GENES OF PLANTS, TRANSGENIC PLANTS CONTAINING
; TITLE OF INVENTION: SAME, AND METHODS OF USE
; FILE REFERENCE: SCRIP1300-3
; CURRENT APPLICATION NUMBER: US/09/938,842A
; CURRENT FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: US 60/227,866
; PRIOR FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: US 60/264,647
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: US 60/300,111
; PRIOR FILING DATE: 2001-06-22
; NUMBER OF SEQ ID NOS: 5379
; SEQ ID NO 3337
; LENGTH: 2000
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
```

US-09-938-842A-3337

Query Match 0.9%; Score 25; DB 9; Length 2000;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2655 AATTGACAAAAA 2679
DB 1268 AATTGACAAAAA 1244

Search completed: May 15, 2004, 12:03:05
Job time : 1595 secs

GenCore version 5.1.6
Copyright (C) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 14, 2004, 23:36:46 ; Search time 10039 Seconds
(without alignments)
7968.999 Million cell updates/sec

Title: US-10-048-046-1
Perfect score: 2679
Sequence: 1 asgaattgcgcagggccg.....acaaaaaaaaaaaaaaaaa 2679

Scoring table: OLIGO NUC
Gapop_60.0 , Gapext 60.0

Searched: 27513289 seqs, 14931090276 residues

Word size : 0

Total number of hits satisfying chosen parameters: 55026578

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Listing first 45 summaries

Database : EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estnu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hctc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rod:*
26: em_gss_pbg:*
27: em_gss_vrl:*
28: gp_gss1:*
29: gp_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	825	30.8	1201	9	AL539798
2	722	27.0	921	13	BUI176559
3	703	26.2	992	13	BQ073354
4	698	26.1	877	14	CD243458

5 647 24.2 897 10 BF971929
6 620 23.1 840 12 BG395714
7 600 22.4 680 9 AUI134937
8 583 21.8 870 13 BQ215731
9 565 21.1 916 12 BM459647
10 563 21.0 1143 12 BM542545
11 560 20.9 666 10 BE407732
12 539 20.1 1201 9 AL539797
13 519 19.4 934 10 BF971838
14 513 19.1 729 14 CA916737
15 488 18.2 690 10 BE280165
16 478 17.8 910 13 BUI148471
17 477 17.8 938 13 BQ887242
18 477 17.8 1092 12 BM541730
19 469 17.5 909 13 BX409791
20 468 17.5 824 9 AUI132825
21 456 17.0 712 10 BE257482
22 456 17.0 1096 12 BG335362
23 452 16.9 1022 12 BM558904
24 450 16.8 953 13 BQ936072
25 447 16.7 938 13 BQ924736
26 436 16.3 535 13 BX486289
27 436 16.3 557 13 BX486564
28 435 16.2 811 14 CB989147
29 433 16.2 806 14 CB961597
30 426 15.9 518 9 AUI54212
31 421 15.7 687 9 AUI138310
32 420 15.7 876 13 BQ876252
33 418 15.6 650 10 AW957709
34 412 15.4 635 12 BG481936
35 409 15.3 490 10 BF109790
36 404 15.1 881 13 BUI53737
37 394 14.7 944 13 BX409790
38 386 14.4 475 9 AI200393
39 382 14.3 824 12 BG831289
40 381 14.2 797 12 BI460002
41 364 13.6 1070 12 BM802324
42 354 13.2 636 10 BE407797
43 335 12.5 697 12 BG473597
44 326 12.2 527 10 BF439206
45 320 11.9 722 9 AUI135780

ALIGNMENTS

RESULT 1
AL539798
LOCUS
DEFINITION
AL539798 Homo sapiens FETAL BRAIN Homo sapiens cDNA clone
CSODF031YA23 5-PRIME, mRNA sequence.
ACCESSION
AL539798.2 GI:31264361
VERSION
EST.
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 1201)
Li W.B., Gruber C., Jesses J. and Polayes D.
Full-length cDNA libraries and normalization
Unpublished (2001)
JOURNAL
On Feb 15, 2001 this sequence version replaced gi:12869349.
COMMENT
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6792.r For more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODF031YA23&cluster=6792.r. Contact :
Peng Liang Email : fliang@lifetech.com URL :

AL539798 1201 bp mRNA linear EST 31-MAY-2003
AL539798 Homo sapiens FETAL BRAIN Homo sapiens cDNA clone
CSODF031YA23 5-PRIME, mRNA sequence.
AL539798.2 GI:31264361
EST.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1201)
Li W.B., Gruber C., Jesses J. and Polayes D.
Full-length cDNA libraries and normalization
Unpublished (2001)
JOURNAL
On Feb 15, 2001 this sequence version replaced gi:12869349.
COMMENT
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6792.r For more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODF031YA23&cluster=6792.r. Contact :
Peng Liang Email : fliang@lifetech.com URL :

BF971929 602240332
BG395714 602458365
AUI134937 AUI134937
BQ215731 AGENCOURT
BM459647 AGENCOURT
BM542545 AGENCOURT
BE407732 601239777
AL539797 AL539797
BF971838 602240424
CA916737 30LSPRIM2
BE280165 601158370
BUI148471 AGENCOURT
BQ887242 AGENCOURT
BM541730 AGENCOURT
BX409791 BX409791
AUI132825 AUI132825
BE257482 60111439
BG335362 602404192
BM558904 AGENCOURT
BQ936072 AGENCOURT
BQ924736 AGENCOURT
BX486289 DRFP886P
BX486564 DRFP886H
CB989147 AGENCOURT
CB961597 AGENCOURT
AUI54212 AUI54212
AUI138310 AUI138310
BQ876252 AGENCOURT
AW957709 EST369779
BG481936 602528853
BF109790 7169A04.X
BUI53737 AGENCOURT
BX409790 BX409790
AI200393 Gf86e04.X
BG831289 602766120
BI460002 603201532
BM802324 AGENCOURT
BE407797 601299183
BG473597 602515946
BF439206 nab60h05.
AUI135780 AUI135780

http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DF031A12QF1.
Location/Qualifiers
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF031A23"
/tissue_type="FETAL BRAIN"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL BRAIN"
/note="Organ: brain; Vector: pCMVSPORT 6; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

FEATURES
source
Query Match 30.8%; Score 825; DB 9; Length 1201;
Best Local Similarity 100.0%; Pred. No. 1.4e-155;
Matches 825; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 GTTCGGCGGGCGGGATGATCCGATGGAGCGCGCGGAGGCAAGCAGTCG 120
DB 67 GTTCGGCGGGCGGGATGATCCGATGGAGCGCGCGGAGGCAAGCAGTCG 126

QY 121 CGCCGCGCGACCTCGGGACGGCTCTCGGCTCTGGGCGGGAGGCGAGCGCGAC 180
DB 127 CGCCGCGCGACCTCGGGACGGCTCTCGGCTCTGGGCGGGAGGCGAGCGCGAC 186

QY 181 GTTCCTCTGAGAACGGGAGTGACCATCGGGCGGAGACAGGTTGGACCTTCTTC 240
DB 187 GTTCCTCTGAGAACGGGAGTGACCATCGGGCGGAGACAGGTTGGACCTTCTTC 246

QY 241 CCAGCAATAACTGTCTCTGAGATCACTAGATTTAGTGGATGAAATTCAGGT 300
DB 247 CCAGCAATAACTGTCTCTGAGATCACTAGATTTAGTGGATGAAATTCAGGT 306

QY 301 CAGGTGACACTGGAAGATACCAAGCCAGTGGAACAGTGATTAACAAGCTGAAGTTGTT 360
DB 307 CAGGTGACACTGGAAGATACCAAGCCAGTGGAACAGTGATTAACAAGCTGAAGTTGTT 366

QY 361 AAGAGCAGACATGCCCTTACAGACTGGGATGTCATCTTGGTGTACAGGAAGAT 420
DB 367 AAGAGCAGACATGCCCTTACAGACTGGGATGTCATCTTGGTGTACAGGAAGAT 426

QY 421 GAACCGGAACACAGCTGGCATACCTCTATGATCTTTAAGTGAAGCAAGGCGATGCA 480
DB 427 GAACCGGAACACAGCTGGCATACCTCTATGATCTTTAAGTGAAGCAAGGCGATGCA 486

QY 481 CAGATATCTTTGAGCTTAAGCAAGGAATGTTCATGGGACCAAGATACCTCAGGT 540
DB 487 CAGATATCTTTGAGCTTAAGCAAGGAATGTTCATGGGACCAAGATACCTCAGGT 546

QY 541 GCAGGTGACGGGCGAGGGCGGATCCCGGGTCCCTCGCTGCTCGCCGCCACTCAGGTG 600
DB 547 GCAGGTGACGGGCGAGGGCGGATCCCGGGTCCCTCGCTGCTCGCCGCCACTCAGGTG 606

QY 601 TGTCTTGAGAACCAAGCCATCAACATCGAGTCAAGCTTCTCCACAGCCCTCGGCC 660
DB 607 TGTCTTGAGAACCAAGCCATCAACATCGAGTCAAGCTTCTCCACAGCCCTCGGCC 666

QY 661 TCTTCCACGGAGCTTCTCTGCGAGGGCGAGAGCGTTCTCCAGTTGTGGGTCTGGGGGT 720
DB 667 TCTTCCACGGAGCTTCTCTGCGAGGGCGAGAGCGTTCTCCAGTTGTGGGTCTGGGGGT 726

QY 721 GGTGGCATCTCCCTAAAGAGATGTGCTCTCTGTGGGCAAGTGATGATCTCCAGCTTT 780
DB 727 GGTGGCATCTCCCTAAAGAGATGTGCTCTCTGTGGGCAAGTGATGATCTCCAGCTTT 786

QY 781 GCTCAGCTCTCCACAGAGAGACTGCTGCTCTCTTTCTGCTGGAACCCCGAGGATCAG 840
DB 787 GCTCAGCTCTCCACAGAGAGACTGCTGCTCTCTTTCTGCTGGAACCCCGAGGATCAG 846

QY 841 GAGGATTTCGAGCCCGTGAAGAGAAATGAGAGAGATGGGAC 885
DB 847 GAGGATTTCGAGCCCGTGAAGAGAAATGAGAGAGATGGGAC 891

RESULT 2
BUI76559
LOCUS
DEFINITION BUI76559 921 bp mRNA linear EST 04-SRP-2002
AGENCOURT 7940317 NIH_MGC_67 Homo sapiens cDNA clone IMAGE:6143609
5', mRNA sequence.
ACCESSION BUI76559
VERSION BUI76559.1 GI:22690543
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgaabs@mail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLNL3467 row: e column: 18
High quality sequence stop: 697.
Location/Qualifiers
1..921
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6143609"
/tissue_type="retinoblastoma"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 67"
/notes="Organ: eye; Vector: pCMV-SPORT6; Site 1: NotI;
Site 2: SalI; Cloned unidirectionally. Primer: Oligo dr.
Average insert size 1.75 kb. Library constructed by Life
Technologies."

ORIGIN
Query Match 27.0%; Score 722; DB 13; Length 921;
Best Local Similarity 99.9%; Pred. No. 5.5e-135;
Matches 772; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1889 TGTGTTACTCTGCGCTGCGCAGCTTCGTCAGCTGACCTATCAGTATCGGCAGAAC 1948
DB 1 TGTGTTACTCTGCGCTGCGCAGCTTCGTCAGCTGACCTATCAGTATCGGCAGAAC 60

QY 1949 TTCTGTTCCGAGTTGCCAGTGGCGGTAACTCCCGTCTGACTGCTACTGGGGCGGTA 2008
DB 61 TTCTGTTCCGAGTTGCCAGTGGCGGTAACTCCCGTCTGACTGCTACTGGGGCGGTA 120

QY 2009 ACTGCCGCACTCAGGTGAAGCTCACACGCCATGAATTCATATCTGTGAACAGA 2068
DB 121 ACTGCCGCACTCAGGTGAAGCTCACACGCCATGAATTCATATCTGTGAACAGA 180

QY 2069 CAAGGTTCAAAACTAAGCATCCAGAGGCCCTGAGCAGCTTTTTCAGCCTGGAGGTGAGA 2128
DB 181 CAAGGTTCAAAACTAAGCATCCAGAGGCCCTGAGCAGCTTTTTCAGCCTGGAGGTGAGA 240

QY 2129 GAGCGTGTCTTTAAATACAGACAGCAGCTCAAGGTGTTTTTTCAGCCCCCTGAGGG 2188
DB 241 GAGCGTGTCTTTAAATACAGACAGCAGCTCAAGGTGTTTTTTCAGCCCCCTGAGGG 300

QY 2189 AAGGACGCGAGGGTCTCCGACAGGTGCTCTGGGGTGACTCTTCTGTGAGCTTTTACCC 2248

Db 301 AAGGAGCGAGGCTCCGACAGGTCTCTGGGGTGAATCTCTCTGGGAGCTTTTACCC 360
Qy TCTGAGTGAGACCTCCCGAGAGCCCGGGGGCGGCGAGCCCGCCCTCTCTGGTGGAGCGCTG 2308
Db TCTGAGTGAGACCTCCCGAGAGCCCGGGGGCGGCGAGCCCGCCCTCTCTGGTGGAGCGCTG 420
Qy GCGAGGCTCTGGTGGCATCAGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2368
Db GCGAGGCTCTGGTGGCATCAGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 480
Qy CCGCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2428
Db CCGCGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 540
Qy GTCTGTTTTCAGGAAAGAGTTTCAAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2488
Db GTCTGTTTTCAGGAAAGAGTTTCAAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 600
Qy GAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2548
Db GAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 660
Qy CCACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2608
Db CCACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 720
Qy TAAATGTCACAACTGTAGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2661
Db TAAATGTCACAACTGTAGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 773

RESULT 3
BQ073354 992 bp mRNA linear EST 02-APR-2002
LOCUS BQ073354.1 GI:19902400
DEFINITION AGENCOURT 7052199 NIH_MGC_101 Homo sapiens cDNA clone IMAGE:5806143
5', mRNA sequence.
ACCESSION BQ073354
VERSION BQ073354.1
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 992)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Rubin Laboratory
DNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)
Clone Distribution: Agencourt Bioscience Corporation
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: L10CM2046 row: h column: 16
High quality sequence stop: 670.
Location/Qualifiers
1. 992
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5806143"
/tissue_type="epidermoid carcinoma, cell line"
/lab_hosts="DH10B (phage-resistant)"
/clone_lib="NIH_MGC 101"
/note="Organ: lung; Vector: pOTB7; Site 1: EcoRI; Site 2:
XhoI; cDNA made by oligo-dT priming. Directionally cloned
into EcoRI/XhoI sites using the following 5' adaptor:
GGCAGCAG(G). Library constructed by Ling Hong in the
laboratory of Gerald M. Rubin (University of California,

Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and
Superscript II RT (Life Technologies). Note: this is a
NIH_MGC Library."
ORIGIN
Query Match 26.2%; Score 703; DB 13; Length 992;
Best Local Similarity 100.0%; Pred. No. 3.1e-131;
Matches 703; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 551 GCGAGGCGGCGATCCCGGGTCCCTCGTGTGCGCCCGCCACTCAGGTGTGCTTTGAGG 610
Db 1 GCGAGGCGGCGATCCCGGGTCCCTCGTGTGCGCCCGCCACTCAGGTGTGCTTTGAGG 60
Qy 611 AACACAGCAGCATCAATCGAGCTCAGACCTCTTCCCCACAGCCTTCGGCCTCTTCCACGG 670
Db 61 AACACAGCAGCATCAATCGAGCTCAGACCTCTTCCCCACAGCCTTCGGCCTCTTCCACGG 120
Qy 671 AGCTTCTCTGCGAGGCGAGAGGCTTCTCAGTGTGGGTCTGGGTGTGGTGTGCACT 730
Db 121 AGCTTCTCTGCGAGGCGAGAGGCTTCTCAGTGTGGGTCTGGGTGTGGTGTGCACT 180
Qy 731 CCCCTAAAGGAGTGGTCCCTCTGTGGCAAGTGTGAGTGTCCAGCTTTGCCTCAGGTC 790
Db 181 CCCCTAAAGGAGTGGTCCCTCTGTGGCAAGTGTGAGTGTCCAGCTTTGCCTCAGGTC 240
Qy 791 TCCACAGAGAGAGAGAGTGGTCTTCTTCTGTTGGAAACCCACAGGATCAGAGAGATTTGG 850
Db 241 TCCACAGAGAGAGAGTGGTCTTCTTCTGTTGGAAACCCACAGGATCAGAGAGATTTGG 300
Qy 851 AGCCGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 910
Db 301 AGCCGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 360
Qy 911 TCGCACAAACCGGTGAGAAATGCCAAACCGTCCACAGAGAGTCCAGAGCAGCGGTGGGA 970
Db 361 TCGCACAAACCGGTGAGAAATGCCAAACCGTCCACAGAGAGTCCAGAGCAGCGGTGGGA 420
Qy 971 AGCCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1030
Db 421 AGCCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 480
Qy 1031 GGGTGGTTCAGAGCCCTGCATGACAGAGTCTTGGCGGCTTGTCTACCTCGGCTCGATGG 1090
Db 481 GGGTGGTTCAGAGCCCTGCATGACAGAGTCTTGGCGGCTTGTCTACCTCGGCTCGATGG 540
Qy 1091 AGCGCTCGCTCTGTGTCTTACCTACCTGCCCTGTCCGTTGGAGGAGATCTGTAAAAACCA 1150
Db 541 AGCGCTCGCTCTGTGTCTTACCTACCTGCCCTGTCCGTTGGAGGAGATCTGTAAAAACCA 600
Qy 1151 TCCTCAACAACTCTGTGGAGCATACCTCAGCATCCAGAGAGAGAGAGAGAGAGAGAGAGAG 1210
Db 601 TCCTCAACAACTCTGTGGAGCATACCTCAGCATCCAGAGAGAGAGAGAGAGAGAGAGAGAG 660
Qy 1211 AAGATGTGCAAGTATGGATGCGAGAGATCAAAATCACTCAAGA 1253
Db 661 AAGATGTGCAAGTATGGATGCGAGAGATCAAAATCACTCAAGA 703

RESULT 4
CD243458 877 bp mRNA linear EST 22-MAY-2003
LOCUS CD243458
DEFINITION AGENCOURT 14121909 NIH_MGC 180 Homo sapiens cDNA clone
IMAGE:30383176 5', mRNA sequence.
ACCESSION CD243458
VERSION CD243458.1 GI:31003922
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 877)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL COMMENT

Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs@mail.nih.gov
cDNA Library Preparation: Invitrogen Corp
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: NDAM446 row: j column: 17
High quality sequence stop: 660.

FEATURES

Source

1.877
Location/Qualifiers

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:30383176"
/lab_host="DH10B-Ton A (T1 and T5 phage resistances)"
/clone_lib="NIH MGC 180"
/note="Organ: Testis; Vector: pCMV-SPORT6.1; Site.1: NotI; Site.2: EcoRV (destroyed); Library is oligo-dT primed and directionally cloned (EcoRV site is destroyed upon cloning). Average insert size 1.68 kb. Library was constructed by (Invitrogen). Note: this is a NIH_MGC Library."

ORIGIN

Query Match 26.1%; Score 698; DB 14; Length 877;
Best Local Similarity 99.9%; Pred. No. 3.4e-130;
Matches 748; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1527 AGAAGCCACGCGCTGTGACCTGTCTTCAGGCCATGCCGACCGAGAGCGGCG 1586
DB 4 AGAAGCCACGCGCTGTGACCTGTCTTCAGGCCATGCCGACCGAGAGCGGCG 63
QY 1587 CAGCAGGACCGCGCTGTGCGCCCTCAGCAGTGTGCGGTCTCGTGCAGCTTTCTGCCA 1646
DB 64 CAGCAGGACCGCGCTGTGCGCCCTCAGCAGTGTGCGGTCTCGTGCAGCTTTCTGCCA 123
QY 1647 CTGTACTGCGGTGCACCGGACCGCTGTCTACGCTGCGTGGCCCGCTTTGTGAGCT 1706
DB 124 CTGTACTGCGGTGCACCGGACCGCTGTCTACGCTGCGTGGCCCGCTTTGTGAGCT 183
QY 1707 CAACCTGSGTGACAGTGTCTGGAGCGGTGTGTAACAACAACAGCTACGAGTCAGACAT 1766
DB 184 CAACCTGSGTGACAGTGTCTGGAGCGGTGTGTAACAACAACAGCTACGAGTCAGACAT 243
QY 1767 CTGAGAGATTACCTGGCAACGAGGTGTGACATGGAACAAACATGTTACCGAGCGCT 1826
DB 244 CTGAGAGATTACCTGGCAACGAGGTGTGACATGGAACAAACATGTTACCGAGCGCT 303
QY 1827 CGTGGCTCTCCAGCGGGAGTGTCTCTGTCTGATTAACAGAGTCACGGGAGACACCGT 1886
DB 304 CGTGGCTCTCCAGCGGGAGTGTCTCTGTCTGATTAACAGAGTCACGGGAGACACCGT 363
QY 1887 TCTGTGTACTGTGCGCTGCGAGCTTCGCTGAGCTGACCTATCAGTATCGGCAGAA 1946
DB 364 TCTGTGTACTGTGCGCTGCGAGCTTCGCTGAGCTGACCTATCAGTATCGGCAGAA 423
QY 1947 CATTCCTGTCTCCAGTGTGCGAGTGGCCGTAACATCCCGTCTCTGAGTGTCTACTGGGGCG 2006
DB 424 CATTCCTGTCTCCAGTGTGCGAGTGGCCGTAACATCCCGTCTCTGAGTGTCTACTGGGGCG 483
QY 2007 TAACTGCGGACTCAGGTGAAGCTCACCAGCGCATGAATTCATCATCTGTGAGCA 2066
DB 484 TAACTGCGGACTCAGGTGAAGCTCACCAGCGCATGAATTCATCATCTGTGAGCA 543
QY 2067 GACAAGGTTCAAAAATTAAGCATCCAGAGCGCCCTGAGAGCTTTTCAGCACTGGAGGTGAA 2126
DB 544 GACAAGGTTCAAAAATTAAGCATCCAGAGCGCCCTGAGAGCTTTTCAGCACTGGAGGTGAA 603
QY 2127 GAGAGCGTGTGTTTTAAATATACAGACAGCAGCTCAAGGTGTTTTTCAGAGCCCTGTAG 2186

Db 604 GAGAGCGTGTGTTTTAAATATACAGACAGCAGCTCAAGGTGTTTTTCAGAGCCCTGTAG 663
QY 2187 GGAAGGAGCGAGCGGTCTCCGACAGGTCTCTGGGTGAGTCTTCTGTGAGGTTTTTAC 2246
DB 664 GGAAGGAGCGAGCGGTCTCCGACAGGTCTCTGGGTGAGTCTTCTGTGAGGTTTTTAC 723
QY 2247 CCTCTGAGTGAGACCTCCCGAGAGCCCC 2275
DB 724 CCTCTGAGTGAGACCTCCCGAGAGCCCC 752

RESULT 5
BP971929 897 bp mRNA linear EST 22-JAN-2001
LOCUS 602240332F1 NIH_MGC_46 Homo sapiens cDNA clone IMAGE:4329079 5',
DEFINITION mRNA sequence.
ACCESSION BP971929
VERSION BP971929.1 GI:12339144
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 897)
NIH-MGC http://mgs.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs@mail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Ling Hong/Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LHCMI189 row: p column: 08
High quality sequence stop: 728.

FEATURES

source

1.897
Location/Qualifiers

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4329079"
/tissue_type="leiomyosarcoma cell line"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 46"
/note="Organ: uterus; Vector: pOTB7; Site.1: XhoI; Site.2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGACAGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies). Note: this is a NIH_MGC Library."

ORIGIN

Query Match 24.2%; Score 647; DB 10; Length 897;
Best Local Similarity 100.0%; Pred. No. 4.7e-120;
Matches 647; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1908 GCGCAGCTTCGCTGAGTGCACCTATCAGTATCGGCAGAACATTCCTCTCCAGTTGCC 1967
DB 1 GCGCAGCTTCGCTGAGTGCACCTATCAGTATCGGCAGAACATTCCTCTCCAGTTGCC 60
QY 1968 AGTGGCGTTAACTCCCGTCTGACTGCTGCGGCGGTAAGTGGGCACTCAGGTGA 2027
DB 61 AGTGGCGTTAACTCCCGTCTGACTGCTGCGGCGGTAAGTGGGCACTCAGGTGA 120
QY 2028 AGCTCACACGCGCATGAATTCATCATCTGTGAACACAGAGTTCAAAACTAAGC 2087

Db 121 AGCTACACCGCATGAATTCATATCTGTGAACAGACAGGTTCAAAAATAAGC 180
QY 2088 ATCCAGAGCCCTGAGCAGCTTTTACAGCACTGGAGGTGAGAGAGCGTGTGTTTAAATATAC 2147
Db 181 ATCCAGAGCCCTGAGCAGCTTTTACAGCACTGGAGGTGAGAGAGCGTGTGTTTAAATATAC 240
QY 2148 AGAGCAAGCAGCTCAAGTGTGTTTACAGCCCTTGAAGGAGGAGCGAGGCTCTCG 2207
Db 241 AGAGCAAGCAGCTCAAGTGTGTTTACAGCCCTTGAAGGAGGAGCGAGGCTCTCG 300
QY 2208 ACAGGTGCTCTGGGTGAGCTCTTCTGTGAGCTTTTACCTCTCAGTGAGACCTCTCCC 2267
Db 301 ACAGGTGCTCTGGGTGAGCTCTTCTGTGAGCTTTTACCTCTCAGTGAGACCTCTCCC 360
QY 2268 AGAGCCCTGGGGCGCGACGCCCTCTCTGTGAGCGCTGGGCGAGGCTCTGTGTGGA 2327
Db 361 AGAGCCCTGGGGCGCGACGCCCTCTCTGTGAGCGCTGGGCGAGGCTCTGTGTGGA 420
QY 2328 TCAGCAGCAGACGAGCGCTTCTGTACATGCGCGCTCCCGCGAGAGGGCAGTTT 2387
Db 421 TCAGCAGCAGACGAGCGCTTCTGTACATGCGCGCTCCCGCGAGAGGGCAGTTT 480
QY 2388 TGCTCTTTTGTACATTTCCGAACTTACAGTAAAGCAGAGTCTGTTTTCAGGAAAAGT 2447
Db 481 TGCTCTTTTGTACATTTCCGAACTTACAGTAAAGCAGAGTCTGTTTTCAGGAAAAGT 540
QY 2448 TTCAAGGGAGAGGGCAAGTTTATCAAAAACATGTTTTCAGGAGAGGAGCATAAGTTT 2507
Db 541 TTCAAGGGAGAGGGCAAGTTTATCAAAAACATGTTTTCAGGAGAGGAGCATAAGTTT 600
QY 2508 ACAGCTTACAGGACGTACACAAATATCTGCTGCTGGGAAAACACAG 2554
Db 601 ACAGCTTACAGGACGTACACAAATATCTGCTGCTGGGAAAACACAG 647

RESULT 6
BG395714 840 bp mRNA linear EST 12-MAR-2001
LOCUS 60245835F1 NIH_MGC_16 Homo sapiens cDNA clone IMAGE:4580633 5',
DEFINITION mRNA sequence.

ACCESSION BG395714
VERSION BG395714.1 GI:13289162
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 840)
AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-x@mail.nih.gov
Tissue Procurement: ATCC

cDNA Library Preparation: Ling Hong/Rubin Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov
Plate: LLCM300 row: a column: 18
High quality sequence stop: 775.

FEATURES
Location/Qualifiers
1..840
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4580633"
/issue_type="retinoblastoma"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH_MGC_16"
/note="Organ: eye; Vector: pOTB7; Site: 1; XhoI; Site 2:
EcoRI; cDNA made by oligo-dT priming. Directionally
cloned into EcoRI/XhoI sites using the following 5'

adaptor: GGCACGAG(G). Library constructed by Ling Hong
in the laboratory of Gerald M. Rubin (University of
California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC Library."

ORIGIN

Query Match 23.1%; Score 620; DB 12; Length 840;
Best Local Similarity 99.9%; Pred. No. 1.2e-114; Indels 0; Gaps 0;
Matches 670; Conservative 0; Mismatches 1;

QY 1294 GAAGGGAGTTTCAGAGGACCTGCTGGAGCTGTCAGACGTTTACACAGTGTGAGTCTCTCAGACATT 1353
Db 2 GAAGGGAGTTTCAGAGGACCTGCTGGAGCTGTCAGACGTTTACACAGTGTGAGTCTCTCAGACATT 61
QY 1354 AGCCAGCATACTGTCGTGTGTCGGGAGTGTCTGTAGTACAGAGGAGGCGGCGGCGACCT 1413
Db 62 AGCCAGCATACTGTCGTGTGTCGGGAGTGTCTGTAGTACAGAGGAGGCGGCGGCGACCT 121
QY 1414 CCCCACTGCCAGCACCCGAGGGGAGCCAGGAGGCCCAAGGCCCTTGGGGGATGCAACCC 1473
Db 122 CCCCACTGCCAGCACCCGAGGGGAGCCAGGAGGCCCAAGGCCCTTGGGGGATGCAACCC 181
QY 1474 TCCACGTCCGTTCAGCTTCAGCAGCAGTTCAGAGTTCAGGATTACGTGTGCCCTCTGTCAAGGAAGC 1533
Db 182 TCCACGTCCGTTCAGCTTCAGCAGCAGTTCAGAGTTCAGGATTACGTGTGCCCTCTGTCAAGGAAGC 241
QY 1534 CAGCCCTGTGCACCTCTGCTTCCAGCCCATGCCCCAGCGAGAGCGGAGCGGAGCAG 1593
Db 242 CAGCCCTGTGCACCTCTGCTTCCAGCCCATGCCCCAGCGAGAGTGTGAGGGGAGCAG 301
QY 1594 GACCCGCTGTGCGCCCTTCAGCAGTGTGCGGTCTGCTGAGCCCTTCTGCACTGTAC 1653
Db 302 GACCCGCTGTGCGCCCTTCAGCAGTGTGCGGTCTGCTGAGCCCTTCTGCACTGTAC 361
QY 1654 TGGGGCTGCACCCGAGCGGCTGCTAGCGTGCCTGCCCGCCCGTGTGTGAGCTCAACTG 1713
Db 362 TGGGGCTGCACCCGAGCGGCTGCTAGCGTGCCTGCCCGCCCGTGTGTGAGCTCAACTG 421
QY 1714 GGTGCAAGTGTCTGGAGCGGCTGCTGAAACAACAGCTACGAGTACAGATCCTGAAG 1773
Db 422 GGTGCAAGTGTCTGGAGCGGCTGCTGAAACAACAGCTACGAGTACAGATCCTGAAG 481
QY 1774 AATTACCTGGCAACAGAGTTTGACATGGAACATGTTGACCGAGAGCTCGTGCT 1833
Db 482 AATTACCTGGCAACAGAGTTTGACATGGAACATGTTGACCGAGAGCTCGTGCT 541
QY 1834 CTCAGAGGGGAGTGTGTTCTGCTGTCTGATTACAGAGTACAGGAGACACCGTTCGTGT 1893
Db 542 CTCAGAGGGGAGTGTGTTCTGCTGTCTGATTACAGAGTACAGGAGACACCGTTCGTGT 601
QY 1894 TACTGCTGTGCGCTGCGCAGCTTCGCTGAGTGTACCTATCAGTATCGGAGAACTTCCT 1953
Db 602 TACTGCTGTGCGCTGCGCAGCTTCGCTGAGTGTACCTATCAGTATCGGAGAACTTCCT 661
QY 1954 GCTTCCGAGTT 1964
Db 662 GCTTCCGAGTT 672

RESULT 7
AUI34937 680 bp mRNA linear EST 02-AUG-2002
LOCUS AUI34937 PLACE1 Homo sapiens cDNA clone PLACE1000852 5', mRNA
DEFINITION sequence.

ACCESSION AUI34937
VERSION AUI34937.1 GI:10995476
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 680)

BQ215731	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
----------	-------	------------	-----------	---------	----------	--------	----------	-----------	---------	-------	---------	---------

[illegible]

QY 1336 AGTGAATCTCAGACATTAGCCAGCCATAGCTCGTGTGGCGGAGTGTCTGAGTACAGA 1395

Db 421 AGTGAATCTCAGACATTAGCCAGCCATAGCTCGTGTGGCGGAGTGTCTGAGTACAGA 480

QY 1396 AGGAGGCGGCGAGCGCTCCCTCCACTGCCAGCACCAGGCGGAGCCAGAGCCCCACAG 1455

Db 481 AGGAGGCGGCGAGCGCTCCCTCCACTGCCAGCACCAGGCGGAGCCAGAGCCCCACAG 540

QY 1456 GCCTGTGGGAGTGCACCTCCAGCTCGTGTGAGCTGACGACAG 1498

Db 541 GCCTGTGGGAGTGCACCTCCAGCTCGTGTGAGCTGACGACAG 583

RESULT 9

BM459647

LOCUS

DEFINITION AGENCOURT_6418058 NIH_MGC_71 Homo sapiens cDNA clone IMAGE:5534277

5', mRNA sequence.

ACCESSION BM459647

VERSION BM459647.1

KEYWORDS GI:18508687

SOURCE EST.

ORGANISM Homo sapiens (human)

REFERENCE 1 (bases 1 to 916)

AUTHORS NIH-MGC http://mgc.nci.nih.gov/.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM12220 row: h column: 22
High quality sequence stop: 642.

FEATURES

source

1..916

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:5534277"

/tissue_type="leiomyosarcoma"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH MGC 71"

/note="Organ: uterus; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 2.1 kb."

ORIGIN

Query Match 21.1%; Score 565; DB 12; Length 916;

Best Local Similarity 100.0%; Pred. No. 9.7e-104; Mismatches 0; Indels 0; Gaps 0;

Matches 565; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 709 GGGTCTGGGGGTGGTGGCATCTCCCTAAAGGAAGTGTCTCTCTGTGGCAAGTATGAA 768

Db 155 GGGTCTGGGGGTGGTGGCATCTCCCTAAAGGAAGTGTCTCTCTGTGGCAAGTATGAA 214

QY 769 GTCTCCAGCTTTGGCTCAGCTCTCCAGCAGAAAGACTGGCTCTTTTGTGTGGAA 828

Db 215 GTCTCCAGCTTTGGCTCAGCTCTCCAGCAGAAAGACTGGCTCTTTTGTGTGGAA 274

QY 829 CCCAGGATCAGGAGGATTTGGAGCCCTGAGAGAAATGAGAGAGATGGGACCTT 888

Db 275 CCCAGGATCAGGAGGATTTGGAGCCCTGAGAGAAATGAGAGAGATGGGACCTT 334

QY 889 GACTGAACGGGCGAGTTGTTGGTGCACCAACCGGCTAGAAATGCCCAACCGTCCAGAG 948

Db 335 GACTGAACGGGCGAGTTGTTGGTGCACCAACCGGCTAGAAATGCCCAACCGTCCAGAG 394

QY 949 GACGTACAGCAGCGGCTGGAGCCAGACAGATGAGGAGAGCTGACATGCATCATC 1008

Db 395 GACGTACAGCAGCGGCTGGAGCCAGACAGATGAGGAGAGCTGACATGCATCATC 454

QY 1009 TGCCAGGACCTGCTGCACGACTGGGTGAGTTGTGAGCCCTGCATGCACACGTTCTGCGCG 1068

Db 455 TGCCAGGACCTGCTGCACGACTGGGTGAGTTGTGAGCCCTGCATGCACACGTTCTGCGCG 514

QY 1069 GCTTGTCTACTCGGGCTGGATGGAGCGCTGCTCTCTGTGCTTACTGCGGCTGTCCCGTG 1128

Db 515 GCTTGTCTACTCGGGCTGGATGGAGCGCTGCTCTCTGTGCTTACTGCGGCTGTCCCGTG 574

QY 1129 GAGCGGATCTGTAACACCATCTCAACAACTCGTGGAGCATATCTCATCCAGCAT 1188

Db 575 GAGCGGATCTGTAACACCATCTCAACAACTCGTGGAGCATATCTCATCCAGCAT 634

QY 1189 CCAGCAAGAGTCCGAGTGAAGAGATGTCAAAAGTATGAGATGCCAGAAATAAATCACT 1248

Db 635 CCAGCAAGAGTCCGAGTGAAGAGATGTCAAAAGTATGAGATGCCAGAAATAAATCACT 694

QY 1249 CAAGACATGCTGCAGCCCAAGTCA 1273

Db 695 CAAGACATGCTGCAGCCCAAGTCA 719

RESULT 10

BM542545

LOCUS

DEFINITION AGENCOURT_6426028 NIH_MGC_71 Homo sapiens cDNA clone IMAGE:5520909

5', mRNA sequence.

ACCESSION BM542545

VERSION BM542545.1

KEYWORDS GI:18772149

SOURCE EST.

ORGANISM Homo sapiens (human)

REFERENCE 1 (bases 1 to 1143)

AUTHORS NIH-MGC http://mgc.nci.nih.gov/.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM12185 row: k column: 22
High quality sequence stop: 666.

FEATURES

source

1..1143

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:5520909"

/tissue_type="leiomyosarcoma"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH MGC 71"

/note="Organ: uterus; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dt. Average insert size 2.1 kb."

ORIGIN

Query Match 21.0%; Score 563; DB 12; Length 1143;

Best Local Similarity 100.0%; Pred. No. 2e-103; Mismatches 563; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2099 CTGAGCAGCTTCAGCACTGGAGGTGAGAGAGCGCTGTTTAAATACAGACAGCA 2158

RESULT 11	
BE407732	
LOCUS	666 bp mRNA linear EST 21-JUL-2000
DEFINITION	G01299777F1 NIH_MGC_21 Homo sapiens cDNA clone IMAGE:3629882 5', mRNA sequence.
ACCESSION	BE407732
VERSION	BE407732.1 GI:9344182
KEYWORDS	EST.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens

```

FEATURES
source
Location/Qualifiers
1. .666
/organism="Homo sapiens"
/mol type="mana"
/db_xref="taxon:9606"
/cdname="IMAGE:3629682"
/tissue type="choriocarcinoma"
/lab host="DHI10B (phage-resistant)"

```

Query Match	20.9%	Score 560;	DB 10;	Length 666;
Best Local Similarity	99.8%;	Pred. No. 1.3e-102;		
Matches 610;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;

RESULT 12	AL539797	1201 bp	mRNA	linear	EST 31-MAY-2003
LOCUS	AL539797/c				
DEFINITION	AL539797 Homo sapiens FETAL BRAIN Homo sapiens CDNA clone				
	CS00F031YA23 3-PRIME, mRNA sequence.				
ACCESSION	AL539797				
VERSION	AL539797.2	GI:31264360			
KEYWORDS	EST.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1 (bases 1 to 1201)				

AUTHORS Li, W.B., Gruber, C., Jesse, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On Feb 15, 2001 this sequence version replaced gi:12869347.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 131 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 6792.r For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DF031AA12NP1&cluster=6792.r. Contact :
Peng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DF031AA12NP1.
FEATURES
Location/Qualifiers
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF031YA23"
/tissue_type="FETAL BRAIN"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL BRAIN"
/notes="Organ: brain; Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."
ORIGIN
Query Match 20.1%; Score 539; DB 9; Length 1201;
Best Local Similarity 100.0%; Pred. No. 1.1e-98;
Matches 539; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1704 GCTCAACCTGGGTGACAAGTGTGTGACGGCGTGTGAACACACAGCTACAGTCA 1763
DB 940 GCTCAACCTGGGTGACAAGTGTGTGACGGCGTGTGAACACACAGCTACAGTCA 881
QY 1764 CATCTGAGAAATTACTGTGCAACACAGAGTTTGACATGGAATAATCTGCACGAG 1823
DB 880 CATCTGAGAAATTACTGTGCAACACAGAGTTTGACATGGAATAATCTGCACGAG 821
QY 1824 CTTCTGGTCTCCAGCGGGAGTGTCTGTGTCTGTATACAGAGTCACGGGAGAC 1883
DB 820 CTTCTGGTCTCCAGCGGGAGTGTCTGTGTCTGTATACAGAGTCACGGGAGAC 761
QY 1884 CTTCTGTGTACTGTGTGGCTGGCGAGCTTCCGTGAGCTGACCTATCAGTATCGCA 1943
DB 760 CTTCTGTGTACTGTGTGGCTGGCGAGTCTCCGTGAGCTGACCTATCAGTATCGCA 701
QY 1944 GAACATTCCTGCTCCAGTGTGCGAGTGGCGTAAACATCCCGTCTGACTGTCTGGGG 2003
DB 700 GAACATTCCTGCTCCAGTGTGCGAGTGGCGTAAACATCCCGTCTGACTGTCTGGGG 641
QY 2004 CCGTAATCGCGCACTCAGGTGAAGTCAACAGCCGATGAATTCATATCTGTGA 2063
DB 640 CCGTAATCGCGCACTCAGGTGAAGTCAACAGCCGATGAATTCATATCTGTGA 581
QY 2064 ACAGAGAGGTTTCAAAACTAAGCATCCAGAGCCCTGAGCAGCTTTTCAAGCTGAGGT 2123
DB 580 ACAGAGAGGTTTCAAAACTAAGCATCCAGAGCCCTGAGCAGCTTTTCAAGCTGAGGT 521
QY 2124 GAAGAGAGCGTGTGTGTAAATACAGAGCAACAGCAGTCAAGGTGTGTTCACAGCCCT 2183
DB 520 GAAGAGAGCGTGTGTGTAAATACAGAGCAACAGCAGTCAAGGTGTGTTCACAGCCCT 461
QY 2184 GAGGAAGGACCGAGGTCTCCGACAGGTGCTCGGGTGTCTTCTGTGAGCTTT 2242
DB 460 GAGGAAGGACCGAGGTCTCCGACAGGTGCTCGGGTGTCTTCTGTGAGCTTT 402

RESULT 13
BF971838
LOCUS 602240424F1 NIH_MGC_46 Homo sapiens cDNA clone IMAGE:4329076 5',
DEFINITION mRNA sequence.
ACCESSION BF971838
VERSION BF971838
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 934)
NIH-MGC http://mgc.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgsb@remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Ling Hong/Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: L1CM189 row: p column: 05
High quality sequence stop: 748.
FEATURES
Location/Qualifiers
1..934
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4329076"
/tissue_type="leiomyosarcoma cell line"
/lab_hosts="DH10B (phage-resistant)"
/clone_lib="NIH_MGC_46"
/notes="Organ: uterus; Vector: pOTB7; Site 1: XhoI; Site 2:
EcoRI; cDNA made by oligo-dT priming. Directionally cloned
into EcoRI/XhoI sites using the following 5' adaptor:
GGCACGAG(G). Size-selected >500bp for average insert size
1.8kb. Library constructed by Ling Hong in the laboratory
of Gerald M. Rubin (University of California, Berkeley)
using ZAP-cDNA synthesis kit (Stratagene) and Superscript
II RT (Life Technologies). Note: this is a NIH_MGC
Library."
ORIGIN
Query Match 19.4%; Score 519; DB 10; Length 934;
Best Local Similarity 99.8%; Pred. No. 1.4e-94;
Matches 539; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
QY 1908 GCGCAGCTTCGTCGAGTACCTATCAGTATCGGCAGACATTCCTGCTCCGAGTTGCC 1967
DB 1 GCGCAGCTTCGTCGAGTACCTATCAGTATCGGCAGACATTCCTGCTCCGAGTTGCC 60
QY 1968 AGTGCCGTAACTCCCGTCTGCTGCTACTGGGCGGTAACTGCGGCACTCAGGTGAA 2027
DB 61 AGTGCCGTAACTCCCGTCTGCTGCTACTGGGCGGTAACTGCGGCACTCAGGTGAA 120
QY 2028 AGCTCACACACCCATGAATTCATATCTGTGAACAGCAAGGTTCAAAACTAAGC 2087
DB 121 AGCTCACACACCCATGAATTCATATCTGTGAACAGCAAGGTTCAAAACTAAGC 180
QY 2088 ATCCAGAGCCCTGAGCAGCTTTCAGGACCTGAGAGAGCGTGTGTAAATATAC 2147
DB 181 ATCCAGAGCCCTGAGCAGCTTTCAGGACCTGAGAGAGCGTGTGTAAATATAC 240
QY 2148 AGAGCAAGCAGCTCAAGGTGTGTTCACGCCCTGAGGGAAGGACGAGGTCTCCG 2207
DB 241 AGAGCAAGCAGCTCAAGGTGTGTTCACGCCCTGAGGGAAGGACGAGGTCTCCG 300
QY 2208 ACAGGTGCTGGGGTGTCTTCTGTGAGCTTTTACCTCTGAGTGACACCTCC 2267

301 ACAGTGCTCTGGGGTGACTCTTCTGTGGAGCTTTTACCTCTGTAGTGAGACCTCCCC 360
2268 AGAGCCCGGGGGCGAGCCGCGCTCTCTGGTGAGCGCTGGGAGGGCTCGTGTGGCA 2327
361 AGAGCCCGGGGGCGAGCCGCG-CCTCCTGGTGAGCGCTGGGAGGGCTCGTGTGGCA 419
2328 TCAGCAGCAGAGACGAGCCCTTCTGTAAACATGCGGCGCTCCCGCCGAGAGGGGCGAGTTT 2387
420 TCAGCAGCAGAGACGAGCCCTTCTGTAAACATGCGGCGCTCCCGCCGAGAGGGGCGAGTTT 479
2388 TGCTCTTTGTACATTTTCCGAACATACAGTTAAAGCAGAGTCTGTTCAGGAAAGT 2447
480 TGCTCTTTGTACATTTTCCGAACATACAGTTAAAGCAGAGTCTGTTCAGGAAAGT 539
2448 TTCAGGGAGAGGCGCAAGTTTATCAAAACATTTGTTTCAGGAGAGGGAGCATAAGTTT 2507
540 TTCAGGGAGAGGCGCAAGTTTATCAAAACATTTGTTTCAGGAGAGGGAGCATAAGTTT 599
2508 ACAGCCTACAGAGCTACACAAATATCTCTGCTGTGGGAAA 2547
600 ACAGCCTACAGAGCTACACAAATATCTCTGCTGTGGGAAA 639

RESULT 14
CA916737
LOCUS
DEFINITION
30LSPRIM2-5A human lymphocyte Matchmaker cDNA library Homo sapiens
cDNA clone L5 5' similar to CHFR RF; cell cycle check point, mRNA
sequence.
ACCESSION
CA916737
VERSION
CA916737.1 GI:28951974
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
REFERENCE
1 (bases 1 to 729)
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS
Scarafia L.E., Stonfer S.D. and Swinney D.C.
TITLE
Identification of Ring Finger proteins that interact with Ubch5a,
an ubiquitin-conjugating enzyme
JOURNAL
Unpublished (2002)
COMMENT
Contact: Scarafia LE
Enzymology
Roche Bioscience
3401 Hillview Ave, S3-1, Palo Alto, CA 94304-1397, USA
Tel: 650 354 7997
Fax: 650 354 7554
Email: liliana.scarafia@roche.com
Seq primer: matchmaker 5' AD (ctattcgatgatgaagatccccaccccaaccc)
POLYA=No.

FEATURES
source
1. 729
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="L5"
/cell_type="B cell"
/cell_lines="EBV-transformed human peripheral blood
lymphocyte; B cell population; IG (+)"
/lab_host="yeast/2.coli"
/clone_lib="human lymphocyte Matchmaker cDNA library"
/note="Vector: pACT; Site 1: XhoI; Site 2: XhoI;
Matchmaker yeast two-hybrid system from Clontech; pACT has
GAL4 AD under ADHI promoter. This oligo-dT primed library
was screened with human Ubch5a as bait, to obtain
interacting proteins."

ORIGIN
Query Match 19.1%; Score 513; DB 14; Length 729;
Best Local Similarity 99.5%; Pred. No. 2.6e-93;
Matches 663; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 560 CCGATCCCGGGTCCCTCGTGTGCGCGCCGACATCAGGTGTGCTTTGAGGAACACAGC 619

13 CCGATCCCGGGTCCCTCGTGTGCGCGCCGACCTCAGGTGTGCTTTGAGGAACACAGC 72
620 CATCAACATCAGCTCAGACCTCTTCCCAAGCTCTGGCTCTTCCAGGAGCCCTTCTC 679
73 CATCAACATCAGCTCAGACCTCTTCCCAAGCTCTGGCTCTTCCAGGAGCCCTTCTC 132
680 CTGACGGGCGAGAGCGTTCTCCAGTTGTGGGTCTGCGGCGTGGTGGCATCTCCCTAAAG 739
133 CTGACGGGCGAGAGCGTTCTCCAGTTGTGGGTCTGCGGCGTGGTGGCATCTCCCTAAAG 192
740 GAAGTGTCTCTCTGTGGCAAGTGAAGTCTCAGCTTTGCTCTCAGCTCTCCAGACA 799
193 GAAGTGTCTCTCTGTGGCAAGTGAAGTCTCAGCTTTGCTCTCAGCTCTCCAGACA 252
800 GAAAGACTCGCTCTCTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG 859
253 GAAAGACTCGCTCTCTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGG 312
860 AGAAGAAATGAGAGAGATGGGAGCTTGACCTGAAAGGAGCTGTGTGTGGCAGAC 919
313 AGAAGAAATGAGAGAGATGGGAGCTTGACCTGAAAGGAGCTGTGTGTGGCAGAC 372
920 CCGTAGAATGCCAAACCGTCCAGAGGAGCTCAGAGCAGCGCTGGGAGCCAGACA 979
373 CCGTAGAATGCCAAACCGTCCAGAGGAGCTCAGAGCAGCGCTGGGAGCCAGACA 432
980 AGATGAGAGAGAGCTGACATCATCTGCGAGGAGCTGCTGCGAGCTGCGTGGAGTT 1039
433 AGATGAGAGAGAGCTGACATCATCTGCGAGGAGCTGCTGCGAGCTGCGTGGAGTT 492
1040 TGCAGCCCTGTCATGACAGCTTCTCGGGGCTTGTCTCGGGCTGGATGGAGCGCTCGT 1099
493 TGCAGCCCTGTCATGACAGCTTCTCGGGGCTTGTCTCGGGCTGGATGGAGCGCTCGT 552
1100 CCGTGTGCTTACCTCCGCTCTCCGCTGAGCGGATCTGTAACACACATCTCTCAACA 1159
553 CCGTGTGCTTACCTCCGCTCTCCGCTGAGCGGATCTGTAACACACATCTCTCAACA 612
1160 ACTCGTGAAGCATACCTCATCCAGCATCCAGAGCTGCGAGTGAAGAGATGTC 1219
613 ACTCGTGAAGCATACCTCATCCAGCATCCAGAGCTGCGAGTGAAGAGATGTC 672
1220 AAAGTA 1225
673 AAAGTA 678

RESULT 15
BE280165
LOCUS
DEFINITION
601158370F1 NIH_MGC_21 Homo sapiens cDNA clone IMAGE:3504928 5',
mRNA sequence.
ACCESSION
BE280165
VERSION
BE280165.1 GI:9155072
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
REFERENCE
1 (bases 1 to 690)
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS
NIH-MGC http://mgc.nci.nih.gov/.
TITLE
National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL
Unpublished (1999)
COMMENT
Contact: Robert Strausberg, Ph.D.
Email: cgaabs-r@mail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Ling Hong/Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at: image.llnl.gov
Plate: LLM180 row: 1 column: 17

High quality sequence stop: 626.
Location/Qualifiers
source
1. .690
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/db_xref="IMAGE:3504928"
/issue_type="choriocarcinoma"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 21"
/note="Organ: Placenta; Vector: pOTB7; Site: 1: XhoI;
Site 2: EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(G). Size-selected >500bp
for average insert size 1.8kb. Library constructed by
Ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies)."

ORIGIN

Query Match 18.2%; Score 488; DB 10; Length 690;
Best Local Similarity 99.8%; Pred. No. 2.6e-88;
Matches 538; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1156 AACAACTCGTGAAGCATACCTCATCCAGCATCCAGACAGATCGCAGTCCGACGAGAGAT 1215
Db |||||
QY 1216 GTGCAAGTATGATGCCAGGAAATAAATCACTCAAGACATGCTGCAGCCCAAGTCAGG 1275
Db |||||
QY 1276 CGGTCTTTTCTGATGAAGAGGAGTTTCAGAGGACCTCTCGAGCTGTTCAGACGTTGAC 1335
Db |||||
QY 1396 AGTGTAGTCTCAGACATTAGCCAGCCATACGTCGTGTGCCGCGAGTCTCTGAGTACAGA 1395
Db |||||
QY 1456 GGCCTGGGGGATGCACCTCCAGTCCGTCAGCCTGACGACAGCAGTCCAGGATTACGTG 1515
Db |||||
QY 1516 TGCCCTTCTCAAGGAGCACGCCCTGTGTCACCTGTCTTCCAGCCCATGCCGACCGG 1575
Db |||||
QY 1576 AGAGCGGAGCGGAGCAGACCGGGGTGTCGGCCCTCAGAGTGTGGGTCTGCGTGCAG 1635
Db |||||
QY 1636 CCTTTCTGCCACCTGTACTGGGGCTGCACCCGGACCGGCTGTACGGCTGCTGGCCCC 1694
Db |||||
QY 481 CCTTTCTGCCACCTGTACTGGGGCTGCACCCGGACCGGCTGTACGGCTGCTGGCCCC 539

Search completed: May 15, 2004, 07:58:44
Job time : 10042 secs

26	158	4.4	650	7	ADC31511	ADC31511 Human nov
27	154.5	4.3	731	6	ABJ19398	ABJ19398 Human int
28	152	4.2	245	5	AAW59134	AAW59134 Mus muscu
29	151.5	4.2	502	5	ABP51312	ABP51312 Human MDD
30	146.5	4.1	220	4	AB94801	AB94801 Human pro
31	146.5	4.1	220	5	AAU80360	AAU80360 Human cel
32	146.5	4.1	284	6	ABU69600	ABU69600 Human NF-
33	146	4.1	303	6	ABU92033	ABU92033 Human pro
34	143	4.0	1601	4	ABB60248	ABB60248 Drosophil
35	142.5	4.0	499	5	AAO22598	AAO22598 493-mer S
36	142.5	4.0	1213	5	AAO22597	AAO22597 1213-mer
37	141.5	3.9	1208	4	AB95292	AB95292 Human pro
38	139	3.9	825	6	ABP71596	ABP71596 HSV-2 ICP
39	139	3.9	4675	5	ABP70085	ABP70085 Human NOV
40	139	3.9	4691	5	ABP70084	ABP70084 Human NOV
41	138.5	3.9	353	5	AAU80359	AAU80359 Mouse cel
42	138.5	3.9	533	7	ADC31279	ADC31279 Human nov
43	138	3.8	255	4	AAO73609	AAO73609 Human col
44	137	3.8	1215	6	ABU11763	ABU11763 Human MDD
45	135	3.8	67	2	AA60624	AA60624 Varicella

ALIGNMENTS

RESULT 1
AAB83843
ID AAB83843 standard; protein; 664 AA.
XX AC AAB83843;
XX DT 22-AUG-2001 (first entry)
XX DE Amino acid sequence of a human ring finger protein designated FHAR1.
XX KW FHAR1; RING finger protein; cancer; vaccine.
XX OS Homo sapiens.
XX EN WO200142430-A1.
XX PD 14-JUN-2001.
XX PF 07-DEC-2000; 2000WO-US033094.
XX PR 08-DEC-1999; 99US-00456876.
XX PA (SMIK) SMITHKLINE BEECHAM CORP.
XX PI Zhou B, Zhu Y, Chaturvedi P, Hurle MR, Li X;
XX DR WPI; 2001-381663/40.
XX N-PSDB; AAF89709.
XX New FHAR1 polypeptide, a member of the RING finger protein family for
XX diagnosing and treating cancer, and for use in anti-cancer vaccines.
XX Claim 1; Page 19; 28pp; English.
XX The present sequence represents a FHAR1 polypeptide, which is a member of
XX the RING finger protein family. FHAR1 is useful in the treatment of
XX cancer, and as a vaccine for inducing an immunological response in a
XX mammal. FHAR1 polynucleotides may also be used as a diagnostic reagent
XX through detection of mutations in the associated gene, and for chromosome
XX localization studies, and tissue expression studies. FHAR1 antibodies are
XX useful to isolate and to identify clones expressing the polypeptides, or
XX to purify the polypeptides by affinity chromatography and to treat cancer
XX Sequence 664 AA;
Query Match 100.0%; Score 3585; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 9.8e-270;
Matches 664; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.
OM protein - protein search, using sw model
Run on: May 7, 2004, 14:36:57 ; Search time 136.025 Seconds
(without alignments)
1379.240 Million cell updates/sec
Title: US-10-048-046-2
Perfect score: 3585
Sequence: 1 MERPEKGQPPPPQWGRLL.....VKAHAKFNHCETQRFKN 664
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 1586107 seqs, 282547505 residues
Total number of hits satisfying chosen parameters: 1586107
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries
Database : A_Geneseq_29Jan04:.*
1: Geneseqp1380s:.*
2: Geneseqp1990s:.*
3: Geneseqp2000s:.*
4: Geneseqp2001s:.*
5: Geneseqp2002s:.*
6: Geneseqp2003as:.*
7: Geneseqp2003bs:.*
8: Geneseqp2004s:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3585	100.0	664	4	AAB83843 Amino aci
2	3585	100.0	664	4	AAB20219 Human Chf
3	3504	97.7	652	4	AAB93168 Human pro
4	3168.5	88.4	623	5	ABB97233 Novel hum
5	3162.5	88.2	623	4	AAB93182 Human pro
6	1954.5	54.5	426	4	AAU15856 Human nov
7	1954.5	54.5	426	6	ABU54925 Human nov
8	1364	38.0	269	4	AAO08972 Human pol
9	843.5	23.5	230	4	AAU16317 Human nov
10	843.5	23.5	230	6	ABU5386 Human nov
11	566	15.8	128	6	ADA54231 Human pro
12	474	13.2	92	4	AAU16156 Human nov
13	474	13.2	92	6	ABU55225 Human nov
14	432	12.1	99	4	AAU16157 Human nov
15	432	12.1	99	4	AAU16576 Human nov
16	432	12.1	99	6	ABU55645 Human nov
17	432	12.1	99	6	ABU55645 Human nov
18	355	9.9	426	3	AAO20353 Arabidops
19	355	9.9	426	3	AAO20352 Arabidops
20	355	9.9	453	3	AAO20352 Arabidops
21	355	9.9	453	3	AAO20352 Arabidops
22	354	9.9	350	3	AAO20354 Arabidops
23	354	9.9	350	3	AAO20354 Arabidops
24	203	5.7	485	4	ABU5017 Human pro
25	160.5	4.5	352	5	AAU80358 Human cel

QY 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRRCGLSFPNKLVSQDH 60
 Db 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRRCGLSFPNKLVSQDH 60
 QY 61 CRIVDEKSGQVLTSTSTGTVINKLVKKQKOTCPLOTGVDVILVYRKNEPENVAYLY 120
 Db 61 CRIVDEKSGQVLTSTSTGTVINKLVKKQKOTCPLOTGVDVILVYRKNEPENVAYLY 120
 QY 121 ESLSEKQGMTOESFEANKENVFHGTGKTSAGAGRGADPRVPPSPATQVCFEFPQST 180
 Db 121 ESLSEKQGMTOESFEANKENVFHGTGKTSAGAGRGADPRVPPSPATQVCFEFPQST 180
 QY 181 TSDLFTTASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDKTA 240
 Db 181 TSDLFTTASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDKTA 240
 QY 241 SFSSLEFPQDELEPVKKQKRGDGLDLNGQLLVAAQPRNAQTVDHEDVRAAGKPDKWE 300
 Db 241 SFSSLEFPQDELEPVKKQKRGDGLDLNGQLLVAAQPRNAQTVDHEDVRAAGKPDKWE 300
 QY 301 TLTCIIQDLHDCVSLQPCMTFCAACYSGWMERSSLCPTCRCPVERICKNHILNIVE 360
 Db 301 TLTCIIQDLHDCVSLQPCMTFCAACYSGWMERSSLCPTCRCPVERICKNHILNIVE 360
 QY 361 AVLIQHPDKSRSEEDVQSMDSANKITQDMLQPKVRSFSDSEGSDELLELSDVDSSE 420
 Db 361 AVLIQHPDKSRSEEDVQSMDSANKITQDMLQPKVRSFSDSEGSDELLELSDVDSSE 420
 QY 421 ISQPVVVCQCEYRQAAOPHCPAPGEPGAPQALGDAPSTSVLTAVQDVVCPLOG 480
 Db 421 ISQPVVVCQCEYRQAAOPHCPAPGEPGAPQALGDAPSTSVLTAVQDVVCPLOG 480
 QY 481 SHALCTCCFPQPDRAEREDQPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFCELN 540
 Db 481 SHALCTCCFPQPDRAEREDQPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFCELN 540
 QY 541 LGDKCLDGLVNNVSEDLKNYLATRGLTWKNNMLTSVALQRGVLLSDYRVGTDTVL 600
 Db 541 LGDKCLDGLVNNVSEDLKNYLATRGLTWKNNMLTSVALQRGVLLSDYRVGTDTVL 600
 QY 601 CYCCGLRSFRELTYQYRQNPASELPVATSRPDCYWGRCRTQVKAHAMKFNHICEQT 660
 Db 601 CYCCGLRSFRELTYQYRQNPASELPVATSRPDCYWGRCRTQVKAHAMKFNHICEQT 660
 QY 661 RPKN 664
 Db 661 RPKN 664

RESULT 2
 AAB20219
 ID AAB20219 standard; protein; 664 AA.
 XX AC AAB20219;
 XX DT 14-MAY-2001 (first entry)
 XX DE Human Chfr (checkpoint with FHA and ring finger) protein.
 KW Checkpoint with forkhead associated domain and ring finger; Chfr; human;
 KW mitosis; cell cycle; tumour; diagnosis; antitumour; drug screening;
 KW ubiquitin-protein ligase.
 XX OS Homo sapiens.
 XX FH Key
 XX FT Domain
 XX FT 31..103
 XX FT /label= Forkhead-associated_domain
 XX FT 303..346
 XX FT /label= Ring_finger-domain
 XX FT 476..641
 XX FT /note= "cysteine-rich region"

FT Misc-difference 580
 XX /note= "Met in U2OS cells"
 FN WC200109150-A2.

XX 08-FEB-2001.
 XX 14-JUN-2000; 2000WO-US016391.
 XX 29-JUL-1999; 99US-0146194P.
 XX (WIST-) WISTAR INST ANATOMY & BIOLOGY.

XX Halazonetis T, Scolnick D;
 XX WPI; 2001-182927/18.
 XX N-PSDB; AAF30352.

XX Novel nucleic acid sequence of mitotic checkpoint gene encoding a
 XX checkpoint with forkhead-associated domain and ring finger protein, for
 XX diagnosing tumorigenic cells and in screening for anticancer drugs.

XX Claim 8(a); Fig 4A-C; 85pp; English.

XX The present sequence is that of human mitotic checkpoint protein Chfr,
 XX having a forkhead associated domain (FEA) and a ring finger domain. The
 XX protein is required for regulation of the transition of cells from
 XX prophase to metaphase during mitosis. It has ubiquitin-protein ligase
 XX activity. The Chfr checkpoint was evident in primary human cells, but was
 XX inactivated in 4 of 8 human cancer cell lines. In U2OS cells, a mutation
 XX was identified that caused a Val to Met amino acid substitution in the
 XX highly conserved C-terminal Cys-rich region of the Chfr protein. In the
 XX absence of the Chfr checkpoint, cells subjected to mitotic stress
 XX condensed their chromosomes despite failing to separate their
 XX chromosomes. Chfr may monitor centrosome separation. Inactivation of the
 XX Chfr gene (see AAF30352) in human cancer is theorized to underlie the
 XX increased sensitivity of cancer cells to antimitotic drugs. Polypeptides
 XX comprising the present sequence, or sequences comprising at least amino
 XX acids 31-103, 303-346 and/or 476-641 of this sequence, are claimed.
 XX Claimed methods of determining the tumorigenic potential of a cell
 XX comprise examining the cell for the presence of Chfr expression or for
 XX the presence of Chfr-mediated ubiquitin-protein ligase activity (in both
 XX cases, absence of expression indicating predisposition to tumorigenesis
 XX upon exposure to mitotic stress). A diagnostic kit for detecting the
 XX tumorigenic potential of cell cells comprises may comprise a ligand that
 XX binds to Chfr, such as an antibody or its fragment. Inhibitors of Chfr
 XX are identified by monitoring their effect on Chfr expression, and are
 XX used to retard the growth of cancer cells

XX Sequence 664 AA;

Query Match 100.0%; Score 3585; DS 4; Length 664;
 Best Local Similarity 100.0%; Pred. No. 9.8e-270;
 Matches 664; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRRCGLSFPNKLVSQDH 60
 Db 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRRCGLSFPNKLVSQDH 60
 QY 61 CRIVDEKSGQVLTSTSTGTVINKLVKKQKOTCPLOTGVDVILVYRKNEPENVAYLY 120
 Db 61 CRIVDEKSGQVLTSTSTGTVINKLVKKQKOTCPLOTGVDVILVYRKNEPENVAYLY 120
 QY 121 ESLSEKQGMTOESFEANKENVFHGTGKTSAGAGRGADPRVPPSPATQVCFEFPQST 180
 Db 121 ESLSEKQGMTOESFEANKENVFHGTGKTSAGAGRGADPRVPPSPATQVCFEFPQST 180
 QY 181 TSDLFTTASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDKTA 240
 Db 181 TSDLFTTASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDKTA 240
 QY 241 SFSSLEFPQDELEPVKKQKRGDGLDLNGQLLVAAQPRNAQTVDHEDVRAAGKPDKWE 300
 Db 241 SFSSLEFPQDELEPVKKQKRGDGLDLNGQLLVAAQPRNAQTVDHEDVRAAGKPDKWE 300

Db 241 SPSSLEPQDELEPVKKKRGDGLDLNGQLLVAQPRNAQTVEDVRAAGKPKMEE 300
QY 301 TLTCTICQDILLHDCVSLQPCMTFCAACYSWMSRSLCPTCRCPVERICKNHLNVLVE 360
Db 301 TLTCTICQDILLHDCVSLQPCMTFCAACYSWMSRSLCPTCRCPVERICKNHLNVLVE 360
QY 361 AYLIQHPDKSRSEEDVQSDMANKITQDMLOPKVRSFSDSEGSSEDLLELSDVDSESD 420
Db 361 AYLIQHPDKSRSEEDVQSDMANKITQDMLOPKVRSFSDSEGSSEDLLELSDVDSESD 420
QY 421 ISQPVVVCRCPEYRQAAPPHCPAPEGEPGAQALGDAPSTVSLTAVQDYVCPLOQ 480
Db 421 ISQPVVVCRCPEYRQAAPPHCPAPEGEPGAQALGDAPSTVSLTAVQDYVCPLOQ 480
QY 481 SHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCRTGCGCLAPFCELN 540
Db 481 SHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCRTGCGCLAPFCELN 540
QY 541 LGDKCLDGLVNNNSYEDILKNYLATRGLTWKNMLTESLVALQRGVFLSDYRVGTDL 600
Db 541 LGDKCLDGLVNNNSYEDILKNYLATRGLTWKNMLTESLVALQRGVFLSDYRVGTDL 600
QY 601 CYCCGLRSFRELTYQYRONIPASELPVAVTSRDPDGYWGNCRTOVKAHAMKFNHICEQT 660
Db 601 CYCCGLRSFRELTYQYRONIPASELPVAVTSRDPDGYWGNCRTOVKAHAMKFNHICEQT 660
QY 661 RFKN 664
Db 661 RFKN 664

RESULT 3
AAB93168
ID AAB93168 standard; protein; 652 AA.

XX AAB93168;
XX 26-JUN-2001 (first entry)
XX Human protein sequence SEQ ID NO:12100.
XX Human; primer; detection; diagnosis; antisense therapy; gene therapy.

OS Homo sapiens.
XX EP1074617-A2.
XX 07-FEB-2001.
XX 28-JUL-2000; 2000EP-00116126.
XX 29-JUL-1999; 99JP-00248036.
XX 27-AUG-1999; 99JP-00300253.
XX 11-JAN-2000; 2000JP-00118776.
XX 02-MAY-2000; 2000JP-00183767.
XX 09-JUN-2000; 2000JP-00241899.
XX (HELI-) HELIX RES INST.
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX WPI; 2001-318749/34.

XX Primer sets for synthesising polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.

XX Claim 8; SEQ ID NO 12100; 2537pp + Sequence Listing; English.

XX The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises:

CC (a) an oligo-dT primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesising polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention

XX SQ Sequence 652 AA;

Query Match 97.7%; Score 3504; DB 4; Length 652;
Best Local Similarity 98.2%; Pred. No. 1.9e-263;
Matches 652; Conservative 0; Mismatches 0; Indels 12; Gaps 1;

QY 1 MERPEEGKQPPQPWGLRLGLAECEGEPHVLKREWTIGRRGCDLSPFNKLVSGDH 60
Db 1 MERPEEGKQPPQPWGLRLGLAECEGEPHVLKREWTIGRRGCDLSPFNKLVSGDH 60
QY 61 CRIVVDEKSGQVLTEDTSTGTVINKLKVVKKQTCPLQTDGVILVYRKQEPHNVAIY 120
Db 61 CRIVVDEKSGQVLTEDTSTGTVINKLKVVKKQTCPLQTDGVILVYRKQEPHNVAIY 120
QY 121 ESLSEKQGMTQESFEANKENVFHTGKDTSGAGAGRGADPRVPSSSPATQVCFEPQSPST 180
Db 121 ESLSEKQGMTQESF-----DTSGAGAGRGADPRVPSSSPATQVCFEPQSPST 168
QY 181 TSDLPFTASASTEPSAGRRSSSCSGGGGIPKSGSPSVASDEVSSASALPDKRTA 240
Db 169 TSDLPFTASASTEPSAGRRSSSCSGGGGIPKSGSPSVASDEVSSASALPDKRTA 228
QY 241 SFSSLEPQDQEDLEPVKKKRGDGLDLNGQLLVAQPRNAQTVEDVRAAGKPKMEE 300
Db 229 SFSSLEPQDQEDLEPVKKKRGDGLDLNGQLLVAQPRNAQTVEDVRAAGKPKMEE 288
QY 301 TLTCTICQDILLHDCVSLQPCMTFCAACYSWMSRSLCPTCRCPVERICKNHLNVLVE 360
Db 289 TLTCTICQDILLHDCVSLQPCMTFCAACYSWMSRSLCPTCRCPVERICKNHLNVLVE 348
QY 361 AYLIQHPDKSRSEEDVQSDMANKITQDMLOPKVRSFSDSEGSSEDLLELSDVDSESD 420
Db 349 AYLIQHPDKSRSEEDVQSDMANKITQDMLOPKVRSFSDSEGSSEDLLELSDVDSESD 408
QY 421 ISQPVVVCRCPEYRQAAPPHCPAPEGEPGAQALGDAPSTVSLTAVQDYVCPLOQ 480
Db 409 ISQPVVVCRCPEYRQAAPPHCPAPEGEPGAQALGDAPSTVSLTAVQDYVCPLOQ 468
QY 481 SHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCRTGCGCLAPFCELN 540
Db 469 SHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCRTGCGCLAPFCELN 528
QY 541 LGDKCLDGLVNNNSYEDILKNYLATRGLTWKNMLTESLVALQRGVFLSDYRVGTDL 600
Db 529 LGDKCLDGLVNNNSYEDILKNYLATRGLTWKNMLTESLVALQRGVFLSDYRVGTDL 588
QY 601 CYCCGLRSFRELTYQYRONIPASELPVAVTSRDPDGYWGNCRTOVKAHAMKFNHICEQT 660
Db 589 CYCCGLRSFRELTYQYRONIPASELPVAVTSRDPDGYWGNCRTOVKAHAMKFNHICEQT 648
QY 661 RFKN 664
|||

Db 649 RFXN 652

RESULT 4

AB97233

ID ABB97233 standard; protein; 623 AA.

XX ABB97233;

AC ABB97233;

XX 27-JUN-2002 (first entry)

DT Novel human protein SEQ ID NO: 501.

DE Human, antianemic; vulnary; antiinflammatory; immunomodulator;

XX Human, antianemic; vulnary; antiinflammatory; immunomodulator;

KW antifertility; cerebroprotective; cytostatic; rheumatic; gene therapy;

KW neuroprotective; antiparkinsonian; protein therapy; EST;

XX expressed sequence tag.

OS Homo sapiens.

XX Homo sapiens.

PN WO200222660-A2.

XX WO200222660-A2.

PD 21-MAR-2002.

XX 21-MAR-2002.

PF 10-SEP-2001; 2001WO-US026015.

XX 10-SEP-2001; 2001WO-US026015.

PR 11-SEP-2000; 2000US-00659671.

XX 11-SEP-2000; 2000US-00659671.

PA (HYSE-) HYSEQ INC.

PI Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;

PI Xue AJ, Yang Y, Wehrman T, Drmanac RT;

XX Xue AJ, Yang Y, Wehrman T, Drmanac RT;

DR WPI: 2002-292408/33.

DR N-PSDB; ABN32419.

XX N-PSDB; ABN32419.

PT An isolated polynucleotide for treating diseases associated with its

PT encoded polypeptide such as cancer and multiple sclerosis.

XX Example 2; SEQ ID NO 501; 509pp; English.

XX The present invention provides the protein and coding sequences of 444

CC novel human proteins. These were isolated from expressed sequences tags

CC (ESTs). They can be used to stimulate cell growth, to regulate

CC haematopoiesis e.g. to treat aplastic anaemia, to help tissue regrowth

CC e.g. in burn treatment, to regulate the immune system e.g. to treat

CC multiple sclerosis, to regulate activin or inhibin e.g. to treat

CC infertility, to regulate haemostasis or thrombolysis e.g. to treat stroke

CC and cancer, to screen for drugs, to treat inflammatory conditions e.g.

CC rheumatoid arthritis, and to treat nervous system disorders e.g.

CC Parkinson's disease. The present sequence is a protein of the invention

XX

SQ Sequence 623 AA;

Query Match 88.4%; Score 3168.5; DB 5; Length 623;

Best Local Similarity 88.7%; Fred. NO. 2.2e-237;

Matches 595; Conservative 5; Mismatches 16; Indels 55; Gaps 2;

QY 1 MERPEGKQSPPPQPPQGRLLRLGAEAGEPHVLLKREWTIGRRGCDLSFPPNKLVSQDH 60

DB 1 MERPEGKQSPPPQPPQGRLLRLGAEAGEPHVLLKREWTIGRRGCDLSFPPNKLVSQDH 60

QY 61 CRIVWDEKSGQVLTEDTSGTVINKLVKKQTCPLQGTGVLYVYKNEPEHNVAVLY 120

DB 61 CRIVWDEKSGQVLTEDTSGTVINKLVKKQTCPLQGTGVLYVYKNEPEHNVAVLY 120

QY 121 ESLSEKQGMTOESFEANKENVFHTKDTSCAGAGRGADPRVPPSPATQVCFEPQPTS 180

DB 121 ESLSEKQGMTOESFEANKENVFHTKDTSCAGAGRGADPRVPPSPATQVCFEPQPTS 180

QY 181 TSDLFFPTASA-----SSTPEPAGRGRSSSCGSGGSGISPKGSGPSVASDEVSPASA 233

DB 136 ---MVPCCAQAAGKLGLGSDPTLASQIVITGSGGGGSGISPKGSGPSVASDEVSPASA 192

QY 234 LPDRKTA⁵SSLEPQOEDLEPVKKQMRGGDLDLNGQLLVQAQPRNAQTVHEDVRAAG 293

DB 193 LPDRKTA⁵SSLEPQOEDLEPVKKQMRGGDLDLNGQLLVQAQPRNAQTVHEDVRAAG 252

QY 294 KPDKMEETLT¹CIICQDLLHDCVSLQPCMTFCAACYSGWMSRSSLCPTCPCPVERICKNH 353

DB 253 KPDKMEETLT¹CIICQDLLHDCVSLQPCMTFCAACYSGWMSRSSLCPTCPCPVERICKNH 312

QY 354 ILNNLVEAYLIQHPDKSRSEEDVQSDARKKITQDMLQPKVRRSFSDGSSDLELSD 413

DB 313 ILNNLVEAYLIQHPDKSRSEEDVQSDARKKITQDMLQPKVRRSFSDGSSDLELSD 372

QY 414 VDESSDISOPYVVCQCPYRRAQAPPHCPAPEGEPGAPQALGAPSTSVSLTTAVQD 473

DB 373 VDESSDISOPYVVCQCPYRRAQAPPHCPAPEGEPGAPQALGAPSTSVSLTTAVQD 432

QY 474 YVCPLOGSHALCTCCFPMPDRRAEREQDPRAVPAQCAVCLQPFCHLYWGCTRTGCGCL 533

DB 433 YVCPLOGSHALCTCCFPMPDRRAEREQDPRAVPAQCAVCLQPFCHLYWGCTRTGCGCL 492

QY 534 APFCELNLGDKCLDGVLNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYR 593

DB 493 APFCELNLGDKCLDGVLNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYR 552

QY 594 VTGDTVLCYCCGLRSFRELTYQYRONIPASELPVAVTSRPPDCYWGRCRTQVKAHAMKF 653

DB 553 VTGDTVLCYCCGLRSFRELTYQYRONIPASELPVAVTSRPPDCYWGRCRTQVKAHAMKF 612

QY 654 NHICEQTRPKN 664

DB 613 NHICEQTRPKN 623

RESULT 5

AAB93182

ID AAB93182 standard; protein; 623 AA.

XX AAB93182;

AC AAB93182;

DT 26-JUN-2001 (first entry)

DE Human protein sequence SEQ ID NO:12128.

XX Human; primer; detection; diagnosis; antisense therapy; gene therapy.

KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.

XX Homo sapiens.

OS Homo sapiens.

PN EP1074617-A2.

XX EP1074617-A2.

PD 07-FEB-2001.

XX 07-FEB-2001.

PF 28-JUL-2000; 2000EP-00116126.

XX 28-JUL-2000; 2000EP-00116126.

PR 29-JUL-1999; 99JP-00248036.

XX 29-JUL-1999; 99JP-00248036.

PR 27-AUG-1999; 99JP-00300253.

XX 27-AUG-1999; 99JP-00300253.

PR 11-JAN-2000; 2000JP-00118776.

XX 11-JAN-2000; 2000JP-00118776.

PR 02-MAY-2000; 2000JP-00183767.

XX 02-MAY-2000; 2000JP-00183767.

PR 09-JUN-2000; 2000JP-00241899.

XX 09-JUN-2000; 2000JP-00241899.

PA (HELI-) HELIX RES INST.

XX (HELI-) HELIX RES INST.

PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

XX Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

DR WPI: 2001-318749/34.

XX WPI: 2001-318749/34.

PT Primer sets for synthesizing polynucleotides, particularly the 5602 full-

PT length cDNAs defined in the specification, and for the detection and/or

PT diagnosis of the abnormality of the proteins encoded by the full-length

PT cDNAs.

XX Claim 8; SEQ ID NO 12128; 2537pp + Sequence Listing; English.

Db 649 RFXN 652

RESULT 4

AB97233

ID ABB97233 standard; protein; 623 AA.

XX ABB97233;

AC ABB97233;

XX 27-JUN-2002 (first entry)

DT Novel human protein SEQ ID NO: 501.

DE Human, antianemic; vulnary; antiinflammatory; immunomodulator;

XX Human, antianemic; vulnary; antiinflammatory; immunomodulator;

KW antifertility; cerebroprotective; cytostatic; rheumatic; gene therapy;

KW neuroprotective; antiparkinsonian; protein therapy; EST;

XX expressed sequence tag.

OS Homo sapiens.

XX Homo sapiens.

PN WO200222660-A2.

XX WO200222660-A2.

PD 21-MAR-2002.

XX 21-MAR-2002.

PF 10-SEP-2001; 2001WO-US026015.

XX 10-SEP-2001; 2001WO-US026015.

PR 11-SEP-2000; 2000US-00659671.

XX 11-SEP-2000; 2000US-00659671.

PA (HYSE-) HYSEQ INC.

PI Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;

PI Xue AJ, Yang Y, Wehrman T, Drmanac RT;

XX Xue AJ, Yang Y, Wehrman T, Drmanac RT;

DR WPI: 2002-292408/33.

DR N-PSDB; ABN32419.

XX N-PSDB; ABN32419.

PT An isolated polynucleotide for treating diseases associated with its

PT encoded polypeptide such as cancer and multiple sclerosis.

XX Example 2; SEQ ID NO 501; 509pp; English.

XX The present invention provides the protein and coding sequences of 444

CC novel human proteins. These were isolated from expressed sequences tags

CC (ESTs). They can be used to stimulate cell growth, to regulate

CC haematopoiesis e.g. to treat aplastic anaemia, to help tissue regrowth

CC e.g. in burn treatment, to regulate the immune system e.g. to treat

CC multiple sclerosis, to regulate activin or inhibin e.g. to treat

CC infertility, to regulate haemostasis or thrombolysis e.g. to treat stroke

CC and cancer, to screen for drugs, to treat inflammatory conditions e.g.

CC rheumatoid arthritis, and to treat nervous system disorders e.g.

CC Parkinson's disease. The present sequence is a protein of the invention

XX

SQ Sequence 623 AA;

Query Match 88.4%; Score 3168.5; DB 5; Length 623;

Best Local Similarity 88.7%; Fred. NO. 2.2e-237;

Matches 595; Conservative 5; Mismatches 16; Indels 55; Gaps 2;

QY 1 MERPEGKQSPPPQPPQGRLLRLGAEAGEPHVLLKREWTIGRRGCDLSFPPNKLVSQDH 60

DB 1 MERPEGKQSPPPQPPQGRLLRLGAEAGEPHVLLKREWTIGRRGCDLSFPPNKLVSQDH 60

QY 61 CRIVWDEKSGQVLTEDTSGTVINKLVKKQTCPLQGTGVLYVYKNEPEHNVAVLY 120

DB 61 CRIVWDEKSGQVLTEDTSGTVINKLVKKQTCPLQGTGVLYVYKNEPEHNVAVLY 120

QY 121 ESLSEKQGMTOESFEANKENVFHTKDTSCAGAGRGADPRVPPSPATQVCFEPQPTS 180

DB 121 ESLSEKQGMTOESFEANKENVFHTKDTSCAGAGRGADPRVPPSPATQVCFEPQPTS 180

QY 181 TSDLFFPTASA-----SSTPEPAGRGRSSSCGSGGSGISPKGSGPSVASDEVSPASA 233

DB 136 ---MVPCCAQAAGKLGLGSDPTLASQIVITGSGGGGSGISPKGSGPSVASDEVSPASA 192

QY 234 LPDRKTA⁵SSLEPQOEDLEPVKKQMRGGDLDLNGQLLVQAQPRNAQTVHEDVRAAG 293

DB 193 LPDRKTA⁵SSLEPQOEDLEPVKKQMRGGDLDLNGQLLVQAQPRNAQTVHEDVRAAG 252

QY 294 KPDKMEETLT¹CIICQDLLHDCVSLQPCMTFCAACYSGWMSRSSLCPTCPCPVERICKNH 353

DB 253 KPDKMEETLT¹CIICQDLLHDCVSLQPCMTFCAACYSGWMSRSSLCPTCPCPVERICKNH 312

QY 354 ILNNLVEAYLIQHPDKSRSEEDVQSDARKKITQDMLQPKVRRSFSDGSSDLELSD 413

DB 313 ILNNLVEAYLIQHPDKSRSEEDVQSDARKKITQDMLQPKVRRSFSDGSSDLELSD 372

QY 414 VDESSDISOPYVVCQCPYRRAQAPPHCPAPEGEPGAPQALGAPSTSVSLTTAVQD 473

DB 373 VDESSDISOPYVVCQCPYRRAQAPPHCPAPEGEPGAPQALGAPSTSVSLTTAVQD 432

QY 474 YVCPLOGSHALCTCCFPMPDRRAEREQDPRAVPAQCAVCLQPFCHLYWGCTRTGCGCL 533

DB 433 YVCPLOGSHALCTCCFPMPDRRAEREQDPRAVPAQCAVCLQPFCHLYWGCTRTGCGCL 492

QY 534 APFCELNLGDKCLDGVLNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYR 593

DB 493 APFCELNLGDKCLDGVLNNSYESDILKNYLATRGITWKNMLTESLVALQRGVFLLSDYR 552

QY 594 VTGDTVLCYCCGLRSFRELTYQYRONIPASELPVAVTSRPPDCYWGRCRTQVKAHAMKF 653

DB 553 VTGDTVLCYCCGLRSFRELTYQYRONIPASELPVAVTSRPPDCYWGRCRTQVKAHAMKF 612

QY 654 NHICEQTRPKN 664

DB 613 NHICEQTRPKN 623

RESULT 5

AAB93182

ID AAB93182 standard; protein; 623 AA.

XX AAB93182;

AC AAB93182;

DT 26-JUN-2001 (first entry)

DE Human protein sequence SEQ ID NO:12128.

XX Human; primer; detection; diagnosis; antisense therapy; gene therapy.

KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.

XX Homo sapiens.

OS Homo sapiens.

PN EP1074617-A2.

XX EP1074617-A2.

PD 07-FEB-2001.

XX 07-FEB-2001.

PF 28-JUL-2000; 2000EP-00116126.

XX 28-JUL-2000; 2000EP-00116126.

PR 29-JUL-1999; 99JP-00248036.

XX 29-JUL-1999; 99JP-00248036.

PR 27-AUG-1999; 99JP-00300253.

XX 27-AUG-1999; 99JP-00300253.

PR 11-JAN-2000; 2000JP-00118776.

XX 11-JAN-2000; 2000JP-00118776.

PR 02-MAY-2000; 2000JP-00183767.

XX 02-MAY-2000; 2000JP-00183767.

PR 09-JUN-2000; 2000JP-00241899.

XX 09-JUN-2000; 2000JP-00241899.

PA (HELI-) HELIX RES INST.

XX (HELI-) HELIX RES INST.

PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

XX Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

DR WPI: 2001-318749/34.

XX WPI: 2001-318749/34.

PT Primer sets for synthesizing polynucleotides, particularly the 5602 full-

PT length cDNAs defined in the specification, and for the detection and/or

PT diagnosis of the abnormality of the proteins encoded by the full-length

PT cDNAs.

XX Claim 8; SEQ ID NO 12128; 2537pp + Sequence Listing; English.

XX The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises: (a) an oligo-dr primer and an oligonucleotide complementary to the complementary strand of a polynucleotide which comprises one of the 5602 nucleotide sequences defined in the specification, where the oligonucleotide comprises at least 15 nucleotides; or (b) a combination of an oligonucleotide comprising a sequence complementary to the complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises a 3'-end sequence, where the oligonucleotide comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesising polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention

XX Sequence 623 AA;

Query Match 88.2%; Score 3162.5; DB 4; Length 623;
Best Local Similarity 88.5%; Pred. No. 6.5e-237;
Matches 594; Conservative 5; Mismatches 17; Indels 55; Gaps 2;

QY 1 MERPEGKQSPPPQWGRLLRLGAEGBEPHVLRLKKEWTIGRRGCDLSFPFNKLVSQDH 60
DB 1 MERPEGKQSPPPQWGRLLRLGAEGBEPHVLRLKKEWTIGRRGCDLSFPFNKLVSQDH 60

QY 61 CRIVDEKSGQVLEDTSGTVINKLVKKQTCPLQGDVILVYRKNNEPHNVAVLY 120
DB 61 CRIVDEKSGQVLEDTSGTVINKLVKKQTCPLQGDVILVYRKNNEPHNVAVLY 120

QY 121 ESLSEKQGMTOESFEANKENVFHGTGDTGAGAGRADPRVPSPATQVCFEFPQSTS 180
DB 121 ESLSEKQGMTOESFE ----- 135

QY 181 TSLFTTASA-----SSTEPSAGRERSSSGSGGGISPKGSPSVASDEVSSFASA 233
DB 136 ---WVCCVAQAAGLKLLGSDPTLASQSIIVTGGGGISPKGSPSVASDEVSSFASA 192

QY 234 LPDRKTASFSSLPQDLEPVPKXRGDGLDLNGQLLVQAQPRNAQTVHEDVRAAAG 293
DB 193 LPDRKTASFSSLPQDLEPVPKXRGDGLDLNGQLLVQAQPRNAQTVHEDVRAAAG 252

QY 294 KPDKMBETLTCIIQDILLHDCVSLQPMHTFCAACYSGWMSRSLCPTCRCPVERICKNH 353
DB 253 KPDKMBETLTCIIQDILLHDCVSLQPMHTFCAACYSGWMSRSLCPTCRCPVERICKNH 312

QY 354 ILNNLVEAYLIQHPDKSRSEEDVQSMARKITQDMLOPKVRRSFSDSEGSSEDLLELSD 413
DB 313 ILNNLVEAYLIQHPDKSRSEEDVQSMARKITQDMLOPKVRRSFSDSEGSSEDLLELSD 372

QY 414 VDESSEDSIQPVYVQCPEYRQAQPHCPAPEGEPQALGAPSTSVSLTAVQD 473
DB 373 VDESSEDSIQPVYVQCPEYRQAQPHCPAPEGEPQALGAPSTSVSLTAVQD 432

QY 474 YVCPLOQSHALCTCCQPMEDRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCL 533
DB 433 YVCPLOQSHALCTCCQPMEDRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCL 492

QY 534 APFCELNGLDKLDGLVNNNSYESDILKNYLATRGLTWKNMLTESLVALQGVFLLSYDR 593
DB 493 APFCELNGLDKLDGLVNNNSYESDILKNYLATRGLTWKNMLTESLVALQGVFLLSYDR 552

QY 594 VTGDTVLCYCCGLRSFELTYQYRONIPASELPAVTSRPPDCYGCNCRTOVKAHAMKF 653
DB 553 VTGDTVLCYCCGLRSFELTYQYRONIPASELPAVTSRPPDCYGCNCRTOVKAHAMKF 612

QY 654 NHICEOTRFKN 664
DB 613 NHICEOTRFKN 623

RESULT 6
AAU15856
ID AAU15856 standard; protein; 426 AA.
XX AAU15856;
AC AAU15856;
XX 07-NOV-2001 (first entry)
DT Human novel secreted protein, Seq ID 809.
DE Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX Homo sapiens.
OS WO200155322-A2.
PN 02-AUG-2001.
PD 17-JAN-2001; 2001WO-US001341.
PF 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226688P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.

PR	01-SEP-2000;	2000US-0229345P.	PR	17-NOV-2000;	2000US-0249215P.
PR	05-SEP-2000;	2000US-0229509P.	PR	17-NOV-2000;	2000US-0249216P.
PR	05-SEP-2000;	2000US-0229513P.	PR	17-NOV-2000;	2000US-0249217P.
PR	06-SEP-2000;	2000US-0230437P.	PR	17-NOV-2000;	2000US-0249218P.
PR	06-SEP-2000;	2000US-0230438P.	PR	17-NOV-2000;	2000US-0249244P.
PR	06-SEP-2000;	2000US-0231242P.	PR	17-NOV-2000;	2000US-0249245P.
PR	08-SEP-2000;	2000US-0231243P.	PR	17-NOV-2000;	2000US-0249246P.
PR	08-SEP-2000;	2000US-0231244P.	PR	17-NOV-2000;	2000US-0249265P.
PR	08-SEP-2000;	2000US-0231413P.	PR	17-NOV-2000;	2000US-0249297P.
PR	08-SEP-2000;	2000US-0231414P.	PR	17-NOV-2000;	2000US-0249299P.
PR	08-SEP-2000;	2000US-0232080P.	PR	17-NOV-2000;	2000US-0249300P.
PR	08-SEP-2000;	2000US-0232081P.	PR	01-DEC-2000;	2000US-0250160P.
PR	12-SEP-2000;	2000US-0232196P.	PR	01-DEC-2000;	2000US-0250391P.
PR	14-SEP-2000;	2000US-0232397P.	PR	05-DEC-2000;	2000US-0251030P.
PR	14-SEP-2000;	2000US-0232398P.	PR	05-DEC-2000;	2000US-0251988P.
PR	14-SEP-2000;	2000US-0232399P.	PR	05-DEC-2000;	2000US-0256719P.
PR	14-SEP-2000;	2000US-0232400P.	PR	06-DEC-2000;	2000US-0251479P.
PR	14-SEP-2000;	2000US-0232401P.	PR	08-DEC-2000;	2000US-0251856P.
PR	14-SEP-2000;	2000US-0233063P.	PR	08-DEC-2000;	2000US-0251868P.
PR	14-SEP-2000;	2000US-0233064P.	PR	08-DEC-2000;	2000US-0251869P.
PR	21-SEP-2000;	2000US-0233065P.	PR	08-DEC-2000;	2000US-0251989P.
PR	21-SEP-2000;	2000US-0233223P.	PR	08-DEC-2000;	2000US-0251990P.
PR	21-SEP-2000;	2000US-0234274P.	PR	11-DEC-2000;	2000US-0254097P.
PR	25-SEP-2000;	2000US-0234277P.	PR	05-JAN-2001;	2001US-0259678P.
PR	25-SEP-2000;	2000US-0234997P.	XX		
PR	26-SEP-2000;	2000US-0234998P.	XX		
PR	26-SEP-2000;	2000US-0235484P.	XX		
PR	27-SEP-2000;	2000US-0235834P.	XX		
PR	27-SEP-2000;	2000US-0235836P.	XX		
PR	29-SEP-2000;	2000US-0236327P.	XX		
PR	29-SEP-2000;	2000US-0236367P.	XX		
PR	29-SEP-2000;	2000US-0236368P.	XX		
PR	29-SEP-2000;	2000US-0236369P.	XX		
PR	29-SEP-2000;	2000US-0236369P.	XX		
PR	29-SEP-2000;	2000US-0236370P.	XX		
PR	02-OCT-2000;	2000US-0236802P.	XX		
PR	02-OCT-2000;	2000US-0237037P.	XX		
PR	02-OCT-2000;	2000US-0237038P.	XX		
PR	02-OCT-2000;	2000US-0237039P.	XX		
PR	02-OCT-2000;	2000US-0237040P.	XX		
PR	13-OCT-2000;	2000US-0239935P.	XX		
PR	13-OCT-2000;	2000US-0239937P.	XX		
PR	20-OCT-2000;	2000US-0240960P.	XX		
PR	20-OCT-2000;	2000US-0241221P.	XX		
PR	20-OCT-2000;	2000US-0241785P.	XX		
PR	20-OCT-2000;	2000US-0241786P.	XX		
PR	20-OCT-2000;	2000US-0241787P.	XX		
PR	20-OCT-2000;	2000US-0241808P.	XX		
PR	20-OCT-2000;	2000US-0241809P.	XX		
PR	20-OCT-2000;	2000US-0241826P.	XX		
PR	01-NOV-2000;	2000US-0244617P.	XX		
PR	08-NOV-2000;	2000US-0246474P.	XX		
PR	08-NOV-2000;	2000US-0246475P.	XX		
PR	08-NOV-2000;	2000US-0246476P.	XX		
PR	08-NOV-2000;	2000US-0246477P.	XX		
PR	08-NOV-2000;	2000US-0246478P.	XX		
PR	08-NOV-2000;	2000US-0246523P.	XX		
PR	08-NOV-2000;	2000US-0246524P.	XX		
PR	08-NOV-2000;	2000US-0246525P.	XX		
PR	08-NOV-2000;	2000US-0246526P.	XX		
PR	08-NOV-2000;	2000US-0246527P.	XX		
PR	08-NOV-2000;	2000US-0246528P.	XX		
PR	08-NOV-2000;	2000US-0246532P.	XX		
PR	08-NOV-2000;	2000US-0246609P.	XX		
PR	08-NOV-2000;	2000US-0246610P.	XX		
PR	08-NOV-2000;	2000US-0246611P.	XX		
PR	08-NOV-2000;	2000US-0246613P.	XX		
PR	17-NOV-2000;	2000US-0249207P.	XX		
PR	17-NOV-2000;	2000US-0249208P.	XX		
PR	17-NOV-2000;	2000US-0249209P.	XX		
PR	17-NOV-2000;	2000US-0249210P.	XX		
PR	17-NOV-2000;	2000US-0249211P.	XX		
PR	17-NOV-2000;	2000US-0249212P.	XX		
PR	17-NOV-2000;	2000US-0249213P.	XX		
PR	17-NOV-2000;	2000US-0249214P.	XX		

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WFI; 2001-488783/53.

N-PSDB; AAS25843.

New nucleic acid molecules encoding 461 human secreted proteins for diagnosing, preventing, treating or ameliorating medical conditions and used as food additives or preservatives.

Claim 11; SEQ ID NO 809; 980pp; English.

The invention relates to isolated nucleic acid molecules and their encoded secreted proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues and in chemotaxis. The polypeptides can also be used as a food additive or preservative to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrates, vitamins, minerals, cofactors and other nutritional components. The present sequence represents a novel secreted protein of the invention. Note: The sequence data for this patent did not form part of the printed

Query Match	54.5%;	Score 1954.5;	DB 4;	Length 426;
Best Local Similarity	74.1%;	Pred. No. 3.3e-143;		
Matches	389;	Conservative	5;	Mismatches 22; Indels 109; Gaps 5;
Qy	1	MERPECKQSPFPQPGWRLRLGAEAGEPHVLRKREWTIGRRGCDLSPFNKLVSGDH	60	
Db	3	MERPECKQSPFPQPGWRLRLGAEAGEPHVLRKREWTIGRRGCDLSPFNKLVSGDH	62	
Qy	61	CRIVDEKSCQVLEDTSTGTFINKLVKVKCTCPLQTGDIYLYVRKPEPHNVAYL	120	

Db 63 CRIVDEKSGQVTELESTSTGTVINKLVKKVQTCPLQTDGVIYLVYRKNPEHR----- 117
 QY 121 ELSLSEKQGTQSFENKENVPHGTQKTSAGAGRGADPRVPPSSPATQVCFEFPQPTS 180
 Db 118 ----- 117
 QY 181 TSDLFTASASTEPSPACGRSSSSCGSGGGISPKSGSPSVASDEVSSFASALPDKRTA 240
 Db 118 -----SGGGISPKSGSPSVASDEVSSFASALPDKRTA 150
 QY 241 SPSLEPQOELEPVKKQKRGDGLDNLGQLLVQPRNAQTVDHEDVRAAGKPKMEE 300
 Db 151 SPSLEPQOELEPVKKQKRGDGLDNLGQLLVQPRNAQTVDHEDVRAAGKPKMEE 210
 QY 301 TLTCICQLLDHCVSLQPCMTFFCAACYSGWNRSSLCPTCRCPVERICKHILNLLVE 360
 Db 211 TLTCICQLLDHCVSLQPCMTFFCAACYSGWNRSSLCPTCRCPVERICKHILNLLVE 270
 QY 361 AYLIQHPDKSRSEEDVQMDARKKITQDMLQPKVRSPFDEGSSDLELSDVDSSESD 420
 Db 271 AYLIQHPDKSRSEEDVQMDARKKITQDMLQPKVRSPFDEGSSDLELSDVDSSESD 330
 QY 421 ISQPVVCRQCPRYRQAQPPHCPAPEGEPGAQALGDAPSTSVSLTTAVQDYVCPLQG 480
 Db 331 ISQPVVCRQCPRYRQAQPPHCPAPEGEPGAQALGDAPSTSVSLTT-----VRI 382
 QY 481 SHALC---TCCQFQMPDRAREQDPRVAPQ-----QCQAVCLQPF 517
 Db 383 TCALCKEATPC-APASAHARPESGTRTGPRVXXLNKCKXGLQAF 426
 RESULT 7
 ABUS4925
 ID ABUS4925 standard; protein; 426 AA.
 XX
 AC ABUS4925;
 XX
 DT 18-MAR-2003 (first entry)
 DE
 DE Human novel polypeptide #12.
 XX
 KW Human; neural disorder; immune system disorder; renal disorder;
 KW muscular disorder; respiratory disease; reproductive disorder;
 KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
 KW hyperproliferative disorder; inflammatory disease; allergic reaction;
 KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
 KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
 KW haemostatic; antiarteriosclerotic.
 XX
 OS Homo sapiens.
 XX
 PN US2002132753-A1.
 XX
 PD 19-SEP-2002.
 XX
 PF 17-JAN-2001; 2001US-00764864.
 XX
 PR 31-JAN-2000; 2000US-0179065P.
 PR 04-FEB-2000; 2000US-0180282P.
 PR 28-JUN-2000; 2000US-0214886P.
 PR 07-JUL-2000; 2000US-0216647P.
 PR 07-JUL-2000; 2000US-0216880P.
 PR 11-JUL-2000; 2000US-0217487P.
 PR 11-JUL-2000; 2000US-0217496P.
 PR 14-JUL-2000; 2000US-0218290P.
 PR 26-JUL-2000; 2000US-0220963P.
 PR 26-JUL-2000; 2000US-0220964P.
 PR 14-AUG-2000; 2000US-0224518P.
 PR 14-AUG-2000; 2000US-0224519P.
 PR 14-AUG-2000; 2000US-0225267P.
 PR 14-AUG-2000; 2000US-0225268P.
 PR 14-AUG-2000; 2000US-0225270P.
 PR 14-AUG-2000; 2000US-0225447P.

PR 14-AUG-2000; 2000US-0225757P.
 PR 14-AUG-2000; 2000US-0225758P.
 PR 22-AUG-2000; 2000US-0226868P.
 PR 30-AUG-2000; 2000US-0228924P.
 PR 01-SEP-2000; 2000US-0229287P.
 PR 01-SEP-2000; 2000US-0229343P.
 PR 01-SEP-2000; 2000US-0229344P.
 PR 01-SEP-2000; 2000US-0229345P.
 PR 05-SEP-2000; 2000US-0229509P.
 PR 05-SEP-2000; 2000US-0229513P.
 PR 08-SEP-2000; 2000US-0231413P.
 PR 21-SEP-2000; 2000US-0234223P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 25-SEP-2000; 2000US-0234997P.
 PR 27-SEP-2000; 2000US-0235834P.
 PR 29-SEP-2000; 2000US-0236327P.
 PR 29-SEP-2000; 2000US-0236367P.
 PR 29-SEP-2000; 2000US-0236368P.
 PR 29-SEP-2000; 2000US-0236389P.
 PR 29-SEP-2000; 2000US-0236370P.
 PR 02-OCT-2000; 2000US-0236802P.
 PR 02-OCT-2000; 2000US-0237037P.
 PR 02-OCT-2000; 2000US-0237038P.
 PR 02-OCT-2000; 2000US-0237039P.
 PR 13-OCT-2000; 2000US-023935P.
 PR 20-OCT-2000; 2000US-0240960P.
 PR 20-OCT-2000; 2000US-0241785P.
 PR 20-OCT-2000; 2000US-0241809P.
 PR 01-NOV-2000; 2000US-0244617P.
 PR 17-NOV-2000; 2000US-0249299P.
 PR 08-DEC-2000; 2000US-0251856P.
 PR 08-DEC-2000; 2000US-0251858P.
 PR 08-DEC-2000; 2000US-0251869P.
 XX
 PA (ROSE/) ROSEN C A.
 PA (RUBE/) RUBEN S M.
 PA (BARA/) BARASH S C.
 XX
 PI Rosen CA, Ruben SM, Barash SC;
 XX
 DR WPI; 2003-147444/14.
 DR N-PSDB; ABX73184.
 XX
 PT New polypeptides and nucleic acids, useful in gene therapy for treating,
 PT inhibiting or preventing e.g. neural, immune system, muscular,
 PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
 PT renal disorders.
 XX
 PS Claim 11; SEQ ID NO 809; 402pp; English.
 XX
 CC The invention relates to human novel polypeptides and their associated
 CC polynucleotides. The polypeptides and polynucleotides are useful in gene
 CC therapy for treating, inhibiting or preventing neural disorders, immune
 CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
 CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
 CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
 CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
 CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
 CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
 CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
 CC leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
 CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
 CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
 CC infarction) and cancerous diseases. Sequences ABUS4914-ABUS5699 and
 CC ABUS5748 represent human novel polypeptides of the invention
 XX
 SQ Sequence 426 AA;

Query Match 54.5%; Score 1954.5; DB 6; Length 426;
 Best Local Similarity 74.1%; Pred. No. 3.3e-143;
 Matches 389; Conservative 5; Mismatches 22; Indels 109; Gaps 5;

QY 1 MERPEGKSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRRCGLSFFSNKLVSGDH 60
Db 3 MERPEGKSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRRCGLSFFSNKLVSGDH 62
QY 61 CRIVDEKSGQVTLBETSTSGTVINKLKVKKQTQPLQTDVYLYVYRKNEPEHNAYLY 120
Db 63 CRIVDEKSGQVTLBETSTSGTVINKLKVKKQTQPLQTDVYLYVYRKNEPEHR----- 117
QY 121 ESLSEKQGMVQESFEANKENVFHGTDKTSAGAGRGADPRVPSPSPATQVCPEEPQPS 180
Db 118 ----- 117
QY 181 TSDLPFTASASTEPSAGRRSSCGGGGSGISPKGSPSVASDEVSSFASALPDRKTA 240
Db 118 -----SGGGGSGISPKGSPSVASDEVSSFASALPDRKTA 150
QY 241 SPSLEPOQEDLEPVKKMRGGDLDLNGQLLVQAPRNAQTVHEDVRAAGKPKDKEE 300
Db 151 SPSLEPOQEDLEPVKKMRGGDLDLNGQLLVQAPRNAQTVHEDVRAAGKPKDKEE 210
QY 301 TLTCIIQDLHDCVSLQPCMTFFCAACYSYGMWERSLCTPCRCPVERICKHILNNLVE 360
Db 211 TLTCIIQDLHDCVSLQPCMTFFCAACYSYGMWERSLCTPCRCPVERICKHILNNLVE 270
QY 361 AYLIQHPDKSRSEEDVQSDARNKITQDMLQPKVRSFSDGSSDLELSDVDSSESD 420
Db 271 AYLIQHPDKSRSEEDVQSDARNKITQDMLQPKVRSFSDGSSDLELSDVDSSESD 330
QY 421 ISQYVYVCRQCPYRRQAQPHCPAPEGEPGAPQALGAPSTSVLTTAVQDYVCPQ 480
Db 331 ISQYVYVCRQCPYRRQAQPHCPAPEGEPGAPQALGAPSTSVLTT-----VRI 382
QY 481 SHALC---TCCFPMPDRAREQDPRVAPQ-----QCACVCLQPF 517
Db 383 TCALCKEATPC-APASAHARPESGTRGPRVXXLNKCKGLLOAF 426

RESULT 8
AAU08972
ID AAC08972 standard; protein; 269 AA.
XX AC AAC08972;
XX AC
DT 06-NOV-2001 (first entry)
XX DE Human polypeptide SEQ ID NO 22864.
XX DE
XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation.
XX OS Homo sapiens.
XX KW
XX WO200164835-A2.
XX FN
XX PD 07-SEP-2001.
XX XX
XX 26-FEB-2001; 2001WO-US004927.
XX PF
XX 28-FEB-2000; 2000US-00515126.
XX PR 18-MAY-2000; 2000US-00577409.
XX XX
XX (HYSE-) HYSEQ INC.
XX XX
XX Tang YT, Liu C, Drmanac RT;
XX PI
XX WPI; 2001-514838/56.
XX DR N-PSDB; AAI88903.
XX XX
XX Isolated nucleic acids and polypeptides, useful for preventing diagnosing
PT and treating e.g. leukemia, inflammation and immune disorders.
XX PT
XX

PS Claim 20; SEQ ID NO 22864; 1399pp + Sequence Listing; English.
XX
XX The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to
CC cytokine, cell proliferation or cell differentiation, which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
XX directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

Seq Sequence 269 AA;
Query Match 38.0%; Score 1364; DB 4; Length 269;
Best Local Similarity 99.6%; Pred. No. 1.5e-97;
Matches 242; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 422 SQPVVCRQCPYRRQAQPHCPAPEGEPGAPQALGAPSTSVLTTAVQDYVCPQGS 481
Db 27 SQPVVCRQCPYRRQAQPHCPAPEGEPGAPQALGAPSTSVLTTAVQDYVCPQGS 86
QY 482 HALCTCCFPMPDRAREQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFCELNL 541
Db 87 HALCTCCFPMPDRAREQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFCELNL 146
QY 542 GDKCLDGVLLNNNSVESDILKNYLATRGLTWKNMLTESLVALQGVFLSDYVGTDTVLC 601
Db 147 GDKCLDGVLLNNNSVESDILKNYLATRGLTWKNMLTESLVALQGVFLSDYVGTDTVLC 206
QY 602 YCCGLRSFRELTYQYRONIPASELPVAVTSRPPCYWGNCRCTOVKAHMKFNHICBQTR 661
Db 207 YCCGLRSFRELTYQYRONIPASELPVAVTSRPPCYWGNCRCTOVKAHMKFNHICBQTR 266
QY 662 FXN 664
Db 267 FXN 269

RESULT 9
AAU16317
ID AAU16317 standard; protein; 230 AA.
XX AC AAU16317;
XX AC
DT 07-NOV-2001 (first entry)
XX DE Human novel secreted protein, Seq ID 1270.
XX DE
XX Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnery;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
XX KW preservative; antiproliferative.
XX OS Homo sapiens.
XX XX
XX WO200155322-A2.
XX FN
XX PD 02-AUG-2001.
XX XX
XX 17-JAN-2001; 2001WO-US001341.
XX PF
XX 31-JAN-2000; 2000US-0179065P.
XX PR 04-FEB-2000; 2000US-0180628F.
XX PR

24-FEB-2000; 2000US-0184664P. PR
02-MAR-2000; 2000US-0186350P. PR
16-MAR-2000; 2000US-0189874P. PR
17-MAR-2000; 2000US-0190076P. PR
18-APR-2000; 2000US-0198123P. PR
19-MAY-2000; 2000US-0205515P. PR
07-JUN-2000; 2000US-0209467P. PR
28-JUN-2000; 2000US-0214886P. PR
30-JUN-2000; 2000US-0215135P. PR
07-JUL-2000; 2000US-0216647P. PR
11-JUL-2000; 2000US-0216880P. PR
11-JUL-2000; 2000US-0217487P. PR
11-JUL-2000; 2000US-0217496P. PR
14-JUL-2000; 2000US-0218290P. PR
26-JUL-2000; 2000US-0220963P. PR
26-JUL-2000; 2000US-0220964P. PR
14-AUG-2000; 2000US-0224518P. PR
14-AUG-2000; 2000US-0224519P. PR
14-AUG-2000; 2000US-0225213P. PR
14-AUG-2000; 2000US-0225214P. PR
14-AUG-2000; 2000US-0225267P. PR
14-AUG-2000; 2000US-0225268P. PR
14-AUG-2000; 2000US-0225270P. PR
14-AUG-2000; 2000US-0225447P. PR
14-AUG-2000; 2000US-0225757P. PR
14-AUG-2000; 2000US-0225758P. PR
14-AUG-2000; 2000US-0225759P. PR
18-AUG-2000; 2000US-0226279P. PR
22-AUG-2000; 2000US-0226681P. PR
22-AUG-2000; 2000US-0226686P. PR
22-AUG-2000; 2000US-0227182P. PR
23-AUG-2000; 2000US-0227009P. PR
30-AUG-2000; 2000US-0228924P. PR
01-SEP-2000; 2000US-0229287P. PR
01-SEP-2000; 2000US-0229343P. PR
01-SEP-2000; 2000US-0229344P. PR
01-SEP-2000; 2000US-0229345P. PR
05-SEP-2000; 2000US-0229509P. PR
05-SEP-2000; 2000US-0229513P. PR
06-SEP-2000; 2000US-0230437P. PR
06-SEP-2000; 2000US-0230438P. PR
08-SEP-2000; 2000US-0231242P. PR
08-SEP-2000; 2000US-0231243P. PR
08-SEP-2000; 2000US-0231244P. PR
08-SEP-2000; 2000US-0231413P. PR
08-SEP-2000; 2000US-0231414P. PR
08-SEP-2000; 2000US-0232080P. PR
08-SEP-2000; 2000US-0232081P. PR
12-SEP-2000; 2000US-0231968P. PR
14-SEP-2000; 2000US-0232397P. PR
14-SEP-2000; 2000US-0232398P. PR
14-SEP-2000; 2000US-0232399P. PR
14-SEP-2000; 2000US-0232400P. PR
14-SEP-2000; 2000US-0232401P. PR
14-SEP-2000; 2000US-0233063P. PR
14-SEP-2000; 2000US-0233064P. PR
14-SEP-2000; 2000US-0233065P. PR
21-SEP-2000; 2000US-0234223P. PR
21-SEP-2000; 2000US-0234274P. PR
25-SEP-2000; 2000US-0234997P. PR
25-SEP-2000; 2000US-0234998P. PR
26-SEP-2000; 2000US-0235484P. PR
27-SEP-2000; 2000US-0235834P. PR
27-SEP-2000; 2000US-0235836P. PR
29-SEP-2000; 2000US-0236327P. PR
29-SEP-2000; 2000US-0236367P. PR
29-SEP-2000; 2000US-0236368P. PR
29-SEP-2000; 2000US-0236369P. PR
29-SEP-2000; 2000US-0236370P. PR
02-OCT-2000; 2000US-0236802P. PR
02-OCT-2000; 2000US-0237037P. PR
02-OCT-2000; 2000US-0237038P. PR
02-OCT-2000; 2000US-0237039P. PR
12-OCT-2000; 2000US-0237040P. PR
13-OCT-2000; 2000US-0239935P. PR
13-OCT-2000; 2000US-0239937P. PR
20-OCT-2000; 2000US-0240960P. PR
20-OCT-2000; 2000US-0241221P. PR
20-OCT-2000; 2000US-0241785P. PR
20-OCT-2000; 2000US-0241786P. PR
20-OCT-2000; 2000US-0241808P. PR
20-OCT-2000; 2000US-0241809P. PR
20-OCT-2000; 2000US-0241826P. PR
01-NOV-2000; 2000US-0244617P. PR
08-NOV-2000; 2000US-0246474P. PR
08-NOV-2000; 2000US-0246475P. PR
08-NOV-2000; 2000US-0246478P. PR
08-NOV-2000; 2000US-0246477P. PR
08-NOV-2000; 2000US-0246478P. PR
08-NOV-2000; 2000US-0246523P. PR
08-NOV-2000; 2000US-0246524P. PR
08-NOV-2000; 2000US-0246525P. PR
08-NOV-2000; 2000US-0246526P. PR
08-NOV-2000; 2000US-0246527P. PR
08-NOV-2000; 2000US-0246528P. PR
08-NOV-2000; 2000US-0246532P. PR
08-NOV-2000; 2000US-0246609P. PR
08-NOV-2000; 2000US-0246610P. PR
08-NOV-2000; 2000US-0246611P. PR
08-NOV-2000; 2000US-0246613P. PR
17-NOV-2000; 2000US-0249207P. PR
17-NOV-2000; 2000US-0249208P. PR
17-NOV-2000; 2000US-0249209P. PR
17-NOV-2000; 2000US-0249210P. PR
17-NOV-2000; 2000US-0249211P. PR
17-NOV-2000; 2000US-0249212P. PR
17-NOV-2000; 2000US-0249213P. PR
17-NOV-2000; 2000US-0249214P. PR
17-NOV-2000; 2000US-0249215P. PR
17-NOV-2000; 2000US-0249216P. PR
17-NOV-2000; 2000US-0249217P. PR
17-NOV-2000; 2000US-0249218P. PR
17-NOV-2000; 2000US-0249244P. PR
17-NOV-2000; 2000US-0249245P. PR
17-NOV-2000; 2000US-0249246P. PR
17-NOV-2000; 2000US-0249265P. PR
17-NOV-2000; 2000US-0249266P. PR
17-NOV-2000; 2000US-0249267P. PR
17-NOV-2000; 2000US-0249297P. PR
17-NOV-2000; 2000US-0249299P. PR
17-NOV-2000; 2000US-0249300P. PR
01-DEC-2000; 2000US-0250160P. PR
01-DEC-2000; 2000US-0250391P. PR
05-DEC-2000; 2000US-0251030P. PR
05-DEC-2000; 2000US-0251988P. PR
05-DEC-2000; 2000US-0256719P. PR
06-DEC-2000; 2000US-0251479P. PR
08-DEC-2000; 2000US-0251856P. PR
08-DEC-2000; 2000US-0251868P. PR
08-DEC-2000; 2000US-0251869P. PR
08-DEC-2000; 2000US-0251989P. PR
08-DEC-2000; 2000US-0251990P. PR
11-DEC-2000; 2000US-0254097P. PR
05-JAN-2001; 2001US-0259678P. PR
(HUMA-) HUMAN GENOME SCI INC. PA
Rosen CA, Barash SC, Ruben SM; XX
WFI; 2001-488783/53. XX
N-PSDB; AAS26304. DR
New nucleic acid molecules encoding 461 human secreted proteins for XX
diagnosing, preventing, treating or ameliorating medical conditions and PT
used as food additives or preservatives. PT
XX

PS Claim 11; SEQ ID NO 1270; 980pp; English.

XX The invention relates to isolated nucleic acid molecules and their encoded secreted proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiodysplasia, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues and in chemotaxis. The polypeptides can also be used as a food additive or preservative to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors and other nutritional components. The present sequence represents a novel secreted protein of the invention. Note: The sequence data for this patent did not form part of the printed

Query Match 23.5%; Score 843.5; DB 4; Length 230;
Best Local Similarity 76.3%; Pred. No. 3.5e-57;
Matches 167; Conservative 2; Mismatches 19; Indels 31; Gaps 4;

QY 319 PCMHTECAACYSQWERSILCTPCPVERICKNHLNNLVEAYLIQHPDKSRSEEDVQS 378
DB 5 PCMHTECAACYSQWERSILCTPCPVERICKNHLNNLVEAYLIQHPDKSRSEEDVQS 64

QY 379 MDARNKITQMLQPKVRRSFSEDEGSDDLLELSDVDESSDISQPVVVCRCPIYRQA 438
DB 65 MDARNKITQMLQPKVRRSFSEDEGSDDLLELSDVDESSDISQPVVVCRCPIYRQA 124

QY 439 AQPHPCPAPEGEPGAPQALGDAPSTSVLTAVQDVCPLOGSHALCTCCFQMP----- 493
DB 125 AQPHPCPAPEGEPGAPQALGDAPSTSVLTAVQDVCPLOGSHALCTCCFQMP----- 493

QY 494 --DRRAE--REOPRVA-----PQCAVCLQPF 517
DB 174 SAHARPESGREQDPRXALXXPPVLGLHPDLRLILAPF 212

RESULT 10
ABU55386
ID ABU55386 standard; protein; 230 AA.
XX ABU55386;
XX
XX 18-MAR-2003 (first entry)
XX Human novel polypeptide #473.
XX Human; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.
XX
XX Homo sapiens.
XX
XX US2002132753-A1.
XX
XX 19-SEP-2002.
XX
XX 17-JAN-2001; 2001US-00764864.

XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216800P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 22-AUG-2000; 2000US-0226868P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 08-SEP-2000; 2000US-0229513P.
PR 21-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 17-NOV-2000; 2000US-0244617P.
PR 08-DEC-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
XX (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
PI Rosen CA, Ruben SM, Barash SC;
XX WPI; 2003-147444/14.
XX N-PSDB; ABX73645.
XX New polypeptides and nucleic acids, useful in gene therapy for treating, inhibiting or preventing e.g. neural, immune system, muscular, respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or renal disorders.
XX Claim 11; SEQ ID NO 1270; 402pp; English.
XX The invention relates to human novel polypeptides and their associated polynucleotides. The polypeptides and polynucleotides are useful in gene therapy for treating, inhibiting or preventing neural disorders, immune system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis), muscular disorders, respiratory diseases (e.g.

CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
 CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
 CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
 CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
 CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
 CC leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
 CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
 CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
 CC infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
 CC ABU55748 represent human novel polypeptides of the invention
 XX
 XX Sequence 230 AA;
 SQ

Query Match	23.5%;	Score	843.5;	DB	6;	Length	230;	
Best Local Similarity	76.3%;	Pred. No.	3.5e-57;					
Matches 167;	Conservative	2;	Mismatches	19;	Indels	31;	Gaps	4
QY	319	P	CWHTFCACACSGWMMERS	SLCPT	CRC	PVERICKNHLINNLVEAYLQHPDKSRSE	DVQS	378
Db	5	P	CWHTFCACACSGWMMERS	SLCPT	CRC	PVERICKNHLINNLVEAYLQHPDKSRSE	DVQS	64
QY	379	M	DARKKITQDMLQPKVR	FSFDEGSGSE	DLLEISDVDS	SSDSISQBYVVCROCPYR	RQA	438
Db	65	M	DARKKITQDMLQPKVR	FSFDEGSGSE	DLLEISDVDS	SSDSISQBYVVCROCPYR	RQA	124
QY	439	A	OPHCPCPAPGEPGAPQ	ALGDPATSV	SLTAVQDYV	CPQSGSHALCTCC	FOMP	493
Db	125	A	OPHCPCPAPGEPGAPQ	ALGDPATSV	SLTAVQDYV	CPQSGSHALCTCC	FOMP	173
QY	494	--	DRRAE	--	RQDPRVA	-----	PQCAVCTQPF	517
Db	174	S	AHAPESGREGDPEXAL	XXXPPVLGLHPORLFL	LAPF	:	:	212

RESULT 11	
ADA54231	
ID	ADA54231 standard; protein; 128 AA.
XX	
XX	
AC	ADA54231;
XX	
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Human protein, SEQ ID 1799.
XX	
XX	
KW	Cytostatic; Anti-inflammatory; Osteopathic; Neuroprotective; Nootropic;
KW	Gene Therapy; human; secretory protein; membrane proteins; cancer;
KW	Inflammatory disease; osteoporosis; neurological disease.

XX	Homo sapiens.	
OS		
XX		
PN	EP1293569-A2.	
XX		
PD	19-MAR-2003.	
XX		
PF	21-MAR-2002; 2002EP-00006586.	
XX		
PR	14-SEP-2001; 2001JP-00328381.	
PR	24-JAN-2002; 2002US-0350435P.	
XX		
XX	(HELI-) HELIX RES INST.	
PA	(KEAS-) RES ASSOC BIOTECHNOLOGY.	
PA		
XX		
XX	Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S, Imai Y, Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irrie R, Tamechika I, Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y,	
PI		
PI		
PI		
XX	WPI; 2003-395539/38.	
DR	N-PSDB; ADA52592.	
DR		

XX New polynucleotides encoding full-length polypeptides, e.g. secretory
PT and/or membrane proteins, useful for developing medicines for diseases in
PT which the gene is involved, or as target molecules for gene therapy.
XX

PS Claim 14; SEQ ID NO 1799; 205pp; English.

XX The present invention relates to novel human secretory or membrane
CC proteins (ADA54072-ADA55710) and their coding sequences (ADA52433-
CC ADA54071). The coding sequences are useful in the gene therapy of
CC diseases caused by abnormalities of the proteins, e.g. cancer,
CC inflammatory diseases, osteoporosis or neurological disease.
XX

XX Sequence 128 AA;
SQ

Query Match 15.8%; Score 566; DB 6; Length 128;
Best Local Similarity 99.0%; Pred. No. 5.9e-36;
Matches 103; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 561 KNYLATRGITWKNMLTESIALVQLQGVELLSDYRVGTGDTVLVCYCGGLSPRELTGYQRNI 620
DB 25 QNYLATRGITWKNMLTESIALVQLQGVELLSDYRVGTGDTVLVCYCGGLSPRELTGYQRNI 84

QY 621 PASELPVAVTSRDCYWGNCRTQVKAHAMKFNHICEQTRFKN 664
DB 85 PASELPVAVTSRDCYWGNCRTQVKAHAMKFNHICEQTRFKN 128

RESULT 12
AAU16156
ID ID AAU16156 standard; protein; 92 AA.
XX AC AAU16156;
AC
XX
DT DT 07-NOV-2001 (first entry)
XX
DE DE Human novel secreted protein, Seq ID 1109.
XX
KW Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiac; vasotropic; cerebroprotective; neutropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
XX preservative; antiproliferative.
XX
OS Homo sapiens.
XX
PN WO2001155322-A2.
XX
PP 02-AUG-2001.
XX
PP 17-JAN-2001; 2001WO-US001341.
XX
PP 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-020515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 28-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.

PR	14-AUG-2000;	2000US-0225266P;
PR	14-AUG-2000;	2000US-0225267P;
PR	14-AUG-2000;	2000US-0225268P;
PR	14-AUG-2000;	2000US-0225270P;
PR	14-AUG-2000;	2000US-0225447P;
PR	14-AUG-2000;	2000US-0225575P;
PR	14-AUG-2000;	2000US-0225758P;
PR	14-AUG-2000;	2000US-0225759P;
PR	18-AUG-2000;	2000US-0226279P;
PR	22-AUG-2000;	2000US-0226681P;
PR	22-AUG-2000;	2000US-0226868P;
PR	22-AUG-2000;	2000US-0227182P;
PR	23-AUG-2000;	2000US-0227809P;
PR	30-AUG-2000;	2000US-0228924P;
PR	01-SEP-2000;	2000US-0229287P;
PR	01-SEP-2000;	2000US-0229343P;
PR	01-SEP-2000;	2000US-0229344P;
PR	01-SEP-2000;	2000US-0229345P;
PR	05-SEP-2000;	2000US-0229509P;
PR	05-SEP-2000;	2000US-0229551P;
PR	06-SEP-2000;	2000US-0230437P;
PR	06-SEP-2000;	2000US-0230438P;
PR	08-SEP-2000;	2000US-0231242P;
PR	08-SEP-2000;	2000US-0231243P;
PR	08-SEP-2000;	2000US-0231244P;
PR	08-SEP-2000;	2000US-0231413P;
PR	08-SEP-2000;	2000US-0231414P;
PR	08-SEP-2000;	2000US-0232080P;
PR	12-SEP-2000;	2000US-0232196P;
PR	14-SEP-2000;	2000US-0233297P;
PR	14-SEP-2000;	2000US-0233398P;
PR	14-SEP-2000;	2000US-0233399P;
PR	14-SEP-2000;	2000US-0233400P;
PR	14-SEP-2000;	2000US-0233401P;
PR	14-SEP-2000;	2000US-0233063P;
PR	14-SEP-2000;	2000US-0233064P;
PR	14-SEP-2000;	2000US-0233065P;
PR	21-SEP-2000;	2000US-0234223P;
PR	21-SEP-2000;	2000US-0234274P;
PR	25-SEP-2000;	2000US-0234997P;
PR	25-SEP-2000;	2000US-0234998P;
PR	26-SEP-2000;	2000US-0234984P;
PR	27-SEP-2000;	2000US-0235634P;
PR	27-SEP-2000;	2000US-0235635P;
PR	29-SEP-2000;	2000US-0236327P;
PR	29-SEP-2000;	2000US-0236327P;
PR	29-SEP-2000;	2000US-0237038P;
PR	02-OCT-2000;	2000US-0237039P;
PR	02-OCT-2000;	2000US-0237040P;
PR	13-OCT-2000;	2000US-0239335P;
PR	13-OCT-2000;	2000US-0239337P;
PR	20-OCT-2000;	2000US-0240906P;
PR	20-OCT-2000;	2000US-0241221P;
PR	20-OCT-2000;	2000US-0241785P;
PR	20-OCT-2000;	2000US-0241786P;
PR	20-OCT-2000;	2000US-0241787P;
PR	20-OCT-2000;	2000US-0241808P;
PR	20-OCT-2000;	2000US-0241809P;
PR	20-OCT-2000;	2000US-0241826P;
PR	01-NOV-2000;	2000US-0244617P;
PR	08-NOV-2000;	2000US-0246474P;
PR	08-NOV-2000;	2000US-0246475P;
PR	08-NOV-2000;	2000US-0246476P;
PR	08-NOV-2000;	2000US-0246477P;
PR	08-NOV-2000;	2000US-0246478P;
PR	08-NOV-2000;	2000US-0246523P;
PR	08-NOV-2000;	2000US-0246524P;

[illegible]

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI: 2001-488783/53.

N-PSDB: AAS26143.

New nucleic acid molecules encoding 461 human secreted proteins for diagnosing, preventing, treating or ameliorating medical conditions and used as food additives or preservatives.

Claim 11: SEO ID NO 1109; 980pp; English.

The invention relates to isolated nucleic acid molecules and their encoded proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to

CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed

Query Match 13.2%; Score 474; DB 4; Length 92;
Best Local Similarity 98.9%; Pred. No. 5.3e-29;
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MERPEEGKQSPPPQPGWGLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 60
Db 3 MERPEEGKQSPPPQPGWGLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 62

QY 61 CRIVVDEKSGQVLTEDTSTGTVINKLVV 90
Db 63 CRIVVDEKSGQVLTEDTSTGTVINKLVV 92

RESULT 13
ABU55225
ID ABU55225 standard; protein; 92 AA.
XX AC ABU55225;
XX DT 18-MAR-2003 (first entry)
XX DE Human novel polypeptide #312.
XX KW Human; neural disorder; immune system disorder; renal disorder;
XX muscular disorder; respiratory disease; reproductive disorder;
XX gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
XX hyperproliferative disorder; inflammatory disease; allergic reaction;
XX blood related disorder; cancer; immunosuppressive; antiinflammatory;
XX cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
XX haemostatic; antiarteriosclerotic.
XX OS Homo sapiens.
XX PN US2002132753-A1.
XX PD 19-SEP-2002.
XX PF 17-JAN-2001; 2001US-00764864.
XX PR 31-JAN-2000; 2000US-0179065P.
XX PR 04-FEB-2000; 2000US-0180628P.
XX PR 28-JUN-2000; 2000US-0214886P.
XX PR 07-JUL-2000; 2000US-0216647P.
XX PR 07-JUL-2000; 2000US-0216880P.
XX PR 11-JUL-2000; 2000US-0217487P.
XX PR 11-JUL-2000; 2000US-0217496P.
XX PR 14-JUL-2000; 2000US-0218290P.
XX PR 26-JUL-2000; 2000US-0220963P.
XX PR 26-JUL-2000; 2000US-0220964P.
XX PR 14-AUG-2000; 2000US-0224518P.
XX PR 14-AUG-2000; 2000US-0224519P.
XX PR 14-AUG-2000; 2000US-0225267P.
XX PR 14-AUG-2000; 2000US-0225268P.
XX PR 14-AUG-2000; 2000US-0225270P.
XX PR 14-AUG-2000; 2000US-0225447P.
XX PR 14-AUG-2000; 2000US-0225757P.
XX PR 14-AUG-2000; 2000US-0225758P.
XX PR 22-AUG-2000; 2000US-0226868P.
XX PR 30-AUG-2000; 2000US-0228924P.
XX PR 01-SEP-2000; 2000US-0229287P.
XX PR 01-SEP-2000; 2000US-0229343P.
XX PR 01-SEP-2000; 2000US-0229344P.
XX PR 01-SEP-2000; 2000US-0229345P.
XX PR 05-SEP-2000; 2000US-0229509P.
XX PR 05-SEP-2000; 2000US-0229513P.
XX PR 08-SEP-2000; 2000US-0231413P.

PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251869P.
XX (ROSE/) ROSEN C A.
XX (RUBE/) RUBEN S M.
XX (BARA/) BARASH S C.
XX Rosen CA, Ruben SM, Barash SC;
XX WPI: 2003-147444/14.
XX N-PSDB; ABX73484.
XX New polypeptides and nucleic acids, useful in gene therapy for treating,
XX inhibiting or preventing e.g. neural, immune system, muscular,
XX respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
XX renal disorders.
XX Claim 11; SEQ ID NO 1109; 402pp; English.
XX The invention relates to human novel polypeptides and their associated
XX polynucleotides. The polypeptides and polynucleotides are useful in gene
XX therapy for treating, inhibiting or preventing neural disorders, immune
XX system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
XX and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
XX nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
XX gastrointestinal disorders, pulmonary disorders, cardiovascular disorders,
XX (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
XX heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
XX renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
XX leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
XX appendicitis), allergic reactions and conditions (e.g. asthma), blood
XX related disorders (e.g. thrombosis, atherosclerosis and myocardial
XX infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
XX ABU55748 represent human novel polypeptides of the invention

Sequence 92 AA;
Query Match 13.2%; Score 474; DB 6; Length 92;
Best Local Similarity 98.9%; Pred. No. 5.3e-29;
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MERPEEGKQSPPPQPGWGLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 60
Db 3 MERPEEGKQSPPPQPGWGLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 62

QY 61 CRIVVDEKSGQVLTEDTSTGTVINKLVV 90
Db 63 CRIVVDEKSGQVLTEDTSTGTVINKLVV 92

RESULT 14
AAU16157

ID	AAU16157 standard; protein; 99 AA.	PR	08-SEP-2000;	2000US-0231413P.
XX	AAU16157;	PR	08-SEP-2000;	2000US-0231414P.
AC	AAU16157;	PR	08-SEP-2000;	2000US-0232080P.
XX	07-NOV-2001 (first entry)	PR	08-SEP-2000;	2000US-0232081P.
DT	Human novel secreted protein, Seq ID 1110.	PR	12-SEP-2000;	2000US-0231968P.
XX		PR	14-SEP-2000;	2000US-0232397P.
DE		PR	14-SEP-2000;	2000US-0232398P.
XX		PR	14-SEP-2000;	2000US-0232399P.
KW	Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;	PR	14-SEP-2000;	2000US-0232400P.
KW	cardiac; vasotropic; cerebroprotective; nootropic; neuroprotective;	PR	14-SEP-2000;	2000US-0232401P.
KW	antibacterial; virucide; fungicide; ophthalmological; vulnerary;	PR	14-SEP-2000;	2000US-0233063P.
KW	secreted protein; rheumatoid arthritis; hyperproliferative disorder;	PR	14-SEP-2000;	2000US-0233064P.
KW	cardiovascular disorder; cardiac arrest; cerebrovascular disorder;	PR	14-SEP-2000;	2000US-0233065P.
KW	cerebral ischaemia; angiogenesis; nervous system disorder;	PR	21-SEP-2000;	2000US-0234223P.
KW	Alzheimer's disease; infection; ocular disorder; corneal infection;	PR	21-SEP-2000;	2000US-0234274P.
KW	wound healing; epithelial cell proliferation; skin ageing; food additive;	PR	25-SEP-2000;	2000US-0234998P.
KW	preservative; antiproliferative.	PR	26-SEP-2000;	2000US-0235484P.
XX		PR	27-SEP-2000;	2000US-0235834P.
OS	Homo sapiens.	PR	27-SEP-2000;	2000US-0235836P.
XX		PR	29-SEP-2000;	2000US-0236327P.
XX		PR	29-SEP-2000;	2000US-0236367P.
PN	WO20015322-A2.	PR	29-SEP-2000;	2000US-0236368P.
XX		PR	29-SEP-2000;	2000US-0236369P.
PD	02-AUG-2001.	PR	29-SEP-2000;	2000US-0236370P.
XX		PR	02-OCT-2000;	2000US-0236802P.
PF	17-JAN-2001; 2001WO-US001341.	PR	02-OCT-2000;	2000US-0237037P.
XX		PR	02-OCT-2000;	2000US-0237038P.
PR	31-JAN-2000; 2000US-0179065P.	PR	02-OCT-2000;	2000US-0237039P.
PR	04-FEB-2000; 2000US-0180628P.	PR	02-OCT-2000;	2000US-0237040P.
PR	24-FEB-2000; 2000US-0184664P.	PR	13-OCT-2000;	2000US-0239935P.
PR	02-MAR-2000; 2000US-0186350P.	PR	13-OCT-2000;	2000US-0239937P.
PR	16-MAR-2000; 2000US-0189874P.	PR	20-OCT-2000;	2000US-0240960P.
PR	17-MAR-2000; 2000US-0190076P.	PR	20-OCT-2000;	2000US-0241211P.
PR	18-APR-2000; 2000US-0198123P.	PR	20-OCT-2000;	2000US-0241785P.
PR	19-MAY-2000; 2000US-0205515P.	PR	20-OCT-2000;	2000US-0241786P.
PR	07-JUN-2000; 2000US-0209467P.	PR	20-OCT-2000;	2000US-0241787P.
PR	28-JUN-2000; 2000US-0214886P.	PR	20-OCT-2000;	2000US-0241808P.
PR	30-JUN-2000; 2000US-0215135P.	PR	20-OCT-2000;	2000US-0241809P.
PR	07-JUL-2000; 2000US-0215647P.	PR	20-OCT-2000;	2000US-0241826P.
PR	07-JUL-2000; 2000US-0216880P.	PR	01-NOV-2000;	2000US-024617P.
PR	11-JUL-2000; 2000US-0217487P.	PR	08-NOV-2000;	2000US-0246474P.
PR	11-JUL-2000; 2000US-0217496P.	PR	08-NOV-2000;	2000US-0246475P.
PR	14-JUL-2000; 2000US-0218290P.	PR	08-NOV-2000;	2000US-0246476P.
PR	26-JUL-2000; 2000US-0220963P.	PR	08-NOV-2000;	2000US-0246477P.
PR	26-JUL-2000; 2000US-0220964P.	PR	08-NOV-2000;	2000US-0246478P.
PR	14-AUG-2000; 2000US-0224518P.	PR	08-NOV-2000;	2000US-0246523P.
PR	14-AUG-2000; 2000US-0224519P.	PR	08-NOV-2000;	2000US-0246524P.
PR	14-AUG-2000; 2000US-0225213P.	PR	08-NOV-2000;	2000US-0246525P.
PR	14-AUG-2000; 2000US-0225214P.	PR	08-NOV-2000;	2000US-0246526P.
PR	14-AUG-2000; 2000US-0225266P.	PR	08-NOV-2000;	2000US-0246527P.
PR	14-AUG-2000; 2000US-0225267P.	PR	08-NOV-2000;	2000US-0246528P.
PR	14-AUG-2000; 2000US-0225268P.	PR	08-NOV-2000;	2000US-0246532P.
PR	14-AUG-2000; 2000US-0225270P.	PR	08-NOV-2000;	2000US-0246609P.
PR	14-AUG-2000; 2000US-0225447P.	PR	08-NOV-2000;	2000US-0246610P.
PR	14-AUG-2000; 2000US-0225477P.	PR	08-NOV-2000;	2000US-0246611P.
PR	14-AUG-2000; 2000US-0225758P.	PR	08-NOV-2000;	2000US-0246613P.
PR	14-AUG-2000; 2000US-0225759P.	PR	17-NOV-2000;	2000US-0249207P.
PR	18-AUG-2000; 2000US-0226279P.	PR	17-NOV-2000;	2000US-0249208P.
PR	22-AUG-2000; 2000US-0226681P.	PR	17-NOV-2000;	2000US-0249209P.
PR	22-AUG-2000; 2000US-0226688P.	PR	17-NOV-2000;	2000US-0249210P.
PR	22-AUG-2000; 2000US-0227182P.	PR	17-NOV-2000;	2000US-0249211P.
PR	23-AUG-2000; 2000US-0227009P.	PR	17-NOV-2000;	2000US-0249212P.
PR	30-AUG-2000; 2000US-0228242P.	PR	17-NOV-2000;	2000US-0249213P.
PR	01-SEP-2000; 2000US-0229287P.	PR	17-NOV-2000;	2000US-0249214P.
PR	01-SEP-2000; 2000US-0229343P.	PR	17-NOV-2000;	2000US-0249215P.
PR	01-SEP-2000; 2000US-0229344P.	PR	17-NOV-2000;	2000US-0249216P.
PR	01-SEP-2000; 2000US-0229345P.	PR	17-NOV-2000;	2000US-0249217P.
PR	05-SEP-2000; 2000US-0229509P.	PR	17-NOV-2000;	2000US-0249218P.
PR	05-SEP-2000; 2000US-0229513P.	PR	17-NOV-2000;	2000US-0249244P.
PR	08-SEP-2000; 2000US-0230437P.	PR	17-NOV-2000;	2000US-0249245P.
PR	06-SEP-2000; 2000US-0230438P.	PR	17-NOV-2000;	2000US-0249246P.
PR	08-SEP-2000; 2000US-0231242P.	PR	17-NOV-2000;	2000US-0249247P.
PR	08-SEP-2000; 2000US-0231243P.	PR	17-NOV-2000;	2000US-0249248P.
PR	08-SEP-2000; 2000US-0231244P.	PR	17-NOV-2000;	2000US-0249249P.
PR	08-SEP-2000; 2000US-0231245P.	PR	17-NOV-2000;	2000US-0249250P.
PR	08-SEP-2000; 2000US-0231246P.	PR	17-NOV-2000;	2000US-0249251P.
PR	08-SEP-2000; 2000US-0231247P.	PR	17-NOV-2000;	2000US-0249252P.
PR	08-SEP-2000; 2000US-0231248P.	PR	17-NOV-2000;	2000US-0249253P.
PR	08-SEP-2000; 2000US-0231249P.	PR	17-NOV-2000;	2000US-0249254P.
PR	08-SEP-2000; 2000US-0231250P.	PR	17-NOV-2000;	2000US-0249255P.
PR	08-SEP-2000; 2000US-0231251P.	PR	17-NOV-2000;	2000US-0249256P.
PR	08-SEP-2000; 2000US-0231252P.	PR	17-NOV-2000;	2000US-0249257P.
PR	08-SEP-2000; 2000US-0231253P.	PR	17-NOV-2000;	2000US-0249258P.
PR	08-SEP-2000; 2000US-0231254P.	PR	17-NOV-2000;	2000US-0249259P.
PR	08-SEP-2000; 2000US-0231255P.	PR	17-NOV-2000;	2000US-0249260P.
PR	08-SEP-2000; 2000US-0231256P.	PR	17-NOV-2000;	2000US-0249261P.
PR	08-SEP-2000; 2000US-0231257P.	PR	17-NOV-2000;	2000US-0249262P.
PR	08-SEP-2000; 2000US-0231258P.	PR	17-NOV-2000;	2000US-0249263P.
PR	08-SEP-2000; 2000US-0231259P.	PR	17-NOV-2000;	2000US-0249264P.
PR	08-SEP-2000; 2000US-0231260P.	PR	17-NOV-2000;	2000US-0249265P.
PR	08-SEP-2000; 2000US-0231261P.	PR	17-NOV-2000;	2000US-0249266P.
PR	08-SEP-2000; 2000US-0231262P.	PR	17-NOV-2000;	2000US-0249267P.
PR	08-SEP-2000; 2000US-0231263P.	PR	17-NOV-2000;	2000US-0249268P.
PR	08-SEP-2000; 2000US-0231264P.	PR	17-NOV-2000;	2000US-0249269P.
PR	08-SEP-2000; 2000US-0231265P.	PR	17-NOV-2000;	2000US-0249270P.
PR	08-SEP-2000; 2000US-0231266P.	PR	17-NOV-2000;	2000US-0249271P.
PR	08-SEP-2000; 2000US-0231267P.	PR	17-NOV-2000;	2000US-0249272P.
PR	08-SEP-2000; 2000US-0231268P.	PR	17-NOV-2000;	2000US-0249273P.
PR	08-SEP-2000; 2000US-0231269P.	PR	17-NOV-2000;	2000US-0249274P.
PR	08-SEP-2000; 2000US-0231270P.	PR	17-NOV-2000;	2000US-0249275P.
PR	08-SEP-2000; 2000US-0231271P.	PR	17-NOV-2000;	2000US-0249276P.
PR	08-SEP-2000; 2000US-0231272P.	PR	17-NOV-2000;	2000US-0249277P.
PR	08-SEP-2000; 2000US-0231273P.	PR	17-NOV-2000;	2000US-0249278P.
PR	08-SEP-2000; 2000US-0231274P.	PR	17-NOV-2000;	2000US-0249279P.
PR	08-SEP-2000; 2000US-0231275P.	PR	17-NOV-2000;	2000US-0249280P.
PR	08-SEP-2000; 2000US-0231276P.	PR	17-NOV-2000;	2000US-0249281P.
PR	08-SEP-2000; 2000US-0231277P.	PR	17-NOV-2000;	2000US-0249282P.
PR	08-SEP-2000; 2000US-0231278P.	PR	17-NOV-2000;	2000US-0249283P.
PR	08-SEP-2000; 2000US-0231279P.	PR	17-NOV-2000;	2000US-0249284P.
PR	08-SEP-2000; 2000US-0231280P.	PR	17-NOV-2000;	2000US-0249285P.
PR	08-SEP-2000; 2000US-0231281P.	PR	17-NOV-2000;	2000US-0249286P.
PR	08-SEP-2000; 2000US-0231282P.	PR	17-NOV-2000;	2000US-0249287P.
PR	08-SEP-2000; 2000US-0231283P.	PR	17-NOV-2000;	2000US-0249288P.
PR	08-SEP-2000; 2000US-0231284P.	PR	17-NOV-2000;	2000US-0249289P.
PR	08-SEP-2000; 2000US-0231285P.	PR	17-NOV-2000;	2000US-0249290P.
PR	08-SEP-2000; 2000US-0231286P.	PR	17-NOV-2000;	2000US-0249291P.
PR	08-SEP-2000; 2000US-0231287P.	PR	17-NOV-2000;	2000US-0249292P.
PR	08-SEP-2000; 2000US-0231288P.	PR	17-NOV-2000;	2000US-0249293P.
PR	08-SEP-2000; 2000US-0231289P.	PR	17-NOV-2000;	2000US-0249294P.
PR	08-SEP-2000; 2000US-0231290P.	PR	17-NOV-2000;	2000US-0249295P.
PR	08-SEP-2000; 2000US-0231291P.	PR	17-NOV-2000;	2000US-0249296P.
PR	08-SEP-2000; 2000US-0231292P.	PR	17-NOV-2000;	2000US-0249297P.
PR	08-SEP-2000; 2000US-0231293P.	PR	17-NOV-2000;	2000US-0249298P.
PR	08-SEP-2000; 2000US-0231294P.	PR	17-NOV-2000;	2000US-0249299P.
PR	08-SEP-2000; 2000US-0231295P.	PR	17-NOV-2000;	2000US-0249300P.
PR	08-SEP-2000; 2000US-0231296P.	PR	17-NOV-2000;	2000US-0249301P.
PR	08-SEP-2000; 2000US-0231297P.	PR	17-NOV-2000;	2000US-0249302P.
PR	08-SEP-2000; 2000US-0231298P.	PR	17-NOV-2000;	2000US-0249303P.
PR	08-SEP-2000; 2000US-0231299P.	PR	17-NOV-2000;	2000US-0249304P.
PR	08-SEP-2000; 2000US-0231300P.	PR	17-NOV-2000;	2000US-0249305P.
PR	08-SEP-2000; 2000US-0231301P.	PR	17-NOV-2000;	2000US-0249306P.
PR	08-SEP-2000; 2000US-0231302P.	PR	17-NOV-2000;	2000US-0249307P.
PR	08-SEP-2000; 2000US-0231303P.	PR	17-NOV-2000;	2000US-0249308P.
PR	08-SEP-2000; 2000US-0231304P.	PR	17-NOV-2000;	2000US-0249309P.
PR	08-SEP-2000; 2000US-0231305P.	PR	17-NOV-2000;	2000US-0249310P.
PR	08-SEP-2000; 2000US-0231306P.	PR	17-NOV-2000;	2000US-0249311P.
PR	08-SEP-2000; 2000US-0231307P.	PR	17-NOV-2000;	2000US-0249312P.
PR	08-SEP-2000; 2000US-0231308P.	PR	17-NOV-2000;	2000US-0249313P.
PR	08-SEP-2000; 2000US-0231309P.	PR	17-NOV-2000;	2000US-0249314P.
PR	08-SEP-2000; 2000US-0231310P.	PR	17-NOV-2000;	2000US-0249315P.
PR	08-SEP-2000; 2000US-0231311P.	PR	17-NOV-2000;	2000US-0249316P.
PR	08-SEP-2000; 2000US-0231312P.	PR	17-NOV-2000;	2000US-0249317P.
PR	08-SEP-2000; 2000US-0231313P.	PR	17-NOV-2000;	2000US-0249318P.
PR	08-SEP-2000; 2000US-0231314P.	PR	17-NOV-2000;	2000US-0249319P.
PR	08-SEP-2000; 2000US-0231315P.	PR	17-NOV-2000;	2000US-0249320P.
PR	08-SEP-2000; 2000US-0231316P.	PR	17-NOV-2000;	2000US-0249321P.
PR	08-SEP-2000; 2000US-0231317P.	PR	17-NOV-2000;	2000US-0249322P.
PR	08-SEP-2000; 2000US-0231318P.	PR	17-NOV-2000;	2000US-0249323P.
PR	08-SEP-2000; 2000US-0231319P.	PR	17-NOV-2000;	2000US-0249324P.
PR	08-SEP-2000; 2000US-0231320P.	PR	17-NOV-2000;	2000US-0249325P.
PR	08-SEP-2000; 2000US-0231321P.	PR	17-NOV-2000;	2000US-0249326P.
PR	08-SEP-2000; 2000US-0231322P.	PR	17-NOV-2000;	2000US-0249327P.
PR	08-SEP-2000; 2000US-0231323P.	PR	17-NOV-2000;	2000US-0249328P.
PR	08-SEP-2000; 2000US-0231324P.	PR	17-NOV-2000;	2000US-0249329P.
PR	08-SEP-2000; 2000US-0231325P.	PR	17-NOV-2000;	2000US-0249330

PR 17-NOV-2000; 2000US-02492972.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 05-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254087P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-488783/53.
XX N-PSDB; AAS26144.
XX
XX New nucleic acid molecules encoding 461 human secreted proteins for
PT diagnosing, preventing, treating or ameliorating medical conditions and
PT used as food additives or preservatives.
XX
XX Claim 11; SEQ ID NO 1110; 980pp; English.
XX
XX The invention relates to isolated nucleic acid molecules and their
CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiodysplasia,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed
Query Match 12.1%; Score 432; DB 4; Length 99;
Best Local Similarity 92.3%; Pred. No. 1.1e-25;
Matches 86; Conservative 1; Mismatches 4; Indels 2; Gaps 1;
QY 42 RRGCDLSPFNKLVSDHCRIVVDEKSGQVLTSTGTVINKLVKVKQTCPIQTGD 101
Db 9 RDRGPD--FPXKLVSDHCRIVVDEKSGQVLTSTGTVINKLVKVKQTCPIQTGD 66
QY 102 VIVLVYRNKPEHNVAYLYESLSEKQGMTCESF 134
Db 67 VIVLVYRNKPEHNVAYLYESLSEKQGMTCESF 99
RESULT 15
AAU16576
ID AAU16576 standard; protein; 99 AA.
XX
XX AAU16576;
AC

XX
DT 07-NOV-2001 (first entry)
XX
DE Human novel secreted protein, Seq ID 1529.
XX
KW Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnery;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
OS
XX Homo sapiens.
XX WO200155322-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001341.
XX
XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 23-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.

PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0241826P.
PR 08-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.

PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 11-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX WPI; 2001-498783/53.
XX N-PSDB; AAS26563.
XX
XX New nucleic acid molecules encoding 461 human secreted proteins for
XX diagnosing, preventing, treating or ameliorating medical conditions and
XX used as food additives or preservatives.
XX
XX Claim 11; SEQ ID NO 1529; 980pp; English.
XX
XX The invention relates to isolated nucleic acid molecules and their
XX encoded secreted proteins. The nucleic acids and proteins are used to
XX prevent, treat or ameliorate a medical condition in e.g. humans, mice,
XX rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
XX in diagnosing a pathological condition or susceptibility to a
XX pathological condition. Antibodies to the proteins can also be used in
XX alleviating symptoms associated with the disorders and in diagnostic
XX immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays
XX (ELISA). Disorders which are diagnosed or treated include autoimmune
XX diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
XX neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
XX arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
XX nervous system disorders e.g. Alzheimer's disease, infections caused by
XX bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
XX and many other disorders listed in the specification. The polypeptides
XX can also be used to aid wound healing and epithelial cell proliferation,
XX to prevent skin aging due to sunburn, to maintain organs before
XX transplantation, for supporting cell culture of primary tissues, to
XX regenerate tissues and in chemotaxis. The polypeptides can also be used
XX as a food additive or preservative to increase or decrease storage
XX capabilities, fat content, lipid, protein, carbohydrate, vitamins,
XX minerals, cofactors and other nutritional components. The present
XX sequence represents a novel secreted protein of the invention. Note: The
XX sequence data for this patent did not form part of the printed

Query Match 12.1%; Score 432; DB 4; Length 99;
Best Local Similarity 92.5%; Pred. No. 1, 1e-25;
Matches 86; Conservative 1; Mismatches 4; Indels 2; Gaps 1;
Qy 42 RRGCDLSPSPNKLVSQDHCRIWVDEKSGQVLTSTSGTVINKLVKVKQTCLQTGD 101
Db 9 RDKGPD--FPXNKLVSQDHCRIWVDEKSGQVLTSTSGTVINKLVKVKQTCLQTGD 66
Qy 102 VYLVYKNEPEHNVAYLESSEKQGMTOESF 134
Db 67 VYLVYKNEPEHNVAYLESSEKQGMTOESF 99

Search completed: May 7, 2004, 14:45:44
Job time : 139.275 secs

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:42:23 ; Search time 44.1732 Seconds

(without alignments)
776.028 Million cell updates/sec

Title: US-10-048-046-

Perfect score: 3585

Sequence: 1 MERPEEGKQSPPPQPWGRLL.....VKAHAMKFNHICEQTRFKN 664

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 200000000
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

POST-PROCESSING: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

```

database :
1: /cqn2 6/ptodata/2/iaa/5A COMB.pep:*

```

2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*

3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*

4: /cgn2_6/ptodata/2/iaa/6B_COMB.pcp.*

5: /cgn2_6/ptodata/2/iaa/pctus_comb.per

6: /cgn2_6/ptodata/2/iaa/backfiles1.per

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	152	4.2	245	2	US-08-897-340-36	Sequence 36, Appl
2	152	4.2	245	3	US-09-252-329-36	Sequence 36, Appl
3	135	3.8	67	1	US-07-945-283-7	Sequence 7, Appl
4	135	3.8	245	2	US-08-897-340-35	Sequence 35, Appl
5	135	3.8	245	3	US-09-252-329-35	Sequence 35, Appl
6	134.5	3.8	826	4	US-09-894-998A-47	Sequence 47, Appl
7	132.5	3.7	2414	1	US-08-227-536-2	Sequence 2, Appl
8	132.5	3.7	2414	5	FCI-US95-04682-2	Sequence 2, Appl
9	131	3.7	1848	3	US-08-296-791-6	Sequence 6, Appl
10	131	3.7	1848	4	US-09-839-996-6	Sequence 6, Appl
11	131	3.7	1848	4	US-10-080-505-6	Sequence 6, Appl
12	131	3.7	1848	5	FCI-US95-10661A-6	Sequence 6, Appl
13	127.5	3.6	989	4	US-08-213-419B-4	Sequence 4, Appl
14	126.5	3.5	933	3	US-08-764-870-14	Sequence 14, Appl
15	126.5	3.5	933	3	US-08-980-115-14	Sequence 14, Appl
16	125.5	3.5	989	4	US-08-213-419B-2	Sequence 2, Appl
17	125	3.5	2482	4	US-09-252-991A-16967	Sequence 16967, A
18	123.5	3.4	1233	4	US-09-688-188B-89	Sequence 89, Appl
19	123.5	3.4	1233	4	US-09-291-417D-89	Sequence 89, Appl
20	123	3.4	395	2	US-08-841-349-9	Sequence 9, Appl
21	123	3.4	395	4	US-09-431-184A-9	Sequence 9, Appl
22	122	3.4	778	6	5198347-4	Patent No. 5198347
23	121.5	3.4	848	1	US-08-045-806-4	Sequence 4, Appl
24	121.5	3.4	848	1	US-08-366-051B-4	Sequence 4, Appl
25	121.5	3.4	1719	2	US-08-459-568-4	Sequence 4, Appl
26	121.5	3.4	1719	2	US-08-399-411-4	Sequence 4, Appl
27	121.5	3.4	1719	3	US-08-516-859A-4	Sequence 4, Appl

28	121.5	3.4	1719	4	US-09-586-472-4	Sequence 4, Appl
29	121.5	3.4	1719	4	US-09-528-706-4	Sequence 4, Appl
30	120.5	3.4	326	2	US-08-786-606-8	Sequence 8, Appl
31	120.5	3.4	797	4	US-09-417-197-141	Sequence 141, App
32	120.5	3.4	808	4	US-08-971-188-12	Sequence 12, Appl
33	120.3	3.3	984	1	US-08-257-073-3	Sequence 3, Appl
34	120.3	3.3	984	1	US-08-184-009-120	Sequence 120, App
35	120.3	3.3	984	2	US-08-458-356-120	Sequence 120, App
36	120.3	3.3	984	3	US-08-460-736-120	Sequence 120, App
37	120.3	3.3	984	4	US-09-535-370-120	Sequence 120, App
38	119.5	3.3	381	4	US-09-563-608-200	Sequence 200, App
39	119	3.3	8991	4	US-08-714-741-32	Sequence 32, Appl
40	117.5	3.3	381	2	US-08-867-057-1	Sequence 1, Appl
41	117.5	3.3	381	2	US-09-128-369-1	Sequence 1, Appl
42	117.5	3.3	605	2	US-08-689-402-2	Sequence 2, Appl
43	117.5	3.3	381	4	US-09-107-5328-7146	Sequence 7146, Ap
44	117	3.4	223	4	US-09-327-983-5	Sequence 5, Appl
45	116.5	3.2	2441	1	US-08-194-468-2	Sequence 2, Appl

ALIGNMENTS

RESULT 1
 US-08-897-340-36
 ; Sequence 36, Application US/08897340
 ; Patent No. 595306
 ; GENERAL INFORMATION:
 ; APPLICANT: Glimeno, Carlos J. and Errada, Patrick, R.
 ; TITLE OF INVENTION: Weight Control Pathway Genes and Uses
 ; TITLE OF INVENTION: Therefor
 ; NUMBER OF SEQUENCES: 36
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: LAHIVE & COCKFIELD, LLP
 ; STREET: 28 State Street
 ; CITY: Boston
 ; STATE: Massachusetts
 ; COUNTRY: USA
 ; ZIP: 02109
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/897,340
 ; FILING DATE:
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/715,032
 ; FILING DATE: 17-SEP-1996
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Silveri, Jean M.
 ; REGISTRATION NUMBER: 39,030
 ; REFERENCE/DOCKET NUMBER: NMI-005CP
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (617)227-7400
 ; TELEFAX: (617)227-5941
 ; INFORMATION FOR SEQ ID NO: 36:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 245 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; FRAGMENT TYPE: internal
 ; US-08-897-340-36

```
Query Match      : 4.2%; Score 152; DB 2; Length 245;
Best Local Similarity 27.4%; Pred. No. 5.3e-05;
```

286 EDVRAAGKPKMEETLTICIQDLLHDCVSLQPCMHTFCAACYSGWMERSSL-CPTCRC 344 OV

Db 3 EELSAAT---SYTDDFYCPVCQVLTPTVTAACQHVFCRCKFLTAMRESGIHCPLCRG 59
QY 345 PV---ERICKNHIL-----NNLVEAYLIQHPDKS-----RSEEDVQSNDA 381
Db 60 SVTRERACPERALDENIMRFRSGSCCKKIKFYRHHYKSKYQYGVGVSSVIP 119
QY 382 RNKITQDMLQPKVRRFSDEGSSDLLELSDVDSESSDISQPVVCRQCP---YRQ-- 437
Db 120 NFKISQDSV-----RSSNRSETSASDNTETQEDTSSS---GHPTFKCPLCQESNFTQRL 172
QY 438 -----AAQPPHCP-----APEGEP 451
Db 173 LDHCNSNHLFQIVPVTCFICVSLPWGDP 200

RESULT 2

US-09-252-329-36
; Sequence 36, Application US/09252329
; Patent No. 6147192
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Carlos J. and Errada, Patrick, R.
; TITLE OF INVENTION: Weight Control Pathway Genes and Uses
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/252,329
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/897,340
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Silveri, Jean M.
; REGISTRATION NUMBER: 39,030
; REFERENCE/DOCKET NUMBER: MNI-005CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 245 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
US-09-252-329-36

Query Match 4.2%; Score 152; DB 3; Length 245;
Best Local Similarity 27.4%; Pred. No. 5.3e-05;
Matches 57; Conservative 22; Mismatches 77; Indels 52; Gaps 10;
QY 286 EDVRAAGKPDKMEETLTICIQDLHDCVSLQPCNHTFCACYSYSGWMSRL-CPTCRC 344
Db 3 EELSAAT---SYTDDFYCPVCQVLTPTVTAACQHVFCRCKFLTAMRESGIHCPLCRG 59
QY 345 PV---ERICKNHIL-----NNLVEAYLIQHPDKS-----RSEEDVQSNDA 381
Db 60 SVTRERACPERALDENIMRFRSGSCCKKIKFYRHHYKSKYQYGVGVSSVIP 119
QY 382 RNKITQDMLQPKVRRFSDEGSSDLLELSDVDSESSDISQPVVCRQCP---YRQ-- 437

Db 120 NFKISQDSV-----RSSNRSETSASDNTETQEDTSSS---GHPTFKCPLCQESNFTQRL 172
QY 438 -----AAQPPHCP-----APEGEP 451
Db 173 LDHCNSNHLFQIVPVTCFICVSLPWGDP 200

RESULT 3

US-07-945-283-7
; Sequence 7, Application US/07945283
; Patent No. 5352596
; GENERAL INFORMATION:
; APPLICANT: Cheung, Andrew K.
; APPLICANT: Wesley, Ronald D.
; TITLE OF INVENTION: Pseudorabies Virus Deletion Mutants
; TITLE OF INVENTION: Involving The EPO and LIT Genes
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Curtis P. Ribando
; STREET: 1815 No. 5352596th University Street
; CITY: Peoria
; STATE: IL
; COUNTRY: USA
; ZIP: 61604
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/945,283
; FILING DATE: 19920911
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Ribando, Curtis P.
; REGISTRATION NUMBER: 27976
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 309-685-4011 ext.513
; TELEFAX: 309-685-4128
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 67 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: Varicella-zoster virus
US-07-945-283-7

Query Match 3.8%; Score 135; DB 1; Length 67;
Best Local Similarity 36.7%; Pred. No. 0.00022;
Matches 22; Conservative 6; Mismatches 32; Indels 0; Gaps 0;

QY 303 TCICQDLHDCVSLQPCNHTFCACYSYSGWMSRL-CPTCRCPVERICKHILNLVEAY 362
Db 5 TCTICMSTVSDLGKTMPCLDHDFCVCIRAWTSTVQCPLCRCPVQSLILHKIVSDTSYKEY 64

RESULT 4

US-08-897-340-35
; Sequence 35, Application US/08897340
; Patent No. 5953306
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Carlos J. and Errada, Patrick, R.
; TITLE OF INVENTION: Weight Control Pathway Genes and Uses
; TITLE OF INVENTION: Therefor
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts

```

; APPLICATION NUMBER: US/09/252,329
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/897,340
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Silveri, Jean M.
; REGISTRATION NUMBER: 39,030
; REFERENCE/DOCKET NUMBER: MNI-005CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 245 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FRAGMENT TYPE: internal
; US-09-252-329-35

Query Match 3.8%; Score 135; DB 3; Length 245;
Best Local Similarity 26.0%; Pred. No. 0.0015;
Matches 54; Conservative 23; Mismatches 79; Indels 52; Gaps 10;

QY 286 EDVRAAGKEDKMEETLTCTIIQDLLHDCVSLQPCMHFTCAACY-SGWMERSSLCPTCRC 344
Db 3 EDLSAAT---SVTEDDFCVQCVELKTPVTTTACQHFVCRKCFLTAMRESGAHCPLCRG 59
QY 345 PV---ERICKNHLN-----NIVEAYLICHDPKS-----RSEEDVQSMDA 381
Db 60 NVTTRERACPERALDLENTMRPFGSGRCRCAKQIKFYRMHHYKCKYQDEYGVSSIIIP 119
QY 382 RNKITQDMLQPKVRRFSDEGSSDLELSDVDSESSDISQPYVVCRCQPE--YRQ-- 437
Db 120 NQIISQDSVGNR-----SETSTSDNTYQENTSS--GHFTKCPCLCOESNFTQRL 172
QY 438 -----AAQPPHCP-----APEGEP 451
Db 173 LDHCNSNHLFQIVPVVTPICVSLPWGDP 200

RESULT 6
US-09-894-998A-47
; Sequence 47, Application US/09894998A
; Patent No. 6537555
; GENERAL INFORMATION:
; APPLICANT: Hosken, Nancy Ann
; APPLICANT: Craig H. Day
; APPLICANT: David C. Dillon
; APPLICANT: McGowan, Patrick
; APPLICANT: Sleath, Paul R.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; TITLE OF INVENTION: TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
; FILE REFERENCE: 210121.538
; CURRENT APPLICATION NUMBER: US/09/894,998A
; CURRENT FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 826
; TYPE: PRT
; ORGANISM: HSV-2
; US-09-894-998A-47

Query Match 3.8%; Score 134.5; DB 4; Length 826;
Best Local Similarity 22.0%; Pred. No. 0.01;
Matches 80; Conservative 33; Mismatches 129; Indels 121; Gaps 19

QY 152 GAGRGADP---RVPPSSPATQVCFEERPPQSTSTSDLEPTASASTEPSAG-----RE 201
Db 6 GTSRADGPGERPRTQPTGTPA--APHANGMLNDMQWLASSDSEETEVGISDDDLHRD 63

```

QY 202 RSSCGSGGGISPKSGSPVASDEVSPASALPDRKTASFSLSLEPQDQEDLEPVKKMR 261
 Db 64 STSEAG-----SDDTTFEAGLMDAAT-----PPARPPAERQ 96
 QY 262 GDGDLNLGOLLVAQPRNAQTVHEDVRAAAGKPKDMEETLCIIQDILLHDCVSLQ--P 319
 Db 97 SPTPADAQSC-----GGGFVGESEAEAGGGD-----VCAVCTDEIAPPLRCQSP 143
 QY 320 CMHFTCAACYSGWMSRSLCPTCRCPVERICKHILNVLVEAYLIQHPKSRSEEDVQSM 379
 Db 144 CLHPFCIPCKMTWILPLANTCLNTPV-----AYLIVGTASGSFSTPIV 189
 QY 380 -DARKKITQDMLQPKVRRSFSDEGSSDILL-----ELSL-----412
 Db 190 NDRPTRVEAEA-----AVRAGTAVDFITWGNPRTAPRSLSLGHTVRLSPPTPPW 240
 QY 413 DVDSESDISQ--PYV--VCEQCE-----YARQAQPHC-PAPEGEPAQ--ALG 458
 Db 241 GTDDEDDLDAGVDVPPAPRAPRRGGGAGATRGTSQAPATRAP-----PGAPRSSSG 297
 QY 459 DAP 461
 Db 298 GAP 300

RESULT 7

US-08-227-536-2
 ; Sequence 2, Application US/08227536
 ; Patent No. 5658784
 ; GENERAL INFORMATION:
 ; APPLICANT: Ecken, Richard
 ; APPLICANT: Ewen, Mark
 ; APPLICANT: Livingston, David
 ; TITLE OF INVENTION: NUCLEIC ACID, ENCODING TRANSCRIPTION
 ; TITLE OF INVENTION: FACTOR P300 AND USES OF P300
 ; NUMBER OF SEQUENCES: 13
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Weingarten, Schurgin, Gagnebin & Hayes
 ; STREET: Ten Post Office Square
 ; CITY: Boston
 ; STATE: MA
 ; COUNTRY: US
 ; ZIP: 02109

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA: US/08/227,536
 FILING DATE: 14-APR-1994
 CLASSIFICATION: 436
 ATTORNEY/AGENT INFORMATION:
 NAME: Williams Ph.D., Kathleen A.
 REGISTRATION NUMBER: 34,380
 REFERENCE/DOCKET NUMBER: DFCI-308XX
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (617) 542-2290
 TELEFAX: (617) 451-0313
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 2414 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein

US-08-227-536-2
 Query Match 3.7%; Score 132.5; DB 1; Length 2414;
 Best Local Similarity 21.4%; Pred. No. 0.078;
 Matches 128; Conservative 75; Mismatches 235; Indels 169; Gaps 31;
 QY 4 PEEKQSPFPQ-----PWGRLLAGAEGEPH-----VLL-----RKREWTI 40

Db 300 PNMGOQ--PAPVOQPPGLVTPVAQMGSGAHTADPEKRKLIQQOLVLLHAKHCORREAN 358
 QY 41 GRRRGCDLSF---PSNKLVSGDHCRIVWDEKSOVLTEDTSGTVINKLVKVVKQTCPL 97
 Db 359 GEVRQCNLPHCRTMKVNLNHTHCQ---SGKCOVA--HCASSRQIISHKWKTRHDCPV 413
 QY 98 -----QTGDVILYVRKNEPEHNVAVLYESLSKQKQTOESFE--ANKENVFHGYKDTSG 150
 Db 414 CLPLKXNAGD-----XNQOQPILTGAPVGLGNPSLGVGQCSAPNLTSTVSQIDPSSIERAY 468
 QY 151 AGAGRGADPRVPSSPATQVCFFEE--PQPSTSTSDLPFTASASTSTPSPAGRRSSSCSG 209
 Db 469 AALGLPQVQNMQTPQVQAKNQONQPGQSPQGMPEMNSA---SPMG-----VNG 518
 QY 210 GGGISPKSGSPVASDEVSPASALPDR-----KTASFSSLEPQD---QEDLEPVKKMR 261
 Db 519 GVGQVT-----PSLSD--SMLHSAINSQNMMSSENASVPSLGFMTAAQPSSTTGIRKQWH 572
 QY 262 GDGDLNLGOLLVAQPRNAQTVHEDVRAAAGKPD-----KMEETLTCT--ICQDLLH 312
 Db 573 EDITQDLRNLH-----VHKLVAQIFPTPDPAALKDRRMENLVAYARKVEGDMYE 621
 QY 313 DCVSLQPCMHFTCAACYSGWMSRSLCPTCRCPVERICKHILNN---LVEAYLIQHPDK 369
 Db 622 SANRAEYHLLAEKIYKIQKELEKRT-----RLQKNMLPNAAGHVPVSMPPGNM 675
 QY 370 SRSEEDVQSM-----ARNKITQDMLQPKVRRSFSDEGSSDILLSELSDVDESSDIS 422
 Db 676 GQPPGQMTSNGPLPDPDMIRGSPVNMMPRIITPQSGLNQFG-----QMSMA 721
 QY 423 QPVVCRQCP--RYRQAQAP-----PHCPAPEGE-----P 451
 Db 722 QPFIIVPQTPPLQHQHQLQALPGALPFGYGRPMQPSNQGFPLQTPFPSCGMVTHIP 781
 QY 452 GAOALGDAPSTSVLTAVQDVVCL-----QGSALCTCCFQMPDRRAEED 502
 Db 782 LAPSS--GOAPVSOAQWSSS-----SCPVNSPIMPPGSGSHHCPQLPQP-----ALHQS 831
 QY 503 PRVAPQ 509
 Db 832 PSPVSR 838

RESULT 8

PCT-US95-04682-2
 ; Sequence 2, Application PC/TUS9504682
 ; GENERAL INFORMATION:
 ; APPLICANT:
 ; TITLE OF INVENTION: NUCLEIC ACID ENCODING TRANSCRIPTION
 ; TITLE OF INVENTION: FACTOR P300 AND USES OF P300
 ; NUMBER OF SEQUENCES: 13
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Weingarten, Schurgin, Gagnebin & Hayes
 ; STREET: Ten Post Office Square
 ; CITY: Boston
 ; STATE: MA
 ; COUNTRY: US
 ; ZIP: 02109
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US95/04682
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/227,536
 ; FILING DATE: 14-April-1994
 ; CLASSIFICATION:
 ; ATTORNEY/AGENT INFORMATION:

NAME: Holliday C. Heine, Ph.D.
REGISTRATION NUMBER: 34,346
REFERENCE/DOCKET NUMBER: DFCI-308X999
TELEPHONE: (617) 542-2290
TELEFAX: (617) 451-0313
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 2414 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: Protein
PCT-US95-04682-2

Query Match 3.7%; Score 132.5; DB 5; Length 2414;
Best Local Similarity 21.1%; Pred. No. 0.078;
Matches 128; Conservative 75; Mismatches 235; Indels 169; Gaps 31;
QY 4 PERGKSPPPQ-----PWGLLLRLGAEGPH-----VLL-----RKREWTI 40
Db 300 PNNQQ-PAPVQQPGLVTPVAQMGSGAHTDPKRLIQOQLVLLHAHKCORREQAN 358
QY 41 GRERGDLSP---PSNKLVSCHCRIVVDEKSGQVLTSTSGTVINKLVVKKQTCPL 97
Db 359 GEVRCQNLPHCRITKKNVLEHWHQ---SGKSCQVA--HCASSRQIISHWKNCTRHDQV 413
QY 98 -----QTGVDVILVYKRNPEHNVAIYSLSEKQMTQESPE--ANKENVFHGKDTSG 150
Db 414 CLPLKNAGD-----XRNQPIILTGAPVGLGNPSLGVQQSQAPNLSTVQIDPSSIERAY 468
QY 151 AGAGRGADPRVPSSPATQVCFEE-POPSTSTSDLEPTASASTEPSAGRERSSCSGG 209
Db 469 AALGLPYQNMOTQVQAKNQONQPGQSPQGMPEMNSA---SPWG-----VNG 518
QY 210 GGGISPKGSPVASDEVSSFSASALPDR-----KTASFSLSPQD---QEDLEPVKKQKR 261
Db 519 GVGVTQ-----PSLLSD--SMLHSAINSQNPMSSENASVPSLGPMTAAQPSITGIRKQWH 572
QY 262 GCGDLDLNGOLLVAQPRNAQTVEHRAAGKPD-----KMEETLACI--ICODLLH 312
Db 573 EDTQDLRNLH-----VHKLVAIPTPDPAALKDRKMNLYAVARKVEGDMYE 621
QY 313 DCVSLQPCMTTCAACYSYGMWSSSLCPTCRCPVERICKNHLNN---LVEAYLIQHDPK 369
Db 622 SANNAEYVHLLAEKIYKIQKELEKERT-----RLQKNMLPNAAGVVPVSMNPGPNM 675
QY 370 SRSEEDVQSM-----ARKITQDMLQPKVRRSFSDEGSSDLELSDVDSSESDIS 422
Db 676 GQPGQMTSNGPLPDPMSIRGSPVNMPPRITPQSGLNQFG-----QMSMA 721
QY 423 QPVVCRQCP--EYRRAQAP-----PHCPAPEGE-----P 451
Db 722 QPPIVPRQTPPLQHHGQLAQPGALNPMGYPGRMQQPSNQQLPOTQPPSQGMVNTIP 781
QY 452 GAPOALGDAPSTVSLTAVQDVVCP-----QGSALCTCCFQMPDRRAEROD 502
Db 782 LAPSS-QQAPVQQAQMSSS-----SCPVNSPIMPFGSGSHICPQLPOP-----ALHQS 831
QY 503 PRVAPQ 509
Db 832 PSPVPSR 838

US-08-296-791-6
Sequence 6, Application US/08296791
Patent No. 6245337
GENERAL INFORMATION:
APPLICANT: St. Gene III, Joseph W.
APPLICANT: Falkow, Stanley
TITLE OF INVENTION: Haemophilus Adherence and Penetration
TITLE OF INVENTION: Protein
NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESS:
ADDRESSEE: Flehr, Hohbach, Test, Albritton & Herbert
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: United States
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA: US/08/296,791
APPLICATION NUMBER: US/08/296,791
FILING DATE: 25-AUG-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Trecartin, Richard F.
REGISTRATION NUMBER: 31,801
REFERENCE/DOCKET NUMBER: A-59941/RFT/RMS
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 1848 amino acids
TYPE: amino acid
TOPOLOGY: unknown
US-08-296-791-6

Query Match 3.7%; Score 131; DB 3; Length 1848;
Best Local Similarity 19.9%; Pred. No. 0.07;
Matches 99; Conservative 67; Mismatches 185; Indels 146; Gaps 22;
QY 53 NKLVSCHCRIVVDEKSG-----QVLTSTSTGTVINKLVVKKQTCPLQTVGVILVY 107
Db 929 NKSATGNFTLQVAD-KTGEFNHNLTLFDASNA--TRNNLEVT-----LANGSVDRAG 979
QY 108 RKNPEHNVAI-LYESLSEKQMTQE-----SFEANKENVFHGKDTSGA 151
Db 980 KYKLVNNGRDLNPEVEKKNQIVDTNITPNDIQADAPSAQSNNEIAR----- 1031
QY 152 GAGRGADPRVPSSPATQVCFEEPOPSTSTSD-----LFTPASASTEPSAGRERSSC 206
Db 1032 -----VETPVFPAPATESALASEQPETPAETAQAPEMETNTANSTETAPKS----- 1079
QY 207 GSGGGISPKGSPVASDEVSSFSASALPDRKTASFSLSPQDQEDLEPVKKMRGDCUL 266
Db 1080 -----DTATQTNPNSESVPSETTEKVAENPQENETV--AKNEQATEPT 1123
QY 267 DLNGOLLA-QPRRNAQTVEHRAAGKPD-----KMEETLTCIICDILLHDCVSL- 317
Db 1124 PQNGEVAKEDQPTVEANTQTNATQSEKGTBEETQTAETKSEPTESVTVSENQPEKTVSQS 1183
QY 318 -----QPCNHTTCAACYSYGMWSSSLCP--TCRCP-----VERICKNHLNN 357
Db 1184 TEDKVVVKEEKARVET-----EETQKAVQVTSKEPPKQABPAPEVPTD--TN 1230
QY 358 LVEAYLIQH-----PKSRSEEDVQSMDEANKITQDMLQPKVRRSFSDEGS 404
Db 1231 AEEAQLQQTQTTVAATAETSPNSKPAEETQQPS-----KTNAEPVTPVSENTATQTE 1287
QY 405 SEDLLESDVDSSESDISQPVVCRQCPVEYRRAQAPPHCPAPEGEPG----- 452
Db 1288 TE---ETARVEKETQ-EVPQVQSQSPKQPAKQPAQTKPOABPARENVLTKNVE 1343
QY 453 -APOALGDAPSTVSLT 468
Db 1344 POPAQPOQTQSTAVPTT 1360

RESULT 10

US-09-839-996-6
; Sequence 6, Application US/09839996
; Patent No. 6642371
; GENERAL INFORMATION:
; APPLICANT: St. Geme III, Joseph W.
; Falkow, Stanley
; TITLE OF INVENTION: Haemophilus Adherence and Penetration Protein
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Flehr, Hobbach, Test, Albritton & Herbert
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: United States
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/839,996
; FILING DATE: 20-Apr-2001
; CLASSIFICATION: <unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/296,791
; FILING DATE: 25-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Trecartin, Richard F.
; REGISTRATION NUMBER: 31,801
; REFERENCE/DOCKET NUMBER: A-59941/RFT/RMS
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1848 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-839-996-6
Query Match 3.7%; Score 131; DB 4; Length 1848;
Best Local Similarity 19.9%; Pred. No. 0.07;
Matches 99; Conservative 67; Mismatches 185; Indels 146; Gaps 22;
QY 53 NKLVS GDHCRIVVDEKSG-----QVTLEDTSTSGTVINKLVKKQTCPLQTDGVILVY 107
Db 929 NKSATGNFTLOVAD-KTGPNNHNLTLFDASNA--TRNNLEVT-----LANGSVDRGAW 979
QY 108 RKNPEHNWAY-LYBSLSKQKGTQZ-----SFEANKENVFHGKTDTSGA 151
Db 980 KYKLRNVNGRYDLYNPEVEKRNQTVDTNITTPNDIQADAPSAQSNNEIAR----- 1031
QY 152 GAGRGADPRVPSPSPATQVCFEPPQSTSTSD-----LFPTASASTSPSPAGRERSSC 206
Db 1032 -----VETVPFPAPATESAIASEQPETAETAQAPAMEETNTANSTETAPKS----- 1079
QY 207 GSGGGGISPKGSPSVASDEVSSAFALPDRKTASFSSLEPQDQEDLEPVKKMKGDDGL 266
Db 1080 -----DTATQTNPNSESVFSETTEKVAENPPQENETV--AKNEQATEPT 1123
QY 267 DLNGQLLVA-QPRRNAQTVHEDVRAAAGKPD-----KMEETLTCTIICQDLLHDCVSL- 317
Db 1124 PQNGEVAKEDQPTVEANTQTNBATQSEKTEETQTAETKSEPTESVTVSENQPEKTVSQS 1183
QY 318 -----QPCMTTFCAACVSGMWRSSSLCP--TCRCP-----VERICKNHLN 357
Db 1184 TEDKVVVEKEEKAKVET-----EETQKAPQVTSKEPPKQAPPAPEEVPD---TN 1230
QY 358 LVEAYLIQH-----PDKSRSEEDVQSM DARNKITQDMLQPKVRRSFSDEGS 404
Db 1231 ABEAQAQQOQPTTVA A A E T T S F N S K P A E T T Q P S E ---K T N A E P V T P V S E N T A T Q P T E 1287
QY 405 SEDLLELSVDSESDISQPYVVCRCQCEYRRQAAPPHCPAPEGEPG----- 452
Db 1288 TE---ETAKVEKEKQ--EVPQVASQSPKQEQPAKPAQATKQAPARENVLTITKNVGE 1343
QY 453 -APQALGDAPSTSVSLT 468
Db 1344 PQPQAQPTQSTAVPTT 1360
RESULT 11
US-10-080-505-6
; Sequence 6, Application US/10080505
; Patent No. 6676948
; GENERAL INFORMATION:
; APPLICANT: St. Geme, Joseph W.
; TITLE OF INVENTION: HAEMOPHILUS ADHERENCE AND PENETRATION PROTEINS
; FILE REFERENCE: A-59941-1/RFT/DCF/DHR
; CURRENT APPLICATION NUMBER: US/10/080,505
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: US 08/296,791
; PRIOR FILING DATE: 1994-10-25
; PRIOR APPLICATION NUMBER: US 09/839,996
; PRIOR FILING DATE: 2001-04-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 6
; LENGTH: 1848
; TYPE: PRT
; ORGANISM: Haemophilus influenzae
US-10-080-505-6
Query Match 3.7%; Score 131; DB 4; Length 1848;
Best Local Similarity 19.9%; Pred. No. 0.07;
Matches 99; Conservative 67; Mismatches 185; Indels 146; Gaps 22;
QY 53 NKLVS GDHCRIVVDEKSG-----QVTLEDTSTSGTVINKLVKKQTCPLQTDGVILVY 107
Db 929 NKSATGNFTLOVAD-KTGPNNHNLTLFDASNA--TRNNLEVT-----LANGSVDRGAW 979
QY 108 RKNPEHNWAY-LYBSLSKQKGTQZ-----SFEANKENVFHGKTDTSGA 151
Db 980 KYKLRNVNGRYDLYNPEVEKRNQTVDTNITTPNDIQADAPSAQSNNEIAR----- 1031
QY 152 GAGRGADPRVPSPSPATQVCFEPPQSTSTSD-----LFPTASASTSPSPAGRERSSC 206
Db 1032 -----VETVPFPAPATESAIASEQPETAETAQAPAMEETNTANSTETAPKS----- 1079
QY 207 GSGGGGISPKGSPSVASDEVSSAFALPDRKTASFSSLEPQDQEDLEPVKKMKGDDGL 266
Db 1080 -----DTATQTNPNSESVFSETTEKVAENPPQENETV--AKNEQATEPT 1123
QY 267 DLNGQLLVA-QPRRNAQTVHEDVRAAAGKPD-----KMEETLTCTIICQDLLHDCVSL- 317
Db 1124 PQNGEVAKEDQPTVEANTQTNBATQSEKTEETQTAETKSEPTESVTVSENQPEKTVSQS 1183
QY 318 -----QPCMTTFCAACVSGMWRSSSLCP--TCRCP-----VERICKNHLN 357
Db 1184 TEDKVVVEKEEKAKVET-----EETQKAPQVTSKEPPKQAPPAPEEVPD---TN 1230
QY 358 LVEAYLIQH-----PDKSRSEEDVQSM DARNKITQDMLQPKVRRSFSDEGS 404
Db 1231 ABEAQAQQOQPTTVA A A E T T S F N S K P A E T T Q P S E ---K T N A E P V T P V S E N T A T Q P T E 1287
QY 405 SEDLLELSVDSESDISQPYVVCRCQCEYRRQAAPPHCPAPEGEPG----- 452
Db 1288 TE---ETAKVEKEKQ--EVPQVASQSPKQEQPAKPAQATKQAPARENVLTITKNVGE 1343
QY 453 -APQALGDAPSTSVSLT 468
Db 1344 PQPQAQPTQSTAVPTT 1360

RESULT 14
US-08-764-870-14
; Sequence 14, Application US/08764870

```
Db      :          :          :          :          :          :          :
1184    TEDKVVVEKEAKVET-----EETQKAPQVTSKEPPKQAEPAAPEEPTD---TN 1230
                                :          :          :          :          :
369     LVFAYLVITH-----PDKSPSEENVOSMDANKITODMLQPKVRVSFSDSEGGS 404
```

Patent No. 6236946
 GENERAL INFORMATION:
 APPLICANT: Scanlan, Thomas S
 APPLICANT: Baxter, John D
 APPLICANT: Fletcher, Robert J
 APPLICANT: Wagner, Richard L
 APPLICANT: Kushner, Peter J
 APPLICANT: Aprilletti, James W
 APPLICANT: West, Brian
 TITLE OF INVENTION: Nuclear Receptor Ligands and Ligand
 NUMBER OF SEQUENCES: 16
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Cooley Godward
 STREET: Five Palo Alto Square, 3000 El Camino Real
 CITY: Palo Alto
 STATE: CA
 COUNTRY: USA
 ZIP: 94306
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/764,870
 FILING DATE: 13-DEC-1996
 CLASSIFICATION: 530
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 60/008,540
 FILING DATE: 13-DEC-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 60/008,543
 FILING DATE: 13-DEC-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 60/008,606
 FILING DATE: 14-DEC-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Nakamura, Jackie N
 REGISTRATION NUMBER: 35,966
 REFERENCE/POCKET NUMBER: UCAL-246/01US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (650)843-5000
 INFORMATION FOR SEQ ID NO: 14:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 933 amino acids
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-764-870-14

Query Match 3.5%; Score 126.5; DB 3; Length 933;
 Best Local Similarity 21.3%; Pred. No. 0.061;
 Matches 117; Conservative 60; Mismatches 196; Indels 177; Gaps 30;
 QY 124 SEKQMTQESFEANKENVFGTKDTSGAGAGRADPR-----VPPSSPATQV 170
 DB 70 SDEKTDQOQSL-SDVEGAYSRAEATRGAGSSSPPEKDSGLDLSVLDTLAPSGFG--- 125
 QY 171 CFEPQPS-----TSTSDLF-----PTASASSTEPSAGRRSSSCGSGGG----- 211
 DB 126 --SQSPSPACEVTSSWCLFGPELPEDPPAAPATQVLSPLMSRGCKVGDSSGTAATAAH 182
 QY 212 GISPKGSGPS-----VASDEVSSPAPALPDKRTASFSSSLEPQDQEDLEP-----VKKK 259
 DB 183 KVLPRGLSPARQLLLPASE--SPHWSGAPVKPSPQAAAVEEEDSSESEESAGPLLKGR 240
 QY 260 MRGDDGLDNLGQLVAQFRENQTV-----HEDVRAAAGKPKDMEE-----TLTICIC 307
 DB 241 PRALGGAAGGAACPFGAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTV 300
 QY 308 QDLHDCVSLQPCXHTFCAA-----CYSQWM-----ERSSLC----- 339

DB 301 MDTFH--VPILPLNHALAARTQLEDESVDGGAASAFAPPTSPCASSTPVAVGDF 358
 QY 340 PTCRCPVERICKNHLNVLVEAYLI-----QHPD-KSRSEEDVQSMARKKIT----- 386
 DB 359 PDCAYPDPAEPKD-----DAYPLYSDFQPPALKIKEEEGAGASARSFSLVAGANP 411
 QY 387 -----QDMLQPKVRSPFSDREG--SSDLELLESDVDSESSDISQPYVVCRCQPEY 434
 DB 412 AAPDFPFLGPPPLPPRATPSRFEAAVTAAPASASVSASSSGSTL-----ECILY 463
 QY 435 RRQAAQP---PHCPAPEGEPGAPQAL---GDAPSTSVSLTTA-VQYVVCPLQGSALCTC 487
 DB 464 KAEGAPQOGPEAPPCKAPGAGCCLPRDGLPSTSSASAAAGAAPALYPALGLNGLPOL 523
 QY 488 CFQP-----MPDRAERQDPRA-----PQQ-CAVCLQPFCHLYWGC 524
 DB 524 GYQAAVLKEGLPVYPYLYLRLPD--SEASQPSQVSESLFKKCLIC-----GD 572
 QY 525 TRTGC-YGCL 533
 DB 573 EASGCHYGL 582
 RESULT 15
 US-08-980-115-14
 Sequence 14, Application US/08980115
 Patent No. 6266622
 GENERAL INFORMATION:
 APPLICANT: Scanlan, Thomas S.
 APPLICANT: Baxter, John D.
 APPLICANT: Fletcher, Robert J.
 APPLICANT: Wagner, Richard L.
 APPLICANT: Kushner, Peter J.
 APPLICANT: Aprilletti, James W.
 APPLICANT: West, Brian L.
 APPLICANT: Shiau, Andrew K.
 TITLE OF INVENTION: NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS
 FILE REFERENCE: UCAL-246/02US
 CURRENT APPLICATION NUMBER: US/08/980,115
 CURRENT FILING DATE: 1997-11-26
 EARLIER APPLICATION NUMBER: 08/764,870
 EARLIER FILING DATE: 1996-12-13
 EARLIER APPLICATION NUMBER: 60/008,606
 EARLIER FILING DATE: 1995-12-14
 EARLIER APPLICATION NUMBER: 60/008,543
 EARLIER FILING DATE: 1995-12-13
 EARLIER APPLICATION NUMBER: 60/008,540
 EARLIER FILING DATE: 1995-12-13
 NUMBER OF SEQ ID NOS: 17
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 14
 LENGTH: 933
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
 NAME/KEY: DOMAIN
 LOCATION: (659)..(918)
 OTHER INFORMATION: minimal ligand binding domain
 US-08-980-115-14

Query Match 3.5%; Score 126.5; DB 3; Length 933;
 Best Local Similarity 21.3%; Pred. No. 0.061;
 Matches 117; Conservative 60; Mismatches 196; Indels 177; Gaps 30;
 QY 124 SEKQMTQESFEANKENVFGTKDTSGAGAGRADPR-----VPPSSPATQV 170
 DB 70 SDEKTDQOQSL-SDVEGAYSRAEATRGAGSSSPPEKDSGLDLSVLDTLAPSGFG--- 125
 QY 171 CFEPQPS-----TSTSDLF-----PTASASSTEPSAGRRSSSCGSGGG----- 211
 DB 126 --SQSPSPACEVTSSWCLFGPELPEDPPAAPATQVLSPLMSRGCKVGDSSGTAATAAH 182

QY	212	GISPKGSGRS-----VASDEVSSFASALPDRKTA	SPSSLEPOQEDLEP-----VKKK	259
Db	183	KVLPRLGLSPARQLLLPASE--SPHWSGAFVKPSPQAA	AVEVEEEDSSEESAGPLKKG	240
QY	260	MREGDLDLNGQLLVQPRNAQTV-----HEDVRAA	AGKPKMEE-----TLTCIIC	307
Db	241	PRALGGAAGGGAACPPGGAAGGVALVPKEDSRFS	APRVAVLEQDAPMAPGRSPLATTV	300
QY	308	QDLHLDCVSLQPCWHTFCAA-----CYS	GWM-----ERSSLC-----	339
Db	301	MDFIH--VPILPLNHALLAARTQLEDES	YDGGAGAASAFAPPRTPCASSTPVAVGDF	358
QY	340	PTCRCPVERICKNHILNNLVEAYLI-----QHPD	-KSRSEEDVOSMDARKIT-----	386
Db	359	PDCAYPDDAEPKD-----DAYPLYSDFOP	PALKIKEEEGAEASARSRSYLVAGANP	411
QY	387	-----QDMLQPKVRESFSDEEG--SSEDLLE	LSVDSESSDISQPYVVCROCPEY	434
Db	412	AAPDFPLGPPPLPPRATPSRGEAAVTHAP	ASASVSSASSSGSTL-----ECILY	463
QY	435	RRQAAQF---PHCPAPEGEFGAPQAL---GD	APSTSVSLTTA-VQDYVCPLOQSHALCTC	487
Db	464	KASGAPQOGFFAPFPCKAFGASGCLLPRDGL	PSTGSASAAAAGAAPALYPALGLNGLPQL	523
QY	488	CFQP-----MPDRAEREO	PRVA-----PQO-CAVCLQPFCHLYWGC	524
Db	524	GYQAANLKEGLPQYPPYLYNLRPD--SEAS	QSPQYSFESLPKICLIC-----GD	572
QY	525	TRTGC-YGCL	533	
Db	573	EASGCHYGL	582	

Search completed: May 7, 2004, 14:51:21
Job time : 46.1732 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:49:13 ; Search time 105.174 Seconds
(without alignments)
1752.371 Million cell updates/sec

Title: US-10-048-046-2

Perfect score: 3585

Sequence: 1 MERPEEGKQSPPPQWGRLL.....VKAHAKFNHICEQTRFKN 664

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1140673 seqs, 277566755 residues

Total number of hits satisfying chosen parameters: 1140673

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/2/pubaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/2/pubaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/2/pubaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/2/pubaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/2/pubaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/2/pubaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/2/pubaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/2/pubaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/2/pubaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/2/pubaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/2/pubaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/2/pubaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/2/pubaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/2/pubaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/2/pubaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/2/pubaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/2/pubaa/US60_NEW_PUB.pep.*
18: /cgn2_6/ptodata/2/pubaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	DB ID	Description
1	3585	100.0	664	9	US-09-780-525-2
2	1954.5	54.5	426	9	US-09-764-864-809
3	1803	50.3	349	15	US-10-108-260A-4516
4	843.5	23.5	120	9	US-09-764-864-1270
5	566	15.8	128	15	US-10-094-749-1799
6	474	13.2	92	9	US-09-764-864-1109
7	432	12.1	99	9	US-09-764-864-1110
8	432	12.1	99	9	US-09-764-864-1529
9	252	7.0	287	12	US-10-424-599-264601
10	146.5	4.1	284	12	US-10-126-103-114
11	146	4.1	303	15	US-10-108-260A-3965
12	142	4.0	648	12	US-10-425-114-63379
13	139	3.9	775	14	US-10-224-999A-3462
14	139	3.9	825	14	US-10-121-988-161
15	139	3.9	825	14	US-10-200-562-161

16	139	3.9	825	14	US-10-237-551-161	Sequence 161, App
17	139	3.9	825	14	US-10-210-428-1	Sequence 1, Appli
18	139	3.9	4675	15	US-10-093-463-74	Sequence 74, Appl
19	139	3.9	4691	15	US-10-093-463-72	Sequence 72, Appl
20	138	3.8	255	14	US-10-106-698-4393	Sequence 4383, Ap
21	138	3.8	376	12	US-10-424-599-233512	Sequence 233512,
22	136.5	3.8	420	12	US-10-425-114-70107	Sequence 40966,
23	136.5	3.8	424	12	US-10-425-114-70107	Sequence 70107, A
24	136	3.8	521	15	US-10-259-194A-118	Sequence 118, App
25	135	3.8	245	9	US-09-998-667-9	Sequence 9, Appli
26	135	3.8	285	9	US-09-764-864-841	Sequence 841, App
27	135	3.8	285	15	US-10-364-049-3125	Sequence 3125, Ap
28	135	3.8	478	12	US-10-425-114-56089	Sequence 56089, A
29	135	3.8	993	15	US-10-259-194A-72	Sequence 72, Appl
30	134.5	3.8	353	12	US-10-424-599-187336	Sequence 187336,
31	134.5	3.8	826	9	US-09-894-998-47	Sequence 47, Appl
32	134.5	3.8	826	14	US-10-121-988-47	Sequence 47, Appl
33	134.5	3.8	826	14	US-10-200-562-47	Sequence 47, Appl
34	134.5	3.8	826	14	US-10-237-551-47	Sequence 37376, A
35	134	3.7	331	12	US-10-425-114-37376	Sequence 2672, Ap
36	133.5	3.7	610	15	US-10-104-047-2672	Sequence 65516, A
37	133	3.7	346	12	US-10-425-114-65516	Sequence 54084, A
38	132.5	3.7	440	12	US-10-425-114-54084	Sequence 203186,
39	132.5	3.7	441	12	US-10-424-599-203186	Sequence 5784, Ap
40	132.5	3.7	3507	15	US-10-369-493-5784	Sequence 818, App
41	132	3.7	658	9	US-09-764-864-818	Sequence 387, App
42	131.5	3.7	191	16	US-10-389-566-387	Sequence 1277, Ap
43	131.5	3.7	563	9	US-09-764-864-1277	Sequence 6, Appli
44	131	3.7	1848	10	US-09-839-996-6	Sequence 6, Appli
45	131	3.7	1848	12	US-10-645-655-6	

ALIGNMENTS

RESULT 1
US-09-780-525-2
; Sequence 2, Application US/09780525
; Patent No. US20020004223A1
; GENERAL INFORMATION:
; APPLICANT: Bin-Bing Zhou
; APPLICANT: Yuan Zhu
; APPLICANT: Priya Chaturvedi
; APPLICANT: Mark R. Hurlle
; APPLICANT: Xiaotong Li
; TITLE OF INVENTION: FHAR1, A NEW RING FINGER PROTEIN
; FILE REFERENCE: GP-70668-C1
; CURRENT FILING DATE: 2001-02-09
; PRIOR FILING DATE: 1999-12-08
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 664
; TYPE: PRT
; ORGANISM: HOMO SAPIENS
US-09-780-525-2

Query Match 100.0%; Score 3585; DB 9; Length 664;
Best Local Similarity 100.0%; Pred. No. 5e-271;
Matches 664; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MERPEEGKQSPPPQWGRLLRLGAEQEPHVLRLKREWTIGRRGCDLSFPNKLVSQDH 60
Db 1 MERPEEGKQSPPPQWGRLLRLGAEQEPHVLRLKREWTIGRRGCDLSFPNKLVSQDH 60
QY 61 CRIVVDEKSGQVLTEDTSTSGTVINKLVKKQKOTPLQGDVILVYLRKNEPEHNVAIYL 120
Db 61 CRIVVDEKSGQVLTEDTSTSGTVINKLVKKQKOTPLQGDVILVYLRKNEPEHNVAIYL 120
QY 121 ELSLSEKQGTQBSFRANKENVFHGTDTSGAGAGRGADPRVPPSSPATVCPPEPSPSTS 180

Db 121 ESLSEKQGMTOESPEANKENVFHGTGKDTSGAGAGADPRVPPSSPATQVCFEPOPSTS 180
Qy 181 TSDLPPTASASTPSPAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDRKTA 240
Db 181 TSDLPPTASASTPSPAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDRKTA 240
Qy 241 SFSSLEPOQDELEPVKKMGDGLDLNGQLLVAQPRNAQTVDHVRAAAGKPKDKEE 300
Db 241 SFSSLEPOQDELEPVKKMGDGLDLNGQLLVAQPRNAQTVDHVRAAAGKPKDKEE 300
Qy 301 TLTCIIICODLLHDCVSLQPCMTTCAACYSWMERSSLCPTCPCVERICKNHLINLVE 360
Db 301 TLTCIIICODLLHDCVSLQPCMTTCAACYSWMERSSLCPTCPCVERICKNHLINLVE 360
Qy 361 AYLIOHPDKSRSEEDVQSMADARKITQDMLQPKVRSFSDSESSDLELSDVDSSED 420
Db 361 AYLIOHPDKSRSEEDVQSMADARKITQDMLQPKVRSFSDSESSDLELSDVDSSED 420
Qy 421 ISQPVVCRQCEYRRAQAQPPHCPAPGEPGAPQALGDAPSTSVSLTTAVQDYVCPLOG 480
Db 421 ISQPVVCRQCEYRRAQAQPPHCPAPGEPGAPQALGDAPSTSVSLTTAVQDYVCPLOG 480
Qy 481 SHALCTCCFQMPDRAAREQDPRVAPOQCAVCLQPPCHLYWGCTRTGCGCLAPFCELN 540
Db 481 SHALCTCCFQMPDRAAREQDPRVAPOQCAVCLQPPCHLYWGCTRTGCGCLAPFCELN 540
Qy 541 LGDKCLDGLVNNNSYESDILKXLYLATRGLTWKNMLTSLVALQRGVFLLSYRVGTDTVL 600
Db 541 LGDKCLDGLVNNNSYESDILKXLYLATRGLTWKNMLTSLVALQRGVFLLSYRVGTDTVL 600
Qy 601 CYCCGLRSFRELTYQYRONIPASLPAVATSRPCYGNCRTOVKAHAKFNHICEQT 660
Db 601 CYCCGLRSFRELTYQYRONIPASLPAVATSRPCYGNCRTOVKAHAKFNHICEQT 660
Qy 661 RFKN 664
Db 661 RFKN 664

RESULT 2
US-09-764-864-809
; Sequence 809, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 809
; LENGTH: 426
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (414)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (415)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (420)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-809

Query Match 54.5%; Score 1954.5; DB 9; Length 426;
Best Local Similarity 74.1%; Pred. No. 5.9e-144;
Matches 389; Conservative 5; Mismatches 22; Indels 109; Gaps 5;

Qy 1 MERPEEGKQSPFPQWGRLLRGAEGEPHVLRRKRENTIGRRRCGLDLSFSSNKLVSGDH 60

Db 3 MERPEEGKQSPFPQWGRLLRGAEGEPHVLRRKRENTIGRRRCGLDLSFSSNKLVSGDH 62
Qy 61 CRIVVDEKSGQVLTEDTSTSGTVINKLVKKQKOTCPLQTDGVIYLVYKNEPEHNVAIY 120
Db 63 CRIVVDEKSGQVLTEDTSTSGTVINKLVKKQKOTCPLQTDGVIYLVYKNEPEHR----- 117
Qy 121 ESLSEKQGMTOESPEANKENVFHGTGKDTSGAGAGADPRVPPSSPATQVCFEPOPSTS 180
Db 118 ----- 117
Qy 181 TSDLPPTASASTPSPAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDRKTA 240
Db 118 -----SGGGISPKGSGPSVASDEVSSFASALPDRKTA 150
Qy 241 SFSSLEPOQDELEPVKKMGDGLDLNGQLLVAQPRNAQTVDHVRAAAGKPKDKEE 300
Db 151 SFSSLEPOQDELEPVKKMGDGLDLNGQLLVAQPRNAQTVDHVRAAAGKPKDKEE 210
Qy 301 TLTCIIICODLLHDCVSLQPCMTTCAACYSWMERSSLCPTCPCVERICKNHLINLVE 360
Db 211 TLTCIIICODLLHDCVSLQPCMTTCAACYSWMERSSLCPTCPCVERICKNHLINLVE 270
Qy 361 AYLIOHPDKSRSEEDVQSMADARKITQDMLQPKVRSFSDSESSDLELSDVDSSED 420
Db 271 AYLIOHPDKSRSEEDVQSMADARKITQDMLQPKVRSFSDSESSDLELSDVDSSED 330
Qy 421 ISQPVVCRQCEYRRAQAQPPHCPAPGEPGAPQALGDAPSTSVSLTTAVQDYVCPLOG 480
Db 331 ISQPVVCRQCEYRRAQAQPPHCPAPGEPGAPQALGDAPSTSVSLTT-----VRI 382
Qy 481 SHALC-----TCCQPMPEDRAREEQDPRVAPO-----QCAVCLQPPF 517
Db 383 TCALCKEATPC-APAASAHAPESGTRTGPRVXNLKCKXGLLOAF 426

RESULT 3
US-10-108-260A-4516
; Sequence 4516, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1e1 full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 4516
; LENGTH: 349
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-4516

Query Match 50.3%; Score 1803; DB 15; Length 349;
Best Local Similarity 99.4%; Pred. No. 3e-132; 2; Indels 0; Gaps 0;
Matches 331; Conservative 0; Mismatches 2;

Qy 205 SCGSGGGISPKGSGPSVASDEVSSFASALPDRKTASFSSLEPQDELEPVKKMGD 264
Db 5 SFSGSGGGISPKGSGPSVASDEVSSFASALPDRKTASFSSLEPQDELEPVKKMGD 64
Qy 265 DLDLNGQLLVAQPRNAQTVDHVRAAAGKPKDKEETLTCIIICODLLHDCVSLQPCMTT 324
Db 65 DLDLNGQLLVAQPRNAQTVDHVRAAAGKPKDKEETLTCIIICODLLHDCVSLQPCMTT 124
Qy 325 CAACYSWMERSSLCPTCPCVERICKNHLINLVEAYLIQHPDKSRSEEDVQSMADARK 384
Db 125 CAACYSWMERSSLCPTCPCVERICKNHLINLVEAYLIQHPDKSRSEEDVQSMADARK 184
Qy 385 ITQDMLQPKVRSFSDSESSDLELSDVDSSEDSISQPVVCRQCEYRRAQAQPPHCP 444
Db 185 ITQDMLQPKVRSFSDSESSDLELSDVDSSEDSISQPVVCRQCEYRRAQAQPPHCP 244

QY 445 PAPEGEPGAPALGDAPSTSVSLTAVODYVCPLOGSHALCTCCGFMPPDRRAERQDPR 504
DB 245 PAPEGEPGAPALGDAPSTSVSLTAVODYVCPLOGSHALCTCCGFMPPDRRAERQDPR 304
QY 505 VAPQCAVCLQPFCHLYWGCTRTGCGCLAPFC 537
DB 305 VAPQCAVCLQPFCHLYWGCTRTGCGCLAPFC 337

RESULT 4

US-09-764-864-1270
; Sequence 1270, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: ROSEN ET AL.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; PRIOR FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1270
; LENGTH: 230
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (4)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (189)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (192)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (193)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (194)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (213)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (223)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (229)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (230)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1270

Query Match 23.5%; Score 843.5; DB 9; Length 230;
Best Local Similarity 76.3%; Pred. No. 1.4e-57;
Matches 167; Conservative 2; Mismatches 19; Indels 31; Gaps 4;
QY 319 PCHTFCACACYSGWERSLLCTCRCEVERICKNHNILNVEAYLIQHDPKSRSEEDVQS 378
DB 5 PCHTFCACACYSGWERSLLCTCRCEVERICKNHNILNVEAYLIQHDPKSRSEEDVQS 64
QY 379 MDARKITQDMLQPKVRSFSDGSSDLELSDVDSSESDISQPVVVCRCPEYRQA 439
DB 65 MDARKITQDMLQPKVRSFSDGSSDLELSDVDSSESDISQPVVVCRCPEYRQA 124
QY 439 AQPCHFAPEGEPGAPALGDAPSTSVSLTAVQDVVCPLOGSHALCTCCGFMPP 493
DB 125 AQPCHFAPEGEPGAPALGDAPSTSVSLTAVQDVVCPLOGSHALCTCCGFMPP 173

QY 494 --DRRAE--REODRVA-----PQCAVCLQPF 517
DB 174 SAHARPEGSEREQDPRXALXXXPPVVLGLHPDRLLRLLAPE 212

RESULT 5

US-10-094-749-1799
; Sequence 1799, Application US/10094749
; Publication No. US20030219741A1
; GENERAL INFORMATION:
; APPLICANT: ISOGAI, TAKAO
; APPLICANT: SUGIYAMA, TOMOYASU
; APPLICANT: OTSUKI, TETSUJI
; APPLICANT: WAKAMATSU, AI
; APPLICANT: SATO, HIROYUKI
; APPLICANT: ISHII, SHIZUKO
; APPLICANT: YAMAMOTO, JUN-ICHI
; APPLICANT: ISONO, YUUKO
; APPLICANT: HIO, YORI
; APPLICANT: OTSUKA, KAORU
; APPLICANT: NAGAI, KEIICHI
; APPLICANT: IRIE, RYOTARO
; APPLICANT: TAMECHIKA, ICHIRO
; APPLICANT: SEKI, NAOHICO
; APPLICANT: YOSHIKAWA, TSUTOMU
; APPLICANT: OTSUKA, MOTOFUKI
; APPLICANT: NAGAHARI, KENJI
; APPLICANT: MASUHO, YASUHIKO
; TITLE OF INVENTION: NOVEL FULL-LENGTH CDNA
; FILE REFERENCE: 084335/0160
; CURRENT APPLICATION NUMBER: US/10/094,749
; CURRENT FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/350,435
; PRIOR FILING DATE: 2002-01-24
; PRIOR APPLICATION NUMBER: JP 2001-328381
; PRIOR FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 3381
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1799
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-094-749-1799

Query Match 15.8%; Score 566; DB 15; Length 128;
Best Local Similarity 99.0%; Pred. No. 2.9e-36;
Matches 103; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 561 KNYLATEGLTWKMLTESLVALQGVLLSDYRVGTGDTVLCYCCGLRSFRLTYQRONI 620
DB 25 QNYLATEGLTWKMLTESLVALQGVLLSDYRVGTGDTVLCYCCGLRSFRLTYQRONI 84
QY 621 PASELPVAVTSRDPDCYWGRCNCRTPQVKAHAMKFNHICEOTREFN 664
DB 85 PASELPVAVTSRDPDCYWGRCNCRTPQVKAHAMKFNHICEOTREFN 128

RESULT 6

US-09-764-864-1109
; Sequence 1109, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: ROSEN ET AL.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1109
; LENGTH: 92
; TYPE: PRT

ORGANISM: Homo sapiens
FEATURE: SITE
NAME/KEY: (80)
LOCATION: (80)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1109

Query Match 13.2%; Score 474; DB 9; Length 92;
Best Local Similarity 98.9%; Pred. No. 2.8e-29;
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MERPEEKQPPPPQPPQWGLRLRLGAECEPHVLLRKREWTIGRRGCDLSFFPSNKLVSQDH 60
DB 3 MERPEEKQPPPPQPPQWGLRLRLGAECEPHVLLRKREWTIGRRGCDLSFFPSNKLVSQDH 62
QY 61 CRIVVDEKSGQVLTEDTSGTGVINKLVV 90
DB 63 CRIVVDEKSGQVLTEDTSGTGVINKLVV 92

RESULT 7
US-09-764-864-1110
Sequence 1110, Application US/09764864
Patent No. US20020132753A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PT223
CURRENT APPLICATION NUMBER: US/09/764,864
CURRENT FILING DATE: 2001-01-17
Prior application data removed - consult PALM or file wrapper
NUMBER OF SEQ ID NOS: 1792
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 1110
LENGTH: 99
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE: SITE
NAME/KEY: (17)
LOCATION: (17)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (96)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1110

Query Match 12.1%; Score 432; DB 9; Length 99;
Best Local Similarity 92.5%; Pred. No. 5.9e-26;
Matches 86; Conservative 1; Mismatches 4; Indels 2; Gaps 1;
QY 42 RRRGCDLSFSPNKLVSQDHCRIVVDEKSGQVLTEDTSGTGVINKLVVKKQTCPLOTGD 101
DB 9 RDKGPD--FPXNKLVSQDHCRIVVDEKSGQVLTEDTSGTGVINKLVVKKQTCPLOTGD 66
QY 102 VYLVYRKNEPEHNVAYLVESLSEKQGMTOESP 134
DB 67 VYLVYRKNEPEHNVAYLVESLSEKQGMTOESP 99

RESULT 8
US-09-764-864-1529
Sequence 1529, Application US/09764864
Patent No. US20020132753A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PT223
CURRENT APPLICATION NUMBER: US/09/764,864
CURRENT FILING DATE: 2001-01-17
Prior application data removed - consult PALM or file wrapper
NUMBER OF SEQ ID NOS: 1792
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 1529

LENGTH: 99
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE: SITE
NAME/KEY: (17)
LOCATION: (17)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (96)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1529

Query Match 12.1%; Score 432; DB 9; Length 99;
Best Local Similarity 92.5%; Pred. No. 5.9e-26;
Matches 86; Conservative 1; Mismatches 4; Indels 2; Gaps 1;
QY 42 RRRGCDLSFSPNKLVSQDHCRIVVDEKSGQVLTEDTSGTGVINKLVVKKQTCPLOTGD 101
DB 9 RDKGPD--FPXNKLVSQDHCRIVVDEKSGQVLTEDTSGTGVINKLVVKKQTCPLOTGD 66
QY 102 VYLVYRKNEPEHNVAYLVESLSEKQGMTOESP 134
DB 67 VYLVYRKNEPEHNVAYLVESLSEKQGMTOESP 99

RESULT 9
US-10-424-599-264601
Sequence 264601, Application US/10424599
Publication No. US20040031072A1
GENERAL INFORMATION:
APPLICANT: La Rosa Thomas J
APPLICANT: Kovalic David K
APPLICANT: Zhou Yihua
APPLICANT: Cao Yongwei
TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
FILE REFERENCE: 38-21(53223)B
CURRENT APPLICATION NUMBER: US/10/424,599
CURRENT FILING DATE: 2003-04-28
NUMBER OF SEQ ID NOS: 285684
SEQ ID NO 264601
LENGTH: 287
TYPE: PRT
ORGANISM: Glycine max
FEATURE:
OTHER INFORMATION: Clone ID: PAT_MRT3847_80956C.1.pep
US-10-424-599-264601

Query Match 7.0%; Score 252; DB 12; Length 287;
Best Local Similarity 24.2%; Pred. No. 3.1e-11;
Matches 83; Conservative 39; Mismatches 145; Indels 76; Gaps 10;
QY 340 PTCRCPEVERICKNHLNVLVEAYLIQHPDKSRSEEDVQSDARNKITQDMLQPKVRSFS 399
DB 2 PQCRVVFAGKNHFLRTAEDMLRADSSLSQSHDEVALDT-----YALVRSNLV 52
QY 400 DEEGSSDLELSDDVSSSDISQPVVCRQCPEYRROAOPPHCPAGEGEPGAPQALGD 459
DB 53 IGSCKKRXRAYTPLDDQSDG---TYHQCCQC-----81
QY 460 APSTSVSLTAVQDYVCPQLQSGSHALCTCFQFMPDRRAERQDPRVAPQCAVCLQPFCH 519
DB 82 -----VTEVAFGRCKYDTVHLQCAQCGGWPBRTGFG-----IPQYCSGCDRSFCG 127
QY 520 LYW---GCTRTGCGCLAPFCBLN---LGDKCLDGV---LNNSVESDILKYLATRG 568
DB 128 AYWHALGVTVNGSY----PVCSDTLRFISDHSISRIPLLAHEKNLHEQNITDSCIRQM 183
QY 569 LTWNKMLTSLVALQ-----RGVFLSDYRVGTGTVLCCGLRSFRELTYQYRONIPA 622
DB 184 RTLPDVISEWIAKFENREIDRRMMLNAEMITARTFVCQDCYHKLVSFLLYWFLRLSIPK 243
QY 623 SELPVAVTSPDCYWGRCNCRTOVKA-HHAKFNHICEQTRFKN 664

Db 244 HLLPFDESAREDCWYACRTHRSOEHAQRNHYCRPTRGSN 286
Query Match 4.1%; Score 146.5; DB 12; Length 284;
Best Local Similarity 21.5%; Pred. No. 0.0054;
Matches 63; Conservative 38; Mismatches 99; Indels 93; Gaps 13;
US-10-126-103-114
; Sequence 114, Application US/10126103
; Publication No. US20030224486A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY
; FILE REFERENCE: D0108.DP
; CURRENT APPLICATION NUMBER: US/10/126,103
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: US 60/284,962
; PRIOR FILING DATE: 2001-04-19
; PRIOR APPLICATION NUMBER: US 60/286,645
; PRIOR FILING DATE: 2001-04-26
; PRIOR APPLICATION NUMBER: US 60/346,986
; PRIOR FILING DATE: 2002-01-09
; NUMBER OF SEQ ID NOS: 284
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 114
; LENGTH: 284
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-126-103-114
Query Match 4.1%; Score 146.5; DB 12; Length 284;
Best Local Similarity 21.5%; Pred. No. 0.0054;
Matches 63; Conservative 38; Mismatches 99; Indels 93; Gaps 13;
QY 164 SSPATQVCEEP-QPSTSTSLPPTASAS-STEPSP-----AGR----- 200
Db 4 SSSLTRACPPHPQQGEGWGNKTKTSLGVSHSPSGTSLQSPNRLRAGRRPAIM 63
QY 201 -----BRSSSCGGGGISPKSGSPS-----VASDEVSSFSAL-PDRKTASPS 244
Db 64 TKLRYADADRAALRGDPGASAGSSQKTDDEPVAAGTDCQAFGGTSGRLGSAFM 123
QY 245 LEPOQDEBLEPVKKRGDGLDLNQLLVAQPRN-AQTVH----- 285
Db 124 ASPQ-----GGCIATAMRLNQLQSVYKMDPLRNEVGROGYCG 163
QY 286 ---EDVRAAGKPKMEETITCIICDILLHDCVSLQPCMHITFCAACYSGMWSRLCPTC 342
Db 164 RPAEVRV---KIKDLNEHIVCLCAGYFVDATTITECLHTCKSCIVKYLQTSKYCPMC 220
QY 343 RC-----PVERICKNHLNLVEAYL--IQHPDKSRSEEDVQSMARKKITQ 387
Db 221 NIKIHETQPLNLKLDVMDIVYKLVPLGLQDSEKRIREFYQSR-GLDRVTQ 272
RESULT 11
US-10-108-260A-3965
; Sequence 3965, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1el full length cdna
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 3965
; LENGTH: 303
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-3965
Query Match 4.1%; Score 146; DB 15; Length 303;
Best Local Similarity 22.4%; Pred. No. 0.0064;
US-10-108-260A-3965

Matches 76; Conservative 33; Mismatches 125; Indels 106; Gaps 20;
QY 302 LTC--IICQDLHDCVSLQPCMHITFCAACYSGWME---RSSLPTRCRCPVERICKNHLN 356
Db 28 ITCXCLCEQSLDKMTTLOECQCICTACLKQYMLAIREGCGSPITCP-DMVCLNH--- 83
QY 357 NLVEAYLIQHPDKSRSEEDVQSMARKKITQDMLQPKVRSFSDEGSSDLELSVDVS 416
Db 84 -----GTQEAIEIACLVDPDQFQLYQRLKFERE-----VHL----- 114
QY 417 BSSDISQYVVCRCQPEYRQAAPPHCPAPEGEPPGAPALGDAPSTSVSLTTAVQDYVC 476
Db 115 -----DPYRT--WCPVADQTV---CPVASSDPGQP-VLVECPSS-----C 148
QY 477 PLQSHALCTCCFPMPDRAREQDPRVAP-----QQCAVCLQPFCHLY 521
Db 149 HLK-----FCSCCKDAWAEVSCRSQSPVILFTEHRAFGTDAEAPIKQCPVC-RVIYERN 203
QY 522 WGCRTTCYGCCLAPFCBLNLGDKCLDGLNN---NSYESILKNYL--ATRGLTW-KNML 575
Db 204 EGCAQWCKCKKHTFCWY-----CLQNLNDIPLRHYDKGPCRNKLGHSRASVMNRTOV 258
QY 576 TESLVALQGVFLLSDYRVGTDTVL-----CYCCGLASFR 610
Db 259 VGIIVGL--GIIAL-----VTSPLLLASPCIIICVCKSCR 292
RESULT 12
US-10-425-114-63379
; Sequence 63379, Application US/10425114
; Publication No. US20040034889A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Jingdong
; APPLICANT: Zhou, Yihua
; APPLICANT: Kovalic, David K.
; APPLICANT: Screen, Steven E.
; APPLICANT: Tabaska, Jack E.
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53313)B
; CURRENT APPLICATION NUMBER: US/10/425,114
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 63379
; LENGTH: 648
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: UC-ZMFLS73195H06_FLI.pep
US-10-425-114-63379
Query Match 4.0%; Score 142; DB 12; Length 648;
Best Local Similarity 19.8%; Pred. No. 0.04;
Matches 102; Conservative 52; Mismatches 169; Indels 192; Gaps 26;
QY 159 PRVPSSPATQVCEEPQSPSTSDLPFTASASTESP-----AGRSSSCG----- 207
Db 14 PHPPSPNP--RGCF-----ATLSRLPPRGRRRDPDPFRCWSGSGARRRAEAQWNP 66
QY 208 -----SGGGISPKSGPSVASDEVSSFASALPDRKTASFSLEPDQE 251
Db 67 RTICTQTTPPKMTSTAAGRLVSP---PATTQTITRTTTTPRSS-----SPTDSS 118
QY 252 DLBPVKKMRGDDLD-LNGQLLVAQPR-----RN-----AQTVHED-----VRAAGK 294
Db 119 ILSEVDIKRQEDDINRVSTVLSISKPEACVLLKNYWSVKVHDEWFADDERVKVGL 178
QY 295 PDK-----MBETLTICIIDILLHDC-----VSLQPCMHITFCAACYSGMWSRLCPTC 344
Db 179 PEKHIEMENDREVTCIGC---FSCPLGMSAAACGHPFCGTCWRGYTSTAISDPPGC-- 233
QY 345 PVERICKNHLNLVEAYLIQHPDKSRSEEDVQSMARKKITQDMLQPKVRSFSDEGSS 404

[illegible]

```

RESULT 13
US-10-224-999A-3462
; Sequence 3462, Application US/10224999A
; Publication No. US2003017318A1
; GENERAL INFORMATION:
; APPLICANT: Myriad Genetics, Inc.
; APPLICANT: Morham, Scott
; APPLICANT: Zavitz, Kenton
; APPLICANT: Hobden, Adrian
; TITLE OF INVENTION: Composition and Method for Treating Viral Infection
; FILE REFERENCE: 5004.01
; CURRENT APPLICATION NUMBER: US/10/224,999A
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/313,695
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 3484
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3462
; LENGTH: 775
; TYPE: prt
; ORGANISM: human herpesvirus 1
US-10-224-999A-3462

```

Query Match	3.9%	Score 139,	DB 14,	Length 775;
Best Local Similarity	22.6%;	Pred. No. 0.088;		
Matches	80;	Conservative	34;	Mismatches 142;
				Indels 98;
				Gaps 16;
Qy	156	GADPRVPPSSPATQVCFEEPPST	----	STSDLPPTASSTPSPAGRERSSSCGSGG 211
Db	6	GASTRPEGRPO	----	REPAPDVWFPCDRDL--PDSSEAEATEVGR
Qy	212	GISPKSGSPSVASDEVSSFASALPRKTASFSSLEPOQEDLBFVKKKMRGGDLDLNGQ	271	
Db	49	-----GDADHDD-----	-----	DSASEADSTDTLFTGLLPGQVD--GGA 84
Qy	272	LLVAQPRRNAQTVHEDVRAAAGPKDK	----	MEETILCIIQDILL--HDCVSLQPCMHFC 325
Db	85	VSGGSPPR	----	EEDPGSCGAPPREDGGSDGDCVACTEIAPLRCLDFTFCMHFC 139
Qy	326	AACYSGWMERSSLCPTCCPVERICKNHLNNLVEAVLIQHPDKSR	----	SEEDYQSMDAEN 383
Db	140	IPCCKTWQMLRCTLPCLNAGVYLVIVTVPGSGSFSTIPIVNDQTRMEAEAAVACTAVD	199	
Qy	384	KI	-----	TQDMLQPKVRRSFSDGESSDLLELSVDSESSDISQPV 426
Db	200	PIWTGNQRAPRVLITGGHTVEALSPTHPEPTTDED	-----	DDDLDDADYVPP-- 247
Qy	427	VCRCQPEY--RROAAQPP	-----	HCAPAPGEGCAQOA--LGDAPSTSVSLTT 469
Db	248	APRTTRAPPRGAAPPYVTGASHAQAQPAARTAPPSPAPIGPHGSSNTTTT	301	

RESULT 14

```

US-10-121-988-161
; Sequence 161, Application US/10121988
; Publication No. US20030068327A1
; GENERAL INFORMATION:
; APPLICANT: Hoeken, Nancy Ann
; APPLICANT: McGowan, Patrick
; APPLICANT: Sleath, Paul R.
; APPLICANT: Mossman, Sally P.
; APPLICANT: Evans, Lawrence S.
; APPLICANT: Swanson, Ryan M.
; APPLICANT: McNeill, Patricia D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; TITLE OF INVENTION: TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
; FILE REFERENCE: 210121.538C1
; CURRENT APPLICATION NUMBER: US/10/121,988
; CURRENT FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 183
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 825
; TYPE: PRT
; ORGANISM: HSV2
US-10-121-988-161

```

Query Match	3.9%;	Score 139;	DB 14;	Length 825;
Best Local Similarity	22.7%;	Pred. No. 0.056;		
Matches	82;	Conservative	33;	Mismatches 127;
				Indels 120;
				Gaps 19;
QY	152	GACRGADP	--RVPPGSPATQVCFEFPQ	STSDTSLFFPTASASTESPAG-----RE 201
Db	6	GTSRADP	PGERPRQTPTQPA--	APHAWGLNDMQLASSDSEETEVGISDLDLHRD 63
QY	202	RSSCGSGGGI	SPKSGPSVADSEVSSPASALP	PDRKTASFSSLEPQODELPEVKKMR 261
Db	64	STSEAG	-----STDTMFPFAGLMDAAT	-----PPAPFPAERQG 96
QY	262	DGDGLDLNGQLLVAQ	PRNAQTVHEDVRAAGKPEDKMEETL	TCIICODLLHDCVSLQ--P 319
Db	97	SPTPADAQSGC	-----GGGPGVEEAEAGGGD	-----VCAVCTDETAPPLRCQSFP 143
QY	320	CMHTFCAACYS	GWMERSSLCPTCRCPVERICKNHL	NNLVYLIQHPDKRSSEEDVQSM 379
Db	144	CLHPFCIPCKMT	PLANTCPLCNTPV-----	AVLIVGTAGSFSFTPIV 189
QY	380	-DARKKITQDNL	-----QPKVR-RGFS	-----DEEGSSEDLLEL 411
Db	190	NDPRTRYEAEAAV	RAGTAVDFIWTGNPRTAPRSL	LGCHTVRALSPFPPFGCTDDEDDL 249
QY	412	SDVDSSESDISQPV	--VCRQCE-----	YRQAAQPPHC-PAPEGEPAQO--ALGD 459
Db	250	ADVD-----	YVPAPRAEPREGGGAGATGTSQ	PAATRAP--PGAPRSSSGG 297
QY	460	AP 461		
Db	298	AP 299		

```

RESULT 15
US-10-200-562-161
; Sequence 161, Application US/10200562
; Publication No. US20030165819A1
; GENERAL INFORMATION:
; APPLICANT: McGowen, Patrick
; APPLICANT: Hosken, Nancy A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; TITLE OF INVENTION: TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
; FILE REFERENCE: 210121.538C2
; CURRENT APPLICATION NUMBER: US/10/200,562
; CURRENT FILING DATE: 2003-07-19
; NUMBER OF SEQ ID NOS: 212
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 825

```

```
; TYPE: PRT
; ORGANISM: HSV2
US-10-200-562-161

Query Match      3.9%; Score 139; DB 14; Length 825;
Best Local Similarity 22.7%; Pred. No. 0.096;
Matches 82; Conservative 33; Mismatches 127; Indels 120; Gaps 19;

QY 152 GAGRGADP---RVPPSSPATQVCFEEPPQBPSTSTSLFPTASASSTEPSAG-----RE 201
Db 152 GAGRGADP---RVPPSSPATQVCFEEPPQBPSTSTSLFPTASASSTEPSAG-----RE 201
QY 6 GTSSRADPGFPPRQTGTGTPA--APHAWGLNDQWMLASSDSEETEVEVGLSDDDLHRD 63
Db 6 GTSSRADPGFPPRQTGTGTPA--APHAWGLNDQWMLASSDSEETEVEVGLSDDDLHRD 63
QY 202 RSSSCSGGGGSPKSGSPSVASDEVSSPASLPDRKTAFFSLSLPQDQEDLEPVKKIWR 261
Db 202 RSSSCSGGGGSPKSGSPSVASDEVSSPASLPDRKTAFFSLSLPQDQEDLEPVKKIWR 261
QY 64 STSEAG-----STDEMEFAGLMDAAT-----PPARPPAERQG 96
Db 64 STSEAG-----STDEMEFAGLMDAAT-----PPARPPAERQG 96
QY 262 GPGDLNLNQLLVAQPRRNAQTVHEDVRAAAGKPKDMEETLTCIQDILLHDCVSLQ--P 319
Db 262 GPGDLNLNQLLVAQPRRNAQTVHEDVRAAAGKPKDMEETLTCIQDILLHDCVSLQ--P 319
QY 97 SPTPADAQSC-----GGGFPVGEAEAEAGGGD-----VCAVCTDEIAPPLRCQSF 143
Db 97 SPTPADAQSC-----GGGFPVGEAEAEAGGGD-----VCAVCTDEIAPPLRCQSF 143
QY 320 CMHTFCAACYSGWHERSSLCPTCRCQVERICKNHILNVLVEAYLIQHDPKRSSEEDVQSM 379
Db 320 CMHTFCAACYSGWHERSSLCPTCRCQVERICKNHILNVLVEAYLIQHDPKRSSEEDVQSM 379
QY 144 CLHFFCIPCWKTIPLRNCTCLCNTPV-----AYLIVGTASGSFSTIPIV 189
Db 144 CLHFFCIPCWKTIPLRNCTCLCNTPV-----AYLIVGTASGSFSTIPIV 189
QY 380 -DARKKITQDML-----QPKVR-RSFS-----DEEGSSDLLEL 411
Db 380 -DARKKITQDML-----QPKVR-RSFS-----DEEGSSDLLEL 411
QY 190 NDRTRVEAEAAVRACTAVDFIWTGNPRTAPRSLSLGCHTVRALSPTPPWPCTDDEDDL 249
Db 190 NDRTRVEAEAAVRACTAVDFIWTGNPRTAPRSLSLGCHTVRALSPTPPWPCTDDEDDL 249
QY 412 SVDSESSDISQPIV--VCRQPE-----YRQAAQPPHC-PAPEGEPPAQ--ALGD 459
Db 412 SVDSESSDISQPIV--VCRQPE-----YRQAAQPPHC-PAPEGEPPAQ--ALGD 459
QY 250 ADVD-----YVPPAPRRAPRGGGAGATRGTSQPAATRPAP---PGAPRSSSGG 297
Db 250 ADVD-----YVPPAPRRAPRGGGAGATRGTSQPAATRPAP---PGAPRSSSGG 297
QY 460 AP 461
Db 298 AP 299
```

Search completed: May 7, 2004, 15:06:49
Job time : 107.174 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:41:17 ; Search time 37.1616 Seconds

(without alignments)
1718.743 Million cell updates/sec

Title: US-10-048-046-2

Perfect score: 3585

Sequence: 1 MERPEEGKQSPFPQWGRLL.....VKAHAKFNHICEQTRFKN 664

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR 78.*

1: PIR1.*

2: PIR2.*

3: PIR3.*

4: PIR4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1678	46.8	306	T46399	hypothetical prote
2	357.5	10.0	473	C96516	Fl6N3.15 [imported
3	168.5	4.7	467	1 WZB861	gene 61 protein -
4	145	4.0	1603	2 S17983	gene posterior sex
5	144.5	4.0	2322	2 T10542	hypothetical prote
6	142	4.0	532	2 T49467	related to COP1-in
7	141.5	3.9	424	2 G96742	unknown protein p1
8	141.5	3.9	1208	2 T00362	hypothetical prote
9	139	3.9	775	1 EDB811	immediate-early pr
10	139	3.9	825	1 EDB8XD	immediate-early pr
11	138	3.8	387	2 T39653	probable DNA repai
12	138	3.8	639	2 T16648	hypothetical prote
13	137.5	3.8	973	2 B89009	protein T27C4.4 [i
14	136.5	3.8	1331	2 T04938	hypothetical prote
15	136.5	3.8	1495	2 A85240	hypothetical prote
16	136.5	3.8	1495	2 T10549	hypothetical prote
17	136	3.8	315	2 D48560	immediate-early pr
18	132.5	3.7	2414	2 A54277	transcription adap
19	132.5	3.7	3507	2 T34513	hypothetical prote
20	131.5	3.7	551	2 JC7562	glioblastoma RING
21	131	3.7	794	2 S59069	Z13 protein - mous
22	131	3.7	1849	2 C41859	IGA-specific metal
23	130.5	3.6	248	2 D96535	RING-H2 finger pro
24	129.5	3.6	453	2 G96895	hypothetical prote
25	129.5	3.6	776	2 T20738	hypothetical prote
26	129.5	3.6	933	1 QRHUP	progesterone recep
27	129.5	3.6	1083	2 C88854	protein Fl1A10.3 [
28	129	3.6	222	2 JC4296	ring finger protei
29	129	3.6	638	2 JC7753	ring finger B-box

30 129 3.6 1280 2 T00365 hypothetical prote
31 128.5 3.6 1888 2 T14273 zinc finger protei
32 127.5 3.6 245 2 T45652 RNA binding-like p
33 127 3.5 572 2 S21325 probable exo-gluca
34 126.5 3.5 406 2 S59296 probable finger pr
35 126.5 3.5 676 1 EDBE23 immediate-early pr
36 125.5 3.5 568 2 T71614 chromatinic RING f
37 125.5 3.5 989 2 A54505 serine-repeat anti
38 125.5 3.5 2163 2 T15276 hypothetical prote
39 125 3.5 630 2 A49656 estrogen-responsiv
40 124.5 3.5 1576 2 S65774 homeotic protein H
41 124.5 3.5 3869 2 A48205 All-1 protein +GRE
42 124 3.5 676 1 EDBE22 immediate-early pr
43 123 3.5 1712 2 A38261 masking protein pr
44 123.5 3.4 892 2 T09193 ataxin 7 - human
45 123.5 3.4 1233 2 T30989 serine/threonine p

ALIGNMENTS

RESULT 1

T46399

hypothetical protein DKFZp434N2420.1 - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 04-Feb-2000 #sequence_revision 04-Feb-2000 #text_change 04-Feb-2000

C:Accession: T46399

R:Ottewaelder, B.; Obermaier, B.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.

submitted to the Protein Sequence Database, January 2000

A:Reference number: Z23031

A:Accession: T46399

A:Status: Preliminary

A:Molecule type: mRNA

A:Residues: 1-306 <AAA>

A:Cross-references: EMBL:AL137561

A:Experimental source: adult testis; clone DKFZp434N2420

C:Genetics:

A:Note: DKFZp434N2420.1

Query Match 46.8%; Score 1678; DB 2; Length 306;
Best Local Similarity 100.0%; Pred. No. 1.9e-100;
Matches 306; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 359 VEAYLIQHPPKSRSEEDVQSMARDNKITQDMLOPKVRRSFSDSESSDLSLSDVDSSES 418
DB 1 VEAYLIQHPPKSRSEEDVQSMARDNKITQDMLOPKVRRSFSDSESSDLSLSDVDSSES 60
QY 419 SDISQPVVVCRCQCPYRRQAQPPHCPAPEGHPGAQALGDAPSTSVSLTTAVQDYVCPL 478
DB 61 SDISQPVVVCRCQCPYRRQAQPPHCPAPEGHPGAQALGDAPSTSVSLTTAVQDYVCPL 120
QY 479 QGSHALCTCCFPMPDRRAERQDPVAPQQCAVCLQPFCHLYWGCRTGCGCLAPFCE 538
DB 121 QGSHALCTCCFPMPDRRAERQDPVAPQQCAVCLQPFCHLYWGCRTGCGCLAPFCE 180
QY 539 LNLGDKCLDGLVNNNSYESDLKNYLATRLGKTNMLTESLVALQGVFLLSDYRTVGT 598
DB 181 LNLGDKCLDGLVNNNSYESDLKNYLATRLGKTNMLTESLVALQGVFLLSDYRTVGT 240
QY 599 VLYCCGLSFRLLTYQYQNTIPASLPVAVTSRDPDQYWRNCRTOVKAHAMKFNHICE 658
DB 241 VLYCCGLSFRLLTYQYQNTIPASLPVAVTSRDPDQYWRNCRTOVKAHAMKFNHICE 300
QY 659 QTRFKN 664
DB 301 QTRFKN 306

RESULT 2

C96516

Fl6N3.15 [imported] - Arabidopsis thaliana

C:Species: Arabidopsis thaliana (mouse-ear cross)

C:Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 31-Mar-2001

C:Accession: C96516
R:Theologias, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,
Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;
ansen, N.F.; Hughes, B.; Huizar, L.
Nature 408, 816-820, 2000
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziali,
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A:Authors: Salberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A:Reference number: A86141; MUID:21016719; PMID:11130712
A:Accession: C96516
A:Status: Preliminary
A:Molecule type: DNA
A:Residues: 1-473 <STO>
A:Cross-references: GB:A8005173; NID:G5668816; PIDN:AAD46042.1; GSPDB:GN00141
C:Genetics:
A:Gene: F16N3.15
A:Map position: 1

Query Match 10.0%; Score 357.5; DB 2; Length 473;
Best Local Similarity 23.6%; Pred. No. 1.8e-15;
Matches 130; Conservative 65; Mismatches 201; Indels 155; Gaps 20;

QY 177 PBTSTDLFPTASASTPS-----PAGRRSS 204
Db 7 PNTTTAE---TQSSGSKPSDDAWAKLVPLDTRESIEIRCNDMVICSEIKPSLEKHE 63
QY 205 SCSSGGGIGSPKSGFVSASDEVSFASALPRKTASPSSELPQDQDELEPVKKMGDGG 264
Db 64 WCR-----ITKNLQGSATIHKSSDALVDK-----AVPK-----DG 97
QY 265 DLD-LNGQLLVAQPRNAQTVEHVRAAAGKPKDMEETL-----TCICQDLHDC 314
Db 98 AVDIISGSEIVPGPEEQGLQYRFTMPA--PESRTQLQISIDPEHAKCSICLINIHDV 155
QY 315 VSLQCMHTFCAACVSGWMSRS-----LCPTCCPVERICKNHLNLYEAVLIQHPD 368
Db 156 VTAAPCLNFCNFCSEFWRRSEEEKHVLCPQCTTVQYVGNKHLKNIQEEILKVDA 215
QY 369 KRSSEEDVQSDARNKITDML---QPKVRSFSDEEGSDDLLELSVDSESDISQPY 425
Db 216 LRPADIAVLDSSASIQSLNLIIGSKRRLNWPATHEERDSLRL----- 261
QY 426 VVRCQPEYRQAAPFHCPCPEGEPGAPQALGDAPSTVSLTTAVQDYVCPLOGSHALC 485
Db 262 ---OCPO-----CVANIG-----GYRCEHGHQHLQC 284
QY 486 TCCFQMPDRAERQDPVAPQCAVCLQPFCHLYWGTRTGCYGLAPFCELN---L 541
Db 285 HLCQGMPPRANLQ-----VFLHCKGCDRPFCCGAYWS-SENVTQVSGPVCTRETPPI 337
QY 542 GDKCLDGV---LNNNSYESDILKNLYATRGTLTKNMLTESL-----VALQGVFLSDY 592
Db 338 SERTITRIFPITHMNRHQDITQRCIAHMTXTPDVVAEWLRLFNREIDRSRMLNHA 397
QY 593 R-VTGDTVLCCYGLRSFRELTYVQRNIPASELIVANTSRDPCYWGNCRTQ-VKAHHA 650
Db 398 ETITASTHVCNDCYDKLVGLFYWFRITLFRNHLPADVAAREDCWIGYACRIQHNEHDA 457
QY 651 MKFNHICEQTR 661
Db 458 RKENHVCRTPR 468

RESULT 3
WZBE61
Gene 61 protein - human herpesvirus 3
C:Species: human herpesvirus 3, varicella-zoster virus
C:Date: 30-Sep-1988 #sequence_revision 30-Sep-1988 #text_change 17-Mar-2000
C:Accession: I27215
R:Davidson, A.J.; Scott, J.E.

J. Gen. Virol. 67, 1759-1816, 1986
A:Title: The complete DNA sequence of varicella-zoster virus.
A:Reference number: A27345; MUID:86306657; PMID:3018124
A:Accession: I27215
A:Molecule type: DNA
A:Residues: 1-467 <DAV>
A:Cross-references: EMBL:X04370; NID:G59989; PIDN:CRA27944.1; PID:G60050
C:Genetics:
A:Gene: 61
A:Superfamily: varicella-zoster virus gene 61 protein; RING finger homology
C:Keywords: DNA binding; transcription regulation; zinc finger
F:15-63/Domain: RING finger homology <RNG>
F:19-57/Region: zinc finger C3HC4 motif

Query Match 4.7%; Score 168.5; DB 1; Length 467;
Best Local Similarity 26.3%; Pred. No. 0.0024;
Matches 64; Conservative 20; Mismatches 106; Indels 53; Gaps 10;

QY 287 DVRAAGKPKDMEETLTCIICQDLHDCVSLQPCVHTFCAACVSGWMSRSILCPTCRCPV 346
Db 2 DTLAGSGTSDASDNTCTICMTVSDLGKTKPCLHDFCFVIRAWTSTVQCPLCRCPV 61
QY 347 ERICKNHLNLYEAVLIQHPDKSRSEEDVQSDARNKITQDMLQPKVRSFSDEEGSSE 406
Db 62 QSLHLKIVSDTSYKEV-HP-----SDDGFS-----EPPSDESIDILPGDVI 104
QY 407 DLLELSDVSESDISQPYVCRQCEYRQAAPHCPCPEGEPGAPQALGDAPSTVS 466
Db 105 DLLPPSPGFSRES-IQOP-----TSRSREPIQSP-----NPGLOSSAREP-TASS 149
QY 467 LTTAVQDYVCP--LQSSHALCTCC-----FQMPDRA-----EREQDPV 505
Db 150 PDSQDSIQPTTRDSPPGVTKCTSTASFLKVFQDPAVRSATPVVYGSIESAQOQPT 209
QY 506 APQ 508
Db 210 GGQ 212

RESULT 4
S17983
gene posterior sex combs protein - fruit fly (Drosophila melanogaster)
N:Alternate names: regulatory protein Psc
C:Species: Drosophila melanogaster
C:Date: 22-Nov-1993 #sequence_revision 26-May-1995 #text_change 21-Jul-2000
C:Accession: S17983; S17880
R:Brunk, B.P.; Martin, E.C.; Adler, P.N.
Nature 353, 351-353, 1991
A:Title: Drosophila genes Posterior Sex Combs and Suppressor two of zeste encode protein
A:Reference number: S17983; MUID:92018190; PMID:1833647
A:Accession: S17983
A:Status: nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-1603 <BRU>
A:Cross-references: EMBL:X59275; NID:G8357; PIDN:CAA41965.1; PID:G8358
A:Note: translation of nucleotide sequence is not complete
R:van Lohuizen, M.; Frasch, M.; Wientjens, E.; Berns, A.
Nature 353, 353-355, 1991
A:Title: Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophi
A:Reference number: S17880; MUID:92018191; PMID:1922340
A:Accession: S17880
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 231-452, 'I', 454-591 <LOH>
C:Genetics:
A:Gene: FlyBase:Psc
A:Cross-references: FlyBase:FBgn0005624
C:Superfamily: RING finger homology
C:Keywords: DNA binding; nucleus
F:261-309/Domain: RING finger homology <RNG>

Query Match 4.0%; Score 145; DB 2; Length 1603;
Best Local Similarity 20.3%; Pred. No. 0.35;

R:Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; ansen, N.F.; Hughes, B.; Huizar, L.
Nature 408, 816-820, 2000
C:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.A.; Li, J.H.; Li, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Mailli, R.; Marziani, Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A:Title: Sequence and analysis of chromosome 1 of the Plant Arabidopsis.
A:Reference number: A86141; MUID:21016719; PMID:11130712
A:Accession: G96742
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-424 <STO>
A:Cross-references: GB:AB005173; NID:96978922; PIDN:AAF34314.1; GSPDB:GN00141
C:Genetics:
A:Gene: F17M19.13
A:Map position: 1

Query Match 3.9%; Score 141.5; DB 2; Length 424;
Best Local Similarity 26.3%; Pred. No. 0.11;
Matches 67; Conservative 27; Mismatches 108; Indels 53; Gaps 12;

Qy 268 LAGQLVAPRRNAQTVEDVRAAGKEDKMEETLTCTIICQD--LLHDCVSLQPCMHTEFC 325
Db 182 MSRLVAMPPLIFSSPHEDNTTA-----FTCAICLEDYTGDKLRLPCCKHFH 231
Qy 326 AACVSGWNER--SSLCPTCRCPVERICKNHILNNLVEAYLIQHPDKSRSEEDVQSMARK 384
Db 232 AACVDSWLTSTWRTCP-----VCKEDARTSTGE-----PPASESTPLLS--AASS 275
Qy 385 ITQMLQPKVVR-----SFDSEGSSEDLLESDVSESDISQPIVVC 428
Db 276 FTSSSLHSSVRASSALLIGPSLGSFTSISFPAYASSYIRQ--SFSSSNRRSPPIISVS 333
Qy 429 RQCEYRQAAPPHCPAPE---GEPGAQALGDAPSTSVSLTAVQDY--VCPLOQSHAL 484
Db 334 RSVVDLQQAASPPSPSPQSRYSVISHMASPQSLG--YPIISPNTRYMSPYRSPNASPAM 392
Qy 485 CTCFCQPM--PDRRAE 498
Db 393 AGSSNYPLNPLRYSE 407

RESULT 8
T00362
hypothetical protein KIAA0675 - human
C:Species: Hmo sapiens (man)
C:Date: 01-Feb-1999 #sequence_revision 01-Feb-1999 #text_change 02-Sep-2000
A:Accession: T00362
R:Tsukawa, K.; Nagase, T.; Suyama, M.; Miyajima, N.; Tanaka, A.; Kotani, H.; Nomura, N.
DNA Res. 5, 169-176, 1998
A:Title: Prediction of the coding sequences of unidentified human genes. X. The complete
A:Reference number: Z14142; MUID:98403880; PMID:9734811
A:Accession: T00362
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-1208 <ISH>
A:Cross-references: EMBL:AB014575; NID:93327163; PIDN:BAA31650.1; PID:93327164
A:Experimental source: brain; Clone HK02566
C:Genetics:
A:Note: KIAA0675
C:Superfamily: RING finger homology
F:1144-1193/Domain: RING finger homology <RRN>

Query Match 3.9%; Score 141.5; DB 2; Length 1208;
Best Local Similarity 26.1%; Pred. No. 0.42;
Matches 54; Conservative 28; Mismatches 92; Indels 33; Gaps 8;

Qy 159 PRVPPSSPATQCFEPPQSTSTSLFTTASSTSTSPAGRRSSSCGSGGSPKGS 218
Db 999 PRAP---LMTGIATWALPAP---VGDVPPSAGLRSDPSIMNWERITD-----RLKTA 1044

Qy 219 GPSVASDEVSSFASALPDKRTASFSLEPOD-----QEDLEPVKKMRGDDLDLN----- 269
Db 1045 PFQOTRKELTDPLRLKDAYKSLSELTFDEIVCKISQFIDPKKSQSGKSVNVCVSP 1104
Qy 270 -----GQLLVAPRRNAQTVEDVRAA-----AGKED-KMEETLTCTIC-QDILLHDCVSLQ 319
Db 1105 SHSPSQDAAQPPKAPMRLPLTSQQPATWEGASNPDEEEBEEPCVICHENLSPENLSVIP 1164
Qy 320 CNHTFCAACYSWMMERSLCTPCPCPV 346
Db 1165 CAHKPHAQCIIRPWLWQQTCTPCRLHV 1191

RESULT 9
EDBE11
immediate-early protein IE110 - human herpesvirus 1 (strain 17)
C:Species: human herpesvirus 1
C:Date: 31-Mar-1988 #sequence_revision 31-Mar-1988 #text_change 17-Mar-2000
C:Accession: A29152
J:Perry, D.J.; Rixon, F.J.; Everett, R.D.; Frame, M.C.; McGeoch, D.J.
J. Gen. Virol. 67, 2385-2390, 1986
A:Title: Characterization of the IE110 gene of herpes simplex virus type 1.
A:Reference number: A29152; MUID:87059760; PMID:3023529
A:Accession: A29152
A:Molecule type: DNA
A:Residues: 1-775 <PER>
A:Cross-references: GB:X04614; NID:959832; PIDN:CAA28285.1; PID:959833
C:Genetics:
A:Insertions: 19/3; 242/1
C:Superfamily: herpesvirus immediate-early protein IE110; RING finger homology
C:Keywords: DNA binding; early protein; transcription regulation; zinc finger
F:112-162/Domain: RING finger homology <RNG>
F:116-156/Region: zinc finger C3HC4 motif

Query Match 3.9%; Score 139; DB 1; Length 775;
Best Local Similarity 22.6%; Pred. No. 0.35;
Matches 80; Conservative 34; Mismatches 142; Indels 98; Gaps 16;

Qy 156 GADPRVPPSSPATQCFEPPQST-----STSLFTTASSTSTSPAGRRSSSCGSGG 211
Db 6 GASTRPEGRPQ-----REPAPDVVFPDCRDL--PDSSDSEATEVGR----- 48
Qy 212 GISPKGSGPSVASDEVSSFASALPDKRTASFSLEPODLEPVKKMRGDDLDLNQ 271
Db 49 -----GDADHDD-----DSASEADSTDELFTGLGPGVD--GGA 84
Qy 272 LLVAQPRRNAQTVEDVRAAGKPKD---MEETLTCTICQDLL--HDCVSLQPCMHTEFC 325
Db 85 VSGGSPR-----EEDPGCGAPREDGSGDEGVCVCTDEIAPHLCRCDTFPCWHRFC 139
Qy 326 AACYSWMMERSLCTPCPCVERICKNHILNNLVEAYLIQHPDKSR--SEEDVQSDARN 383
Db 140 IPCMKTWMLRNTCPLCNKLVLIIVGVTPSGSFSTIPVNDPQTRMEAEAVRAGTAVD 199
Qy 384 KI-----TQDMLQPKVRSFSDSESSDLELSDVSESDISQPIV 426
Db 200 FIWGNQRPAPRYLTUGGHTVRLALSTHEPTTDED-----DDDDDDADYVPP-- 247
Qy 427 VCRQCEY--RRQAQPP-----HCPAPEGPGAPQA--LGDAPSTSVSLTT 469
Db 248 APRTPRAPRRGAAPPVTTGGASHAAPQAPAAARTAPPAPIGPHGSSNTTTT 301

RESULT 10
EDBEXD
immediate-early protein RL2 - human herpesvirus 2 (strain HG52)
N:Alternate names: RL2 protein
C:Species: human herpesvirus 2
A:Note: host Homo sapiens (man)
C:Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 19-Jan-2001
C:Accession: JQ1501
R:McGeoch, D.J.; Cunningham, C.; McIntyre, G.; Dolan, A.

J. Gen. Virol. 72, 3057-3075, 1991
A;Title: Comparative sequence analysis of the long repeat regions and adjoining parts of
A;Reference number: JQ1494; MUID:92113549; PMID:1662697
A;Accession: JQ1501
A;Molecule type: DNA
A;Residues: 1-825 <MC>
A;Cross-references: GB:D10471; DBJ:D01128; NID:G221784; PIDN:BAA23427.1; PID:G2626942
C;Genetics:
A;Gene: RL2
A;Introns: 25/3; 252/1
C;Superfamily: herpesvirus immediate-early protein IB110; RING finger homology
C;Keywords: DNA binding; immediate-early protein; tandem repeat; transcription regulatio
F;122-172/Domain: RING finger homology <RNG>
F;126-166/Region: zinc finger C3HC4 motif
F;589-623/Region: 5-residue repeats (A-S-S-S-S)

Query Match 3.9%; Score 139; DB 1; Length 825;
Best Local Similarity 22.7%; Pred. No. 0.38;
Matches 82; Conservative 33; Mismatches 127; Indels 120; Gaps 19;

QY 152 GAGRGADP--RVPPSPATQVCFEPQSTSTSDLFPTASASTPSPAG-----RE 201
DB 6 GTSRADPGEPFRPTQTPA--APHAWGLNDQWLASSDSEETEVGISDDDLHD 63
QY 202 RSSSCSGGGGIGSPKSGSPVASDESSPASALPDRTKTAFFSLSLEPDQEDLEPVKKVR 261
DB 64 STSEAG-----STDTEPTEAGLMDAAT-----PPARPPAERQG 96
QY 262 GDGDLNLGQLLVAPRRNAQTVEVRAAGKPDQMEETLTICICODLLHDCVSLQ--P 319
DB 97 SPTPADAQGC-----GGPGVGEAEAGGGD-----VCAVCTDIAPLRQSPF 143
QY 320 CMHTFCAACYSGWMSRLCPTCCPVERICKNHLNLVAYLIQHHPKSRSEEDVQSM 379
DB 144 CLHPFCIPCKMTWPLENTCPLCNTPV-----AVLIIVGTASGSFSTIPTIV 189
QY 380 -DARKITQDML-----OPKVR-RSFS-----DEEGSSEDLLEL 411
DB 190 NDRTRVEAEAAVRAGTAVDFITGNPRTAPRSLSLGHTVRLSTPFPFGTDDDDLL 249
QY 412 SDVDSSESDISQPVV--VCRQCE-----YRRAQAQPHC-PAPEGSPGAPO--ALGD 459
DB 250 ADVD-----YVPPAPRAPRRGGGAGATRGTSQAATRAPAP---PGAPRSSSGG 297
QY 460 AP 461
DB 298 AP 299

RESULT 11
T39553
Probable DNA repair and recombination protein - fission yeast (Schizosaccharomyces pombe)
C;Species: Schizosaccharomyces pombe
C;Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 02-Sep-2000
C;Accession: T39553
R;Lyne, M.; Rajandream, M.A.; Barrell, B.G.; Rieger, M.
submitted to the EMBL Data Library, October 1998
A;Reference number: 221868
A;Accession: T39553
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-387 <LYN>
A;Cross-references: EMBL:AL031856; PIDN:CAA21300.1; GSPDB:GN00067; SPDB:SPBC1734.06
A;Experimental source: strain 972h-; cosmid c1734
C;Genetics:
A;Gene: SPDB:SPBC1734.06
A;Map position: 2
A;Superfamily: RING finger homology
F;25-72/Domain: RING finger homology <RRN>

Query Match 3.8%; Score 138; DB 2; Length 387;
Best Local Similarity 25.2%; Pred. No. 0.17;
Matches 38; Conservative 28; Mismatches 71; Indels 14; Gaps 6;

QY 298 MEETLTICICODLLHDCVSLQPCWHTFCAACYSGWMSRLCPTCCPVE--RICKNHL 355
DB 23 LDSSRLCLICHEYFR-APLITSCSHTFCSCIRDLREHPCMPACRAPEQESRLRKNTIL 81
QY 356 NNLVAYLIQHHPKSRSEEDVQSMARNKITQDMLQPKVRRSFSDRGSSDDLLELDVD 415
DB 82 EEILLESFKVIRPTL-----FEFLKVEN-VFKPVQAPETVIAQDSASGDEWED--DLA 132
QY 416 SESSDISQPVVYVCRQCEPQYRRQAQPPHCPA 446
DB 133 SNSSPASIAKTSRDSKRRKE--DLVHCPA 161

RESULT 12
T16648
Hypothetical protein R02E12.4 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 02-Sep-2000
C;Accession: T16648
R;Leimbach, D.
submitted to the EMBL Data Library, April 1996
A;Description: The sequence of C. elegans cosmid R02E12.
A;Reference number: Z18554
A;Accession: T16648
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-639 <LEI>
A;Cross-references: EMBL:U5337; NID:G1255833; PID:G1255835; PIDN:AAA96184.1; GSPDB:GN000
A;Experimental source: strain Bristol N2; clone R02E12
C;Genetics:
A;Gene: CESP:R02E12.4
A;Map position: X
A;Introns: 63/3; 90/1; 136/2; 177/1; 220/2; 242/3; 294/2; 427/2; 464/3; 505/3; 580/1
C;Superfamily: RING finger homology
F;22-70/Domain: RING finger homology <RRN>

Query Match 3.8%; Score 138; DB 2; Length 639;
Best Local Similarity 28.8%; Pred. No. 0.32;
Matches 44; Conservative 21; Mismatches 66; Indels 22; Gaps 7;

QY 283 TVHEVRAAAGKPD--KME-ETLTCICODLLHDCVSLQPCWHTFCAACYSGWMSRLC 339
DB 2 TVEEQVEMNLNLPESLEFEDVQCHICFQVNHFPVTLTKHSICACAGNWLSSCSVC 61
QY 340 PTCRCPVERICKNHLNLVAYLIQHHPKSRSEEDVQ-----SMDARNKITQ- 387
DB 52 FMCRTVRVEIHLNDDLKKSLEFLKLHPEQ-ELPEDIKWEQCCHETVFWSLQQRKANES 120
QY 388 DML-----QPKVRRSFSDRGSSDDLLELDVD 416
DB 121 DAVFYGSQPVVPEHLASAE--SNDPIETKRLN 151

RESULT 13
B89009
protein T27C4.4 [imported] - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 10-May-2001
C;Accession: B89009
R;anonymous, The C. elegans Sequencing Consortium.
Science 282, 2012-2016, 1998
A;Title: Genome sequence of the nematode C. elegans: a platform for investigating biology
A;Reference number: A75000; MUID:99069613; PMID:9851916
A;Note: see websites genome.wustl.edu/gsc/C_elegans/ and www.sanger.ac.uk/Projects/C_eleg
A;Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and
A;Accession: B89009
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-973 <STO>
A;Cross-references: GB:chr_V; PIDN:AAC17700.1; PID:G3165588; GSPDB:GN00023; CESP:T27C4.4
C;Genetics:
A;Gene: T27C4.4

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:37:32 ; Search time 22.4372 Seconds

(without alignments)
1540.951 Million cell updates/sec

Title: US-10-048-046-2

Perfect score: 3585

Sequence: 1 MERPEGKSPFPQNGRL.....VKAHAMKFNHCQTRFKN 664

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_42.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	203.5	5.7	485	1 RNFB HUMAN	O76064 homo sapien
2	197	5.5	488	1 RNFB MOUSE	O8vc56 mus musculus
3	168.5	4.7	467	1 ICP0 VZVD	P09309 varicella-z
4	145	4.0	1603	1 PSC DROME	P35820 drosophila
5	139	3.9	775	1 ICP0 HSV11	P08393 herpes simp
6	139	3.9	825	1 ICP0 HSV2H	P28284 herpes simp
7	138	3.8	387	1 RH18 SCHPO	O74747 schizosacch
8	134.5	3.8	551	1 RN27 HUMAN	O9bzt9 homo sapien
9	134	3.7	624	1 RN12 HUMAN	O9nvx2 homo sapien
10	132.5	3.7	1300	1 SAL3 HUMAN	O9bxa9 homo sapien
11	132.5	3.7	2414	1 P300 HUMAN	Q09472 homo sapien
12	131.5	3.7	600	1 RN12 MOUSE	Q9wtv7 mus musculus
13	131	3.7	1849	1 IGA4 HASTN	P45386 haemophilus
14	130.5	3.6	551	1 RN27 MOUSE	Q99pj2 mus musculus
15	129	3.6	1341	1 ACIN HUMAN	O8ukv3 homo sapien
16	128.5	3.6	933	1 PRGR HUMAN	O6401 homo sapien
17	128	3.6	407	1 RPF2 HUMAN	O80858 homo sapien
18	128	3.6	1338	1 ACIN MOUSE	Q99466 homo sapien
19	128	3.6	2003	1 NTC4 HUMAN	Q9umc6 homo sapien
20	127	3.5	2715	1 MLL4 HUMAN	P29128 bovine herp
21	126.5	3.5	676	1 ICP0 HSVBJ	O75382 homo sapien
22	126	3.5	744	1 TRM3 HUMAN	Q9dd48 seriola qui
23	125.5	3.5	423	1 MKR2 SERQU	Q9dd48 seriola qui
24	125.5	3.5	989	1 SRAA FLAFG	P13823 plasmodium
25	125	3.5	630	1 TRM3 HUMAN	Q4258 homo sapien
26	125	3.5	744	1 TRM3 RAT	O70277 rattus norv
27	125	3.5	777	1 BAR1 HUMAN	Q99728 homo sapien
28	125	3.5	794	1 ICA1 BOVIN	Q60821 mus musculus
29	124.5	3.5	705	1 ICA1 BOVIN	P08111 bos taurus
30	124.5	3.5	1127	1 TRIG HUMAN	Q9upn9 homo sapien
31	124.5	3.5	3866	1 HXK MOUSE	P55200 mus musculus
32	124	3.5	676	1 ICP0 HSVBK	P29836 bovine herp
33	124	3.5	1712	1 LFB1 RAT	Q00918 rattus norv

34	124	3.5	2842	1 APC RAT	P70478 rattus norv
35	123.5	3.4	892	1 ATX7 HUMAN	O15265 homo sapien
36	123.5	3.4	1233	1 M4K4 MOUSE	P97820 mus musculus
37	123	3.4	605	1 PJAI MOUSE	O55176 mus musculus
38	123	3.4	898	1 CIZ1 HUMAN	O8ulv3 homo sapien
39	123	3.4	1007	1 SAL2 HUMAN	Q9y467 homo sapien
40	122	3.4	433	1 TIG CHLMU	Q9p119 chiampydia m
41	122	3.4	501	1 UVS2 NEUCR	P33288 neurospora
42	122	3.4	507	1 MKR3 HUMAN	Q13064 homo sapien
43	122	3.4	605	1 CORO CAREL	Q21624 caenorhabdi
44	122	3.4	1004	1 SAL2 MOUSE	Q9qx96 mus musculus
45	122	3.4	1073	1 PVDA FLAKN	P22545 plasmodium

ALIGNMENTS

RESULT 1
ID RNFB HUMAN STANDARD; PRT; 485 AA.
AC O76064;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE RING finger protein 8.
GN RNFB OR KIAA0646.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Seki N., Yamauchi M., Saito T.;
RT "Isolation and chromosomal assignment of the gene for a novel zinc
finger protein."
RL Submitted (APR-1998) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Ishikawa K.-I., Nagase T., Suyama M., Miyajima N., Tanaka A.,
RA Kotani H., Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. X.
The complete sequences of 100 new cDNA clones from brain which can
code for large proteins in vitro."
RL DNA Res. 5:169-176 (1998).
RN [3]
RP SEQUENCE FROM N.A.
RA Tracey A.;
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,
Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalon D.K., Munz D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Faney J., Heiton B., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
Whiting M., Madan A., Young A.C., Green E.D., Dickson M.C.,
Blakesley R.W., Touchman J.W., Schenck J., Myers R.M.,
Rodriguez A.C., Grimwood J., Schmutz J., Skalska U., Smallos D.E.,
Butterfield Y.S.N., Krzywinski M.I., Jones S.J.M., Marra M.A.,
Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length

Db 61 RSHC-VLKONPEQWIMDNKSLNGVWLNARERLAPLQGYCIRKGDHIOQGV-PLESRETA 118
QY 117 AYLYESLSE-----KQGTQESFEA-NKENV-----141
Db 119 EYEVIEEDWESLAPCLAPNDQRMKEKHGSRTKKFSFSGLENI-PARGSSDLRCPLAN 178
QY 142 -----FHGTQKTSAGAG-----RGADPRVPPSPAT-----Q 169
Db 179 VASKPIPEKXLGKGDASSQSLGCLPGLTSLKASERAAGPHACSPKVLSELCPPKKQK 238
QY 170 VCEEPQPSSTSDLPFTASSTSPAGRERSSCGSGGGISPKGSGPSVASDE--- 226
Db 239 AC--RFSASONSUELFKVTWMSRMKLKTMQOEKQIAV-LNVKQTRKSGSKKIVRNEKEL 295
QY 227 --VSSFASALPDRKTASFSSLEFQDDELBPVKKMKRGDGLDLNGLQLVAQPRNA--- 281
Db 296 RNLQSQLYAQAQAQARVEQLEKTFQEEAHYLGQLEKEQECBCKQQLVQALQEQHQLME 355
QY 282 -----QTVHEDVRAAAGKP-----DKMEETLTCTICQDQLLHD 313
Db 356 ELNCSKQDFEKKIOAKNKELEQTKKEKQVQAKQEEVLHSHMNDLLENELQCIICSEYFIE 415
QY 314 CVSLQPCWHTFCAACYSQWMMERSLCTCRCPVERICKHILNNLV 359
Db 416 AVTLN-CAHFCFCFCINEMWKRKVECPICRDKIESRTNSILVLDNCI 460
RESULT 3
ICPO_VZVD STANDARD; PRT; 467 AA.
AC P09309;
DT 01-MAR-1989 (Rel. 10, Created)
DT 01-MAR-1989 (Rel. 10, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Trans-acting transcriptional protein ICPO.
GN 61.
OS Varicella-zoster virus (strain Dumas) (VZV).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Varicellovirus.
OX NCBI_TaxID=10339;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93059681; PubMed=1366099;
RA Moriuchi H., Moriuchi M., Smith H.A., Straus S.E., Cohen J.I.;
RT "Varicella-zoster virus open reading frame 61 protein is functionally
RT homologous to herpes simplex virus type 1 ICPO.";
RL J. Virol. 66:7303-7308 (1992).
CC -!- FUNCTION: REPRESSES THE EXPRESSION OF VIRAL IE, EARLY, AND LATE
CC GENE PROMOTERS.
CC -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC -!- SIMILARITY: TO OTHER HERPESVIRUSES ICPO PROTEIN.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; X04370; CAA27944.1; --
CC PIR; I27215; WZBE61.
CC HSP; P28990; ICHC.
CC InterPro; IPR001841; Znf_ring.
CC Pfam; PF00097; zf-C3HC4; 1.
CC SMART; SMO0184; RING; 1.

DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS0089; ZF_RING_2; 1.
KW Transcription regulation; Trans-acting factor; Repressor; Zinc-finger;
KW DNA-binding.
FT ZN_FING 19 58 RING-TYPE.
SQ SEQUENCE 467 AA; 50916 MW; 25EFA6977EA6994C CRC64;
Query Match 4.7%; Score 168.5; DB 1; Length 467;
Best Local Similarity 26.3%; Pred. No. 0.0028;
Matches 64; Conservative 20; Mismatches 106; Indels 53; Gaps 10;
QY 287 DVRAAGKPDKNMEETLTCTICQDQLLHDVCSLQPCWHTFCAACYSQWMMERSLCTCRCPV 346
Db 2 DTLAGSGGTSDASDNTCTICWSTVSLGKTMPLCHDFCFVCIRAWTSTSVQCPLCRCPV 61
QY 347 ERICKHILNNLVAYLIQHDPKRSSEEDVQSDARKKITQDMLQPKVRRSFEESGSE 406
Db 62 QSILFKIVSDTSYKEYEV-HP-----SDDGFS-----EPSFSDIDILPGDVI 104
QY 407 DLLESLDVDSSESDISQPVVYVCRQCPVEYRROAOPPHCPAPEGEPGAPQALGDAPSTSVS 466
Db 105 DLLPSPGSPRES-IQPP-----TSRSRPIQSP-----NFGPLQSSARSP-TAES 149
QY 467 LTTAVQDYVCP--LQGSALCTCC-----FQMPDPRRA-----EREQDRV 505
Db 150 PSDSQDSIQPPTRDSSPGVTKCTGASTFLRKVFKDQPAVRSATPVVYVGSIESAQPRPT 209
QY 506 APQ 508
Db 210 GQQ 212
RESULT 4
PSC_DROME STANDARD; PRT; 1603 AA.
ID_PSC_DROME
AC P35820;
DT 01-JUN-1994 (Rel. 29, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Posterior sex combs protein.
GN PSC.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92018190; PubMed=1833647;
RA Brunk B.P., Martin E.C., Sharp E., Adler P.N.;
RT "Drosophila genes Posterior Sex Combs and Suppressor two of zeste
RT encode proteins with homology to the murine bmi-1 oncogene.";
RL Nature 353:351-353 (1991).
CC -!- FUNCTION: The Polycomb group (PC-G) genes are needed to maintain
CC expression patterns of the homeotic selector genes of the
CC antennapedia (Antp-C) and bithorax (Bx-C) complexes, and hence for
CC the maintenance of segmental determination.
CC -!- SUBCELLULAR LOCATION: Nuclear (Probable).
CC -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; X59275; CAA41965.1; --
CC PIR; S17983; S17983.
CC FlyBase; Fgn0005624; Psc.
CC InterPro; IPR001841; Znf_ring.
CC Pfam; PF00097; zf-C3HC4; 1.

```
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00518; ZF_RING_2; 1.
KW Zinc-finger; Developmental protein; DNA-binding; Nuclear protein.
FT DOMAIN 47 53 POLY-THR.
FT DOMAIN 83 88 POLY-THR.
FT DOMAIN 91 98 POLY-THR.
FT DOMAIN 145 152 POLY-THR.
FT DOMAIN 184 202 POLY-SER.
FT ZN FING 265 304 RING-TYPE.
FT DOMAIN 642 651 POLY-SER.
FT DOMAIN 1066 1069 POLY-GLY.
FT DOMAIN 1185 1189 POLY-PRO.
FT DOMAIN 1214 1217 POLY-PRO.
FT DOMAIN 1391 1396 POLY-PRO.
FT DOMAIN 1458 1461 POLY-ALA.
FT DOMAIN 1517 1520 POLY-GLY.
SQ SEQUENCE 1603 AA; 169999 MW; 77024F4097736473 CRC64;

Query Match
Best Local Similarity 4.0%; Score 145; DB 1; Length 1603;
Matches 84; Conservative 70; Mismatches 203; Indels 56; Gaps 12;

QY 67 EKSGQVLTEDTSGTV-----INKLVKKVQTCPLQTDGTVILVYRKNEPEHNVAIYES 122
DB 17 KQTABATPEATATTMAHTQKQSLSTLAKTTTTTATNKAASVVSANSGNNSKKLA 76

QY 123 LSEKQGMTOESPEANKENVFHTKDTSGAGAGRGPVPPSPATQVCF-----E 173
DB 77 LSCSQKTTTTTTPPTT-----TTTITABATNAD-KVQKQQLKQQLFAACSIKVSE 130

QY 174 EPQPTSTDLPTASSTEPSAGRSRSCGGGGISPKGSGPSVADSVSSPASA 233
DB 131 NALATTATAAL-AAATTTTATPALATGKAATILENGIKKESTPPAVESASSSSS 189

QY 234 LPDRKTASSESLPQDQEDLEPKVKMGDGLDLNGQLLVAQPRNAQTVHEDVRAAAG 293
DB 190 SSSSSSSSSSSSTTRATSEDAASNGASADEEEDPTAAVASSTATTSLATTS 249

QY 294 KPDKMEET-----LTICIIQDILLHCVSLQPCMTFTCAACYSQGMWERSLCPTRCPYER 348
DB 250 RRPVLLTAVNPHIICHLQGVLINATTIVECLHGFCHSCLINHLRKFRCPCRCWINN 309

QY 349 ICQN-----HIINLVEAVLIQHPD-KSRSEE-DVQSDARKNTQDMLQPK 393
DB 310 AKENIKSDTTLQAVVYKLVFGLYERELMRKAFYKDRPEEALATPEQRGDDTEHLI--- 366

QY 394 VRSPFDEEGSSDLELSDVDSESDISQPVVYVCRQCPEYRQRAQPPHCPA 446
DB 367 --FSPSDMSLSLEYAELGELKTD-----SEPELVDTLRPRYLQ-----CPA 406

RESULT 5
ICPO_HSV11 STANDARD; PRT; 775 AA.
AC P08333; 1988 (Rel. 08, Created)
DT 01-AUG-1988 (Rel. 08, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Trans-acting transcriptional protein ICPO (Immediate-early protein
DE IE110) (VIM110) (Alpha-0 protein).
GN ICPO OR IE110.
OS Herpes simplex virus (type 1 / strain 17).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Simplexvirus.
OX NCBI_TaxID=10299;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88274327; PubMed=2839594;
RA McGeoch D.J., Dalrymple M.A., Davison A.J., Dolan A., Frame M.C.,
RA McNab D., Perry L.J., Scott J.E., Taylor P.;
RT "The complete DNA sequence of the long unique region in the genome of
RT herpes simplex virus type 1.";
```

```
J. Gen. Virol. 69:1531-1574 (1988).
[2] SEQUENCE FROM N.A.
RX MEDLINE=87059760; PubMed=3023529;
RA Perry L.J., Rixon F.J., Everett R.D., Frame M.C., McGeoch D.J.;
RT "Characterization of the IE110 gene of herpes simplex virus type 1.";
J. Gen. Virol. 67:2365-2380 (1986).
[3] SEQUENCE FROM N.A.
RX MEDLINE=89036163; PubMed=2846760;
RA Perry L.J., McGeoch D.J.;
RT "The DNA sequences of the long repeat region and adjoining parts of
RT the long unique region in the genome of herpes simplex virus type
RT 1.";
J. Gen. Virol. 69:2831-2846 (1988).
CC -!- FUNCTION: ICPO IS A GENERAL TRANSACTIVATOR OF ALL THREE CLASSES OF
CC HSV GENES WHICH FUNCTIONS SYNERGISTICALLY WITH ICPO. OFTEN TERMED
CC AS A PROMISCUOUS TRANSACTIVATOR. MAY PLAY A ROLE IN THE BALANCE
CC BETWEEN THE LATENT AND LYTIC STATES, REACTIVATING LATENT HSV. ICPO
CC MIGRATES TO THE ND10 NUCLEAR BODIES IN THE EARLY TIMES OF
CC INFECTION AND DISRUPTS THEM. BINDS TO HAUSP AND MAY MODIFY ITS
CC DRUG-INACTIVATING SUBSTRATE SPECIFICITY OR ACTIVITY ON VIRAL OR
CC CELLULAR TARGETS, LEADING TO AN INCREASED OR DECREASED STABILITY
CC OF THESE PROTEINS
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
CC -!- SIMILARITY: TO OTHER HERPESVIRUSES ICPO PROTEIN.
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
EMBL; X14112; CA32336.1; -
DR EMBL; X14112; CA32336.1; -
DR EMBL; X04614; CA28285.1; -
DR PIR; A29152; EDBE11.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00518; ZF_RING_2; 1.
DR Transcription regulation; Trans-acting factor; Activator; Zinc-finger;
KW DNA-binding; Early protein.
FT ZN FING 116 157 RING-TYPE.
FT DOMAIN 233 243 POLY-ASP.
FT DOMAIN 305 308 POLY-GLY.
FT DOMAIN 558 568 POLY-SER.
SQ SEQUENCE 775 AA; 78456 MW; DF38A1C539DAB15C CRC64;

Query Match
Best Local Similarity 3.9%; Score 139; DB 1; Length 775;
Matches 80; Conservative 34; Mismatches 142; Indels 98; Gaps 16;

QY 156 GADPRVPPSPATQVCFEPQST-----STSDLPFTASASTPSPAGRSRSCSGSGG 211
DB 6 GASTREPEGRQ-----REPAPVWVPFCRDLL-PDSSDSEAEVGG- 48
QY 212 GISPKGSPVASDEVSSFSALPDRKTAFSSLSLEPOQEDLEPKVKMGDGLDLNGQ 271
DB 49 -----GDADHDD-----DSASEADSTDTLFTGLLPQGVDD-GGA 84
QY 272 LLVAQPRRNAQTVHEDVRAAAGPKD-----MEETLTCTIIQDILL--HDCVSLQPCMTFTC 325
DB 85 VSGGSPPR-----EEDFGSCGAPPPEDGGSGDEGVCVCTDEIAPHLCRCDTFCMRHFC 139
QY 326 AACVSGWERSLCPTRCPCVERICKNHLNVLVEAVLIQHPDKSR--SEEDVQSDMARN 383
DB 140 IFCMKTWQLENTCPLCNALVILVGVTPSGSFSTPIVNDPQTRWEAEAVRAGTAVD 199
QY 394 KI-----TQDMLQPKVRRSFSDEGSSDLELSDVDSESDISQPV 426
```

200 FIWGNQAPRVLTLGGHTVRLSPHPTDDE-----DDLDLDADYVPP--- 247
427 VCQCPEY--RRQAAPP-----HCPAPEGGAQA--LGDAPSTSVSLTT 469
248 APRTPRRRGAAPPVTTGGSHAAPQAAARTAPPAPIGPHGSSNTNTTT 301

RESULT 6
ICP0 HSV2H STANDARD; PRT; 825 AA.
AC P28284; (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Trans-acting transcriptional protein ICP0 (Vmw118 protein).
GN RL2.
OS Herpes simplex virus (type 2 / strain HG52).
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae; Simplexvirus.
OX NCBI_TaxID=10315;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=92113549; PubMed=1662697;
RA McGeoch D.J., Cunningham C., McIntyre G., Dolan A.;
RT "Comparative sequence analysis of the long repeat regions and
RT adjoining parts of the long unique regions in the genomes of herpes
RT simplex viruses types 1 and 2";
RN J. Gen. Virol. 72:3057-3075(1991).
RN [2]
RP SEQUENCE FROM N.A.
RX Dolan A.;
RL Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: Contains 1 RING-type zinc finger.
CC -1- SIMILARITY: TO OTHER HERPESVIRUSES ICP0 PROTEIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/)
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; D10471; BAA23427.1; -
DR EMBL; Z86099; CAB06760.1; -
DR PIR; JQ1501; EDBEXD.
DR HSRP; P28990; ICHC.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00519; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
DR Transcription regulation; Trans-acting factor; Activator; Zinc-finger;
KW DNA-binding.
FT DOMAIN 120 123 POLY-GLY.
FT ZN_FING 126 167 RING-TYPE.
FT POLY-GLY 266 271 POLY-GLY.
FT DOMAIN 292 295 POLY-SER.
FT DOMAIN 342 345 POLY-ALA.
FT DOMAIN 386 389 POLY-SER.
FT DOMAIN 395 400 POLY-GLY.
FT DOMAIN 425 428 POLY-ALA.
FT POLY-ALA 590 627 POLY-SER.
SQ SEQUENCE 825 AA; 81986 MW; 5CEB1585553A274 CRC64;

Query Match 3.9%; Score 139; DB 1; Length 825;
Best Local Similarity 22.7%; Pred. No. 0.36;
Matches 82; Conservative 33; Mismatches 127; Indels 120; Gaps 19;
152 GAGRGADP---RVPPSSPATQVCFEPPQSTSTDLPTASASTEPSPAG-----RE 201
6 GTSSRADPGPPPPPTGTQPA--APHAWGLNDQMQLASSDSSEETEVGISDLDLHRD 63

202 RSSSCGGGGGSPKSGSPSVASDEVSSFASALPDRKTASFSSLEPOQEDLEPVKKMR 261
64 STSEAG-----STDTEMFEAGLMDAAT-----PPAPPAERQG 96
262 GDGDLNLGQLLVAQPRRNAQTVHEDVRAAAGKPKMEETLTCTICQDLHDCVSLQ--P 319
97 SPTPADAGSC-----GGGPVGEAEAGGGD-----VCAVCTDEIAPPLRCQSPF 143
320 CMHTFCAACYSWMERSLCTPCPCVERICKNHLNVLVEAYLIQHDPKRSSEDEVQSM 379
144 CLHPFCIPCKMTWPLRNTCLCNTFV-----AYLIVGVTSAGSSTIPV 189
380 -DARNKITQDML-----QPKVR-RSFS-----DEGSGESDLEL 411
190 NDPRTRVEAEAAVRAGTAVDFWNTGNPTAPRSLSLGHGTVRLSPHPTDDEDDL 249
412 SDVDSSESDISQPVV--VCRCPE-----YRQAAPPHC-PAPEGEPAQ--ALGD 459
250 ADVD-----YVPPAPRAPRRGGGAGATGTSQPAATRPAP---PGAPRSSSGG 297
460 AP 461
298 AP 299

RESULT 7
RH18_SCHPO STANDARD; PRT; 387 AA.
ID RH18_SCHPO
AC O74747;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Postreplication repair protein rhp18 (RAD18 homolog).
GN RHP18 OR SPBC1734.06
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
OX NCBI_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A. AND FUNCTION.
RX MEDLINE=2155918; PubMed=11702950;
RA Kitamura K., Katayama S., Dhut S., Sato M., Watanabe Y., Yamamoto M.,
RA Toda T.;
RT "Phosphorylation of Mei2 and Stell by Pat1 kinase inhibits sexual
RT differentiation via ubiquitin proteolysis and 14-3-3 protein in
RT fission yeast";
RL Dev. Cell 1:389-399(2001).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=972;
RX MEDLINE=21848401; PubMed=11859360;
RA Wood V., Gilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
RA Sgouras J., Peat N., Hayles J., Baker S., Chillingworth T., Churcher C.M.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Fraser A.,
RA Collins M., Connor R., Cronin A., Davis P., Feltwell T., Fraser A.,
RA Gentles S., Godle A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
RA Oliver K., O'Neil S., Pearson D., Quail M.A., Rabinowitsch E.,
RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
RA Skellon J., Simmonds M., Squares R., Squares S., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA Woodward J., Volkart G., Aert R., Robben J., Grymonprez B., Auer S.,
RA Weltjens I., Vanstreels E., Rieger M., Schaefer M., Mueller-Auer S.,
RA Gabel C., Fuchs M., Fritz C., Holzer C., Holzer E., Moestl D., Hilbert H.,
RA Borzym K., Langer I., Beck A., Leinhardt R., Reinhardt R., Pohl T.M.,
RA Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
RA Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaure V., Motter S.,
RA Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas M., Rochet M., Gaillardin C., Tallada V.A., Garzon A., Thode G.,

Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J., Dominguez A., Revuelta J.B., Moreno S., Armstrong J., Forsburg S.L., Cerrutti L., Lowe T., McComb W.R., Paulsen I., Potashkin J., Shpakowski G.V., Usery D., Barrell B.G., Nurse P.; "The genome sequence of Schizosaccharomyces pombe.";

Nature 415:871-880(2002).

-!- FUNCTION: Involved in postreplication repair of UV-damaged DNA.

-!- Postreplication repair functions in gap-filling of a daughter strand on replication of damaged DNA. Has ssDNA binding activity (by similarity).

-!- SUBCELLULAR LOCATION: Nuclear (By similarity).

-!- SIMILARITY: Contains 1 RING-type zinc finger.

-!- SIMILARITY: Contains 1 SAP domain.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announcements or send an email to licenses@isb-sib.ch).

EMBL; AB079544; BAB84669.1; --

EMBL; AL031856; CAA21300.1; --

PIR; T39653; T39653.

HSP; PL5919; IRMSD.

GenADB_SPombe; SPBCU734.06; --

InterPro; IPRO004580; Rad18.

InterPro; IPRO03034; SAP.

InterPro; IPRO06642; Znf_Rad18.

InterPro; IPRO01841; Znf_ring.

Pfam; PF02037; SAP; 1.

Pfam; PF00097; zf-C3HC4; 1.

SMART; SM00184; RING; 1.

SMART; SM00513; SAP; 1.

SMART; SM00734; Znf_Rad18; 1.

TIGRFAMs; TIGR00599; rad18; 1.

PROSITE; PS00800; SAP; 1.

PROSITE; PS00518; ZF_RING_1; 1.

PROSITE; PS00089; ZF_RING_2; 1.

KW zinc-finger; DNA-binding; DNA damage; DNA repair; Nuclear protein.

FT ZN_FING 29 67 RING-TYPE.

FT DOMAIN 240 274 SAP.

FT DOMAIN 181 190 POLY-SER.

SEQUENCE 387 AA; 43437 MW; 1E8140FB645299B CRC64;

Query Match 3.8%; Score 138; DB 1; Length 387;

Best Local Similarity 25.2%; Pred.No. 0.16;

Matches 38; Conservative 28; Mismatches 71; Indels 14; Gaps 6;

Qy 298 MEETITCIICQLLDHCVSLGPOCHMTTCACYSQWERSLCTGCPV--RIKWHIL 355
::: ||| ::||| ::||| ::||| ::||| ::||| ::||| ::||| ::|||

Db 23 LDSSRLCLICHEYFR-APLITSCHTSHTFCSDIRYLSEHPMCACPAPQESRLRNKTL 81

Qy 356 NNIVLAYLLQHDPKSRSEEDVQSDARKNKITQDMLPQKVRPSDEGSSELLEISDVD 415
::: ::||| ::||| ::||| ::||| ::||| ::||| ::||| ::||| ::|||

Db 82 EELESFKVIRPTL-----FEFLKVEN-VKPVLQAPETVIQAQDSAGDEWEED--DLA 132

Qy 416 SESSDISIQPVVVCRCQPEYRRQAQPCHPA 446
||| |::| ::| ::| ::| ::| ::| ::| ::| ::|

Db 133 SNSSPASIAKKTSRDSKKKRE--DLVHCPA 161

RESULT 8

RN27 HUMAN ID RN27 HUMAN STANDARD; PRT; 551 AA.

AC Q9EZRG; O9C028;

DT 16-OCT-2001 (Rel. 40, Created)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE RING finger protein 27 (Glioblastoma-expressed ring finger protein)

GN (Tripartite motif-containing protein 8).

DN TRIM8 OR RNF27 OR GERP.

```

DR PROSITE; PS50089; ZF_RING_2; 1.
KW Nuclear protein; Coiled coil; Zinc-finger; Repeat.
FT ZN_FING 15 56 RING-TYPE.
FT ZN_FING 92 132 B_BOX-TYPE 1.
FT ZN_FING 140 182 B_BOX-TYPE 2.
FT DOMAIN 181 249 COILED_COIL (POTENTIAL).
FT CONFLICT 174 174 H -> R (IN REF. 1).
SQ SEQUENCE 551 AA; 61489 MW; 1FEF89029BE9BAC CRC64;

Query Match 3.8%; Score 134.5; DB 1; Length 551;
Best Local Similarity 23.8%; Pred. No. 0.41; Mismatches 87; Gaps 11;
Matches 58; Conservative 20;

QY 299 EETLTICIQDLHDCVSLQPCMHTEFAACY-SGMWRSLL--CPTCRPVER---ICKN 352
Db 10 EEBELICPCLHVFVEPVL-PCKHNEFCRGIGBNAKAGSLVRCPECNAYNQKPLEKN 68
QY 353 HILNNLVEAYLQHPDKS-----RSEEDVQSDAENKIKTDWL 390
Db 69 LKLTNIVEKFNALHVEKPPAALHVCFCRGPPLPQAKVCLRCAPC---CQSHVQTHLQ 124
QY 391 QPKVRSFSDSEGSRLLELSVDSESDISQYVVCRCPEYRQAQPPHCPAPEGE 450
Db 125 QPSTARGLH-----LYEADDVRAWS-----CFQH--NAVRLVHCEAEQ-- 160
QY 451 PGAPQALGDAPSTVSLTTAVQDYVCPLOGSHALCTCC-----FQMPDPRRAE 498
Db 161 -----VAVQCYCCYSGAHQGHVSDVCEYRREIRKMLKQQRLEE 202
QY 499 REQD 502
Db 203 REQD 206

RESULT 9
RN12_HUMAN STANDARD; PRT; 624 AA.
AC Q9V598;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE RING finger protein 12 (LIM domain interacting RING finger protein)
DE (RING finger LIM domain-binding protein) (R-LIM) (NY-REN-43 antigen).
GN RNF12 OR RLIM.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP MEDLINE=20469411; PubMed=11013082;
RX Ostendorff H.P., Bossenz M., Mincheva A., Copeland N.G., Gilbert D.J.,
RA Jenkins N.A., Lichter P., Bach T.;
RT "Functional characterization of the gene encoding RLIM, the
RT corepressor of LIM homeodomain transcription factors.";
RL Genomics 69:120-130(2000).
[2]
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Renal cell carcinoma;
RX MEDLINE=99438124; PubMed=10508479;
RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA Jongeneel C.V., Gure A.O., Jager D., Jager E., Knuth A., Chen Y.-T.,
RA Old L.J.;
RT "Antigens recognized by autologous antibody in patients with renal-
RT cell carcinoma.";
RL Int. J. Cancer 83:456-464(1999).
[3]
RN [3]
RP SEQUENCE FROM N.A.
RA Isegai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,
RA Wagatsuma M., Hosoi T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,

```

```

RA Yamamoto J., Wakamatsu A., Nakamura Y., Nagahari K., Masuho Y.,
RA Ninomiya K., Iwayanagi T.;
RL "NEDO human cDNA sequencing project.";
CC Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Acts as a negative co-regulator for LIM homeodomain
CC transcription factors. Via the recruitment of the SIN3a/histone
CC deacetylase corepressor complex.
CC -!- SUBUNIT: Associates with LIM/homeobox factors.
CC -!- TISSUE SPECIFICITY: Expressed in many tissues.
CC -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC -!- CAUTION: Ref.2 sequence differs from that shown due to frameshifts
CC in position 134 and 142.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AJ271670; CAC14228.1; .
CC EMBL; AF155109; AAD42875.1; ALT_FRAME.
CC EMBL; AK001334; BAA91632.1; .
CC Genew: HGNC:13429; RNF12.
CC MIM; 300379; .
CC GO; GO:0017033; C:transcriptional repressor complex; NAS.
CC GO; GO:0003714; F:transcription co-repressor activity; NAS.
CC GO; GO:0016481; F:negative regulation of transcription; NAS.
CC InterPro; IPR001841; Znf_ring.
CC Pfam; PF00097; zf-C3HC4; 1.
CC SMART; SM00184; RING; 1.
CC PROSITE; PS00518; ZF_RING_1; FALSE_NEG.
CC PROSITE; PS0089; ZF_RING_2; 1.
CC TRANSIT: 422 506 RING-TYPE.
CC DOMAIN 422 506 SER-RICH.
CC ZN_FING 570 611 RING-TYPE.
CC FT DOMAIN 453 481 POLY-SER.
CC FT DOMAIN 500 506 POLY-SER.
CC FT CONFLICT 126 126 S -> C (IN REF. 1).
CC FT CONFLICT 134 134 N -> D (IN REF. 3).
CC FT CONFLICT 144 145 YS -> NR (IN REF. 3).
CC FT CONFLICT 418 418 Y -> H (IN REF. 3).
CC SQ SEQUENCE 624 AA; 68527 MW; DE3ADE09ACACBFC8 CRC64;

Query Match 3.7%; Score 134; DB 1; Length 624;
Best Local Similarity 22.3%; Pred. No. 0.52;
Matches 55; Conservative 34; Mismatches 106; Indels 52; Gaps 9;

QY 100 GDVYLVYRKNEPEHNVAIYELSEKQGTQESFEANKENVFGTKDTSGAGAGRGADP 159
Db 414 GELSYFYWYSDSDSEPT-----GSVSNENMERAES-----RSGRGGSGGGSSSS 459
QY 160 RVPSSPATQVCPEEPOPSTSTDLFTASASSTEPSAGRERSSSCGSGGSGSPKSG 219
Db 460 SSSSSSSSSSSSSSSSSSSSGG---ESSETSDLEGSNEGSSSSSGSGSARREGHRA 516
QY 220 PSVASDEVSSPASLPDRKTASFSLPQOELEPVKKKRGDGLDLNQLLVAQPR- 278
Db 517 P-VTFDE---SGSLPFLSLAQFFLLNEDDDD-----CPRG 547
QY 279 RNAQTVHEDVRAAGKPKMEETLTCTICQLLHDCVSLQ--PCWHTFCAACYSGMWS 336
Db 548 LTKSQIDNLAVRSFGENDALK---TCSVCITTEYTGKRLKPLCSHYHVCIDRWLSEN 604
QY 337 SLCPCTR 343
Db 605 STCPICR 611

RESULT 10
SAL3_HUMAN
ID SAL3_HUMAN STANDARD; PRT; 1300 AA.

```


Q9BXA9; Q9UGH1;
28-FEB-2003 (Rel. 41, Created)
28-FEB-2003 (Rel. 41, Last sequence update)
10-OCT-2003 (Rel. 42, Last annotation update)
Sal-like protein 3 (zinc finger protein SALL3) (hsSALL3).
SALL3.
GN Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
CX [1]
RN SEQUENCE FROM N.A. (ISOFORM 3).
RA Gooding R., Angelicheva D., Blechschmidt K., Swoboda K., Molnar M.,
RA Tournev I., Kalaydjieva L.,
RA "Exclusion of HSALL3 and refinement of the region for the CCFDN
RT gene";
RT Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.
RL [2]
RN SEQUENCE OF 29-1300 FROM N.A., AND ALTERNATIVE SPLICING.
RX MEDLINE=20079154; PubMed=10610715;
RA Kohlbase J., Hausmann S., Stojmenovic G., Dixkens C., Bink K.,
RA Scholz-Schaeffer W., Altmann M., Engel W.,
RT "SALL3, a new member of the human spalt-like gene family, maps to
RT 18q23.";
RL Genomics 62:216-222(1999).
RN [3]
RP VARIANT LEU-593, AND REVISIONS TO 787; 797-802; 808; 1138 AND 1141.
RA Kohlbase J.;
RL Submitted (JUL-2002) to Swiss-Prot.
CC -!- FUNCTION: Probable transcription factor.
CC -!- SUBCELLULAR LOCATION: Nuclear (Probable).
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=4;
CC Name=3;
CC IsoId=Q9BXA9-1; Sequence=Displayed;
CC Name=1;
CC IsoId=Q9BXA9-2; Sequence=VSP_006833;
CC Note=Lacks two zinc finger domains. Major isoform with isoform
CC 2;
CC Name=2;
CC IsoId=Q9BXA9-3; Sequence=VSP_006832, VSP_006833;
CC Note=Lacks two zinc finger domains. Major isoform with isoform
CC 1;
CC Name=4;
CC IsoId=Q9BXA9-4; Sequence=VSP_006832;
CC -!- TISSUE SPECIFICITY: Widely expressed in adult with highest levels
CC in heart. Expressed in fetal brain (in neurons of hippocampus,
CC cortex, mediodorsal and ventrolateral thalamic nuclei, putamen,
CC cerebellum and brainstem).
CC -!- DEVELOPMENTAL STAGE: In fetal brain of the 24th gestational week.
CC -!- SIMILARITY: BELONGS TO THE SALL FAMILY OF C2H2-TYPE ZINC-FINGER
CC PROTEINS.

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

EMBL; AF347021; AAK18311.1; .
EMBL; AJ007421; CAB65124.1; ALT_SEQ.
HSP; P07248; IARE.
GN; HGN:10527; SALL3.
MIM; 605079; .
DR InterPro; IPR007087; Znf_C2H2.
DR Pfam; PF00096; zf-C2H2; 10.
DR SMART; SM00355; Znf_C2H2; 10.
DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 9.
DR PROSITE; PS00157; ZINC_FINGER_C2H2_2; 8.
KW Transcription regulation; DNA-binding; Nuclear protein; Zinc-finger;
KW Metal-binding; Repeat; Alternative splicing; Polymorphism.

FT	ZN_FING	420	442	C2H2-TYPE.
FT	ZN_FING	448	470	C2H2-TYPE.
FT	ZN_FING	679	701	C2H2-TYPE.
FT	ZN_FING	707	729	C2H2-TYPE.
FT	ZN_FING	739	761	C2H2-TYPE.
FT	ZN_FING	977	999	C2H2-TYPE.
FT	ZN_FING	1005	1027	C2H2-TYPE.
FT	ZN_FING	1113	1135	C2H2-TYPE.
FT	ZN_FING	1141	1163	C2H2-TYPE.
FT	DOMAIN	198	201	POLY-ALA.
FT	DOMAIN	213	216	POLY-GLN.
FT	DOMAIN	897	902	POLY-SER.
FT	VARSPLIT	1	133	Missing (in isoform 2 and isoform 4). /FtId=VSP_006832.
FT	VARSPLIT	973	1044	Missing (in isoform 1 and isoform 2). /FtId=VSP_006833.
FT	VARIANT	593	593	V->L. /FtId=VAR_014132.
FT	CONFLICT	235	235	R->C (IN REF. 2).
FT	SEQUENCE	1300 AA;	135371 MW;	82CF3BCB6D59150 CRC64;
Query Match		3.7%;	Score 132.5;	DB 1; Length 1300;
Best Local Similarity		21.5%;	Pred. No. 1.6;	
Matches 134;	Conservative	61;	Mismatches 220;	Indels 209; Gaps 34;
QY	127	QGMTQESFEANKENVFR	-----GTKDTSGAGAGRGADPRVPFSSSPATQVCFE	173
Db	460	KGNLKVFHQRKEKYPHIOMNPVPYELDNVPTCSGIPYGM	-----LPPEKPVTTWLD	515
QY	174	EP-QPSTST	-----DLFPT	213
Db	516	KVLPVTPTSVGLQLPPTVPGAGYADSPATPASRSPQSP	-----SEACSLSGLN	571
QY	214	-----SPKG--SGPSVASDE	-----VVSFASALPDRKTASFSL	245
Db	572	HVESGVSAATRESPOSLLGGPPVTKAEPVSLPCTNARAGDAPVGAQAASAPTSVDGAPTSL	-----	631
QY	246	EPQDQEDLEPVKKMGDGLDLGALLVAQPRNAQTVEHDVRAAGKPDKNKEETLTC	-----	304
Db	632	GSPGLPVSQFKAQFPFGGLD	-----SMQTSKLOQLV-ENI	681
QY	305	IICODLLHDCVSLQCM	-----HT-----FCAACYSGWMERSL	343
Db	682	VIC-----HRVLSQCSALKMVRTHGTGERPFKCKICGRAFTTKGNLKTHTFGVHRAKPLRV	-----	737
QY	344	---CPVERICKHNLNLVAYLIQH	-----PKSRSEEDVQSMADARKITQDMLQ	391
Db	738	QHSCP---ICQKFTNAV	-----LQCHIRMGMGGQIPNTPLEGFQDAMD--SELAYDDKN	789
QY	392	PKVRSFSD--EGSSDLELSDVDSESDISQPVV-VCRQCPEYRQAQPP	-----	442
Db	790	AETLSSYDDMDENSMEDDAELKDA	-----ATDPAKFLLSYAGSCP-----PSPSPSVISSI	840
QY	443	-----HCPAPGEPAPGALGDAPSTSVSLTAVQDYVCPQLGSHAL	-----	484
Db	841	AALENQMKMIDSVMSCOOLTGLKXSVENGESDRLSNDSSAVGDLSESRAGSPALSESS	-----	900
QY	485	CTCCFCQWMPDR	-----RAEREQDPVRVAPQCAVCLQ	515
Db	901	SSQALSAPNSGESFRSKSPCLGAPPEPQIPPLKTERPDSFAAAGSGGAPGRAGIKEEA	-----	960
QY	516	PFCHLYWG-----CSTRGCVGCLAPP-CELNLDGKCDGLVNNNSYED	-----ILKNY	563
Db	961	PFSLFLSRERKCPSTVCGVCGKPFACKSAL	-----EIHVRSHTKERPFVCAALCRG	1013
QY	564	LATRLTQKMLTESLVALQGVF	587	
Db	1014	CSTMGNLKQHLTHRLKELPSQLF	1037	
RESULT 11				
P300_HUMAN				
ID P300_HUMAN	STANDARD;	PRT;	2414 AA.	

AC Q09472;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DE 10-OCT-2003 (Rel. 42, Last annotation update)
DE EIA-associated protein p300 (EC 2.3.1.48).
GN EP300 OR P300.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95011587; PubMed=7523245;
RA Eckner R., Ewen M.E., Newsome D., Gerdes M., Decaprio J.A.,
RA Lawrence J.B., Livingston D.M.;
RT "Molecular cloning and functional analysis of the adenovirus EIA-
RT associated 300-kD protein (p300) reveals a protein with properties of
RT a transcriptional adaptor.";
RL Genes Dev. 8:869-884(1994).
RN [2]
RN ENZYMMATIC ACTIVITY.
RX MEDLINE=97100994; PubMed=8945521;
RX Ogrzyzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y.;
RT "The transcriptional coactivators p300 and CBP are histone
RT acetyltransferases.";
RL Cell 87:953-959(1996).
RN [3]
RN INTERACTION WITH PCAF.
RX MEDLINE=96300317; PubMed=8684459;
RX Yang X.-J., Ogrzyzko V.V., Nishikawa J.-I., Howard B.H., Nakatani Y.;
RT "A p300/CBP-associated factor that competes with the adenoviral
RT oncoprotein E1A.";
RL Nature 382:319-324(1996).
RN [4]
RN INTERACTION WITH HIF1A AND CREBBP.
RX MEDLINE=97075102; PubMed=8917528;
RX Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C.,
RA Goldberg M.A., Bunn H.F., Livingston D.M.;
RT "An essential role for p300/CBP in the cellular response to hypoxia.";
RL Proc. Natl. Acad. Sci. U.S.A. 93:12963-12973(1996).
RN [5]
RN INTERACTIONS WITH NR3C1.
RX MEDLINE=98250578; PubMed=950696;
RX Fryer C.J., Archer T.K.;
RT "Chromatin remodelling by the glucocorticoid receptor requires the
RT BRG1 complex.";
RL Nature 393:88-91(1998).
RN [6]
RN INTERACTION WITH NCOA6.
RX MEDLINE=20283976; PubMed=10823961;
RX Ko L., Cardona G.R., Chin W.W.;
RT "Thyroid hormone receptor-binding protein, an LXXLL motif-containing
RT protein, functions as a general coactivator.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:6212-6217(2000).
RN [7]
RN INTERACTION WITH DTX1.
RX MEDLINE=21576166; PubMed=11564735;
RX Yamamoto N., Yamamoto S.-I., Inagaki F., Kawauchi A.,
RX Kishi N., Matsuno K., Nakamura K., Weinmaster G., Okano H.,
RX Nakafuku M.;
RT "Role of Deltex-1 as a transcriptional regulator downstream of the
RT Notch receptor.";
RL J. Biol. Chem. 276:45031-45040(2001).
RN [8]
RN PHOSPHORYLATION, AND INTERACTION WITH TCF7L2 AND LEF1.
RX MEDLINE=22450614; PubMed=12446687;
RX Hecht A., Stemmler M.P.;
RT "Identification of a promoter-specific transcriptional activation
RT domain at the C-terminus of the Wnt-effector protein TCF4.";
RL J. Biol. Chem. 278:3776-3785(2003).
RN [9]
RN VARIANTS BREAST CANCER PRO-927 AND GLY-1013, VARIANT PANCREATIC CANCER
RP TYR-1650, AND VARIANT COLORECTAL CANCER GLN-2221.

RX MEDLINE=20164332; PubMed=10700188;
RA Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K.,
RA Chin S.-P., Daigo Y., Russell P., Wilson A., Sowter H.M.,
RA Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.;
RT "Mutations truncating the EP300 acetylase in human cancers.";
RL Nat. Genet. 24:300-303(2000).
RN [10]
RN STRUCTURE BY NMR OF 302-418 IN COMPLEX WITH 786-826 OF HIF1A.
RX MEDLINE=21957254; PubMed=11959990;
RX Freedman S.J., Sun Z.Y., Poy F., Kung A.L., Livingston D.M.,
RX Wagner G., Eck M.J.;
RT "Structural basis for recruitment of CBP/p300 by hypoxia-inducible
RT factor-1 alpha.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:5367-5372(2002).
CC -!- FUNCTION: Functions as histone acetyltransferase and regulates
CC transcription via chromatin remodeling. Acetylates all four core
CC histones in nucleosomes. Histone acetylation gives an epigenetic
CC tag for transcriptional activation. Binds to and may be involved
CC in the transforming capacity of the adenovirus E1A protein.
CC -!- CATALYTIC ACTIVITY: Acetyl-CoA + histone = CoA + acetyl-histone.
CC -!- SUBUNIT: Interacts with NR3C1, PCAF, NCOA6, LEF1 and TCF7L2. The
CC TAZ-type 1 domain interacts with HIF1A. Probably part of a complex
CC with HIF1A and CREBBP. Interacts with DTX1.
CC -!- SUBCELLULAR LOCATION: Nuclear.
CC -!- PTM: Phosphorylated.
CC -!- DISEASE: Defects in EP300 may play a role in epithelial cancer.
CC -!- SIMILARITY: Contains 1 bromodomain.
CC -!- SIMILARITY: Contains 1 ZAZ-type zinc finger.
CC -!- SIMILARITY: Contains 2 TAZ-type zinc fingers.
CC -!- DATABASE: NAME-Atlas Genet. Cytogenet. Oncol. Haematol.;
CC WWW=http://www.infobiogen.fr/services/chronocancer/Genes/P300ID97.html".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; U01877; AAA18639.1; -.
DR PIR; A54277; A54277.
DR PDB; 1L3E; 11-FEB-03.
DR TRNSPAC; T01427; -.
DR Genew; HGNC:3373; EP300.
DR MIM; 602700; -.
DR GO; GO:0008022; P:protein C-terminus binding; TAS.
DR GO; GO:0003713; F:transcription co-activator activity; TAS.
DR GO; GO:0003700; F:transcription factor activity; TAS.
DR GO; GO:0007399; P:neurogenesis; TAS.
DR GO; GO:0007165; P:signal transduction; TAS.
DR InterPro; IPR001487; Bromodomain.
DR InterPro; IPR003101; KIX.
DR InterPro; IPR00197; TAZ finger.
DR InterPro; IPR00433; Znf_ZZ.
DR Pfam; PF00439; Bromodomain; 1.
DR Pfam; PF02172; KIX; 1.
DR Pfam; PF02135; Zf-TAZ; 2.
DR Pfam; PF00569; Zf; 1.
DR PRINTS; PR00503; BROMODOMAIN.
DR SMART; SM00297; BROMO; 1.
DR SMART; SM00551; Znf_TAZ; 2.
DR SMART; SM00291; Znf_ZZ; 1.
DR PROSITE; PS00633; BROMODOMAIN_1; 1.
DR PROSITE; PS50014; BROMODOMAIN_2; 1.
DR PROSITE; PS50134; ZF_TAZ; 2.
DR PROSITE; PS01357; ZF_ZZ_1; 1.
DR PROSITE; PS0135; ZF_ZZ_2; 1.
DR Transfaser; Transcription regulation; Nuclear protein; Bromodomain;
KW Cell cycle; Zinc-finger; Phosphorylation; Disease mutation;
KW 3D-structure.
FT DOMAIN 11 17 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
FT ZN_FING 331 417 TAZ-TYPE 1.

FT DOMAIN 1067 1139 BROMODOMAIN.
FT DOMAIN 1572 1818 BINDING REGION FOR E1A ADENOVIRUS.
FT ZN_FING 1684 1707 ZN-TYPE.
FT ZN_FING 1728 1809 TAZ-TYPE 2.
FT DOMAIN 797 800 POLY-SER.
FT DOMAIN 1519 1526 POLY-GLU.
FT DOMAIN 2066 2069 POLY-GLN.
FT DOMAIN 2190 2195 POLY-GLN.
FT VARIANT 827 827 L -> P (in breast cancer).
FT VARIANT 1013 1013 /FTID-VAR_014428.
FT VARIANT 1650 1650 E -> G (in breast cancer).
FT VARIANT 2221 2221 S -> Y (in pancreatic cancer).
FT VARIANT 2221 2221 /FTID-VAR_014430.
FT VARIANT 2221 2221 P -> Q (in colorectal cancer).
FT SEQUENCE 2414 AA; 264143 MW; 68PF909E4B9D693 CRC64; /FTID-VAR_014431.
Query Match 3.7%; Score 132.5; DB 1; Length 2414;
Best Local Similarity 21.1%; Pred. No. 3.4;
Matches 128; Conservative 75; Mismatches 235; Indels 169; Gaps 31;
QY 4 PEEGQSPPPQ-----PWGRLRLGAEGEPEH-----VLL-----RRREWTI 40
Db 300 FNMGOQ-FAPVQQPGLVTPVAGVSGGTAADPEKRLIQOQLVLLHAKKQREQAN 358
QY 41 GRRRGCDLSE---PKNLVSGDHCRIVDEKGGVLTEDTSTGTVINKLVKKVKTQPL 97
Db 359 GEVRCNLPCHCRMTKXNLNHTHCQ---SGKSCQVA--HCASSRQIISHWKNCTRHDQCP 413
QY 98 -----QTGDVILVYRKNPEHNVAIVYLSLEKQGTQESPE--ANKENVFHGFKDTSG 150
Db 414 CUEPLKNAGD-----KKNQCPILITGAPVGLGNPSSLGVGQOQAPNLSTVSDIPDSIERAY 468
QY 151 AGAGRGADPRVPFSPATQCFEE-PQPSTSTDLFTTASSTPSPAGRSRSCGSG 209
Db 469 AALGLPYQVQNPQTQVQAKNQOQPGQSGKRPMSNMSA---SPMG-----VNG 518
QY 210 GGGISPKGGPSVASDEVSPASALPDR-----KTASPSLEPQD---QEDLEPVKKMR 261
Db 519 GVGVTQ-----PSLLSD--SMLHSAINSONPMMSNASVPSGLGMPMTAAQSPSTGIRKQWH 572
QY 262 GDGDLINGQLLVAQPRNAQTVHEDVRAAGKPD-----KMBETLTCTI--ICODLLH 312
Db 573 EDITQDLRNL-----VHKLVAQIFPTPDPAALKDRRMENLVAYARKVGDVME 621
QY 313 DCVSLQFQMTTCAACYSGMERSLCPTRCPVERICKNHLNN---LVEAYLLOHDK 369
Db 622 SANNAEYVHLLAEKTYKIQKELEKRRT-----RLQKNMLPNAAGMVPVSMNPGNM 675
QY 370 SRSEEDVQND-----ARNKITQMLQPKVRSFSDSEGSDELLESDVDSESDIS 422
Db 676 GQFQPGTNGPLDPDSMIRGVSFNQMPRITPQSGINQFG-----QMSWA 721
QY 423 QPYVVCRCQP--BYRRQAAP-----PHCPAPEGE-----P 451
Db 722 QPPIVPRQTPLQHHGQLAQPGALNPMGYGRMQQPSNQGFPLPOTQFPFSGMNVNIP 781
QY 452 GAPQALGDASTSVSLTAVQDVVCL-----QGSNALCTCCFPMPDRRAREQD 502
Db 782 LAPSS--GAQFVSAQMSSS-----SCPVNSPIMPFGSGSHIHCPQLQP-----ALHQS 831
QY 503 PRVAPQ 509
Db 832 PSVPFR 838
RESULT 12
RN12 MOUSE STANDARD; PRT; 600 AA.
ID RN12 MOUSE
AC Q9WT7;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE RING finger protein 12 (LIM domain interacting RING finger protein)
GN RNF12 OR RLIM.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Bach I.;
RT "Opposing developmental functions of positive and negative
coregulators of LIM homeodomain factors.";
RL Submitted (JUN-1998) to the EMBL/GenBank/DBJ databases.
RN [2]
RP FUNCTION.
RX MEDLINE=99364422; PubMed=10431247;
RA Bach I., Rodriguez-Esteban C., Carriere C., Bhushan A., Krones A.,
Rose D.W., Glass C.K., Andersen B., Izpisua-Belmonte J.-C.,
Rosenfeld M.G.;
RT "RIM inhibits functional activity of LIM homeodomain transcription
factors via recruitment of the histone deacetylase complex.";
RL Nat. Genet. 22:394-399(1999).
CC !- FUNCTION: Acts as a negative co-regulator for LIM homeodomain
transcription factors. Via the recruitment of the SIN3a/histone
deacetylase corepressor complex.
CC !- SUBUNIT: Associates with LIM/homeobox factors.
CC !- SIMILARITY: Contains 1 RING-type zinc finger.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC EMBL; AF069992; AAD34209.1; -
DR MGD; MGI:1342291; Rnf12.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00518; ZF_RING_1; FALSE_NEG.
DR PROSITE; PS0089; ZF_RING_2; 1.
KW Transcription regulation; Zinc-finger.
FT DOMAIN 415 484 SER-RICH.
FT ZN_FING 546 587 RING-TYPE.
FT DOMAIN 447 461 POLY-SER.
FT SEQUENCE 600 AA; 66470 MW; 568299530126E41D CRC64;
Query Match 3.7%; Score 131.5; DB 1; Length 600;
Best Local Similarity 23.4%; Pred. No. 0.7;
Matches 60; Conservative 29; Mismatches 80; Indels 87; Gaps 11;
QY 100 GDVILVYRKNPEHNVAIVYLSLEKQGTQESFEANKENVFHGTXTDTCAGAGRGADP 159
Db 407 GELSYFWISDSDFSA-----SVSSRNVERVES-----RNGRSGSGGNSSG-- 449
QY 160 RVPSPSPATQVCFEPQPTSTDLFTTASSTPSPAGRSRSCGSGGSGISPKGSG 219
Db 450 -----SSSSSPSPSSGSSSSSKMFESEGS-----SG 482
QY 220 PS-----VASDEVSSPASALPDKTASFSLSLEPQDQEDLEPVKKRGDGLDLNG 270
Db 483 PSRKDGRHRAEPTFDE-----SGSLPFFSLAQFFLIN-EDDED----- 519
QY 271 QLLVAQPR-RNAQTVHEDVRAAGKPKMBETLTCTIIC--QDLHDCVSLQPCMHITCAA 327
Db 520 -----QPRGLTKEQIDNLAMRSFGENDALK---TCSVCITEYTEGDKLRKLPCHSEPHVH 571
QY 328 CYSGWMSRSSLCPTCR 343
Db 572 CIDRWLSENSTCPTCR 587

CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL; AF281047; AAG53088.1; -;
DR EMBL; AF220035; AAG53489.1; -;
DR MGD; MGI:193302; Trime.
DR GO; GO:0005634; C:nucleus binding; IPA.
DR GO; GO:0005515; F:protein binding; IDA.
DR InterPro; IPR000315; Znf_Box.
DR InterPro; IPR001841; Znf_Box.
DR Pfam; PF00643; Zf-B_Box; 1.
DR Pfam; PF00097; Zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00119; ZF-BROX; FALSE_NEG.
DR PROSITE; PS00518; ZF_RING; 1.
DR PROSITE; PS50089; ZF_RING; 2; 1.
DR Nuclear protein; Coiled coil; Zinc-finger; Repeat.
FT ZN_FING 15 56 RING-TYPE
FT ZN_FING 92 132 B_BOX-TYPE 1.
FT ZN_FING 140 182 B_BOX-TYPE 2.
FT DOMAIN 181 249 COILED COIL (POTENTIAL).
FT DOMAIN 274 295 COILED COIL (POTENTIAL).
FT CONFLICT 259 259 G -> A (IN REF. 2).
SQ SEQUENCE 551 AA; 61591 MW; CECB2D70C8B1E0B6 CRC64;

Query Match 3.6%; Score 130.5; DB 1; Length 551;
Best Local Similarity 23.4%; Pred. No. 0.72;
Matches 57; Conservative 21; Mismatches 79; Indels 87; Gaps 11;

QY 299 EETLTCTTCQDILLHCVSLQPMFTCAACY-SGWMERSLI--CPTCRCPVER---ICKN 352
D5 10 EEELICPICLHVFEVPVL-PCKNFCRCGICGEAWKDSGLVRCPCNQAYNQKPGLEKN 68
QY 353 HILNNLVEAYLIQHPDKS-----RSEEDVQSDARNKITQDML 390
D5 69 LKLTNIVKFNALHVEKPTALHCVFCRRGPPLEPAQVKLCLEAPC---CQSHVQTHLQ 124
QY 391 QPKVRRSFSDREGSEDLLELSDVSDSSDISQPVVWCRCQPEYRQAAPFCPEPEGE 450
D5 125 QPSTARGHL-----LVEADDDVRAWS-----CFQH-NAYRLYHCSEAQ-- 160
QY 451 PGAPALGDAPSTSVSLTAVQDYVCPQSGHALCTCC-----PQMPDPAEAE 498
D5 161 -----VAVCYCCYSGAHQGHVCDVIRNEIRNKLMLKQOERLEE 202
QY 499 REQD 502
D5 203 REQD 206

RESULT 15
ACIN HUMAN
ID ACIN HUMAN STANDARD; PRT; 1341 AA.
AC Q9UKV3; Q75158; Q9UG91; Q9UKV1; Q9UKV2;
DT 28-FEB-2003 (Rel. 41; Created)
DT 28-FEB-2003 (Rel. 41; Last sequence update)
DT 28-FEB-2003 (Rel. 41; Last annotation update)
DE Apoptotic chromatin condensation inducer in the nucleus (Acinus).
GN ACINUS OR KIAA0670.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3), PARTIAL SEQUENCE, FUNCTION,
RP AND MUTAGENESIS OF ASP-1093.
RX MEDLINE=99418558; PubMed=10490026;
RA Sahara S., Aoto M., Eguchi Y., Imamoto N., Yoneda Y., Tsujimoto Y.;
RT "Acinus is a caspase-3-activated protein required for apoptotic
RT chromatin condensation."

Nature 401:168-173(1999).
[2] SEQUENCE FROM N.A. (ISOFORM 4).
RP TISSUE=Uterus.
RC Wambutt R., Heubner D., Mewes H.-W., Gassenhuber J., Wiemann S.;
RA Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
[3] SEQUENCE FROM N.A. (ISOFORM 3).
RP TISSUE=Fetal brain;
RA Li W.B., Gruber C., Jessee J., Polayes D.;
RX MEDLINE=98403880; PubMed=9734811;
RA Ishikawa K.-I., Nagase T., Suyama M., Miyajima N., Tanaka A.,
Kotani H., Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. X.
RT The complete sequences of 100 new cDNA clones from brain which can
RT code for large proteins in vitro."
RL DNA Res. 5:169-176(1998).
CC -!- FUNCTION: Induces apoptotic chromatin condensation after
CC activation by CASP3.
CC -!- SUBCELLULAR LOCATION: Nuclear.
CC Event-Alternative splicing; Named isoforms=4;
CC Name=1; Synonyms=S;
CC IsoID=Q9UKV3-1; Sequence=Displayed;
CC Name=2; Synonyms=S';
CC IsoID=Q9UKV3-2; Sequence=VSP_004025, VSP_004028;
CC Name=3; Synonyms=S;
CC IsoID=Q9UKV3-3; Sequence=VSP_004026, VSP_004029;
CC Name=4;
CC IsoID=Q9UKV3-4; Sequence=VSP_004027;
CC -!- TISSUE SPECIFICITY: Ubiquitous.
CC -!- PTM: Undergoes proteolytic cleavage; the processed form is active,
CC contrary to the uncleaved form.
CC -!- SIMILARITY: Contains 1 SAP domain.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL; AF124726; AAD56724.1; -;
DR EMBL; AF124727; AAD56725.1; -;
DR EMBL; AF124728; AAD56726.1; -;
DR EMBL; AL050382; CAB43681.1; -;
DR EMBL; BX247975; CAB62309.1; -;
DR EMBL; AB014570; BAA31645.2; -;
DR Genew; HGNC:17066; ACINUS.
DR MIM; 604562; -;
DR GO; GO:0005634; C:nucleus; IDA.
DR GO; GO:0016887; F:ATPase activity; NAS.
DR GO; GO:0019899; F:enzyme binding; NAS.
DR GO; GO:003676; F:nucleic acid binding; NAS.
DR GO; GO:0030263; P:apoptotic chromosome condensation; IDA.
DR GO; GO:0030218; P:erythrocyte differentiation; IEP.
DR GO; GO:0045657; P:positive regulation of monocyte differentiation. . . IEP.
DR InterPro; IPR003034; SAP.
DR Pfam; PF02037; SAP; 1.
DR SMART; SM00513; SAP; 1.
DR PROSITE; PS50800; SAP; 1.
DR Apoptosis; Nuclear protein; Alternative splicing.
FT DOMAIN 72 106 SAP.
FT DOMAIN 142 442 GLU-RICH.
FT DOMAIN 573 676 SER-RICH.
FT DOMAIN 1114 1131 PRO-RICH.
FT DOMAIN 1132 1341 ARG/ASP/GLU/LYS-RICH.

FT	SITE	1093	1094	CLEAVAGE (BY CASPASE-3).
FT	VARSPLIC	1	727	Missing (in isoform 2).
FT				/FTid=VSP 004025.
FT	VARSPLIC	1	758	Missing (in isoform 3).
FT				/FTid=VSP 004026.
FT	VARSPLIC	1	1152	Missing (in isoform 4).
FT				/FTid=VSP 004027.
FT	VARSPLIC	728	766	GSPKCEAEAEAPPAATQPTSETOTSHLPSERIHTTV
FT				-> MSPADRCRSANTIEPATSSLALFLLQLRQDSRTGRL
FT				P (in isoform 2).
FT				/FTid=VSP 004028.
FT	VARSPLIC	759	766	SERIHTV -> MLSEKEG (in isoform 3).
FT				/FTid=VSP 004029.
FT	MUTAGEN	1093	1093	D->A: ABOLISHES CLEAVAGE BY CASP3 AND
FT				CHROMATIN CONDENSATION ACTIVITY.
FT	CONFLICT	139	139	Q -> H (IN REF. 4).
SQ	SEQUENCE	1341	AA; 151887	MW; 8FE286681F3AB5C CRC64;
Query Match				
Best Local Similarity 20.2%; Pred. No. 2.7;				
Matches 127; Conservative 78; Mismatches 239; Indels 184; Gaps 30;				
QY	2	ERPEEGKQSPQPQWGRLLRLGAECEGPHVLLRKRWITIGRRG	-----CDLSFSPSNKL	55
Db	406	EOTASEETPPP-----LITKASGPPHPQLHSEE-EIEPWEGPAPPVLQLSPN	----	456
QY	56	VSGDHCRIVVDEKSGQVT-----LEDTSTSGTVINKLKVVKQTCPLQTGDVI--YLVR	108	
Db	457	TDADTRELIVSQHTVQLVGLSPDSTKAESPAEKVPESVLPLVKSTLADYSAQK	516	
QY	109	KNEPEHN-----VAVLYESLSKQMTQESFE-----ANKEN-----VFHGTQDTSGA	151	
Db	517	DLEPESDRSAQPLPLKIEELALAKGITECLKQPSLEQKEGRRASHTLLPSHRLKQSADS	576	
QY	152	GAGRGADPRVPSSPATQVCFEEPPQSTSTSLDFTTAS-----ASSTEPSPAG-----	199	
Db	577	SSRSRSS-----SSSSSRSRSRSPDSSGSRSH-SPLRSKQRDVAQARTHANPRGRPKMS	631	
QY	200	-----RERSSCGGGGGIGSPKSGSPVASDEVSPFASALPDRKTASFSLPQEQEDL	253	
Db	632	RSTSESRSRSRSRSRSSASNSRKSLSFGVSRDSTSYT-----ETKDPSSGQEV	680	
QY	254	--EPVKKKRGDGLDLNGQLLVAQPRNAQTVDHEDVRA-AAGKPKMBEETLTCIICQDL	310	
Db	681	ATPPVP-----QLQVCEKERTSTSSSVQARRLSQPESAEK-----	717	
QY	311	LHDCVSLQPCMTFCAACYSGMWRSSLCPTCRCPVERI-----CKNHILANLVRA	361	
Db	718	-HVTQRLQP-----ERGS-----PKKCEAEAEPPAATQPTSETQTSHLPS	759	
QY	362	YLIQHPDKSRSEEDVQSDMRANKITQDMLQPKVRSFSDSEGSSEDLLELSDVDSSESDI	421	
Db	760	ERIHHTVEEK--EVTMDTSENRPENDVPEPMPPIA---DQVSNDDRPEGSVEDEEKES	814	
QY	422	SOFYVVCROCPEYRRQAQPP-HCPAPEGEPGAQALGDAPST-----SVSLTT-----	469	
Db	815	SUPKSPKRIKISVVSATKGVPAGNSDTEGGQPGKRHWGASTATTQKKPSISITTESLKS	874	
QY	470	-----AVQDYVCPL-----QGS-----ALCTCCPQMP-----	493	
Db	875	IPDIKPLAGCAEAVVDLHADDSRISEDETERNGDGDGTHDXGLKICRTVTQVWPAGQENG	934	
QY	494	----DRAAREQDPRVAPO-QCAVCLQP	516	
Db	935	REEESEKEPEAEPPVPVQVSVEVALPP	962	

Search completed: May 7, 2004, 14:46:30
Job time : 26.4372 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:40:47 ; Search time 96.0591 seconds
(without alignments)
2180.991 Million cell updates/sec

Title: US-10-048-046-2
Perfect score: 3585
Sequence: 1 MERPEEGKQSPPPQPGWGRLL.....VKAHAMKFNHCIEQTRFKN 664

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues
Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL_25.*

- 1: sp_archaea.*
- 2: sp_bacteria.*
- 3: sp_fungi.*
- 4: sp_human.*
- 5: sp_invertebrate.*
- 6: sp_mammal.*
- 7: sp_mhc.*
- 8: sp_organelle.*
- 9: sp_phage.*
- 10: sp_plant.*
- 11: sp_rodent.*
- 12: sp_virus.*
- 13: sp_vertebrate.*
- 14: sp_unclassified.*
- 15: sp_rvirus.*
- 16: sp_bacteriap.*
- 17: sp_archaeap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3585	100.0	664	Q9NRt4	Q9nr4 homo sapien
2	3504	97.7	652	Q96SL3	Q96sl3 homo sapien
3	3500	97.6	652	Q96EP1	Q96ep1 homo sapien
4	3162.5	88.2	623	Q9NVD5	Q9nvd5 homo sapien
5	2916	81.3	664	Q810L3	Q810l3 mus musculu
6	2891.5	80.7	663	Q8BJZ9	Q8bjz9 mus musculu
7	1678	46.8	306	Q9NT32	Q9nt32 homo sapien
8	896.5	25.0	254	Q8BWH4	Q8bwh4 mus musculu
9	357.5	10.0	473	Q9SX88	Q9sx88 arabidopsis
10	167.5	4.7	540	Q7ZX20	Q7zx20 xenopus lae
11	167	4.7	485	Q803C1	Q803c1 brachydanio
12	160.5	4.5	352	Q8BYE7	Q8bye7 homo sapien
13	160.5	4.5	432	Q8IUD6	Q8iud6 homo sapien
14	160	4.5	1546	Q7Z3L3	Q7z3l3 homo sapien
15	155.5	4.3	733	Q9RI88	Q9rl88 mus musculu
16	154.5	4.3	731	Q8NH2	Q8nh2 homo sapien

17	152	4.2	245	11	Q9CQB0	Q9cqb0 mus musculu
18	151.5	4.2	350	4	Q8N3R7	Q8n3r7 homo sapien
19	150	4.2	513	3	Q9CLX4	Q9clx4 schizosacch
20	149	4.2	209	11	Q99PD2	Q99pd2 rattus norv
21	149	4.2	689	10	Q9FNZ7	Q9fnz7 oryza sativ
22	148.5	4.1	209	11	Q9WTR9	Q9wtr9 mus musculu
23	148	4.1	753	11	Q9D4H7	Q9d4h7 mus musculu
24	146.5	4.1	220	4	Q96SJ1	Q96sj1 homo sapien
25	146.5	4.1	277	4	Q96ID9	Q96id9 homo sapien
26	146	4.1	303	4	Q7Z4I9	Q7z4i9 homo sapien
27	145	4.0	504	16	Q87PU0	Q87pu0 vibrio para
28	144.5	4.0	2322	10	Q8SV27	Q8sv27 arabidopsis
29	143.5	4.0	638	11	Q8BX92	Q8bxp2 mus musculu
30	143.5	4.0	700	12	Q7T400	Q7t400 simian herp
31	143.5	4.0	887	11	Q8CFF5	Q8cff5 mus musculu
32	143.5	4.0	1033	11	Q8CGC8	Q8cgc8 mus musculu
33	143.5	4.0	1033	11	Q8OZ37	Q8oz37 mus musculu
34	143	4.0	1102	5	Q9V5P3	Q9v5p3 drosophila
35	143	4.0	1601	5	Q9V6I9	Q9v6i9 drosophila
36	142	4.0	532	3	Q8WZL0	Q8wz10 neurospora
37	142	4.0	781	3	Q9C2M7	Q9c2m7 neurospora
38	142	4.0	818	4	Q8WU72	Q8wu72 homo sapien
39	141.5	3.9	424	10	Q9C8W4	Q9c8w4 arabidopsis
40	141.5	3.9	444	10	Q9M621	Q9m621 arabidopsis
41	141.5	3.9	448	10	Q8VZ14	Q8vz14 arabidopsis
42	141.5	3.9	628	13	Q7ZVC1	Q7zvcl brachydanio
43	141.5	3.9	852	4	Q86FI5	Q86fi5 homo sapien
44	141.5	3.9	1208	4	Q75162	Q75162 homo sapien
45	140.5	3.9	765	5	Q9UQA3	Q9uaq3 caenorhabdi

ALIGNMENTS

RESULT 1

ID Q9NRt4 PRELIMINARY; PRT; 664 AA.

AC Q9NRt4;

DT 01-OCT-2000 (T-EMBLrel.. 15, Created)

DT 01-OCT-2000 (T-EMBLrel.. 15, Last sequence update)

DT 01-OCT-2003 (T-EMBLrel.. 25, Last annotation update)

DE Cell cycle checkpoint protein CHFR.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OC NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=20388685; PubMed=10935642;

RA Scolnick D.M., Halazonetis T.D.;

RT "Chfr defines a mitotic stress checkpoint that delays entry into metaphase."

RL Nature 406:430-435(2000).

CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.

DR EMBL; AFL70724; AAF91084.1; -.

DR PDB; 1LGP; 07-AUG-02.

DR PDB; 1LQG; 07-AUG-02.

DR Genew; HGNC:20455; CHFR.

DR GO; GO:0007093; P:mitotic checkpoint; TAS.

DR InterPro; IPR000253; FHA.

DR InterPro; IPR008984; SMAD_FHA.

DR InterPro; IPR001841; ZnF_Fing.

DR Pfam; PF00498; FHA; 1.

DR Pfam; PF00097; zf-C3HC4; 1.

DR SMART; SM00240; FHA; 1.

DR SMART; SM00184; RING; 1.

DR PROSITE; PSS0006; FHA DOMAIN; 1.

DR PROSITE; PSS0518; ZF_RING_1; 1.

DR PROSITE; PSS0089; ZF_RING_2; 1.

DR Metal-binding; Zinc; Zinc-finger.

SEQUENCE 664 AA; 73386 MW; 141A1E7FEFAE36A2 CRC64;

Query Match

100.0%; Score 3585; DB 4; Length 664;

Best Local Similarity 100.0%; Pred. No. 2e-275;
Matches 664; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MERPEEGKQSPPOPMGRLLRLGAEGBEPHVLRLKREWTIGRRRCGLDLSFSPNKLVSQDH 60
Db 1 MERPEEGKQSPPOPMGRLLRLGAEGBEPHVLRLKREWTIGRRRCGLDLSFSPNKLVSQDH 60

QY 61 CRIVDEKSGQVLTEDTSTGTVINKLVKVKQTCPLQTDGVIYLVYRKNPEHNVAIY 120
Db 61 CRIVDEKSGQVLTEDTSTGTVINKLVKVKQTCPLQTDGVIYLVYRKNPEHNVAIY 120

QY 121 ELSLEKQGMTOESFEANKENVFHGTGTSAGAGRGADPRVPPSSPATVCFEEQPST 180
Db 121 ELSLEKQGMTOESFEANKENVFHGTGTSAGAGRGADPRVPPSSPATVCFEEQPST 180

QY 181 TSDLPFTASASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDRKTA 240
Db 181 TSDLPFTASASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDRKTA 240

QY 241 SFSLSLEPQDOEDLEPVKKVKGDDLDLNGQLLVAQPRNAQTVDHEDVRAAGKPKDKEE 300
Db 241 SFSLSLEPQDOEDLEPVKKVKGDDLDLNGQLLVAQPRNAQTVDHEDVRAAGKPKDKEE 300

QY 301 TLTCIIICODLLHDCVSLQPCMHFTCAACYSYGMWERSLCTCPCPVERICKNHILNLVE 360
Db 301 TLTCIIICODLLHDCVSLQPCMHFTCAACYSYGMWERSLCTCPCPVERICKNHILNLVE 360

QY 361 AYLIQHPDKSRSEEDVQSDARKITQDMLQPKVRSFSDERSSGSDLELSDVDSBSD 420
Db 361 AYLIQHPDKSRSEEDVQSDARKITQDMLQPKVRSFSDERSSGSDLELSDVDSBSD 420

QY 421 ISQYVVCRCQPEYRQAAQPPHCPAEPGEPGAPALGAPSTSVLTAVQDYVCPLOQ 480
Db 421 ISQYVVCRCQPEYRQAAQPPHCPAEPGEPGAPALGAPSTSVLTAVQDYVCPLOQ 480

QY 481 SHALCTCCFQPMDDRRAREQDPRVAPQCAVCLQPFCHLYGCTRTGCGCLAPFCELN 540
Db 481 SHALCTCCFQPMDDRRAREQDPRVAPQCAVCLQPFCHLYGCTRTGCGCLAPFCELN 540

QY 541 LGDKCLDGLVNNNSYESDILKXNLTATRLGTWKNMLTESLVALQGVFLLSYRVGTDTVL 600
Db 541 LGDKCLDGLVNNNSYESDILKXNLTATRLGTWKNMLTESLVALQGVFLLSYRVGTDTVL 600

QY 601 CYCCGLRSFRELTYQYRQNIASELPVATSRPDCYWGNCRTQVKAHMKFNHICEQT 660
Db 601 CYCCGLRSFRELTYQYRQNIASELPVATSRPDCYWGNCRTQVKAHMKFNHICEQT 660

QY 661 RFXN 664
Db 661 RFXN 664

RESULT 2
Q96SL3
ID Q96SL3 PRELIMINARY; PRT; 652 AA.
AC Q96SL3;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DE 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein FLJ14781.
OS Homo sapiens (human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Isegai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Aotsuka S., Yoshikawa Y.,
RA Matsunawa H., Ishii S., Kawai Y., Saigo K., Yamamoto J., Wakamatsu A.,
RA Nakamura Y., Nagatani K., Masuho Y., Sasaki N.;
RI "NEDO human cDNA sequencing project."
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.

EMBL; AK027687; BAB55297.1; -.
DR InterPro; IPR000253; FHA
DR InterPro; IPR008984; SMAD FHA.
DR InterPro; IPR001841; Znf_Fing.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; zinc-finger.
SQ SEQUENCE 652 AA; 72030 MW; 572F2CE6D1743D80 CRC64;

Query Match 97.7%; Score 3504; DB 4; Length 652;
Best Local Similarity 98.2%; Pred. No. 5.2e-269;
Matches 652; Conservative 0; Mismatches 0; Indels 12; Gaps 1;

QY 1 MERPEEGKQSPPOPMGRLLRLGAEGBEPHVLRLKREWTIGRRRCGLDLSFSPNKLVSQDH 60
Db 1 MERPEEGKQSPPOPMGRLLRLGAEGBEPHVLRLKREWTIGRRRCGLDLSFSPNKLVSQDH 60

QY 61 CRIVDEKSGQVLTEDTSTGTVINKLVKVKQTCPLQTDGVIYLVYRKNPEHNVAIY 120
Db 61 CRIVDEKSGQVLTEDTSTGTVINKLVKVKQTCPLQTDGVIYLVYRKNPEHNVAIY 120

QY 121 ELSLEKQGMTOESFEANKENVFHGTGTSAGAGRGADPRVPPSSPATVCFEEQPST 180
Db 121 ELSLEKQGMTOESFEANKENVFHGTGTSAGAGRGADPRVPPSSPATVCFEEQPST 180

QY 181 TSDLPFTASASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDRKTA 240
Db 181 TSDLPFTASASSTEPSAGRRSSSCGSGGGISPKGSGPSVASDEVSSFASALPDRKTA 240

QY 241 SFSLSLEPQDOEDLEPVKKVKGDDLDLNGQLLVAQPRNAQTVDHEDVRAAGKPKDKEE 300
Db 241 SFSLSLEPQDOEDLEPVKKVKGDDLDLNGQLLVAQPRNAQTVDHEDVRAAGKPKDKEE 300

QY 301 TLTCIIICODLLHDCVSLQPCMHFTCAACYSYGMWERSLCTCPCPVERICKNHILNLVE 360
Db 301 TLTCIIICODLLHDCVSLQPCMHFTCAACYSYGMWERSLCTCPCPVERICKNHILNLVE 360

QY 361 AYLIQHPDKSRSEEDVQSDARKITQDMLQPKVRSFSDERSSGSDLELSDVDSBSD 420
Db 361 AYLIQHPDKSRSEEDVQSDARKITQDMLQPKVRSFSDERSSGSDLELSDVDSBSD 420

QY 421 ISQYVVCRCQPEYRQAAQPPHCPAEPGEPGAPALGAPSTSVLTAVQDYVCPLOQ 480
Db 421 ISQYVVCRCQPEYRQAAQPPHCPAEPGEPGAPALGAPSTSVLTAVQDYVCPLOQ 480

QY 481 SHALCTCCFQPMDDRRAREQDPRVAPQCAVCLQPFCHLYGCTRTGCGCLAPFCELN 540
Db 481 SHALCTCCFQPMDDRRAREQDPRVAPQCAVCLQPFCHLYGCTRTGCGCLAPFCELN 540

QY 541 LGDKCLDGLVNNNSYESDILKXNLTATRLGTWKNMLTESLVALQGVFLLSYRVGTDTVL 600
Db 541 LGDKCLDGLVNNNSYESDILKXNLTATRLGTWKNMLTESLVALQGVFLLSYRVGTDTVL 600

QY 601 CYCCGLRSFRELTYQYRQNIASELPVATSRPDCYWGNCRTQVKAHMKFNHICEQT 660
Db 601 CYCCGLRSFRELTYQYRQNIASELPVATSRPDCYWGNCRTQVKAHMKFNHICEQT 660

QY 661 RFXN 664
Db 661 RFXN 664

RESULT 3
Q96EP1
ID Q96EP1 PRELIMINARY; PRT; 652 AA.
AC Q96EP1;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Placenta;
RA Strausberg K.;
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; BC012072; AAH12072.1; -
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00498; ZF_RING_1; 1.
DR SMART; SM00240; ZF_RING_1; 1.
DR PROSITE; PS000518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 652 AA; 72058 MW; 1A50773CEA679F07 CRC64;

Query Match 97.6%; Score 3500; DB 4; Length 652;
Best Local Similarity 98.0%; Pred. No. 1.4e-268;
Matches 651; Conservative 0; Mismatches 1; Indels 12; Gaps 1;
QY 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 60
DB 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 60
QY 61 CRIVVDEKSGQVLTSTSGTVINKLVKKQTCTPLQTDGVILYVRKNEPEHNVAYLY 120
DB 61 CRIVVDEKSGQVLTSTSGTVINKLVKKQTCTPLQTDGVILYVRKNEPEHNVAYLY 120
QY 121 ELSSEKQGMTQESFEANKENVHGTGTSAGAGRGADPRVPPSPATQVCFEEQPST 180
DB 121 ELSSEKQGMTQESFEANKENVHGTGTSAGAGRGADPRVPPSPATQVCFEEQPST 180
QY 181 TSDFLPTASASTPSPAGRRSSCGSGGGISPKGSGPSVASDVSPALPDKRTA 240
DB 169 TSDFLPTASASTPSPAGRRSSCGSGGGISPKGSGPSVASDVSPALPDKRTA 228
QY 241 SFSSLEPQDQEDLEPVKKRGGDLDLNGQLLVAQPRNAQTVDHEDVRAAGKDPKME 300
DB 229 SFSSLEPQDQEDLEPVKKRGGDLDLNGQLLVAQPRNAQTVDHEDVRAAGKDPKME 288
QY 301 TLTCIIQDILLHDCVSLQPCWHTFCAACYSGWMSRLCPTCRCPVERICKNHLNVL 360
DB 289 TLTCIIQDILLHDCVSLQPCWHTFCAACYSGWMSRLCPTCRCPVERICKNHLNVL 348
QY 361 AYLIQHPDKRSBEDVQSDARKNTQDMLQPKVRSFSDREGSSEDLLELDVDSGSD 420
DB 349 AYLIQHPDKRSBEDVQSDARKNTQDMLQPKVRSFSDREGSSEDLLELDVDSGSD 408
QY 421 ISQYVYVCRQCPYRROAQPHPCHPAPEGPAPALGAPSTSVSLTTAVQDYVCPLO 480
DB 409 ISQYVYVCRQCPYRROAQPHPCHPAPEGPAPALGAPSTSVSLTTAVQDYVCPLO 468
QY 481 SHALCTCCFQPMEDRRAERQDPRVAPQCAVCLQPFCHLYWCCTRTGCGCLAFCELN 540
DB 469 SHALCTCCFQPMEDRRAERQDPRVAPQCAVCLQPFCHLYWCCTRTGCGCLAFCELN 528
QY 541 LGDKCLDGLVNNNSYESDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVGT 600
DB 529 LGDKCLDGLVNNNSYESDILKNYLATRGLTWKMLTESLVALQRGVFLLSDYRVGT 588
QY 601 CYCCGLRSFRELTYOFRONTIPASELPVNTSRPDCYWGNCRTQVKAHMKFNHICQT 660
DB 589 CYCCGLRSFRELTYOFRONTIPASELPVNTSRPDCYWGNCRTQVKAHMKFNHICQT 648

QY 661 RFXN 664
DB 649 RFXN 652

RESULT 4

Q9NVD5
ID Q9NVD5 PRELIMINARY; PRT; 623 AA.
AC Q9NVD5;
DT 01-OCT-2000 (Tremblrel. 15, Created)
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Hypothetical protein FLJ10796.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Isoqai T., Ota T., Hayaashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Aotaka S., Yoshikawa Y.,
RA Matsumura H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,
RA Nakamura Y., Nagahari K., Masuho Y., Sasaki N.,
RT "NEDO human cDNA sequencing project."
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AK001658; BAA91817.1; -
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; ZF_RING_1; 1.
DR Pfam; PF00097; ZF-C3HC4; 1.
DR SMART; SM00240; ZF_RING_1; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Hypothetical protein; Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 623 AA; 69204 MW; 45186D33DAE52711 CRC64;

Query Match 88.2%; Score 3162.5; DB 4; Length 623;
Best Local Similarity 88.5%; Pred. No. 5.7e-242;
Matches 594; Conservative 5; Mismatches 17; Indels 55; Gaps 2;

QY 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 60
DB 1 MERPEEGKQSPPPQWGRLLRLGAEAGEPHVLLRKREWTIGRRGCDLSPFNKLVSGDH 60
QY 61 CRIVVDEKSGQVLTSTSGTVINKLVKKQTCTPLQTDGVILYVRKNEPEHNVAYLY 120
DB 61 CRIVVDEKSGQVLTSTSGTVINKLVKKQTCTPLQTDGVILYVRKNEPEHNVAYLY 120
QY 121 ELSSEKQGMTQESFEANKENVHGTGTSAGAGRGADPRVPPSPATQVCFEEQPST 180
DB 121 ELSSEKQGMTQESFEANKENVHGTGTSAGAGRGADPRVPPSPATQVCFEEQPST 180
QY 181 TSDFLPTASASTPSPAGRRSSCGSGGGISPKGSGPSVASDEVSPASA 233
DB 136 TSDFLPTASASTPSPAGRRSSCGSGGGISPKGSGPSVASDEVSPASA 192
QY 234 LPDRKTASFSLEPQDQEDLEPVKKRGGDLDLNGQLLVAQPRNAQTVDHEDVRAAG 293
DB 193 LPDRKTASFSLEPQDQEDLEPVKKRGGDLDLNGQLLVAQPRNAQTVDHEDVRAAG 252
QY 294 KPDMEETLTCTICQDILLHDCVSLQPCWHTFCAACYSGWMSRLCPTCRCPVERICKN 353
DB 253 KPDMEETLTCTICQDILLHDCVSLQPCWHTFCAACYSGWMSRLCPTCRCPVERICKN 312
QY 354 ILNNLVEAYLIQHPDKRSBEDVQSDARKNTQDMLQPKVRSFSDREGSSEDLLELD 413
DB 313 ILNNLVEAYLIQHPDKRSBEDVQSDARKNTQDMLQPKVRSFSDREGSSEDLLELD 372

```
QY 414 VDSBSSDIQPVVYVCRQCEPVRROAAOPPHCPAPEGEPGAPQALGDAPSTSVSLTTAVQD 473
DB 373 VDSBSSDIQPVVYVCRQCEPVRROAAOPPHCPAPEGEPGAPQALGDAPSTSVSLTTAVQD 432
QY 474 YVCPLOQSHALCTCCFQPMPPDRRAERQDPRVAPQCAVCLQPPCHLYWGCTRTGCGCL 533
DB 433 YVCPLOQSHALCTCCFQPMPPDRRAERQDPRVAPQCAVCLQPPCHLYWGCTRTGCGCL 492
QY 534 APFCBLNLGDKCLDGLVNNNSYESDILKNYLATRLGLTWKNNLTESLVALQGVFLLSYR 593
DB 493 APFCBLNLGDKCLDGLVNNNSYESDILKNYLATRLGLTWKNNLTESLVALQGVFLLSYR 552
QY 594 VTGDTVLYCCGLRSFRELTYQYRONIPASELPVAVTSRDPQVWGRNCRTOVKAHAMKPF 653
DB 553 VTGDTVLYCCGLRSFRELTYQYRONIPASELPVAVTSRDPQVWGRNCRTOVKAHAMKPF 612
QY 654 NHICEQTRFKN 664
DB 613 NHICEQTRFKN 623

RESULT 5
Q810L3 PRELIMINARY; PRT; 664 AA.
AC Q810L3;
DT 01-JUN-2003 (Tremblrel. 24, Created)
DT 01-JUN-2003 (Tremblrel. 24, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE RIKEN cDNA 5730484M20 gene.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Limb;
RA Strausberg R.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBAJ databases.
DR EMBL; BC049792; AAA9792.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMART_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS50006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS50089; ZF_RING_2; 1.
SQ SEQUENCE 664 AA; 73871 MW; D651BE3E463DEBB6 CRC64;

Query Match 81.3%; Score 2916; DB 11; Length 664;
Best Local Similarity 82.0%; Pred. No. 2, 1e-22;
Matches 547; Conservative 41; Mismatches 73; Indels 6; Gaps 4;

QY 1 MERPEGKQSPPPQWGLRLRGAEEGPHVLLRKEWTIGRRGCDLSPSNKLVSGDH 60
DB 1 MELHGEQPPPPQEPWGLRLRGAEEGPHVLLRKEWTIGRRGCDLSPSNKLVSGDH 60
QY 61 CEIVVDEKSGVLTEDTSGTVINKLVKKQTCPLQTDGVILVYKNEPEHNVAIY 120
DB 61 CKLTVDLSISGVTLEDTSNGTVINKLVKKQTCPLQTDGVILVYKNEPEHNVAIY 120
QY 121 ELSLSEKQGMTOBSFANKENVFHGKDTSGAGAGADPRVPPSPATQVCFEPQST 180
DB 121 ELSLSEKQSLTQDSLEANKENMFVTKDCS--GPGQGDPPQVPLLSPMAQTCLSEFPQST 178
QY 181 TSDLPPTASSTEP--SPAGHERSSSCGGGGISPKGSGFVSASDEVSSAFALPDK 238
DB 179 TSDLLPTASTSTPELTSAQKSSSSGPGNNTSISPKRSSLVANGELSLSPVQD-K 237
QY 239 TASFSSLEPDQDELEPVKKQKRGDGLDLNGQLLVAQPRNAQTVHEDVFAAAGKPKDM 298
```

```
DB 238 EASFSLLESKDHEELEPAKXKXMGDGLDTNLQLLVSGQRGNAQTSSDEVKDA SVKPKDM 297
QY 299 EFTLTCIIICODLLHDCVSLQPCMTFCACYSGWMERSSLCPTCRCPVERICKKHILNNL 358
DB 298 EFTLTCIIICODLLHDCVSLQPCMTFCACYSGWMERSSLCPTCRCPVERICKKHILNNL 357
QY 359 VEAYLIQHPDKRSRSEDVQSMADRNKITQDMLQPKVRRSFDEEGSSDLELSVDSES 418
DB 358 VEAYLIQHPDKRSRSEDVQSMADRNKITQDMLQPKVRRSFDEEGSSDLELSVDSES 417
QY 419 SDISOPVYVCRQCEPVRROAAOPPHCPAPEGEPGAPQAL-GDAPSTSVSLTTAVQDYVCP 477
DB 418 SDISOPVYVCRQCEPVRROAAOPPHCPAPEGEPGAPQAL-GDAPSTSVSLTTAVQDYVCP 477
QY 478 LQSHALCTCCFQPMPPDRRAERQDPRVAPQCAVCLQPPCHLYWGCTRTGCGCLAPFC 537
DB 478 LQSHALCTCCFQPMPPDRRAERQDPRVAPQCAVCLQPPCHLYWGCTRTGCGCLAPFC 537
QY 538 ELNLGDKCLDGLVNNNSYESDILKNYLATRLGLTWKNNLTESLVALQGVFLLSYRVTGD 597
DB 538 ELNLGDKCLDGLVNNNSYESDILKNYLATRLGLTWKNNLTESLVALQGVFLLSYRVTGD 597
QY 598 TVLCYCCGLRSFRELTYQYRONIPASELPVAVTSRDPQVWGRNCRTOVKAHAMKFNHIC 657
DB 598 TVLCYCCGLRSFRELTYQYRONIPASELPVAVTSRDPQVWGRNCRTOVKAHAMKFNHIC 657
QY 658 EQTRFKN 664
DB 658 EQTRFKN 664

RESULT 6
Q8BJZ9 PRELIMINARY; PRT; 663 AA.
AC Q8BJZ9;
DT 01-MAR-2003 (Tremblrel. 23, Created)
DT 01-MAR-2003 (Tremblrel. 23, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Similar to cell cycle checkpoint protein CHFR.
GN 5730484M20RIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Body;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium.
RA "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573(2002).
DR EMBL; AK077629; BAC36912.1; -.
DR MGD; MGI:24444898; 5730484M20RIK.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMART_FHA.
DR InterPro; IPR001841; Znf_Ring.
DR Pfam; PF00498; FHA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 2.
DR PROSITE; PS50006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS50089; ZF_RING_2; 1.
SQ SEQUENCE 663 AA; 73855 MW; 42BD653DCB4ADF45 CRC64;

Query Match 80.7%; Score 2891.5; DB 11; Length 663;
Best Local Similarity 81.7%; Pred. No. 1, 9e-220;
Matches 545; Conservative 41; Mismatches 74; Indels 7; Gaps 5;

QY 1 MERPEGKQSPPPQWGLRLRGAEEGPHVLLRKEWTIGRRGCDLSPSNKLVSGDH 60
```

Db 1 MELHGEQPPPPQPPWGRLLRLGAEDEPQILLWKREWTIGRRRCGLSPSPNKLVS GDH 60
QY 61 CRIVVDEKSGQVLTEDTSTGTVINKLVKVKQTPLQGDVIVLYVRKNEPEHNAYLY 120
Db 61 CKLVDEISGEVLTEDTSTGTVINKLVKVKQTPLHSGDIIYLYVRKNEPEHNAYLY 120
QY 121 ELSLSEKQGTQSFSEANKENVEHGTGKDTSGAGAGRGADPRVPPSPATQVCFEPPQPTS 180
Db 121 ELSLSEKQGTQSFSEANKENVEHGTGKDTSGAGAGRGADPRVPPSPATQVCFEPPQPTS 178
QY 181 TDLFTFASSTEP--SPAGRERSSCGSGGGISPKGSGPSVASDEVSSPASALPRK 238
Db 179 TDLFTFASSTEP--SPAGRERSSCGSGGGISPKGSGPSVASDEVSSPASALPRK 237
QY 239 TASFSLPQDQEDLEPVKKRGDGLDLQGLLVAOPRRNAQTTHEDVRAAKCKDKM 298
Db 238 EASFSLSEKQGTQSFSEANKENVEHGTGKDTSGAGAGRGADPRVPPSPATQVCFEPPQPTS 297
QY 299 EETLTCIIQQDLLHDCVSLQPCMHTECAACYSQWMESSSLCTCPCVERICKNHLNLL 358
Db 298 EETLTCIIQQDLLHDCVSLQPCMHTECAACYSQWMESSSLCTCPCVERICKNHLNLL 357
QY 359 VEAYLIQHPDKSRSEEDVQSMARKITQDMLQPKVRRSFDEBGSSEDLLELSDVDS 418
Db 358 VEAYLIQHPDKSRSEEDVQSMARKITQDMLQPKVRRSFDEBGSSEDLLELSDVDS 417
QY 419 SDISQPVVVCRCPEYRQAAOPPHCPAPGEGAPQAL-GDAPSTSVSLTTAVQDYVCP 477
Db 418 SDISQPVVVCRCPEYRQAAOPPHCPAPGEGAPQAL-GDAPSTSVSLTTAVQDYVCP 476
QY 478 LOGSHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFC 537
Db 477 LOGSHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFC 536
QY 538 EUNLGDCKLDGVLNNNSYSDILKNYLATRGITWKNMLTESLVALQRGVFLSDYRVGTG 597
Db 537 EUNLGDCKLDGVLNNNSYSDILKNYLATRGITWKNMLTESLVALQRGVFLSDYRVGTG 596
QY 598 TVLYCCGLRSFRELTYQYRQNIASELPVAVTSRPPDCYWGNCRTQVKAHAMKFNHIC 657
Db 597 TVLYCCGLRSFRELTYQYRQNIASELPVAVTSRPPDCYWGNCRTQVKAHAMKFNHIC 656
QY 658 EQTRFKN 664
Db 657 EQTRFKN 663

RESULT 7
Q9NT32
ID Q9NT32 PRELIMINARY; PRT; 306 AA.
AC Q9NT32; 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Hypothetical protein (Fragment).
GN DKFZP434N2420
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA Ottenwaelder B., Obermaier B., Mewes H.W., Gassenhuber J., Wiemann S.;
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL137561; CAB70812.1; -;
DR F1R; T46399; T46399.
KW Hypothetical protein.
FT NON_TER
SQ SEQUENCE 306 AA; 6B50F04601FB2939 CRC64;
Query Match 46.8%; Score 1678; DB 4; Length 306;
Best Local Similarity 100.0%; Pred. No. 1e-124;

Matches 306; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 359 VEAYLIQHPDKSRSEEDVQSMARKITQDMLQPKVRRSFDEBGSSEDLLELSDVDS 418
Db 1 VEAYLIQHPDKSRSEEDVQSMARKITQDMLQPKVRRSFDEBGSSEDLLELSDVDS 60
QY 419 SDISQPVVVCRCPEYRQAAOPPHCPAPGEGAPQALGDAPSTSVSLTTAVQDYVCP 478
Db 61 SDISQPVVVCRCPEYRQAAOPPHCPAPGEGAPQALGDAPSTSVSLTTAVQDYVCP 120
QY 479 QGSHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFC 538
Db 121 QGSHALCTCCFPMPDRRAERQDPRVAPQCAVCLQPFCHLYWGCTRTGCGCLAPFC 180
QY 539 EUNLGDCKLDGVLNNNSYSDILKNYLATRGITWKNMLTESLVALQRGVFLSDYRVGTG 598
Db 181 EUNLGDCKLDGVLNNNSYSDILKNYLATRGITWKNMLTESLVALQRGVFLSDYRVGTG 240
QY 599 TVLYCCGLRSFRELTYQYRQNIASELPVAVTSRPPDCYWGNCRTQVKAHAMKFNHIC 658
Db 241 TVLYCCGLRSFRELTYQYRQNIASELPVAVTSRPPDCYWGNCRTQVKAHAMKFNHIC 300
QY 659 EQTRFKN 664
Db 301 EQTRFKN 306
RESULT 8
Q8BWH4
ID Q8BWH4 PRELIMINARY; PRT; 254 AA.
AC Q8BWH4; 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Similar to cell cycle checkpoint protein CHFR (Fragment).
GN 5730484M20RIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Lung;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs";
RL Nature 420:563-573(2002).
DR EMBL; AK052473; BAC35008.1; -;
DR MGD; MGI:2444896; 5730484M20RIK.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD_FHA.
DR Pfam; PF00498; FHA; 1.
DR SMART; SM00240; FHA; 1.
DR PROSITE; PS50006; FHA_DOMAIN; 1.
FT NON_TER 254 254
SQ SEQUENCE 254 AA; 27819 MW; 0340571A2BAEB6EF CRC64;
Query Match 25.0%; Score 896.5; DB 11; Length 254;
Best Local Similarity 70.0%; Pred. No. 6.9e-63;
Matches 180; Conservative 23; Mismatches 49; Indels 5; Gaps 3;
QY 1 MERPEEKQPPPPQPPWGRLLRLGAEDEPQILLWKREWTIGRRRCGLSPSPNKLVS GDH 60
Db 1 MELHGEQPPPPQPPWGRLLRLGAEDEPQILLWKREWTIGRRRCGLSPSPNKLVS GDH 60
QY 61 CRIVVDEKSGQVLTEDTSTGTVINKLVKVKQTPLQGDVIVLYVRKNEPEHNAYLY 120
Db 61 CKLVDEISGEVLTEDTSTGTVINKLVKVKQTPLHSGDIIYLYVRKNEPEHNAYLY 120
QY 121 ELSLSEKQGTQSFSEANKENVEHGTGKDTSGAGAGRGADPRVPPSPATQVCFEPPQPTS 180
Db 121 ELSLSEKQGTQSFSEANKENVEHGTGKDTSGAGAGRGADPRVPPSPATQVCFEPPQPTS 180

Db 121 ELSGCKQLTQDSLEANKENMFHVKDCS--GPQGGDDPQVPLLSMAQTCLEEPQPS 178

Qy 181 TSDLEPTASASTEP--SPAGRESSSCGGGGISPKGSPGVSADSVSSFASALPDRK 238

Db 179 TSDLLPTASTSTPETSAGQKSSSGPGNTSISPKGRSSLVANGELSSLPVFEQD-K 237

Qy 239 TASFSSLEPQDCELEP 255

Db 238 EASTSLESKDEBLEP 254

RESULT 9

Q9SX88 PRELIMINARY; PRT; 473 AA.

ID Q9SX88

DT 01-MAY-2000 (TREMBlrel. 13, Created)

DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)

DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)

DE F16N3.15

GN F16N3.15

OS Arabidopsis thaliana (Mouse-ear cress).

OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;

OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.

OX NCBI_TaxID=3702;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=ecv. Columbia;

RA Vytotskaia V.S., Schwartz J.R., Yu G., Toriumi M., Lenz C., Liu S.,

RA Lee J., Liu A., Li J., Kremenetskaia I., Gonzalez A., Altafi H.,

RA Araujo R., Brooks S., Buehler E., Chao Q., Conn L., Conway A.B.,

RA Dunn P., Hansen N., Huizar L., Khan S., Kim C., Palm C., Rowley D.,

RA Shinn P., Walker M., Davis R.W., Ecker J.R., Federspiel N.A.,

RA Theologis A.

RT "Arabidopsis thaliana chromosome 1 BAC F16N3 sequence,"

RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.

CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.

DR EMBL; AC007519; AAD46042.1; --

DR PIR; C96516; C96516.

DR InterPro; IPR001841; Znf_ring.

DR Pfam; PF00097; zf-C3HC4; 1.

DR SMART; SMO0184; RING; 1.

DR PROSITE; PS00089; ZF_RING_2; 1.

KW Metal-binding; Zinc; Zinc-finger.

SQ SEQUENCE 473 AA; 53874 MW; D1721493A81C991 CRC64;

Query Match 10.0%; Score 357.5; DB 10; Length 473;

Best Local Similarity 23.6%; Pred. No. 8.4e-20;

Matches 130; Conservative 65; Mismatches 201; Indels 155; Gaps 20;

Qy 177 PSTSTSLPTASASTEPS-----PAGRESS 204

Db 7 PMTTAE---TGSSGSKSPDDDAWAKLVLDTRFSDIRCNMDVICSEIKPSSLEKHE 63

Qy 205 SCGSGGGISPKGSPGVSADSVSSFASALPDRKTASFSLFPQDQEDLEPVKKMRGDP 264

Db 64 WCR-----ITKNLGQSSATIHNSDAILVDK-----AVVPK-----DG 97

Qy 265 DLD-LNGQLLVAQPRNAQVHEDVRAAGKPKMEETL-----TCITCQLLDHDC 314

Db 98 AVDIISGEIVPGEEGYQYRFTIMPA--PSRTQLQISIDPEHAKCSICLNIWHDV 155

Qy 315 VSLQPMHTFCAACYSQWMSRSS-----LCPTCRCPVERICKNHLNINLVEAYLIQHPD 368

Db 156 VTAAPCLHNFNGCFSEWMSRSEKHKVLCPCRTTVQVGVGNFLKNIQBEILKVDA 215

Qy 369 KSRSEEDVQSDARKNTQDML--OPKVRFSFDESGSDELLLELSDVDSESSDISQPY 425

Db 216 LRPAEDIAVDSASIQSLNLTGSKRKLNPAPTHERDSLR----- 261

Qy 426 VVCRQCFEYRQAAPPCHPCEPAGCAPQALGADPSTSVLTAVQDYVCPLOGSHALC 485

Db 262 ---QCPO-----CVANIG-----GYRCEHGAHLQC 284

Qy 486 TCCQPMPPDRARRERQDRVAPQCCAVCIQPPFCHLLWGTCTGCGYCLAPPCELN----L 541

Db 285 HLCQGMPPFRANLQ-----VPLHCKGCDRPFCCAYWS--SENVTQGVSGVVCVRETFPI 337

Qy 542 GDKCLDGV-----LNNNSYESDILKNYLATRGLTWKMLTESL-----VALQGVFLLSY 592

Db 338 SERTITRIPETHEMNREHODITQRCIAHMEKTPDVVAEMLELFNNRIDSRRPLNHA 397

Qy 593 R-VTGDTVLVCYCCGLRSFRELTYQYQNTIPASLPVAVTSRDPDCYWRNCRTQ-VKHAHA 650

Db 398 ETITASTHVCNDCYKLVGLVFLYFRITLPRNHLPAVAAREDCWGYACRTQHNEHDA 457

Qy 651 MKNHICEQTR 661

Db 458 RKRNVCRPTR 468

RESULT 10

Q7ZX20 PRELIMINARY; PRT; 540 AA.

ID Q7ZX20

AC Q7ZX20;

DT 01-JUN-2003 (TREMBlrel. 24, Created)

DT 01-JUN-2003 (TREMBlrel. 24, Last sequence update)

DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)

DE Similar to ring finger protein (C3HC4 type) 8.

OS Xenopus laevis (African clawed frog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;

OC Xenopodidae; Xenopus.

OX NCBI_TaxID=8355;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Embryo;

RA Klein S., Strausberg R.;

RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.

DR EMBL; BC046256; AAH46256.1; --

DR InterPro; IPR000253; FHA.

DR InterPro; IPR008984; SMAD_FHA.

DR InterPro; IPR001841; Znf_ring.

DR Pfam; PF00498; FHA; 1.

DR Pfam; PF00097; zf-C3HC4; 1.

DR SMART; SMO0240; FHA; 1.

DR SMART; SMO0184; RING; 1.

DR PROSITE; PS00006; FHA_DOMAIN; 1.

DR PROSITE; PS00518; ZF_RING_1; 1.

DR PROSITE; PS50089; ZF_RING_2; 1.

SQ SEQUENCE 540 AA; 51925 MW; A504B796022A1D94 CRC64;

Query Match 4.7%; Score 167.5; DB 13; Length 540;

Best Local Similarity 18.8%; Pred. No. 0.00012;

Matches 101; Conservative 84; Mismatches 216; Indels 135; Gaps 20;

Qy 5 EEGKQPPPPQPGWRLLRLGAEERGEPHVLLRKEWTIGRRRG-----CDLSFFSNKL 55

Db 3 DEG-----PGCMW--CLRRCGRTEDLLLPDGEVTLGRGLGVTYQLKPTLCP-----M 50

Qy 56 VSGDHCEIVVDEKSGQVTLDET-STSGTVINKLVKKVKTCTPLOTGDVYIL-VYRKEPE 113

Db 51 ISTHC-LFKQNTGGVTVTDNKSINGVWRNKRERLPHKAYTLSEGLIQLGPPPNMES 109

Qy 114 HNVAIYLY--ESLSEKQGM-----TQESFANKENVPFGTKDTSAGAGRGADPRVPPSPA 167

Db 110 AEPYMLVREHLEKLSGLIRPLPKTKATRTKRKFTSEDTDASGNEGFSNFSIKFYRV 169

Qy 168 TOYCFSEEPQSTSTSLP--PTASASSTEPSAGRERSSSCGSGGGGISP----- 215

Db 170 SRE-DEDSAKSHTTULYKQPT-----VEPTASGTESRLNSVEAEVAPQQOCSRSLQ 223

Qy 216 -----KSGSP----- 220

Db 224 LSRVQTMESIRRLNVQMOKQMEMQEKLSPLENOVGANSVLAQKELRALHNLHLSNEQ 283

```
QY 221 -----SVASDEVSSPASALPDRKTASFSSLEPQ-----DQEDLEPVKKKRGDGD 265
Db 284 EQHMQSVKELKEIFEBOQSMGS-----RKQVEEHLKEQLAQLOEHTQLMQLNRSKND 339
QY 266 LDINGOLLVAOPRRNAQTVDHVRRAAGKP-----DKMETTCICQDLLHDCVSLQ 318
Db 340 FE---QIIIAKKELQETKEEKVFAQKEVLMNDVLNLEQCIICSEHFTEAVTLN 396
QY 319 PCWHTFCAACYSGWMMERSLCTCRPCVERICKHILNNLVAYLIQHPKRSSEEDVQS 378
Db 397 -CAHSFCSYCIKSKKKEECPCQIEIVTETRSVLVNDICSDMVDKLSPEMKNRRAALI 455
QY 379 MDARNKITQDMQLQPKVRSPFSEDESSDLELDVDSESSDIQPVVVCQCPY 434
Db 456 LERKENVQAEENPVZ--VWSDSSFLSDTFYSSSSSDSDDELGNLDFWMSREEEY 509

RESULT 11
Q803C1
ID Q803C1 PRELIMINARY; PRT; 485 AA.
AC Q803C1
DT 01-JUN-2003 (TRENBLrel. 24, Created)
DT 01-JUN-2003 (TRENBLrel. 24, Last sequence update)
DE 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE Similar to ring finger protein (C3HC4 type) 8.
OC Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC044545; AAH44545.1; -.
DR InterPro; IPR000253; FHA.
DR InterPro; IPR008984; SMAD FHA.
DR Pfam; PF00498; FHA; 1.
DR InterPro; IPR001841; Znf_fing.
DR Pfam; PF00097; ZF-C3HC4; 1.
DR SMART; SM00240; FHA; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00006; FHA DOMAIN; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
SQ SEQUENCE 485 AA; 55325 NW; 088A192AB2A84706 CRC64;

Query Match 4.7%; Score 167; DB 13; Length 485;
Best Local Similarity 19.6%; Pred. No. 0.00011;
Matches 103; Conservative 74; Mismatches 183; Indels 166; Gaps 20;

QY 1 MERPEE-----GKOSPQPWGRLLRLGAEGEFVLLKREWTGRRGCD---LSFP 51
Db 1 MEKTEPSSNNNEEDSPAKEIKWCLQVRG-RDSWLRLFEDSEVSVGRGLNVTHQILSSS 59
QY 52 SNKLVGDHCRIVWDEKSGQVLTEDTSGTVINKLKVKKQTCPLQTQDVI----- 103
Db 60 CPLMISRIHCVFKLNEGQWTVTDNKSINGVWVGKRIPTSTPCILHQSDSVRLGVLGD 119
QY 104 -----YLVYRKNVEHNVAIVLSLSEKQWTCSEFE-ANKENVHGTGDTSGAGAGRG 156
Db 120 NPVEDYILVQKNFDVVK-SFLSGNLGKSDGAASLSQKLNKSKKPKGGDES----- 170
QY 157 ADPRVPPSPATQVCFEPQPTST-DLPTFTAS--ASSTEPSAGRR----- 202
Db 171 -----EPCPTQHSKSLYRSPAPDKSRAQPCPSGRRRTLLKLSRPLE 213
QY 203 -----SSCGSGGGGISP-----KG--SGPSVASDEVSSPASALPDRKTA 240
Db 214 EDRDAGSSSSSTCSOSSOHLATLHYRNSLMVLGRVGDTPKRAAELEQQQTTPREK- 272
QY 241 SFSSLEPQD-QBDLEPVKKKRG-----DGDLDLNG 270
```

```
Db 273 -----EMQDLQLEALRGQLRSQEQALRMETLEKSFCEERRRLETEKAQQNEVLCK 327
QY 271 QI-----LVAQPRRNAQTVDHVRRAAGK-----PDKME 299
Db 328 QEEALKHKKVIBELKHAMQGFKEVLOAKDELEVTKESKAKAKOEVTVMTEVLE 387
QY 300 ETLTICIQDLLHDCVSLQPCWHTFCAACYSGWMMERSLCTCRPCVERICKHILNNLV 359
Db 388 SELQSCISELFEIAVTILN-CAHSFCQHCISEWNRNKKDKPCMCWQNTITSQTRSLVLDNCI 446
QY 360 EAYLIQHPDKRSSEEDVQSDMARNKITQDMQLQPKVRSPFSEDESS 405
Db 447 D-----RMVENL-SADMRERRLVILNERKGERKSESISSS 481

RESULT 12
Q9BYE7
ID Q9BYE7 PRELIMINARY; PRT; 352 AA.
AC Q9BYE7
DT 01-JUN-2001 (TRENBLrel. 17, Created)
DT 01-JUN-2001 (TRENBLrel. 17, Last sequence update)
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)
DE HMBLR protein.
GN HMBLR.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Takahashi N.; Akasaka T.; Nakayama T.; Koseki H.; Koga H.;
RT "Identification and characterization of hMBLR."
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Strausberg R.;
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AB047006; BAB40779.1; -.
DR EMBL; BC010235; AAH10235.1; -.
DR Genew; HGNC:21156; RNF134.
DR InterPro; IPR002350; kazal.
DR InterPro; IPR001841; Znf_fing.
DR Pfam; PF00097; ZF-C3HC4; 1.
DR SMART; SM00184; RING; 1.
DR PROSITE; PS00282; KAZAL; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Metal-binding; Zinc; Zinc-finger.
SQ SEQUENCE 352 AA; 39241 MW; 559F971A86D9A093 CRC64;

Query Match 4.5%; Score 160.5; DB 4; Length 352;
Best Local Similarity 21.4%; Pred. No. 0.00023;
Matches 62; Conservative 35; Mismatches 128; Indels 65; Gaps 7;

QY 139 ENVFHGTGDTSGAGAGRGADPRVPPSPATQVCFEPQPTSTSTDLPTASASTEPSA 198
Db 2 EGVAVTVAGSVGAKEGGAALPPP-----PPPPVSPALTPAPAGEGAPL 50
QY 199 GRESSSCGGGGGIPKSGSPVASDEVSSPASALPDRKTASFSSLEPQDQEDLEPVK 258
Db 51 SETGAPG-----SGSRPPELE-----PERSLGRFRGFEDDEEEEEE- 90
QY 259 KMRGDGLDLNGOLLVAQPRRNAQTVDHVRRAAGKFDKMEET-----LTCII 306
Db 91 -----ELEEEEEEDMSHFSRLGSGQDSEDEERLINLSLTPYLCSI 138
QY 307 CODLLHDCVSLQPCWHTFCAACYSGWMMERSLCTCR-----PVERICKHILNNLV 360
Db 139 CKGYLDATTITCLHTFCKSCIVRHFYYSNRCPKCNVHVHQTPLYNRLRQLODIY 198
```

QY 361 AVLIQHPDKSRSEEDVQSDARNKITQDMLQPKVRSFSDRGSSDLE 410
 Db 199 KLVINLEER-----EKKQMHDFYKRGLEVPKPAVPQVPSSKGRSKVLE 244

RESULT 13
 Q81UD6
 ID Q81UD6 PRELIMINARY; PRT; 432 AA.
 AC Q81UD6
 DT 01-MAR-2003 (TREMBlrel. 23, Created)
 DT 01-MAR-2003 (TREMBlrel. 23, Last sequence update)
 DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
 DE Hypothetical protein.
 GN MGC13061.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21375674; PubMed=11468690;
 RA Jenne D.E., Tinschert S., Reimann H., Lasinger W., Thiel G.,
 RA Hameister H., Kehrer-Sawatzki H.,
 RT "Molecular characterization and gene content of breakpoint boundaries
 RT in NF1 patients with long range deletions.";
 RL Am. J. Hum. Genet. 69:516-527(2001).
 RN [2]
 RP SEQUENCE FROM N.A.
 RA Jenne D.E., Tinschert S., Stegmann E., Reimann H., Nuernberg P.,
 RA Horn D., Naumann I., Buske A., Thiel G.,
 RT "A common set of at least 11 functional genes is lost in the majority
 RT of NF1 patients with gross deletions.";
 RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RA Jenne D.E., Dorschner M.O., Stephens K., Hameister H., Tinschert S.,
 RA Kehrer-Sawatzki H.,
 RT "Complete physical map and gene repertoire around the NF1 gene in man
 RT and mice.";
 RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ496729; CAD43140.1; -
 DR Genew; HGNC:21158; RNF135.
 DR InterPro; IPR001870; B302.
 DR InterPro; IPR003877; SPRY receptor.
 DR InterPro; IPR001841; Znf_Ring.
 DR Pfam; PF00622; SPRY; 1.
 DR Pfam; PF00097; ZF-C3HC4; 1.
 DR SMART; SM00184; RING; 1.
 DR SMART; SM00449; SPRY; 1.
 DR PROSITE; PS00518; ZF_RING_1; 1.
 DR PROSITE; PS00089; ZF_RING_2; 1.
 KN Hypothetical protein.
 SQ SEQUENCE 432 AA; 47873 MW; A6756ECF81A6A2A6 CRC64;

Query Match 4.5%; Score 160.5; DB 4; Length 432;
 Best Local Similarity 21.0%; Pred. No. 0.00031;
 Matches 85; Conservative 45; Mismatches 158; Indels 117; Gaps 16;

QY 299 BEYLTCILCOLLHDCVSLQPCGHTTCAACYSG-WMERSS---LCPTCR---CPVERICK 351
 Db 16 EDLGLCICGLL-DWPAFLPGHSFGRHCLALWGARDARRWACFTCRQGAQPHLRK 74

QY 352 NHIINLIVEAY-----LIQHPDKSRSEEDVQSDARNKITQ- 387
 Db 75 NTLQLDLADKYRAARIQAGSDPAHCPCPGSSSLSSAAARPRRRPELQKVAVERKITEV 134

QY 388 -----DMLQPKVRSFSDRGSSDLELSDVDSSESDIS----- 422
 Db 135 AQELTELVEHLVDIVRSLOQRPLSESGPDNELSLGKAFSSGVDLSMASPKLVTSDTAA 194

QY 423 -----QPVVCRQCFEYRRQ-----AAQPPHCPAPEGEPGAPQALGDA 460
 Db 195 GKTRDILHLEETQELQKQESVWKEAPEAQMQGELLEAPSSSSCPPLDQSHPALREASRF 254

QY 461 PSTSVSLTTAVQDVYVCPLOQS--HALCTCCFQMPDR-RAERQDDPRVAPQCAVCLQPP 517
 Db 255 AQWAIHTFNLKSLSCSLEGSKDSRTVTYSHRQPFYWCERFSTQVL---CSQALSSG 311

QY 518 CHLYWGCTRTGCGYCLAPFCELNLGDKCLDGVNLNNNSYESDIILKNYLATRLGLTWK----- 572
 Db 312 KH-YWEVDTRNC-----SHWAVGASWMSRDQVLGRTWDSCCVWKGTSOL 357

QY 573 ---NMLTESLVALQR---GVEL-----LSDYRVVTGDTVLCYCC 604
 Db 358 SAHMKVETVLGSDRDPGVGILNLBEGKLAFYVDNQEKLLYEC 402

RESULT 14
 Q723L3
 ID Q723L3 PRELIMINARY; PRT; 1546 AA.
 AC Q723L3
 DT 01-OCT-2003 (TREMBlrel. 25, Created)
 DT 01-OCT-2003 (TREMBlrel. 25, Last sequence update)
 DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
 DE Hypothetical protein DKFZP686H0793 (Fragment).
 GN DKFZP686H0793.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Human retina;
 RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
 RA Pobo G., Han M., Wiemann S.,
 RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BX537764; CAD97829.1; -
 KW Hypothetical protein.
 FT NON TER 1
 SQ SEQUENCE 1546 AA; 170918 MW; 0702441126BAC818 CRC64;

Query Match 4.5%; Score 160; DB 4; Length 1546;
 Best Local Similarity 21.1%; Pred. No. 0.0019;
 Matches 109; Conservative 74; Mismatches 182; Indels 152; Gaps 24;

QY 51 PSNKLVSQDHCRIVVDKSGQVLTEDTSTGTVNKLKVVKKQTCPLQTDGTVLVTRKN 110
 Db 68 PSHGRVAGFEVQSLQD-AGNQLGMEDTSLSSGML-----TQNTNVPILG----- 111

QY 111 EPEHNVAYLYESLSEKQMTQESFEA-NKENVFGTKDTSGAGAGRGADPRVPSSPATQ 169
 Db 112 -----VDVAISQGITLPSLESFHLNHIHGKHLHATGSKRKKKTLRP-GPVTQ 160

QY 170 -----VCFEPPQSTSTSDLPFTASASTEPSPAGRERSSCSGGGGSPKSGSPSVA 223
 Db 161 EDRCDHLTKEP-----FSGEPSEVKEE-----GGKPMNSEGEIPLSLP 200

QY 224 SDVSSFSASALPDRKT-----ASFSSLEPQDOEDLEPV 256
 Db 201 SGQSASKPVSQPRKSTQPDVCASPOEKPLRTLPHQPEEIEDGGLFIPMEQDNESEKR 260

QY 257 KKKVRG-----DG-----DLDLNGQLIVAQPRRNAQTVDHEDVRAAAGKPKDMETL 302
 Db 261 RKKKGTGKRKEDGRGQSGTLAYDLKLDML-----DRTLEDGAK-----QHNL 303

QY 303 TCITCQDLHLHDCVSLQPCGHTTCAACYSG-WMERSS---LCPTCR---CPVERICK 344
 Db 304 TAVNRVILHEVITNEHVAVMMKAAISETEDMPFEPMTRSKLKEVVEKGVVITPNWIS 363

QY 345 PVERICKHIL-NNLVAYLIQHPDKSRSEEDVQSDARNKIT--QDMLQPKVRSFSD 401
 Db 364 PIKK--ANEIKPPQFVDIHL---BEDDSSDEYQPDDEEDETAESILLESDESTASSP 418

QY 402 EGSSEDLI-----ELSDVDSSESDISQPVVCRQCFEYRRQAAQPHCPAPEGEPGAPQAL 457
 Db 419 RGAKSKRLRQSEMETDESGILSEAKV--TAPAIRHISAE-----VVPMPGPPPPPKPK 472

Db 207 PKLDHSVSTNGHRWQIFQDILL-----GTDQDNLDLANVNLMLLELLVQKKQL 254
QY 416 -----SESSDISQPYVVCRCQ 431
Db 255 EASHAAQLILMEFLKVARNRKEQLQIOKELSVLEEDIKRVEEMSGLYSPVSESTV 314
QY 432 PEYRRQAQPPHC-----PAPEGEFPAQAL-----GDAPSTSVSLTTAVQDYVCP 477
Db 315 PQF--EAPSPSHSSIIDSTEYSQPPGSGTSTKKQWYNSTLASRRKRLTAHPED---- 368
QY 478 LQGHALCTCCFQPMPPDRAREBQDPRVAPQ--QCAVCLQPFCHLYWCCTTGCYGLAP 535
Db 369 -----LEQCYFS--TRMSRISDDSRASQDDEFQCLSKF-----TR---YNSVRP 409
QY 536 FCELNLDGKCLDGVNLNNNSYESDILKNYLATRGLTWKQMLTESLVALQRGVFLLSYRV 595
Db 410 LATLSYASDLNGSSIVSSIEFDRDCDYFAIAGVTKIKVYEYGTVIQDAV----DIHYP 465
QY 596 GDTVLC-----YCCGLRSFRELTYQYRONIPAS 623
Db 466 ENEMTCNSKISCISWSS-----YHKULLAS 490

Search completed: May 7, 2004, 14:49:01
Job time : 100.059 secs

QY 458 GDAPSTSVSLTTAVQDYVVCPLQSHALCTCCFQPMED 494
Db 473 QTRDSTFMEXLHVADEBEL-----ASSPVCWDSFQPMDD 505

RESULT 15
Q9RIAS PRELIMINARY; PRT; 733 AA.
AC Q9RIAS, 2000 (TEMBLrel. 13, Created)
DT 01-MAY-2002 (TEMBLrel. 22, Last sequence update)
DT 01-JUN-2003 (TEMBLrel. 24, Last annotation update)
DE Constitutive photomorphogenic protein.
GN COP1.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eutelestomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J;
RX MEDLINE=93324249; PubMed=10395541;
RA Wang H., Kang D., Deng X.W., Wei N.;
RT "Evidence for functional conservation of a mammalian homologue of the
RT light-responsive plant protein COP1.";
RL Curr. Biol. 9:711-714(1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J;
RA Yi C., Deng X.-W.;
RL "The study of mammalian COP1s.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AF151110; AAD51094.2; -.
DR MGD; MGI:1347046; Cop1.
DR InterPro; IPR001680; WD40.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF00400; WD40; 6.
DR Pfam; PF00097; zf-C3HC4; 1.
DR PRINTS; PR00320; GPROTEINBRP.
DR SMART; SM00184; RING; 1.
DR SMART; SM00320; WD40; 6.
DR PROSITE; PS00678; WD_REPEATS_1; 1.
DR PROSITE; PS00082; WD_REPEATS_2; 2.
DR PROSITE; PS00294; WD_REPEATS_REGION; 1.
DR PROSITE; PS00518; ZF_RING_1; 1.
DR PROSITE; PS00089; ZF_RING_2; 1.
KW Metal-binding; Repeat; WD-repeat; Zinc; Zinc-finger.
SQ SEQUENCE 733 AA; 80441 MW; 894AEA12BACC737 CRC64;

Query Match 4.3%; Score 155.5; DB 11; Length 733;
Best Local Similarity 21.3%; Pred. No. 0.0016;
Matches 122; Conservative 53; Mismatches 208; Indels 189; Gaps 24;

QY 153 AGRGADRPVPPSPATQVCFEEBPQSTSTDLPTASASTEPSPAGRERSSCGSGGG 212
Db 7 AGSGAGTSPGSSAASV-----TSAS-----SSLSSSPSPSVAASATLVSGGV 52
QY 213 ISPKGSG-----PSVASDEVSFASALPDRKTASFSSLEPOQDLEFPVKKMRGDDG 265
Db 53 APAAGSGGLGPGRPVLVAASGSASA-----GGAVSAGQKLSCAARPSAGVG 103
QY 266 LDINGQLLVAPRNAGTV-----HEDVRAAGKPKMEETLTCTICQDLLHDCVS 316
Db 104 ---SSSLGSSSRKRLPLVFLCNLLNSYED-----KSNDFVCPICPDIMEEAY- 149
QY 317 LQPCMHFTCAACYSYGMWERSLQCTKCPVERICKHILNNLVEAYLIQHPDKSRSEEDV 376
Db 150 MTKGHSFCYKCTHQSLSDNNRCFKCNVVDNI--DHLFNFVLNELL-KQKQFEKR 206
QY 377 QSMQD-----ARNKITQMLQPKVRRSPSDEGSEDLLELSVD----- 415

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:36:57 ; Search time 14.9546 Seconds
(without alignments)
1379.240 Million cell updates/sec

Title: US-10-048-046-2_COPY_31_103

Perfect score: 378
Sequence: 1 VLLRKEWTIGRRGCDLSF.....INKLKVKKQTCPLQTGDVI 73

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq 29Jan04:.*
1: geneseqp1980s:.*
2: geneseqp1990s:.*
3: geneseqp2000s:.*
4: geneseqp2001s:.*
5: geneseqp2002s:.*
6: geneseqp2003as:.*
7: geneseqp2003bs:.*
8: geneseqp2004s:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	378	100.0	426	AAU15856	AAU15856 Human nov
2	378	100.0	426	ABU54925	ABU54925 Human nov
3	378	100.0	623	AAU93182	AAU93182 Human pro
4	378	100.0	623	ABB97233	ABB97233 Novel hum
5	378	100.0	652	AAU93168	AAU93168 Human pro
6	378	100.0	664	AAU93168	AAU93168 Human pro
7	378	100.0	664	AAU20219	AAU20219 Human Chf
8	304	80.4	92	AAU16156	AAU16156 Human nov
9	304	80.4	92	ABU55225	ABU55225 Human nov
10	275	72.8	99	AAU16157	AAU16157 Human nov
11	275	72.8	99	AAU16576	AAU16576 Human nov
12	275	72.8	99	ABU55645	ABU55645 Human nov
13	275	72.8	99	ABU55226	ABU55226 Human nov
14	107.5	28.4	776	AAU72894	AAU72894 Yeast MEC
15	107.5	28.4	821	AAU28664	AAU28664 Yeast Che
16	107.5	28.4	821	ABP54942	ABP54942 Saccharom
17	107.5	28.4	821	ABR53872	ABR53872 Protein s
18	107.5	28.4	821	ABU61612	ABU61612 Yeast SPK
19	99	26.2	699	AAU03445	AAU03445 Candida a
20	99	26.2	699	ABP73798	ABP73798 Candida a
21	86	22.8	176	ABP65604	ABP65604 Bifidobac
22	79	20.9	345	ABR59714	ABR59714 Human tra
23	78.5	20.8	175	ABP64143	ABP64143 Human ORF
24	78.5	20.8	244	AAU16158	AAU16158 Human nov
25	78.5	20.8	244	ABU55227	ABU55227 Human nov

26	76.5	20.2	517	5	AAU47789	AAU47789 Protein k
27	72	19.0	199	5	ABG77255	ABG77255 Selected
28	72	19.0	199	5	ABU11126	ABU11126 Yeast sel
29	72	19.0	350	5	ABU11042	ABU11042 Yeast sel
30	71	18.8	409	6	ABU36268	ABU36268 Protein e
31	70.5	18.7	874	6	ABU17261	ABU17261 Protein e
32	70.5	18.7	877	6	ADA36875	ADA36875 Acinetoba
33	68	18.0	399	4	AAU92565	AAU92565 Human pro
34	68	18.0	754	3	AAU51669	AAU51669 Human nib
35	68	18.0	754	3	AAU32373	AAU32373 Nibrin, e
36	66.5	17.6	288	4	AAU89798	AAU89798 C glutami
37	66	17.5	131	3	AAU01640	AAU01640 Human sec
38	66	17.5	288	2	AAU95501	AAU95501 B. subtil
39	66	17.5	992	2	AAU69742	AAU69742 SAPAP2 pr
40	66	17.5	992	2	AAU69740	AAU69740 SAPAP1 pr
41	65	17.2	945	4	ABB63213	ABB63213 Drosophil
42	63	16.7	138	4	ABB52816	ABB52816 Escherich
43	62.5	16.5	527	5	ABU05697	ABU05697 M. tuberc
44	62.5	16.5	528	4	AAU81105	AAU81105 Mycobacte
45	62	16.4	1724	4	ABB11806	ABB11806 Human sec

ALIGNMENTS

RESULT 1
AAU15856
ID AAU15856 standard; protein; 426 AA.
XX
AC AAU15856;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human novel secreted protein, Seq ID 809.
XX
KW Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW Human; vasotropic; cerebroprotective; nootropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX
OS Homo sapiens.
XX
PN WO20015322-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001341.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190078P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.

PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0228868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 25-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.

XX
XX
XX
PI
XX
DR
DR
FT
PT
XX
PS
XX
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC

(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-488783/53.
N-FSDB; AAS25843.
New nucleic acid molecules encoding 461 human secreted proteins for diagnosing, preventing, treating or ameliorating medical conditions and used as food additives or preservatives.
Claim 11; SEQ ID NO 809; 980pp; English.
The invention relates to isolated nucleic acid molecules and their encoded secreted proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. cardiac neoplasms of the breast or liver, cardiovascular disorders e.g. cerebral ischaemia, angiogenesis, arrest, cerebrovascular disorders e.g. Alzheimer's disease, infections caused by nervous system disorders e.g. Alzheimer's disease, ocular disorders e.g. corneal infection, bacteria, viruses and fungi and other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation.

CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed
Query Match 100.0%; Score 378; DB 4; Length 426;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVV 60
DB 33 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVV 92
QY 61 KKQTCPLQTGDVI 73
DB 93 KKQTCPLQTGDVI 105
RESULT 2
ABU54925
ID ABU54925 standard; protein; 426 AA.
XX AC ABU54925;
XX DT 18-MAR-2003 (first entry)
XX DE Human novel polypeptide #12.
XX KW Human; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.
XX OS Homo sapiens.
XX PN US2002132753-A1.
XX PD 19-SEP-2002.
XX PF 17-JAN-2001; 2001US-00764864.
XX PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0216547P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218390P.
PR 26-JUL-2000; 2000US-0220563P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 22-AUG-2000; 2000US-0226858P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.

PR 05-SEP-2000; 2000US-0229513P.
PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236357P.
PR 29-SEP-2000; 2000US-0236388P.
PR 29-SEP-2000; 2000US-0236399P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251866P.
PR 08-DEC-2000; 2000US-0251869P.
XX (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
XX PI Rosen CA, Ruben SM, Barash SC;
XX WPI; 2003-147444/14.
DR N-PSDB; ABX73184.
XX New polypeptides and nucleic acids, useful in gene therapy for treating,
PT inhibiting or preventing e.g. neural, immune system, muscular,
PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
PT renal disorders.
XX Claim 11; SEQ ID NO 809; 402pp; English.
XX The invention relates to human novel polypeptides and their associated
CC polynucleotides. The polypeptides and polynucleotides are useful in gene
CC therapy for treating, inhibiting or preventing neural disorders, immune
CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
CC leukaemia), hyperproliferative disorders (e.g. Hodgkin's disease and
CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
CC infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
CC ABU55748 represent human novel polypeptides of the invention
XX Sequence 426 AA;
SQ Query Match 100.0%; Score 378; DB 6; Length 426;
Best Local Similarity 100.0%; Pred. No. 1.5e-40;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVV 60
DB 33 VLLRKEWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVV 92
QY 61 KKQTCPLQTGDVI 73
DB 93 KKQTCPLQTGDVI 105

```

QY      61 KKQTCPLOQTGDVI 73
Db      91 KKQTCPLOQTGDVI 103

RESULT 4
ABB97233
ID ABB97233 standard; protein; 623 AA.
XX
AC ABB97233;
XX
DT 27-JUN-2002 (first entry)
XX
Novel human protein SEQ ID NO: 501.
DE
DE Human; antianaemic; vulnery; antiinflammatory; immunomodulator;
KW antiinfertility; cerebroprotective; cytosatic; rheumatic; gene therapy;
KW neuroprotective; antiparkinsonian; protein therapy; EST;
KW expressed sequence tag.
XX
OS Homo sapiens.
OS
WO200222660-A2.
PN
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US026015.
XX
PR 11-SEP-2000; 2000US-00659671.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
PI Xue AJ, Yang Y, Wehrman T, Dmanac RT;
XX WFEI; 2002-292408/33.
DR N-PSDB; ABN32419.
DR
XX
XX An isolated polynucleotide for treating diseases associated with its
PT encoded polypeptide such as cancer and multiple sclerosis.
XX
XX Example 2; SEQ ID NO 501; 509pp; English.
XX
CC The present invention provides the protein and coding sequences of 444
CC novel human proteins. These were isolated from expressed sequences tags
CC (ESTs). They can be used to stimulate cell growth, to regulate
CC haematopoiesis e.g. to treat aplastic anaemia, to help tissue regrowth
CC e.g. in burn treatment, to regulate the immune system e.g. to treat
CC multiple sclerosis, to regulate activin or inhibin e.g. to treat
CC infertility, to regulate haemostasis or thrombolysis e.g. to treat stroke
CC and cancer, to screen for drugs, to treat inflammatory conditions e.g.
CC rheumatoid arthritis, and to treat nervous system disorders e.g.
CC Parkinson's disease. The present sequence is a protein of the invention
XX
SQ Sequence 623 AA;

Query Match          100.0%; Score 378; DB 5; Length 623;
Best Local Similarity 100.0%; Pred. No. 2.5e-40;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VLARKRWITGRRGCDDLSPFNKLYSGDCHRIWDEKSQVLTEDTSTGTINKLVKVV 60
Db      31 VLARKRWITGRRGCDDLSPFNKLYSGDCHRIWDEKSQVLTEDTSTGTINKLVKVV 90
QY      61 KKQTCPLOQTGDVI 73
Db      91 KKQTCPLOQTGDVI 103

RESULT 5
AAB93168
ID AAB93168 standard; protein; 652 AA.
XX
```

AC AAB93168;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:12100.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-00116126.
XX
PR 29-JUL-1999; 99JP-00248036.
XX
PR 27-AUG-1999; 99JP-00300253.
XX
PR 11-JAN-2000; 2000JP-00118776.
XX
PR 02-MAY-2000; 2000JP-00183767.
XX
PR 09-JUN-2000; 2000JP-00241899.
XX
XX (HELI-) HELIX RES INST.
XX
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI: 2001-318749/34.
XX
XX Primer sets for synthesising polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
XX
XX Claim 8; SEQ ID NO 12100; 2537pp + Sequence Listing; English.
XX
XX The present invention describes primer sets for synthesising 5602 full-length cDNAs defined in the specification. Where a primer set comprises:
CC (a) an oligo-dT primer and an oligonucleotide complementary to the
CC complementary strand of a polynucleotide which comprises one of the 5602
CC nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in the
CC specification. The primer sets can be used in antisense therapy and in
CC gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893
CC represent human amino acid sequences; and AAH13629 to AAH13632 represent
CC polynucleotides, all of which are used in the exemplification of the
XX present invention
XX
XX Sequence 652 AA;
SQ
Query Match 100.0%; Score 378; DB 4; Length 652;
Best Local Similarity 100.0%; Pred. No. 2.6e-40;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VLLKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVV 60
DB 31 VLLKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
DB 91 KKQTCPLQTGDVI 103

RESULT 6
AAB83843
ID AAB83843 standard; protein; 664 AA.
XX
AC AAB83843;
XX
DT 22-AUG-2001 (first entry)
XX
DE Amino acid sequence of a human ring finger protein designated FHAR1.
XX
KW FHAR1; RING finger protein; cancer; vaccine.
XX
OS Homo sapiens.
XX
PN WO200142430-A1.
XX
PD 14-JUN-2001.
XX
PF 07-DEC-2000; 2000WO-US033094.
XX
PR 08-DEC-1999; 99US-00456876.
XX
XX (SMIK) SMITHKLINE BEECHAM CORP.
XX
XX Zhou B, Zhu Y, Chaturvedi P, Hurle MR, Li X;
PI
XX
XX WPI: 2001-381563/40.
DR N-PSDB; AAF89709.
XX
XX New FHAR1 polypeptide, a member of the RING finger protein family for
PT diagnosing and treating cancer, and for use in anti-cancer vaccines.
XX
XX Claim 1; Page 19; 28pp; English.
XX
XX The present sequence represents a FHAR1 polypeptide, which is a member of
CC the RING finger protein family. FHAR1 is useful in the treatment of
CC cancer, and as a vaccine for inducing an immunological response in a
CC mammal. FHAR1 polynucleotides may also be used as a diagnostic reagent
CC through detection of mutations in the associated gene, and for chromosome
CC localization studies, and tissue expression studies. FHAR1 antibodies are
CC useful to isolate and to identify clones expressing the polypeptides, or
CC to purify the polypeptides by affinity chromatography and to treat cancer
XX
XX Sequence 664 AA;
SQ
Query Match 100.0%; Score 378; DB 4; Length 664;
Best Local Similarity 100.0%; Pred. No. 2.7e-40;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VLLKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVV 60
DB 31 VLLKREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVV 90
QY 61 KKQTCPLQTGDVI 73
DB 91 KKQTCPLQTGDVI 103
RESULT 7
AAB20219
ID AAB20219 standard; protein; 664 AA.
XX
AC AAB20219;
XX
DT 14-MAY-2001 (first entry)
XX
DE Human Chfr (checkpoint with FHA and ring finger) protein.
XX
KW Checkpoint with forkhead associated domain and ring finger; Chfr; human;
XX mitosis; cell cycle; tumour; diagnosis; antitumour; drug screening;
XX ubiquitin-protein ligase.
XX

```
OS XX Homo sapiens.
FH Key Location/Qualifiers
FT Domain 31..103
FT /label= Forkhead-associated_domain
FT Domain 303..346
FT /label= Ring_finger-domain
FT Region 476..641
FT /note= "cysteine-rich region"
FT Misc-difference 580
FT /note= "Met in U2OS cells"
XX
XX WO200109150-A2.
XX
XX 08-FEB-2001.
XX
XX 14-JUN-2000; 2000WO-US016391.
XX
XX 29-JUL-1999; 99US-0146194P.
XX
XX (WIST-) WISTAR INST ANATOMY & BIOLOGY.
XX
XX Halazonetis T, Scolnick D;
XX
XX WPI; 2001-182927/18.
XX N-PSDB; AAF30352.
XX
XX Novel nucleic acid sequence of mitotic checkpoint gene encoding a
XX checkpoint with forkhead-associated domain and ring finger protein, for
XX diagnosing tumorigenic cells and in screening for anticancer drugs.
XX
XX Claim 8(a); Fig 4A-C; 85pp; English.
XX
XX The present sequence is that of human mitotic checkpoint protein Chfr,
XX having a forkhead associated domain (FHA) and a ring finger domain. The
XX protein is required for regulation of the transition of cells from
XX prophase to metaphase during mitosis. It has ubiquitin-protein ligase
XX activity. The Chfr checkpoint was evident in primary human cells, but was
XX inactivated in 4 of 8 human cancer cell lines. In U2OS cells, a mutation
XX was identified that caused a Val to Met amino acid substitution in the
XX highly conserved C-terminal Cys-rich region of the Chfr protein. In the
XX absence of the Chfr checkpoint, cells subjected to mitotic stress
XX condensed their chromosomes despite failing to separate their
XX chromosomes. Chfr may monitor centrosome separation. Inactivation of the
XX Chfr gene (see AAF30352) in human cancer is theorized to underlie the
XX increased sensitivity of cancer cells to antimitotic drugs. Polypeptides
XX comprising the present sequence, or sequences comprising at least amino
XX acids 31-103, 303-346 and/or 476-641 of this sequence, are claimed.
XX Claimed methods of determining the tumorigenic potential of a cell
XX comprise examining the cell for the presence of Chfr expression or for
XX the presence of Chfr-mediated ubiquitin-protein ligase activity (in both
XX cases, absence of expression indicating predisposition to tumorigenesis
XX upon exposure to mitotic stress). A diagnostic kit for detecting the
XX tumorigenic potential of cell cells comprises may comprise a ligand that
XX binds to Chfr, such as an antibody or its fragment. Inhibitors of Chfr
XX are identified by monitoring their effect on Chfr expression, and are
XX used to retard the growth of cancer cells
XX
XX Sequence 664 AA;
XX
XX Query Match 100.0%; Score 378; DB 4; Length 664;
XX Best Local Similarity 100.0%; Pred No. 2,7e-40;
XX Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 VLLRKREWTGRRRGCDLFFPNKLVSGDHCRIVVDEKSGQVLTSTSGVINKLVK 60
XX 31 VLLRKREWTGRRRGCDLFFPNKLVSGDHCRIVVDEKSGQVLTSTSGVINKLV 90
XX
XX 61 KKQTCPLQGDV 73
XX
XX 91 KKQTCPLQGDV 103
XX
XX
```

PR 08-SEP-2000; 2000US-0231243P.
 PR 08-SEP-2000; 2000US-0231244P.
 PR 08-SEP-2000; 2000US-0231413P.
 PR 08-SEP-2000; 2000US-0231414P.
 PR 08-SEP-2000; 2000US-0232080P.
 PR 08-SEP-2000; 2000US-0232081P.
 PR 13-SEP-2000; 2000US-0231968P.
 PR 14-SEP-2000; 2000US-0232397P.
 PR 14-SEP-2000; 2000US-0232398P.
 PR 14-SEP-2000; 2000US-0232399P.
 PR 14-SEP-2000; 2000US-0232400P.
 PR 14-SEP-2000; 2000US-0232401P.
 PR 14-SEP-2000; 2000US-0233063P.
 PR 14-SEP-2000; 2000US-0233064P.
 PR 14-SEP-2000; 2000US-0233065P.
 PR 21-SEP-2000; 2000US-0234223P.
 PR 21-SEP-2000; 2000US-0234224P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 25-SEP-2000; 2000US-0234997P.
 PR 25-SEP-2000; 2000US-0234998P.
 PR 26-SEP-2000; 2000US-0235484P.
 PR 27-SEP-2000; 2000US-0235834P.
 PR 27-SEP-2000; 2000US-0235836P.
 PR 29-SEP-2000; 2000US-0236327P.
 PR 29-SEP-2000; 2000US-0236367P.
 PR 29-SEP-2000; 2000US-0236368P.
 PR 29-SEP-2000; 2000US-0236369P.
 PR 29-SEP-2000; 2000US-0236370P.
 PR 02-OCT-2000; 2000US-0236802P.
 PR 02-OCT-2000; 2000US-0237037P.
 PR 02-OCT-2000; 2000US-0237038P.
 PR 02-OCT-2000; 2000US-0237039P.
 PR 02-OCT-2000; 2000US-0237040P.
 PR 13-OCT-2000; 2000US-0239335P.
 PR 13-OCT-2000; 2000US-0239337P.
 PR 20-OCT-2000; 2000US-0240960P.
 PR 20-OCT-2000; 2000US-0241212P.
 PR 20-OCT-2000; 2000US-0241785P.
 PR 20-OCT-2000; 2000US-0241786P.
 PR 20-OCT-2000; 2000US-0241787P.
 PR 20-OCT-2000; 2000US-0241808P.
 PR 20-OCT-2000; 2000US-0241809P.
 PR 20-OCT-2000; 2000US-0241826P.
 PR 01-NOV-2000; 2000US-0244617P.
 PR 08-NOV-2000; 2000US-0246474P.
 PR 08-NOV-2000; 2000US-0246475P.
 PR 08-NOV-2000; 2000US-0246476P.
 PR 08-NOV-2000; 2000US-0246477P.
 PR 08-NOV-2000; 2000US-0246478P.
 PR 08-NOV-2000; 2000US-0246523P.
 PR 08-NOV-2000; 2000US-0246524P.
 PR 08-NOV-2000; 2000US-0246525P.
 PR 08-NOV-2000; 2000US-0246526P.
 PR 08-NOV-2000; 2000US-0246527P.
 PR 08-NOV-2000; 2000US-0246528P.
 PR 08-NOV-2000; 2000US-0246532P.
 PR 08-NOV-2000; 2000US-0246609P.
 PR 08-NOV-2000; 2000US-0246610P.
 PR 08-NOV-2000; 2000US-0246611P.
 PR 08-NOV-2000; 2000US-0246613P.
 PR 17-NOV-2000; 2000US-0249207P.
 PR 17-NOV-2000; 2000US-0249208P.
 PR 17-NOV-2000; 2000US-0249209P.
 PR 17-NOV-2000; 2000US-0249210P.
 PR 17-NOV-2000; 2000US-0249211P.
 PR 17-NOV-2000; 2000US-0249212P.
 PR 17-NOV-2000; 2000US-0249213P.
 PR 17-NOV-2000; 2000US-0249214P.
 PR 17-NOV-2000; 2000US-0249215P.
 PR 17-NOV-2000; 2000US-0249216P.
 PR 17-NOV-2000; 2000US-0249217P.
 PR 17-NOV-2000; 2000US-0249218P.
 PR 17-NOV-2000; 2000US-0249244P.
 PR 17-NOV-2000; 2000US-0249245P.

PR 17-NOV-2000; 2000US-0249264P.
 PR 17-NOV-2000; 2000US-0249285P.
 PR 17-NOV-2000; 2000US-0249297P.
 PR 17-NOV-2000; 2000US-0249299P.
 PR 17-NOV-2000; 2000US-0249300P.
 PR 01-DEC-2000; 2000US-0250160P.
 PR 01-DEC-2000; 2000US-0250391P.
 PR 05-DEC-2000; 2000US-0251030P.
 PR 05-DEC-2000; 2000US-0251988P.
 PR 05-DEC-2000; 2000US-0256719P.
 PR 06-DEC-2000; 2000US-0251479P.
 PR 08-DEC-2000; 2000US-0251856P.
 PR 08-DEC-2000; 2000US-0251868P.
 PR 08-DEC-2000; 2000US-0251869P.
 PR 08-DEC-2000; 2000US-0251989P.
 PR 08-DEC-2000; 2000US-0251990P.
 PR 11-DEC-2000; 2000US-0254097P.
 PR 05-JAN-2001; 2001US-0259678P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX Rosen CA, Barash SC, Ruben SM;
 PI WPI; 2001-488783/53.
 XX N-PSDB; AAS26143.
 PT New nucleic acid molecules encoding 461 human secreted proteins for
 PT diagnosing, preventing, treating or ameliorating medical conditions and
 PT used as food additives or preservatives.
 XX Claim 11; SEQ ID NO 1109; 980pp; English.
 XX The invention relates to isolated nucleic acid molecules and their
 CC encoded secreted proteins. The nucleic acids and proteins are used to
 CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
 CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
 CC in diagnosing a pathological condition or susceptibility to a
 CC pathological condition. Antibodies to the proteins can also be used in
 CC alleviating symptoms associated with the disorders and in diagnostic
 CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays
 CC (ELISA). Disorders which are diagnosed or treated include autoimmune
 CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
 CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
 CC arrest, cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
 CC nervous system disorders e.g. Alzheimer's disease, infections caused by
 CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
 CC and many other disorders listed in the specification. The polypeptides
 CC can also be used to aid wound healing and epithelial cell proliferation,
 CC to prevent skin aging due to sunburn, to maintain organs before
 CC transplantation, for supporting cell culture of primary tissues, to
 CC regenerate tissues and in chemotaxis. The polypeptides can also be used
 CC as a food additive or preservative to increase or decrease storage
 CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
 CC minerals, cofactors and other nutritional components. The present
 CC sequence represents a novel secreted protein of the invention. Note: The
 CC sequence data for this patent did not form part of the printed
 Query Match 80.4%; Score 304; DB 4; Length 92;
 Best Local Similarity 98.3%; Pred. No. 1.1e-31;
 Matches 59; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 VLLRKRWTIGRRRCGLSFPNSKLVSGDHCRIVVDEKSGQVTLDTSTGVINKLVV 60
 Db 33 VLLRKRWTIGRRRCGLSFPNSKLVSGDHCRIVVDEKSGQVTLDTSTGVINKLVV 92
 RESULT 9
 ABUS5225
 ID ABUS5225 standard; protein; 92 AA.
 XX ABUS5225;
 AC
 XX 18-MAR-2003. (first entry)
 DT

XX DE Human novel polypeptide #312.
 XX KW Human; neural disorder; immune system disorder; renal disorder;
 XX KW muscular disorder; respiratory disease; reproductive disorder;
 KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
 KW hyperproliferative disorder; inflammatory disease; allergic reaction;
 KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
 KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
 KW haemostatic; antiarteriosclerotic.
 XX OS Homo sapiens.
 XX PN US2002132753-A1.
 XX PD 19-SEP-2002.
 XX PF 17-JAN-2001; 2001US-00764864.
 XX 31-JAN-2000; 2000US-0179065P.
 PR 04-FEB-2000; 2000US-0180628P.
 PR 28-JUN-2000; 2000US-0214886P.
 PR 07-JUL-2000; 2000US-0215647P.
 PR 07-JUL-2000; 2000US-0216880P.
 PR 11-JUL-2000; 2000US-0217487P.
 PR 11-JUL-2000; 2000US-0217496P.
 PR 14-JUL-2000; 2000US-0218290P.
 PR 26-JUL-2000; 2000US-0220963P.
 PR 26-JUL-2000; 2000US-0220964P.
 PR 14-AUG-2000; 2000US-0224518P.
 PR 14-AUG-2000; 2000US-0224519P.
 PR 14-AUG-2000; 2000US-0225267P.
 PR 14-AUG-2000; 2000US-0225268P.
 PR 14-AUG-2000; 2000US-0225270P.
 PR 14-AUG-2000; 2000US-0225447P.
 PR 14-AUG-2000; 2000US-0225447P.
 PR 14-AUG-2000; 2000US-0225757P.
 PR 14-AUG-2000; 2000US-0225758P.
 PR 22-AUG-2000; 2000US-0226868P.
 PR 30-AUG-2000; 2000US-0228924P.
 PR 01-SEP-2000; 2000US-0229287P.
 PR 01-SEP-2000; 2000US-0229343P.
 PR 01-SEP-2000; 2000US-0229344P.
 PR 01-SEP-2000; 2000US-0229345P.
 PR 05-SEP-2000; 2000US-0229509P.
 PR 05-SEP-2000; 2000US-0229513P.
 PR 08-SEP-2000; 2000US-0231413P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 21-SEP-2000; 2000US-0234274P.
 PR 27-SEP-2000; 2000US-0234997P.
 PR 27-SEP-2000; 2000US-0235834P.
 PR 29-SEP-2000; 2000US-0236327P.
 PR 29-SEP-2000; 2000US-0236367P.
 PR 29-SEP-2000; 2000US-0236368P.
 PR 29-SEP-2000; 2000US-0236369P.
 PR 02-OCT-2000; 2000US-0236802P.
 PR 02-OCT-2000; 2000US-0237037P.
 PR 02-OCT-2000; 2000US-0237038P.
 PR 02-OCT-2000; 2000US-0237039P.
 PR 02-OCT-2000; 2000US-0237040P.
 PR 13-OCT-2000; 2000US-0239355P.
 PR 20-OCT-2000; 2000US-0240960P.
 PR 20-OCT-2000; 2000US-0241785P.
 PR 20-OCT-2000; 2000US-0241809P.
 PR 01-NOV-2000; 2000US-0244817P.
 PR 17-NOV-2000; 2000US-0249299P.
 PR 08-DEC-2000; 2000US-0251856P.
 PR 08-DEC-2000; 2000US-0251868P.
 PR 08-DEC-2000; 2000US-0251869P.
 XX (ROSE/) ROSEN C A.
 PA (RUBE/) RUBEN S M.
 PA (BARA/) BARASH S C.

XX PI Rosen CA, Ruben SM, Barash SC;
 XX DR WPI; 2003-147444/14.
 XX DR N-PSDB; ABX73484.
 XX New polypeptides and nucleic acids, useful in gene therapy for treating,
 PT inhibiting or preventing e.g. neural, immune system, muscular,
 PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
 PT renal disorders.
 XX Claim 11; SEQ ID NO 1109; 402pp; English.
 XX The invention relates to human novel polypeptides and their associated
 CC polynucleotides. The polypeptides and polynucleotides are useful in gene
 CC therapy for treating, inhibiting or preventing neural disorders, immune
 CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
 CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
 CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
 CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
 CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
 CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
 CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
 CC leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
 CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
 CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
 CC infarction) and cancerous diseases. Sequences ABU54914-ABU55659 and
 CC ABU55748 represent human novel polypeptides of the invention
 XX SQ Sequence 92 AA;
 Query Match 80.4%; Score 304; DB 6; Length 92;
 Best Local Similarity 98.3%; Pred No. 1.1e-31;
 Matches 59; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 VLLKREWTIGRRGCDLSPFNKLVSGDHCRIWVDEKSGQVLTSTSTGTINKLVK 60
 DB 33 VLLKREWTIGRRGCDLSPFNKLVSGDHCRIWVDEKSGQVLTSTSTGTINKLVK 92
 RESULT 10
 AAU16157
 ID AAU16157 standard; protein; 99 AA.
 AC AAU16157;
 XX 07-NOV-2001 (first entry)
 DT Human novel secreted protein, Seq ID 1110.
 DE Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
 KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;
 KW antibacterial; virucide; fungicide; opthalmological; vulnerary;
 KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
 KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
 KW cerebral ischaemia; angiogenesis; nervous system disorder;
 KW Alzheimer's disease; infection; ocular disorder; corneal infection;
 KW wound healing; epithelial cell proliferation; skin ageing; food additive;
 KW preservative; antiproliferative.
 XX Homo sapiens.
 OS WO200155322-A2.
 XX 02-AUG-2001.
 PD 17-JAN-2001; 2001WO-US001341.
 PF 31-JAN-2000; 2000US-0179065P.
 PR 04-FEB-2000; 2000US-0180628P.
 PR 24-FEB-2000; 2000US-0184664P.
 PR 02-MAR-2000; 2000US-0186350P.
 PR 16-MAR-2000; 2000US-0189874P.

PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 14-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.

PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249246P.
PR 17-NOV-2000; 2000US-0249255P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 05-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 06-DEC-2000; 2000US-0256719P.
PR 08-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-02559678P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-488783/53.
XX N-PSDB; AAS26144.
XX
XX New nucleic acid molecules encoding 461 human secreted proteins for
PT diagnosing, preventing, treating or ameliorating medical conditions and
PT used as food additives or preservatives.
XX
XX Claim 11; SEQ ID NO 1110; 980pp; English.
XX
XX The invention relates to isolated nucleic acid molecules and their
CC

CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed

Query Match 72.8%; Score 275; DB 4; Length 99;
Best Local Similarity 90.3%; Pred. No. 7.3e-28;
Matches 56; Conservative 1; Mismatches 3; Indels 2; Gaps 1;
QY 12 RRGCDLSPFNKLVSGDHCRIWVDKSGQVLTSTSGTVINKLVKKQTCPLQGD 71
DB 9 RDKGPD--FPXNKLVS GDHCRIWVDKSGQVLTSTSGTVINKLVKKQTCPLQGD 66
QY 72 VI 73
DB 67 VI 68

RESULT 11

AAU16576
ID AAU16576 standard; protein; 99 AA.

XX AC AAU16576;

XX DT 07-NOV-2001 (first entry)

XX DE Human novel secreted protein, Seq ID 1529.

XX KW Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; neurotropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cerebrovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.

XX OS Homo sapiens.

XX PN WO200153322-A2.

XX PD 02-AUG-2001.

XX PF 17-JAN-2001; 2001WO-US0001341.

XX PR 31-JAN-2000; 2000US-0179065P.

XX PR 04-FEB-2000; 2000US-0180628P.

XX PR 24-FEB-2000; 2000US-0184654P.

XX PR 02-MAR-2000; 2000US-0186350P.

XX PR 16-MAR-2000; 2000US-0189874P.

XX PR 17-MAR-2000; 2000US-0190076P.

XX PR 18-APR-2000; 2000US-0198123P.

XX PR 19-MAY-2000; 2000US-0205515P.

PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216800P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226688P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 05-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 13-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239353P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.

20-OCT-2000; 2000US-0241785P.
20-OCT-2000; 2000US-0241786P.
20-OCT-2000; 2000US-0241787P.
20-OCT-2000; 2000US-0241808P.
20-OCT-2000; 2000US-0241809P.
20-OCT-2000; 2000US-0241826P.
01-NOV-2000; 2000US-0244617P.
08-NOV-2000; 2000US-0246474P.
08-NOV-2000; 2000US-0246475P.
08-NOV-2000; 2000US-0246476P.
08-NOV-2000; 2000US-0246477P.
08-NOV-2000; 2000US-0246478P.
08-NOV-2000; 2000US-0246523P.
08-NOV-2000; 2000US-0246524P.
08-NOV-2000; 2000US-0246525P.
08-NOV-2000; 2000US-0246526P.
08-NOV-2000; 2000US-0246527P.
08-NOV-2000; 2000US-0246528P.
08-NOV-2000; 2000US-0246532P.
08-NOV-2000; 2000US-0246609P.
08-NOV-2000; 2000US-0246610P.
08-NOV-2000; 2000US-0246611P.
08-NOV-2000; 2000US-0246613P.
17-NOV-2000; 2000US-0249207P.
17-NOV-2000; 2000US-0249208P.
17-NOV-2000; 2000US-0249209P.
17-NOV-2000; 2000US-0249210P.
17-NOV-2000; 2000US-0249211P.
17-NOV-2000; 2000US-0249212P.
17-NOV-2000; 2000US-0249213P.
17-NOV-2000; 2000US-0249214P.
17-NOV-2000; 2000US-0249215P.
17-NOV-2000; 2000US-0249216P.
17-NOV-2000; 2000US-0249217P.
17-NOV-2000; 2000US-0249218P.
17-NOV-2000; 2000US-0249244P.
17-NOV-2000; 2000US-0249245P.
17-NOV-2000; 2000US-0249264P.
17-NOV-2000; 2000US-0249265P.
17-NOV-2000; 2000US-0249297P.
17-NOV-2000; 2000US-0249299P.
17-NOV-2000; 2000US-0249300P.
01-DEC-2000; 2000US-0250160P.
01-DEC-2000; 2000US-0250391P.
05-DEC-2000; 2000US-0251030P.
05-DEC-2000; 2000US-0251988P.
05-DEC-2000; 2000US-0256719P.
06-DEC-2000; 2000US-0251479P.
08-DEC-2000; 2000US-0251856P.
08-DEC-2000; 2000US-0251868P.
08-DEC-2000; 2000US-0251869P.
08-DEC-2000; 2000US-0251989P.
08-DEC-2000; 2000US-0251990P.
11-DEC-2000; 2000US-0254037P.
05-JAN-2001; 2001US-0259678P.
(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-485783/53.
N-PSDB; AAS25563.
New nucleic acid molecules encoding 461 human secreted proteins for
diagnosing, preventing, treating or ameliorating medical conditions and
used as food additives or preservatives.
Claim 11; SEQ ID NO 1529; 980pp; English.
The invention relates to isolated nucleic acid molecules and their
encoded secreted proteins. The nucleic acids and proteins are used to
prevent, treat or ameliorate a medical condition in e.g. humans, mice,
rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used

CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infectious caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed
Query Match 72.8%; Score 275; DB 4; Length 99;
Best Local Similarity 90.3%; Pred. No. 7,3e-28;
Matches 56; Conservative 1; Mismatches 3; Indels 2; Gaps 1;
QY 12 RRGCDLSPPSNKLVSGBDCHRIIVVDEKSGQVLTSTSGTVINKLVKVKQTCPLOTGD 71
Db 9 RDXGPD--PPXNKLVSGBDCHRIIVVDEKSGQVLTSTSGTVINKLVKVKQTCPLOTGD 66
QY 72 VI 73
Db 67 VI 68
RESULT 12
ABUS55645
ID ABUS55645 standard; protein; 99 AA.
XX ABUS55645;
XX 18-MAR-2003 (first entry)
XX Human novel polypeptide #732.
XX Human; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.
XX Homo sapiens.
XX US2002132753-A1.
XX 19-SEP-2002.
XX 17-JAN-2001; 2001US-00764864.
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
XX 28-JUN-2000; 2000US-0214886P.
XX 07-JUL-2000; 2000US-0216647P.
XX 07-JUL-2000; 2000US-0216880P.
XX 11-JUL-2000; 2000US-0217487P.
XX 11-JUL-2000; 2000US-0217496P.
XX 14-JUL-2000; 2000US-0218290P.
XX 26-JUL-2000; 2000US-0220963P.
XX 26-JUL-2000; 2000US-0220964P.
XX 14-AUG-2000; 2000US-0224518P.
XX 14-AUG-2000; 2000US-0224519P.
XX 14-AUG-2000; 2000US-0225267P.

PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 22-AUG-2000; 2000US-0226868P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-023497P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239335P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244817P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
XX
XX (ROSE/) ROSEN C A.
XX (RUBE/) RUBEN S M.
XX (BARA/) BARASH S C.
XX
XX Rosen CA, Ruben SM, Barash SC;
XX WPI; 2003-147444/14.
XX N-PSDB; ABX73904.
XX
XX New polypeptides and nucleic acids, useful in gene therapy for treating,
XX inhibiting or preventing e.g. neural, immune system, muscular,
XX respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
XX renal disorders.
XX
XX Claim 11; SEQ ID NO 1529; 402pp; English.
XX
XX The invention relates to human novel polypeptides and their associated
XX polynucleotides. The polypeptides and polynucleotides are useful in gene
XX therapy for treating, inhibiting or preventing neural disorders, immune
XX system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
XX and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
XX nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
XX gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
XX (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
XX heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
XX renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
XX leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
XX appendicitis), allergic reactions and conditions (e.g. asthma), blood
XX related disorders (e.g. thrombosis, atherosclerosis and myocardial
XX infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
XX ABU55748 represent human novel polypeptides of the invention
XX
XX Sequence 99 AA;
XX
XX Query Match 72.8%; Score 275; DB 6; Length 99;

Best Local Similarity 90.3%; Pred. No. 7.3e-28;
Matches 56; Conservative 1; Mismatches 3; Indels 2; Gaps 1;
Qy 12 RRRGCDLSPSPKLVSGDHCRIVVDKSGQVLTEDTSTGTVINKLKVKKQTCPLQTGD 71
Db 9 RDKGPD--FFXKNLVSGDHCRIVVDKSGQVLTEDTSTGTVINKLKVKKQTCPLQTGD 66
Qy 72 VI 73
Db 67 VI 68
RESULT 13
ABU55226
ID ABU55226 standard; protein; 99 AA.
XX
XX AC ABU55226;
XX
XX DT 18-MAR-2003 (first entry)
XX
XX DE Human novel polypeptide #313.
XX
XX Human; neural disorder; immune system disorder; renal disorder;
XX muscular disorder; respiratory disease; reproductive disorder;
XX gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
XX hyperproliferative disorder; inflammatory disease; allergic reaction;
XX blood related disorder; cancer; immunosuppressive; antiinflammatory;
XX cardiovascular; nephrotropic; cancer; immunosuppressive; antiinflammatory;
XX haemostatic; antiarteriosclerotic.
XX
XX OS Homo sapiens.
XX
XX PN US2002132753-A1.
XX
XX PD 19-SEP-2002.
XX
XX PF 17-JAN-2001; 2001US-00764864.
XX
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
XX 28-JUN-2000; 2000US-0214886P.
XX 07-JUL-2000; 2000US-0216647P.
XX 07-JUL-2000; 2000US-0216880P.
XX 11-JUL-2000; 2000US-0217487P.
XX 11-JUL-2000; 2000US-0217496P.
XX 16-JUL-2000; 2000US-0218290P.
XX 26-JUL-2000; 2000US-0220963P.
XX 26-JUL-2000; 2000US-0220964P.
XX 14-AUG-2000; 2000US-0224518P.
XX 14-AUG-2000; 2000US-0224519P.
XX 14-AUG-2000; 2000US-0225267P.
XX 14-AUG-2000; 2000US-0225268P.
XX 14-AUG-2000; 2000US-0225270P.
XX 14-AUG-2000; 2000US-0225447P.
XX 14-AUG-2000; 2000US-0225757P.
XX 14-AUG-2000; 2000US-0225758P.
XX 22-AUG-2000; 2000US-0226868P.
XX 30-AUG-2000; 2000US-0228924P.
XX 01-SEP-2000; 2000US-0229287P.
XX 01-SEP-2000; 2000US-0229343P.
XX 01-SEP-2000; 2000US-0229345P.
XX 05-SEP-2000; 2000US-0229509P.
XX 05-SEP-2000; 2000US-0229513P.
XX 08-SEP-2000; 2000US-0231413P.
XX 21-SEP-2000; 2000US-0234223P.
XX 25-SEP-2000; 2000US-0234274P.
XX 27-SEP-2000; 2000US-023497P.
XX 29-SEP-2000; 2000US-0235834P.
XX 29-SEP-2000; 2000US-0236327P.
XX 29-SEP-2000; 2000US-0236367P.
XX 29-SEP-2000; 2000US-0236368P.
XX 29-SEP-2000; 2000US-0236369P.

PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
XX
PA (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
XX WPI; 2003-147444/14.
DR N-PSDB; ABX73485.
XX
XX New polypeptides and nucleic acids, useful in gene therapy for treating,
PT inhibiting or preventing e.g. neural, immune system, muscular,
PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
PT renal disorders.
XX
XX Claim 11; SEQ ID NO 1110; 402pp; English.
XX
XX The invention relates to human novel polypeptides and their associated
CC polynucleotides. The polypeptides and polynucleotides are useful in gene
CC therapy for treating, inhibiting or preventing neural disorders, immune
CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
CC leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
CC infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
CC ABU55748 represent human novel polypeptides of the invention
XX
XX Sequence 99 AA;
Query Match 72.8%; Score 275; DB 6; Length 99;
Best Local Similarity 90.3%; Pred. No. 7.3e-28;
Matches 56; Conservative 1; Mismatches 3; Indels 2; Gaps 1;
QY 12 RRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVKVKQTCPLQD 71
Db 9 RDXGPD--FPFNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVKVKQTCPLQD 66
QY 72 VI 73
Db 67 VI 68
RESULT 14
AAW73894
ID AAW73894 standard; protein; 776 AA.
XX
AC AAW73894;
XX
XX 08-APR-1999 (first entry)
XX
XX Yeast MEC2 protein sequence.
XX

KW Cell cycle checkpoint gene; yeast; radiation resistance; detection;
KW G2/M checkpoint.
XX
XX Saccharomyces cerevisiae.
XX
XX US5866338-A.
XX
XX 02-FEB-1999.
XX
XX 06-JUN-1997; 97US-00870693.
XX
XX 12-MAY-1992; 92US-00882051.
XX 14-MAY-1992; 92US-00884426.
XX 12-MAY-1993; 93WO-US004458.
XX 18-FEB-1994; 94US-00198446.
XX
XX (UNIW) UNIV WASHINGTON.
XX (UYAR-) UNIV ARIZONA.
XX (HUTC-) HUTCHINSON CANCER RES CENT FRED.
XX
XX Plon SE, Groudine MT, Hartwell LH, Weinert TA;
XX
XX WPI; 1999-141919/12.
DR N-PSDB; AAX01275.
XX
XX Nucleotide sequences that hybridise to huRAD cDNA - method for isolating
PT human checkpoint cDNA, and antibody to CDC34.
XX
XX Example 4; Col 89-96; 73pp; English.
XX
XX This sequence is the yeast MEC2 protein. The DNA encoding this sequence
CC is necessary for G2/M cell cycle checkpoint control. This sequence was
CC identified using the method of the invention for isolating a human
CC checkpoint cDNA that is capable of restoring growth at a restrictive
CC temperature in a yeast test cell, where the yeast test cell comprises a
CC genome having a first gene that forms a DNA strand break at a restrictive
CC temperature and a second gene that fails to induce a cell cycle arrest in
CC response to the DNA strand break, whereby the growth of the yeast test
CC cell is inhibited at the restrictive temperature, comprising: (a)
CC obtaining a human cDNA library comprising several human cDNA clones; (b)
CC inserting the human cDNA clones individually into plasmid vectors
CC containing a selectable marker gene; (c) transforming a culture of the
CC yeast test cells with the plasmid vectors from the preceding step; (d)
CC selecting for yeast test cells transformed with the selectable marker
CC gene; (e) growing the selected transformants at the restrictive
CC temperature and isolating a candidate transformant capable of growing at
CC the restrictive temperature; and (f) identifying the human cDNA carried
CC by the candidate transformant as a human checkpoint cDNA by sequencing that
CC the human cDNA carried by the candidate transformant and determining that
CC the human cDNA is less than 50% homologous with both the first gene and
CC the second gene. The nucleotide sequence of huRADcompB can be used to
CC confer radiation resistance on a cell
XX
XX Sequence 776 AA;
Query Match 28.4%; Score 107.5; DB 2; Length 776;
Best Local Similarity 37.7%; Pred. No. 8.7e-05;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;
QY 5 KREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVKVKQTC 64
Db 63 KKWTTFGRNPACDYHLGNISRLSNKHPQILLGE-DGNLLINDISTNGTTLNGQVKVNSN 121
QY 65 PLOTGQDVI 73
Db 122 QLLSQGDEI 130
RESULT 15
AAW26664
ID AAW26664 standard; protein; 821 AA.
XX
XX AAW26664;
XX

Mon May 17 11:17:07 2004

us-10-048-046-2_copy_31_103.rag

Search completed: May 7, 2004, 14:45:46
Job time : 17.2046 secs

XX 25-MAR-2003 (revised)
DT 25-FEB-1998 (first entry)
XX
DE Yeast checkpoint control protein MEC2.
XX
KW MEC2; cell cycle; checkpoint gene; yeast; DNA damage; cancer; therapy.
XX
OS Saccharomyces cerevisiae.
XX
FH Key Location/Qualifiers
FT Protein 1..776
FT /note= "in the Sequence Listing MEC2 terminates at
FT residue 775"
XX
XX
PN US5674996-A.
XX
XX 07-OCT-1997.
XX
XX 18-FEB-1994; 94US-00198446.
XX
XX 12-MAY-1992; 92US-00882051.
PR 14-MAY-1992; 92US-00884426.
PR 12-MAY-1993; 93WO-US004456.
XX
XX (UYAR-) UNIV ARIZONA.
PA (UNIW) UNIV WASHINGTON.
PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
XX
XX Groudine MT, Weinert TA, Plon SE, Hartwell LH;
XX
XX WPI; 1997-502392/46.
DR N-PSDB; AAT91040.
XX
XX Nucleotide sequence capable of hybridising with huCDC34 - which is human
PT checkpoint gene, useful to increase sensitivity of tumour cells to
PT chemotherapeutic drugs or radiation.
XX
XX Example 4; Col 85-90; 54pp; English.
PS
XX This protein is encoded by novel yeast checkpoint control gene MEC2 (see
XX AAT91040). Yeast checkpoint control genes RAD17, RAD24, MEC1, MEC2 and
XX MEC3 (AAT91037-41, respectively) are responsible for recognising if the
XX cell has suffered DNA damage in the form of radiation or chemical damage
XX or if the cell has failed to complete DNA replication because of chemical
XX inhibition or intrinsic error. Upon recognising damage or failure, the
XX genes are responsible for inhibiting mitosis. The purpose of this
XX checkpoint control is that it preserves the viability of the cell and the
XX integrity of the genome by providing the cell time to repair these
XX insults prior to undertaking mitosis. The genes are potentially useful in
XX developing cancer chemotherapeutics, cancer chemoprevention agents, and
XX environmental toxicology tests. They can be used to produce proteins (see
XX AAW26661-65) that can then be screened for chemical agents that would
XX interfere with checkpoint controls. Cloned genes can also be used to
XX develop yeast strains in which these genes are deleted. Such yeast
XX strains can then be used to find the homologous human genes (see AAT91034
XX -36). (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ Sequence 821 AA;
Query Match 28.4%; Score 107.5; DB 2; Length 821;
Best Local Similarity 37.7%; Pred. No. 9.3e-05;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;
QY 5 KREWTIGRRGCDLSPFSKNLVSDHCRIVVDKSGGVTLDTSTGTINKLVKKQT 64
DB 63 KKVWTFGRNACDYLHGNISRLSNKHFQILLGE-DGNLLINDISTNGTWLNGQKVENSN 121
QY 65 CPLQTQDVI 73
DB 122 QLLSQGDEI 130

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:42:23 ; Search time 4.85639 Seconds
(without alignments)
776.028 Million cell updates/sec

Title: US-10-048-046-2_COPY_31_103

Perfect score: 378
Sequence: 1 VLLKREWTIGRRGCDLSF.....INKLKVVKKTCPLQTQDVI 73

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/6C_COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	107.5	28.4	776	1	US-08-198-446B-17
2	107.5	28.4	776	2	US-08-870-693-17
3	107.5	28.4	821	1	US-08-198-446B-6
4	107.5	28.4	821	2	US-08-870-693-6
5	97	25.7	65	4	US-09-300-008B-46
6	79.5	21.0	558	4	US-09-252-991A-17202
7	76.5	20.2	517	4	US-09-849-617-2
8	74.5	19.7	64	4	US-09-300-008B-44
9	70.5	18.7	877	4	US-09-328-352-8162
10	68	18.0	754	4	US-09-300-008B-2
11	67	17.7	63	4	US-09-300-008B-43
12	64.5	17.1	64	4	US-09-300-008B-41
13	61	16.1	212	4	US-09-328-352-5652
14	61	16.1	1070	4	US-09-107-532A-6735
15	59.5	15.7	804	3	US-08-855-910-4
16	59.5	15.7	824	4	US-09-134-000C-4908
17	59	15.6	1045	1	US-07-596-467-6
18	59	15.6	1045	1	US-07-934-374-6
19	59	15.6	1045	1	US-07-783-861C-6
20	58.5	15.5	475	4	US-09-252-991A-22693
21	58.5	15.5	502	4	US-09-232-991A-30007
22	58	15.3	721	4	US-08-851-435-2
23	58	15.3	746	4	US-08-851-435-6
24	57.5	15.2	80	4	US-09-540-236-2410
25	57.5	15.2	443	4	US-09-134-001C-3148
26	57.5	15.2	632	3	US-09-354-129-8
27	57.5	15.2	632	4	US-09-504-357-8

28	57	15.1	368	3	US-08-961-083-76	Sequence 76, Appl
29	57	15.1	368	4	US-09-536-784-76	Sequence 76, Appl
30	57	15.1	870	4	US-09-543-681A-5184	Sequence 5184, Ap
31	56.5	14.9	440	4	US-09-198-452A-755	Sequence 755, App
32	56	14.8	543	4	US-09-529-093A-2	Sequence 2, Appl
33	56	14.8	543	4	US-09-529-154-2	Sequence 20, Appl
34	56	14.8	830	3	US-08-804-439A-20	Sequence 20, Appl
35	56	14.8	830	3	US-08-720-229-20	Sequence 20, Appl
36	56	14.8	878	4	US-09-489-039A-13174	Sequence 13174, A
37	56	14.8	913	4	US-09-252-991A-22127	Sequence 22127, A
38	56	14.8	3256	4	US-09-919-172-98	Sequence 98, Appl
39	56	14.8	3256	4	US-09-978-594-22	Sequence 22, Appl
40	55.5	14.7	1548	4	US-09-252-991A-22301	Sequence 22301, A
41	55	14.6	65	4	US-09-300-008B-48	Sequence 48, Appl
42	55	14.6	283	4	US-09-107-532A-6481	Sequence 6481, Ap
43	55	14.6	312	4	US-09-107-532A-5790	Sequence 5790, Ap
44	55	14.6	356	4	US-09-540-236-3075	Sequence 3075, Ap
45	55	14.6	1302	4	US-09-423-890-2	Sequence 2, Appl

ALIGNMENTS

RESULT 1
US-08-198-446B-17
; Sequence 17, Application US/08198446B
; Patent No. 5674996
; GENERAL INFORMATION:
; APPLICANT: Hartwell, Leland H.
; APPLICANT: Weinert, Ted A.
; APPLICANT: Pion, Sharon E.
; APPLICANT: Grondine, Mark T.
; TITLE OF INVENTION: Cell Cycle Checkpoint Genes
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson Kindness PLLC
; STREET: 1420 Fifth Ave., Suite 2800
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/198.446B
; FILING DATE: 18-FEB-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Sheiness, Diana K.
; REGISTRATION NUMBER: 35,356
; REFERENCE/DOCKET NUMBER: FHCRI7537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-682-8100
; TELEFAX: 206-224-0779
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 776 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; DESCRIPTION: Yeast MEC2 protein
US-08-198-446B-17

Query Match 28.4%; Score 107.5; DB 1; Length 776;
Best Local Similarity 37.7%; Pred. No. 2.4e-05;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;
OY 5 KREWTIGRRRGCDLSFPPSNKLVSGDHCRIVVDEKSGQVLTEDTSGTVINKLVKKQT 64
Db 63 KKVTFGRNPACDYLHGNISRLSNKHFOILLGE-DGNLLINDISTNGTWLNGQVKKNSN 121

QY 65 CPLQTDGVI 73
DB 122 QLLSQGDEI 130

RESULT 2

US-08-870-693-17
; Sequence 17, Application US/08870693
; Patent No. 5866338
; GENERAL INFORMATION:
; APPLICANT: Hartwell, Leland H.
; APPLICANT: Weinert, Ted A.
; APPLICANT: Plon, Sharon E.
; APPLICANT: Groudine, Mark T.
; TITLE OF INVENTION: Cell Cycle Checkpoint Genes
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson Kindness PLLC
; STREET: 1420 Fifth Ave., Suite 2800
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/870,693
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/198,446
; FILING DATE: February 18, 1994
; APPLICATION NUMBER: PCT/US93/04458
; FILING DATE: May 12, 1993
; APPLICATION NUMBER: US 07/884,426
; FILING DATE: May 14, 1992
; APPLICATION NUMBER: US 07/882,051
; FILING DATE: May 12, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Sheiness, Diana K.
; REGISTRATION NUMBER: 35,356
; REFERENCE/DOCKET NUMBER: FHCRI10798
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-682-8100
; TELEFAX: 206-224-0779
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 776 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; DESCRIPTION: Yeast MEC2 protein
US-08-870-693-17

Query Match 28.4%; Score 107.5; DB 2; Length 776;
Best Local Similarity 37.7%; Pred. No. 2.4e-05;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;
QY 5 KREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVKKQT 64
DB 63 KKWTFGRNPACDYHLGNISRLNKHQILLGE-DGNLLNDISTNGTWNLGQVKNSN 131
QY 65 CPLQTDGVI 73
DB 122 QLLSQGDEI 130

RESULT 3

US-08-198-446B-6

; Sequence 6, Application US/08198446B
; Patent No. 5674996
; GENERAL INFORMATION:
; APPLICANT: Hartwell, Leland H.
; APPLICANT: Weinert, Ted A.
; APPLICANT: Plon, Sharon E.
; APPLICANT: Groudine, Mark T.
; TITLE OF INVENTION: Cell Cycle Checkpoint Genes
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson Kindness PLLC
; STREET: 1420 Fifth Ave., Suite 2800
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/198,446B
; FILING DATE: 18-FEB-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Sheiness, Diana K.
; REGISTRATION NUMBER: 35,356
; REFERENCE/DOCKET NUMBER: FHCRI17537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-682-8100
; TELEFAX: 206-224-0779
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 821 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; DESCRIPTION: Yeast MEC2 protein
US-08-198-446B-6
Query Match 28.4%; Score 107.5; DB 1; Length 821;
Best Local Similarity 37.7%; Pred. No. 2.6e-05;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;
QY 5 KREWTIGRRGCDLSPFNKLVSGDHCRIVVDEKSGQVLTSTSGTVINKLVKKQT 64
DB 63 KKWTFGRNPACDYHLGNISRLNKHQILLGE-DGNLLNDISTNGTWNLGQVKNSN 121
QY 65 CPLQTDGVI 73
DB 122 QLLSQGDEI 130
RESULT 4
US-08-870-693-6
; Sequence 6, Application US/08870693
; Patent No. 5866338
; GENERAL INFORMATION:
; APPLICANT: Hartwell, Leland H.
; APPLICANT: Weinert, Ted A.
; APPLICANT: Plon, Sharon E.
; APPLICANT: Groudine, Mark T.
; TITLE OF INVENTION: Cell Cycle Checkpoint Genes
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson Kindness PLLC
; STREET: 1420 Fifth Ave., Suite 2800
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98101-2347

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
FILING DATE: US/08/870,693
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/198,446
FILING DATE: February 18, 1994
APPLICATION NUMBER: PCT/US93/04458
FILING DATE: May 12, 1993
APPLICATION NUMBER: US 07/884,426
FILING DATE: May 14, 1992
APPLICATION NUMBER: US 07/882,051
FILING DATE: May 12, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Sheiness, Diana K.
REGISTRATION NUMBER: 35,356
REFERENCE/DOCKET NUMBER: FHCRI10798
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-682-8100
TELEFAX: 206-224-0779
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 821 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
DESCRIPTION: Yeast MEC2 protein
US-08-870-693-6

Query Match 28.4%; Score 107.5; DB 2; Length 821;
Best Local Similarity 37.7%; Pred. No. 2.6e-05;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;

Qy 5 KRWITGRRGCDLSFSPNKLVS GDHCRIVVDEKSGQVLTEDTSTGTVINKLVKVKQT 64
Db 63 KKVWTFGRNPACDYLHGNISRLSNKHFQILLG-DGNLLNDISTNGTWLNGQVKVNSN 121

Qy 55 CPLQTGDVI 73
Db 122 QLLSQGDEI 130

RESULT 5
US-09-300-008B-46
Sequence 46, Application US/09300008B
Patent No. 6458334
GENERAL INFORMATION:
APPLICANT: Concannon et al.
TITLE OF INVENTION: A GENE ASSOCIATED WITH NUMENGEN BREAKAGE
TITLE OF INVENTION: SYNDROME, ITS GENE PRODUCT AND METHODS FOR THEIR USE
FILE REFERENCE: 9924-0003-228
CURRENT APPLICATION NUMBER: US/09/300,008B
CURRENT FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: US 60/083,269
PRIOR FILING DATE: 1998-04-27
NUMBER OF SEQ ID NOS: 64
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 46
LENGTH: 65
TYPE: PRT
ORGANISM: Saccharomyces cerevisiae
US-09-300-008B-46

Query Match 25.7%; Score 97; DB 4; Length 65;
Best Local Similarity 36.4%; Pred. No. 2.3e-05;
Matches 24; Conservative 8; Mismatches 30; Indels 4; Gaps 1;

Qy 8 WTIGRRGCDLSFSPNKLVS GDHCRIVVDEKSGQVLTEDTSTGTVINKLVKVKQTCP 67
Db 1 WTFGRNPACDYLHGNISRLSNKHFQILL-----GNLLNDISTNGTWLNGQVKVNSNOLL 56

Qy 68 QTGDVI 73
Db 57 SQGDEI 62

RESULT 6
US-09-252-991A-17202
Sequence 17202, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
CURRENT FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 17202
LENGTH: 558
TYPE: PRT
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-17202

Query Match 21.0%; Score 79.5; DB 4; Length 558;
Best Local Similarity 32.5%; Pred. No. 0.07;
Matches 25; Conservative 16; Mismatches 27; Indels 9; Gaps 4;

Qy 2 LURKRWITGRRGCDLSFSPNKLVS GDHCRIVVDEKSGQVLTEDTSTGTVI-----NK 56
Db 85 VIDQGLTIGRGDNDWVLPDPERLVSSRHCTIL--NRDGVYVLTDTSTNGVLLVNAHR 142

Qy 57 LKVVKKQTCPLQTGDVI 73
Db 143 LR-RNSEPLQDGETV 157

RESULT 7
US-09-849-617-2
Sequence 2, Application US/09849617
Patent No. 6593110
GENERAL INFORMATION:
APPLICANT: CALIFORNIA INSTITUTE OF TECHNOLOGY
APPLICANT: GUO, Zijian
APPLICANT: DUNPHY, William
TITLE OF INVENTION: CHECKPOINT-ACTIVATING OLIGONUCLEOTIDES
FILE REFERENCE: CITI1350-1
CURRENT APPLICATION NUMBER: US/09/849,617
CURRENT FILING DATE: 2001-09-17
PRIOR APPLICATION NUMBER: US 60/202,028
PRIOR FILING DATE: 2000-05-04
NUMBER OF SEQ ID NOS: 14
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2
LENGTH: 517
TYPE: PRT
ORGANISM: Xenopus laevis
US-09-849-617-2

Query Match 20.2%; Score 76.5; DB 4; Length 517;
Best Local Similarity 31.9%; Pred. No. 0.16;
Matches 23; Conservative 9; Mismatches 29; Indels 11; Gaps 2;

Qy 7 EWTIGRRGCDLSF-----PSNKLVS GDHCRIVVDEKSGQ---VTLEDTSTGTVIN 55
Db 84 EYVFGDRKCDYTFDIPVLNQTDYKTSKRHFRIQELGHGHSRVANIEDLSGNGTFVN 143


```
QY 56 KLKVKVKQTCPL 67
| : | : |
Db 144 KEIIGKRTPL 155

RESULT 8
US-09-300-008B-44
; Sequence 44, Application US/09300008B
; Patent No. 6458534
; GENERAL INFORMATION:
; APPLICANT: Concannon et al.
; TITLE OF INVENTION: A GENE ASSOCIATED WITH NIJMEGEN BREAKAGE
; FILE REFERENCE: 9924-0003-228
; CURRENT APPLICATION NUMBER: US/09/300,008B
; CURRENT FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: US 60/083,269
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 44
; LENGTH: 64
; TYPE: PRT
; ORGANISM: Schizosaccharomyces pombe
US-09-300-008B-44

Query Match 19.7%; Score 74.5; DB 4; Length 64;
Best Local Similarity 31.8%; Pred. No. 0.019;
Matches 21; Conservative 9; Mismatches 31; Indels 5; Gaps 2;

QY 8 WTIGRRGCDLSPPSNKLVS GDHCRIVVDKSGQVLTSTSGTVINKLVKVKQTCPL 67
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 1 WGFGRHKSCVVL-NGPRVSNFHEIY----QGVVFLHDHSSNGTFLNFERLAKNSRTIL 55
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

QY 68 QTGDVI 73
| : | : |
Db 56 SNGDEI 61

RESULT 9
US-09-328-352-8162
; Sequence 8162, Application US/09328352
; Patent No. 6562958
; GENERAL INFORMATION:
; APPLICANT: Gary L. Breton et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER
; FILE REFERENCE: GTC99-03PA
; CURRENT APPLICATION NUMBER: US/09/328,352
; CURRENT FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 8252
; SEQ ID NO 8162
; LENGTH: 877
; TYPE: PRT
; ORGANISM: Acinetobacter baumannii
US-09-328-352-8162

Query Match 18.7%; Score 70.5; DB 4; Length 877;
Best Local Similarity 25.9%; Pred. No. 1.9;
Matches 22; Conservative 12; Mismatches 24; Indels 27; Gaps 4;

QY 1 VLLRREWTIGRR--GCDLSPPSNKLVS GDHCRIVVDKSGQVLTSTST-----49
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 430 VQFLSDWGVSRQRYWGPDI-----PMINCDTC-----QGVTPSDQLPVLPDVI 476
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

QY 50 ---SGTVINKLVKVKQTCPLQTGD 71
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 477 PDGSGNPLKNKEFFETKPCCGGD 501
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

RESULT 10
US-09-300-008B-2
; Sequence 2, Application US/09300008B
; Patent No. 6458534
; GENERAL INFORMATION:
; APPLICANT: Concannon et al.
; TITLE OF INVENTION: A GENE ASSOCIATED WITH NIJMEGEN BREAKAGE
; FILE REFERENCE: 9924-0003-228
; CURRENT APPLICATION NUMBER: US/09/300,008B
; CURRENT FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: US 60/083,269
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 754
; TYPE: PRT
; ORGANISM: Homo sapien
US-09-300-008B-2

Query Match 18.0%; Score 68; DB 4; Length 754;
Best Local Similarity 24.7%; Pred. No. 3.2;
Matches 20; Conservative 21; Mismatches 30; Indels 10; Gaps 2;

QY 2 LLRKREWTIGRRGCDLSPPSNKLVS GDHCRIVVD-----EKSGQVLTSTSGT 52
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 18 LLTGVEYVVG-RKNCALLIENDQISGRNHAULTANFSVTNLSTQDEIPVLTLDKNSKYGT 76
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

QY 53 VINKLVKVKQTCPLQTGDVI 73
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 77 FVNEERMQNGFSRTLKSGDGI 97
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

RESULT 11
US-09-300-008B-43
; Sequence 43, Application US/09300008B
; Patent No. 6458534
; GENERAL INFORMATION:
; APPLICANT: Concannon et al.
; TITLE OF INVENTION: A GENE ASSOCIATED WITH NIJMEGEN BREAKAGE
; FILE REFERENCE: 9924-0003-228
; CURRENT APPLICATION NUMBER: US/09/300,008B
; CURRENT FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: US 60/083,269
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 43
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-300-008B-43

Query Match 17.7%; Score 67; DB 4; Length 63;
Best Local Similarity 34.3%; Pred. No. 0.18;
Matches 23; Conservative 10; Mismatches 24; Indels 10; Gaps 3;

QY 9 TIGERRGCD--LSFPPSNKLVS GDHCRIVVDKSGQVLTSTSGTVINKLVKVKQTCP 66
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 2 TIGRSRCDVILSEPDISTHAEFHLLIN-----VIDKSRNGTFINGRLVKKDYI- 53
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

QY 67 LOTGDVI 73
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 54 LKNGDRI 60
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

RESULT 12
US-09-300-008B-41
; Sequence 41, Application US/09300008B
; Patent No. 6458534
; GENERAL INFORMATION:
; APPLICANT: Concannon et al.
; TITLE OF INVENTION: A GENE ASSOCIATED WITH NIJMEGEN BREAKAGE
```

```
; Sequence 2, Application US/09300008B
; Patent No. 6458534
; GENERAL INFORMATION:
; APPLICANT: Concannon et al.
; TITLE OF INVENTION: A GENE ASSOCIATED WITH NIJMEGEN BREAKAGE
; FILE REFERENCE: 9924-0003-228
; CURRENT APPLICATION NUMBER: US/09/300,008B
; CURRENT FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: US 60/083,269
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 754
; TYPE: PRT
; ORGANISM: Homo sapien
US-09-300-008B-2

Query Match 18.0%; Score 68; DB 4; Length 754;
Best Local Similarity 24.7%; Pred. No. 3.2;
Matches 20; Conservative 21; Mismatches 30; Indels 10; Gaps 2;

QY 2 LLRKREWTIGRRGCDLSPPSNKLVS GDHCRIVVD-----EKSGQVLTSTSGT 52
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 18 LLTGVEYVVG-RKNCALLIENDQISGRNHAULTANFSVTNLSTQDEIPVLTLDKNSKYGT 76
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

QY 53 VINKLVKVKQTCPLQTGDVI 73
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 77 FVNEERMQNGFSRTLKSGDGI 97
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

RESULT 11
US-09-300-008B-43
; Sequence 43, Application US/09300008B
; Patent No. 6458534
; GENERAL INFORMATION:
; APPLICANT: Concannon et al.
; TITLE OF INVENTION: A GENE ASSOCIATED WITH NIJMEGEN BREAKAGE
; FILE REFERENCE: 9924-0003-228
; CURRENT APPLICATION NUMBER: US/09/300,008B
; CURRENT FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: US 60/083,269
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 43
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-09-300-008B-43

Query Match 17.7%; Score 67; DB 4; Length 63;
Best Local Similarity 34.3%; Pred. No. 0.18;
Matches 23; Conservative 10; Mismatches 24; Indels 10; Gaps 3;

QY 9 TIGERRGCD--LSFPPSNKLVS GDHCRIVVDKSGQVLTSTSGTVINKLVKVKQTCP 66
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 2 TIGRSRCDVILSEPDISTHAEFHLLIN-----VIDKSRNGTFINGRLVKKDYI- 53
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

QY 67 LOTGDVI 73
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db 54 LKNGDRI 60
| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

RESULT 12
US-09-300-008B-41
; Sequence 41, Application US/09300008B
; Patent No. 6458534
; GENERAL INFORMATION:
; APPLICANT: Concannon et al.
; TITLE OF INVENTION: A GENE ASSOCIATED WITH NIJMEGEN BREAKAGE
```

; TITLE OF INVENTION: SYNDROME, ITS GENE PRODUCT AND METHODS FOR THEIR USE
; FILE REFERENCE: 9924-0003-228
; CURRENT APPLICATION NUMBER: US/09/300,008B
; CURRENT FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: US 60/083,269
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 41
; LENGTH: 64
; TYPE: PRT
; ORGANISM: Homo sapien
; US-09-300-008B-41

Query Match 17.1%; Score 64.5; DB 4; Length 64;
Best Local Similarity 25.8%; Pred. No. 0.38; 25; Indels 5; Gaps 2;
Matches 17; Conservative 19; Mismatches 25; Indels 5; Gaps 2;

QY 8 WTGRRGCDLSPFNKLVGSDHCRIVVDKSGQVLTSTGTVINKLVKVKQTCP 67
DB 1 YVVG-RKNCAILLENDQSISRNEAVLT---ANVLTKDNSKYGTTFVNEEKMGNGFSRTL 55

QY 68 QTGDVI 73
DB 56 KSGDGI 61

RESULT 13
US-09-328-352-5652
; Sequence 5652, Application US/09328352
; Patent No. 6562958
; GENERAL INFORMATION:
; APPLICANT: Gary L. Breton et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER
; FILE REFERENCE: GTC99-03PA
; CURRENT APPLICATION NUMBER: US/09/328,352
; CURRENT FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 8252
; SEQ ID NO 5652
; LENGTH: 212
; TYPE: PRT
; ORGANISM: Acinetobacter baumannii
; US-09-328-352-5652

Query Match 16.1%; Score 61; DB 4; Length 212;
Best Local Similarity 23.2%; Pred. No. 5.1;
Matches 16; Conservative 24; Mismatches 23; Indels 6; Gaps 4;

QY 6 REWTGRRGCDLSPFNKLVGSDHCRIVVDKSGQVLTED-TSTSGTVINKLVKVKQT 64
DB 24 RDLVGRHQDADLLQAAB-ISRRAALLKQQA--LWVQDLNSNGTFVNDMRI--EQE 78

QY 65 CPLQTGDVI 73
DB 79 KQLHGDIV 87

RESULT 14
US-09-107-532A-6735
; Sequence 6735, Application US/09107532A
; Patent No. 6583275
; GENERAL INFORMATION:
; APPLICANT: Lynn A Doucette-Stamm and David Bush
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
; ENTEROCOCCUS FAECIUM FOR DIAGNOSTICS AND THERAPEUTICS
; NUMBER OF SEQUENCES: 7310
; CORRESPONDENCE ADDRESS:
; ADDRESS: GENOME THERAPEUTICS CORPORATION
; STREET: 100 Beaver Street
; CITY: Waltham
; STATE: Massachusetts
; COUNTRY: USA

; ZIP: 02354
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-ROM ISO9660
; COMPUTER: PC
; OPERATING SYSTEM: <Unknown>
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/107,532A
; FILING DATE: 30-Jun-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/085,598
; FILING DATE: 14 May 1998
; APPLICATION NUMBER: 60/051571
; FILING DATE: July 2, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Ariniello, Pamela Deneke
; REGISTRATION NUMBER: 40,489
; REFERENCE/DOCKET NUMBER: GTC-012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (781)893-5007
; TELEFAX: (781)893-8277
; INFORMATION FOR SEQ ID NO: 6735:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1070 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHEICAL: YES
; ORIGINAL SOURCE:
; ORGANISM: Enterococcus faecium
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (B) LOCATION 1...1070
; SEQUENCE DESCRIPTION: SEQ ID NO: 6735:
; US-09-107-532A-6735

Query Match 16.1%; Score 61; DB 4; Length 1070;
Best Local Similarity 42.3%; Pred. No. 41;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 18 LSPFNKLVGSDHCRIVVDKSGQVT 43
DB 866 LSIPEQLFAGDVLIVLNDQAGEAT 891

RESULT 15
US-08-855-910-4
; Sequence 4, Application US/08855910
; Patent No. 6221640
; GENERAL INFORMATION:
; APPLICANT: Tao, Jianshi
; APPLICANT: Sassanfar, Mandana
; APPLICANT: Gallant, Paul L.
; APPLICANT: Shen, Xiaoyu
; APPLICANT: Avruch, Anthony S.
; APPLICANT: Yu, Russell V.
; APPLICANT: Nair, Shamila
; TITLE OF INVENTION: ENTEROCOCCAL AMINOACYL-tRNA SYNTHETASE
; TITLE OF INVENTION: PROTEINS, NUCLEIC ACIDS AND STRAINS COMPRISING SAME
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:

```

/ APPLICATION NUMBER: US/08/855,910
/ FILING DATE: 14-MAY-1997
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Brook, David E.
/ REGISTRATION NUMBER: 22,592
/ REFERENCE/DOCKET NUMBER: CPT95-08
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (781) 861-6240
/ TELEFAX: (781) 861-9540
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 804 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
US-08-855-910-4

```

```

Query Match      15.7% ; Score 59.5 ; DB 3 ; Length 804 ;
Best Local Similarity 31.5% ; Pred. No. 45 ;
Matches 23 ; Conservative 12 ; Mismatches 21 ; Indels 17 ; Gaps 4 ;

QY      5 KREWTIGRRRCGLSPSPNKLVSGDHCRIWVEDEKQGV---TLEDT---STSGTVINKLV 59
          : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      218 ORNW-IGRSEGANVF-----KVAQTESEFTVTPDPLFGATVTVLAPLEL 265

```

QY 60 VKQTCPLQTDV 72
Dp 266 VKKITTEQTAAY 278

Search completed: May 7, 2004, 14:51:22
Job time : 5.85639 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2004, 14:41:17 ; Search time 4.08553 Seconds
(without alignments)
1718.743 Million cell updates/sec

Title: US-10-048-046-2_COPY_31_103

Perfect score: 378
Sequence: 1 VLLRKEEWIGRRGCDLSF.....INKLKVVKQTCLQTQDVI 73

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_78.*
1: PIR1.*
2: PIR2.*
3: PIR3.*
4: PIR4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	107.5	28.4	821	1 A39616	protein kinase RAD
2	88	23.3	159	2 A36962	PHA-domain contain
3	79.5	21.0	497	2 F83634	hypothetical prote
4	79	20.9	358	2 A61188	probable transcrip
5	77.5	20.5	460	2 S88882	protein kinase Cds
6	76	20.1	2541	2 T29340	hypothetical prote
7	74.5	19.7	265	2 B61188	Sci protein - mous
8	72	19.0	513	1 S43941	protein kinase DUN
9	71	18.8	409	2 S73738	phosphoglycerate k
10	70.5	18.7	230	2 A93872	hypothetical prote
11	70.5	18.7	301	2 T40402	forkhead nuclear s
12	68.5	18.1	157	2 S76488	hypothetical prote
13	68	18.0	399	2 AC3089	conserved hypothet
14	68	18.0	399	2 G86197	hypothetical prote
15	68	18.0	754	2 T00393	Nijmegen breakage
16	67.5	17.9	234	2 AF2214	hypothetical prote
17	66.5	17.6	546	2 A61899	adenylate cyclase
18	66	17.5	287	2 G69901	cell wall-binding
19	66	17.5	604	2 S82706	probable membrane
20	66	17.5	692	2 T00025	PSP-95 binding pro
21	66	17.5	977	2 T00014	DAP-1 alpha protei
22	64	16.9	1441	1 GNVSUV	M polyprotein prec
23	63.5	16.8	445	2 T43420	probable protein k
24	63.5	16.8	938	2 C84480	hypothetical prote
25	62.5	16.5	357	2 H82645	conserved hypothet
26	62.5	16.5	468	2 D96904	probable membrane
27	62.5	16.5	527	2 B70700	hypothetical prote
28	62	16.4	273	2 AF0041	L-thanosase operon
29	62	16.4	749	2 S75331	penicillin-binding

30	62	16.4	1471	2 D72758	hypothetical prote
31	62	16.4	1637	2 T00070	hypothetical prote
32	62	16.4	2938	2 T30249	cell proliferation
33	61.5	16.3	287	2 H64690	type IIS restricti
34	61.5	16.3	463	2 T10015	hypothetical prote
35	61.5	16.3	488	2 F86911	conserved hypothet
36	61	16.1	484	2 S48403	FKH1 protein - yea
37	61	16.1	1433	1 GNVUWU	M polyprotein prec
38	61	16.1	1441	1 GNVULC	adenylate cyclase
39	60.5	16.0	337	2 S75018	hypothetical prote
40	60.5	16.0	397	2 D83437	hypothetical prote
41	60.5	16.0	661	2 T15073	conserved hypothet
42	60	15.9	353	2 E81680	hypothetical prote
43	60	15.9	560	2 D72478	hypothetical prote
44	60	15.9	952	2 T18837	hypothetical prote
45	60	15.9	969	2 B87083	excinuclease ABC s

ALIGNMENTS

RESULT 1

A39616
protein kinase RAD53 (EC 2.7.1.1-) - Yeast (Saccharomyces cerevisiae)
N/Alternate names: protein P2588; protein YPL153c; SPK1 protein
C/Species: Saccharomyces cerevisiae
C/Date: 30-Jun-1993 #sequence revision 30-Jun-1993 #text_change 21-Jul-2000
C/Accession: A39616; S65164; S69446; S13321
R/Stern, D.F.; Zheng, P.; Beidler, D.R.; Zerillo, C.
Mol. Cell. Biol. 11, 987-1001, 1991
A/Title: Spk1, a new kinase from Saccharomyces cerevisiae, phosphorylates proteins on ser
A/Reference number: A39616; MUID:91117267; PMID:1899289
A/Accession: A39616
A/Molecule type: DNA
A/Residues: 1-821 <STE>
A/Cross-references: GB:M55623; NID:gl72656; PIDN:AAA35070.1; PID:gl72657
A/Experimental source: strain S288C
R/Zheng, P.; Fay, D.S.; Burton, J.; Xiao, H.; Pinkham, J.L.; Stern, D.F.
Mol. Cell. Biol. 13, 5829-5842, 1993
A/Title: SPK1 is an essential S-phase-specific gene of Saccharomyces cerevisiae that enc
A/Reference number: A54697; MUID:93361015; PMID:8355715
A/Contents: annotation
R/Purnelle, B.; Coster, F.; Goffeau, A.
submitted to the Protein Sequence Database, May 1996
A/Reference number: S65154
A/Accession: S65164
A/Molecule type: DNA
A/Residues: 1-821 <PUR>
A/Cross-references: EMBL:Z73509; NID:gl370325; PIDN:CAA97858.1; PID:gl370326; GSPDB:GN000
A/Experimental source: strain S288C (AB972)
R/Purnelle, B.; Combles, S.; Coster, F.; Naveau, F.; Goffeau, A.
submitted to the EMBL Data Library, March 1996
A/Description: The sequence of 55 kb on the left arm of yeast chromosome XVI identifies ;
ogue to the human phosphotyrosyl phosphatase activator PTPA and a homologue to the plant
A/Reference number: S69446
A/Accession: S69446
A/Molecule type: DNA
A/Residues: 1-821 <PUW>
A/Cross-references: EMBL:X96770; NID:gl403537; PIDN:CAA65568.1; PID:gl403556
C/Genetics:
A/Gene: SGP:RAD53; SPK1; MEC2; SAD1; MIPS:YPL153C
A/Cross-references: SGP:S0006074; MIPS:YPL153C
A/Map position: 16L
C/Function:
A/Description: serine/threonine-specific protein kinase
A/Note: contains low activity as tyrosine-specific protein kinase
C/Superfamily: protein kinase SPK1; kinase interaction domain homology; protein kinase hc
C/Keywords: ATP; cell cycle control; nucleus; phosphotransferase; serine/threonine-specifi
F:68-133/Domain: kinase interaction domain homology <KIH>
F:196-466/Domain: protein kinase homology <KIN>
F:204-213/Region: protein kinase ATP-binding motif
F:227/Active site: Lys #status predicted

Query Match 28.4%; Score 107.5; DB 1; Length 821;
Best Local Similarity 37.7%; Pred.No. 0.00028;
Matches 26; Conservative 9; Mismatches 33; Indels 1; Gaps 1;

QY 5 KREWTIGRRGCDLSFPSNKLVSGDHCRIVVDEKSGOVTLDETSTGVINKLVKKVKQT 64
: : : : : : : : : : : : : : : : : : : : : : : : : :
Db 63 KKWTFGSNPACDYHLGNISRLSNKHFOILLGE-DGNLLNDISTNGTWLNGOKVEKSN 121
: : : : : : : : : : : : : : : : : : : : : : : : : :
QY 65 CPLOTGDVI 73
Db 122 QLILSQGDEI 130

RESULT 2
A96962
FHA-domain containing secreted protein [imported] - Clostridium acetobutylicum
C/Species: Clostridium acetobutylicum
C/Date: 14-Sep-2001 #sequence_revision 14-Sep-2001 #text_change 14-Sep-2001
C/Accession: A96962
R:Nolling, J.; Berton, G.; Omelchenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee,
J.; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.
J. Bacteriol. 183, 4823-4839, 2001
A/Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium Clio
A/Reference number: A96900; MUID:21359325; PMID:21359325
A/Accession: A96962
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-159 <CUR>
A/Cross-references: GB:AE001437; PIDN:AAK78484.1; PID:g1S023366; GSPDB:GN00168
A/Experimental source: Clostridium acetobutylicum ATCC824
C/Genetics:
A/Gene: CAC0504

Query Match 23.3%; Score 88; DB 2; Length 159;
Best Local Similarity 41.4%; Pred.No. 0.0086;
Matches 29; Conservative 12; Mismatches 21; Indels 8; Gaps 5;

QY 6 REWTIGRRGCDLSFPSNK-LVSGDHCRIVVDKSGQVTLED-TTSGTVINKLVKKVKQ 63
: : : : : : : : : : : : : : : : : : : : : : : : : :
Db 85 REITIGRKD--DNSIMNEGYSVGHARVL--RNNOYTILEDLNSTGTVLNGSKI--KS 138
: : : : : : : : : : : : : : : : : : : : : : : : : :
QY 64 TCPLQTGDVI 73
Db 139 XAVIKSGDEI 148
: : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 3
F83634
hypothetical protein PA0081 [imported] - Pseudomonas aeruginosa (strain PAO1)
C/Species: Pseudomonas aeruginosa
C/Date: 15-Sep-2000 #sequence_revision 15-Sep-2000 #text_change 31-Dec-2000
C/Accession: F83634
R/Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warrenner, P.; Hickey, M.J.; Bu
adman, S.; Yuan, Y.; Brody, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Larbig, K.; Lim,
J.; Lory, S.; Olson, M.V.
Nature 406, 959-964, 2000
A/Title: Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic patho
A/Reference number: A82950; MUID:20437337; PMID:10984043
A/Accession: F83634
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-497 <STO>
A/Cross-references: GB:AE004447; GB:AE004091; NID:g9945902; PIDN:AAG03471.1; GSPDB:GN001
A/Experimental source: strain PAO1
C/Genetics:
A/Gene: PAU0081

[illegible]

A;Accession: T52473
A;Status: preliminary; translated from GB/EMBL/DBSJ
A;Molecule type: DNA
A;Residues: 1-202, 'I', 204-237, 'F', 239-460 <LIN>
A;Cross-references: EMBL:AJ222869; NID:G2689196; PIDN:CAA11019.1; PID:G2689197
A;Genetics:
A;Gene: SPBC1885.11c; cds1
A;Map position: 3
A;Introns: 86/3; 103/1; 113/3; 142/1; 228/3; 298/3; 368/2
A;Function:
C;Description: EC 2.7.1.-; protein kinase Cds1 [validated, MUID:98119835]; is required for the G2/M transition and is activated by S-phase arrest and activated by DNA damage
C;Superfamily: protein kinase Cds1; kinase interaction domain homology; protein kinase h
C;Keywords: ATP; phosphotransferase; serine/threonine-specific protein kinase
F;62-133/Domain: kinase interaction domain homology <KH>
F;165-433/Domain: protein kinase homology <KIN>
F;173-181/Region: protein kinase ATP-binding motif

Query Match 20.5%; Score 77.5; DB 2; Length 460;
Best Local Similarity 30.6%; Pred. No. 0.45;
Matches 22; Conservative 9; Mismatches 34; Indels 7; Gaps 2;

Qy 8 WTGRRGCDLSPFNKLVGDHCRIV-----VDEKSGQVTLDTSTGTVINKLVVK 61
Db 60 WRFGHKSCVVL-NGPRVSNFPEIYQGRNDSSENVVFLHDHSSNGTFLNFERLAK 118
Qy 62 KQTCPLQTGDVI 73
Db 119 NSRTILNGDEI 130

RESULT 6
T29340
Hypothetical protein F21C10.7 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C;Accession: T29340
R;Du, Z.; Gattung, S.
A;Title: The sequence of C. elegans cosmid F21C10.
A;Reference number: 220610
A;Accession: T29340
A;Status: preliminary; translated from GB/EMBL/DBSJ
A;Molecule type: DNA
A;Residues: 1-2541 <DUZ>
A;Cross-references: EMBL:U55364; PIDN:AAA97973.1; GSPDB:GN00023; CESP:F21C10.7
A;Experimental source: strain Bristol N2; clone F21C10
A;Genetics:
A;Gene: CESP:F21C10.7
A;Map position: 5
A;Introns: 50/3; 91/3; 153/3; 184/3; 215/1; 254/3; 350/1; 392/3; 538/1; 589/3; 625/3; 75

Query Match 20.1%; Score 76; DB 2; Length 2541;
Best Local Similarity 31.0%; Pred. No. 4.3;
Matches 22; Conservative 13; Mismatches 24; Indels 12; Gaps 3;

Qy 5 KREWTIGRRGCDLSPFNKLVGDHCRIVDE-----KSGQVTLDTSTGTVIN--KLX 58
Db 1265 KEETA VKESERVHLTF-----SGDHQMIIDKTVPLDTGIYTRAKNVHGEVANFCOLR 1318
Qy 59 VVKKQTCPLQT 69
Db 1319 VVPKQPPPT 1329

RESULT 7
B61188
SCL protein - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 19-Mar-1997 #sequence_revision 13-Mar-1998 #text_change 07-May-1999
C;Accession: B61188
R;Ku, D.H.; Chang, C.; Koniecki, J.; Cannizzaro, L.A.; Boghosian-Sell, L.; Alder, H.; Ba
Cell Growth Differ. 2, 179-186, 1991

A;Title: A new growth-regulated complementary DNA with the sequence of a putative trans-
A;Reference number: A61188; MUID:91329275; PMID:1868030
A;Accession: B61188
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-265 <KUA>

Query Match 19.7%; Score 74.5; DB 2; Length 265;
Best Local Similarity 28.6%; Pred. No. 0.55;
Matches 18; Conservative 18; Mismatches 22; Indels 5; Gaps 3;

Qy 16 CDLSP-PNKK--LVSGDHCRIVDEKSG--QVTLDTSTGTVINKLVKKQTCPLQTG 70
Db 40 CDVALRPOQEPGLISGVHAEFLAQGDMDRVSLEDSHQGTLVNNVRLPGRHRLSDG 99
Qy 71 DVI 73
Db 100 DLL 102

RESULT 8
S43941
protein kinase DUN1 (EC 2.7.1.-) - Yeast (Saccharomyces cerevisiae)
N;Alternate names: protein D2370; protein YDL101C
C;Species: Saccharomyces cerevisiae
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 16-Jun-2000
C;Accession: S43941; S67643; S67418; S72106
R;Zhou, Z.; Elledge, S.J.
Cell 75, 1119-1127, 1993
A;Title: DUN1 encodes a protein kinase that controls the DNA damage response in yeast.
A;Reference number: S43941; MUID:94084787; PMID:8261511
A;Accession: S43941
A;Molecule type: DNA
A;Residues: 1-513 <ZHO>
A;Cross-references: EMBL:I25548; NID:G435616; PIDN:AAA16324.1; PID:G435617
R;Ballesta, J.P.G.; Remacha, M.; Soler-Mira, A.; Jimenez, A.; Garcia-Cantalejo, J.M.; Boi
submitted to the Protein Sequence Database, July 1996
A;Reference number: S67629
A;Accession: S67643
A;Molecule type: DNA
A;Residues: 1-513 <BAL>
A;Cross-references: EMBL:Z74149; NID:G1431139; PIDN:CAA98668.1; PID:G1431140; GSPDB:GN000
A;Experimental source: strain S288C
R;Bostovic, J.; Saiz, J.E.; Soler-Mira, A.; Garcia-Cantalejo, J.; Revuelta, J.L.; Jimine
submitted to the EMBL Data Library, February 1996
A;Reference number: S67406
A;Accession: S67418
A;Molecule type: DNA
A;Residues: 1-513 <BOS>
A;Cross-references: EMBL:X95644; NID:G1199535; PIDN:CAA64912.1; PID:G1199548
R;Saiz, J.E.; Buitrago, M.J.; Garcia, R.; Revuelta, J.L.; del Rey, F.
Yeast 12, 1077-1084, 1996
A;Title: The sequence of a 20.3 kb DNA fragment from the left arm of Saccharomyces cerevi
A;Reference number: S72094; MUID:97051597; PMID:8896274
A;Accession: S72106
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-513 <SAI>
A;Cross-references: EMBL:X95644; NID:G1199535; PIDN:CAA64912.1; PID:G1199548
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, February 1996
C;Genetics:
A;Gene: SGD:DUN1; MIPS:YDL101C
A;Cross-references: MIPS:YDL101C; SGD:S0002259
A;Map position: 4L
C;Function:
C;Superfamily: catalyzes the formation of peptidyl-serine-phosphate or peptidyl-threonine
C;Keywords: ATP; nucleus; phosphoprotein; phosphotransferase; serine/threonine-specific k
F;58-128/Domain: kinase interaction domain homology <KH>
F;198-480/Domain: protein kinase homology <KIN>
F;206-214/Region: protein kinase ATP-binding motif

Query Match 19.0%; Score 72; DB 1; Length 513;

```

Db      23 VKKESWSIGRLGSKWPKDIAF--DNVFTSRKHALLYVEE--GVFVKDLDSKHGTYYNDQR 79
Qy      59 VVKKQTCPLOTGD 71
Db      80 LAPHAPERLSHG 92

RESULT 11
T40402
forhead nuclear signaling protein - fission yeast (Schizosaccharomyces pombe)
C;Species: Schizosaccharomyces pombe
C;Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 07-Dec-1999
C;Accession: T40402
R;Lyne, M.; Rajandream, M.A.; Barrell, B.G.; Jimenez Martinez, J.
submitted to the EMBL Data Library, August 1998
A;Reference number: Z21926
A;Accession: T40402
A;Status: preliminary; translated from GB/EMBL/DDJ
A;Molecule type: DNA
A;Residues: 1-301 <LYN>
A;Cross-references: EMBL:AL031261; PIDN:CAA20309.1; GSPDB:GNC0067; SPDB:SPBC3H7.13
A;Experimental source: strain 972h-; cosmid C3H7
C;Genetics:
A;Gene: SPDB:SPBC3H7.13
A;Map position: 2

Query Match          18.7%; Score 70.5; DB 2; Length 301;
Best Local Similarity 27.3%; Pred. No. 1.8;
Matches 21; Conservative 18; Mismatches 27; Indels 11; Gaps 4;

Qy      8 WTIGRRGGDL-SFPSN-----KLVS GDHCRIVVDKSGQVTLED-TSGTVINKLV 60
Db      27 YKIGRTNKSTSPSNLFNSKVLRQAELWLKDITLSVIRDVKSSNGIFVNTRLIS 86

Qy      61 KKQ-----TCPLQTGDVI 73
Db      87 PENKPSAPCKLMSGDIV 103

RESULT 12
S76488
hypothetical protein - Synechocystis sp. (strain PCC 6803)
C;Species: Synechocystis sp.
A;Variety: PCC 6803
C;Date: 25-Apr-1997 #sequence_revision 25-Apr-1997 #text_change 08-Oct-1999
C;Accession: S76488
R;Kaneko, T.; Sato, S.; Kotani, H.; Tanaka, A.; Asamizu, E.; Nakamura, Y.; Miyajima, N.;
O, K.; Okumura, S.; Shimpo, S.; Takeuchi, C.; Wada, T.; Watanabe, A.; Yamada, M.; Yasuda
DNA Res. 3, 109-136, 1996
A;Title: Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis
s.
A;Reference number: S74322; MUID:97061201; PMID:8905231
A;Accession: S76488
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-157 <KAN>
A;Cross-references: EMBL:D90915; GB:AB001339; NID:gl653604; PIDN:BAA18617.1; PID:d101935
A;Note: The nucleotide sequence was submitted to the EMBL Data Library, June 1996

Query Match          18.1%; Score 68.5; DB 2; Length 157;
Best Local Similarity 32.2%; Pred. No. 1.5;
Matches 28; Conservative 11; Mismatches 25; Indels 23; Gaps 4;

Qy      1 VLLRKREWTIGRRRGCDLSFPSPKNLVSGDHC-----RIVVDEKSGQVTLED 46
Db      25 VLLTFETFYIGRS PRADIRIKS-QFVSRHAHLVRKSSDDVQAAYRIIDGEDGQ----- 78

Qy      47 TTSSTGTVINKLVKKVCPTQTGDVI 73
Db      79 SSVNGLMGKKV---QEHIITGDEI 102

```

RESULT 15
T00393
Niimezen breakage syndrome protein NBS1 - human

Search completed: May 7, 2004, 14:50:07
Job time : 5.33553 secs